<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003443.pub3" GROUP_ID="SCHIZ" ID="757501052211504514" MERGED_FROM="" MODIFIED="2015-03-05 15:30:16 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2015-03-05 15:30:16 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Perphenazine for schizophrenia</TITLE>
<CONTACT MODIFIED="2015-03-05 15:30:16 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="47582939521085724166111208154807" ROLE="AUTHOR"><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Sampson</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>stephanie.sampson@nottingham.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Jubilee Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441158231287</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-03-05 15:30:16 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="1184FD3182E26AA201DC7B3ED3CB490C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Benno</FIRST_NAME><LAST_NAME>Hartung</LAST_NAME><POSITION>Forensic pathologist</POSITION><EMAIL_1>benno.hartung@gmx.de</EMAIL_1><EMAIL_2>Benno.Hartung@med.uni-duesseldorf.de</EMAIL_2><MOBILE_PHONE>0049 (0)178 536 5833</MOBILE_PHONE><ADDRESS><DEPARTMENT>Institute for Legal Medicine</DEPARTMENT><ORGANISATION>University Hospital Düsseldorf</ORGANISATION><ADDRESS_1>Moorenstr. 5</ADDRESS_1><CITY>Düsseldorf</CITY><ZIP>40225</ZIP><REGION>North Rhine Westphalia</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+0049 (0)211 81 19362</PHONE_1><FAX_1>+0049 (0)211 81 19366</FAX_1></ADDRESS></PERSON><PERSON ID="47582939521085724166111208154807" ROLE="AUTHOR"><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Sampson</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>stephanie.sampson@nottingham.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Jubilee Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441158231287</PHONE_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-03-05 15:27:54 +0000" MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="4" MONTH="9" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="9" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="3" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2014-12-04 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-12-02 10:46:16 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="12" YEAR="2014"/>
<DESCRIPTION>
<P>Six new trials added after 2013 update search, results from these trials did not change overall conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-12-04 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Update search run in September 2013</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="10" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-03-05 15:06:30 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-03-05 15:06:30 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-03-05 15:06:30 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Cochrane Collaboration Programme Grant 2011, UK</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-05 15:28:28 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-14 17:29:32 +0100" MODIFIED_BY="[Empty name]">Perphenazine for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment for these symptoms of schizophrenia is antipsychotic drugs. Perphenazine is an old antipsychotic drug (typical or first-generation) formulated in the 1950s with an effectiveness similar to another antipsychotic drug called haloperidol. Perphenazine is particularly popular in Northern European countries and Japan.</P>
<P>The aim of the review was to examine the effectiveness and safety of perphenazine for schizophrenia. A search for relevant randomised studies was run in September 2013. The review authors included 31 studies that randomised people with schizophrenia to receive either perphenazine or placebo or another antipsychotic drug. A total of 4662 people participated in these studies. The quality of evidence presented by the trials was rated by the review authors to be very low quality. It was found that perphenazine was no better or worse than other older antipsychotic drugs in treating the symptoms of schizophrenia, and like other older antipsychotic drugs, the side effects of perphenazine included tremors, uncontrollable shaking, the inability to sit still and feeling restless.</P>
<P>Although perphenazine has been used for more than 50 years, poor studies with bad reporting of information mean that it is difficult to draw more clear findings and conclusions as to the effectiveness and safety of perphenazine. However, perphenazine is inexpensive and a popular antipsychotic drug in many countries, so further research and trials on its effectiveness and safety are much needed.</P>
<P>Ben Gray, Senior Peer Researcher, McPin Foundation.<A HREF="http://mcpin.org/">http://mcpin.org/</A>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-02-25 13:08:46 +0000" MODIFIED_BY="[Empty name]">
<P>Perphenazine is an old phenothiazine antipsychotic with a potency similar to haloperidol. It has been used for many years and is popular in the northern European countries and Japan.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-02-25 13:08:57 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the clinical effects and safety of perphenazine for those with schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-12-11 11:02:19 +0000" MODIFIED_BY="[Empty name]">
<P>We updated our original search using the Cochrane Schizophrenia Group's register (September 2013), references of all included studies and contacted pharmaceutical companies and authors of included studies in order to identify further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-02-25 13:09:11 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials that compared perphenazine with other treatments for people with schizophrenia and/or schizophrenia-like psychoses. We excluded trials of depot formulations of perphenazine.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently inspected citations and, where possible, abstracts. We ordered papers, inspected and quality assessed them. We extracted data, again working independently. If loss to follow-up was greater than 50% we considered results as 'prone to bias'. For dichotomous data, we calculated risk ratios (RR) and for continuous data we calculated mean differences (MD), both with the 95% confidence intervals (CI). We assessed quality of data using the GRADE (Grading of Recommendations Assessment, Development and Evaluationtool) and assessed risk of bias for included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>Thirty-one studies fulfilled the inclusion criteria, with a total of 4662 participants (of which 4522 were receiving the drugs relevant to our comparison) and presented data that could be used for at least one comparison. The trial centres were located in Europe (especially Scandinavia), Japan and Northern America.</P>
<P>When comparing perphenazine with placebo, for our primary outcome of clinical response, results favoured perphenazine with significantly more people receiving placebo rated as either 'no better or deterioration' for global state than people receiving perphenazine (1 RCT, n = 61 RR 0.32 CI 0.13 to 0.78, <I>very low quality evidence</I>). More people receiving placebo relapsed, although not a statistically significant number (1 RCT, n = 48, RR 0.14 CI 0.02 to 1.07, <I>very low quality evidence</I>). Death was not reported in the perphenazine versus placebo comparison. Experiences of dystonia were equivocal between groups (1 RCT, n = 48, RR 1.00 CI 0.07 to 15.08, <I>very low quality evidence</I>); other outcomes not reported in this comparison include serious adverse events, economic outcomes, and service use and hospitalisation.</P>
<P>For the comparison of perphenazine versus any other antipsychotic drugs, no real differences in effect between the drugs were found. There was no significant difference between groups for those considered 'no better or deterioration' (17 RCTs, n = 1879, RR 1.04 CI 0.91 to 1.17, <I>very low quality evidence</I>). For mental state outcome of 'no effect' of the study drug, there was again no significant difference between groups (4 RCTs, n = 383, RR 1.24 CI 0.61 to 2.52, <I>very low quality evidence</I>). Death was not reported in any of the included studies. There was no significant difference in rates of dystonia with perphenazine versus any other antipsychotic drugs (4 RCTs, n = 416, RR 1.36 CI 0.23 to 8.16, <I>very low quality evidence</I>), nor was there a significant difference between groups for serious adverse events (2 RCTs, n = 1760, RR 0.98 CI 0.68 to 1.41, <I>very low quality evidence</I>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>Although perphenazine has been used in randomised trials for more than 50 years, incomplete reporting and the variety of comparators used make it impossible to draw clear conclusions. All data for the main outcomes in this review were of very low quality evidence. At best we can say that perphenazine showed similar effects and adverse events as several of the other antipsychotic drugs. Since perphenazine is a relatively inexpensive and frequently used compound, further trials are justified to clarify the properties of this classical antipsychotic drug.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-05 15:09:16 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>The term 'schizophrenia was first used in 1908 by Paul Eugen Bleuler to describe a state of splitting of the functions between thought, memory, personality and perception (<LINK REF="REF-Bleuler-1908" TYPE="REFERENCE">Bleuler 1908</LINK>). It has since been recognised as a chronic, serious mental health condition that alters a person's perceptions, behaviours and mental state; it is experienced differently between individuals who develop the illness. It is typically characterised by the presence of both 'positive' symptoms (hallucinations, delusions and disturbance of thought) and 'negative' symptoms (deficits of normal response and thought processes, including poverty of speech, apathy, lack of motivation and avolition). Schizophrenia affects roughly 24 million people worldwide (<A HREF="http://www.who.int/mental_health/management/schizophrenia/en/">WHO 2014</A>), with a high prevalence of between 0.4% to 1.4% due to chronicity but, a low incidence rate of approximately 0.11 per 1000 (<LINK REF="REF-Cannon-1996" TYPE="REFERENCE">Cannon 1996</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>Perphenazine was formulated in the 1950s. It was first marketed as an oral preparation in late 1957, and as an injectable form for intravenous or intramuscular treatment of acutely ill people in the 1970s (<LINK REF="REF-Parfitt-1999" TYPE="REFERENCE">Parfitt 1999</LINK>). Furthermore, two long-acting depot formulations (perphenazine enanthate and decanoate) have been developed. Perphenazine's main indication is the treatment of schizophrenia, but it is also used for other psychiatric disorders such as mania, agitated behaviour and severe anxiety. Outside psychiatry, it is said to be effective for the management of post-operative or chemotherapy-induced nausea and vomiting, and for the treatment of intractable hiccup. Perphenazine is available in many countries. Although we have not found precise data on how much perphenazine is used, it seems to be especially popular in the Nordic states of Europe, and in Japan.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>Perphenazine is a phenothiazine antipsychotic with a piperazine side-chain (<LINK REF="REF-Parfitt-1999" TYPE="REFERENCE">Parfitt 1999</LINK>). It has a neuroleptic potency similar to that of haloperidol, so extrapyramidal adverse effects are said to be common (<LINK REF="REF-Benkert-1996" TYPE="REFERENCE">Benkert 1996</LINK>). There is a substantial first-pass effect and its bioavailability is only about 40%. The main metabolites of perphenazine are glucuronides and sulphoxides found in the urine. Only two per cent of the absorbed perphenazine is excreted non-metabolised by the urine. Its elimination half-life period is about 20 hours and it is able to pass the placenta, although the concentrations found in the foetus and amnion are low. Perphenazine is also distributed into breast milk where similar concentrations to those reported in the blood can be found (<LINK REF="REF-Bundesverband-2001" TYPE="REFERENCE">Bundesverband 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>In terms of the costs of schizophrenia, this was estimated at about £6.7 billion in England in 2004/05, of which the direct costs were £2 million, while the indirect costs accounted for the rest (<LINK REF="REF-Mangalore-2007" TYPE="REFERENCE">Mangalore 2007</LINK>). The cost of perphenazine itself is expensive compared to other typical antipsychotic drugs, at £34.25 for 100 tablets of 4 mg each. The maximum daily dose of perphenazine is 24 mg per day, which costs £2.1 per day, or £63 per month (<LINK REF="REF-BNF-2012" TYPE="REFERENCE">BNF 2012</LINK>). The newer, atypical antipsychotic drugs in comparison are more expensive than typical antipsychotic drugs, with olanzapine available at £13.11 for 28 5 mg tablets, and clozapine (Clozaril) at £21.56 for 28 100 mg tablets.</P>
<P>It is essential to complement the clinical effectiveness of perphenazine with its cost-effectiveness. <LINK REF="REF-Davies-2007" TYPE="REFERENCE">Davies 2007</LINK> conducted a study on cost-effectiveness of first-generation antipsychotic drugs (i.e. flupentixol, trifluoperazine, chlorpromazine) and the second-generation antipsychotic drugs (i.e. risperidone, olanzapine, amisulpiride). The study findings argue that there is no evidence to suggest that atypical (second-generation) antipsychotic drugs are more cost-effective than typical (first-generation) antipsychotic drugs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-12-11 11:03:51 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the effects of perphenazine for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>We included all relevant randomised controlled trials. We included trials that were described as double-blind, but that did not mention whether the study was randomised, in a sensitivity analysis. If there was no substantive difference within the primary outcomes (see '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>') when these studies were added, then we included them in the final analysis. If there was a substantive difference, we used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia and schizophrenia-like disorders such as schizophreniform disorder, delusional disorder or schizoaffective disorder, diagnosed by any criteria. We also included studies involving people with 'serious/chronic mental illness' or 'psychotic illness'. If possible we excluded people with dementing illnesses, depression and primarily problems associated with substance misuse.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Perphenazine</HEADING>
<P>Any dose and route of administration (however, we excluded the depot formulations perphenazine enanthate and decanoate, because these were the topic of another review, <LINK REF="REF-David-2005" TYPE="REFERENCE">David 2005</LINK>) against one or more of the following:</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Placebo or no treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Other antipsychotic drugs</HEADING>
<P>Any dose or pattern of administration.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>We divided all outcomes into short-term (less than three months), medium-term (three to six months) and long-term follow-up (longer than six months).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-03-05 11:40:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Clinical response (Global or mental state)</HEADING>
<P>1.1 Clinically significant response in global state - as defined by each of the studies<BR/>1.2 Clinically significant response in mental state - as defined by each of the studies</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical response (Global or mental state)</HEADING>
<P>2.1 Clinically significant response in global state - as defined by each of the studies<BR/>2.2 Average score/change in global state<BR/>2.3 Clinically significant response in mental state - as defined by each of the studies<BR/>2.4 Average score/change in mental state<BR/>2.5 Clinically significant response on positive symptoms - as defined by each of the studies<BR/>2.6 Average score/change in positive symptoms<BR/>2.7 Clinically significant response on negative symptoms - as defined by each of the studies<BR/>2.8 Average score/change in negative symptoms</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Behaviour</HEADING>
<P>3.1 Clinically significant response in behaviour (e.g. aggressive behaviour, behaviour on the ward etc) - as defined by each of the studies<BR/>3.2 Average score/change in behaviour</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Adverse events - movement disorders</HEADING>
<P>4.1 Incidence of use of antiparkinson drugs<BR/>4.2 Clinically significant extrapyramidal side effects - as defined by each of the studies<BR/>4.3 Average score/change in extrapyramidal side effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Other adverse effects, general and specific</HEADING>
<P>5.1 Anticholinergic<BR/>5.2 Arousal<BR/>5.3 At least one adverse event<BR/>5.4 Cardiovascular<BR/>5.5 Central nervous system<BR/>5.6 Endocrine<BR/>5.7 Gastrointestinal<BR/>5.8 Genitourinary<BR/>5.9 Haematology<BR/>5.10 Skin<BR/>5.11 Others</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Economic</HEADING>
<P>6.1 Average change in total cost of medical and mental health care<BR/>6.2 Total indirect and direct costs<BR/>6.3 Direct resource use:<BR/>
<I>6.3.1 Outpatients - number of contacts (GP consultation, psychiatrist, psychologists, psychiatric nurse, counsellor, social worker)</I>
<BR/>
<I>6.3.2 Hospitalisation (taking battery of tests, patients&#8217; physical, psychiatric and psychological profile and psychological assessment, number of days, relapse)</I>
<BR/>
<I>6.3.3 Medication (different types of antipsychotic drugs to include dose and frequency, treatment of side effects)</I>
<BR/>
<I>6.3.4 Psychological therapies (different types of psychological therapies to include session numbers and frequency)</I>
<BR/>
<I>6.3.5 Other resources (day centres, night shelter) and transportation for medical care visits</I>
<BR/>6.4 Indirect resource use:<BR/>
<I>6.4.1 Family, relative and friends resources</I>
<BR/>
<I>6.4.2 Police, criminal justice system</I>
<BR/>
<I>6.4.3 Benefits paid, social security payments</I>
<BR/>
<I>6.4.4 Employment agency workers, absence from work, loss of productivity</I>
<BR/>6.5 Cost-effectiveness ratios represented by ICER (incremental cost-effectiveness ratio)<BR/>6.6 Cost-utilities represented by incremental costs per QALY (quality-adjusted life year) or DALYs (disability-adjusted life year)<BR/>6.7 Cost benefit represented by net Benefit Ratio, others.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Service use and hospitalisation</HEADING>
<P>7.1 Hospital admission<BR/>7.2 Medication use<BR/>7.3 Engagement with health services</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Satisfaction</HEADING>
<P>8.1 Satisfaction with treatment<BR/>8.2 Satisfaction with care<BR/>8.3 Quality of life outcomes<BR/>8.4 Employment status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. 'Summary of findings' tables</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and the GRADE profiler (<A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADEPRO</A>) to import data from RevMan 5 (<A HREF="http://www.ims.cochrane.org/revman">Review Manager</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' tables.</P>
<OL>
<LI>Clinical response in global state (as defined by each of the studies)</LI>
<LI>Clinical response in mental state (as defined by each of the studies)</LI>
<LI>Adverse events: death</LI>
<LI>Adverse events: extrapyramidal adverse effects (dystonia; akathisia; Parkinsonism; tardive dyskinesia)</LI>
<LI>Adverse events: serious adverse events (as defined by each of the studies)</LI>
<LI>Economic outcomes</LI>
<LI>Service use and hospitalisation: admission</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-12-11 11:04:20 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-12-11 11:04:20 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, we searched the Cochrane Schizophrenia Group's old MeerKat MS Access database [MK060213] (September 2013) searched by query &#8216;[(Title like &#8216;*Perphenazine*&#8217;) or (Abstract like &#8216;*Perphenazine*&#8217;)] and [Keyword not like &#8216;*Perphenazine*&#8217;].</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-03-12 12:01:53 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>Review authors (SS and BH) inspected the reference lists of all identified studies, including existing reviews, for relevant citations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>Review authors (SS and BH) contacted the first author of each relevant study for information on unpublished trials. We also consulted experts in the area of schizophrenia and weight gain. We contacted authors and experts by email or post to establish missing details in the methods and results sections of the written reports and to determine their knowledge of or involvement in any current work in the area. We also asked contacts at major pharmaceutical companies if they have conducted or were currently undertaking any weight-related interventions in relation to schizophrenia (including representatives from Janssen Pharmaceuticals, Pfizer Inc, Eli Lilly and Company, Astra Zeneca, and Bristol-Myers Squibb). Responses to our letters are noted in notes of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2013 update, SS independently inspected citations from the new electronic search and identified relevant abstracts. SS also inspected full articles of the abstracts meeting inclusion criteria. <LINK REF="REF-CEA" TYPE="REFERENCE">CEA</LINK> carried out the reliability check of all citations from the new electronic search.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-26 14:50:30 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>For this 2013 update, SS extracted data from included studies. We extracted data presented only in graphs and figures whenever possible. When further information was necessary, we contacted authors of studies in order to obtain missing data or for clarification. It was not possible to extract data relevant to each component centre separately of the identified multi-centre studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>)); c) if a scale started from a positive value (such as PANSS which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD &gt; (S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in 'other tables' within the data and analyses section rather than into a statistical analysis. Skewed data pose less of a problem when looking at the mean if the sample size is large; we entered such data from studies with over 200 participants into syntheses. When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not; we entered skewed change data into the analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>Had we identified such data, to facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). However, we did not identify such data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors. Some included studies provided a definition of response as a reduction in PANSS or Clinical Global Impression (CGI) scores, in which case we employed the dichotomous data provided from the primary study report.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for perphenazine.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2013 update, review author SS worked independently by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain additional information.</P>
<P>We have noted the level of risk of bias in both the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-02-21 15:58:31 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The Number Needed to Treat/Harm (NNT/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' table/s, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. </P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>We did not identify any cluster-randomised studies. In future versions of this review, we remain aware that studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering is not accounted for in primary studies, we will present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but will adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported, it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies will be possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we planned only to use data of the first phase of cross-over studies. However, we did not identify any cross-over studies in our search.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two-by-two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <I>Handbook </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms were not relevant, we did not reproduce these data. Five studies had multiple treatment arms, each of which were relevant to this review and subsequently presented in relevant comparisons (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>); four studies involved treatment arms that were not relevant to this review (mainly anti-depressants) and therefore those particular treatment arms were excluded (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>; <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). One study had multiple treatment arms that were relevant, as well as treatment arms that were not (including phenobarbital); relevant treatment arms were included in the relevant comparisons (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. Had we identified such levels of attrition where more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have addressed this within the 'Summary of findings' table/s by down-rating quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stayed in the study - in that particular arm of the trial - were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were compared to the intention-to-treat analysis using the above assumptions (see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome was between 0% and 50% and completer-only data were reported, we reproduced these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>We did not impute standard deviations (SD) in any included study. In future versions of this review where we may identify such data, if SDs are not reported, we will first try to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or T value available for differences in mean, we can calculate them according to the rules described in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we would calculate the SDs according to a validated imputation method based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless will examine the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we have reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2 </SUP>statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-02-21 16:58:43 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots are possible, we sought statistical advice in their interpretation. We used a funnel plot for our primary outcome in the comparison of perphenazine versus any antipsychotic (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the random-effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses - only primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Clinical state, stage or problem</HEADING>
<P>We proposed to undertake this review and provide an overview of the effects of perphenazine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. In particular, we included data for people in acute phase of schizophrenia.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, then we did not pool data and discussed issues. We know of no supporting research for this 10% cut-off, but we use prediction intervals as an alternative to this unsatisfactory state.</P>
<P>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>We applied all sensitivity analyses to the primary outcomes of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up and missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings on primary outcomes when we used our assumption compared with complete data only. We undertook a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We planned to undertake a sensitivity analysis to assess the effects of including data from trials if we used imputed values for ICC in calculating the design effect in cluster-randomised trials.</P>
<P>Had we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed-effect and random-effects</HEADING>
<P>We synthesised data using a random-effects model, however synthesised data for primary outcomes using a fixed-effect model to investigate whether this altered the estimate of the effect.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-05 15:09:16 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-27 10:10:37 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>In the 2013 update search, we identified 618 records and screened 615 after duplicates were removed (See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for original results of search). Of these 334 records were excluded based on title and abstract, with the remaining 187 full-text references assessed for eligibility by inspecting their full citations. A total of 108 studies were excluded with reasons, with 14 awaiting classification for either inclusion or exclusion. This current review includes a total of 31 studies in meta-analyses (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). One study that was awaiting assessment from the previous version of this review has now been included since the update study search identified newer references with published results (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). Three more studies that were previously awaiting assessment have now been excluded: <LINK REF="STD-Akimoto-1966" TYPE="STUDY">Akimoto 1966</LINK> because there was no control group; <LINK REF="STD-Eklund-1976" TYPE="STUDY">Eklund 1976</LINK> because the study was judged to not be adequately randomised, and <LINK REF="STD-Galdi-1988" TYPE="STUDY">Galdi 1988</LINK> because it was found that perphenazine was not used as a study drug, nor were all the included participants diagnosed with schizophrenia. Conversely, two studies that were previously included have now been excluded: <LINK REF="STD-Nahunek-1967" TYPE="STUDY">Nahunek 1967</LINK> because it was described as an 'open cross-over' study, with no description of randomisation; and <LINK REF="STD-Whittaker-1963" TYPE="STUDY">Whittaker 1963</LINK> because participants were 'arbitrarily allocated', which was judged to not amount to adequate randomisation.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-27 10:10:37 +0000" MODIFIED_BY="[Empty name]">
<P>Thirty-one studies fulfilled the inclusion criteria, with a total of n = 4662 (of which n = 4522 were receiving the drugs relevant to our comparison) and presented data that could be used for at least one comparison. The trial centres were located in Europe (especially Scandinavia), Japan and Northern America.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of trials</HEADING>
<P>The duration of included trials covered a range from 10 days to 18 months, with the most common being 12 weeks (mean 11 weeks). We classified 28 of the studies as 'short term' and only one study (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>) fell into the 'medium-term' category. The longest study was 18 months and classified as 'long term' for this systematic review (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). One study did not specify its length (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Design</HEADING>
<P>All trials used a parallel-group design. Only seven of the included studies adequately described randomisation methods (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>; <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>; <LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>Only 11 studies described the diagnostic criteria used: <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK> used the Diagnostic and Statistical Manual of Mental disorders, Third edition, Revised (DSM-III-R), and four studies (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>) used the Diagnostic and Statistical Manual, Fourth Edition (DSM-IV). <LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK> used the International Classification of Diseases, ninth revision (ICD-9) criteria; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK> used Research Diagnostic Criteria (RDC) criteria and four Chinese studies used Chinese Classification of Mental Disorders (CCMD) criteria, including CCMD-2-R (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>) and CCMD-3 (<LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>; <LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). The remaining studies probably used clinical criteria to diagnose study participants. In <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>, there was a special inclusion criterion that the participants had to be "anergic and withdrawn" people with schizophrenia. Only four studies also included some participants who did not suffer from schizophrenia: <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK> included people with acute schizophreniform psychotic episodes, acute exacerbation of a chronic schizophrenic process and psychogenic psychoses. Among the 115 participants in <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>, 99 had a diagnosis of schizophrenia, the other diagnoses were not specified. <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK> included 52 participants with a neurotic or a personality disorder and 270 with schizophrenia. <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK> described the included participants as having "predominantly" schizophrenia. These four studies were included because the majority of randomised participants had schizophrenia. Seven studies included participants with acute schizophrenia, and were included in an acute subgroup in meta-analysis (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>; <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>; <LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>).</P>
<P>In the studies that gave information on the sex of participants, there were 2442 males and 1345 females. Among the studies in which the participants' age was indicated, these ages ranged from 13 to 70 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Setting</HEADING>
<P>Seventeen studies were multi-centre, with the remaining studies single-centre. Most of the included studies were undertaken in Japan, followed by North America, UK, Germany, Denmark and Findland.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Study size</HEADING>
<P>Twenty-eight per cent of the studies included more than 100 people. The number of people in the included studies ranged from 28 (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>) to 1493 (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). Only around 10% of the studies had 40 or less participants, with a mean sample size of around 150. A total of 4662 people participated in the 31 trials, 4551 of whom had been randomised to interventions that were relevant for the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 perphenazine</HEADING>
<P>A total of 1457 people were given perphenazine in the included studies. Doses varied from a minimum of 2 to 4 mg (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>) to a maximum of 90 mg/day (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). The mode of administration and dose in <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK> is unclear. Six studies used a fixed dose (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>; <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>; <LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>), whilst the remaining studies used a flexible dose, most often according to the judgement of each physician in each individual study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Control interventions</HEADING>
<TABLE COLS="4" ROWS="32">
<TR>
<TH>
<P>Control Intervention</P>
</TH>
<TH>
<P>Average dose (control)</P>
</TH>
<TH>
<P>Studies</P>
</TH>
<TH>
<P>Average dose (perphenazine)</P>
</TH>
</TR>
<TR>
<TD>
<P>vs Placebo</P>
</TD>
<TD>
<P>to match study drug</P>
</TD>
<TD>
<P>
<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977;</LINK> <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967;</LINK> <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>
</P>
</TD>
<TD>
<P>mean 13 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Aripiprazole</P>
</TD>
<TD>
<P>mean 26.8 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>
</P>
</TD>
<TD>
<P>mean 25.15 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Benperidol</P>
</TD>
<TD>
<P>range 6 or 12 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>
</P>
</TD>
<TD>
<P>range 12 or 24 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Bromperidol</P>
</TD>
<TD>
<P>mean 6 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>
</P>
</TD>
<TD>
<P>mean 20 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Chlorpromazine</P>
</TD>
<TD>
<P>mean 487.63 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>
</P>
</TD>
<TD>
<P>mean 40.91 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Clocapramine</P>
</TD>
<TD>
<P>range 75 to 150 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>
</P>
</TD>
<TD>
<P>range 9 to 18 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Clopenthixol</P>
</TD>
<TD>
<P>range 25 to 250 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>
</P>
</TD>
<TD>
<P>range 8 to 80 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Clothiapine</P>
</TD>
<TD>
<P>range 12 mg/day increased to 24 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>
</P>
</TD>
<TD>
<P>range 45 mg/day increased to 90 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Clozapine</P>
</TD>
<TD>
<P>range 0 to 600 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>
</P>
</TD>
<TD>
<P>range 0 to 60 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Clozapine + perphenazine</P>
</TD>
<TD>
<P>range 32 to 50 mg + 100 to 300 mg/mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>
</P>
</TD>
<TD>
<P>range 8 to 60 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Fluphenazine</P>
</TD>
<TD>
<P>mean 5.92 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>
</P>
</TD>
<TD>
<P>mean 38.61 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Haloperdiol</P>
</TD>
<TD>
<P>range 3 to 6 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>
</P>
</TD>
<TD>
<P>range 9 to 18 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Loxapine</P>
</TD>
<TD>
<P>range 20 mg/day to max 150 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>
</P>
</TD>
<TD>
<P>range 16 mg/day to max 120 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Mepazine</P>
</TD>
<TD>
<P>mean 151 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>
</P>
</TD>
<TD>
<P>mean 42 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Methyperidol</P>
</TD>
<TD>
<P>range 15 mg to 30 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>
</P>
</TD>
<TD>
<P>range 9 mg/day to 18 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Olanzapine</P>
</TD>
<TD>
<P>mean 16.5 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>
</P>
</TD>
<TD>
<P>mean 24.9 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Penfluridol</P>
</TD>
<TD>
<P>2 mg/day the flexible up to max 100 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>
</P>
</TD>
<TD>
<P>12 mg/day then flexible dose age up to max 60 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Prochlorperazine</P>
</TD>
<TD>
<P>mean 59.9 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>
</P>
</TD>
<TD>
<P>mean 40.91 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Quetiapine</P>
</TD>
<TD>
<P>mean 401.16 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>
</P>
</TD>
<TD>
<P>mean 22.65 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Promazine</P>
</TD>
<TD>
<P>mean 438.92 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>
</P>
</TD>
<TD>
<P>mean 30.83 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Risperidone</P>
</TD>
<TD>
<P>mean 5.3 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>
</P>
</TD>
<TD>
<P>mean 25.4 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Sulpiride</P>
</TD>
<TD>
<P>mean 900 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>
</P>
</TD>
<TD>
<P>mean 20.5 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Thioproprazate</P>
</TD>
<TD>
<P>mean 20.83 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>
</P>
</TD>
<TD>
<P>mean 38.61 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Thioridazine</P>
</TD>
<TD>
<P>mean 193.46 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>
</P>
</TD>
<TD>
<P>mean 38.61 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Thiothixene</P>
</TD>
<TD>
<P>no details</P>
</TD>
<TD>
<P>
<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>
</P>
</TD>
<TD>
<P>no details</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Timiperone</P>
</TD>
<TD>
<P>range 2 mg/day up to max of 12 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>
</P>
</TD>
<TD>
<P>range 8 mg/day up to max of 48 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Trifluoperazine</P>
</TD>
<TD>
<P>mean 11.49 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>
</P>
</TD>
<TD>
<P>mean 38.61 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Trifluopromazine</P>
</TD>
<TD>
<P>mean 124.13 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>
</P>
</TD>
<TD>
<P>mean 40.9 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Ziprasidone</P>
</TD>
<TD>
<P>mean 112.8 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>
</P>
</TD>
<TD>
<P>mean 20.8 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Zotepine</P>
</TD>
<TD>
<P>range 75 mg/day to max 150 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Imai-1980" TYPE="STUDY">Imai 1980</LINK>
</P>
</TD>
<TD>
<P>range 12 mg/day to max 24 mg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>vs Zuclopenthixol</P>
</TD>
<TD>
<P>mean 37 mg/day</P>
</TD>
<TD>
<P>
<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>
</P>
</TD>
<TD>
<P>mean 30 mg/day</P>
</TD>
</TR>
</TABLE>
<P>The number of comparators is greater than the total number of included studies because several studies used more than one comparison group (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>; <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1 General remarks</HEADING>
<P>There was a relatively high degree of inconsistency in terms of the outcome measures used in the included trials. In addition, many trials presented results in graphical form, which made it difficult to extract data. The use of continuous data were often not possible because standard deviations were not indicated, and in other cases because the data seemed to be skewed. For skewed data, results are shown in the 'other data tables'. The outcomes that could be used most frequently were 'global clinical state', 'leaving the study early' and 'adverse events' (movement disorders and others).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.2 Acceptability and efficacy</HEADING>
<P>We could extract the number of people 'leaving the studies early', which can be used as a measure of acceptability of treatment, from 28 studies; data were not available for <LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>. The number of people who showed no improvement or deteriorated according to the Clinical Global Impression (CGI) was given in 17 studies. The Brief Psychiatric Rating Scale (BPRS) is one of the most widely used rating scales to monitor the general mental state of those with schizophrenia, but only <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK> provided usable data. <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK> were the only studies that used the Positive and Negative Symptom Scale (PANSS) to evaluate symptoms. Behavioural changes were assessed in the three studies by Itoh (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>; <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>; <LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>) using the 'Behaviour Scale', a Japanese scale about which we were not able to obtain further information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.3 Adverse events</HEADING>
<P>The number of participants with at least one adverse event could be extracted from many trials. Extrapyramidal adverse events (EPS) were most intensively monitored in the studies. An outcome related to EPS - the number of participants who needed antiparkinsonian medication at least once - was also frequently recorded. The occurrence of adverse events other than EPS was much less consistently indicated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4 Outcome scales</HEADING>
<P>Details of scales that provided usable data are shown below. Reasons for the exclusion of data from other instruments are given under 'Outcomes' in the 'Included studies' section.</P>
<SUBSECTION>
<HEADING LEVEL="6">7.4.1 Global state</HEADING>
<P>
<I>i. Clinical Global Impression - CGI</I> (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is a rating instrument that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. Only one included study provided continuous data using this scale (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.4.2 Mental state</HEADING>
<P>
<I>i. Brief Psychiatric Rating Scale - BPRS</I> (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This scale is used to assess the severity of abnormal mental states. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0 - 6 or 1 - 7. Scores can range from 0 - 108 or 18 - 126, respectively. High scores indicate more severe symptoms. The BPRS-positive cluster comprises four items, which are conceptual disorganisation, suspiciousness, hallucinatory behaviour and unusual thought content. The BPRS-negative cluster comprises only three items, which are emotional withdrawal, motor retardation, and blunted affect. Four included studies provided dichotomised data using this scale (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>); only one study provided continuous data using this scale (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>); while two studies provided skew data (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>).</P>
<P>
<I>ii. Positive and Negative Symptom Scale - PANSS</I> (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>The positive and negative syndrome scale was originated as a method for evaluating positive, negative and other symptom dimensions in schizophrenia. The scale has 30 items, and each item can be rated on a seven-point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P) and negative symptoms (PANSS-N). A low score indicates low levels of symptoms. Three included studies reported dichotomised data using this scale (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>); three studies reported continuous data using this scale (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>); and two studies reported skew data using this scale (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.4.3. Behaviour</HEADING>
<P>
<I>i. Wing-Scale B </I>(<LINK REF="REF-Wing-1961" TYPE="REFERENCE">Wing 1961</LINK>)</P>
<P>This is a 12-item rating scale, measuring such behaviours as 'slowness of movement', 'underactivity', 'conversation', 'laughing and talking to self', 'threatening violent behaviour', and others including 'personal hygiene'. The items are rated 0 to 2, (0 = no particular behaviour present, and 2 = extreme behaviour present). Only one study provided data using this scale (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.4.4 Adverse events</HEADING>
<P>
<I>i. TESS</I> (<LINK REF="REF-ICH-E3-1995" TYPE="REFERENCE">ICH E3 1995</LINK>)</P>
<P>The <LINK REF="REF-ICH-E3-1995" TYPE="REFERENCE">ICH E3 1995</LINK> guideline has stated that 'treatment-emergent signs and symptoms' (TESS) are to be defined as "events not seen at baseline and events that worsened even if present at baseline". It can be difficult to document this accurately taking into account variables in time, dosage, adverse events and severity. Generally, TESS scores for particular adverse events are categorised as 'mild', 'moderate', or 'severe', with an appropriate action taken (e.g. none; discontinued; dose changed' hospitalisation; additional medication given. It is not often that studies publish continuous data from these measurements, with the more common presentation of dichotomised TESS ratings. Only one study provided continuous data using this rating (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.5 Missing outcomes</HEADING>
<P>Many important outcomes such as economic costs, issues of hospital admission, death and satisfaction with care were not addressed in the included studies.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>In this updated review, we excluded a total of 19 studies in addition to those already excluded from the previous review, totaling 108 excluded studies. Several of these studies were not randomised (<LINK REF="STD-Affleck-1969" TYPE="STUDY">Affleck 1969</LINK>; <LINK REF="STD-Eklund-1976" TYPE="STUDY">Eklund 1976</LINK>; <LINK REF="STD-Opjordsmoen-2000" TYPE="STUDY">Opjordsmoen 2000</LINK>; <LINK REF="STD-Sharpley-1964" TYPE="STUDY">Sharpley 1964</LINK>). Other studies were excluded because they did not compare appropriate interventions (perphenazine enanthate or decanoate; perphenazine in combination with other drugs; perphenazine versus perphenazine; perphenazine versus unlicensed neuroleptics). Eight studies did not use a placebo or neuroleptic comparator group. Sixteen studies were randomised controlled trials, but we had to exclude them because outcome data were no longer available. With the exception of <LINK REF="STD-Levine-1997" TYPE="STUDY">Levine 1997</LINK>, all of the latter studies were undertaken by the research group under Professor Svestka (Brno, Czech Republic) who kindly informed us that the data are no longer available. Other exclusions included comparisons of perphenazine combined with psychological therapy versus perphenazine alone (<LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>), and perphenazine versus 1-stepholidine (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>; <LINK REF="STD-Zhong-2001" TYPE="STUDY">Zhong 2001</LINK>), both are topics which would be interesting and appropriate in another review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>We have obtained 14 publications but cannot use them without further information from authors and have written letters to the primary authors requesting more information. Answers from these authors are still due but have become unlikely. We hope that someone may provide us with the missing information in the future, and therefore, we have retained these studies in the category 'awaiting assessment'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified no ongoing studies.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>For a graphical overview, see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>Although all trials were described as 'randomised', only seven publications presented adequate information about sequence generation (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>; <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>; <LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). All other 24 included studies were rated as 'unclear', because it was unknown exactly how the randomisation had been undertaken.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-02-18 10:41:11 +0000" MODIFIED_BY="[Empty name]">
<P>All studies apart from one (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>) were stated to have been conducted in a double-blind fashion. How blindness was assured in this one study is unclear, with possible single-blinding implied, and therefore rated as a 'high' risk of bias. Ten studies were rated as a 'low' risk of bias for providing adequate information as to blinding with most studies using capsules identical in appearance to assist in maintaining blindness (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>; <LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>; <LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>; <LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>), with the remaining studies rated as 'unclear. </P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>Nine studies were rated as a 'high' risk of bias for failing to describe participants who may have discontinued or left the studies early (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>; <LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). These studies either had a high attrition rate (of more than 50%), or did not adequately explain which data were included in the final data analysis. Six studies were rated as a 'low' risk of bias, for either having no losses (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>), or for clearly explaining all participants who discontinued early and including them in full analysis on either ITT or LOCF (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>; <LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>). All of the remaining studies were rated as an 'unclear' risk for inadequate explanation.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-26 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>Ten studies were rated as a 'high' risk for reporting bias (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>; <LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>; <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>; <LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>; <LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>), mainly due to stated outcomes either not being reported at all in results, or data rendered unusable - specifically continuous data, which in some studies were not reported in their entirety (i.e. including mean, standard deviation, reported by group). Five studies were rated as a 'low' risk (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>; <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). All remaining studies were rated as an 'unclear' risk for inadequate information provided in the study reports. We constructed a funnel plot for our primary outcome of global state: change over time - no better or deterioration (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), which demonstrates asymmetry - publication bias (selective reporting or analysis reporting) is one possible explanation, however poor methodological design is another factor to consider.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-02-18 11:11:38 +0000" MODIFIED_BY="[Empty name]">
<P>The vast majority of studies were rated as 'unclear' for other potential sources of bias, as these can be difficult to detect - particularly because the reporting standards of included studies were generally quite low due to the age of included studies (ranging from the years 1961 to 2005). We rated four studies as a 'high' risk on this domain (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>), largely due to pharmaceutical industry support in each of these studies, as well as potential protocol deviation detected (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-03-05 15:09:16 +0000" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes we calulated risk ratios (RR) and for continuous outcomes we calculated mean differences (MD), both with the associated 95% confidence intervals (CI).</P>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 1: PERPHENAZINE versus PLACEBO</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 203). There was no significant difference between perphenazine and placebo (RR 0.26 CI 0.01 to 4.92, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 25.5; df = 2; P &lt; 0.00001; I<SUP>2</SUP> = 92%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 0.40 CI 0.08 to 1.90, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 61) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was a statistically significant difference (P = 0.05) favouring placebo over perphenazine (RR 16.47 CI 0.99 to 273.29, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 5.00 CI 0.25 to 99.82, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Overall, there was a statistically significant difference (P = 0.03) favouring placebo in the short and medium term (2 RCTS, n = 119, RR 9.43 CI 1.22 to 73.11).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 84). There was a statistically significant difference (P = 0.001) favouring perphenazine over placebo (RR 0.10 CI 0.03 to 0.42, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 61) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was a statistically significant (P = 0.01) difference favouring perphenazine over placebo (RR 0.32 CI 0.13 to 0.78, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Mental state: 1. Relapse (clinical diagnosis)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.14 CI 0.02 to 1.07, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Behaviour: 1a. Wing-Scale B: social withdrawal - mean change from baseline to endpoint</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.6.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>). There was no significant difference between perphenazine and placebo (MD 0.76 CI -0.51 to 2.03, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Behaviour: 1b. Wing-Scale B: socially embarrassing behaviour - mean change from baseline to endpoint</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>). There was no significant difference between perphenazine and placebo (MD 0.10 CI -0.54 to 0.74, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.8.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo, with no events reported in either group (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.2 body rocking - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 3.00 CI 0.13 to 70.16, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.3 dystonia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.00 CI 0.07 to 15.08, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.4 extrapyramidal signs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.75 CI 0.59 to 5.21, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.5 facial mask - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 5.00 CI 0.25 to 98.96, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.6 oculogyric crisis - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 3.00 CI 0.13 to 70.16, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.7 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>). There was no significant difference between perphenazine and placebo (RR 7.00 CI 0.38 to 129.74, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.8 posture and gait - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 5.00 CI 0.25 to 98.96, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.9 rigidity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.33 CI 0.33 to 5.33, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.10 tremor - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.50 CI 0.27 to 8.19, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.11 tremor - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 1.00 CI 0.15 to 6.63, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.12 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 36) (<LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>). There was no significant difference between perphenazine and placebo (RR 3.00 CI 0.13 to 69.09, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.9.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo, with no events reported in either group (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.00 CI 0.07 to 15.08, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.3 dry mouth - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 1.50 CI 0.27 to 8.32, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.4 nasal congestion - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 3.00 CI 0.13 to 70.16, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.10 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.10.1 agitation - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 0.80 CI 0.24 to 2.68, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.2 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.17 CI 0.02 to 1.28, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.3 drowsiness - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 0.33 CI 0.01 to 7.86, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.4 excitement - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was a statistically significant difference (P = 0.01) favouring perphenazine over placebo (RR 0.38 CI 0.18 to 0.79, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.5 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.56 CI 0.31 to 1.01, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.6 insomnia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo, with no events reported in either group (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.11 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.11.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 94). There was no significant difference between perphenazine and placebo (RR 1.50 CI 0.47 to 4.76, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.12 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.12.1 ECG abnormalities - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 36) (<LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>). There was no significant difference between perphenazine and placebo (RR 2.00 CI 0.42 to 9.58, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.12.2 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.00 CI 0.15 to 6.53, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.12.3 faintness, dizziness, weakness - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 1.00 CI 0.22 to 4.55, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.12.4 hypotension - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 5.00 CI 0.25 to 99.82, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.12.5 tachycardia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.33 CI 0.01 to 7.80, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.13 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.13.1 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.75 CI 0.19 to 3.00, <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.14 Other adverse events: 6. Endocrine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.14.1 lactation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo, with no events reported in either group (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.15 Other adverse events: 7. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.15.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.80 CI 0.24 to 2.62, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.15.2 diarrhoea - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.33 CI 0.01 to 7.80, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.15.3 nausea or vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.60 CI 0.16 to 2.23, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.15.4 nausea or vomiting - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 5.00 CI 0.25 to 99.82, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.16 Other adverse events: 8. Haematology - abnormal laboratory results</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.16.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 1.50 CI 0.48 to 4.65, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.17 Other adverse events: 9. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.17.1 dermatitis - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 0.33 CI 0.01 to 7.80, <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.17.2 oedema - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 0.33 CI 0.01 to 7.86, <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.18 Other adverse events: 10. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.18.1 salivation increased - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 48) (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>). There was no significant difference between perphenazine and placebo (RR 2.00 CI 0.19 to 20.61, <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.18.2 tenseness - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Hanlon-1964" TYPE="STUDY">Hanlon 1964</LINK>). There was no significant difference between perphenazine and placebo (RR 0.50 CI 0.05 to 5.21, <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 2: PERPHENAZINE versus ANY ANTIPSYCHOTIC</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 short term</HEADING>
<P>In this subgroup we found 21 relevant trials (n = 2500). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.09 CI 0.83 to 1.42, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 34.32; df = 17; P = 0.008; I<SUP>2</SUP> = 50%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.92 CI 0.86 to 4.25, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.3 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 1520). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.01 CI 0.94 to 1.09, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Across all short, medium and long term, there was no significant difference between perphenazine and any other antipsychotic drugs (24 RCTs, n = 4067, RR 1.10 CI 0.92 to 1.31).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 short term</HEADING>
<P>In this subgroup we found nine relevant trials (n = 1661). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.13 CI 0.70 to 1.83, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 12.82; df = 8; P = 0.12; I<SUP>2</SUP> = 38%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.88 CI 0.12 to 67.29, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 1506). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.07 CI 0.79 to 1.47, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Across all short, medium and long term, there was no significant difference between perphenazine and any other antipsychotic drugs (12 RCTs, n = 3214, RR 1.11 CI 0.82 to 1.52).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 979). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.26 CI 0.78 to 2.03, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.15 CI 0.41 to 3.25, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.3 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 1506). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.07 CI 0.85 to 1.34, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>Across all short, medium and long term, there was no significant difference between perphenazine and any other antipsychotic drugs (10 RCTs, n = 2532, RR 1.10 CI 0.90 to 1.35).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1 short term</HEADING>
<P>In this subgroup we found 16 relevant trials (n = 1803). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.03 CI 0.9 to 1.17, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 22.17; df = 15; P = 0.10; I<SUP>2</SUP> = 32%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.20 CI 0.73 to 1.97, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>Across both short and medium term, there was no significant difference between perphenazine and any other antipsychotic drugs (17 RCTs, n = 1850 RR 1.04 CI 0.92 to 1.17).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Global state: 2. Average endpoint score (CGI-S)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 294) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (MD -0.20 CI -0.56 to 0.16, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Mental state: 2a. State - BPRS score reduction ('no effect')</HEADING>
<P>For mental state outcome of 'no effect' of the study drug (BPRS score) reduction, there was again no significant difference between groups (4 RCTs, n = 383, RR 1.24 CI 0.61 to 2.52, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1 less than 20% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.81 CI 0.61 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2 less than 25% reduction - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 129). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.38 CI 0.46 to 4.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.3 less than 30% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.44 CI 0.86 to 13.79).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Mental state: 2b. State - BPRS total score (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (MD 1.10 CI -1.26 to 3.46, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Mental state: 2c. State - BPRS end score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.8.1 medium term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Mental state: 2c. State - BPRS end score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.9.1 long term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.10 Mental state: 2d. State - PANSS score reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.10.1 less than 20% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.86 CI 0.64 to 1.15, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.10.2 less than 25% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.00 CI 0.40 to 10.11, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.10.3 less than 40% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.70 CI 0.30 to 9.50, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.11 Mental state: 2e. State - PANSS: mean change/endpoint from baseline (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.11.1 total - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 232). There was a statistically significant difference (P &lt; 0.0001) favouring any antipsychotic drugs over perphenazine (MD 3.65 CI 1.86 to 5.43, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.11.2 positive - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 125). There was no significant difference between perphenazine and any antipsychotic drugs (MD 4.45 CI -3.00 to 11.90, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). This subgroup had important high levels of heterogeneity (Chi<SUP>2</SUP> = 74.07; df = 1; P = 0.0; I<SUP>2</SUP> = 99%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.11.3 negative - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 125). There was a statistically significant difference (P = 0.04) favouring any antipsychotic drugs over perphenazine (MD 1.20 CI 0.07 to 2.33, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 1.47; df = 1; P = 0.225; I<SUP>2</SUP> = 32%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.11.4 general psychopathology - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over any antipsychotic drugs (MD -0.39 CI -0.79 to 0.01, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.12 Mental state: 2f. State - PANSS total change score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.12.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.13 Mental state: 2g. State - PANSS total endpoint score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.13.1 long term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.14 Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</HEADING>
<P>For this outcome we found three relevant trials (n = 244). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.03 CI 0.86 to 1.23, <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.15 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.15.1 akathisia - short term</HEADING>
<P>In this subgroup we found 11 relevant trials (n = 1736). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.12 CI 0.79 to 1.58, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 21.74; df = 10; P = 0.016; I<SUP>2</SUP> = 54%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.2 akathisia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.88 CI 0.64 to 12.82, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.3 akathisia - long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 1346). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.10 CI 0.65 to 1.85, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.4 akinesia - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 475). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.44 CI 0.11 to 1.70, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.5 ataxia - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 514). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.77 CI 0.25 to 2.41, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.6 dyskinesia - short term</HEADING>
<P>In this subgroup we found eight relevant trials (n = 1282). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.63 CI 0.39 to 1.04, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.7 dyskinesia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.48 CI 0.05 to 4.93, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.8 dystonia - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 416). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.36 CI 0.23 to 8.16, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 6.48; df = 3; P = 0.09; I<SUP>2 </SUP>= 54%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.9 extrapyramidal signs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.90 CI 0.62 to 1.31, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.10 EPS - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 429). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.23 CI 0.88 to 5.67, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.11 EPS - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1281) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.58 to 1.73, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.12 hyperkinesia - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 135). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.64 CI 0.88 to 7.91, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.13 myotony - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.06 CI 0.92 to 4.62, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.14 parkinsonism - short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 1254). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.10 CI 0.89 to 1.35, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.15 rigidity - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 210). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.81 CI 0.38 to 8.64, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 9.17; df = 3; P = 0.027; I<SUP>2</SUP> = 67%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.16 rigidity - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.64 CI 0.12 to 3.48, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.17 tardive dyskinesia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1073) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.23 CI 0.89 to 1.70, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.18 tremor - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 329). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.79 CI 0.73 to 4.39, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 9.85; df = 3; P = 0.02; I<SUP>2</SUP> = 70%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.19 tremor - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.34 CI 0.50 to 3.63, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.20 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we found eight relevant trials (n = 996). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.04 CI 0.83 to 1.30, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 14.59; df = 7; P = 0.042; I<SUP>2 </SUP>= 52%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.21 use of antiparkinsonian drugs - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.15.22 use of antiparkinsonian drugs - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 46) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.34 to 26.76, <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.16 Adverse events: Movement disorders - TESS total score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.16.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.17 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.17.1 blurred vision - short term</HEADING>
<P>In this subgroup we found eight relevant trials (n = 1028). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.80 CI 0.40 to 1.61, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 10.85; df = 7; P = 0.145; I2 = 35%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.17.2 dry mouth - short term</HEADING>
<P>In this subgroup we found nine relevant trials (n = 1017). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.43 CI 0.82 to 2.47, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>). This subgroup had moderate levels of heterogeneity (Chi2 = 13.64; df = 8; P = 0.092; I<SUP>2</SUP> = 41%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.17.3 dry mouth - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.92 CI 0.19 to 19.73, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.17.4 increased salivation - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 211). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.42 CI 0.00 to 35.79, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2 </SUP>= 7.33; df = 1; P = 0.007; I<SUP>2</SUP> = 86%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.17.5 increased salivation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.17.6 nasal congestion - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 71.51, <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.18 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.18.1 agitation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.05 CI 0.63 to 1.77, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.2 agitation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.33 to 27.23, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.3 anxiety - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.19 CI 0.63 to 2.24, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.4 anxiety - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.25 CI 0.37 to 4.21, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.5 depression - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.34 CI 0.76 to 2.35, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.6 drowsiness - short term</HEADING>
<P>In this subgroup we found five relevant trials (n = 442). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.88 CI 0.53 to 1.44, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.7 emotional indifference - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.06 CI 0.58 to 1.94, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.8 excitation - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 463). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.59 CI 0.57 to 11.84, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 20.68; df = 3; P = 0.0; I<SUP>2</SUP> = 85%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.9 excitation - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.28 CI 0.32 to 5.10, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.10 increased dream activity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.51 CI 0.62 to 3.67, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.11 insomnia - short term</HEADING>
<P>In this subgroup we found 11 relevant trials (n = 1422). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.01 CI 0.86 to 1.18, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.12 insomnia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.24 CI 0.03 to 1.99, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.13 insomnia - long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 1520). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.15 CI 0.41 to 11.29, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 2.95; df = 1; P = 0.086; I<SUP>2</SUP> = 66%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.14 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we found five relevant trials (n = 448). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.93 CI 0.74 to 1.16, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.15 need of additional benzodiazepines - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.60 CI 0.43 to 5.93, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.16 need of additional benzodiazepines - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 46) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.91 CI 0.76 to 1.09, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.17 restlessness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P &lt; 0.0001) favouring any antipsychotic drugs over perphenazine (RR 3.75 CI 1.96 to 7.18, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.18 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 991). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.19 CI 0.87 to 1.62, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.19 sleepiness/sedation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.98 CI 0.79 to 1.21, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.20 somnolence - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over any antipsychotic drugs (RR 0.36 CI 0.13 to 0.98, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.18.21 tension - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.97 CI 0.63 to 1.50, <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.19 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.19.1 short term</HEADING>
<P>In this subgroup we found nine relevant trials (n = 974). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.02 CI 0.95 to 1.09, <LINK REF="CMP-002.19" TYPE="ANALYSIS">Analysis 2.19</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.20 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.20.1 angina pectoris - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 391). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.57 CI 0.26 to 1.26, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.2 bradycardia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.3 dizziness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.91 CI 0.59 to 1.40, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.4 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 930). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.27 CI 0.82 to 1.96, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.5 faintness, dizziness, weakness - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.02 CI 0.70 to 1.50, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.6 orthostatic hypotension - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.17 CI 0.02 to 1.31, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.7 hypotension - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.8 lassitude - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 305). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.68 to 1.45, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.9 palpitations - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 391). There was a statistically significant difference (P = 0.01) favouring perphenazine over any antipsychotic drugs (RR 0.22 CI 0.07 to 0.73, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.20.10 tachycardia - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 413). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.54 CI 0.21 to 1.39, <LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 8.03; df = 3; P = 0.045; I<SUP>2</SUP> = 63%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.21 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.21.1 confusion - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.67 CI 0.11 to 3.90, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.2 difficulty in concentration - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.06 CI 0.71 to 1.58, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.3 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we found four relevant trials (n = 648). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.84 CI 0.10 to 6.78, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.4 dysarticulation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.83 CI 0.38 to 1.84, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.5 electroencephalogram (increase) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 25) (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.57 CI 0.09 to 3.64, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.6 headache - short term</HEADING>
<P>In this subgroup we found nine relevant trials (n = 1304). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.72 CI 0.50 to 1.03, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.7 headache - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.71 CI 0.25 to 2.00, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.8 hypertonia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.9 paraesthesia - short term</HEADING>
<P>In this subgroup we found six relevant trials (n = 726). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.37 CI 0.57 to 3.26, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.10 seizure - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs, with no events reported in either group (<LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.21.11 vertigo - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 364). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.87 CI 0.44 to 1.74, <LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.22 Other adverse events: 6. Endocrine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.22.1 amenorrhoea (women only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 30) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 68.26, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.22.2 amenorrhoea - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.32 CI 0.04 to 2.85, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.22.3 gynaecomastia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.22.4 lactation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.21 CI 0.01 to 4.30, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.22.5 lactation - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.19 CI 0.01 to 3.80, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.22.6 menorrhagia (women only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 30) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 68.26, <LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.23 Other adverse events: 7. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.23.1 constipation - short term</HEADING>
<P>In this subgroup we found nine relevant trials (n = 1017). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.71 CI 0.40 to 1.28, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 18.83; df = 8; P = 0.016; I<SUP>2</SUP> = 58%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.2 diarrhoea - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.3 diarrhoea - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.22 to 4.56, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.4 dyspepsia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.59 CI 0.27 to 1.30, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.5 gastroenteritis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.6 icterus - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 450). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.96, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.7 loss of appetite - short term</HEADING>
<P>In this subgroup we found six relevant trials (n = 699). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.96 CI 0.69 to 1.33, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.8 nausea and vomiting - short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 806). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.12 CI 0.75 to 1.67, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.9 nausea and vomiting - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.32 CI 0.04 to 2.85, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.10 nausea and vomiting - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.07 to 15.26, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.11 weight loss - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 171). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.03 CI 0.75 to 12.20, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.12 weight gain - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 235). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.53 CI 0.29 to 8.10, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 6.33; df = 2; P = 0.042; I<SUP>2</SUP> = 68%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.23.13 weight gain - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1316) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.02) favouring perphenazine over any antipsychotic drugs (RR 0.66 CI 0.46 to 0.95, <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.24 Other adverse events: 8. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.24.1 cellulitis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.2 eczema - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.3 fungal dermatitis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.4 oedema</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.17 CI 0.13 to 76.16, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.5 pruritus - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 498). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.77 CI 0.31 to 1.93, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.6 rash - short term</HEADING>
<P>In this subgroup we found seven relevant trials (n = 806). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.90 CI 0.37 to 2.17, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.7 rash - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.07 to 15.26, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.24.8 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.66 CI 0.23 to 1.89, <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.25 Other adverse events: 9. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.25.1 diminished sexual desire</HEADING>
<P>In this subgroup we found four relevant trials (n = 1958). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.03 CI 0.82 to 1.30, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.2 ejaculatory dysfunction (men only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.18 CI 0.02 to 1.43, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.3 erectile dysfunction (men only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.90 CI 0.30 to 2.70, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.4 galactorrhoea - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.5 galactorrhoea/gynaecomastia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.56 CI 0.20 to 1.56, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.6 increased sexual desire - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 212). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.06 CI 0.22 to 5.01, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.7 micturition disturbances - short term</HEADING>
<P>In this subgroup we found five relevant trials (n = 635). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.59 CI 0.22 to 1.63, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.25.8 orgastic dysfunction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 5.28 CI 0.26 to 107.51, <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.26 Other adverse events: 10. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.26.1 abdominal pain - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.2 allergic reaction - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.3 back pain - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.4 cramps - short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 450). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.47 CI 0.05 to 4.46, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.5 failing memory - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.27 CI 0.60 to 2.68, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.6 muscle pain - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 71.51, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.7 sweating - short term</HEADING>
<P>In this subgroup we found six relevant trials (n = 726). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.73 CI 0.39 to 1.37, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.8 incontinence nocturia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.03) favouring perphenazine over any antipsychotic drugs (RR 0.41 CI 0.18 to 0.92, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.9 urinary hesitancy, dry mouth, constipation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.86 CI 0.67 to 1.10, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.10 suicide attempt - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.77 CI 0.09 to 6.33, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.26.11 psychosis - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.63 CI 0.29 to 1.40, <LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.27 Other adverse events: 11. Lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.27.1 abnormal EKG/ECG - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 211). There was no significant difference between perphenazine and any antipsychotic drugs (RR 2.44 CI 0.62 to 9.59, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 2.06; df = 1; P = 0.151; I<SUP>2</SUP> = 51%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.2 abnormal liver function - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 4.00 CI 0.92 to 17.40, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.3 anaemia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.07 to 15.26, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.4 decrease in white blood cell count and haemoglobin level - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.07 to 15.30, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.5 ECG - atrial extrasystole &amp; flattening of T-wave in V6 - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 6.72 CI 0.37 to 123.33, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.6 ECG abnormality (1st degree atrioventricular block)</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P = 0.007) favouring perphenazine over any antipsychotic drugs (RR 15.82 CI 2.12 to 118.27, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.7 high white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.03 CI 0.10 to 11.09, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.8 increase in white blood cell count and haemoglobin level - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.50 CI 0.10 to 2.54, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.9 liver function (GPT+) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.69 CI 0.23 to 2.02, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.10 low white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.17 CI 0.02 to 1.28, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.11 prolactin: clinically significant high levels</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring any antipsychotic drugs over perphenazine (RR 12.66 CI 6.06 to 26.45, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.12 prolonged QTc interval (&#8805;450 msec and &#8805;10% increase from baseline) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs, with no events reported in either group (<LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.13 rise in alkaline phosphate and GOT levels - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 3.00 CI 0.13 to 71.00, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.14 slight T-wave changes on EKG - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.00 CI 0.15 to 6.55, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.27.15 ventricular extrasystole - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.32 CI 0.01 to 7.48, <LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.28 Other adverse events: 11a. Lab data (skew)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.28.1 weight change</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-002.28" TYPE="ANALYSIS">Analysis 2.28</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.29 Other adverse events: 12. Any serious adverse event</HEADING>
<P>Overall there was no significant difference between groups for serious adverse events (2 RCTs, n = 1760, RR 0.98 CI 0.68 to 1.41 (<LINK REF="CMP-002.29" TYPE="ANALYSIS">Analysis 2.29</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.29.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 0.79 CI 0.49 to 1.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.29.2 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 1460) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (RR 1.15 CI 0.78 to 1.69).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 3: PERPHENAZINE versus ANY ANTIPSYCHOTICS (ACUTE)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Dichotomous outcomes for acute participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 Leaving the study early: 1. Any reason</HEADING>
<P>In this subgroup we found seven relevant trials (n = 447). There was a statistically significant difference (P = 0.007) between perphenazine and any antipsychotic drugs (acute) (RR 1.25 CI 1.06 to 1.47, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.2 Leaving the study early: 2. Due to adverse events</HEADING>
<P>In this subgroup we found three relevant trials (n = 314). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.55 CI 0.72 to 3.34, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 2.97; df = 2; P = 0.226; I<SUP>2</SUP> = 33%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<P>In this subgroup we found two relevant trials (n = 129). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.46 CI 0.34 to 6.26, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.4 Global state: 1. Change over time - no better or deterioration</HEADING>
<P>In this subgroup we found five relevant trials (n = 240). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.87 CI 0.27 to 2.82, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 13.71; df = 4; P = 0.008; I<SUP>2</SUP> = 71%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.5 Mental state: 1. State - less than 20% BPRS reduction ('no effect')</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.81 CI 0.61 to 1.08, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.6 Mental state: 2. State - less than 20% PANSS reduction ('no effect')</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.86 CI 0.64 to 1.15, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.7 Adverse events: 1. Movement disorders - dystonia</HEADING>
<P>In this subgroup we found two relevant trials (n = 129). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.11 CI 0.12 to 10.02, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 2.1; df = 1; P = 0.147; I<SUP>2</SUP> = 52%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.8 Adverse events: 2. Movement disorders - extrapyramidal signs</HEADING>
<P>In this subgroup we only found one relevant trial (n = 22) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.86 CI 0.39 to 1.88, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.9 Adverse events: 3. Movement disorders - use of antiparkinson drugs</HEADING>
<P>In this subgroup we found two relevant trials (n = 129). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.07 CI 0.65 to 1.76, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.10 Adverse events: 4. Movement disorders - hyperkinesia</HEADING>
<P>In this subgroup we found two relevant trials (n = 135). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 2.64 CI 0.88 to 7.91, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.11 Other adverse events: 5. Anticholinergic - dry mouth</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 7.40 CI 0.39 to 139.81, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.12 Other adverse events: 6. Arousal - drowsiness</HEADING>
<P>In this subgroup we found two relevant trials (n = 50). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.01 CI 0.12 to 8.33, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 3.72; df = 1; P = 0.054; I<SUP>2</SUP> = 73%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.13 Other adverse events: 7. Arousal - insomnia</HEADING>
<P>In this subgroup we found two relevant trials (n = 161). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.84 CI 0.16 to 4.50, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2 </SUP>= 3.11; df = 1; P = 0.078; I<SUP>2</SUP> = 68%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.14 Other adverse events: 8. Arousal - need of additional benzodiazepines</HEADING>
<P>In this subgroup we only found one relevant trial (n = 17) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.71 CI 0.35 to 1.46, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.15 Other adverse events: 9. Arousal - sleepiness/sedation</HEADING>
<P>In this subgroup we found two relevant trials (n = 161). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.19 CI 0.71 to 2.00, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.16 Other adverse events: 10. Arousal - tension</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.97 CI 0.63 to 1.50, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.17 Other adverse events: 11. At least one</HEADING>
<P>In this subgroup we found three relevant trials (n = 157). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.04 CI 0.88 to 1.23, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.18 Other adverse events: 12. Cardiovascular - faintness, dizziness, weakness</HEADING>
<P>In this subgroup we found two relevant trials (n = 161). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.12 CI 0.54 to 2.33, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.19 Other adverse events: 13. Cardiovascular - lassitude</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.97 CI 0.61 to 1.52, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.20 Other adverse events: 14. Cardiovascular - tachycardia</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.57 CI 0.25 to 1.32, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.21 Other adverse events: 15. Central nervous system - difficulty in concentration</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.06 CI 0.71 to 1.58, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.22 Other adverse events: 16. Central nervous system - headache</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.53 CI 0.14 to 2.01, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.23 Other adverse events: 17. Central nervous system - paraesthesia</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.24 Other adverse events: 18. Gastrointestinal - constipation</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.07 CI 0.00 to 1.20, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.25 Other adverse events: 19. Gastrointestinal - diarrhoea</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.26 Other adverse events: 20. Gastrointestinal - nausea and vomiting</HEADING>
<P>In this subgroup we found two relevant trials (n = 154). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.64 CI 0.24 to 1.68, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.27 Other adverse events: 21. Gastrointestinal - weight loss</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 2.12 CI 0.56 to 8.02, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.28 Other adverse events: 22. Gastrointestinal - weight gain</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was a statistically significant difference (P = 0.04) favouring perphenazine over any antipsychotic drugs (acute) (RR 0.50 CI 0.26 to 0.97, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.29 Other adverse events: 23. Skin - pruritus</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.79 CI 0.19 to 3.38, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.30 Other adverse events: 24. Skin - rash</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.31 Other adverse events: 25. Skin - sweating</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.66 CI 0.23 to 1.89, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.32 Other adverse events: 26. Genitourinary - diminished sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.06 CI 0.22 to 5.01, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.33 Other adverse events: 27. Genitourinary - ejaculatory dysfunction (men only)</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.18 CI 0.02 to 1.43, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.34 Other adverse events: 28. Genitourinary - erectile dysfunction (men only)</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.90 CI 0.30 to 2.70, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.35 Other adverse events: 29. Genitourinary - galactorrhoea</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.36 Other adverse events: 30. Genitourinary - increased sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.06 CI 0.22 to 5.01, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.37 Other adverse events: 31. Genitourinary - orgastic dysfunction</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 5.28 CI 0.26 to 107.51, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.38 Other adverse events: 32. Others - abdominal pain</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.39 Other adverse events: 33. Others - failing memory</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 1.27 CI 0.60 to 2.68, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.40 Other adverse events: 34. Others - sweating</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (RR 0.96 CI 0.45 to 2.07, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Continuous outcomes for acute participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Mental state: 1. State - PANSS: mean change from baseline to endpoint</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and any antipsychotic drugs (acute) (MD 4.00 CI -5.04 to 13.04, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 4: PERPHENAZINE versus ARIPIPRAZOLE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.74 CI 0.50 to 1.11, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.53 CI 0.27 to 1.05, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.84 CI 0.34 to 2.08, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 294) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 1.02 CI 0.89 to 1.17, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Global state: 2. Average endpoint score (CGI-S)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.5.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 294) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (MD -0.20 CI -0.56 to 0.16, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.6 Mental state: 2a. State - BPRS score reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.6.1 less than 25% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 65) (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 1.45 CI 0.26 to 8.14, <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.7 Mental state: 2b. State - PANSS: mean endpoint from baseline (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.7.1 total - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 65) (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). There was no significant difference between perphenazine and aripiprazole (MD 1.38 CI -2.66 to 5.42, <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.2 positive - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 65) (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). There was no significant difference between perphenazine and aripiprazole (MD 0.63 CI -0.80 to 2.06, <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.3 negative - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 65) (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>). There was no significant difference between perphenazine and aripiprazole (MD 0.33 CI -1.46 to 2.12, <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.8 Mental state: 2c. State - PANSS total change score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.8.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.9 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.9.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 2.29 CI 0.89 to 5.85, <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.9.2 EPS - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 365). There was no significant difference between perphenazine and aripiprazole (RR 1.65 CI 0.70 to 3.88, <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.9.3 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P = 0.04) favouring aripiprazole over perphenazine (RR 1.56 CI 1.01 to 2.41, <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.10 Adverse events: Movement disorders - TESS total score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.10.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.11 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.11.1 agitation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 1.05 CI 0.63 to 1.77, <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.11.2 anxiety - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 1.19 CI 0.63 to 2.24, <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.11.3 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.86 CI 0.56 to 1.31, <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.11.4 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 2.64 CI 0.85 to 8.22, <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.12 Other adverse events: 2. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.12.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P = 0.03) favouring aripiprazole over perphenazine (RR 5.27 CI 1.18 to 23.66, <LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.13 Other adverse events: 3. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.13.1 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.55 CI 0.29 to 1.03, <LINK REF="CMP-004.13" TYPE="ANALYSIS">Analysis 4.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.14 Other adverse events: 4. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.14.1 dyspepsia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.59 CI 0.27 to 1.30, <LINK REF="CMP-004.14" TYPE="ANALYSIS">Analysis 4.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.15 Other adverse events: 5. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.15.1 ECG abnormality (1st degree atrioventricular block)</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P = 0.007) favouring aripiprazole over perphenazine (RR 15.82 CI 2.12 to 118.27, <LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.15.2 prolactin: clinically significant high levels</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring aripiprazole over perphenazine (RR 12.66 CI 6.06 to 26.45, <LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.15.3 prolonged QTc interval (&#8805; 450 msec and &#8805; 10% increase from baseline) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole, with no events reported in either group (<LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.16 Other adverse events: 6. any serious adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.16.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.79 CI 0.49 to 1.28, <LINK REF="CMP-004.16" TYPE="ANALYSIS">Analysis 4.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.16.2 psychosis - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 300) (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>). There was no significant difference between perphenazine and aripiprazole (RR 0.63 CI 0.29 to 1.40, <LINK REF="CMP-004.16" TYPE="ANALYSIS">Analysis 4.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 5: PERPHENAZINE versus BENPERIDOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>). There was no significant difference between perphenazine and benperidol, with no events reported in either group (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>). There was a statistically significant difference (P = 0.002) favouring perphenazine over benperidol (RR 0.13 CI 0.03 to 0.47, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 6: PERPHENAZINE versus BROMPERIDOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>). There was no significant difference between perphenazine and bromperidol, with no events reported in either group (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>). There was no significant difference between perphenazine and bromperidol (RR 2.50 CI 0.94 to 6.66, <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.3.1 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>). There was no significant difference between perphenazine and bromperidol (RR 0.80 CI 0.40 to 1.60, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.4 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.4.1 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 40) (<LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>). There was no significant difference between perphenazine and bromperidol (RR 1.10 CI 0.61 to 1.99, <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 7: PERPHENAZINE versus CHLORPROMAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">7.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1.1 short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 178). There was no significant difference between perphenazine and chlorpromazine (RR 1.10 CI 0.89 to 1.35, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.2.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 168). There was a statistically significant difference (P = 0.0002) favouring perphenazine over chlorpromazine (RR 0.33 CI 0.18 to 0.59, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 63) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and chlorpromazine (RR 0.57 CI 0.22 to 1.52, <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.4.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and chlorpromazine (RR 6.87 CI 0.88 to 53.89, <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and chlorpromazine, with no events reported in either group (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and chlorpromazine (RR 1.96 CI 0.18 to 20.99, <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and chlorpromazine (RR 1.96 CI 0.63 to 6.12, <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.5 Other adverse events: 1. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.5.1 electroencephalogram (increase) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 10) (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>). There was no significant difference between perphenazine and chlorpromazine (RR 0.33 CI 0.05 to 2.21, <LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 8: PERPHENAZINE versus CLOCAPRAMINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">8.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.40 CI 0.59 to 3.34, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.61 CI 0.15 to 2.49, <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 2.38 CI 0.63 to 8.94, <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.15 CI 0.88 to 1.49, <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.5 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.5.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.84 CI 0.49 to 1.44, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.5.2 ataxia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.34 CI 0.04 to 3.21, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.5.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.57 CI 0.20 to 1.63, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.5.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.98 CI 0.60 to 1.59, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.5.5 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.88 CI 0.69 to 1.13, <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.6 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.6.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.41 CI 0.08 to 2.05, <LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.6.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.68 CI 0.25 to 1.84, <LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.7 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.7.1 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.16 CI 0.83 to 1.63, <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.7.2 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.09 CI 0.81 to 1.46, <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.7.3 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.02 CI 0.47 to 2.24, <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.8 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.8.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.92 CI 0.78 to 1.07, <LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.9 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.9.1 angina pectoris - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.68 CI 0.20 to 2.34, <LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.9.2 palpitations - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.34 CI 0.07 to 1.64, <LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.10 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.10.1 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine, with no events reported in either group (<LINK REF="CMP-008.10" TYPE="ANALYSIS">Analysis 8.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.10.2 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 2.55 CI 0.83 to 7.86, <LINK REF="CMP-008.10" TYPE="ANALYSIS">Analysis 8.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.10.3 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 4.08 CI 0.46 to 35.88, <LINK REF="CMP-008.10" TYPE="ANALYSIS">Analysis 8.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.10.4 vertigo - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.02 CI 0.45 to 2.34, <LINK REF="CMP-008.10" TYPE="ANALYSIS">Analysis 8.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.11 Other adverse events: 6. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.11.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.25 CI 0.54 to 2.87, <LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.11.2 icterus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine, with no events reported in either group (<LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.11.3 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.76 CI 0.89 to 3.50, <LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.11.4 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was a statistically significant difference (P = 0.04) favouring clocapramine over perphenazine (RR 2.30 CI 1.05 to 5.03, <LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.12 Other adverse events: 7. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.12.1 pruritus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.02 CI 0.15 to 7.10, <LINK REF="CMP-008.12" TYPE="ANALYSIS">Analysis 8.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.12.2 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.02 CI 0.15 to 7.10, <LINK REF="CMP-008.12" TYPE="ANALYSIS">Analysis 8.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.13 Other adverse events: 8. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.13.1 diminished sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 1.02 CI 0.06 to 16.09, <LINK REF="CMP-008.13" TYPE="ANALYSIS">Analysis 8.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.13.2 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.51 CI 0.10 to 2.72, <LINK REF="CMP-008.13" TYPE="ANALYSIS">Analysis 8.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.14 Other adverse events: 9. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.14.1 cramps - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine, with no events reported in either group (<LINK REF="CMP-008.14" TYPE="ANALYSIS">Analysis 8.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.14.2 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 192) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and clocapramine (RR 0.17 CI 0.02 to 1.39, <LINK REF="CMP-008.14" TYPE="ANALYSIS">Analysis 8.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 9: PERPHENAZINE versus CLOPENTHIXOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">9.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was no significant difference between perphenazine and clopenthixol (RR 1.00 CI 0.15 to 6.55, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was no significant difference between perphenazine and clopenthixol (RR 0.67 CI 0.21 to 2.08, <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.3.1 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was a statistically significant difference (P = 0.02) favouring perphenazine over clopenthixol (RR 0.53 CI 0.31 to 0.89, <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9.4 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.4.1 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was no significant difference between perphenazine and clopenthixol (RR 0.50 CI 0.24 to 1.03, <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9.5 Other adverse events: 2. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.5.1 slight T-wave changes on EKG - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 50) (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). There was no significant difference between perphenazine and clopenthixol (RR 1.00 CI 0.15 to 6.55, <LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 10: PERPHENAZINE versus CLOTHIAPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">10.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.00 CI 0.21 to 4.66, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.2 Leaving the study early: 2. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.00 CI 0.15 to 6.76, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.31 CI 0.81 to 2.12, <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.4 Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</HEADING>
<P>For this outcome we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.96 CI 0.69 to 1.34, <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.5 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.5.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.63 CI 0.76 to 3.49, <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.5.2 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.56 CI 0.20 to 1.51, <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.5.3 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.31 CI 0.81 to 2.12, <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.5.4 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.31 CI 0.81 to 2.12, <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.6 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.6.1 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.25 CI 0.03 to 2.14, <LINK REF="CMP-010.06" TYPE="ANALYSIS">Analysis 10.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.6.2 nasal congestion - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 3.00 CI 0.13 to 71.51, <LINK REF="CMP-010.06" TYPE="ANALYSIS">Analysis 10.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.7 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.7.1 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.91 CI 0.44 to 1.90, <LINK REF="CMP-010.07" TYPE="ANALYSIS">Analysis 10.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.7.2 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.25 CI 0.55 to 2.84, <LINK REF="CMP-010.07" TYPE="ANALYSIS">Analysis 10.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.7.3 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.00 CI 0.42 to 2.40, <LINK REF="CMP-010.07" TYPE="ANALYSIS">Analysis 10.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.8 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.8.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.09 CI 0.91 to 1.30, <LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.9 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.9.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.67 CI 0.43 to 6.51, <LINK REF="CMP-010.09" TYPE="ANALYSIS">Analysis 10.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.10 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.10.1 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.33 CI 0.01 to 7.95, <LINK REF="CMP-010.10" TYPE="ANALYSIS">Analysis 10.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.11 Other adverse events: 6. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.11.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.25 CI 0.06 to 1.11, <LINK REF="CMP-010.11" TYPE="ANALYSIS">Analysis 10.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.11.2 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 1.33 CI 0.32 to 5.58, <LINK REF="CMP-010.11" TYPE="ANALYSIS">Analysis 10.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.11.3 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 3.00 CI 0.13 to 71.51, <LINK REF="CMP-010.11" TYPE="ANALYSIS">Analysis 10.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.12 Other adverse events: 7. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.12.1 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.50 CI 0.05 to 5.30, <LINK REF="CMP-010.12" TYPE="ANALYSIS">Analysis 10.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.13 Other adverse events: 8. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.13.1 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 0.50 CI 0.05 to 5.30, <LINK REF="CMP-010.13" TYPE="ANALYSIS">Analysis 10.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10.14 Other adverse events: 9. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.14.1 muscle pain - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 80) (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>). There was no significant difference between perphenazine and clothiapine (RR 3.00 CI 0.13 to 71.51, <LINK REF="CMP-010.14" TYPE="ANALYSIS">Analysis 10.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 11: PERPHENAZINE versus CLOZAPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">11.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.1.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 130). There was no significant difference between perphenazine and clozapine (RR 1.87 CI 0.48 to 7.23, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was no significant difference between perphenazine and clozapine (RR 2.60 CI 0.31 to 22.05, <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.3 Mental state: 1. State - less than 30% BPRS reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 2.55 CI 0.52 to 12.52, <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.4 Mental state: 2. State - BPRS end score (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.4.1 total score - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 102) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (MD 0.94 CI -1.49 to 3.37, <LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.4.2 anxiety-depression score - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 102) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a significant difference (P = 0.002) favouring clozapine over perphenazine (MD 0.92 CI 0.34 to 1.50, <LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.5 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.5.1 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was no significant difference between perphenazine and clozapine, with no events reported in either group (<LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.5.2 hyperkinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was no significant difference between perphenazine and clozapine, with no events reported in either group (<LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.5.3 myotony - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.03) favouring clozapine over perphenazine (RR 21.43 CI 1.29 to 355.77, <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.5.4 rigidity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was no significant difference between perphenazine and clozapine (RR 6.13 CI 0.35 to 108.58, <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.5.5 tremor - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.03) favouring clozapine over perphenazine (RR 5.10 CI 1.18 to 22.09, <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.6 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.6.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 0.85 CI 0.49 to 1.49, <LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.6.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.003) favouring clozapine over piperazine (RR 4.59 CI 1.68 to 12.58, <LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.6.3 increased salivation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P &lt; 0.0001) favouring perphenazine over clozapine (RR 0.05 CI 0.01 to 0.20, <LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.7 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.7.1 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was a statistically significant difference (P = 0.03) favouring perphenazine and over clozapine (RR 0.43 CI 0.20 to 0.94, <LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.7.2 excitement - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.002) favouring clozapine over perphenazine (RR 21.44 CI 3.00 to 153.14, <LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.7.3 somnolence - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.001) favouring perphenazine and over clozapine (RR 0.19 CI 0.07 to 0.52, <LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.7.4 restlessness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.001) favouring clozapine over perphenazine (RR 5.10 CI 1.88 to 13.83, <LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.8 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.8.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 28) (<LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>). There was no significant difference between perphenazine and clozapine (RR 2.60 CI 0.31 to 22.05, <LINK REF="CMP-011.08" TYPE="ANALYSIS">Analysis 11.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.9 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.9.1 dizziness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 0.92 CI 0.56 to 1.51, <LINK REF="CMP-011.09" TYPE="ANALYSIS">Analysis 11.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.9.2 tachycardia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference between (P &lt; 0.00001) favouring perphenazine over clozapine (RR 0.23 CI 0.13 to 0.42, <LINK REF="CMP-011.09" TYPE="ANALYSIS">Analysis 11.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.10 Other adverse events: 5. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.10.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring perphenazine over clozapine (RR 0.33 CI 0.20 to 0.54, <LINK REF="CMP-011.10" TYPE="ANALYSIS">Analysis 11.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.11 Other adverse events: 6. Lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.11.1 abnormal EKG - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 1.33 CI 0.73 to 2.44, <LINK REF="CMP-011.11" TYPE="ANALYSIS">Analysis 11.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.11.2 high white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 1.02 CI 0.07 to 15.86, <LINK REF="CMP-011.11" TYPE="ANALYSIS">Analysis 11.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.11.3 low white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 0.17 CI 0.02 to 1.36, <LINK REF="CMP-011.11" TYPE="ANALYSIS">Analysis 11.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11.11.4 liver function (GPT+) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 97) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine (RR 0.58 CI 0.18 to 1.86, <LINK REF="CMP-011.11" TYPE="ANALYSIS">Analysis 11.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11.12 Other adverse events: 7. Average endpoint score (TESS, skew)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">11.12.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-011.12" TYPE="ANALYSIS">Analysis 11.12</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 12: PERPHENAZINE versus CLOZAPINE + PERPHENAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">12.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 102) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 3.00 CI 0.32 to 27.89, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.2 Mental state: 1. State - less than 30% BPRS reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 147) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 3.44 CI 0.86 to 13.79, <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.3 Mental state: 1a. State - BPRS end score (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.3.1 total score - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 102) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (MD 0.74 CI -1.72 to 3.20, <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.3.2 anxiety-depression score - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 102) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (MD 0.51 CI -0.10 to 1.12, <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.4.1 myotony - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 1.04 CI 0.48 to 2.28, <LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.4.2 tremor - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 1.04 CI 0.48 to 2.28, <LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.5 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.5.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 0.98 CI 0.55 to 1.75, <LINK REF="CMP-012.05" TYPE="ANALYSIS">Analysis 12.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.5.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 1.88 CI 0.97 to 3.64, <LINK REF="CMP-012.05" TYPE="ANALYSIS">Analysis 12.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.5.3 increased salivation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P &lt; 0.0001) favouring perphenazine over clozapine + perphenazine (RR 0.06 CI 0.01 to 0.22, <LINK REF="CMP-012.05" TYPE="ANALYSIS">Analysis 12.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.6 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.6.1 excitement - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.002) favouring clozapine + perphenazine over perphenazine alone (RR 21.88 CI 3.06 to 156.33, <LINK REF="CMP-012.06" TYPE="ANALYSIS">Analysis 12.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.6.2 restlessness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.005) favouring clozapine + perphenazine over perphenazine alone (RR 2.98 CI 1.39 to 6.39, <LINK REF="CMP-012.06" TYPE="ANALYSIS">Analysis 12.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.6.3 somnolence - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 2.08 CI 0.0 to 10.85, <LINK REF="CMP-012.06" TYPE="ANALYSIS">Analysis 12.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.7 Other adverse events: 3. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.7.1 dizziness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 0.89 CI 0.55 to 1.46, <LINK REF="CMP-012.07" TYPE="ANALYSIS">Analysis 12.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.7.2 tachycardia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.0001) favouring perphenazine alone over clozapine + perphenazine (RR 0.29 CI 0.16 to 0.55, <LINK REF="CMP-012.07" TYPE="ANALYSIS">Analysis 12.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.8 Other adverse events: 4. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.8.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was a statistically significant difference (P = 0.002) favouring perphenazine alone over clozapine + perphenazine (RR 0.44 CI 0.26 to 0.73, <LINK REF="CMP-012.08" TYPE="ANALYSIS">Analysis 12.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.9 Other adverse events: 5. Lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.9.1 abnormal EKG - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 1.97 CI 0.97 to 3.98, <LINK REF="CMP-012.09" TYPE="ANALYSIS">Analysis 12.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.9.2 high white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 1.04 CI 0.07 to 16.19, <LINK REF="CMP-012.09" TYPE="ANALYSIS">Analysis 12.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.9.3 low white blood cell count - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 0.17 CI 0.02 to 1.39, <LINK REF="CMP-012.09" TYPE="ANALYSIS">Analysis 12.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12.9.4 liver function (GPT+) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 98) (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). There was no significant difference between perphenazine and clozapine + perphenazine (RR 0.83 CI 0.24 to 2.92, <LINK REF="CMP-012.09" TYPE="ANALYSIS">Analysis 12.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12.10 Other adverse events: 6. Average endpoint score (TESS, skewed)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">12.10.1 short term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-012.10" TYPE="ANALYSIS">Analysis 12.10</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 13: PERPHENAZINE versus FLUPHENAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">13.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">13.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over fluphenazine (RR 0.62 CI 0.38 to 1.01, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">13.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">13.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and fluphenazine (RR 1.00 CI 0.15 to 6.84, <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">13.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">13.3.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and fluphenazine (RR 1.17 CI 0.42 to 3.24, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">13.3.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and fluphenazine, with no events reported in either group (<LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">13.3.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and fluphenazine (RR 2.00 CI 0.19 to 21.40, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">13.3.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and fluphenazine (RR 1.14 CI 0.45 to 2.93, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 14: PERPHENAZINE versus HALOPERIDOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">14.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.84 CI 0.40 to 1.77, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.49 CI 0.13 to 1.92, <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.39 CI 0.46 to 4.21, <LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.01 CI 0.79 to 1.29, <LINK REF="CMP-014.04" TYPE="ANALYSIS">Analysis 14.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.5 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.5.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.70 CI 0.42 to 1.16, <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.5.2 ataxia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.49 CI 0.05 to 5.36, <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.5.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.45 CI 0.16 to 1.24, <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.5.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.77 CI 0.49 to 1.20, <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.5.5 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.87 CI 0.68 to 1.11, <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.6 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.6.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.25 CI 0.05 to 1.13, <LINK REF="CMP-014.06" TYPE="ANALYSIS">Analysis 14.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.6.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.54 CI 0.21 to 1.40, <LINK REF="CMP-014.06" TYPE="ANALYSIS">Analysis 14.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.7 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.7.1 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.97 CI 0.71 to 1.32, <LINK REF="CMP-014.07" TYPE="ANALYSIS">Analysis 14.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.7.2 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.01 CI 0.76 to 1.34, <LINK REF="CMP-014.07" TYPE="ANALYSIS">Analysis 14.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.7.3 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.21 CI 0.53 to 2.78, <LINK REF="CMP-014.07" TYPE="ANALYSIS">Analysis 14.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.8 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.8.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.05 CI 0.88 to 1.25, <LINK REF="CMP-014.08" TYPE="ANALYSIS">Analysis 14.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.9 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.9.1 angina pectoris - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.57 CI 0.17 to 1.87, <LINK REF="CMP-014.09" TYPE="ANALYSIS">Analysis 14.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.9.2 palpitations - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.28 CI 0.06 to 1.33, <LINK REF="CMP-014.09" TYPE="ANALYSIS">Analysis 14.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.10 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.10.1 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.33 CI 0.01 to 8.00, <LINK REF="CMP-014.10" TYPE="ANALYSIS">Analysis 14.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.10.2 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.90 CI 0.40 to 2.02, <LINK REF="CMP-014.10" TYPE="ANALYSIS">Analysis 14.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.10.3 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.99 CI 0.25 to 3.84, <LINK REF="CMP-014.10" TYPE="ANALYSIS">Analysis 14.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.10.4 vertigo - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.82 CI 0.37 to 1.82, <LINK REF="CMP-014.10" TYPE="ANALYSIS">Analysis 14.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.11 Other adverse events: 6. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.11.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.84 CI 0.40 to 1.77, <LINK REF="CMP-014.11" TYPE="ANALYSIS">Analysis 14.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.11.2 icterus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol, with no events reported in either group (<LINK REF="CMP-014.11" TYPE="ANALYSIS">Analysis 14.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.11.3 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.75 CI 0.45 to 1.27, <LINK REF="CMP-014.11" TYPE="ANALYSIS">Analysis 14.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.11.4 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.62 CI 0.81 to 3.24, <LINK REF="CMP-014.11" TYPE="ANALYSIS">Analysis 14.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.12 Other adverse events: 7. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.12.1 pruritus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.66 CI 0.11 to 3.86, <LINK REF="CMP-014.12" TYPE="ANALYSIS">Analysis 14.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.12.2 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 1.98 CI 0.18 to 21.46, <LINK REF="CMP-014.12" TYPE="ANALYSIS">Analysis 14.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.13 Other adverse events: 8. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.13.1 diminished sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.99 CI 0.06 to 15.59, <LINK REF="CMP-014.13" TYPE="ANALYSIS">Analysis 14.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.13.2 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.49 CI 0.09 to 2.64, <LINK REF="CMP-014.13" TYPE="ANALYSIS">Analysis 14.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14.14 Other adverse events: 9. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">14.14.1 cramps - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.33 CI 0.01 to 8.00, <LINK REF="CMP-014.14" TYPE="ANALYSIS">Analysis 14.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14.14.2 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 189) (<LINK REF="STD-Kurihara-1983" TYPE="STUDY">Kurihara 1983</LINK>). There was no significant difference between perphenazine and haloperidol (RR 0.16 CI 0.02 to 1.34, <LINK REF="CMP-014.14" TYPE="ANALYSIS">Analysis 14.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 15: PERPHENAZINE versus LOXAPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">15.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.96 CI 0.32 to 2.88, <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.2 Leaving the study early: 2. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.96 CI 0.06 to 14.43, <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.85 CI 0.40 to 1.82, <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.4.1 dystonia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">15.4.2 extrapyramidal signs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.90 CI 0.62 to 1.31, <LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">15.4.3 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 1.18 CI 0.75 to 1.86, <LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.5 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.5.1 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 1.60 CI 0.43 to 5.93, <LINK REF="CMP-015.05" TYPE="ANALYSIS">Analysis 15.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.6 Other adverse events: 2. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.6.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was a statistically significant difference (P = 0.05) favouring loxapine over perphenazine (RR 1.30 CI 1.00 to 1.68, <LINK REF="CMP-015.06" TYPE="ANALYSIS">Analysis 15.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15.7 Other adverse events: 3. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">15.7.1 ECG &#8211; atrial extrasystole &amp; flattening of T-wave in V<SUB>6 </SUB>- short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 6.72 CI 0.37 to 123.33, <LINK REF="CMP-015.07" TYPE="ANALYSIS">Analysis 15.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">15.7.2 ventricular extrasystole - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). There was no significant difference between perphenazine and loxapine (RR 0.32 CI 0.01 to 7.48, <LINK REF="CMP-015.07" TYPE="ANALYSIS">Analysis 15.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 16: PERPHENAZINE versus MEPAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">16.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">16.1.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 68). There was no significant difference between perphenazine and mepazine (RR 1.18 CI 0.91 to 1.53, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">16.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">16.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and mepazine (RR 6.97 CI 0.93 to 52.20, <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">16.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">16.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 58) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over mepazine (RR 0.40 CI 0.16 to 1.00, <LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">16.4 Other adverse events: 1. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">16.4.1 electroencephalogram (increase) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 10) (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>). There was no significant difference between perphenazine and mepazine (RR 1.00 CI 0.08 to 11.93, <LINK REF="CMP-016.04" TYPE="ANALYSIS">Analysis 16.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 17: PERPHENAZINE versus METHYPERIDOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">17.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.00 CI 0.35 to 2.83, <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 4.00 CI 0.47 to 34.20, <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.05 CI 0.68 to 1.64, <LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.4 Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</HEADING>
<P>For this outcome we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.88 CI 0.61 to 1.26, <LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.5 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.5.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.25 CI 0.36 to 4.31, <LINK REF="CMP-017.05" TYPE="ANALYSIS">Analysis 17.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.5.2 ataxia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.05" TYPE="ANALYSIS">Analysis 17.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.5.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.20 CI 0.02 to 1.63, <LINK REF="CMP-017.05" TYPE="ANALYSIS">Analysis 17.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.5.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.80 CI 0.35 to 1.81, <LINK REF="CMP-017.05" TYPE="ANALYSIS">Analysis 17.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.6 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.6.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.20 CI 0.01 to 4.04, <LINK REF="CMP-017.06" TYPE="ANALYSIS">Analysis 17.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.6.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 2.00 CI 0.19 to 21.16, <LINK REF="CMP-017.06" TYPE="ANALYSIS">Analysis 17.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.7 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.7.1 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.64 CI 0.28 to 1.47, <LINK REF="CMP-017.07" TYPE="ANALYSIS">Analysis 17.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.7.2 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.50 CI 0.10 to 2.57, <LINK REF="CMP-017.07" TYPE="ANALYSIS">Analysis 17.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.8 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.8.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.96 CI 0.70 to 1.33, <LINK REF="CMP-017.08" TYPE="ANALYSIS">Analysis 17.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.9 Other adverse events: 4. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.9.1 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.09" TYPE="ANALYSIS">Analysis 17.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.9.2 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.00 CI 0.06 to 15.43, <LINK REF="CMP-017.09" TYPE="ANALYSIS">Analysis 17.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.9.3 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.09" TYPE="ANALYSIS">Analysis 17.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.9.4 vertigo - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.33 CI 0.01 to 7.94, <LINK REF="CMP-017.09" TYPE="ANALYSIS">Analysis 17.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.10 Other adverse events: 5. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.10.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.33 CI 0.01 to 7.94, <LINK REF="CMP-017.10" TYPE="ANALYSIS">Analysis 17.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.10.2 icterus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.10" TYPE="ANALYSIS">Analysis 17.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.10.3 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.60 CI 0.15 to 2.34, <LINK REF="CMP-017.10" TYPE="ANALYSIS">Analysis 17.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.10.4 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.50 CI 0.27 to 8.49, <LINK REF="CMP-017.10" TYPE="ANALYSIS">Analysis 17.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.11 Other adverse events: 6. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.11.1 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 1.00 CI 0.06 to 15.43, <LINK REF="CMP-017.11" TYPE="ANALYSIS">Analysis 17.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.12 Other adverse events: 7. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.12.1 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol (RR 0.33 CI 0.01 to 7.94, <LINK REF="CMP-017.12" TYPE="ANALYSIS">Analysis 17.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17.13 Other adverse events: 8. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">17.13.1 cramps - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.13" TYPE="ANALYSIS">Analysis 17.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">17.13.2 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 78) (<LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>). There was no significant difference between perphenazine and methyperidol, with no events reported in either group (<LINK REF="CMP-017.13" TYPE="ANALYSIS">Analysis 17.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 18: PERPHENAZINE versus OLANZAPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">18.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.1.1 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 657). There was a statistically significant difference (P = 0.004) favouring olanzapine over perphenazine (RR 1.16 CI 1.05 to 1.29, <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.2.1 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 643). There was no significant difference between perphenazine and olanzapine (RR 0.85 CI 0.59 to 1.21, <LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.3.1 long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 643). There was no significant difference between perphenazine and olanzapine (RR 1.24 CI 0.47 to 3.29, <LINK REF="CMP-018.03" TYPE="ANALYSIS">Analysis 18.3</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 2.39; df = 1; P = 0.122; I<SUP>2 </SUP>= 58%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.4 Mental state: 1a. State - BPRS end score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.4.1 long term</HEADING>
<P>Data for this outcome are skewed, and are best inspected by viewing <LINK REF="CMP-018.04" TYPE="ANALYSIS">Analysis 18.4</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.5 Mental state: 1b. State - PANSS total endpoint score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.5.1 long term</HEADING>
<P>Data for this outcome are skewed, and are best inspected by viewing <LINK REF="CMP-018.05" TYPE="ANALYSIS">Analysis 18.5</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.6 Mental state: 1c. State - PANSS: mean endpoint score from baseline (high = poor)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.6.1 total - short term</HEADING>
<P>In this subgroup we found one relevant trial (n = 60). There was a statistically significant difference (P &lt; 0.0001) favouring olanzapine over perphenazine (MD 4.2 CI 2.17 to 6.25, <LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.6.2 positive - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring olanzapine over perphenazine (MD 8.23 CI 7.26 to 9.20, <LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.6.3 negative - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was a statistically significant difference (P = 0.0009) favouring olanzapine over perphenazine (MD 1.58 CI 0.64 to 2.52, <LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.6.4 general psychopathology - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over olanzapine (MD -0.39 CI -0.79 to 0.01, <LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.7 Mental state: 1d. State - less than 25% PANSS reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>). There was no significant difference between perphenazine and olanzapine (RR 2.00 CI 0.40 to 10.11, <LINK REF="CMP-018.07" TYPE="ANALYSIS">Analysis 18.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.8 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.8.1 akathisia - long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 591). There was no significant difference between perphenazine and olanzapine (RR 1.33 CI 0.68 to 2.60, <LINK REF="CMP-018.08" TYPE="ANALYSIS">Analysis 18.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.8.2 EPS - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 539) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.79 CI 0.42 to 1.49, <LINK REF="CMP-018.08" TYPE="ANALYSIS">Analysis 18.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.8.3 tardive dyskinesia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 473) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.28 CI 0.83 to 1.95, <LINK REF="CMP-018.08" TYPE="ANALYSIS">Analysis 18.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.8.4 use of antiparkinsonian drugs - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 46) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.34 to 26.76, <LINK REF="CMP-018.08" TYPE="ANALYSIS">Analysis 18.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.9 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.9.1 increased salivation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-018.09" TYPE="ANALYSIS">Analysis 18.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.10 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.10.1 agitation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.33 to 27.23, <LINK REF="CMP-018.10" TYPE="ANALYSIS">Analysis 18.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.10.2 anxiety - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.25 CI 0.37 to 4.21, <LINK REF="CMP-018.10" TYPE="ANALYSIS">Analysis 18.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.10.3 insomnia - long term</HEADING>
<P>In this subgroup we found two relevant trials (n = 657). There was no significant difference between perphenazine and olanzapine (RR 2.34 CI 0.62 to 8.89, <LINK REF="CMP-018.10" TYPE="ANALYSIS">Analysis 18.10</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 2.11; df = 1; P = 0.146; I<SUP>2</SUP> = 53%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.10.4 sleepiness/sedation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.92 CI 0.71 to 1.18, <LINK REF="CMP-018.10" TYPE="ANALYSIS">Analysis 18.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.11 Other adverse events: 3. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.11.1 bradycardia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-018.11" TYPE="ANALYSIS">Analysis 18.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.11.2 faintness, dizziness, weakness - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.20 CI 0.75 to 1.95, <LINK REF="CMP-018.11" TYPE="ANALYSIS">Analysis 18.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.11.3 hypotension - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-018.11" TYPE="ANALYSIS">Analysis 18.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.12 Other adverse events: 4. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.12.1 headache - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.71 CI 0.25 to 2.00, <LINK REF="CMP-018.12" TYPE="ANALYSIS">Analysis 18.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.12.2 hypertonia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-018.12" TYPE="ANALYSIS">Analysis 18.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.13 Other adverse events: 5. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.13.1 gastroenteritis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-018.13" TYPE="ANALYSIS">Analysis 18.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.13.2 weight gain - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 550) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring perphenazine over olanzapine (RR 0.40 CI 0.27 to 0.58, <LINK REF="CMP-018.13" TYPE="ANALYSIS">Analysis 18.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.14 Other adverse events: 6. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.14.1 cellulitis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-018.14" TYPE="ANALYSIS">Analysis 18.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.14.2 eczema - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-018.14" TYPE="ANALYSIS">Analysis 18.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.14.3 fungal dermatitis - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-018.14" TYPE="ANALYSIS">Analysis 18.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.14.4 rash - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.00 CI 0.07 to 15.26, <LINK REF="CMP-018.14" TYPE="ANALYSIS">Analysis 18.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.15 Other adverse events: 7. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.15.1 diminished sexual desire - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.91 CI 0.69 to 1.19, <LINK REF="CMP-018.15" TYPE="ANALYSIS">Analysis 18.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.15.2 galactorrhoea/gynaecomastia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.74 CI 0.22 to 2.49, <LINK REF="CMP-018.15" TYPE="ANALYSIS">Analysis 18.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.16 Other adverse events: 8. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.16.1 allergic reaction - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.33 CI 0.01 to 7.87, <LINK REF="CMP-018.16" TYPE="ANALYSIS">Analysis 18.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.16.2 back pain - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 3.00 CI 0.13 to 70.83, <LINK REF="CMP-018.16" TYPE="ANALYSIS">Analysis 18.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.16.3 incontinence nocturia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.43 CI 0.17 to 1.07, <LINK REF="CMP-018.16" TYPE="ANALYSIS">Analysis 18.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.16.4 suicide attempt - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.64 CI 0.06 to 7.06, <LINK REF="CMP-018.16" TYPE="ANALYSIS">Analysis 18.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.16.5 urinary hesitancy, dry mouth, constipation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 0.93 CI 0.69 to 1.25, <LINK REF="CMP-018.16" TYPE="ANALYSIS">Analysis 18.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.17 Other adverse events: 9. any serious adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.17.1 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.17 CI 0.72 to 1.88, <LINK REF="CMP-018.17" TYPE="ANALYSIS">Analysis 18.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.18 Other adverse events: 10. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.18.1 anaemia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). There was no significant difference between perphenazine and olanzapine (RR 1.00 CI 0.07 to 15.26, <LINK REF="CMP-018.18" TYPE="ANALYSIS">Analysis 18.18</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.19 Other adverse events: 11a. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.19.1 mean weight change (lb) - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring perphenazine over olanzapine (MD -11.40 CI -14.19 to -8.61, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.19.2 change in blood glucose - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.004) favouring perphenazine over olanzapine (MD -9.80 CI -16.54 to -3.06, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.19.3 change in glycosylated haemoglobin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.004) favouring perphenazine over olanzapine (MD -0.31 CI -0.52 to -0.10, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.19.4 change in cholesterol - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.003) favouring perphenazine over olanzapine (MD -9.20 CI -15.30 to -3.10, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.19.5 change in triglycerides - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.002) favouring perphenazine over olanzapine (MD -34.60 CI -62.51 to -6.69, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">18.19.6 change in prolactin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 597) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.002) favouring olanzapine over perphenazine (MD 6.50 CI 2.42 to 10.58, <LINK REF="CMP-018.19" TYPE="ANALYSIS">Analysis 18.19</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18.20 Other adverse events: 11b. lab data (skewed)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">18.20.1 weight change</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-018.20" TYPE="ANALYSIS">Analysis 18.20</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 19: PERPHENAZINE versus PENFLURIDOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">19.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.49 CI 0.20 to 1.19, <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.92 CI 0.64 to 1.31, <LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.3.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.66 CI 0.39 to 1.11, <LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.3.2 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.82 CI 0.33 to 2.05, <LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.3.3 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.13 CI 0.80 to 1.60, <LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.4 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.4.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.06 CI 0.15 to 7.24, <LINK REF="CMP-019.04" TYPE="ANALYSIS">Analysis 19.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.4.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.32 CI 0.57 to 3.09, <LINK REF="CMP-019.04" TYPE="ANALYSIS">Analysis 19.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.5 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.5.1 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.98 CI 0.49 to 1.94, <LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.5.2 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.97 CI 0.62 to 1.52, <LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.6 Other adverse events: 3. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.6.1 angina pectoris - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.53 CI 0.17 to 1.65, <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.6.2 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.85 CI 0.50 to 1.45, <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.6.3 palpitations - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was a statistically significant difference (P = 0.04) favouring perphenazine over penfluridol (RR 0.12 CI 0.02 to 0.90, <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.7 Other adverse events: 4. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.7.1 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.79 CI 0.37 to 1.72, <LINK REF="CMP-019.07" TYPE="ANALYSIS">Analysis 19.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.7.2 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.53 CI 0.05 to 5.66, <LINK REF="CMP-019.07" TYPE="ANALYSIS">Analysis 19.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.8 Other adverse events: 5. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.8.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.38 CI 0.66 to 2.86, <LINK REF="CMP-019.08" TYPE="ANALYSIS">Analysis 19.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.8.2 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.91 CI 0.46 to 1.77, <LINK REF="CMP-019.08" TYPE="ANALYSIS">Analysis 19.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.8.3 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.85 CI 0.36 to 1.98, <LINK REF="CMP-019.08" TYPE="ANALYSIS">Analysis 19.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.9 Other adverse events: 6. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.9.1 oedema</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 3.17 CI 0.13 to 76.16, <LINK REF="CMP-019.09" TYPE="ANALYSIS">Analysis 19.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.9.2 pruritus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-019.09" TYPE="ANALYSIS">Analysis 19.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.9.3 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.06 CI 0.07 to 16.48, <LINK REF="CMP-019.09" TYPE="ANALYSIS">Analysis 19.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.10 Other adverse events: 7. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.10.1 diminished sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol, with no events reported in either group (<LINK REF="CMP-019.10" TYPE="ANALYSIS">Analysis 19.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.10.2 increased sexual desire - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol, with no events reported in either group (<LINK REF="CMP-019.10" TYPE="ANALYSIS">Analysis 19.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">19.10.3 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 1.06 CI 0.15 to 7.24, <LINK REF="CMP-019.10" TYPE="ANALYSIS">Analysis 19.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19.11 Other adverse events: 8. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">19.11.1 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>). There was no significant difference between perphenazine and penfluridol (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-019.11" TYPE="ANALYSIS">Analysis 19.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 20: PERPHENAZINE versus PROCHLORPERAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">20.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">20.1.1 short term</HEADING>
<P>In this subgroup we found three relevant trials (n = 175). There was no significant difference between perphenazine and prochlorperazine (RR 0.90 CI 0.37 to 2.19, <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 9.87; df = 1; P = 0.002; I<SUP>2</SUP> = 90%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">20.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">20.2.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 165). There was no significant difference between perphenazine and prochlorperazine (RR 2.37 CI 0.80 to 7.05, <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">20.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">20.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 0.67 CI 0.24 to 1.87, <LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">20.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">20.4.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 2.29 CI 0.63 to 8.38, <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">20.4.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 0.33 CI 0.01 to 7.85, <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">20.4.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 1.96 CI 0.18 to 20.99, <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">20.4.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 1.96 CI 0.63 to 6.12, <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">20.5 Other adverse events: 1. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">20.5.1 electroencephalogram (increase) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 10) (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>). There was no significant difference between perphenazine and prochlorperazine (RR 0.33 CI 0.05 to 2.21, <LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 21: PERPHENAZINE versus QUETIAPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">21.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 3.00 CI 0.33 to 27.33, <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.1.2 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.04) favouring perphenazine over quetiapine (RR 0.91 CI 0.84 to 1.00, <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.2.1 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.05 CI 0.72 to 1.55, <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.3.1 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.91 CI 0.69 to 1.20, <LINK REF="CMP-021.03" TYPE="ANALYSIS">Analysis 21.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.4 Mental state: 2a. State - BPRS score reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.4.1 less than 25% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.33 CI 0.32 to 5.49, <LINK REF="CMP-021.04" TYPE="ANALYSIS">Analysis 21.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.5 Mental state: 2b. State - BPRS total score (high = worse)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.5.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (MD 1.10 CI -1.26 to 3.46, <LINK REF="CMP-021.05" TYPE="ANALYSIS">Analysis 21.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.6 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.6.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 7.00 CI 0.91 to 53.68, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.2 akathisia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 546) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.27 CI 0.65 to 2.48, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.3 EPS - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 541) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.53 CI 0.73 to 3.21, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.4 rigidity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 11.00 CI 0.63 to 191.04, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.5 tardive dyskinesia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 473) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.36 CI 0.88 to 2.10, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.6 torsion dystonia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 15.00 CI 0.89 to 252.09, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.6.7 tremor - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was a statistically significant difference (P = 0.01) favouring perphenazine over quetiapine (RR 12.00 CI 1.66 to 86.94, <LINK REF="CMP-021.06" TYPE="ANALYSIS">Analysis 21.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.7 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.7.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was a statistically significant difference (P = 0.04) favouring quetiapine over perphenazine (RR 4.50 CI 1.05 to 19.22, <LINK REF="CMP-021.07" TYPE="ANALYSIS">Analysis 21.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.7.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 3.00 CI 0.65 to 13.76, <LINK REF="CMP-021.07" TYPE="ANALYSIS">Analysis 21.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.8 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.8.1 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.67 CI 0.12 to 3.73, <LINK REF="CMP-021.08" TYPE="ANALYSIS">Analysis 21.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.8.2 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.60 CI 0.16 to 2.30, <LINK REF="CMP-021.08" TYPE="ANALYSIS">Analysis 21.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.8.3 insomnia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.04) favouring quetiapine over perphenazine (RR 1.37 CI 1.01 to 1.87, <LINK REF="CMP-021.08" TYPE="ANALYSIS">Analysis 21.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.8.4 sleepiness/sedation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.93 CI 0.72 to 1.19, <LINK REF="CMP-021.08" TYPE="ANALYSIS">Analysis 21.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.9 Other adverse events: 3. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.9.1 faintness, dizziness, weakness - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.99 CI 0.62 to 1.55, <LINK REF="CMP-021.09" TYPE="ANALYSIS">Analysis 21.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.9.2 orthostatic hypotension - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.17 CI 0.02 to 1.31, <LINK REF="CMP-021.09" TYPE="ANALYSIS">Analysis 21.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.9.3 tachycardia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 2.50 CI 0.52 to 11.96, <LINK REF="CMP-021.09" TYPE="ANALYSIS">Analysis 21.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.10 Other adverse events: 4. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.10.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 2.50 CI 0.52 to 11.96, <LINK REF="CMP-021.10" TYPE="ANALYSIS">Analysis 21.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.10.2 weight gain - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 3.00 CI 0.33 to 27.33, <LINK REF="CMP-021.10" TYPE="ANALYSIS">Analysis 21.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.10.3 weight gain - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 548) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.74 CI 0.48 to 1.14, <LINK REF="CMP-021.10" TYPE="ANALYSIS">Analysis 21.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.11 Other adverse events: 5. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.11.1 diminished sexual desire - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.20 CI 0.89 to 1.62, <LINK REF="CMP-021.11" TYPE="ANALYSIS">Analysis 21.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.11.2 galactorrhoea/gynaecomastia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.86 CI 0.25 to 3.02, <LINK REF="CMP-021.11" TYPE="ANALYSIS">Analysis 21.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.12 Other adverse events: 6. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.12.1 urinary hesitancy, dry mouth, constipation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.01) favouring perphenazine over quetiapine (RR 0.70 CI 0.53 to 0.93, <LINK REF="CMP-021.12" TYPE="ANALYSIS">Analysis 21.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.12.2 suicide attempt - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.29 CI 0.08 to 20.55, <LINK REF="CMP-021.12" TYPE="ANALYSIS">Analysis 21.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.12.3 incontinence nocturia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 0.52 CI 0.20 to 1.31, <LINK REF="CMP-021.12" TYPE="ANALYSIS">Analysis 21.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.13 Other adverse events: 7. any serious adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.13.1 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (RR 1.17 CI 0.73 to 1.88, <LINK REF="CMP-021.13" TYPE="ANALYSIS">Analysis 21.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.14 Other adverse events: 8a. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.14.1 abnormal ECG - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 7.00 CI 0.91 to 53.68, <LINK REF="CMP-021.14" TYPE="ANALYSIS">Analysis 21.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.14.2 abnormal liver function - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). There was no significant difference between perphenazine and quetiapine (RR 4.00 CI 0.92 to 17.40, <LINK REF="CMP-021.14" TYPE="ANALYSIS">Analysis 21.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">21.15 Other adverse events: 8b. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">21.15.1 mean weight change (lb) - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.03) favouring perphenazine over quetiapine (MD -3.10 CI -5.89 to -0.31, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.15.2 change in blood glucose - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (MD -1.60 CI -7.50 to 4.30, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.15.3 change in glycosylated haemoglobin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference between perphenazine and quetiapine (MD 0.05 CI -0.10 to 0.20, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.15.4 change in cholesterol - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (MD -4.80 CI -10.90 to 1.30, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.15.5 change in triglycerides - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and quetiapine (MD -10.90 CI -41.55 to 19.75, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">21.15.6 change in prolactin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 598) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P &lt; 0.0001) favouring quetiapine over perphenazine (MD 9.70 CI 5.38 to 14.02, <LINK REF="CMP-021.15" TYPE="ANALYSIS">Analysis 21.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 22: PERPHENAZINE versus PROMAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">22.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">22.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and promazine (RR 1.20 CI 0.93 to 1.56, <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">22.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">22.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and promazine (RR 2.49 CI 0.73 to 8.50, <LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">22.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">22.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 60) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was a statistically significant difference (P = 0.04) favouring perphenazine over promazine (RR 0.39 CI 0.16 to 0.97, <LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 23: PERPHENAZINE versus RISPERIDONE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">23.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.1.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 709). There was no significant difference between perphenazine and risperidone (RR 1.01 CI 0.92 to 1.11, <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.2.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 709). There was no significant difference between perphenazine and risperidone (RR 1.29 CI 0.73 to 2.29, <LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 1.45; df = 1; P = 0.229; I<SUP>2</SUP> = 31%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.3.1 short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 709). There was no significant difference between perphenazine and risperidone (RR 0.95 CI 0.72 to 1.24, <LINK REF="CMP-023.03" TYPE="ANALYSIS">Analysis 23.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.29 CI 0.79 to 2.12, <LINK REF="CMP-023.04" TYPE="ANALYSIS">Analysis 23.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.5 Mental state: 1a. State - less than 20% BPRS reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.5.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.81 CI 0.61 to 1.08, <LINK REF="CMP-023.05" TYPE="ANALYSIS">Analysis 23.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.6 Mental state: 1b. State - PANSS reduction ('no effect')</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.6.1 less than 20% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.86 CI 0.64 to 1.15, <LINK REF="CMP-023.06" TYPE="ANALYSIS">Analysis 23.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.6.2 less than 40% reduction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.70 CI 0.30 to 9.50, <LINK REF="CMP-023.06" TYPE="ANALYSIS">Analysis 23.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.7 Mental state: 1c. State - PANSS: mean change from baseline to endpoint</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (MD 4.00 CI -5.04 to 13.04, <LINK REF="CMP-023.07" TYPE="ANALYSIS">Analysis 23.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.8 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.8.1 akathisia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 399) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.75 CI 0.38 to 1.49, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.2 dystonia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 2.47 CI 0.67 to 9.04, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.3 EPS - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Wang-2008a" TYPE="STUDY">Wang 2008a</LINK>). There was a statistically significant difference (P = 0.03) favouring risperidone over perphenazine (RR 9.07 CI 1.20 to 68.35, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.4 EPS - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 2.23 CI 0.97 to 5.11, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.5 hyperkinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 2.64 CI 0.88 to 7.91, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.6 tardive dyskinesia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 363) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.21 CI 0.73 to 2.02, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.8.7 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.20 CI 0.67 to 2.14, <LINK REF="CMP-023.08" TYPE="ANALYSIS">Analysis 23.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.9 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.9.1 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 7.40 CI 0.39 to 139.81, <LINK REF="CMP-023.09" TYPE="ANALYSIS">Analysis 23.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.10 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.10.1 depression - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.34 CI 0.76 to 2.35, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.10.2 emotional indifference - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.06 CI 0.58 to 1.94, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.10.3 increased dream activity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.51 CI 0.62 to 3.67, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.10.4 insomnia - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 553). There was no significant difference between perphenazine and risperidone (RR 1.01 CI 0.52 to 1.97, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>). This subgroup had moderate levels of heterogeneity (Chi<SUP>2</SUP> = 1.68; df = 1; P = 0.195; I<SUP>2</SUP> = 40%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.10.5 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 553). There was no significant difference between perphenazine and risperidone (RR 1.16 CI 0.87 to 1.54, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.10.6 tension - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.97 CI 0.63 to 1.50, <LINK REF="CMP-023.10" TYPE="ANALYSIS">Analysis 23.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.11 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.11.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.01 CI 0.85 to 1.21, <LINK REF="CMP-023.11" TYPE="ANALYSIS">Analysis 23.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.12 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.12.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.93 CI 0.36 to 2.37, <LINK REF="CMP-023.12" TYPE="ANALYSIS">Analysis 23.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.12.2 lassitude - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.97 CI 0.61 to 1.52, <LINK REF="CMP-023.12" TYPE="ANALYSIS">Analysis 23.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.12.3 tachycardia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.57 CI 0.25 to 1.32, <LINK REF="CMP-023.12" TYPE="ANALYSIS">Analysis 23.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.13 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.13.1 difficulty in concentration - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.06 CI 0.71 to 1.58, <LINK REF="CMP-023.13" TYPE="ANALYSIS">Analysis 23.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.13.2 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.53 CI 0.14 to 2.01, <LINK REF="CMP-023.13" TYPE="ANALYSIS">Analysis 23.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.13.3 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-023.13" TYPE="ANALYSIS">Analysis 23.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.14 Other adverse events: 6. Endocrine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.14.1 amenorrhoea (women only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 30) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 3.00 CI 0.13 to 68.26, <LINK REF="CMP-023.14" TYPE="ANALYSIS">Analysis 23.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.14.2 gynaecomastia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-023.14" TYPE="ANALYSIS">Analysis 23.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.14.3 lactation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.21 CI 0.01 to 4.30, <LINK REF="CMP-023.14" TYPE="ANALYSIS">Analysis 23.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.14.4 menorrhagia (women only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 30) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 3.00 CI 0.13 to 68.26, <LINK REF="CMP-023.14" TYPE="ANALYSIS">Analysis 23.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.15 Other adverse events: 7. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.15.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.07 CI 0.00 to 1.20, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.15.2 diarrhoea - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.15.3 faintness, dizziness, weakness - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.86 CI 0.52 to 1.42, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.15.4 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.76 CI 0.26 to 2.23, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.15.5 weight loss - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 2.12 CI 0.56 to 8.02, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.15.6 weight gain - short term</HEADING>
<P>In this subgroup we found two relevant trials (n = 511). There was no significant difference between perphenazine and risperidone (RR 0.90 CI 0.29 to 2.81, <LINK REF="CMP-023.15" TYPE="ANALYSIS">Analysis 23.15</LINK>). This subgroup had important levels of heterogeneity (Chi<SUP>2</SUP> = 6.21; df = 1; P = 0.013; I<SUP>2</SUP> = 84%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.16 Other adverse events: 8. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.16.1 pruritus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.79 CI 0.19 to 3.38, <LINK REF="CMP-023.16" TYPE="ANALYSIS">Analysis 23.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.16.2 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.71 CI 0.12 to 4.05, <LINK REF="CMP-023.16" TYPE="ANALYSIS">Analysis 23.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.16.3 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.66 CI 0.23 to 1.89, <LINK REF="CMP-023.16" TYPE="ANALYSIS">Analysis 23.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.17 Other adverse events: 9. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.17.1 diminished sexual desire</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.06 CI 0.22 to 5.01, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.2 ejaculatory dysfunction (men only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.18 CI 0.02 to 1.43, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.3 erectile dysfunction (men only) - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 77) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.90 CI 0.30 to 2.70, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.4 galactorrhoea - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.15 CI 0.01 to 2.85, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.5 galactorrhoea/gynaecomastia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.47 CI 0.14 to 1.65, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.6 increased sexual desire - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.06 CI 0.22 to 5.01, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.17.7 orgastic dysfunction - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 5.28 CI 0.26 to 107.51, <LINK REF="CMP-023.17" TYPE="ANALYSIS">Analysis 23.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.18 Other adverse events: 10. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.18.1 failing memory - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.27 CI 0.60 to 2.68, <LINK REF="CMP-023.18" TYPE="ANALYSIS">Analysis 23.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.18.2 incontinence nocturia - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.43 CI 0.16 to 1.15, <LINK REF="CMP-023.18" TYPE="ANALYSIS">Analysis 23.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.18.3 suicide attempt - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.71 CI 0.04 to 11.26, <LINK REF="CMP-023.18" TYPE="ANALYSIS">Analysis 23.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.18.4 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 107) (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>). There was no significant difference between perphenazine and risperidone (RR 0.96 CI 0.45 to 2.07, <LINK REF="CMP-023.18" TYPE="ANALYSIS">Analysis 23.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.18.5 urinary hesitancy, dry mouth, constipation - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.09 CI 0.76 to 1.58, <LINK REF="CMP-023.18" TYPE="ANALYSIS">Analysis 23.18</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.19 Other adverse events: 11. any serious adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.19.1 long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (RR 1.08 CI 0.63 to 1.87, <LINK REF="CMP-023.19" TYPE="ANALYSIS">Analysis 23.19</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">23.20 Other adverse events: 12. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">23.20.1 mean weight change (lb) - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.05) favouring perphenazine over risperidone (MD -2.80 CI -5.58 to -0.02, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.20.2 change in blood glucose - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (MD -1.50 CI -7.04 to 4.04, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.20.3 change in glycosylated haemoglobin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference between perphenazine and risperidone (MD 0.02 CI -0.12 to 0.16, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.20.4 change in cholesterol - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (MD 2.60 CI -3.25 to 8.45, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.20.5 change in triglycerides - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was no significant difference between perphenazine and risperidone (MD 10.90 CI -14.80 to 36.60, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">23.20.6 change in prolactin - long term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 602) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P &lt; 0.00001) favouring perphenazine over risperidone (MD -15.0 CI -19.44 to -10.56, <LINK REF="CMP-023.20" TYPE="ANALYSIS">Analysis 23.20</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 24: PERPHENAZINE versus SULPIRIDE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">24.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.80 CI 0.24 to 2.71, <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.1.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.92 CI 0.86 to 4.25, <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 3.00 CI 0.13 to 71.00, <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.2.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 2.88 CI 0.12 to 67.29, <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 3.00 CI 0.13 to 71.00, <LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.3.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.15 CI 0.41 to 3.25, <LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.4 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.4.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.80 CI 0.52 to 1.24, <LINK REF="CMP-024.04" TYPE="ANALYSIS">Analysis 24.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.4.2 medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.20 CI 0.73 to 1.97, <LINK REF="CMP-024.04" TYPE="ANALYSIS">Analysis 24.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.5 Mental state: 1. State - BPRS end score (high = poor, skewed data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.5.1 medium term</HEADING>
<P>Data for this outcome are skewed and are best inspected by viewing <LINK REF="CMP-024.05" TYPE="ANALYSIS">Analysis 24.5</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.6 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.6.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.75 CI 0.18 to 3.09, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.2 akathisia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 2.88 CI 0.64 to 12.82, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.3 ataxia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.00 CI 0.07 to 15.30, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.4 dyskinesia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.48 CI 0.05 to 4.93, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.5 rigidity - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.25 CI 0.06 to 1.09, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.6 rigidity - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.64 CI 0.12 to 3.48, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.7 tremor - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.64 CI 0.28 to 1.43, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.8 tremor - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.34 CI 0.50 to 3.63, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.6.9 use of antiparkinsonian drugs - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-024.06" TYPE="ANALYSIS">Analysis 24.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.7 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.7.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.33 CI 0.01 to 7.89, <LINK REF="CMP-024.07" TYPE="ANALYSIS">Analysis 24.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.7.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 5.0 CI 0.25 to 100.2, <LINK REF="CMP-024.07" TYPE="ANALYSIS">Analysis 24.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.7.3 dry mouth - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.92 CI 0.19 to 19.73, <LINK REF="CMP-024.07" TYPE="ANALYSIS">Analysis 24.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.7.4 increased salivation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 5.00 CI 0.25 to 100.20, <LINK REF="CMP-024.07" TYPE="ANALYSIS">Analysis 24.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.8 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.8.1 excitation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.33 CI 0.07 to 1.53, <LINK REF="CMP-024.08" TYPE="ANALYSIS">Analysis 24.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.8.2 excitation - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.28 CI 0.32 to 5.10, <LINK REF="CMP-024.08" TYPE="ANALYSIS">Analysis 24.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.8.3 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.29 CI 0.55 to 3.03, <LINK REF="CMP-024.08" TYPE="ANALYSIS">Analysis 24.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.8.4 insomnia - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.24 CI 0.03 to 1.99, <LINK REF="CMP-024.08" TYPE="ANALYSIS">Analysis 24.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.8.5 need of additional benzodiazepines - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.60 CI 0.43 to 5.93, <LINK REF="CMP-024.08" TYPE="ANALYSIS">Analysis 24.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.9 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.9.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.76 CI 0.50 to 1.17, <LINK REF="CMP-024.09" TYPE="ANALYSIS">Analysis 24.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.10 Other adverse events: 4. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.10.1 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.50 CI 0.05 to 5.24, <LINK REF="CMP-024.10" TYPE="ANALYSIS">Analysis 24.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.10.2 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 5.00 CI 0.25 to 100.20, <LINK REF="CMP-024.10" TYPE="ANALYSIS">Analysis 24.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.11 Other adverse events: 5. Endocrine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.11.1 amenorrhoea - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.32 CI 0.04 to 2.85, <LINK REF="CMP-024.11" TYPE="ANALYSIS">Analysis 24.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.11.2 lactation - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.19 CI 0.01 to 3.80, <LINK REF="CMP-024.11" TYPE="ANALYSIS">Analysis 24.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.12 Other adverse events: 6. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.12.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.50 CI 0.05 to 5.24, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.12.2 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.80 CI 0.24 to 2.71, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.12.3 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.40 CI 0.08 to 1.91, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.12.4 nausea and vomiting - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.32 CI 0.04 to 2.85, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.12.5 weight loss - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 11.00 CI 0.63 to 191.04, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.12.6 weight gain - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 5.00 CI 0.62 to 40.44, <LINK REF="CMP-024.12" TYPE="ANALYSIS">Analysis 24.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.13 Other adverse events: 7. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.13.1 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.33 CI 0.01 to 7.89, <LINK REF="CMP-024.13" TYPE="ANALYSIS">Analysis 24.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.14 Other adverse events: 8. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.14.1 abdominal pain - medium term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 47) (<LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.14 CI 0.01 to 2.52, <LINK REF="CMP-024.14" TYPE="ANALYSIS">Analysis 24.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.14.2 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.20 CI 0.01 to 4.01, <LINK REF="CMP-024.14" TYPE="ANALYSIS">Analysis 24.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">24.15 Other adverse events: 9. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">24.15.1 decrease in white blood cell count and haemoglobin level - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 1.00 CI 0.07 to 15.30, <LINK REF="CMP-024.15" TYPE="ANALYSIS">Analysis 24.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.15.2 increase in white blood cell count and haemoglobin level - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 0.50 CI 0.10 to 2.54, <LINK REF="CMP-024.15" TYPE="ANALYSIS">Analysis 24.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">24.15.3 rise in alkaline phosphate and GOT levels - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 64) (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>). There was no significant difference between perphenazine and sulpiride (RR 3.00 CI 0.13 to 71.00, <LINK REF="CMP-024.15" TYPE="ANALYSIS">Analysis 24.15</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 25: PERPHENAZINE versus THIOPROPRAZATE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">25.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">25.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate (RR 0.73 CI 0.43 to 1.22, <LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">25.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">25.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate (RR 2.00 CI 0.19 to 21.40, <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">25.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">25.3.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate (RR 7.00 CI 0.89 to 54.94, <LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">25.3.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate, with no events reported in either group (<LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">25.3.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate (RR 5.00 CI 0.25 to 101.73, <LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">25.3.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioproprazate (RR 2.67 CI 0.75 to 9.51, <LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 26: PERPHENAZINE versus THIORIDAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">26.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">26.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine (RR 0.73 CI 0.43 to 1.22, <LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">26.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">26.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine (RR 2.00 CI 0.19 to 21.40, <LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">26.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">26.3.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine (RR 15.00 CI 0.88 to 256.16, <LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">26.3.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine, with no events reported in either group (<LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">26.3.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine (RR 5.00 CI 0.25 to 101.73, <LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">26.3.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and thioridazine (RR 2.67 CI 0.75 to 9.51, <LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 27: PERPHENAZINE versus THIOTHIXENE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">27.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.00 CI 0.06 to 15.48, <LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.30 CI 0.93 to 1.83, <LINK REF="CMP-027.02" TYPE="ANALYSIS">Analysis 27.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.3 Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</HEADING>
<P>For this outcome we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.18 CI 0.90 to 1.55, <LINK REF="CMP-027.03" TYPE="ANALYSIS">Analysis 27.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.4.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.58 CI 0.25 to 1.34, <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.4.2 ataxia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.00 CI 0.21 to 4.68, <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.4.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.50 CI 0.26 to 8.53, <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.4.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.80 CI 0.48 to 1.32, <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.4.5 use of antiparkinsonian drugs - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.18 CI 0.81 to 1.73, <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.5 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.5.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.29 CI 0.06 to 1.30, <LINK REF="CMP-027.05" TYPE="ANALYSIS">Analysis 27.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.5.2 dry mouth - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.00 CI 0.38 to 2.61, <LINK REF="CMP-027.05" TYPE="ANALYSIS">Analysis 27.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.6 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.6.1 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.71 CI 0.39 to 1.29, <LINK REF="CMP-027.06" TYPE="ANALYSIS">Analysis 27.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.6.2 need of additional benzodiazepines - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.00 CI 0.21 to 4.68, <LINK REF="CMP-027.06" TYPE="ANALYSIS">Analysis 27.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.6.3 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.90 CI 0.41 to 1.99, <LINK REF="CMP-027.06" TYPE="ANALYSIS">Analysis 27.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.7 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.90 CI 0.68 to 1.20, <LINK REF="CMP-027.07" TYPE="ANALYSIS">Analysis 27.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.8 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.8.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene, with no events reported in either group (<LINK REF="CMP-027.08" TYPE="ANALYSIS">Analysis 27.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.9 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.9.1 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene, with no events reported in either group (<LINK REF="CMP-027.09" TYPE="ANALYSIS">Analysis 27.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.9.2 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 2.00 CI 0.19 to 21.24, <LINK REF="CMP-027.09" TYPE="ANALYSIS">Analysis 27.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.9.3 paraesthesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 5.00 CI 0.25 to 101.18, <LINK REF="CMP-027.09" TYPE="ANALYSIS">Analysis 27.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.10 Other adverse events: 6. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.10.1 constipation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.20 CI 0.40 to 3.64, <LINK REF="CMP-027.10" TYPE="ANALYSIS">Analysis 27.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.10.2 icterus - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.33 CI 0.01 to 7.96, <LINK REF="CMP-027.10" TYPE="ANALYSIS">Analysis 27.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.10.3 loss of appetite - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.88 CI 0.35 to 2.20, <LINK REF="CMP-027.10" TYPE="ANALYSIS">Analysis 27.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.10.4 nausea and vomiting - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene, with no events reported in either group (<LINK REF="CMP-027.10" TYPE="ANALYSIS">Analysis 27.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.11 Other adverse events: 7. Skin</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.11.1 rash - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 3.00 CI 0.13 to 71.65, <LINK REF="CMP-027.11" TYPE="ANALYSIS">Analysis 27.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.12 Other adverse events: 8. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.12.1 micturition disturbances - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene, with no events reported in either group (<LINK REF="CMP-027.12" TYPE="ANALYSIS">Analysis 27.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">27.13 Other adverse events: 9. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">27.13.1 cramps - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 0.33 CI 0.01 to 7.96, <LINK REF="CMP-027.13" TYPE="ANALYSIS">Analysis 27.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">27.13.2 sweating - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 86) (<LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>). There was no significant difference between perphenazine and thiothixene (RR 1.00 CI 0.06 to 15.48, <LINK REF="CMP-027.13" TYPE="ANALYSIS">Analysis 27.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 28: PERPHENAZINE versus TIMIPERONE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">28.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.33 CI 0.67 to 2.67, <LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.33 CI 0.67 to 2.67, <LINK REF="CMP-028.02" TYPE="ANALYSIS">Analysis 28.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.3.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.11 CI 0.79 to 1.55, <LINK REF="CMP-028.03" TYPE="ANALYSIS">Analysis 28.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.4.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 0.85 CI 0.56 to 1.29, <LINK REF="CMP-028.04" TYPE="ANALYSIS">Analysis 28.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.4.2 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was a statistically significant difference (P = 0.04) favouring perphenazine over timiperone (RR 0.36 CI 0.13 to 0.95, <LINK REF="CMP-028.04" TYPE="ANALYSIS">Analysis 28.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.4.3 dystonia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 0.33 CI 0.01 to 8.08, <LINK REF="CMP-028.04" TYPE="ANALYSIS">Analysis 28.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.4.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.21 CI 0.84 to 1.73, <LINK REF="CMP-028.04" TYPE="ANALYSIS">Analysis 28.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.5 Other adverse events: 1. Anticholinergic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.5.1 blurred vision - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 3.00 CI 0.12 to 72.76, <LINK REF="CMP-028.05" TYPE="ANALYSIS">Analysis 28.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.6 Other adverse events: 2. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.6.1 drowsiness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.43 CI 0.57 to 3.60, <LINK REF="CMP-028.06" TYPE="ANALYSIS">Analysis 28.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.6.2 excitation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was a statistically significant difference (P = 0.003) favouring timiperone over perphenazine (RR 4.75 CI 1.68 to 13.46, <LINK REF="CMP-028.06" TYPE="ANALYSIS">Analysis 28.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.6.3 insomnia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.31 CI 0.94 to 1.82, <LINK REF="CMP-028.06" TYPE="ANALYSIS">Analysis 28.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.7 Other adverse events: 3. At least one</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.7.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.01 CI 0.89 to 1.16, <LINK REF="CMP-028.07" TYPE="ANALYSIS">Analysis 28.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.8 Other adverse events: 4. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.8.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.50 CI 0.71 to 3.18, <LINK REF="CMP-028.08" TYPE="ANALYSIS">Analysis 28.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.8.2 lassitude - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.07 CI 0.55 to 2.10, <LINK REF="CMP-028.08" TYPE="ANALYSIS">Analysis 28.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">28.9 Other adverse events: 5. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">28.9.1 confusion - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 0.67 CI 0.11 to 3.90, <LINK REF="CMP-028.09" TYPE="ANALYSIS">Analysis 28.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.9.2 disturbance of consciousness - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 1.00 CI 0.06 to 15.76, <LINK REF="CMP-028.09" TYPE="ANALYSIS">Analysis 28.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.9.3 dysarticulation - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 0.83 CI 0.38 to 1.84, <LINK REF="CMP-028.09" TYPE="ANALYSIS">Analysis 28.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.9.4 headache - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone (RR 0.33 CI 0.09 to 1.19, <LINK REF="CMP-028.09" TYPE="ANALYSIS">Analysis 28.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">28.9.5 seizure - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 198) (<LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>). There was no significant difference between perphenazine and timiperone, with no events reported in either group (<LINK REF="CMP-028.09" TYPE="ANALYSIS">Analysis 28.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 29: PERPHENAZINE versus TRIFLUOPERAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">29.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">29.1.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 0.63 CI 0.38 to 1.03, <LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">29.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">29.2.1 short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 0.65 CI 0.11 to 3.76, <LINK REF="CMP-029.02" TYPE="ANALYSIS">Analysis 29.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">29.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">29.3.1 akathisia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 2.29 CI 0.63 to 8.38, <LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">29.3.2 akinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 0.33 CI 0.01 to 7.85, <LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">29.3.3 dyskinesia - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 0.98 CI 0.14 to 6.71, <LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">29.3.4 parkinsonism - short term</HEADING>
<P>In this subgroup we only found one relevant trial (n = 105) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluoperazine (RR 2.62 CI 0.73 to 9.32, <LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 30: PERPHENAZINE versus TRIFLUOPROMAZINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">30.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">30.1.1 short term</HEADING>
<P>In this subgroup we found three trials (n = 178). There was no significant difference between perphenazine and trifluopromazine (RR 1.14 CI 0.66 to 1.98, <LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>). There were important levels of heterogeneity (Chi<SUP>2</SUP> = 3.19; df = 1; P = 0.07; I<SUP>2</SUP> = 69%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">30.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">30.2.1 short term</HEADING>
<P>In this subgroup we found two trials (n = 168). There was no significant difference between perphenazine and trifluopromazine (RR 2.00 CI 0.74 to 5.39, <LINK REF="CMP-030.02" TYPE="ANALYSIS">Analysis 30.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">30.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">30.3.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 62) (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>). There was no significant difference between perphenazine and trifluopromazine (RR 0.71 CI 0.25 to 2.01, <LINK REF="CMP-030.03" TYPE="ANALYSIS">Analysis 30.3</LINK>)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">30.4 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">30.4.1 akathisia - short term</HEADING>
<P>In this subgroup we found one trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluopromazine (RR 7.00 CI 0.89 to 54.94, <LINK REF="CMP-030.04" TYPE="ANALYSIS">Analysis 30.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">30.4.2 akinesia - short term</HEADING>
<P>In this subgroup we found one trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluopromazine, with no events reported in either group (<LINK REF="CMP-030.04" TYPE="ANALYSIS">Analysis 30.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">30.4.3 dyskinesia - short term</HEADING>
<P>In this subgroup we found one trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was no significant difference between perphenazine and trifluopromazine (RR 5.00 CI 0.25 to 101.73, <LINK REF="CMP-030.04" TYPE="ANALYSIS">Analysis 30.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">30.4.4 parkinsonism - short term</HEADING>
<P>In this subgroup we found one trial (n = 106) (<LINK REF="STD-Hanlon-1965" TYPE="STUDY">Hanlon 1965</LINK>). There was a statistically significant difference (P = 0.05) favouring trifluopromazine over perphenazine (RR 17.00 CI 1.01 to 287.24, <LINK REF="CMP-030.04" TYPE="ANALYSIS">Analysis 30.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">30.5 Other adverse events: 1. Central nervous system</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">30.5.1 electroencephalogram (increase) - short term</HEADING>
<P>In this subgroup we found one trial (n = 10) (<LINK REF="STD-Bennett-1961" TYPE="STUDY">Bennett 1961</LINK>). There was a no significant difference between perphenazine and trifluopromazine (RR 1.00 CI 0.08 to 11.93, <LINK REF="CMP-030.05" TYPE="ANALYSIS">Analysis 30.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 31: PERPHENAZINE versus ZIPRASIDONE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">31.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.1.1 long term</HEADING>
<P>In this subgroup we found one trial (n = 446). There was a no significant difference between perphenazine and ziprasidone (RR 0.95 CI 0.85 to 1.05, <LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.2 Leaving the study early: 2. Due to adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.2.1 long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.01 CI 0.65 to 1.58, <LINK REF="CMP-031.02" TYPE="ANALYSIS">Analysis 31.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.3 Leaving the study early: 3. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.3.1 long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.05 CI 0.75 to 1.46, <LINK REF="CMP-031.03" TYPE="ANALYSIS">Analysis 31.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.4 Adverse events: Movement disorders (completer-only data)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.4.1 akathisia - long term</HEADING>
<P>In this subgroup we found one trial (n = 399) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.75 CI 0.38 to 1.49, <LINK REF="CMP-031.04" TYPE="ANALYSIS">Analysis 31.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.4.2 EPS - long term</HEADING>
<P>In this subgroup we found one trial (n = 395) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.56 CI 0.62 to 3.94, <LINK REF="CMP-031.04" TYPE="ANALYSIS">Analysis 31.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.4.3 tardive dyskinesia - long term</HEADING>
<P>In this subgroup we found one trial (n = 363) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.21 CI 0.73 to 2.02, <LINK REF="CMP-031.04" TYPE="ANALYSIS">Analysis 31.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.5 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.5.1 insomnia - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.84 CI 0.62 to 1.13, <LINK REF="CMP-031.05" TYPE="ANALYSIS">Analysis 31.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.5.2 sleepiness/sedation - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.17 CI 0.85 to 1.60, <LINK REF="CMP-031.05" TYPE="ANALYSIS">Analysis 31.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.6 Other adverse events: 2. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.6.1 faintness, dizziness, weakness - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.86 CI 0.52 to 1.42, <LINK REF="CMP-031.06" TYPE="ANALYSIS">Analysis 31.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.7 Other adverse events: 3. Gastrointestinal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.7.1 weight gain - long term</HEADING>
<P>In this subgroup we found one trial (n = 404) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.60 CI 0.84 to 3.04, <LINK REF="CMP-031.07" TYPE="ANALYSIS">Analysis 31.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.8 Other adverse events: 4. Genitourinary</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.8.1 diminished sexual desire - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.30 CI 0.90 to 1.87, <LINK REF="CMP-031.08" TYPE="ANALYSIS">Analysis 31.8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.8.2 galactorrhoea/gynaecomastia - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.47 CI 0.14 to 1.65, <LINK REF="CMP-031.08" TYPE="ANALYSIS">Analysis 31.8</LINK>.,</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.9 Other adverse events: 5. Others</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.9.1 urinary hesitancy, dry mouth, constipation - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.09 CI 0.76, 1.58, <LINK REF="CMP-031.09" TYPE="ANALYSIS">Analysis 31.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.9.2 suicide attempt - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.71 CI 0.04, 11.26, <LINK REF="CMP-031.09" TYPE="ANALYSIS">Analysis 31.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.9.3 incontinence nocturia - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.43 CI 0.16, 1.15, <LINK REF="CMP-031.09" TYPE="ANALYSIS">Analysis 31.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.10 Other adverse events: 6. any serious adverse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.10.1 long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 1.08 CI 0.63, 1.87, <LINK REF="CMP-031.10" TYPE="ANALYSIS">Analysis 31.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">31.11 Other adverse events: 7. lab data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">31.11.1 mean weight change (lb) - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR -0.40 CI -3.45 to 2.65, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.11.2 change in blood glucose - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 2.90 CI -5.69 to 11.49, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.11.3 change in glycosylated haemoglobin - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 0.20 CI -0.10 to 0.50, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.11.4 change in cholesterol - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 9.70 CI -1.44 to 20.84, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.11.5 change in triglycerides - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a no significant difference between perphenazine and ziprasidone (RR 26.40 CI -2.71 to 55.51, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">31.11.6 change in prolactin - long term</HEADING>
<P>In this subgroup we found one trial (n = 446) (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). There was a statistically significant difference (P = 0.04) favouring ziprasidone over perphenazine (RR 4.90 CI 0.33 to 9.47, <LINK REF="CMP-031.11" TYPE="ANALYSIS">Analysis 31.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 32: PERPHENAZINE versus ZOTEPINE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">32.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">32.1.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 95) (<LINK REF="STD-Imai-1980" TYPE="STUDY">Imai 1980</LINK>). There was a no significant difference between perphenazine and zotepine (RR 1.48 CI 0.63 to 3.48, <LINK REF="CMP-032.01" TYPE="ANALYSIS">Analysis 32.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">32.2 Leaving the study early: 2. Due to relapse/worsening or no improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">32.2.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 95) (<LINK REF="STD-Imai-1980" TYPE="STUDY">Imai 1980</LINK>). There was a no significant difference between perphenazine and zotepine (RR 1.34 CI 0.56 to 3.23, <LINK REF="CMP-032.02" TYPE="ANALYSIS">Analysis 32.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">32.3 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">32.3.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 95) (<LINK REF="STD-Imai-1980" TYPE="STUDY">Imai 1980</LINK>). There was a no significant difference between perphenazine and zotepine (RR 0.98 CI 0.65 to 1.47, <LINK REF="CMP-032.03" TYPE="ANALYSIS">Analysis 32.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">32.4 Other adverse events: 1. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">32.4.1 tachycardia - short term</HEADING>
<P>In this subgroup we found one trial (n = 95) (<LINK REF="STD-Imai-1980" TYPE="STUDY">Imai 1980</LINK>). There was a no significant difference between perphenazine and zotepine (RR 0.31 CI 0.01 to 7.50, <LINK REF="CMP-032.04" TYPE="ANALYSIS">Analysis 32.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON 33: PERPHENAZINE versus ZUCLOPENTHIXOL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">33.1 Leaving the study early: 1. Any reason</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">33.1.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.80 CI 0.69 to 4.67, <LINK REF="CMP-033.01" TYPE="ANALYSIS">Analysis 33.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">33.2 Global state: 1. Change over time - no better or deterioration (ITT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">33.2.1 short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.00 CI 0.07 to 15.18, <LINK REF="CMP-033.02" TYPE="ANALYSIS">Analysis 33.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">33.3 Adverse events: Movement disorders</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">33.3.1 akathisia - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.14 CI 0.48 to 2.71, <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">33.3.2 akinesia - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 0.33 CI 0.07 to 1.51, <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">33.3.3 rigidity - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 2.20 CI 0.88 to 5.48, <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">33.3.4 tremor - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 2.20 CI 0.88 to 5.48, <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">33.4 Other adverse events: 1. Arousal</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">33.4.1 excitation - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.29 CI 0.56 to 2.95, <LINK REF="CMP-033.04" TYPE="ANALYSIS">Analysis 33.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">33.4.2 insomnia - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 0.33 CI 0.07 to 1.51, <LINK REF="CMP-033.04" TYPE="ANALYSIS">Analysis 33.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">33.4.3 sleepiness/sedation - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.71 CI 0.80 to 3.68, <LINK REF="CMP-033.04" TYPE="ANALYSIS">Analysis 33.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">33.5 Other adverse events: 2. Cardiovascular</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">33.5.1 faintness, dizziness, weakness - short term</HEADING>
<P>In this subgroup we found one trial (n = 54) (<LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>). There was a no significant difference between perphenazine and zuclupenthixol (RR 1.50 CI 0.48 to 4.72, <LINK REF="CMP-033.05" TYPE="ANALYSIS">Analysis 33.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">34. SENSITIVITY ANALYSIS</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>For the primary outcome of clinical response (as defined in each study), there was no difference in the estimate of the effect when all studies that did not fully describe randomisation methods (this included all studies rated as 'unclear' risk of bias, with only those rated as a 'low' risk remaining, including <LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>; <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>; <LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>) were excluded from meta-analysis, with 'no better or deterioration' in the comparison of perphenazine versus any antipsychotic remaining as no significant difference between groups (5 RCTs, n = 531, RR 1.05 CI 0.88 to 1.24, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Only one study provided data for this primary outcome in the perphenazine versus placebo comparison (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), which did not adequately explain randomisation methods; subsequently, the exclusion of this study left us with no data to include in the sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up and missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings on primary outcomes when we used our assumption compared with completer data only. We undertook a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption with our primary outcome of global effect: change over time - no better or deterioration. For the perphenazine versus placebo comparison we did not assume any of the outcome data as intention-to-treat was used in the study. For the comparison of perphenazine versus any antipsychotic drugs, assumptions were made in five of the 17 studies providing data for the primary outcome of global state: change over time - no better or worse (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>; <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>). After replacing our assumptions with completer-only data, there was no substantial alteration of the estimate of effect (17 RCTs, n = 1771, RR 1.05 CI 0.91 to 1.22, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). We ultimately continued to employ our assumption.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>Sixteen included studies rated as a 'high' risk of bias across at least one risk of bias domain; this included the one study in the placebo comparison for our primary outcome of 'global effect: change over time - no better or deterioration' (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), again, the exclusion of this study left us with no data to compare. With the perphenazine versus any antipsychotic drugs comparison, again there was no difference (9 RCTs, n = 891, RR 1.06 CI 0.94 to 1.20, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) in the estimate of effect after removing all included studies rated as a 'high' risk across on one or more risk of bias domain (including <LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>; <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>; <LINK REF="STD-Takahashi-1982" TYPE="STUDY">Takahashi 1982</LINK>; <LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>).</P>
<P>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We had planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for intra-class correlation coefficients (ICCs) in calculating the design effect in cluster-randomised trials. However, no cluster-randomised studies were included, therefore we did not undertake this part of the sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed-effect and random-effects</HEADING>
<P>For the perphenazine versus placebo comparison, with only one included study, there was no difference in the estimate of effect for global state: change over time - no better or deterioration when using a fixed-effect model in place of the random-effects model (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). This was also the case when comparing the same outcome for the perphenazine versus any antipsychotic comparison when using a fixed-effect model (17 RCTs, n = 1879, RR 1.01 CI 0.92 to 1.11, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. PERPHENAZINE versus PLACEBO</HEADING>
<P>In general, due to the low number of studies and participants included, we can draw no firm conclusions concerning the effects of perphenazine compared to placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Acceptability of treatment (leaving the studies early)</HEADING>
<P>When we assessed the acceptability of treatment indirectly from the number of people leaving the studies early for any reason, perphenazine did not appear to be more acceptable to those with schizophrenia than placebo. However, more participants in the placebo groups left the studies prematurely due to relapse or insufficient response. This underlines the fact that perphenazine seems an effective treatment for schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Global state</HEADING>
<P>Data from one small study (<LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>) indicate that perphenazine is preferable over placebo for improvement, with more people receiving placebo rated as 'no better or deteriorated'; however, due to the size of this study, results need interpreting with caution (n = 61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Mental state</HEADING>
<P>Findings on relapse rates are again compatible with perphenazine being more effective than placebo in improving mental state. As only n = 87 participants from two trials (<LINK REF="STD-Chouinard-1975" TYPE="STUDY">Chouinard 1975</LINK>; <LINK REF="STD-Whittaker-1963" TYPE="STUDY">Whittaker 1963</LINK>) contributed to this finding, the result must be considered with caution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Behaviour</HEADING>
<P>Based on only one small study (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>), we found no significant effects of perphenazine on behaviour. Again, no conclusion can be drawn on such little data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Adverse events</HEADING>
<P>Although a number of outcomes related to tolerability were analysed (at least one adverse event, movement disorders, anticholinergic events, arousal, cardiovascular events, central nervous system related problems, endocrine events, gastrointestinal events, abnormal laboratory results, skin problems), the results were never based on more than two studies. Therefore, it is not surprising that we found no significant differences between groups, not even for movement disorders, although perphenazine is well known to induce this troublesome adverse effect in clinical routine.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. PERPHENAZINE versus OTHER ANTIPSYCHOTIC DRUG</HEADING>
<P>Again, for this comparison, incomplete reporting of the trials clearly limited our analysis. In addition, many different comparators were used. On the one hand, this diversity may improve applicability to a certain extent. For example, most of the newer 'atypical' antipsychotic drugs, such as risperidone, olanzapine or quetiapine, have mainly been compared with haloperidol, an agent that is associated with a high risk for extrapyramidal side effects (EPS). Therefore, it can only be concluded from such trials that new antipsychotic drugs induce fewer EPS than haloperidol, whereas we do not know how the new drugs compare with other old drugs. On the other hand, the variability in terms of comparators found for perphenazine is problematic, because antipsychotic drugs have very different side-effect profiles and, if pooled in a meta-analysis, differences may cancel each other out. In this review update, we have presented all drug comparisons separately in order to complement the overall pooled analysis, with a total of 30 drug comparators.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the study early</HEADING>
<P>There is no evidence that perphenazine is associated with lower overall tolerability as measured by the numbers of people leaving due to adverse events or with lower efficacy as measured by attrition due to inefficacy of treatment. There were important levels of heterogeneity in the results for leaving the study early for any reason (Chi² = 34.32, df = 17 (P = 0.008); I² = 50%) and due to adverse events (Chi² = 12.82, df = 8 (P = 0.12); I² = 38%), no doubt attributable to the variability in comparisons and varying dosages of either drug used in the individual studies. For leaving the study early due to any reason, the source of heterogeneity was found with <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>, which compared perphenazine with prochlorperazine, triflupromazine, mepazine, chlorpromazine and promazine; as per our protocol, we combined all comparator treatment arms for the 'perphenazine versus any antipsychotic drugs' comparison, which may well explain this heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Global state</HEADING>
<P>A relatively large number of people (n = 1850) contributed to the global efficacy outcome 'change over time - no better or worse'. Around 50% of the participants were considered unimproved or worse, but these people were distributed relatively evenly between perphenazine and other antipsychotic drugs. Only <LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK> presented a usable CGI end score. There was no significant difference between groups. With only one study providing data for this outcome, it is impossible to generalise such a result.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 General</HEADING>
<P>Data were too poorly reported to allow any reasonable assessment of this outcome. Only four studies provided dichotomised data using the BPRS of &lt; 20% reduction in score (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>), &lt; 25% reduction (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>), and &lt; 30% reduction (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>). They found no significant differences between perphenazine and risperidone, quetiapine, aripiprazole or clozapine, respectively. There was a high amount of skewed data reported between studies using both the BPRS and PANSS. Only one statistically significant result was found for mental state using the PANSS total score, which found that significantly more people receiving any other antipsychotic drugs (risperidone, quetiapine, aripiprazole) scored lower on the scale than those receiving perphenazine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Specific</HEADING>
<P>Results for all other outcomes using the various PANSS subscales were equivocal, making it difficult to generalise results. There was a significant degree of heterogeneity in results for the PANSS positive subscale (Chi² = 74.07, df = 1 (P &lt; 0.00001); I<SUP>2</SUP> = 99%), which we suspect is attributable to the differing drug comparisons between studies. (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK> used olanzapine as a comparator; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK> used aripiprazole), as well as the difference in the permitted maximum dose of perphenazine between the studies or 16 mg/day (<LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>) or 60 mg/day (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Behaviour</HEADING>
<P>Only the three early studies published by Itoh in 1969 reported on behaviour in general, but they found no difference between perphenazine and the comparators clotiapine, thiothixene and methylperidol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Tolerability</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.5.1 Movement disorder</HEADING>
<P>According to the 22 studies that provided data on movement disorder, perphenazine showed a similar risk of inducing such adverse effects as other antipsychotic drugs. However, the results appeared on the whole to be relatively heterogeneous, particularly with akathisia, dystonia, rigidity, tremor and use of anti-parkinsonian drugs. This heterogeneity may be partly due to the diversity of comparators used. More studies using the single comparators would be needed to allow a finer grained analysis of the extrapyramidal symptoms (EPS) risk associated with perphenazine and other single antipsychotic drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.5.2 Other adverse events</HEADING>
<P>On the whole, there were no convincing differences between perphenazine and other antipsychotic in terms of other adverse events such as anticholinergic, cardiovascular, dermatological, endocrine, gastrointestinal or genitourinary problems. According to a small number of studies, palpitations were significantly less frequent in the perphenazine group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Missing data</HEADING>
<P>It is disappointing, and remarkable, that even after the 2013 update search, despite considerable investment in clinical trials, no data are available on social functioning, employment status, cognitive functioning, satisfaction with care, hospital admission, family burden and economic costs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. PERPHENAZINE versus OTHER ANTIPSYCHOTICS (ACUTE)</HEADING>
<P>We pooled data for participants in the seven studies that included those in the acute stage of psychosis (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>; <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>; <LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>; <LINK REF="STD-Lepola-1989" TYPE="STUDY">Lepola 1989</LINK>; <LINK REF="STD-Remvig-1987" TYPE="STUDY">Remvig 1987</LINK>; <LINK REF="STD-Van-Praag-1976" TYPE="STUDY">Van Praag 1976</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Leaving the study early</HEADING>
<P>Data demonstrate that significantly more people receiving perphenazine left the study early due to any reason when compared with people receiving any other type of antipsychotic medication. This may suggest that perphenazine is less tolerable and subsequently not as appropriate for people in the acute stage of illness as compared to other antipsychotic drugs, including risperidone, loxapine, sulpiride, zuclopenthixol, and clozapine. However, when assessed individually, there is no difference in the estimate of effect with the occurrence of leaving the study early with 'any other antipsychotic' versus perphenazine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Global state</HEADING>
<P>As regards global state, there was no difference in people considered 'no better or deteriorated'; this outcome did present high degrees of heterogeneity (Chi² = 13.71, df = 4 (P = 0.008); I² = 71%); the source of this was found to be <LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>, interventions of which included perphenazine 12 mg or 24 mg/day versus benperidol 6 mg or 12 mg/day - benperidol is a highly potent butyrophenone derivative that is not commonly prescribed in practice. This may go some way to explaining the inconsistency in the results that include other, less potent comparisons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Mental state</HEADING>
<P>In the individual study that included acute participants and provided mental state outcomes using the BPRS and PANSS (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>, n = 107), there was no significant difference between drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Adverse events</HEADING>
<P>Across all adverse events that were reported, the only significant results was that of weight gain, which was seen more in people receiving risperidone than those receiving perphenazine (<LINK REF="STD-Hoyberg-1993" TYPE="STUDY">Hoyberg 1993</LINK>, n = 107). Again, this finding is based on one small study - more evidence is needed to derive power from this results.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. PERPHENAZINE versus SPECIFIC-NAMED ANTIPSYCHOTICS</HEADING>
<P>All antipsychotic drugs that were used as a comparator have been presented separately from the meta-analysis in comparison two; however, there was never more than three RCTs included in these other comparisons, making a meaningful interpretation of the evidence relating to each specific drug difficult. We have, however, aimed to make available and accessible all specific comparisons, and have summarised the results to these below.</P>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Leaving the study early</HEADING>
<P>In the main comparison of 'perphenazine versus any antipsychotic drugs', the high degree of heterogeneity in the results for leaving the study early for any reason (Chi² = 34.32, df = 17 (P = 0.008); I² = 50%) was found to be attributable to <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>, which compared perphenazine with prochlorperazine, triflupromazine, mepazine, chlorpromazine and promazine; again, as per our protocol, we combined all comparator treatment arms for the 'perphenazine versus any antipsychotic drugs' comparison, which may well explain this heterogeneity. As suspected, when we inspected these drug comparators individually, we identified no significant differences between perphenazine and prochlorperazine (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>), trifluopromazine (<LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>), mepazine (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>), chlorpromazine (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>), and promazine (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>). The addition of <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK> to the body of the evidence has highlighted that people receiving perphenazine were more likely to leave the study early when compared to olanzapine, however with more leaving early if receiving quetiapine, and no difference with risperidone or ziprasidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Global state</HEADING>
<P>For the outcome of global state ('no better or deterioration', which was defined by each individual study), results were significantly in favour of perphenazine when comparing with benperidol (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), mepazine (<LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>) and promazine (<LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK>). However, these findings are based on the results of two studies providing data for these outcomes, with less than n = 60 participants overall (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>; <LINK REF="STD-Kurland-1961" TYPE="STUDY">Kurland 1961</LINK>), therefore, it is not possible to draw meaningful conclusions from these results. All other comparisons demonstrated no difference when compared with perphenazine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Mental state</HEADING>
<P>Generally, there was no difference between specific-named antipsychotic drugs versus perphenazine for both dichotomous and continuous outcomes. However, one small study (<LINK REF="STD-Wang-2008b" TYPE="STUDY">Wang 2008b,</LINK> n = 60) found a statistically significant difference between groups for higher scores (worse mental state) on the PANSS total, positive and negative scores, when comparing perphenazine with olanzapine (<LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>). Another study (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>) found a statistically significant difference between groups for higher scores (worse mental state) on the BPRS anxiety-depression score when comparing perphenazine with clozapine. Again, these data need backing-up with further studies making these specific comparisons in order to draw meaningful conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Behaviour</HEADING>
<P>Only three studies overall provided data for behaviour outcomes (<LINK REF="STD-Itoh-1969" TYPE="STUDY">Itoh 1969</LINK>; <LINK REF="STD-Itoh-1969-II" TYPE="STUDY">Itoh 1969 II</LINK>; <LINK REF="STD-Itoh-1969-III" TYPE="STUDY">Itoh 1969 III</LINK>); each comparator demonstrated no difference (clothiapine, methyperidol and thiothixene) when compared with perphenazine. All other studies, disappointingly, did not provide any useable data relating to behavioural outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Tolerability</HEADING>
<P>as regards movement disorders, there was little light between studies comparing specific antipsychotic drugs with perphenazine; the only statistically significant differences to be found were with instances of EPS, which were more prominent in people receiving perphenazine compared to risperidone (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>). Perphenazine was also less favourable with participants. with significantly more people experiencing tremor than those receiving either clozapine (<LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>) or quetiapine (<LINK REF="STD-Wang-2008c" TYPE="STUDY">Wang 2008c</LINK>). More people receiving perphenazine required EPS drugs compared to those receiving aripiprazole (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>), a significant finding. However, it was found that more people receiving clopenthixol required EPS drugs compared to those receiving perphenazine (<LINK REF="STD-Dehnel-1968" TYPE="STUDY">Dehnel 1968</LINK>). These are all findings that need further evidence from research in order to confirm the differences expected between the various comparator drugs.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Applicability</HEADING>
<P>Eleven studies out of the included 31 used operational criteria to diagnose participants. Since the diagnosis of schizophrenia has changed over time, the use of simple clinical judgement may have led to the inclusion of some people who would nowadays not be considered to have schizophrenia. On the other hand, the studies may reflect clinical practice where diagnostic instruments are rarely used to meticulously-classify patients. Indeed, the participants appear to be broadly similar to those in clinical practice in terms of duration and characteristics of illness. Furthermore, the centres of the trials covered a relatively wide range of geographic regions that included Japan, Europe (especially Scandinavia) and North America. One problem is, however, that the vast majority of studies were undertaken in hospitals. Many people with schizophrenia are treated in the community, but not many outpatient studies on perphenazine are available.</P>
<P>The included studies mainly fell into the 'short-term' category. The lack of longer-term studies is unfortunate because schizophrenia is typically a chronic illness. Only two trials had a duration of more than six months (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>; <LINK REF="STD-Naukkarinen-2000" TYPE="STUDY">Naukkarinen 2000</LINK>). Little can therefore be concluded regarding the long-term effects of perphenazine and more long-term trials are needed.</P>
<P>Regarding interventions and doses, the studies in this review presented strategies that are similar to those used in daily clinical practice. In most of the studies, doses between 8 mg and 24 mg were given. However, in some studies, doses could be increased to up to 120 mg daily (<LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>). Perphenazine was compared with placebo and a wide variety of 30 other antipsychotic drugs. This high variability of comparators may in part explain why the meta-analytic combination of the trials revealed no convincing differences between perphenazine and control antipsychotic drugs. However, even with analysis of perphenazine versus specific antipsychotic drugs, little difference was found between either groups. Finally, it frequently appeared likely that the patients' therapists made the assessments with scales, although clear statements were frequently not made. Many of the data must therefore be considered as prone to bias. The addition of the <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK> study was timely, as it provided the review with evidence from an important RCT concerning the effectiveness of older antipsychotic drugs as compared to the newer 'atypicals', the results of which our review largely concurs.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>The overall quality of the evidence was 'very low'; only seven publications presented adequate information about allocation concealment. All other 24 included studies were rated as 'unclear', because it was unknown exactly how the randomisation had been undertaken. This is a potential fundamental source of bias.</P>
<P>Funnel plots did not suggest evidence for publication bias in the sense that small trials with no beneficial effects for perphenazine might not have been published. However, in most comparisons it was possible to include only a few studies, which clearly limits the power of this method to detect publication bias (if fewer than eight studies were available, funnel-plots were not even considered).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>The review protocol and process of study selection were strictly adhered to throughout the entire review process, and the process for searching for studies was thorough and data were extracted independently; however, this was made difficult due to numerical inconsistencies in parts of the reported data. Review authors adhered to the guidance from the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006196.pub2/full#CD006196-bbs2-0066">Higgins 2011</A>) and the <I>Methodological Expectations for Cochrane Intervention Reviews</I> (<A HREF="http://www.editorial-unit.cochrane.org/mecir">MECIR</A>). Furthermore, authors of included studies were contacted to obtain details of ongoing or unpublished studies, but there remains a possibility that other unpublished trials of the intervention exist to which the review authors do not currently have access. As a consequence, publication bias may have been perpetuated as we worked predominantly with published reports.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>For other formulations of perphenazine that were not included in this review (depot perphenazine decanoate and enanthate), the currently-published Cochrane review demonstrates again little differences between the depot or enanthate compounds and other antipsychotic drugs with similar administration (<LINK REF="REF-David-2005" TYPE="REFERENCE">David 2005</LINK>). As with our review, the body of evidence and the quality was either poor or unclear, with more call for further high quality, large RCTs that will give greater, clearer indication of the benefits or harms of these compounds versus others. The addition of the <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK> study added to the body of evidence that perphenazine seems to be as effective as other antipsychotic drugs for the treatment of schizophrenia.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia</HEADING>
<P>Perphenazine seems to be more effective than placebo and as effective as other antipsychotic drugs for the treatment of schizophrenia. The adverse effect profile of the drug could not be differentiated from that of other antipsychotic drugs, but this is, in part, due to incomplete reporting of data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>Most of the data about perphenazine relate to a short treatment period. We found no clear differences in terms either of efficacy or adverse effects compared to other antipsychotic compounds. We believe that this result was, in part, related to a high variability of comparators used, which may have blurred differences compared to specific groups of antipsychotic drugs, e.g. high/low-potency compounds or 'atypical' antipsychotic drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers or policy makers</HEADING>
<P>Included studies reported no data relating to service utilisation or functioning in the community. No good data are available even for simple clinical questions such as optimum dose. On the other hand, perphenazine is a relatively cheap drug compared to new, 'atypical' antipsychotic drugs. Therefore, investing some money in research on this drug could be cost-saving in the long run. <LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK> performed a cost-effectiveness evaluation of the drugs used in the study, and we anticipate a more complete economic evaluation in a future update of this review.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>The vast majority of the studies took place at least 30 years ago. This explains why reporting may not be to modern standards (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) and thus limiting possibilities of summarising data in a meta-analysis and arriving at clear conclusions. We therefore believe that studies are still warranted, since perphenazine is an inexpensive drug that has been used by physicians over decades. Generally, this review has shown that there is very little difference between perphenazine and other (either 'typical' or 'atypical') antipsychotic medication, and that the decision regarding which antipsychotic will be best for a person should be judged between clinician and patient, according to the latter's individual needs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<P>Future trials should be longer and better-reported than the currently available studies. Such studies should address not only pure 'efficacy', but also clinically relevant outcomes such as relapse, hospital admission, satisfaction with care, social functioning, family burden and employment. The optimum dose of perphenazine needs to be evaluated in dose finding studies. Other objectives might be to compare perphenazine with 'atypical' antipsychotic drugs and with high/low-potency antipsychotic drugs to better identify the profile of the compound.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank the editorial team of the Cochrane Schizophrenia Group for all their help. The Group produces and maintains standard text for use in the methods sections of their reviews. We have used this text as the basis for our protocol and adapted it as required. We would also like to thank Kristian Wahlbeck for translating <LINK REF="STD-Povlsen-1987" TYPE="STUDY">Povlsen 1987</LINK>. We would also like to thank Noriko Yamashita for her help with translating included Japanese studies and Makoto Wada for extracting the data from the Japanese studies. Laux Gerd helped develop the protocol and provided access to further reports on perphenazine, we thank him for his help.</P>
<P>Many letters were sent by the review authors to authors, asking for extra information about their trials. We are very grateful that Profs. Rimon, Levine, van Praag, Shalev and Svestka were kind enough to respond.</P>
<P>Ricardo Harripaul kindly peer reviewed this version.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-05 15:28:28 +0000" MODIFIED_BY="[Empty name]">
<P>Benno Hartung - none known.<BR/>Stephanie Sampson - none known.<BR/>Stefan Leucht - S. Leucht has received lecture honoraria from EliLilly, Lundbeck, Pfizer, Janssen, Johnson and Johnson, BristolMyersSquibb, Lundbeck, Roche, SanofiAventis, ICON and Abbvie; honoraria for consulting from Roche, Janssen, Lundbeck, and EliLilly; for the preparation of educational material and publications from the Lundbeck Institute and Roche. EliLilly has provided medication for a clinical trial led by SL as principal investigator.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-07 10:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Benno Hartung - protocol development, data extraction, writing of the report.<BR/>Stephanie Sampson - quality-assessed; data extracted new studies; wrote update review report<BR/>Stefan Leucht - protocol development, verification of data extraction, writing of the report.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Minor changes:</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Additions made to outcomes of interest; economic and patient-important outcomes added, including:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6. Economic</HEADING>
<P>6.1 Average change in total cost of medical and mental health care<BR/>6.2 Total indirect and direct costs<BR/>6.3 Direct resource use:<BR/>
<I>6.3.1 Outpatients - number of contacts (GP consultation, psychiatrist, psychologists, psychiatric nurse, counsellor, social worker)</I>
<BR/>
<I>6.3.2 Hospitalisation (taking battery of tests, patients&#8217; physical, psychiatric and psychological profile and psychological assessment, number of days, relapse)</I>
<BR/>
<I>6.3.3 Medication (different types of antipsychotic drugs to include dose and frequency, treatment of side effects)</I>
<BR/>
<I>6.3.4 Psychological therapies (different types of psychological therapies to include session numbers and frequency)</I>
<BR/>
<I>6.3.5 Other resources (day centres, night shelter) and transportation for medical care visits</I>
<BR/>6.4 Indirect resource use:<BR/>
<I>6.4.1 Family, relative and friends resources</I>
<BR/>
<I>6.4.2 Police, criminal justice system</I>
<BR/>
<I>6.4.3 Benefits paid, social security payments</I>
<BR/>
<I>6.4.4 Employment agency workers, absence from work, loss of productivity</I>
<BR/>6.5 Cost-effectiveness ratios represented by ICER (incremental cost-effectiveness ratio)<BR/>6.6 Cost-utilities represented by incremental costs per QALY (quality-adjusted life year) or DALYs (disability-adjusted life year)<BR/>6.7 Cost benefit represented by net Benefit Ratio, others.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Service use and hospitalisation</HEADING>
<P>7.1 Hospital admission<BR/>7.2 Medication use<BR/>7.3 Engagement with health services</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Satisfaction</HEADING>
<P>8.1 Satisfaction with treatment<BR/>8.2 Satisfaction with care<BR/>8.3 Quality of life outcomes<BR/>8.4 Employment status"</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-27 11:04:32 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-01-27 11:04:32 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-01-27 11:04:32 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amakusa-1973" MODIFIED="2015-01-27 10:31:48 +0000" MODIFIED_BY="[Empty name]" NAME="Amakusa 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-01-27 10:31:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amakusa T, Majima T</AU>
<TI>The comparison of therapeutic effects of FK-880 (sulpiride) and perphenazine in schizophrenia by a double-blind controlled study</TI>
<SO>Juntendo Igako</SO>
<YR>1973</YR>
<VL>19</VL>
<NO>2</NO>
<PG>239-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett-1961" MODIFIED="2015-01-27 10:31:56 +0000" MODIFIED_BY="[Empty name]" NAME="Bennett 1961" YEAR="1961">
<REFERENCE MODIFIED="2015-01-27 10:31:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett JL, Kooi KA</AU>
<TI>Five phenothiazine derivates. evaluation and toxicity studies</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE-2005" MODIFIED="2015-01-27 10:51:16 +0000" MODIFIED_BY="[Empty name]" NAME="CATIE 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Addington D</AU>
<TI>Impact of second generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia</TI>
<SO>Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:33:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al</AU>
<TI>Impact of second-generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 11:45:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Antipsychotic medications for schizophrenia on equal footing in improving patients' thinking skills</TI>
<SO>Science Update</SO>
<YR>2007</YR>
<PG>1</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="ANON" TYPE="OTHER" VALUE="2007 h"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:34:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ascher-Svanum H, Nyhuis AW, Faries DE, Heiler L, Kinon BJ</AU>
<TI>Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotic drugs during a one-year treatment for schizophrenia</TI>
<SO>Clinical Schizophrenia &amp; Related Psychoses</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>3</NO>
<PG>226-34</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="ASCHER-SVANUM" TYPE="OTHER" VALUE="2008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:34:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bick P, Knoesen N, Castle D</AU>
<TI>Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists</TI>
<SO>Australasian Psychiatry</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>465-9</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CATIE" TYPE="OTHER" VALUE="2003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 10:05:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>CATIE - Schizophrenia Trial</TI>
<SO>National Institute of Mental Health (NIMH), NCT00014001</SO>
<YR>Study start: December 2000; Study completion: December 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:34:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA</AU>
<TI>Effectiveness of switching antipsychotic medications</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>12</NO>
<PG>2090-5</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="ESSOCK" TYPE="OTHER" VALUE="2006 b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:34:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gutierrez-Suela F</AU>
<TI>Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study</TI>
<SO>Farmacia Hospitalaria</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>2</NO>
<PG>83-90</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="GUTIERREZ-SUELA" TYPE="OTHER" VALUE="2008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:34:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Haddad PM, Dursun S</AU>
<TI>Selecting antipsychotic drugs in schizophrenia: lessons from CATIE</TI>
<SO>Journal of Psychopharmacology (Oxford, England)</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>332-4</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CATIE" TYPE="OTHER" VALUE="2003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al</AU>
<TI>The association between weight change and symptom reduction in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>128</VL>
<NO>1-3</NO>
<PG>166-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hermes E, Rosenheck R</AU>
<TI>Choice of randomization to clozapine versus other second generation antipsychotic drugs in the CATIE schizophrenia trial</TI>
<SO>Journal of Psychopharmacology (Oxford, England)</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1194-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA</AU>
<TI>Minimum clinically important difference in the positive and negative syndrome scale with data from the clinical antipsychotic trials of intervention effectiveness (CATIE)</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2012</YR>
<VL>73</VL>
<NO>4</NO>
<PG>526-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, et al</AU>
<TI>Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>1</NO>
<PG>73-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe R</AU>
<TI>Neurocognitive efficacy in patients with chronic schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S577</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al; CATIE Investigators; Neurocognitive Working Group</AU>
<TI>Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>ArchIves of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>6</NO>
<PG>633-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:35:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries D, Lawson T</AU>
<TI>Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study</TI>
<SO>Value in Health</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>7</NO>
<PG>14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH</AU>
<TI>Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>133</VL>
<NO>1-3</NO>
<PG>42-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:51:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MA, Rosenheck RA, Perkins DO, et al</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 11:43:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lin LA</AU>
<TI>Comparing antipsychotic treatments for schizophrenia: A health state approach</TI>
<SO>Dissertation Abstracts International: Section B: The Sciences and Engineering</SO>
<YR>2012</YR>
<VL>73</VL>
<NO>2-B</NO>
<PG>863</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY,Rosenheck RA, et al; CATIE Investigators</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<IDENTIFIERS MODIFIED="2013-11-06 11:52:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-06 11:52:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.163.4.600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al</AU>
<TI>Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</TI>
<SO>Biological Psychiatry</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1013-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al</AU>
<TI>Extrapyramidal side-effects of antipsychotic drugs in a randomised trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<NO>4</NO>
<PG>279-88</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CATIE" TYPE="OTHER" VALUE="2003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nasrallah HA</AU>
<TI>Metabolic findings from the CATIE trial and their relation to tolerability</TI>
<SO>CNS Spectrums</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>7 Suppl 7</NO>
<PG>32-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:36:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Olfson M, Ascher-Svanum H, Faries DE, Marcus SC</AU>
<TI>Predicting psychiatric hospital admission among adults with schizophrenia</TI>
<SO>Psychiatric Services (Washington, D.C.)</SO>
<YR>2011</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1138-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al</AU>
<TI>The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>1</NO>
<PG>17-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA</AU>
<TI>Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>2-3</NO>
<PG>118-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnick SG, Rosenheck RA, Canive JM, Souza CD, Stroup TS, McEvoy J, et al</AU>
<TI>Employment outcomes in a randomized trial of second-generation antipsychotic drugs and perphenazine in the treatment of individuals with schizophrenia</TI>
<SO>Journal of Behavioural Health Services and Research</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>2</NO>
<PG>215-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, et al</AU>
<TI>Second-generation antipsychotic drugs: Reviewing the cost-effectiveness component of the CATIE trial</TI>
<SO>Expert Review of Pharmacoeconomics &amp; Outcomes Research</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>103-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al</AU>
<TI>Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al</AU>
<TI>Cost-effectiveness of second-generation antipsychotic drugs and perphenazine in a randomized trial of treatment for chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>12</NO>
<PG>2080-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulte PFJ, De Haan L</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>Tijdschrift voor Psychiatrie</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>3</NO>
<PG>243-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al</AU>
<TI>Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:37:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Leiberman JA, McEvoy JP, Swartz MS, Davis SM</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>611-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al</AU>
<TI>Results of phase 3 of the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CATIE" TYPE="OTHER" VALUE="2003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al</AU>
<TI>Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<NO>3</NO>
<PG>415-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al</AU>
<TI>The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developme</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>15-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-26 11:18:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stroup TS</AU>
<TI>Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al</AU>
<TI>Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<NO>3</NO>
<PG>428-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, et al</AU>
<TI>What CATIE found: results from the schizophrenia trial</TI>
<SO>Psychiatry Online</SO>
<YR>May 2008</YR>
<VL>59</VL>
<NO>5</NO>
<PG>500-06</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F. et al</AU>
<TI>The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>1-3</NO>
<PG>39-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:38:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al</AU>
<TI>A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial</TI>
<SO>American Journal of Medical Genetics</SO>
<YR>2010</YR>
<VL>153B</VL>
<NO>1</NO>
<PG>336-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:39:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, et al</AU>
<TI>Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2011</YR>
<VL>51</VL>
<NO>11</NO>
<PG>1587-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CATIE"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1975" MODIFIED="2015-01-27 10:39:09 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1975" YEAR="1975">
<REFERENCE MODIFIED="2015-01-27 10:39:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Serrano M, Albert JM, Charette R</AU>
<TI>Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<PG>1295-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1977" MODIFIED="2015-01-27 10:39:18 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-01-27 10:39:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L</AU>
<TI>Phenothiazine-induced ECG abnormalities. Effect of a glucose load</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>8</NO>
<PG>951-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1967" MODIFIED="2015-01-27 10:39:25 +0000" MODIFIED_BY="[Empty name]" NAME="Collins 1967" YEAR="1967">
<REFERENCE MODIFIED="2015-01-27 10:39:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins AD, Dundas J</AU>
<TI>A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1967</YR>
<VL>113</VL>
<PG>1425-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dehnel-1968" MODIFIED="2015-01-27 10:39:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dehnel 1968" YEAR="1968">
<REFERENCE MODIFIED="2015-01-27 10:39:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dehnel LL, Vestre ND, Schiele BC</AU>
<TI>A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>4</NO>
<PG>169-76</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="DEHNEL" TYPE="OTHER" VALUE="1968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Eckmann-1984" NAME="Eckmann 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Eckmann F, Weber J</AU>
<TI>No English version available</TI>
<TO>Vergleich zwischen Perphenazin und Benperidol. Eine kontrollierte Doppelblind-Studie</TO>
<SO>unpublished manuscript</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fruensgaard-1978" MODIFIED="2015-01-27 10:39:44 +0000" MODIFIED_BY="[Empty name]" NAME="Fruensgaard 1978" YEAR="1978">
<REFERENCE MODIFIED="2015-01-27 10:39:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F</AU>
<TI>Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1978</YR>
<VL>5</VL>
<NO>8</NO>
<PG>601-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1964" MODIFIED="2015-01-27 10:39:51 +0000" MODIFIED_BY="[Empty name]" NAME="Hanlon 1964" YEAR="1964">
<REFERENCE MODIFIED="2015-01-27 10:39:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE,Nussbaum K, Wittig B, Hanlon DD, Kurland AA</AU>
<TI>The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients</TI>
<SO>Journal of New Drugs</SO>
<YR>1964</YR>
<VL>4</VL>
<PG>52-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1965" NAME="Hanlon 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA</AU>
<TI>The comparative effectiveness of eight phenothiazines</TI>
<SO>Psychopharmacologia</SO>
<YR>1965</YR>
<VL>7</VL>
<NO>2</NO>
<PG>89-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoyberg-1993" NAME="Hoyberg 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth Nielsen M, Salvesen I</AU>
<TI>Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>6</NO>
<PG>395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imai-1980" MODIFIED="2015-01-27 10:40:05 +0000" MODIFIED_BY="[Empty name]" NAME="Imai 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-01-27 10:40:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imai H, Nakamura M, Fukui Y et al</AU>
<TI>Comparison of efficacy of zotepine and perphenazine in schizophrenia by double-blind, controlled study</TI>
<SO>Shinkei Seishin Yakuri</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>3</NO>
<PG>285-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1969" MODIFIED="2015-01-27 10:40:12 +0000" MODIFIED_BY="[Empty name]" NAME="Itoh 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-01-27 10:40:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Okamoto M, Miura S, Suzuki Y, Takemasa K, Shigeta M, et al</AU>
<TI>A comparison between the clinical effectiveness of a dibenzothiazepine derivative and a phenothiazine derivative in schizophrenia. A controlled double blind study using clotiapine (W 130) and perphenazine</TI>
<SO>Seishin Igaku</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>6</NO>
<PG>465-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1969-II" MODIFIED="2015-01-27 10:40:18 +0000" MODIFIED_BY="[Empty name]" NAME="Itoh 1969 II" YEAR="1969">
<REFERENCE MODIFIED="2015-01-27 10:40:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Miura S, Asai M, et al</AU>
<TI>Comparison of thiothixene and perphenazine in schizophrenic patients using double-blind technique</TI>
<SO>Seishin Igaku</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>4</NO>
<PG>284-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1969-III" MODIFIED="2015-01-27 10:40:25 +0000" MODIFIED_BY="[Empty name]" NAME="Itoh 1969 III" YEAR="1969">
<REFERENCE MODIFIED="2015-01-27 10:40:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Okamoto M, Miura S et al</AU>
<TI>Comparison of a butyrophenone derivative (methylperidol) and a phenothiazine derivative (perphenazine) in schizophrenic patients using double-blind technique: statistical analysis by sequential method and wilcoxon test</TI>
<SO>Seishin Igaku</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>2</NO>
<PG>131-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1976" MODIFIED="2015-01-27 10:40:40 +0000" MODIFIED_BY="[Empty name]" NAME="Itoh 1976" YEAR="1976">
<REFERENCE MODIFIED="2015-01-27 10:40:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Miura S, Yagi G, Ogita K, Ohtsuka N, Koga Y, et al</AU>
<TI>Comparison of clinical effects of penfluridol, a long-acting oral neuroleptic, and perphenazine in schizophrenia using double-blind technique</TI>
<SO>Rinsho Hyoka</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>1</NO>
<PG>101-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2003" MODIFIED="2015-01-27 11:04:32 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-06 13:43:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bristol-Myers S</AU>
<TI>A multicenter, randomized, double-blind study of flexible doses of aripiprazole versus perphenazine in the treatment of patients with treatment-resistant schizophrenia</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="BRISTOL-MYERS" TYPE="OTHER" VALUE="2004"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 13:33:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gismondi R, Meltzer H, Kujawa M, Carson W, Stringfellow J, Iwamoto T, et al</AU>
<TI>Aripiprazole versus perphenazine in treatment-resistant schizophrenia</TI>
<SO>Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24; Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:40:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, et al</AU>
<TI>Aripiprazole in treatment-resistant schizophrenia: a 6-week double- blind comparison study versus perphenazine</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>155-6</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 13:44:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kane J, Carson WH, Kujawa M, Stringfellow J, Marcus R, Sanchez R, et al</AU>
<TI>Aripiprazole in treatment-resistant schizophrenia: A 6-week double-blind comparison study versus perphenazine</TI>
<SO>Conference proceedings</SO>
<YR>2004</YR>
<PG>155-6</PG>
<PB>Elsevier Science Bv</PB>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2004a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-06 13:41:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kane J, McQuade R, Jody D, Carson W, Kujawa M, Stringfellow J, et al</AU>
<TI>Aripiprazole in treatment-resistant schizophrenia: a 6-week double-blind comparison study vs perphenazine</TI>
<SO>Conference proceedings: 12th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:41:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Aripiprazole Study Group</AU>
<TI>Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>2</NO>
<PG>213-23</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:41:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, et al</AU>
<TI>Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S326</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:41:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Modell S, Jody D, Kujawa M, Carson W, Stringfellow J, Iwamoto T, et al</AU>
<TI>Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotic drugs</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S265</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:41:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sanchez R, Meltzer HY, Marcus RN, Stringfellow J, Carson WH, Kane JM</AU>
<TI>Aripiprazole versus perphenazine in Treatment - Resistant Schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>502</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KANE" TYPE="OTHER" VALUE="2003 a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurihara-1983" MODIFIED="2015-01-27 10:41:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kurihara 1983" YEAR="1983">
<REFERENCE MODIFIED="2015-01-27 10:41:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurihara M, Ito H, Kato N et al</AU>
<TI>Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine</TI>
<SO>Rinsho Seishin Igaku</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>4</NO>
<PG>519-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1961" MODIFIED="2015-01-27 10:51:54 +0000" MODIFIED_BY="[Empty name]" NAME="Kurland 1961" YEAR="1961">
<REFERENCE MODIFIED="2015-01-27 10:51:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AM</AU>
<TI>The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1961</YR>
<VL>133</VL>
<NO>1</NO>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Hanlon TE, Tatom MH, Simopoulos AM</AU>
<TI>Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1961</YR>
<VL>132</VL>
<PG>61-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepola-1989" MODIFIED="2015-01-27 10:41:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lepola 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-01-27 10:41:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepola U, Koskinen T, Rimon R, Salo H, Gordin A</AU>
<TI>Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial</TI>
<SO>Acta Psychatrica Scandinavica</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>1</NO>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naukkarinen-2000" MODIFIED="2015-01-27 10:42:01 +0000" MODIFIED_BY="[Empty name]" NAME="Naukkarinen 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-02-25 12:58:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Eli Lilly and Company</AU>
<TI>HGBJ: olz v perphenazine</TI>
<SO>Eli Lilly and Company</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-12 13:16:07 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naukkarinen H, Rimon R, Katila H, Riihikangas R, Heikkilä L</AU>
<TI>Olanzapine and perphenazine in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 16:03:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rimon RH</AU>
<TI>Olanzapine versus perphenazine in the treatment of schizophrenia: a double-blind study</TI>
<SO>Schizophrenia research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>164-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remvig-1987" MODIFIED="2015-01-27 10:42:09 +0000" MODIFIED_BY="[Empty name]" NAME="Remvig 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-01-27 10:42:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Strömgren LS</AU>
<TI>Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<PG>147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" MODIFIED="2015-01-27 10:42:20 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-18 11:43:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sun Z, Liu B, Li Z, Zhang D, et al</AU>
<TI>Clozapine combined with perphenazine in the treatment of schizophrenia</TI>
<TO>&#27695;&#27694;&#24179;&#32852;&#29992;&#22859;&#20035;&#38745;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Hebei Mental Health</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>142-4</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="SUN" TYPE="OTHER" VALUE="2000 (Perp)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-1982" MODIFIED="2015-01-27 10:42:27 +0000" MODIFIED_BY="[Empty name]" NAME="Takahashi 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-01-27 10:42:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi R, Inanaga K, Samejima K, Sarai K, Asada S, Otsuki S, et al</AU>
<TI>Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study</TI>
<SO>Journal of International Medical Research</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>4</NO>
<PG>257-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Praag-1976" MODIFIED="2015-01-27 10:42:35 +0000" MODIFIED_BY="[Empty name]" NAME="Van Praag 1976" YEAR="1976">
<REFERENCE MODIFIED="2015-01-27 10:42:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Praag HM, Korf J, Dolc LCW</AU>
<TI>Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>129</VL>
<PG>547-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008a" MODIFIED="2013-12-18 11:32:11 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-12-18 11:32:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XD, Wang YH, Feng TM, Liu ML, Zhang SX</AU>
<TI>Controlled study of risperidone in elderly treatment of first-episode schizophrenia</TI>
<TO>&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#26399;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008b" MODIFIED="2013-12-18 11:30:29 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2008b" YEAR="">
<REFERENCE MODIFIED="2013-12-18 11:30:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang RF, Yu X, Song ZD</AU>
<TI>Schizophrenia olanzapine and perphenazine in the treatment of positive symptoms</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#38451;&#24615;&#30151;&#29366;&#20026;&#20027;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>6</NO>
<PG>423-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008c" MODIFIED="2013-12-18 11:58:46 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2008c" YEAR="">
<REFERENCE MODIFIED="2013-12-18 11:58:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Wu J, Chen Z, Zhang JF, et al</AU>
<TI>Elderly first controlled study of quetiapine in the treatment of schizophrenia</TI>
<TO>&#21945;&#30827;&#24179;&#27835;&#30103;&#39318;&#21457;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>6</NO>
<PG>463-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woggon-1978" MODIFIED="2015-01-27 10:52:33 +0000" MODIFIED_BY="[Empty name]" NAME="Woggon 1978" YEAR="1978">
<REFERENCE MODIFIED="2015-01-27 10:52:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Woggon B, Angst J</AU>
<TI>Double-blind comparison of bromperidol and perphenazine</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1978</YR>
<VL>13</VL>
<PG>165-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 10:52:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Woggon B</AU>
<TI>Effects and side-effects of bromperidol in comparison with other antipsychotic drugs</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1978</YR>
<VL>78</VL>
<NO>1</NO>
<PG>155-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2010" MODIFIED="2013-12-18 11:54:40 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-18 11:54:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang JL, Zhang J, Shen B</AU>
<TI>Aripiprazole orally disintegrating tablets in the treatment of schizophrenia in old age were observed</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21475;&#33108;&#23849;&#35299;&#29255;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#30340;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>Chinese Journal of Modern Drug Application</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>14</NO>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-01-27 10:45:34 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Affleck-1969" NAME="Affleck 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Affleck JW, Cooper AJ, Forrest AD, Smythies JR, Zealley AK</AU>
<TI>Penicillamine and schizophrenia - a clinical trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1969</YR>
<VL>115</VL>
<NO>519</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahlfors-1980" NAME="Ahlfors 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahlfors UG, Dencker SJ, Gravem A, Remvig J</AU>
<TI>Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1980</YR>
<VL>279</VL>
<PG>77-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akimoto-1966" MODIFIED="2015-01-27 10:43:06 +0000" MODIFIED_BY="[Empty name]" NAME="Akimoto 1966" YEAR="1966">
<REFERENCE MODIFIED="2015-01-27 10:43:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R, Naruse H, et al</AU>
<TI>Current status of pharmacotherapy in schizophrenia</TI>
<SO>Folia Psychiatrica et Neurologica Japonica</SO>
<YR>1966</YR>
<VL>20</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angst-1975" MODIFIED="2015-01-27 10:43:14 +0000" MODIFIED_BY="[Empty name]" NAME="Angst 1975" YEAR="1975">
<REFERENCE MODIFIED="2015-01-27 10:43:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angst J, Woggon B</AU>
<TI>Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, flusipirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1975</YR>
<VL>25</VL>
<NO>2</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1966" NAME="Anonymous 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>Schizophrenic and other psychotic reactions</TI>
<SO>Medical Letter</SO>
<YR>1966</YR>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asada-1976" NAME="Asada 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asada S, Ishimaru T, Kubo S, Kodama H, Masuda K</AU>
<TI>Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double-blind method</TI>
<TO>Etude des effets cliniques du sulpiride et de la perphenazine chez 82 schizophrenes par la methode du double aveugle</TO>
<SO>Encephale</SO>
<YR>1976</YR>
<VL>2</VL>
<NO>1</NO>
<PG>73-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakke-1973" MODIFIED="2009-01-20 08:33:52 +0000" MODIFIED_BY="[Empty name]" NAME="Bakke 1973" YEAR="1973">
<REFERENCE MODIFIED="2009-01-20 08:33:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakke O</AU>
<TI>Clinical experience with depot neuroleptics</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1973</YR>
<VL>246</VL>
<PG>32-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bandelow-1992" MODIFIED="2015-01-27 10:43:25 +0000" MODIFIED_BY="[Empty name]" NAME="Bandelow 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-01-27 10:43:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bandelow B, Muller P, Frick U, Gaebel W, Linden M, Muller Spahn F, et al</AU>
<TI>Depressive syndromes in schizophrenic patients under neuroleptic therapy</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1992</YR>
<VL>241</VL>
<NO>5</NO>
<PG>291-5</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="BANDELOW" TYPE="OTHER" VALUE="1992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1970" MODIFIED="2009-01-20 08:34:41 +0000" MODIFIED_BY="[Empty name]" NAME="Becker 1970" YEAR="1970">
<REFERENCE MODIFIED="2009-01-20 08:34:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE</AU>
<TI>Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1970</YR>
<VL>127</VL>
<NO>6</NO>
<PG>827-131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjerkelund-1965" MODIFIED="2015-01-27 10:43:32 +0000" MODIFIED_BY="[Empty name]" NAME="Bjerkelund 1965" YEAR="1965">
<REFERENCE MODIFIED="2015-01-27 10:43:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjerkelund C, Nitter-Hauge S, Jakobsen E</AU>
<TI>Perphenazine (trilafon) in the prophylaxis of nausea and vomiting following acute myocardial infarct</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1965</YR>
<VL>177</VL>
<PG>729-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00f6_hlau-1985" MODIFIED="2015-01-27 10:43:43 +0000" MODIFIED_BY="[Empty name]" NAME="Böhlau 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-27 10:43:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Böhlau V, Weber J</AU>
<TI>No English title available</TI>
<TO>Therapie dementieller Prozesse bei Alterspatienten</TO>
<SO>Therapiewoche</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>47</NO>
<PG>5445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cannistra-1959" MODIFIED="2015-01-27 10:43:52 +0000" MODIFIED_BY="[Empty name]" NAME="Cannistra 1959" YEAR="1959">
<REFERENCE MODIFIED="2015-01-27 10:43:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cannistra F, Abrams AA</AU>
<TI>Perphenazine in obstetrics. Evaluation of its use to replace an analgesic</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1959</YR>
<VL>14</VL>
<NO>3</NO>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceskova-1994" MODIFIED="2015-01-27 10:43:59 +0000" MODIFIED_BY="[Empty name]" NAME="Ceskova 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-01-27 10:43:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceskova E, Svestka J</AU>
<TI>Risperidone vs. perphenazine - a double-blind comparison and prolactine plasma levels</TI>
<TO>Risperidone gegen Rispehenazine - ein doppelt-blinder Vergleich und Prolaktin-Plasmaspiegel</TO>
<SO>Psychiatria Danubina</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>3-4</NO>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceskova-1996" NAME="Ceskova 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceskova E, Svestka J</AU>
<TI>Efficacy and tolerability of risperidone in different dose levels</TI>
<TO>Ucinnost a snasenlivost risperidonu pri ruznem davkovani (sdeleni z praxe)</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1996</YR>
<VL>92</VL>
<NO>1</NO>
<PG>50-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1981" MODIFIED="2015-01-27 10:44:10 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-01-27 10:44:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke JMC</AU>
<TI>Amitriptyline and perphenazine (triptafen DA) in chronic pain</TI>
<SO>Anaesthesia</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>210-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1958" NAME="Cohen 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Cohen H</AU>
<TI>Trilafon in the treatment of chronically psychotic hospitalized patients</TI>
<SO>Prüfbericht, New York. E. Merck Darmstadt</SO>
<YR>1958</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1979" MODIFIED="2015-01-27 10:44:18 +0000" MODIFIED_BY="[Empty name]" NAME="Cooper 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-01-27 10:44:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SF, Dugal R, Elie R, Albert JM</AU>
<TI>Metabolic interaction between amitriptyline and perphenazine in psychiatric patients</TI>
<SO>Neuro-Psychopharmacology</SO>
<YR>1979</YR>
<VL>3</VL>
<PG>369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Den-Boer-2000" MODIFIED="2015-01-27 10:44:27 +0000" MODIFIED_BY="[Empty name]" NAME="Den Boer 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-01-27 10:44:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Den Boer JA, Vahlne J-O, Post P, Heck AH, Daubenton F, Olbrich R</AU>
<TI>Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>179-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dencker-1994" MODIFIED="2015-01-27 10:44:38 +0000" MODIFIED_BY="[Empty name]" NAME="Dencker 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-01-27 10:44:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Gios I, Martenson E, Norden T, Nyberg G, Persson R, et al</AU>
<TI>A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>114</VL>
<NO>1</NO>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eklund-1976" MODIFIED="2015-01-27 10:44:46 +0000" MODIFIED_BY="[Empty name]" NAME="Eklund 1976" YEAR="1976">
<REFERENCE MODIFIED="2015-01-27 10:44:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eklund KL</AU>
<TI>A double-blind comparison study between penfluridol and perphenazine in acute schizophrenic patients</TI>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1976</YR>
<VL>30</VL>
<NO>5</NO>
<PG>384-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erb-1982" MODIFIED="2015-01-27 10:44:51 +0000" MODIFIED_BY="[Empty name]" NAME="Erb 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-01-27 10:44:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erb RJ, Stoltman WP</AU>
<TI>Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailibility testing</TI>
<SO>Journal of Pharmaceutical Sciences</SO>
<YR>1982</YR>
<VL>71</VL>
<NO>8</NO>
<PG>883-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eufe-1979" MODIFIED="2015-01-27 10:44:58 +0000" MODIFIED_BY="[Empty name]" NAME="Eufe 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-01-27 10:44:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eufe R, Wegener G</AU>
<TI>Double-blind comparison of two depot neuroleptics (perphenazine enanthate and flupentixol enanthate) in chronic schizophrenia</TI>
<SO>Nervenarzt</SO>
<YR>1979</YR>
<VL>50</VL>
<NO>8</NO>
<PG>534-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahn-1964" MODIFIED="2015-01-27 10:45:05 +0000" MODIFIED_BY="[Empty name]" NAME="Fahn 1964" YEAR="1964">
<REFERENCE MODIFIED="2015-01-27 10:45:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahn S</AU>
<TI>Treatment of choreic movements with perphenazine</TI>
<SO>Diseases of The Nervous System</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>653-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farzin-2005" MODIFIED="2014-02-26 14:01:59 +0000" MODIFIED_BY="[Empty name]" NAME="Farzin 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-02-26 14:01:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Farzin D, Hosseini SH, Shafaat A</AU>
<TI>A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia</TI>
<SO>Iranian Journal of Medical Sciences</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>59-62</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="FARZIN" TYPE="OTHER" VALUE="2005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-1969" MODIFIED="2015-01-27 10:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-01-27 10:45:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald CH</AU>
<TI>A double-blind comparison of haloperidol with perphenazine in acute psychiatric patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>8</NO>
<PG>515-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galdi-1988" MODIFIED="2015-01-27 10:45:34 +0000" MODIFIED_BY="[Empty name]" NAME="Galdi 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-01-27 10:45:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galdi J, Bonato RB</AU>
<TI>Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>9</NO>
<PG>816-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1977" MODIFIED="2015-01-27 10:45:27 +0000" MODIFIED_BY="[Empty name]" NAME="Gerlach 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-01-27 10:45:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Rasmussen PT, Hansen L, Kristjansen P</AU>
<TI>Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>55</VL>
<NO>4</NO>
<PG>251-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1988" MODIFIED="2009-01-20 08:36:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gerlach 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-01-20 08:36:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J</AU>
<TI>Tardive dyskinesia:Pathophysiological mechanisms and clinical trials</TI>
<SO>L'Encephale</SO>
<YR>1988</YR>
<VL>14</VL>
<PG>227-232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerson-1964" NAME="Gerson 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerson IM, Chat E, Twigger NA</AU>
<TI>Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>121</VL>
<PG>179-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gianelli-1990" NAME="Gianelli 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gianelli A, Rabboni M, Zarattini F</AU>
<TI>No English title available</TI>
<TO>Profili clinici di azione, indicazioni preferenziali, effeti terapeutici e contraindicazioni di tre neuroletti depot in trial multicentro di confronto</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1990</YR>
<VL>25</VL>
<NO>1</NO>
<PG>7-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hadlik-1970" MODIFIED="2015-01-26 15:03:12 +0000" MODIFIED_BY="[Empty name]" NAME="Hadlik 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-01-26 15:03:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hadlik J, Svestka J, Nahunek K, Rodova A</AU>
<TI>Controlled studies with thiothixene and perphenzine in schizophrenic psychoses</TI>
<TO>Kontrolovana studie s thiothixenem a perfenazinem u psychoz schizofrenniho okruhu</TO>
<SO>Activitas Nervosa Superior</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>1</NO>
<PG>60-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1966" MODIFIED="2014-02-26 14:06:39 +0000" MODIFIED_BY="[Empty name]" NAME="Hanlon 1966" YEAR="1966">
<REFERENCE MODIFIED="2014-02-26 14:06:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hanlon T</AU>
<TI>Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients</TI>
<SO>Psychopharmacologia</SO>
<YR>1966</YR>
<VL>9</VL>
<NO>4</NO>
<PG>328-39</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="HANLON" TYPE="OTHER" VALUE="1966"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1979" NAME="Hansen 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen BL, Elley J, Christensen RT, Laersen NE, Naestoft J, Hvidberg EF</AU>
<TI>Plasma levels of perphenazine and its metabolites during simultaneous treatment with anticholinergic drugs</TI>
<SO>British Journal of clinical Pharmacology</SO>
<YR>1979</YR>
<VL>7</VL>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haran-1960" MODIFIED="2015-01-26 15:03:02 +0000" MODIFIED_BY="[Empty name]" NAME="Haran 1960" YEAR="1960">
<REFERENCE MODIFIED="2015-01-26 15:03:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haran T</AU>
<TI>Perphenazine (Fentazine) in the management of chronic schizophrenia</TI>
<SO>Journal of the Irish Medical Association</SO>
<YR>1960</YR>
<VL>46</VL>
<PG>135-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holden-1969" NAME="Holden 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holden JM, Itil TM, Keskiner A</AU>
<TI>Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects</TI>
<SO>Journal of Clinical Pharmacology and the Journal of New Drugs</SO>
<YR>1969</YR>
<VL>9</VL>
<NO>3</NO>
<PG>163-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollister-1967-II" MODIFIED="2015-01-26 15:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hollister 1967 II" YEAR="1967">
<REFERENCE MODIFIED="2015-01-26 15:02:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollister LE, Overall JE, Shelton J, Pennington V, Kimbell I, Johnson M</AU>
<TI>Drug therapy of depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1967</YR>
<VL>17</VL>
<PG>486-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollister-1974" NAME="Hollister 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollister LE, Overall JE, Kimbell I Jr, Pokorny A</AU>
<TI>Specific indications for different classes of phenothiazines</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>30</VL>
<NO>1</NO>
<PG>94-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1964" MODIFIED="2015-01-26 15:02:40 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 1964" YEAR="1964">
<REFERENCE MODIFIED="2015-01-26 15:02:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang CL, Kurland AA</AU>
<TI>Perphenazine (trilafon) metabolism in psychotic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1964</YR>
<VL>10</VL>
<PG>639-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jprn-2011" MODIFIED="2014-02-26 14:21:54 +0000" MODIFIED_BY="[Empty name]" NAME="Jprn 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-02-26 14:21:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jprn U</AU>
<TI>An intervention study of optimizing algorism-based pharmacological treatment for schizophrenia</TI>
<SO>http://www.umin.ac.jp/ctr/index.htm</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="UMIN000004931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaim-1972" MODIFIED="2015-01-26 15:02:29 +0000" MODIFIED_BY="[Empty name]" NAME="Kaim 1972" YEAR="1972">
<REFERENCE MODIFIED="2015-01-26 15:02:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaim SC, Klett CJ</AU>
<TI>Treatment of delirium tremens. A comparative evaluation of four drugs</TI>
<SO>Quarterly Journal of Studies</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>1065-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaji-1974" MODIFIED="2015-01-26 15:02:22 +0000" MODIFIED_BY="[Empty name]" NAME="Kaji 1974" YEAR="1974">
<REFERENCE MODIFIED="2015-01-26 15:02:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaji S, Tsukada K, Hasegawa S, et al</AU>
<TI>Comparison of clinical efficacy of clocapramine and perphenazine for chronic schizophrenia by the double-blind study</TI>
<SO>Rinsyo Seisin Igaku</SO>
<YR>1974</YR>
<VL>3</VL>
<NO>8</NO>
<PG>867-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawakita-1965" MODIFIED="2015-01-26 15:02:10 +0000" MODIFIED_BY="[Empty name]" NAME="Kawakita 1965" YEAR="1965">
<REFERENCE MODIFIED="2015-01-26 15:02:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawakita Y</AU>
<TI>Drug therapy of acute schizophrenia</TI>
<SO>Saishin Igaku</SO>
<YR>1965</YR>
<VL>20</VL>
<NO>9</NO>
<PG>2440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kistrup-1991" MODIFIED="2015-01-26 15:02:02 +0000" MODIFIED_BY="[Empty name]" NAME="Kistrup 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-01-26 15:02:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kistrup K, Gerlach J, Aaes Jorgensen T, Larsen NE</AU>
<TI>Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose</TI>
<SO>Psychopharmacology</SO>
<YR>1991</YR>
<VL>105</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kline-1968" NAME="Kline 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kline NS, Blair J, Cooper TB, Esser AH, Hackett E, Vestergaard P</AU>
<TI>A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1968</YR>
<VL>206</VL>
<PG>7-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knudsen-1985" MODIFIED="2015-01-26 15:01:50 +0000" MODIFIED_BY="[Empty name]" NAME="Knudsen 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-26 15:01:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knudsen P, Hansen LB, Auken G, Waehrens J, Højholdt K, Larsen NE</AU>
<TI>Perphenazine decanoate vs. Perphenazine enanthate - efficacy and side-effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1985</YR>
<VL>322</VL>
<PG>15-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knudsen-1985a" MODIFIED="2015-01-26 15:01:37 +0000" MODIFIED_BY="[Empty name]" NAME="Knudsen 1985a" YEAR="1985">
<REFERENCE MODIFIED="2015-01-26 15:01:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Knudsen P, Hansen LB, Hojholdt K, Larsen NE</AU>
<TI>Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica. Supplementum</SO>
<YR>1985</YR>
<VL>322</VL>
<PG>29-40</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KNUDSEN" TYPE="OTHER" VALUE="1985 b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-26 15:01:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Knudsen P, Hansen LB, Hojholdt K, Larsen NE</AU>
<TI>Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica. Supplementum</SO>
<YR>1985</YR>
<VL>322</VL>
<PG>41-50</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="KNUDSEN" TYPE="OTHER" VALUE="1985 b"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kothari-1960" MODIFIED="2015-01-26 15:01:20 +0000" MODIFIED_BY="[Empty name]" NAME="Kothari 1960" YEAR="1960">
<REFERENCE MODIFIED="2015-01-26 15:01:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kothari NJ, Saunders JC, Kline NS, Griffen JA</AU>
<TI>A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>358-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapolla-1967" NAME="Lapolla 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lapolla A</AU>
<TI>A double-blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1967</YR>
<VL>3</VL>
<NO>5</NO>
<PG>403-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1997" NAME="Levine 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Caspi N, Laufer N</AU>
<TI>Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>55-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindholm-1978" NAME="Lindholm 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm H, Gullberg B, Ohman A, Sedvall G</AU>
<TI>Effects of perphenazine injections on prolactin levels in plasma from schizophrenic women and men</TI>
<SO>Psychopharmacology</SO>
<YR>1978</YR>
<VL>57</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linnoila1982" MODIFIED="2015-01-26 15:01:08 +0000" MODIFIED_BY="[Empty name]" NAME="Linnoila1982" YEAR="1982">
<REFERENCE MODIFIED="2015-01-26 15:01:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linnoila M, George L, Guthrie S</AU>
<TI>Interaction between antidepressants and perphenazine in psychiatric inpatients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<NO>10</NO>
<PG>1329-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprete-1967" MODIFIED="2015-01-12 13:46:53 +0000" MODIFIED_BY="Heather Maxwell" NAME="Loprete 1967" YEAR="1967">
<REFERENCE MODIFIED="2015-01-12 13:46:53 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprete FP, Palm C</AU>
<TI>Sleep in psychotic patients: a comparative clinical study</TI>
<SO>International journal of neuropsychiatry</SO>
<YR>1967</YR>
<VL>3</VL>
<NO>6</NO>
<PG>497-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mason_x002d_Browne-1957" NAME="Mason-Browne 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason-Browne NL, Borthwick JW</AU>
<TI>Effect of perphenazine (trilafon) on modification of crude consciousness</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1957</YR>
<VL>18</VL>
<PG>300-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason-Browne NL</AU>
<TI>Perphenazine - a drug modifying consciousness</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1957</YR>
<VL>114</VL>
<PG>173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazurek-2003" MODIFIED="2015-01-26 15:00:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mazurek 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-01-26 15:00:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mazurek I, Loza B, Lecyk A</AU>
<TI>Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S347</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="LOZA" TYPE="OTHER" VALUE="2001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1958" MODIFIED="2015-01-26 15:00:50 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 1958" YEAR="1958">
<REFERENCE MODIFIED="2015-01-26 15:00:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DC, Bridenbaugh LD, Ackeren van EG, Cole EV</AU>
<TI>Control of postoperative vomiting with perphenazine (trilafone): a double-blind study</TI>
<SO>Anesthesiology</SO>
<YR>1958</YR>
<VL>19</VL>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00fc_ller-1994" MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" NAME="Müller 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Müller M</AU>
<TI>Pharmacokinetik/Bioavailibility Evaluation of Three Different perphenazine Formulations (Decentan) in 18 healthy volunteers</TI>
<TO>Pharmakokinetik/Bioverfügbarkeits-Studie mit drei verschiedenen Perphenazin-Zubereitungen (Decentan) mit 18 gesunden Freiwilligen</TO>
<SO>E. Merck, Darmstadt</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1967" MODIFIED="2014-02-26 11:49:22 +0000" MODIFIED_BY="[Empty name]" NAME="Nahunek 1967" YEAR="1967">
<REFERENCE MODIFIED="2013-10-04 13:58:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Misurec J</AU>
<TI>Clinical comparison of methophenazine and perphenazine in schizophrenia. A controlled study. Effects on the photomyoclonic threshold</TI>
<TO>Klinischer Vergleich von Methophrenazin (Frenolon) und Perphenazin bei Schizophrenie. Kontrollierte Studie. Beeinflussung der photomyoklonischen Schwelle</TO>
<SO>Activitas Nervosa Superior</SO>
<YR>1967</YR>
<VL>9</VL>
<NO>4</NO>
<PG>404-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1968" NAME="Nahunek 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Rodova A</AU>
<TI>Clinical experience with octoclothepin in psychoses. Comparasion with perphenazine</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>3</NO>
<PG>339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1969" NAME="Nahunek 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Hadlik J, Svestka J, Rodova A, Vanysek J</AU>
<TI>A comparison of therapeutic effects of triperidol and perphenazine in schizophrenia</TI>
<TO>Srovnani lecebneho ucinku triperidolu s perphenazinem u schizofrenie</TO>
<SO>Ceskoslovenska Psychiatrie.</SO>
<YR>1969</YR>
<VL>65</VL>
<NO>5</NO>
<PG>281-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1970" NAME="Nahunek 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Hadlik J, Rodova A, Misurec J, Vanysek J</AU>
<TI>Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold</TI>
<TO>Srovnani triperidolu s perphenazinem u schizofrennich psychoz vliv na fotomyoklonicky prah</TO>
<SO>Activitas Nervosa Superior</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>1</NO>
<PG>56-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1970-II" NAME="Nahunek 1970 II" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Rodova A</AU>
<TI>Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>3</NO>
<PG>247-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1975" NAME="Nahunek 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Misurec J, Rodova A</AU>
<TI>Clinical experience with clozapin</TI>
<TO>Klinicke zkusenosti s clozapinem</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1975</YR>
<VL>71</VL>
<NO>1</NO>
<PG>11-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1976" MODIFIED="2015-01-26 15:00:35 +0000" MODIFIED_BY="[Empty name]" NAME="Nahunek 1976" YEAR="1976">
<REFERENCE MODIFIED="2015-01-26 15:00:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Rodova A, Svestka J</AU>
<TI>Outline classification of neuroleptic drugs based on results of short-term control crossed studies in schizophrenia</TI>
<TO>Pokus o klasifikaci neuroleptik na podklade vysledku kradkodobych kontrolovanych zkrizenyich studii u schizofrenie</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1976</YR>
<VL>72</VL>
<NO>2</NO>
<PG>104-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Ceskova E</AU>
<TI>On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics</TI>
<TO>Kotazce rozdilnosti terapeutickych odpovedi po jednotlivych neurolepticich ve srovnani s perphenazinem u schizofrennich nemocnych</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1981</YR>
<VL>77</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahunek-1980" NAME="Nahunek 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahunek K, Svestka J, Ceskova E</AU>
<TI>Controlled 'comparison' of perphenazine with perphenazine in schizophrenia - a methodical check of a double-blind cross-over design</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1980</YR>
<VL>22</VL>
<NO>3</NO>
<PG>154-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nordic-DS-Group-1986" MODIFIED="2015-01-26 15:00:24 +0000" MODIFIED_BY="[Empty name]" NAME="Nordic DS Group 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-01-26 15:00:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordic Dyskinesia Study Group</AU>
<TI>Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicentre study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden</TI>
<SO>Psychopharmacology</SO>
<YR>1986</YR>
<VL>90</VL>
<NO>4</NO>
<PG>423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Reilly-1957" NAME="O'Reilly 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Reilly PO, Wojcicki HM, Hrychuk W, Keogh RP</AU>
<TI>Perphenazine (Trilafon) in the treatment of pschoses</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1957</YR>
<VL>77</VL>
<PG>952-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oltman-1966" NAME="Oltman 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oltman JE, Friedman S</AU>
<TI>Perphenazine-amitriptyline in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>123</VL>
<NO>5</NO>
<PG>607-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omerov-1989" NAME="Omerov 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omerov M, Wistedt B, Bolvig HL, Larsen NE</AU>
<TI>The relationship between perphenazine plasma levels and clinical response in acute schizophrenia</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opjordsmoen-2000" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="Opjordsmoen 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Opjordsmoen S, Brunsvik S, Melle I, Dahl A, Friis S, Haahr U, et al</AU>
<TI>A comparison between novel and traditional antipsychotic drugs as first-line medication in early psychosis</TI>
<SO>Second international conference on early psychosis</SO>
<YR>2000, 31 March - 2 April</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="OPJORDSMOEN" TYPE="OTHER" VALUE="2000"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfeiffer-1965" NAME="Pfeiffer 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA</AU>
<TI>Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs</TI>
<SO>American Journal of Psychiatry.</SO>
<YR>1965</YR>
<VL>122</VL>
<PG>1147-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1973" NAME="Prien 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Gillis RD, Caffey EM</AU>
<TI>Intermittent pharmacotherapy in chronic schizophrenia</TI>
<SO>Hospital and Community Psychiatry</SO>
<YR>1973</YR>
<VL>24</VL>
<NO>5</NO>
<PG>317-322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prusoff-1979" NAME="Prusoff 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prusoff BA, Williams DH, Weissman MM, Astrachan BM</AU>
<TI>A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1979</YR>
<VL>15</VL>
<NO>2</NO>
<PG>80-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapp-1972" MODIFIED="2015-01-26 15:00:08 +0000" MODIFIED_BY="[Empty name]" NAME="Rapp 1972" YEAR="1972">
<REFERENCE MODIFIED="2015-01-26 15:00:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapp W</AU>
<TI>Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia</TI>
<SO>Pharmakopsychiatrie Neuropsychopharmakologie</SO>
<YR>1972</YR>
<VL>5</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapp-1986" MODIFIED="2015-01-26 15:00:00 +0000" MODIFIED_BY="[Empty name]" NAME="Rapp 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-01-26 15:00:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapp W, Hellbom E, Norrman O, Palm U, et al.</AU>
<TI>A double blind crossover study comparing haloperidol decanoate and perphenazine enanthate</TI>
<SO>Current Therapeutic Research</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>5</NO>
<PG>665-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rappaport-1967" NAME="Rappaport 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rappaport M</AU>
<TI>Competing voice messages. Effects of a message load and drugs on the ability of acute schizophrenics to attend</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1967</YR>
<VL>17</VL>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rappaport-1968" MODIFIED="2015-01-26 14:59:46 +0000" MODIFIED_BY="[Empty name]" NAME="Rappaport 1968" YEAR="1968">
<REFERENCE MODIFIED="2015-01-26 14:59:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rappaport M</AU>
<TI>Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1968</YR>
<VL>146</VL>
<NO>5</NO>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reznik-2000" MODIFIED="2015-01-26 14:59:38 +0000" MODIFIED_BY="[Empty name]" NAME="Reznik 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-01-26 14:59:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reznik I, Sirota P, Psych M</AU>
<TI>Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>410-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Reznik I, Sirota P</AU>
<TI>Treatment of obsessive and compulsive symptoms in schizophrenia with SSRI's and neuroleptics: a randomized controlled trial</TI>
<SO>21st Congress of Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland, UK</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rickels-1982" MODIFIED="2015-01-26 14:59:27 +0000" MODIFIED_BY="[Empty name]" NAME="Rickels 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-01-26 14:59:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rickels K, Csanalosi I, Werblowsky J, Weise CC, Weinstock R, Brown AS</AU>
<TI>Amitriptyline-perphenazine and doxepin in depressed outpatients: a controlled double-blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>10</NO>
<PG>419-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritter-1971" MODIFIED="2015-01-26 14:59:18 +0000" MODIFIED_BY="[Empty name]" NAME="Ritter 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-01-26 14:59:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritter RM, Davidson DE</AU>
<TI>Haloperidol for acute psychiatric emergencies. A double-blind comparison with perphenazine in acute alcoholic psychosis</TI>
<SO>Southern Medical Journal</SO>
<YR>1971</YR>
<VL>64</VL>
<NO>2</NO>
<PG>249-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodova-1971" NAME="Rodova 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodova A, Nahunek K, Svestka J</AU>
<TI>Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1971</YR>
<VL>13</VL>
<NO>3</NO>
<PG>171-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodova-1973" NAME="Rodova 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodova A, Svestka J, Nahunek K, Ceskova E</AU>
<TI>A blind comparison of clozapine and perphenazine in schizophrenics</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>2</NO>
<PG>94-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scurr-1958" MODIFIED="2015-01-26 14:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Scurr 1958" YEAR="1958">
<REFERENCE MODIFIED="2015-01-26 14:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scurr CF, Robbie DS</AU>
<TI>Trials of perphenazine in the prevention of postoperative vomiting</TI>
<SO>British Medical Journal</SO>
<YR>1958</YR>
<VL>1</VL>
<PG>922-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shalev-1993" NAME="Shalev 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shalev A, Hermesh H, Rothberg J, Munitz H</AU>
<TI>Poor neuroleptic response in acutely exacerbated schizophrenic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>2</NO>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharpley-1964" MODIFIED="2014-02-26 13:49:06 +0000" MODIFIED_BY="[Empty name]" NAME="Sharpley 1964" YEAR="1964">
<REFERENCE MODIFIED="2014-02-26 13:49:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sharpley P, Heistad G, Schiele BC</AU>
<TI>Comparison of butaperazine and perphenazine: a double-blind controlled study</TI>
<SO>Psychopharmacology</SO>
<YR>1964</YR>
<VL>13</VL>
<PG>209-16</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="SHARPLEY" TYPE="OTHER" VALUE="1964 a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiloh-2002" MODIFIED="2015-01-26 14:58:47 +0000" MODIFIED_BY="[Empty name]" NAME="Shiloh 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-01-26 14:58:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, et al</AU>
<TI>Mianserin or placebo as adjuncts to typical antipsychotic drugs in resistant schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>2</NO>
<PG>59-64</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="SHILOH" TYPE="OTHER" VALUE="2002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-2000" MODIFIED="2015-01-26 14:58:40 +0000" MODIFIED_BY="[Empty name]" NAME="Silver 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-01-26 14:58:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M</AU>
<TI>Fluvoxamine augmentation of antipsychotic drugs improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simopoulos-1971" NAME="Simopoulos 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J</AU>
<TI>Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin)</TI>
<SO>5th World Congress of Psychiatry, Ciudad de Mexico</SO>
<YR>1971</YR>
<PG>526</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1970" NAME="Simpson 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Krakov L, Kunz-Bartholini E</AU>
<TI>A controlled trial of combined medications on behavioral and extrapyramidal effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1959" NAME="Smith 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith JA, Christian D, Mansfield E, Figaredo A</AU>
<TI>A graphic comparison of five phenothiazines</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>116</VL>
<PG>392-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiker-1985" MODIFIED="2015-01-26 14:58:25 +0000" MODIFIED_BY="[Empty name]" NAME="Spiker 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-26 14:58:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiker DG, Cofsky Weiss J, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al</AU>
<TI>The pharmacological treatment of delusional depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>142</VL>
<PG>430-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2010" MODIFIED="2014-02-26 14:36:28 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-26 14:36:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sun S, Liu Y, Long JL, Wang L</AU>
<TI>Venlafaxine extended release tablets on schizophrenia cognitive function] Google Translate</TI>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>4</NO>
<PG>394-6</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="&#23385;&#32676;&#26143;//&#21016;&#21191;//&#40857;&#37329;&#20142;//&#29579;" TYPE="OTHER" VALUE="2010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2010b" MODIFIED="2014-02-26 14:37:39 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2010b" YEAR="2010">
<REFERENCE MODIFIED="2014-02-26 14:37:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sun J, Xie S, Nisu L, Wang X, Shang X et al</AU>
<TI>acute schizophrenic inpatients converted to aripiprazole treatment efficacy and safety of] Google Translate</TI>
<TO>&#24613;&#24615;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#20303;&#38498;&#24739;&#32773;&#36716;&#25442;&#20026;&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#30103;&#25928;&#21450;&#23433;&#20840;&#24615;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>3</NO>
<PG>179-81</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="&#23385;&#38745;//&#35874;&#19990;&#24179;//&#20522;&#33487;&#29747;//&#29579;" TYPE="OTHER" VALUE="2010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1970" MODIFIED="2013-10-08 11:05:10 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1970" YEAR="1970">
<REFERENCE MODIFIED="2013-10-08 11:05:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K</AU>
<TI>Controlled comparative study of methylperidol and perphenazine in schizophrenic psychoses</TI>
<TO>Kontrolovane srovnani metylperidolu s perfenazinem u psychoz schizofrenniho ikruhu</TO>
<SO>Activitas Nervosa Superior</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1972" MODIFIED="2015-01-26 14:58:09 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1972" YEAR="1972">
<REFERENCE MODIFIED="2015-01-26 14:58:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K</AU>
<TI>A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses</TI>
<SO>Activitas Nervositas Superior</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>2</NO>
<PG>93-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1973" NAME="Svestka 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rodova A, Nahunek K</AU>
<TI>Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>2</NO>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1974" NAME="Svestka 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Rodova A, Ceskova E</AU>
<TI>A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>3</NO>
<PG>165-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1975" NAME="Svestka 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Rodova A, Ceskova E</AU>
<TI>The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>3</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1989" MODIFIED="2015-01-26 14:57:58 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-01-26 14:57:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Ceskova E, Rysanek R, Balsíková, J</AU>
<TI>Controlled cross over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>1</NO>
<PG>32-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1989a" MODIFIED="2015-01-26 14:40:55 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1989a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Ceskova E, Rysanek R, Nahunek K</AU>
<TI>Controlled cross over comparison of carbamazepine with perphenazine in schizophrenic psychoses. 31st Annual Psychopharmacology Meeting (1989, Jesenik, Czechoslovakia)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>4</NO>
<PG>276-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1990" NAME="Svestka 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rysanek R, Nahunek K, Ceskova E</AU>
<TI>Therapeutic results in schizophrenic and schizoaffective psychoses with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa)</TI>
<TO>Vysledky lecby schizofrennich a schizoafektivnich nemocnych sulpiridem (Eglonyl Alkaloid) ve srovnani s perfenazinem (Perfenazin Spofa)</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1990</YR>
<VL>86</VL>
<NO>3</NO>
<PG>145-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Syvalahti-1997" MODIFIED="2015-01-26 14:57:46 +0000" MODIFIED_BY="[Empty name]" NAME="Syvalahti 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-01-26 14:57:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, et al</AU>
<TI>Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients</TI>
<SO>Journal of International Medical Research</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>1</NO>
<PG>24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tegeler-1979" MODIFIED="2015-01-26 14:57:38 +0000" MODIFIED_BY="[Empty name]" NAME="Tegeler 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-01-26 14:57:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tegeler J, Floru L</AU>
<TI>A comparative study of the longacting neuroleptics perphenazine enanthate and flusipirilene</TI>
<SO>Pharmakopsychiatrie Neuropsychopharmakologie</SO>
<YR>1979</YR>
<VL>12</VL>
<NO>5</NO>
<PG>357-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" MODIFIED="2014-02-26 14:42:17 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-02-26 14:42:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang X, Yin J, Yang L, Li W, Wu G et al</AU>
<TI>Double-blind controlled side reaction of the L-stepholidine the treatment of schizophrenia and Nursing Strategy</TI>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3</NO>
<PG>204-6</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="&#29579;&#31168;&#33521;" TYPE="OTHER" VALUE="2001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whittaker-1963" MODIFIED="2014-02-26 11:49:27 +0000" MODIFIED_BY="[Empty name]" NAME="Whittaker 1963" YEAR="1963">
<REFERENCE MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whittaker CB, Hoy RM</AU>
<TI>Withdrawal of perphenazine in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>109</VL>
<PG>422-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2007" MODIFIED="2015-01-26 14:57:27 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-26 14:57:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al</AU>
<TI>A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>10</NO>
<PG>2313-23</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="WOLF" TYPE="OTHER" VALUE="2007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagi-1976" NAME="Yagi 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagi G</AU>
<TI>A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients</TI>
<SO>Rinsho Hyoka (Clinical Evaluation)</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>3</NO>
<PG>351-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2001" MODIFIED="2014-02-26 14:34:55 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-02-26 14:34:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhong C, Guozhang J, Duochen W</AU>
<TI>A double-blind comparison trial of 1-stepholidine and perphenazine in treatment of schizophrenia</TI>
<SO>7th World Congress of Biological Psychiatry, Berlin, Germany</SO>
<YR>2001</YR>
<VL>2</VL>
<EN>Suppl 1</EN>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="ZHONG" TYPE="OTHER" VALUE="2001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2009" MODIFIED="2014-02-26 14:40:55 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-02-26 14:40:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhu S, Liu Y, Sun S, Wang L</AU>
<TI>Psychological care on cognitive function in patients with chronic schizophrenia, the impact of (Google Translate)</TI>
<TO>&#24515;&#29702;&#25252;&#29702;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>China Practical Medicine (&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;)</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>22</NO>
<PG>190-2</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="&#26417;&#29577;&#26143;," TYPE="OTHER" VALUE="2009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-01-26 14:57:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-1960" MODIFIED="2013-11-01 11:51:12 +0000" MODIFIED_BY="[Empty name]" NAME="Casey 1960" YEAR="1960">
<REFERENCE MODIFIED="2013-11-01 11:51:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey JF, Lasky JJ, Klett CJ, Hollister LE</AU>
<TI>Treatment of schizophrenic reactions with phenothiazine derivates. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine and phenobarbital</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>97-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covell-2004" MODIFIED="2014-02-26 11:52:24 +0000" MODIFIED_BY="[Empty name]" NAME="Covell 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-02-26 11:52:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Covell NH, Weissman EM, Essock SM</AU>
<TI>Weight gain with clozapine compared to first generation antipsychotic medications</TI>
<SO>Schizophrenia bulletin</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>2</NO>
<PG>229-40</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="COVELL" TYPE="OTHER" VALUE="2004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferziger-2010" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ferziger 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al</AU>
<TI>A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>35</VL>
<PG>S101-S2</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="FERZIGER" TYPE="OTHER" VALUE="2010 a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al</AU>
<TI>A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology</TI>
<SO>Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida</SO>
<YR>2010</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="FERZIGER" TYPE="OTHER" VALUE="2010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freedman-1961" MODIFIED="2013-11-05 11:39:02 +0000" MODIFIED_BY="[Empty name]" NAME="Freedman 1961" YEAR="1961">
<REFERENCE MODIFIED="2013-11-05 11:39:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freedman DX, Jong de J</AU>
<TI>Thresholds for drug-induced akathisia</TI>
<SO>Journal of American Psychiatry</SO>
<YR>1961</YR>
<VL>117</VL>
<PG>930-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freyhan-1959" NAME="Freyhan 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freyhan FA</AU>
<TI>Therapeutic implications of differential effects of new phenothiazine compounds</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>116</VL>
<PG>577-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-1969" MODIFIED="2015-01-26 14:57:06 +0000" MODIFIED_BY="[Empty name]" NAME="Goldstein 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-01-26 14:57:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein BJ, Brauzer B, Clyde DJ, Caldwell JM</AU>
<TI>The differential prediction of response to two anti-psychotic drugs</TI>
<SO>Psychosomatics</SO>
<YR>1969</YR>
<VL>10</VL>
<NO>3</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollister-1967" MODIFIED="2015-01-26 14:56:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hollister 1967" YEAR="1967">
<REFERENCE MODIFIED="2015-01-26 14:56:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollister LE, Overall JE, Bennett JL, Kimbell I, Shelton J</AU>
<TI>Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1967</YR>
<VL>8</VL>
<NO>2</NO>
<PG>249-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellam-1971" MODIFIED="2015-01-26 14:56:46 +0000" MODIFIED_BY="[Empty name]" NAME="Kellam 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-01-26 14:56:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellam AMP, Jones KS</AU>
<TI>A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1971</YR>
<VL>47</VL>
<NO>2</NO>
<PG>174-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-2004" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="Mahmoud 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D</AU>
<TI>Risperidone versus conventional antipsychotic drugs for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care</TI>
<SO>Clinical drug investigation</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>275-86</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="MAHMOUD" TYPE="OTHER" VALUE="2004 a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT-2011" MODIFIED="2015-01-26 14:56:29 +0000" MODIFIED_BY="[Empty name]" NAME="NCT 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-01-26 14:56:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT</AU>
<TI>Decision aid to facilitate shared decision making during treatment in schizophrenia</TI>
<SO>http://ClinicalTrials.gov/show/NCT01420575</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01420575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Povlsen-1987" MODIFIED="2015-01-26 14:56:19 +0000" MODIFIED_BY="[Empty name]" NAME="Povlsen 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-01-26 14:56:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J</AU>
<TI>The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden</TI>
<TO>Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol+biperiden</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1987</YR>
<VL>149</VL>
<NO>25</NO>
<PG>1682-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulsinger-1958" NAME="Schulsinger 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulsinger F, Jensen R</AU>
<TI>Trilafon (perphenazine) and largactil (chlorpromazine) in chronic schizophrenia. A comparison</TI>
<TO>Trilafon (perfenazin) og largactil (klorpromazin) hos kronisk sindssyge. En sammenligning</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1958</YR>
<VL>120</VL>
<NO>12</NO>
<PG>366-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szafranski-1999" MODIFIED="2015-01-26 14:56:07 +0000" MODIFIED_BY="[Empty name]" NAME="Szafranski 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-01-26 14:56:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szafranski T, Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, et al</AU>
<TI>Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>273</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinar-1968" MODIFIED="2015-01-26 14:55:58 +0000" MODIFIED_BY="[Empty name]" NAME="Vinar 1968" YEAR="1968">
<REFERENCE MODIFIED="2015-01-26 14:55:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinar O</AU>
<TI>Differences in therapeutic effects of phenothiazine drugs</TI>
<SO>Agressolgie</SO>
<YR>1968</YR>
<VL>9</VL>
<NO>2</NO>
<PG>315-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-26 14:55:44 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-26 14:55:44 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2015-01-26 14:55:44 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2015-01-26 14:55:37 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Ollon I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement [comment]</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benkert-1996" NAME="Benkert 1996" TYPE="BOOK">
<AU>Benkert O, Hippius H</AU>
<SO>Psychiatrische Pharmakotherapie</SO>
<YR>1996</YR>
<EN>6th</EN>
<PB>Springer Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2015-01-26 14:55:27 +0000" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Trials in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleuler-1908" MODIFIED="2015-01-12 14:22:58 +0000" MODIFIED_BY="Heather Maxwell" NAME="Bleuler 1908" TYPE="JOURNAL_ARTICLE">
<AU>Bleuler E</AU>
<TI>[The prognosis of dementia praecox - schizophrenia group - Google translate]</TI>
<TO>Die Prognose der Dementia praecox - Schizophreniegruppe</TO>
<SO>Allgemeine Zeitschrift für Psychiatrie</SO>
<YR>1908</YR>
<VL>65</VL>
<PG>436-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2012" MODIFIED="2014-02-03 14:16:50 +0000" MODIFIED_BY="[Empty name]" NAME="BNF 2012" TYPE="OTHER">
<AU>BMJ Group and Pharmaceautical Press</AU>
<TI>British National Formulary No. 63. Antipsychotic drugs</TI>
<SO>BNF</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2013-03-01 11:34:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bundesverband-2001" NAME="Bundesverband 2001" TYPE="OTHER">
<AU>Bundesverband der Pharmazeutischen Industrie (editors)</AU>
<TI>No English title given</TI>
<TO>Fachinformation Decentan</TO>
<SO>Fachinformation Decentan</SO>
<YR>2001</YR>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cannon-1996" MODIFIED="2014-02-25 15:03:56 +0000" MODIFIED_BY="[Empty name]" NAME="Cannon 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cannon M, Jones P</AU>
<TI>Schizophrenia</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1996</YR>
<VL>61</VL>
<PG>604-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CEA" MODIFIED="2014-02-03 14:16:50 +0000" MODIFIED_BY="[Empty name]" NAME="CEA" TYPE="OTHER">
<TI>Cost-Effectiveness Analysis Registry (CEA)</TI>
<SO>https://research.tufts-nemc.org/cear4/ accessed 11/09/13</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2014-05-12 09:34:53 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2000" TYPE="BOOK_SECTION">
<AU>Clarke M, Oxman AD</AU>
<TI>Cochrane Reviewers' Handbook</TI>
<SO>The Cochrane Library [database on disk and CDROM]</SO>
<YR>2000</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-David-2005" MODIFIED="2014-02-27 11:28:08 +0000" MODIFIED_BY="[Empty name]" NAME="David 2005" TYPE="COCHRANE_REVIEW">
<AU>David A, Quraishi SN, Rathbone J</AU>
<TI>Depot perphenazine decanoate and enanthate for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-02-27 11:28:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-27 11:28:08 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001717.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davies-2007" MODIFIED="2015-01-26 14:55:14 +0000" MODIFIED_BY="[Empty name]" NAME="Davies 2007" TYPE="JOURNAL_ARTICLE">
<AU>Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al</AU>
<TI>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>191</VL>
<PG>14-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of the 8th International Cochrane Colloquium</SO>
<YR>2000 Oct 25th-29th</YR>
<PB>Cochrane Collaboration</PB>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2013-10-08 11:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2015-01-26 14:55:04 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<PG>124-585</PG>
<PB>National Institute of Mental Health. DHEW Publication NO (ADM)</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-12 14:25:14 +0000" MODIFIED_BY="Heather Maxwell" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2015-01-26 14:54:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH-E3-1995" MODIFIED="2014-02-18 10:21:27 +0000" MODIFIED_BY="[Empty name]" NAME="ICH E3 1995" TYPE="OTHER">
<AU>ICH Expert Working Group</AU>
<TI>ICH harmonised tripartite guideline: structure and content of clinical study reports</TI>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for huma use</SO>
<YR>30 November 1995</YR>
<IDENTIFIERS MODIFIED="2014-02-18 10:19:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2015-01-26 14:54:40 +0000" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="BOOK_SECTION">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<PB>Elsevier</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, Opler LA</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2013-03-01 11:34:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2013-03-01 11:34:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2013-03-01 11:34:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lowe-1973" MODIFIED="2014-02-20 11:21:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lowe 1973" TYPE="JOURNAL_ARTICLE">
<AU>Lowe GR</AU>
<TI>The phenomenology of hallucinations as an aid to differential diagnosis</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1973</YR>
<VL>123</VL>
<PG>621-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangalore-2007" MODIFIED="2015-01-26 14:54:25 +0000" MODIFIED_BY="[Empty name]" NAME="Mangalore 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mangalore R., Knapp M.</AU>
<TI>Cost of schizophrenia in England</TI>
<SO>Journal of Mental Health Policy and Economics</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>1</NO>
<PG>23-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schultz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2014-02-25 15:07:04 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2010" TYPE="OTHER">
<AU>National Collaborating Centre for Mental Health</AU>
<TI>Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition)</TI>
<SO>National Clinical Guideline Number 82</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parfitt-1999" MODIFIED="2015-01-26 14:54:14 +0000" MODIFIED_BY="[Empty name]" NAME="Parfitt 1999" TYPE="BOOK">
<AU>Parfitt K (editor)</AU>
<SO>Martindale. The Complete Drug Reference</SO>
<YR>1999</YR>
<EN>32nd</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenheck-2009" MODIFIED="2015-01-26 14:54:04 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenheck 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al</AU>
<TI>Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wing-1961" MODIFIED="2015-01-26 14:53:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wing 1961" TYPE="JOURNAL_ARTICLE">
<AU>Wing J</AU>
<TI>A simple and reliable subclassification of chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1967</YR>
<VL>107</VL>
<PG>862-75</PG>
<IDENTIFIERS MODIFIED="2014-02-17 15:25:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-17 15:25:28 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1192/bjp.107.450.862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2013-03-01 11:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-26 14:53:38 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hartune-2005" MODIFIED="2015-01-26 14:53:38 +0000" MODIFIED_BY="[Empty name]" NAME="Hartune 2005" TYPE="COCHRANE_REVIEW">
<AU>Hartung B, Wada M, Laux G, Leucht S</AU>
<TI>Perphenazine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-01-12 14:20:42 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2015-01-12 14:20:42 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003443.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-02-26 14:27:25 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-27 10:30:35 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-27 10:30:35 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-26 14:41:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amakusa-1973">
<CHAR_METHODS MODIFIED="2015-01-26 14:41:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks (preceded by 7 days for decreasing previous drugs and several days wash-out).<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:46:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: chronic schizophrenia (51 hebephrenic, 5 catatonic, 2 delusional type, 6 not otherwise specified).<BR/>N = 64 (32 matched-pairs).<BR/>Age: 18-55 years.<BR/>Sex: 20 F, 44 M.<BR/>History: chronic, inpatient, ill from 2 months to 30 years.</P>
<P>Included: not stated.<BR/>Excluded: no details.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-13 13:39:04 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 4 x 3 mg tablets/day for the first week (12 mg), 6 tablets/day for the second week (18 mg), then increased or decreased according to judgements of each physician in the third week; maximum 10 tablets, N = 32.<BR/>2. Sulpiride: 4 x 100 mg tablets/day for the first week (400 mg), 6 tablets/day for the second week (600 mg), then increased or decreased according to judgements of each physician in the third week; maximum 10 tablets, N = 32.</P>
<P>Antiparkinsonian and sedative medication was given if needed (including trihexyphenidyl, promethazine, pentobarbital, amobarbital and bromovalerylurea).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-20 10:44:58 +0000" MODIFIED_BY="[Empty name]">
<P>Global state: no better or worse (Global Comparative Judgement (GCJ); General improvement rating (GIR)).</P>
<P>Leaving the study early (any reason; adverse effects; relapse/worsening).<BR/>Adverse events (gastrointestinal; movement disorder; anticholinergic; arousal; CNS; at least one adverse effect; general; lab data).</P>
<P>Unable to use -<BR/>Mental state: psychiatric evaluating scale (PES) (developed by three universities - unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-26 14:41:18 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:16:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennett-1961">
<CHAR_METHODS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Duration: 12 weeks, preceded by 2 weeks wash-out.<BR/>Setting: hospital, single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:41:41 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: all except two had chronic schizophrenia.<BR/>N = 30 (n = 25 relevant).<BR/>Age: median ~ 37 years.<BR/>Sex: 30 M.<BR/>History: chronic; 'ill for more than two years'; median number of years hospitalised 2.6; Multidimensional Scale for Rating Psychiatric Patients (MSRPP) showed patients to be more 'perceptually confused, paranoid and mentally agitated than the usual male patients confined to Veterans Administration hospitals'; n = 22 were previously receiving phenothiazine derivatives without sustained improvement; n = 10 received courses of electric shock therapy; n = 7 had been given insulin coma therapy.</P>
<P>Included: not stated.<BR/>Excluded: history of central nervous system disease, seizures, lobotomy, somatic illnesses, which included duodenal ulcer, liver disease, blood dyscrasia, or those psychotic as a result of infection or toxic factors.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 10:16:19 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 16 mg/day gradually increased until by the 5th week 48 mg/day, then until the 12th week 96 mg/day, N = 5.<BR/>2. Chlorpromazine: 200 mg/day gradually increased until by the 5th week 600 mg/day, then until the 12th week 1200 mg/day, N = 5.<BR/>3. Prochlorperazine: 25 mg/day gradually increased until by the 5th week 75 mg/day, then until the 12th week 150 mg/day, N = 5.<BR/>4. Triflupromazine: 50 mg/day gradually increased until by the 5th week 150 mg/day, then until the 12th week 300 mg/day, N = 5.<BR/>5. Mepazine: 50 mg/day gradually increased until by the 5th week 150 mg/day, then until the 12th week 300 mg/day, N = 5.<BR/>
<I>[6. Phenobarbital: 32 mg/day gradually increased until by the 5th week 100 mg/day, then until the 12th week 200 mg/day, N</I> = <I>5 - not included in data and analysis, not an antipsychotic].</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-27 10:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Adverse events: EEG results.</P>
<P>Unable to use -<BR/>Global state: no better or worse (no data for individual groups).<BR/>Mental state: MSRPP, CEPS (no data).<BR/>Adverse events (no data).<BR/>Laboratory tests (no data).<BR/>Cognitive functioning: Porteus Maze (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 14:20:10 +0100" MODIFIED_BY="[Empty name]">
<P>Prior to treatment, participants were given inert identical-appearing placebo for 14 days; "judicious use of conventional short-acting sedatives was allowed during first 4 weeks to control behaviour/ insomnia". </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:16:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE-2005">
<CHAR_METHODS MODIFIED="2013-12-11 14:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: double.</P>
<P>Duration: 18 months.</P>
<P>Setting: 57 clinical US sites (16 university clinics, 10 state mental health agencies, 7 Veterans Affairs medical centers, 6 private non-profit agencies, 4 private-practice sites, and 14 mixed-system sites) January 2001 to December 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:16:50 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (DSM-IV).</P>
<P>N = 1,493.</P>
<P>Age: 40.6 ± 11.1 years old.</P>
<P>Sex: F 380; M 1080.</P>
<P>History: exacerbation in previous 3 months n = 402; mean age of first treatment for any behavioural or emotional problem = 24.0 ± 8.9 years old; years since first antipsychotic medication prescribed = 14.4 ± 10.7 years.</P>
<P>Included: 18 to 65 years&#8217; old; DSM-IV schizophrenia diagnosis; adequate capacity to consent; have a condition appropriate for treatment with oral medication.</P>
<P>Exclusion: severe adverse reactions/ intolerance/ failure to respond to one of the treatments; diagnosis of schizoaffective disorder or mental retardation, pervasive developmental disorder, delirium, dementia, amnesia or other cognitive disorders; first episode schizophrenia; pregnant women/breastfeeding; past or current treatment with clozapine for treatment resistance; people currently stabilised on haloperidol decanoate or Fluphenazine decanoate who require long-acting injections to maintain treatment adherence; people with tardive dyskinesia excluded from assignment to conventional treatment arm; people with cardiac conditions (myocardial infarction in past 6 months, QTc prolongation, cardiac arrhythmia, uncompensated congestive heart failure, heart block [PR interval &gt; 0.22 seconds]).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-13 13:46:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine (8 mg oral tablets), mean modal dose 20.8 mg/ day, n = 261.</P>
<P>2. Olanzapine (7.5 mg oral tablets), mean modal dose 20.1 mg/day, n = 336.</P>
<P>3. Quetiapine (200 mg oral tablets), mean modal dose 543.4 mg/day, n = 337.</P>
<P>4. Risperidone (1.5 mg oral tablets), mean modal dose 3.9 mg/day, n = 341.</P>
<P>5. Ziprasidone (40 mg oral tablets), mean modal dose 112.8 mg/day, n = 185.</P>
<P>First four weeks after randomisation allowed overlap in administration of antipsychotic medication that participants received prior to study-entry to allow gradual transition to study medication. Concomitant medication permitted throughout study, except for additional antipsychotic agents.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-11 14:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: all-cause treatment discontinuation</P>
<P>Secondary outcomes: reasons for discontinuation; weight gain; EPS; sedation; prolactin; (as judged by study doctor). PANSS; CGI; AIMS; Barnes akathisia rating; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-13 13:48:01 +0000" MODIFIED_BY="Heather Maxwell">
<P>We contacted the authors of this study for more information, which was provided, and we were able to include the above data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1975">
<CHAR_METHODS MODIFIED="2015-01-13 13:50:01 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks, preceded by 2 weeks fixed daily dose of 125 mg chlorpromazine.<BR/>Setting: multi-centre, Hôpital St-Jean-de-Dieu, Montréal and Hôpital St-Charles, Joliette (Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic (ambulatory) schizophrenia.<BR/>N = 96 (n = 48 relevant).<BR/>Age: mean ~ 42 ± 9.3 years.<BR/>Sex: 48 F, 48 M.<BR/>History: chronic, outpatient, length of previous hospitalisations ranging from 0.5 to 31.3 years.</P>
<P>Included: 20 to 60 years old; primary hospital diagnosis of schizophrenia confirmed by research psychiatrist; presence of two or more of the following symptoms/ behaviours &#8211; thought or speech disturbance catatonic motor behaviour; paranoid ideation; hallucinations; delusional thinking other than paranoid; blunted or inappropriate affect; disturbance of social behaviour and interpersonal relations.<BR/>Excluded: physical illness, childhood schizophrenia, chronic or acute brain syndrome, IQ below 70, alcoholism, epilepsy, drug addiction.</P>
<P>Consent: all participants gave informed consent after purpose of study and possible side effects were explained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:48:33 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 20 mg/day, N = 24.<BR/>2. Placebo: 5 tablets a day, N = 24.</P>
<P>[3. Amitriptyline-perphenazine: 20 mg/day, N = 24 - not included in data and analysis, not an antipsychotic].<BR/>[4. Amitriptyline hydrochloride: 125 mg/day, N = 24 - not included in data and analysis, not an antipsychotic].</P>
<P>Additional medication: procyclidine hydrochloride for parkinsonism, chlorpromazine (orally in liquid form) for extreme agitation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-16 16:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: change over time - relapse.<BR/>Adverse events:</P>
<P>Abnormal laboratory results: SGOT, SGPT, alkaline phosphate, cholesterol, total serum bilirubin, fasting blood glucose.</P>
<P>Unable to use -<BR/>Global state: CGI end score (no SD).<BR/>Mental state: BPRS, IMPS (no SD).<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-27 15:14:03 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:17:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1977">
<CHAR_METHODS MODIFIED="2013-09-17 12:20:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks, preceded by 2 weeks fixed daily dose of 125 mg chlorpromazine.<BR/>Setting: single-centre, Hôpital St-Jean-de-Dieu, Montréal and Hôpital St-Charles, Joliette (Canada).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:42:34 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 54.<BR/>Age: mean ~ 46 years.<BR/>Sex: 27 F, 27 M.<BR/>History: all participants previously receiving antipsychotic medication (not specified); mean hospitalisations 13.35.</P>
<P>Included: age 20 to 60 years; primary diagnosis of schizophrenia.<BR/>Excluded: organic heart disease; physical illness/ chronic or acute brain syndrome; IQ lower than 70; alcoholism; epilepsy; drug addiction; electrolyte abnormalities.</P>
<P>Consent: all participants gave informed consent after purpose of the study and possible side effects had been explained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:48:54 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine (Trilafan) 20mg/ day, n = 18.<BR/>2. Placebo: 5 tablets a day, n = 18.</P>
<P>
<I>[3. Perphenazine 20 mg/day and amitriptyline 125 mg/day, n</I> = <I>18 - not included in data and analysis, combined with anti-depressant].</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:17:58 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Adverse events: use of antiparkinsonian medication.<BR/>Physical tests: ECG abnormalities (primary outcome).</P>
<P>"Intensified psychopathological condition" - resulting in hop.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-11 13:48:04 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:42:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-1967">
<CHAR_METHODS MODIFIED="2015-01-26 14:42:47 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Duration: 10 weeks, preceded by 2 weeks wash-out .<BR/>Setting: hospital, single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:49:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 87.<BR/>Age: mean ~ 41 years.<BR/>Sex: all male.<BR/>History: chronic 'long-stay' inpatient.</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:49:23 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 4 mg/day for five weeks, then 8 mg/day for another five weeks, n = 29.<BR/>2. Placebo: one tablet daily for the first five weeks, then two tablets daily for another five weeks, n = 29.</P>
<P>
<I>[3. Perphenazine and amitriptyline: 4 mg/day and 25 mg/day for five weeks, then 8 mg/day and 50 mg/day for another five weeks, n</I> = <I>29 - not included in data and analysis, combined with anti-depressant].</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-11 15:35:24 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Behaviour: Wing-Scale B - social withdrawal, socially embarrassing behaviour (SD imputed from standard error).<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: overall improvement; relative improvement (unusable data).<BR/>Physical: body weight (no SD).</P>
<P>Other side effects: nausea; dizziness; skin rash (no data reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-16 16:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>*Night sedatives as needed, but no other medication administered.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:18:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dehnel-1968">
<CHAR_METHODS MODIFIED="2013-12-16 16:48:02 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: double.</P>
<P>Duration: 12 weeks.</P>
<P>Setting: inpatient, US.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:49:28 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia (no further details).</P>
<P>N = 50.</P>
<P>Age: range 25 to 59 years; mean 42.8 years.</P>
<P>Sex: all male.</P>
<P>History: length of hospitalisation ranged from 2 months to 23 years; median 42 months. Prior to study, all but two of the 50 participants were taking one or more psychoactive drugs (mainly phenothiazines).</P>
<P>Included: under 60 years.</P>
<P>Excluded: significant physical illness (such as liver disease/ severe cardiovascular disease).</P>
<P>Consent: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:49:35 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: oral, 8 mg tablets, range 8 to 80 mg, n = 25.</P>
<P>2. Clopenthixol: oral, 25 mg tablets, range 25 to 250 mg, n = 25.</P>
<P>*Initial dose was one tablet per day to be adjusted for each participant (up to maximum of 10 tablets).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:18:45 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events (checklist completed by investigator).</P>
<P>Global rating of improvement (investigator judgement).</P>
<P>Leaving the study early</P>
<P>Unable to use -</P>
<P>BPRS (interviewer rating); PIP (nurses rating) (no means or SD reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>*All participants placed on placebo for wash-out period prior to 12-week trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:43:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eckmann-1984">
<CHAR_METHODS MODIFIED="2013-09-17 12:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Duration: 30 days.<BR/>Setting: hospital, single-centre (Germany).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:49:50 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: acute paranoid-hallucinatory schizophrenia (ICD 295.3).<BR/>N = 40.<BR/>Age: 20 - 45 years, mean ~ 34 years.<BR/>Sex: 16 F, 24 M.<BR/>History: acute, inpatient.</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-26 14:43:09 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 12 mg or 24 mg/day, n = 20.<BR/>2. Benperidol: 6 mg or 12 mg/day, (2 patients received 9mg/day from 4th-6th day and one of them also from 19th-30th day), n = 20.</P>
<P>Additional medication: anticholinergics and sedating drugs (low potent neuroleptics, tranquillisers) as needed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: no better or worse.</P>
<P>Unable to use - <BR/>Mental state: BPRS end score (no SD), AMDP (no data).<BR/>Behaviour: NOSIE end score (no SD).<BR/>Adverse events: SAS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-16 12:24:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:19:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fruensgaard-1978">
<CHAR_METHODS MODIFIED="2013-09-17 12:21:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 3 weeks (for acute) and 12 weeks (for chronic).<BR/>Setting: multi-centre, Denmark.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:19:38 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (group I) acute schizophrenia and &#8220;psychogenic (reactive) psychosis&#8221;, n = 22; (group II) chronic schizophrenia, n = 25.<BR/>N = 47.<BR/>Age: mean ~ 37 years.<BR/>Sex: 15 F, 32 M.<BR/>History: acute and chronic.</P>
<P>Included: no details.<BR/>Excluded: known hypersensitivity to dibenzoxazepine compounds or butyrophenones, manic-depressive illness, electro-convulsive therapy or insulin coma or sub-coma therapy within the preceding 8 weeks, alcoholism or drug dependence as a significant feature of clinical history, serious impairment of renal or hepatic function, a history of increased intra-ocular pressure or history of narrow-angle glaucoma or urinary retention, cardiovascular or metabolic disease (severe cases), pregnancy.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:50:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 8 mg per capsule, initially 2 capsules daily, could be increased to a maximum of 15 capsules daily according to the therapeutic efficacy and side effects, n = 24*.<BR/>2. Loxapine: 10 mg per capsule, initially 2 capsules daily, could be increased to a maximum of 15 capsules daily according to the therapeutic efficacy and side effects, n = 23**.</P>
<P>Additional medication: chloralodol for severe insomnia, antiparkinsonian drugs (orphenadrine and/or biperiden) as necessary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-13 13:55:25 +0000" MODIFIED_BY="Heather Maxwell">
<P>Leaving the study early.<BR/>Global state: CGI &#8211; dichotomised data, no better or deterioration.<BR/>Adverse events.</P>
<P>Laboratory tests (no data).</P>
<P>Unable to use -<BR/>Mental state: BPRS end score (no mean or SD).<BR/>Behaviour: NOSIE end score (no mean or SD).<BR/>Laboratory tests (not all data reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-12 14:50:27 +0000" MODIFIED_BY="Heather Maxwell">
<P>*Perphenazine mean dose for participants with acute schizophrenia = 34 mg after three weeks of treatment; mean dose for participants with chronic schizophrenia = 90.1 mg after two months of treatment.<BR/>**Loxapine mean dose for participants with acute schizophrenia = 54.4 mg after three weeks of treatment; mean dose for participants with chronic schizophrenia = 81.1 mg after two months of treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanlon-1964">
<CHAR_METHODS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks, preceded by 2 weeks wash-out.<BR/>Setting: multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:50:45 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: 115 anergic, withdrawn psychotic patients of which at least 99 with schizophrenia.<BR/>N = 115 (n = 58 relevant).<BR/>Age: range 21 to 74 years, mean 54±10.5 years.<BR/>Sex: 115 F.<BR/>History: inpatient.</P>
<P>Included: no details.<BR/>Excluded: over 75 years of age, diagnosed with one of the chronic brain disorders, manifested complicated physical condition.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-26 14:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 4 mg three times daily for two weeks, then 8 mg three times daily for 10 weeks, N = 29.<BR/>2. Placebo: one tablet three times daily for two weeks, then two tablets three times daily for 10 weeks, N = 29.<BR/>
<I>[3. Amitriptyline: 25 mg three times daily for two weeks, then 50 mg three times daily for 10 weeks, N</I> = <I>29.]</I>
<BR/>
<I>[4. Amitriptyline - perphenazine: 25 mg and 4 mg three times daily for two weeks, then 50 mg and 8 mg three times daily for 10 weeks, N</I> = <I>28.]</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-26 14:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early &#8211; any reason/ adverse events.<BR/>Adverse events: hypotension; dry mouth; nausea; body pains; dizziness; drowsiness; insomnia; weakness; oedema; tremors; tenseness; agitation; severe regression.</P>
<P>Unable to use -<BR/>Mental state: IMPS, PRP (no SD/P value).<BR/>Behaviour: MACC (no SD/P value).<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-26 14:43:39 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-12 14:51:45 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hanlon-1965">
<CHAR_METHODS MODIFIED="2013-09-17 12:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 30 days.<BR/>Setting: multi-centre, inpatient, Baltimore, Maryland (US).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:51:19 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: n = 270 schizophrenia; n = 52 neurotic or manifesting personality disorders*.<BR/>N = 421 (n = 322 remained on the project for at least five days).<BR/>Age: range 18 to 60 years, mean ~ 36 years.<BR/>Sex: 162 F, 160 M.<BR/>History: acutely disturbed, newly-admitted state psychiatric hospital inpatients.</P>
<P>Included: newly admitted; between 18 to 60 years of age; "considered candidates for tranquilizing drug therapy"**.<BR/>Excluded: admission under court order; presence of a complicating physical disease or disability; alcoholism; drug addiction; brain syndrome; senility.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:51:45 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: oral capsules of 8 mg and 16 mg, at least 24 mg/day, average dosage 38.61 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, n = 53.<BR/>2. Chlorpromazine: oral capsules of 100 mg and 200 mg, at least 300 mg/day, average dosage 395.56 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 52.<BR/>3. Thioridazine: oral capsules of 50 mg and 100 mg, at least 150 mg/day, average dosage 193.46 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 53.<BR/>4. Triflupromazine: oral capsules of 25 mg and 50 mg, at least 75 mg/day, average dosage 95.93 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 53.<BR/>5. Prochlorperazine: oral capsules of 12.5 mg and 25 mg, at least 37.5 mg/day, average dosage 51.22 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 52.<BR/>6.Thiopropazate: oral capsules of 5 mg and 10 mg, at least 15 mg/day, average dosage 20.83 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 53.<BR/>7. Trifluoperazine: oral capsules of 2.5 mg and 5 mg, at least 7.5 mg/day, average dosage 11.49 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 52.<BR/>8. Fluphenazine: oral capsules of 1.25 mg and 2.5 mg, at least 3.75 mg/day, average dosage 5.92 mg/day, at least 65 mg phenobarbital t.i.d. for the first 48 hours, N = 53.</P>
<P>All above dosages depended on the clinical judgment of the treating physician.<BR/>Additional medication:<BR/>biperiden for parkinsonism, phenobarbital etc. for mild sedation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-17 11:52:07 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason; due to adverse events.<BR/>Adverse events: skin rash; hypotensive reaction; akathisia; dyskinesia; edema; EPS; Parkinsonism; akinesia. </P>
<P>Unable to use -<BR/>Mental state: MSRPP (no SD), IMPS, MMPI (no data).<BR/>Behaviour: MACC, PRP (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-16 16:58:33 +0100" MODIFIED_BY="[Empty name]">
<P>*Those that were in final evaluation.</P>
<P>**Quote: "to insure the inclusion of the more disturbed patients, all referrals were administered a minimum parenteral dosage of 65 mg phenobarbital t.i.d for the first 28 hours" (p90).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:44:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoyberg-1993">
<CHAR_METHODS MODIFIED="2015-01-26 14:44:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks, preceded by wash-out - no further details.<BR/>Setting: multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:44:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia disorder with acute exacerbation (DSM-III-R).<BR/>N = 107.<BR/>Age: 20 to 67 years, mean ~ 36 years.<BR/>Sex: 30 F, 77 M.<BR/>History: chronic; outpatient; 93% of participants were receiving drugs of diverse categories pre-wash-out (most commonly-used drugs included phenothiazines and thioxanthenes).</P>
<P>Included: aged between 18 to 65; diagnosis of chronic schizophrenia with acute exacerbation (DSM-III-R); informed consent.<BR/>Excluded: mental disorder other than chronic schizophrenic disorder; clinically significant organic disorders; clinically relevant abnormalities in laboratory tests; history of alcohol or drug abuse as defined in DSM-III-R within the 12-month period preceding the study; reception of oral neuroleptic treatment less than 72 hours or depot neuroleptics less than 3 weeks before the start of treatment; commitment to a mental hospital; women of reproductive age without adequate contraception; pregnant or lactating women.</P>
<P>Consent: informed consent required from participants or their relatives or legal guardians; study approved by relevant ethics committees in accordance with the Declaration of Helsinki II.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:52:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 8 mg per capsule, initially 2 capsules daily, dose could be changed during the first 4 weeks according to individual needs to a maximum of 48 mg/day, during the last 4 weeks dose was to be kept unchanged, but could be reduced if adverse events occurred*, n = 52.<BR/>2. Risperidone: 2.5 mg per capsule, initially 2 capsules daily, dose could be changed during the first 4 weeks according to individual needs to a maximum of 15 mg/day, during the last 4 weeks dose was to be kept unchanged, but could be reduced if adverse effects occurred*, n = 55.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 14:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason; due to adverse events.<BR/>Global state: no better or worse (CGI).<BR/>Mental state: PANSS (clinical improvement, defined as 'at least 20% reduction in total PANSS score at endpoint).<BR/>Adverse events: UKU Side Effect Rating Scale</P>
<P>Unable to use -<BR/>Mental state: BPRS; PANSS (no SD).</P>
<P>Global state: CGI (no means or SD).<BR/>Adverse events: ESRS (no SD).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-12 14:52:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>*During the last 4 weeks dose was to be kept unchanged, but could be reduced if adverse effects occurred.</P>
<P>**During the treatment period, n = 42 in the Risperidone group and n = 38 in the perphenazine group required concomitant medication (including benzodiazepines and orphenadrine).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-12 14:52:56 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Imai-1980">
<CHAR_METHODS MODIFIED="2014-01-13 15:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks, preceded by 3 to 7 days wash-out.<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:52:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia.<BR/>N = 95.<BR/>Age: 20 to 55 years.<BR/>Sex: 19 F, 76 M.<BR/>History: inpatient.</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:52:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: initially 12 mg daily and inactive placebo, then according to the symptoms and side effects, maximum dosage 24 mg daily, n = 49.<BR/>2. Zotepine: initially 75 mg daily and inactive placebo, then according to the symptoms and side effects, maximum dosage 150 mg daily, n = 46.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-26 09:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason; due to relapse/ worsening.<BR/>Global state: no better or worse.<BR/>Adverse events: cardiovascular.</P>
<P>Unable to use:<BR/>Mental state: Keio University Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 11:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Additional medication: only after 4 days from the beginning of the study; antiparkinsonians, barbiturates, liver protectors, vitamins, haloperidol, levomepromazine, chlorpromazine, diazepam if needed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-13 15:40:39 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Itoh-1969">
<CHAR_METHODS MODIFIED="2013-09-26 10:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks, preceded by one week wash-out.<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:52:58 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia.<BR/>N = 80.<BR/>Age: mean ~ 34 years.<BR/>Sex: 18 F, 62 M.<BR/>History: inpatient; duration of illness ranged from less than 12 months (6%) to over 10 years (33%).</P>
<P>Included: showing one or more of the following: state of intense excitement; stuporous state; pronounced hallucinations and/ or delusions; pronounced delusions; markedly devoid of spontaneity and apathetic (fresh or subacute hebephrenia; or chronic, terminal deteriorative state); pronounced neurosis-like state.<BR/>Excluded: no details.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-13 15:40:39 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: (oral, 4 mg) + lactose; initially 45 mg daily, increased to 90 mg within one week, then individual dosage according to symptoms and adverse events, n = 40.<BR/>2. Clothiapine: (oral, 15 mg); initially 12mg daily, increased to 24 mg within one week, then individual dosage according to symptoms and adverse events, n = 40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-26 10:39:36 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Behaviour: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Mental state: Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 11:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Antiparkinsonism drugs and hypnotic agents were prepared and used when deemed necessary by the clinician.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-12 14:53:10 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Itoh-1969-II">
<CHAR_METHODS MODIFIED="2013-09-26 14:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: unclear.<BR/>Setting: number of participating centres unclear, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:53:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia.<BR/>N = 86.<BR/>Age: unclear.<BR/>Sex: unclear.<BR/>History: no details.</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:53:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: no further details, n = 43.<BR/>2. Thiothixene: no further details, n = 43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-26 14:16:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early; any reason.<BR/>Global state: no better or worse.<BR/>Behaviour: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Mental state: Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 14:12:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-12 14:53:19 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Itoh-1969-III">
<CHAR_METHODS MODIFIED="2014-01-13 15:59:17 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 60 days, preceded by one week wash-out.<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:53:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia.<BR/>N = 78.<BR/>Age: no details.<BR/>Sex: no details.<BR/>History: no details.</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:53:19 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: initially 9 mg (3 tablets) daily, increased to 18 mg within one week, then individual dosage according to symptoms and adverse events, n = 39.<BR/>2. Methylperidol: initially 15 mg (3 tablets) daily, increased to 30 mg within one week, then individual dosage according to symptoms and adverse events, n = 39.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-26 15:19:47 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Behaviour: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Mental state: Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 15:20:34 +0100" MODIFIED_BY="[Empty name]">
<P>Additional medication: antiparkinson medication if needed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:45:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Itoh-1976">
<CHAR_METHODS MODIFIED="2014-01-13 15:59:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks, preceded by one week wash-out.<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:45:20 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (hebephrenia (n = 74), catatonia (n = 5), paranoid (n = 18) undifferentiated (n = 8)).<BR/>N = 105.<BR/>Age: range 19 to 50.<BR/>Sex: 58 F, 47 M.<BR/>History: inpatient; duration of hospitalisation of less than one year (n = 32), one to five years (n = 29), five years plus (n = 44); duration of illness range from less than one year to 10 years.</P>
<P>Included: not clear.<BR/>Excluded: somatic diseases; allergy; history of side effects of antiparkinsonians; glaucoma; prostate-hypertrophy; children; pregnancy and older patients.</P>
<P>Consent: not clear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:53:44 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: one tablet (a 4 mg) three times daily for the first week, 2 tablets three times daily in the second week, 3 tablets three times daily in the third week, then flexible dose according to the judgement of each physician; maximum 60 mg daily, n = 51.<BR/>2. Penfluridol: 1 tablet (a 20 mg) daily for the first week, 6 tablets in the second week, 9 tablets in the third week, then flexible dose according to the judgement of each physician; maximum 100 mg daily, n = 54.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no SD), Keio University Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 15:40:07 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:45:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2003">
<CHAR_METHODS MODIFIED="2015-01-26 14:45:33 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: double.</P>
<P>Duration: 6 weeks (preceded by 2 weeks screening period; 2 days wash-out; 4-6 weeks open-label treatment [olanzapine vs risperidone] to confirm treatment-resistant; 2-10 days wash-out).</P>
<P>Setting: multi-centre, 59 centres in US &amp; Canada (2000-2002).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:45:33 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) classified as &#8216;treatment resistant*&#8217; (n = 215 paranoid; n = 14 disorganised; n = 71 undifferentiated).</P>
<P>N = 300.</P>
<P>Age: mean 42.1 (Perphenazine mean 41.6; aripiprazole mean 42.6).</P>
<P>Sex: F 92; M 208, (Perphenazine: F 52, M 94; aripiprazole: F 40, M 114).</P>
<P>History: mean age at time of first hospitalisation 22.8 (Perphenazine mean 22.9; aripiprazole mean 22.6).</P>
<P>Included: &gt; 18 years of age; schizophrenia DSM-IV; classified as &#8216;treatment resistant*&#8217;; PANSS total score &#8805; 75 and a score of &#8805; 4 on at least 2 items of conceptual disorganization; suspiciousness, hallucinatory behaviour, or delusions; Clinical Global Impression-Severity of Illness (CGI-S) score &#8805; 4; treated as outpatient for at least 1 continuous 3-month period during 2-years prior to study.</P>
<P>Excluded: DSM-IV schizoaffective disorder, residual schizophrenia, bipolar disorder, clinical presentation or history consistent with delirium, dementia, amnesic or other cognitive disorders; refractory response to prior clozapine treatment administered at therapeutic doses for 6 weeks; previous unsatisfactory response to perphenazine; likelihood to require prohibited concomitant therapy; history of or current drug or alcohol abuse or dependence; history of suicide attempts/ serious suicidal thoughts; known allergy/ hypersensitivity to study drugs; treatment with an investigational drug within 4 weeks of wash-out phase; previous enrolment in aripiprazole study; acute or unstable medical condition; pregnancy or lactating.</P>
<P>Consent: written informed consent required; institutional review board approval obtained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:56:59 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: range 8 to 64 mg/day, mean 39.1 mg/day; started at 8 mg/day and could be increased to 16 mg/day on day 4 if needed; max 64 mg/day, doses greater than 8 mg/day administered twice daily, n = 146.</P>
<P>2. Aripiprazole: 15 to 30 mg/day, mean 30 mg/day; started at 15 mg/day, dose adjustments made to maximum 30 mg/day after week 1, n = 154.</P>
<P>
<I>(Dose reductions also permitted provided participants remain in permitted dose range).</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-13 15:45:38 +0000" MODIFIED_BY="Heather Maxwell">
<P>
<I>Primary outcome</I>: PANSS change from baseline.</P>
<P>
<I>Secondary outcomes:</I> CGI-I; CGI-S; BPRS; QoL using QLS (clinically important improvement defined as &gt; 20% improvement in total score from baseline); response to treatment (&gt; 30% decrease in PANSS total score or CGI-I score of 1 or 2); adverse events; lab data; EPS (SAS, AIMS and BAS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-17 15:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>*</B>treatment resistant defined as &#8220;failure to experience satisfactory symptom relief despite at least 2 periods of treatment (lasting at least 6 weeks) with adequate doses of antipsychotic agents (one of which had to be a typical antipsychotic) during the 2 years prior to the study. Nor should participants have experienced satisfactory symptom relief with their most recent course of antipsychotic therapy (p214).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:46:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurihara-1983">
<CHAR_METHODS MODIFIED="2013-09-26 16:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks.<BR/>Setting: multi-centre, Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-26 14:46:13 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 286.<BR/>Age: no details.<BR/>Sex: 124 F, 160 M.<BR/>History: inpatient.</P>
<P>Included: not clear.<BR/>Excluded: severe excitement; severe stupor; severely delusional hallucinatory; severely deteriorated; hepatic; cardiac or haematological disturbance; pregnancy or suspected; children; elderly people.</P>
<P>Consent: not clear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:58:07 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: initially 9 mg (3 tablets) daily for one week, 18 mg during the second week, then individual dosage according to symptoms and adverse events, n = 95.<BR/>2. Clocapramine: initially 75 mg (3 tablets) daily for one week, 150 mg during the second week, then individual dosage according to symptoms and adverse events, n = 97.<BR/>3. Haloperidol: initially 3 mg (3 tablets) daily for one week, 6 mg during the second week, then individual dosage according to symptoms and adverse events, n = 94.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use - <BR/>Mental state: Psychiatric Rating Scale (unpublished scale).<BR/>Behaviour: Evaluation of Behaviour (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-26 16:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Additional medication: sedatives such as nitrazepam, amobarbital, bromvalerylurea and antiparkinsonians such aspromethazine, biperiden, trihexyphenidyl were given if needed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:24:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurland-1961">
<CHAR_METHODS MODIFIED="2013-09-30 16:48:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks, preceded by 48 hours wash-out.<BR/>Setting: hospital, single-centre, Baltimore, Maryland (US).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:58:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: "predominantly schizophrenia" - no further details.<BR/>N = 238 (n = 209 relevant)<BR/>Age: 18-61 years, mean ~ 39 years.<BR/>Sex: ratio men to women was 1:2 - no further details.<BR/>History: inpatient, newly admitted.</P>
<P>Included: between 18 to 65 years old; referred on basis of target symptoms of anxiety, agitation and restlessness.<BR/>Excluded: alcoholism, admission under court order, chronic brain syndrome, major organic diseases, senility.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 10:24:02 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: initially 5 mg three times daily parenterally for 2 days, then 8 or 16 mg or a multitude of 16 mg orally for 40 days, average 30.83 mg/day, n = 31.<BR/>2. Prochlorperazine: initially 5 mg three times daily parenterally for 2 days, then 10 or 25 mg or a multitude of 25 mg orally for 40 days, average 45.38 mg/day, n = 29.<BR/>3. Triflupromazine: initially 25 mg three times daily parenterally for 2 days, then 25 or 50 mg or a multitude of 50 mg orally for 40 days, average 110.46 mg/day, n = 31.<BR/>4. Mepazine: initially 25 mg three times daily parenterally for 2 days, then 25 or 50 mg or a multitude of 50 mg orally for 40 days, average 135.45 mg/day, n = 27.<BR/>5. Chlorpromazine: initially 25 mg three times daily parenterally for 2 days, then 100 or 200 mg or a multitude of 200 mg orally for 40 days, average 401.35 mg/day, n = 32.<BR/>6. Promazine: initially 50 mg three times daily parenterally for 2 days, then 100 or 200 mg or a multitude of 200 mg orally for 40 days, average 438.92 mg/day, n = 29.<BR/>7. Placebo: active (phenobarbital) and inert (saline/ lactose) initially saline three times daily parenterally for 2 days, then lactose orally for 40 days, average 6 capsules/day, n = 30.</P>
<P>
<I>[8. Phenobarbital: initially 65 mg three times daily parenterally for 2 days, then 32.5 or 65.0 mg or a multitude of 65.0 mg orally for 40 days, average 183.64 mg/day, n</I> = <I>29] - not included in data and analysis (not an antipsychotic).</I>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:24:09 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason; due to adverse events.</P>
<P>Response: no better or worse.</P>
<P>Unable to use -<BR/>Mental state: MSRPP (no SD), PRP (no data), Psychiatric Scale of Target Symptoms (unpublished scale).<BR/>Adverse events (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-01 15:47:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepola-1989">
<CHAR_METHODS MODIFIED="2013-10-01 17:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 4 months, preceded by 4 weeks wash-out.<BR/>Setting: hospital, single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:58:48 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia (n = 17 acute; n = 30 chronic) (RDC).<BR/>N = 47.<BR/>Age: 18 to 66 years, mean ~ 39 years.<BR/>Sex: 27 F, 20 M.<BR/>History: inpatient, Finland.</P>
<P>Included: not stated.<BR/>Excluded: organic cerebral disease, mental retardation apparent from school age, epilepsy, serious physical disability, renal or hepatic insufficiency, haematological disorders, pregnancy.</P>
<P>Consent: informed consent required; trial design was accepted by the Ethic Committee of "Harjam&#257;ki Mental Hospital".</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 4 mg per tablet, initially 3 tablets daily, could be changed when considered necessary according to response or side effects, maximal daily dose 40 mg, n = 24.<BR/>2. Sulpiride: 200 mg per tablet, initially 3 tablets daily, could be changed when considered necessary according to response or side effects, maximal daily dose 2000 mg, n = 23.</P>
<P>Additional medication: biperiden for extrapyramidal symptoms, diazepam or nitrazepam for additional sedation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-01 17:14:49 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Mental state: BPRS.<BR/>Adverse events.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-01 17:14:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:25:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naukkarinen-2000">
<CHAR_METHODS MODIFIED="2015-01-26 14:46:43 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: double.</P>
<P>Duration: 26 weeks + wash-out (time not stated).</P>
<P>Setting: multi-centre, Finland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:58:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: acute or chronic schizophrenia (DSM-IV) with acute symptoms (at least &#8216;moderately ill&#8217; using CGI 4).</P>
<P>N = 60.</P>
<P>Age: range 18 to 70 years; mean (olanzapine) 37.4 (perphenazine) 37.7 years.</P>
<P>Sex: F 18, M 28 (olanzapine: F 10, M 13 &#8211; perphenazine: F 8, M 15).</P>
<P>History: not stated.</P>
<P>Included: acute symptoms present; 18-70 years of age.</P>
<P>Excluded: not described.</P>
<P>Consent: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 8mg to 32 mg/day, n = 30.</P>
<P>2. Olanzapine: 5mg to 29 mg/day, n = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS; BPRS.</P>
<P>Global state: CGI; PGI.</P>
<P>Adverse events: UKU-ConSat; UKU side-effects scale.</P>
<P>Leaving study early; adverse events.</P>
<P>Additional medication.</P>
<P>Change scores in weight increase.</P>
<P>Unable to use -</P>
<P>CGI, PGI, UKU-ConSat, UKU side effects (no mean or SD - authors emailed for further information).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 15:55:37 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Remvig-1987">
<CHAR_METHODS MODIFIED="2013-10-07 14:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 3 to 12 weeks.<BR/>Setting: inpatient, multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 14:59:27 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: acute psychosis or exacerbation of a chronic psychosis.<BR/>N = 54.<BR/>Age: 20 to 60 years, mean 38 ~ years.<BR/>Sex: 25 F, 15 M (of those having completed at least 3 weeks).<BR/>History: recent acute episode; inpatient; more than half of participants had received neuroleptic medication previously, prior to admission.</P>
<P>Included: no details.<BR/>Excluded: suffering from a serious somatic illness (including decreased kidney and liver function); organic brain damage; pregnancy; history of abuse; previous good response to a particular neuroleptic drug.</P>
<P>Consent: informed consent from participants had to be obtained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:59:32 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: initially 16 to 24 mg daily, dose could be increased 2 or 3 times a week if indicated, total average 30 mg daily + zuclopenthixol placebo, n = 27.<BR/>2. Zuclopenthixol: initially 20 to 30 mg daily, dose could be increased 2 or 3 times a week if indicated, total average 37 mg daily + perphenazine placebo, n = 27.</P>
<P>Additional medication: biperiden or orphenadrine for parkinsonism, benzodiazepines, methotrimeprazine for additional neuroleptic treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Adverse events: UKU-Scale for side effects.</P>
<P>Unable to use -<BR/>Mental state: CPRS (unpublished scale).</P>
<P>CGI score ("slightly modified" version of the scale used).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-04 14:52:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:47:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2000">
<CHAR_METHODS MODIFIED="2014-01-07 10:40:35 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: not described.</P>
<P>Duration: 6 weeks.</P>
<P>Setting:no details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-13 15:53:17 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia CCMD-2-R.</P>
<P>N = 103.</P>
<P>Age: mean 31 ± 9 years.</P>
<P>Sex: male and female,</P>
<P>History: length of illness not stated.</P>
<P>Included: not stated.</P>
<P>Excluded: not stated.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 14:59:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 8-60 mg/day, n = 51.</P>
<P>2. Clozapine: 50-600 mg/day, n = 51.</P>
<P>3. Perphenazine + clozapine: 32-50 mg/day + 100-300 mg/day, n = 51.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-26 14:47:24 +0000" MODIFIED_BY="[Empty name]">
<P>Curative effect (improvement: cured = psychiatric symptoms disappeared, insight recovered, BPRS reduction &gt;80%; markedly improved = majority of symptoms disappear, some insight, BPRS reduction &gt; 60% to 79%; improvement = some psychiatric symptoms disappeared, no insight, BPRS reduction &gt; 30% to 59%; no effect = no change/ worse symptoms, BPRS reduction &lt; 30%.</P>
<P>BPRS, TESS score, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-26 14:47:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-1982">
<CHAR_METHODS MODIFIED="2013-10-08 14:16:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double (implied).<BR/>Duration: 12 weeks.<BR/>Setting: inpatient, multi-centre (31 psychiatric institutions), Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 15:00:25 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia (n = 127 hebephrenic, n = 24 catatonic, n = 38 paranoid, n = 4 hebephrenic-catatonic, n = 2 hebephrenic-paranoid, n = 1 schizoaffective, n = 2 undifferentiated).<BR/>N = 205*.<BR/>Age: 13 - 60 years.<BR/>Sex: no details.<BR/>History: inpatient.</P>
<P>Included: not described.<BR/>Excluded: early stages of gestation; severe liver, kidney, cardiovascular and blood diseases; idiosyncrasy to psychotropic drugs; consciousness disturbances or vascular collapse or conditions under strong effects of neuro-depressants; organic brain disorders; those patients whose conditions in the judgement of the attending physician would make it unlikely that they could tolerate the study treatment.</P>
<P>Consent: informed consent obtained from each participant and guardian prior to the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-26 14:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: 4 mg per tablet + placebo tablet matching to the timiperone tablet, initially two or three tablets daily, afterwards individualised according to symptoms and side effects, maximum daily dose was 12 tablets, n = 99.<BR/>2. Timiperone: 1 mg per tablet + placebo tablet matching to the perphenazine tablet, initially two or three tablets daily, afterwards individualised according to symptoms and side effects, maximum daily dose was 12 tablets, n = 99.</P>
<P>Additional medication: mild hypnotics and anti-parkinsonian drugs - no further details.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use - <BR/>Mental state: Keio University Brief Psychiatric Rating Scale (unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:02:47 +0100" MODIFIED_BY="[Empty name]">
<P>*Only 198 participants were evaluated and described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-12 15:00:53 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Van-Praag-1976">
<CHAR_METHODS MODIFIED="2013-10-08 16:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double (implied).<BR/>Duration: 10 days (preceded by 5 to 10 days wash-out).<BR/>Setting: inpatient, single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-12 15:00:48 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: acute psychosis (n = 3 organic psychosis; n = 13 psychogenic psychosis; and n = 8 acute schizophrenia).<BR/>N = 28*.<BR/>Age: 19 - 69 years, mean ~ 35 years.<BR/>Sex: 15 F, 9 M.<BR/>History: acute, inpatient.</P>
<P>Included: according to independent views of attending physician and psychiatrist/ supervisor, the participant showed signs of delusions and/ or hallucinations (<LINK REF="REF-Lowe-1973" TYPE="REFERENCE">Lowe 1973</LINK>).<BR/>Excluded: deep melancholia (i.e. deep endogenous depression with delusions of guilt, sin and/or poverty).</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 15:00:53 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: 2, 4 and 8 mg per capsule, 3 capsules daily according to constitution, range 0 to 24 mg daily, mean 21 mg daily, n = 15.<BR/>2. Clozapine: 50, 100 and 200 mg per capsule, 3 capsules daily according to constitution, range 0 to 600 mg daily, mean 300 mg daily, n = 13.</P>
<P>All daily doses determined by a psychiatrist not engaged in scoring; flexible dosing scheme.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-08 15:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: no better or worse (no data).<BR/>Mental state: BPRS (only significance tests).<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 14:45:48 +0100" MODIFIED_BY="[Empty name]">
<P>Only 24 participants were evaluated and described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:27:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008a">
<CHAR_METHODS MODIFIED="2015-01-27 10:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: no details.</P>
<P>Duration: 8 weeks.</P>
<P>Setting: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:27:12 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3).</P>
<P>N = 64.</P>
<P>Age: risperidone: 65±2 years; perphenazine: 64 ± 3 years.</P>
<P>Sex: F29, M35 (risperidone: M18, F16; perphenazine: M17, F13)</P>
<P>History: length of illness: risperidone: 0.9 ± 1.4; perphenazine: 1.2 ± 1.4 years.</P>
<P>Included: schizophrenia; age &gt; 60; no history of taking antipsychotic drugs; PANNS &gt; 60.</P>
<P>Excluded: severe physical disease; drug abuse.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 10:27:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: start dose 2-4mg/d, maximum dose 30mg/d, 23.5 ± 1.3mg/d, n = 30.<BR/>
</P>
<P>2. Risperidone: 5mg tablet, start dose 0.25-0.5mg/d, maximum dose 3.5mg/d, 2.2 ± 1.2mg/d, n = 34.</P>
<P>No other combinations permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:27:34 +0000" MODIFIED_BY="[Empty name]">
<P>PANSS (marked improvement =&gt; 60 reduction; improved =&gt; 40%; no effect =&lt; 40%).</P>
<P>TESS - adverse effects.</P>
<P>Unable to use -</P>
<P>PANSS score &#8211; no means/ SD.</P>
<P>TESS scores &#8211; no means/ SD.</P>
<P>Not all adverse events reported by group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:28:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008b">
<CHAR_METHODS MODIFIED="2015-01-27 10:27:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
<P>Duration: 6 weeks (2007-2008).</P>
<P>Setting: Shandong Center for Mental Health, Jinan, China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:28:11 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia DSM-IV.</P>
<P>N = 60.</P>
<P>Age: Olanzapine: 33.1±7.6 years; perphenazine: 31.2±3.2 years.</P>
<P>Sex: F26, M34 (Olanzapine F12, M18; perphenazine F14, M16).</P>
<P>History: length of illness olanzapine: 78.5 ± 6.8 months; perphenazine: 79.6 ± 9.5 months.</P>
<P>Included: schizophrenia combined with positive symptoms; PANSS&#8805; 70, Positive score &#8805; 25.</P>
<P>Exclusion: not reported.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 10:28:13 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: start from 8 mg/day, maximum dosage: 60 mg/day, n =30.</P>
<P>2. Olanzapine (Changzhou Watson Pharmacy Ltd.): start from 5 mg/day, maximum dosage: 20 mg/day, n = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:28:21 +0000" MODIFIED_BY="[Empty name]">
<P>PANSS score.</P>
<P>TESS score.</P>
<P>Clinical prognosis assessment: decreased rate of PANSS score = (pre-treatment score-post-treatment score)/pre-treatment score &#8805; 75%--recovery; 50%- to -74% markedly improved; 25% to 49% improved; &lt; 25% no effect.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:29:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008c">
<CHAR_METHODS MODIFIED="2015-01-27 10:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: not stated.</P>
<P>Duration: 8 weeks, 2003-2007 (one-week wash-out)</P>
<P>Setting: Baoji rehabilitation hospital, Shanxi, China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:29:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia CCMD-3.</P>
<P>N = 64.</P>
<P>Age: Quetiapine: 66.08 ± 4.22 years; perphenazine: 65.73 ± 5.53 years.</P>
<P>Sex: F27, M37 (Quetiapine (n = 32): M17 F15; perphenazine (n = 32): M20 F12).</P>
<P>History: length of illness Quetiapine: 3.6 ± 0.5months; perphenazine: 3.4 ± 0.6months.</P>
<P>Included: Schizophrenia CCMD-3; age &#8805; 60 years, first episode; BPRS &#8805; 35.</P>
<P>Exclusion: drug abuse; organic dysphrenia.</P>
<P>Consent: not stated..</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 10:29:34 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perphenazine: start from 4 mg/day to treatment dosage: 20-40 mg/day, average:24.5 ± 5.3mg/day, n = 32.</P>
<P>2. Quetiapine: start from 50 mg/day to the treatment dosage: 200-400 mg/day, average dosage: 258.92 ± 28.13mg/day, n = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:29:51 +0000" MODIFIED_BY="[Empty name]">
<P>Lab data: blood test, urine test, liver function, kidney function, ECG, blood pressure.</P>
<P>Adverse events.</P>
<P>BPRS score.</P>
<P>TESS score.</P>
<P>Clinical prognosis assessment: decreased rate of BPRS score &#8805; 75%--recovery; 50% to 74% markedly improved; 25% to 49% improved; &lt; 25% no effect.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-13 16:02:04 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Woggon-1978">
<CHAR_METHODS MODIFIED="2013-10-09 12:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 30 days.<BR/>Setting: inpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-13 16:02:04 +0000" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia (n = 5 hebephrenic; n = 29 paranoid, acute schizophrenic episode; n = 2 residual; n = 2 schizo-affective psychosis; n = 1 other paranoid syndromes).<BR/>N = 40.<BR/>Age: mean ~ 39 years.<BR/>Sex: 20F, 20M.<BR/>History: inpatient; duration of illness 8.7 ± 10.9 years (bromperidol); 10.1 ± 8.0 (perphenazine).</P>
<P>Included: no details.<BR/>Excluded: no details.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 15:02:54 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: capsules of 3 mg; mean 20 mg/day in two administrations; maximum 24 mg daily, n = 20.<BR/>2. Bromperidol: capsules of 1 mg; mean 6 mg/day in two administrations; maximum 8 mg daily, n = 20.</P>
<P>Additional medication: antiparkinsonian drugs; additional neuroleptics (promazine and levomepromazine); hypnotics (chloralhydrate; nitrazepam; flunitrazepam).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-09 11:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no better or worse.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Mental state: AMP (no SD).</P>
<P>Lab data: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-09 11:48:30 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 10:30:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2010">
<CHAR_METHODS MODIFIED="2014-01-13 10:48:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blindness: no further information.</P>
<P>Duration: 8 weeks.</P>
<P>Setting: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 10:30:22 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Schizophrenia CCMD-3.</P>
<P>N = 65 (or 66).</P>
<P>Age: aripiprazole 64.6 ± 1.8; perphenazine 62.5 ± 3.1 years.</P>
<P>Sex: F34, M32 (aripiprazole M16, F17; perphenazine M16, F17)</P>
<P>History: length of illness - aripiprazole 0.5 ± 1.1; perphenazine 0.8 ± 1.2 years.</P>
<P>Included: schizophrenia CCMD-3; age &gt; 60, no history of taking antipsychotic drugs; BPRS &gt; 35.</P>
<P>Exclusion: severe physical disease; drug abuse.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-13 16:03:40 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Perphenazine: start dose 2-4 mg/day, maximum dose 16 mg/day, average 11.2 ± 3.8mg/day, n = 33.<BR/>2. Aripiprazole: 5 mg tablet, start dose 5 mg/day maximum dose 30 mg/ day, average 23.5 ± 1.7mg/day, n = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 10:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS.</P>
<P>Clinical effect: decreased rate of BPRS score &#8805; 75%--recovery; &#8805; 50% markedly improved; &#8805; 25% improved; &lt; 25% no effect (measured at 1, 2 ,4 ,6, 8 weeks before and after treatment)</P>
<P>BPRS.</P>
<P>TESS (skew).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>General abbreviations:</B>
<BR/>CNS &#8211; central nervous system<BR/>ECG - electrocardiogram<BR/>IQ - intelligence quotient<BR/>ITT - intention to treat<BR/>LOCF &#8211; Last Observation Carried Forward<BR/>mg - milligram<BR/>N = number of participants<BR/>SD - standard deviation<BR/>SGOT - serum glutamic oxaloacetic transaminase<BR/>SGPT - serum glutamic-pyruvic transaminase<BR/>t.i.d. - three times daily (Latin: ter in die)<BR/>
</P>
<P>
<B>Diagnostic tools:</B>
<BR/>CCMD-2-R &#8211; Chinese Classification of Mental Disorders, Second Edition, Revised<BR/>CCMD-3 &#8211; Chinese Classification of Mental Disorders, Third Edition<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, Third edition, Revised<BR/>DSM-IV &#8211; Diagnostic and Statistical Manual, Fourth Edition<BR/>ICD-9 - International Classification of Diseases, ninth revision<BR/>RDC &#8211; Research Diagnostic Criteria</P>
<P>
<B>Global effect scales:</B>
<BR/>GCJ - Global comparative judgement<BR/>CGI - Clinical Global Impression<BR/>CGI-I &#8211; Clinical Global Impression - Improvement<BR/>CGI-S &#8211;Clinical Global Impression - Severity<BR/>GIR - General Improvement Rating<BR/>PGI - Patient Global Impression<BR/>
</P>
<P>
<B>Mental state scales:</B>
<BR/>AMDP, AMP - Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>CEPS - Clinical Estimate of Psychiatric Rating Scale<BR/>CPRS - Comprehensive Psychopathological Rating Scale<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale<BR/>MMPI - Minnesota Multiphase Personality Inventory<BR/>MSRPP - Multidimensional Scale for Rating Psychiatric Patients<BR/>PANSS - Positive and Negative Syndrome Scale for Schizophrenia<BR/>PES - Psychiatric Evaluating Scale</P>
<P>
<B>Behaviour scales:</B>
<BR/>MACC - Behavioural Adjustment Scale<BR/>NOSIE - Nurses Obsrevation Scale for Inpatient Evaluation<BR/>PRP - Psychotic Reaction Profile<BR/>
</P>
<P>
<B>Side effect scales:</B>
<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>BAS - Barnes Akathisia Scale<BR/>EPS &#8211; Extrapyramidal Symptoms<BR/>ESRS - Extrapyramidal Symptoms Rating Scale<BR/>SAS - Simpson and Angus Scale<BR/>TESS &#8211;Treatment Emergent Symptom Severity<BR/>UKU - Side Effect Rating Scale</P>
<P>
<B>Quality of life scales:</B>
<BR/>QoL &#8211; Quality of Life Scale<BR/>QLS - Quality of Life Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-26 14:50:01 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Affleck-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. penicillamine, perphenazine and a placebo vs. penicillamine, penicillamine vs. placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ahlfors-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. clopenthixol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 11:35:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akimoto-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 11:35:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: 'randomly selected'</P>
<P>Participants: schizophrenia</P>
<P>Intervention: perphenazine vs chlorpromazine vs levomepromazine vs prochlorperazine (not parallel-arm study, no control group, all participants received all drugs over one year)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angst-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. fluphenazine decanoate vs. flusipirilene vs. penfluridol vs. pipothiazine palmitate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asada-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised - matched pairs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bakke-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. fluphenazine enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 13:44:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bandelow-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 13:44:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: people with schizophrenia</P>
<P>Interventions: perphenazine enanthate versus perazine versus fluphenazine versus levomepromazine versus thioridazine versus clozapine versus haloperidol decanoate versus fluphenazine decanoate versus flupenthixol decanoate versus fluspirilene</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:33:54 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Becker-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:33:54 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with chronic schizophrenia.<BR/>Interventions: perphenazine and amitriptyline vs. perphenazine and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bjerkelund-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with acute myocardial infarct.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-B_x00f6_hlau-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, open multi-centre study. <BR/>Blindness: double.<BR/>Participants: those with dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cannistra-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind prospective study. <BR/>Participants: obstetric patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ceskova-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. risperidone.<BR/>Data about separate phases not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ceskova-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. haloperidol.<BR/>Data about separate phases not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clarke-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:34:01 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cooper-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:34:01 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. amitriptyline vs. perphenazine and amitriptyline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Den-Boer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dencker-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine decanoate vs. haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 11:30:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eklund-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 11:30:45 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not random</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-26 14:38:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erb-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-26 14:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: healthy normal males.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eufe-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. flupentixol enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fahn-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind prospective study. <BR/>Participants: those with choreic movements.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:03:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farzin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:03:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Interventions: perphenazine + famotidine versus perphenazine + placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-26 14:39:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzgerald-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-26 14:39:00 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double - identical ampoules.<BR/>Participants: those with acute psychiatric episodes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 11:29:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galdi-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 11:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: people with schizophrenia or depression</P>
<P>Intervention: perphenazine vs chlorpromazine vs fluphenazine</P>
<P>Outcomes: no usable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerlach-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:24:38 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gerlach-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:24:38 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allcation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with tardive dyskinesia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerson-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness. double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine or chlorpromazine or trifluoperazine or prochlorperazine or methaminodiazepoxide or fluphenazine or phenelzine or imipramine tranylcypromine vs. 4-(3, 4-dimethoxyphenetyl)-2, 6-piperazinedione and 2-methyl-3-orthotolyl-4-quinazinolone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gianelli-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. fluphenazine decanoate vs. haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hadlik-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. thiothixem.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:09:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanlon-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:09:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: 'acutely disturbed psychiatric patients'</P>
<P>Intervention: perphenazine vs perphenazine-benztropine mesylate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:34:12 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hansen-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:34:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those being on neuroleptic therapy.<BR/>Interventions: perphenazine vs. perphenazine and biperidine vs. perphenazine and orphenadrine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haran-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holden-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised - matched groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hollister-1967-II">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: those with depression as predominant psychiatric symptom.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hollister-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jprn-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Intervention: algorithm-guided treatment (different antipsychotic drugs: perphenazine, aripiprazole, olanzapine, blonanserine, perospiron, quetiapine, risperidone, haloperidol) versus treatment as usual </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaim-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind prospective study. <BR/>Participants: those with delirium tremens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaji-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine and levomepromazine vs. clocapramine and levomepromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawakita-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kistrup-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine decanoate vs. cis(z)-flupentixol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kline-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:34:19 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Knudsen-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:34:19 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine decanoate vs. perphenazine enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 13:50:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knudsen-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 13:50:15 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Interventions: perphenazine decanoate vs perphenazine enanthate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kothari-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapolla-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. chlorpromazine vs. placebo.<BR/>Contacted on March 12th: data about methods no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:34:25 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Lindholm-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:34:25 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. perphenazine enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linnoila1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Blindness: unclear.<BR/>Participants: those with depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-26 14:39:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprete-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-26 14:39:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: serial placement.<BR/>Blindness: unclear.<BR/>Participants: those with schizophrenia and anxiousness and depression.<BR/>Interventions: perphenazine and amitriptyline (Etrafon) vs. perphenazine and amitriptyline (Etrafon forte) vs. non barbiturate hypnotic sedative (Dormison) vs. phenobarbital vs. placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mason_x002d_Browne-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised - matched groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazurek-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: paranoid schizophrenia (ICD-10-R)</P>
<P>Intervention: typical antipsychotic drugs (haloperidol, levomepromazine, perazine, perphenazine, zuclopenthixol) versus atypical (clozapine, risperidone, olanzapine) - not separated by drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-26 14:39:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-26 14:39:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with an anaesthetic for operation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-26 14:40:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00fc_ller-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-26 14:40:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: open, randomised, three-way cross-over, single-dose design.<BR/>Blindness: unclear.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-04 13:59:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nahunek-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-04 13:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: open cross-over design - not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia or endogenous depression.<BR/>Interventions: perphenazine vs. octoclothepin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. triperidol.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. triperidol.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1970-II">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. flupenthixol.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. clozapin.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nahunek-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. clozapin vs. levopromazin vs. thioridazin vs. chlorpromazin vs. flupenthixol vs. methophenazin vs. oxypertin vs. clothiapin vs. pimozid vs. methylperidol vs. triperidol vs. oxyprothepin vs. octoclothepin vs. thiothixen.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:29:27 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Nahunek-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:29:27 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. perphenazine.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nordic-DS-Group-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: those with tardive dyskinesia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Reilly-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia and two epileptics.<BR/>Interventions: perphenazine vs. chlorpromazine or placebo (variable).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oltman-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:29:48 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Omerov-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:29:48 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:00:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opjordsmoen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:00:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not random</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pfeiffer-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prien-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prusoff-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: those with depressive schizophrenia.<BR/>Interventions: amitriptyline and perphenazine vs. placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapp-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. fluphenazine decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapp-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rappaport-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. placebo.<BR/>Outcomes: intelligibility score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rappaport-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. placebo.<BR/>Outcomes: intelligibility score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:30:28 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Reznik-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:30:28 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. perphenazine and fluvoxamine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rickels-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ritter-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with acute withdrawal syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodova-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. clothiapin.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodova-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. clozapine.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scurr-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Blindness: unclear.<BR/>Participants: those with an operation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shalev-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>contacted on March 12th: data about methods no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 13:49:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharpley-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 13:49:43 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not random (controlled)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 13:59:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiloh-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 13:59:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: treatment-resistant schizophrenia</P>
<P>Intervention: mianserin versus placebo (in conjunction with haloperidol or perphenazine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: antipsychotic drug and fluvoxamine vs. antipsychotic drug and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simopoulos-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Participants: those with schizophrenia.<BR/>Interventions: dilantin vs. dilantin and thorazine vs. dilantin and thioridazine vs. dilantin and perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:31:26 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Simpson-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:31:26 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. perphenazine-amitriptyline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spiker-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with delusional depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:14:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:14:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Intervention: venlafaxine extended release tablets + perphenazine versus perphenazine + placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:17:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:17:54 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Intervention: aripiprazole + placebo vs aripiprazole + perphenazine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. methylperidol.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. pimozide.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. oxyprothepine.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. oxypertine.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. trifluoperazine.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:43:56 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Svestka-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:43:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. isofloxythepin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. carbamazepine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over design.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine vs. sulpiride.<BR/>Data about separate phases no more available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:47:56 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Syvalahti-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:47:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: placebo or citalopram vs. perphenazine or haloperidol or chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tegeler-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: perphenazine enanthate vs. flusipirilene.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:33:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia (ICD-10 and CCMD-2-R)</P>
<P>Intervention: perphenazine versus 1-stepholidine (traditional Chinese medicine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-09 11:14:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whittaker-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-09 11:14:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: "open cross-over" - not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:11:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:11:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia </P>
<P>Intervention: aripiprazole versus 'another antipsychotic' - not reported by drug-group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-13 16:33:02 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Yagi-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-13 16:33:02 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Participants: those with schizophrenia.<BR/>Interventions: carpipramine and chlorpromazine vs. perphenazine and chlorpromazine vs. placebo and chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:34:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia (ICD-10 and CCMD-2-R)</P>
<P>Intervention: perphenazine versus 1-stepholidine (Chinese herbal medicine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-26 14:20:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-26 14:20:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random</P>
<P>Participants: schizophrenia</P>
<P>Intervention: psychological care + perphenazine versus perphenazine alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Diagnostic tools:</B>
<BR/>CCMD-2-R &#8211; Chinese Classification of Mental Disorders, Second Edition, Revised<BR/>ICD-10-R - International Classification of Diseases, tenth revision</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-05-12 09:16:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-05-12 09:14:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-1960">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-03-12 11:46:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Covell-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-03-12 11:46:48 +0000" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required (authors contacted October 2013) but no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-03-12 11:47:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferziger-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-03-12 11:47:06 +0000" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required (authors contacted October 2013) but no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:14:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freedman-1961">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freyhan-1959">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldstein-1969">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if randomised, double-blind stated - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hollister-1967">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if randomised, double-blind stated - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kellam-1971">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:20 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-03-12 11:45:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahmoud-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-03-12 11:45:42 +0000" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required, study authors contacted but no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:15:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Povlsen-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>Requires data extraction (Danish).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:16:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulsinger-1958">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:16:03 +0100" MODIFIED_BY="[Empty name]">
<P>Requires data extraction (Danish).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-03-12 11:46:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Szafranski-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-03-12 11:46:07 +0000" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required, authors contacted but no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-12 09:16:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinar-1968">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-05-12 09:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data - more information required.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-27 10:28:55 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-27 10:28:23 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 16:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>Randomised &#8211; matched-pair design. Quote: &#8220;two patients of the same sex, an age difference of less than 10 years and with similar symptoms were classified as a pair then randomly allocated to either intervention or control (p3). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 14:05:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>Randomised - no further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>Randomised: no further details &#8211; emailed authors 18/11/13 &#8211; Jeffrey Lieberman (<A HREF="mailto:jlieberman@columbia.edu">jlieberman@columbia.edu</A>). Author reply (unpublished information) &#8220;[r]andom assignments were computer-generated. Site investigators called-in to an interactive voice response system to get a participant's treatment assignment.&#8221; The randomisation scheme prevented people with current tardive dyskinesia to receive perphenazine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-27 12:19:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>Randomised - quote, "within [groups of] 12 patients, individuals were randomly assigned to one of the four treatment drugs" (p1296). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 13:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>Random - no further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 16:29:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>Random &#8211; &#8220;allotted to treatment groups at random&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-16 16:50:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>Quote, &#8220;Randomly divided into two groups&#8221; (p170) &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-16 13:46:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>Randomised - quote: "randomisiert zugeteilt" (English: randomly allocated). No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 15:08:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>&#8220;Randomly assigned&#8221; &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 16:41:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>Randomised &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-16 16:27:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 14:19:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 09:22:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 10:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>Randomised: randomisation by numbers, quote: "patients with the same type of disorder, clinical features and sex and with differences in ages of less than ten years were paired among those examined by the same physicians at each institution, and the data obtained were analysed by the sequential trial technique of Armitage upon conclusion of the study period. After the code had been broken, the pairs were untied and the data evaluated for testing for the therapeutic efficacy of the two drugs" (p7). Random number table used (p8).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 14:15:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Randomised - randomisation by numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 14:47:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Randomised: randomisation by numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 15:52:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 15:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>Randomised &#8211; no further details; emailed authors 15/11/13.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:48:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-01 16:00:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>Randomised: quote, "the choice of the particular drug to be used in any case was based on a predetermined random selection of the compounds" (p4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-04 11:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>Randomised: no further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:53:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>Randomised: quote, &#8220;performed on the basis of clusters, or blocks, for each investigator, such that patients within a block for a given investigator were randomised in a 1:1 ratio&#8221; (p7).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-04 14:52:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-07 10:42:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>Randomised &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:11:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>Randomised: quote, "participants were assigned randomly" (p258). 'Randomised code' referred to, which was broken only at the end of treatment period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 14:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:27:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>&#8216;Randomised&#8217; &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:28:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>Randomised &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 14:33:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>Randomised &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-09 11:48:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>Randomised: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 10:55:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>Randomised &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-01-27 10:28:28 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>An independent controller randomly allocated the matched pairs to either Sulpiride or perphenazine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 14:06:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-11 14:26:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>As above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-27 14:57:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 13:47:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 16:29:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-16 16:50:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>Quote, &#8220;the investigator who cared for the patient and the other raters did not know which of the two agents any patient was receiving&#8221; (p170).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-16 13:46:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>Not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 15:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 16:41:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>Not stated. Quote: &#8220;ultimate medical responsibility for the patients remained in the hands of the ward physicians, who were aware of the design and study-drugs&#8221; (p53).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 14:19:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 14:19:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 09:24:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 11:12:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>Quote, "bottles were coded so that neither the investigators nor the patients knew whether clothiapine or placebo was being administered at any given time, [and] every investigator was instructed to retain an allocation schedule in a sealed envelope for each matched pair assigned to him in case of medical emergency of a patient under study" (p8) - no such emergency happened and all envelopes were returned unopened to the central statistical unit upon completion of the study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 14:15:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 15:20:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 15:01:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:48:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-01 09:47:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>Quote, "the physician knew a patient had six chances in eight of being given a phenothiazine compound, but did not know which drug was being given, or whether the patient was receiving one of the placebos" (p4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-04 11:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>Randomisation schedule was, quote, &#8220;generated on block size, number of treatments, and number of investigative sites included in the study. The study drugs were assigned to medication kits by a computer-generated random sequence in such a way that there was a 1:1 ratio of olanzapine to perphenazine- treated patients&#8221; (p7). Participants were assigned on their first visit and those who met inclusion criteria were randomly allocated to double-blind at the second visit by assignment of a unique kit number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-07 14:25:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-07 10:42:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 10:58:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 15:52:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:27:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:28:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 14:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-09 11:48:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 10:55:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-01-27 10:28:33 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>Double blind &#8211; quote: &#8220;test and control tablets had similar external appearance&#8230; [the tablets] were placed in bags which were packed into cans of identical design and appearance&#8221; (p3-4). An independent controller randomly allocated the matched pairs to either Sulpiride or perphenazine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>Single-blind (implied) - all participants were given identical-looking placebo 14 days prior to treatment; there is no mention of blinding at treatment commencing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>Double-blind: maintained by prescribing identical-looking capsules of each medication. Nonequivalent choice of dosing regimen and flexible dose raised question of bias to jeopardise integrity of maintaining blind and influencing results; a further study found no bias or effect on results (<LINK REF="REF-Rosenheck-2009" TYPE="REFERENCE">Rosenheck 2009</LINK>).</P>
<P>Quote, &#8220;[b]ecause of product labelling, quetiapine and ziprasidone are given twice daily and olanzapine, perphenazine, and Risperidone once daily. To protect blinding, half the patients randomly assigned to perphenazine, olanzapine and Risperidone were assigned to twice-daily dosing and half to once-daily dosing&#8221; (p1211).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-27 15:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>Double blind - identical-appearing tablets used. Each participant received one tablet three times per day and two at bedtime. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-11 13:47:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>Double: ECG readings (primary outcome) taken by cardiologist unaware &#8220;as to factors under study&#8221; (p.952). Drugs were administered in identically-appearing tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-11 16:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>Double &#8211; quote, &#8220;neither nursing staff nor doctors concerned knew which tablets were which&#8221; (p1428).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-16 16:50:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>Double: all medications, quote, &#8220;as well as the placebo were dispensed in tablets identical in appearance. Medications for each patient during the active drug period were supplied by the pharmacy in an individual bottle with only the patient&#8217;s name and study number appearing on the bottle label&#8221; (p170). Strict double blind conditions adhered to until the end of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-16 13:46:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>Double-blind: Oral liquid medication. No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-18 15:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>Double-blind stated &#8211; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-18 16:41:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>Stated double blind; quote, &#8220;medication, administered in a double blind fashion, was dispensed to the wards from the pharmacy in containers identified only by the patient name and number&#8221; (p53). However, see above (allocation concealment).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-16 16:57:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>Double-blind: identical pink unmarked capsules.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-19 14:34:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>Double-blind: identical tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 09:22:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>Double-blind: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 10:57:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>Double-blind: identical shape and colour of tablets. Quote, "medication and analysis of data obtained were performed by the controlled double-blind method" (p8). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 14:13:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Double-blind: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 14:47:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Double-blind: identical shape and colour of tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 16:08:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Double-blind: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-26 14:45:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>Double-blind treatment phase: treatment-resistant participants, as previously diagnosed, entered a 6-week, open-label treatment phase (olanzapine vs risperidone) to confirm treatment-resistance. If completed, entered 2- to 10-day single-blind placebo wash-out phase; afterwards randomised to double-blind treatment with perphenazine vs aripiprazole.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-26 16:48:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Double-blind: identical appearance of capsules.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-01 16:10:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>Double-blind: identical capsules; quote, "drugs were dispensed in standard unmarked capsules... coloured pink to mask all identifying consistencies and colours of the drugs" (p4). Treatment information was &#8220;secured from the pharmacist and recorded in the patient&#8217;s chart by a member of the nursing staff&#8221; (p5). Quote, "all clinical and research personnel working with patients were bound to the double-blind stipulation imposed by the research plan" (p6).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-04 11:50:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>Double-blind: identical tablets - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-17 16:53:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>Medication kit contained double-blind study medication for each participant; blinding of study was preserved by allowing a &#8220;minimum number of Lilly personnel&#8221; to see the randomisation table and codes before completion of the study (p7).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-07 09:50:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Double-blind: quote, "double-blind, double-dummy" (p147). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-07 10:42:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-26 14:47:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>Double-blind: implied - decoding of drugs at the end of week 12. Code broken at the end of treatment period. Double-dummy design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-08 16:11:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>Double-blind: implied - identical capsules. Quote, "raters and patients were unaware of the type of medication or its dosage; nor were they informed of the biochemical results" (p549).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-27 10:27:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-27 10:28:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-13 14:33:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-09 11:48:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>Double-blind: no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-13 10:55:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-27 10:28:42 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-13 13:41:56 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>14% (n = 9) excluded from analysis: n = 5 receiving sulpiride (n = 3 refused drugs; n = 1 given electro-shock therapy; n = 1 given other drugs for marked excitation) and n = 4 receiving perphenazine (n = 1 discarding drugs; n = 1 refusing drugs; n = 1 due to acute colitis; and n = 1 given other drugs) (ITT used).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:47:29 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>Follow-up 90% - n = 2 people left early (n = 1 from the chlorpromazine group; n = 1 from the prochlorperazine), no explanation provided; not clear which numbers are completed in full analysis and by which group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-26 14:42:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>Out of N = 1432, n = 371 (26%) completed phase 1 of CATIE. Randomised participants who received at least one dose of study medication were included in ITT analysis (n = 1432). Quote, &#8220;[s]eventy-four percent of patients in the intention-to-treat analysis (1,061 of 1,432) discontinued their assigned treatment in phase 1 before 18 months (median, 6).&#8221; (p1212).</P>
<P>Quote, &#8220;all data from one site (33 patients) were excluded before analysis, owing to concern about the integrity of data from that site before the end of the study and before unblinding&#8221; (p1212).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:48:39 +0000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>Of N = 96 entering the study, n = 16 did not complete the full 12-week course because of, quote, "poor response to treatment...but all completed at least four weeks" (p1299), i.e. those that relapsed. For participants leaving the study early, they were rated before being excluded from the study, and these evaluations were used in the final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:49:12 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>Follow-up - N = 38 (70%), with equal amount of males (n = 19) and females (n = 19) remaining.</P>
<P>N = 13 placebo participants were excluded from study because of intensified psychopathological condition resulting in hospitalisation or chlorpromazine use.</P>
<P>N = 1 perphenazine and n = 2 perphenazine-amitriptyline participants were hospitalised and excluded from study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:49:26 +0000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>No losses - N = 29 participants in each treatment group completed the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:49:47 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>Four participants left the study early (n = 2 from each treatment group); clopenthixol: n = 1 discontinued after 6 weeks due to side effects (severe hand and arm tremor), n = 1 discontinued due to worsening of psychiatric condition after 4 weeks. Perphenazine: n = 1 lost from the study when released from hospital against medical advice after first week; n = 1 discontinued due to worsening of psychiatric condition after 4 weeks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-16 13:47:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>No details of people leaving early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:50:41 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>21% (n = 10) dropped-out of the study and excluded from analysis &#8211; n = 5 from perphenazine group and n = 5 for loxapine group (reasons only provided for n = 2 &#8216;inadequate therapeutic response, and n = 2 aversion to continued treatment). Not fully addressed (ITT used).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:51:08 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>11% (n = 13) dropped-out of the study. Quote, "n = 5 placebo patients were discontinued and transferred to the infirmary for medical reasons unrelated to treatment; the remaining three patients were described as either overactive, restless or agitated. One perphenazine patient was dropped because of hypotension and elevated temperature, and another because of nausea and weakness" (p55). Another n = 5 participants were lost in the two other treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:52:02 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>Follow-up: 76% in first evaluation at five days; of the n = 421 randomised, n = 322 remained on the project for at least five days. The n = 99 were not included in any of the post-treatment analyses; the majority of these participants were considered &#8216;unacceptable on the basis of selection criteria&#8217;; n = 5 early side-effect cases; others refused oral medication or were dropped for administrative treatment &#8216;unrelated to drug treatment&#8217;. Remaining post-treatment evaluations: 68% in second evaluation at 15<SUP>th </SUP>day (n = 287) and 59% in third evaluation at 30<SUP>th</SUP> day (n = 248).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-26 14:44:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>Seventy-eight participants (73%) completed the full 8-week trial period; n = 29 withdrew prematurely, of these n = 8 receiving risperidone and n = 6 receiving perphenazine were withdrawn due to adverse effects; n = 2 receiving risperidone and n = 3 receiving perphenazine were withdrawn due to lack of therapeutic effect; n = 4 receiving risperidone and n = 6 receiving perphenazine were withdrawn because they stopped attending the control visits. All participants that had attended at least one clinical assessment were included in the ITT analysis or endpoint analysis (N = 101; n = 50 receiving risperidone and n = 51 receiving perphenazine). All prematurely withdrawn participants were included in side effects analysis, whereas other therapeutic measures were analysed ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 09:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 11:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>No details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 14:15:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 15:20:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 16:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-13 15:47:14 +0000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>N = 512 screened; n = 416 entered open-label treatment phase with olanzapine and Risperidone to confirm treatment resistant; n = 334 completed; of these, n = 34 discontinued due to reasons including adverse events, withdrawal of consent, lost to follow-up; lack of efficacy, patient unreliability, and other causes. N = 300 entered double-blind randomised study phase; of these, n = 225 (75%) completed the full 6-week study (n = 110 receiving aripiprazole; n = 115 receiving perphenazine); of the n = 75 who discontinued, n = 33 was due to adverse events; n = 18 was due to lack of efficacy; n = 11 was due to consent withdrawal; n = 13 unknown cause.<BR/>N = 3 participants did not receive study medication (n = 1 aripiprazole; n = 2 perphenazine). A further n = 3 (all aripiprazole) were excluded due to lacking post-randomisation efficacy rating. QLS analysis included n = 207 participants (n = 104 aripiprazole; n = 103 perphenazine), missing participants were excluded due to lack of baseline/ post-randomisation data. LOCF used; observed case analyses performed to corroborate data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-26 16:48:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:58:39 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>Quote, "those patients on whom data were incomplete, together with those not receiving medication for at least then days, were excluded from the study" (p6). Unclear which participants dropped-out of which treatment arm. One publication makes reference to N = 277 included in the study and presents data for those. Whereas the subsequently-published paper refers to N = 238 included after screening people eligible for study. ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-04 11:50:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:59:24 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>High attrition, with 38% completing the study. Four separate reports provide different numbers of participants included. N = 60 originally randomised, however only n = 46 made reference to follow-up reports. Of the n = 46, only n = 23 (n = 12 in olanzapine and n = 11 in perphenazine) completed the study. N = 53 included in the safety analysis, and n = 46 included in efficacy analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 14:59:40 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Quote, "all patients treated for 3 weeks (21 days) or more were included in the statistical processing of data" (p148). Fourteen participants (n = 5 on zuclopenthixol; n = 9 on perphenazine) had not been treated for the 3-week minimum, and were excluded - reasons including insufficient effect, undesired effect, or discharge from hospital. Binary data analysed with 74% (ITT); continuous data using CGI scale presented data for n = 25 (46%), no LOCF used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-07 10:42:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 15:00:38 +0000" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>Of N = 205 randomised, n = 7 were excluded, either because they had been given other neuroleptics or they revealed physical disease during the trial prior to breaking the randomisation code. A total of n = 198 were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 15:00:58 +0000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>Four participants (n = 3 receiving perphenazine; n = 1 receiving clozapine) failed to complete the study. All cases were due to presence of severe motor unrest, anxiety or aggression non-responsive to permitted medication. ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 10:27:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>Not all outcome measures reported; adverse events not reported fully by group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 10:28:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-12 15:02:30 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>In the quetiapine group, n = 1 left the study due to drowsiness. In the perphenazine group n = 3 left due to EPS. Missing data from participants leaving the study early were not included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-09 12:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-13 10:58:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>One participant not included in results nor accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-01-27 10:28:44 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 16:28:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>Non-reported data by group include: improvement; behaviour (MSRPP); mental state (CEPS); side effects; laboratory testing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-11 14:33:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-27 15:11:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>No (useable) data reported for CGI, BPRS, IMPS or laboratory tests (only P values, or df reported).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 13:47:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-11 16:29:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>Not all adverse effects reported in full; not all means and SD reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-16 16:50:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>No means or standard deviation reported for scale data (BPRS or PIP).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-16 13:47:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>No means or standard deviations reported in results section. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:43:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>Not all adverse event data reported; no means or SDs reported for BPRS, CGI, NOSIE.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:43:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>No SD or P values reported for scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:44:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>No SD or P values reported for scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 14:34:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>CGI scale reported as an outcome measure, however no data are reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 09:33:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 11:37:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 14:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 15:20:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:09:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 15:02:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>None detected from cross-checking published protocol and review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:48:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>No SD or P values reported for scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-04 11:50:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:50:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>Data not provided for CGI, PGI, UKU-ConSat, UKU side effects &#8211; authors contact 13/11/13 for request of full-published version, no response.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-07 15:08:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Quote: "because of the great variation in total scores among the patients, they were stratified <I>post hoc </I>into two subgroups, depending on the total score at baseline" (p149). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-07 10:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:48:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>No means, SD or P values reported for scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 15:53:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>No means or SD reported for scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:27:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>As above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:28:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 14:33:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-09 11:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>No means or SDs reported for continuous outcomes and scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 10:56:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>Not all adverse events reported by group &#8211; unable to include some missing group data. No data reported using BPRS or TESS scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-27 10:28:55 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amakusa-1973">
<DESCRIPTION>
<P>Funding: no details provided.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1961">
<DESCRIPTION>
<P>Funding: no details provided.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-13 13:49:07 +0000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-CATIE-2005">
<DESCRIPTION>
<P>Funding: study sponsored by grant (N01 MH90001) from the NIMH and foundation of Hope and Raleigh, N.C.. Study medications were provided by: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Forest Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly, Otsuka Pharmaceutical, Pfizer, Zenith Goldline Pharmaceuticals, Schering-Plough, and Novartis. All authors report having received research or consultant/advisory board fees from one or more of the following: Eli Lilly, Janssen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmith Kline, Pfizer, or Otsuka. Involvement of pharmaceutical companies stated to be limited: quote, &#8220;each provided advice on the dose of its own drug; they were otherwise not involved in the design of the study, analysis or interpretation of results&#8221; (p1212).</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
<P>Other: quote, &#8220;Two-hundred thirty-one patients with tardive dyskinesia were excluded from random assignment to perphenazine. ziprasidone was added to the trial after approximately 40% of the patients had been enrolled. Consequently, comparisons involving the perphenazine group were limited to patients without tardive dyskinesia, and comparisons involving the ziprasidone group were limited to the cohort of patients who underwent randomisation after ziprasidone was added&#8221; (p1211).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1975">
<DESCRIPTION>
<P>Funding: no details provided.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1977">
<DESCRIPTION>
<P>Funding: unclear.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>Funding: Messrs. Allen &amp; Hanburys Ltd supplied matching tablets of Triptafen Forte, Fentazin and placebo.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-16 16:50:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dehnel-1968">
<DESCRIPTION>
<P>Funding: Supported in part by grant No. MYP-5106 from National Institute of Mental Health, US Public Health Service. Clopenthixol supplied by Ayerst Laboratories, NYC.</P>
<P>Raters: All outcome measures taken by study investigator or nurse. Unclear whether they were independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eckmann-1984">
<DESCRIPTION>
<P>Funding: no details.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 11:34:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>Funding: no details.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 16:46:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanlon-1964">
<DESCRIPTION>
<P>Funding: supported in part by Merck Sharp and Dohme Research Laboratories, West Point, Philadelphia (US).</P>
<P>Raters: not independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-17 17:07:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1965">
<DESCRIPTION>
<P>Funding: Research Project Grant No. MY-2152 of the National Advisory Mental Health Council, National Institutes of Health, US Public Health Service, administered by Friends of Psychiatric Research, Inc., Spring Grove State Hospital, Baltimore, Maryland (US). Pharmaceutical companies provided drugs for study (Sandoz; Schering Corp; GD Searle; Smith Kline and French Laboratories; Squibb; Knoll).</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-19 14:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoyberg-1993">
<DESCRIPTION>
<P>Funding: not stated; two co-authors had affiliations with Janssen Pharma, Denmark and Norway.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 09:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Imai-1980">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 11:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 15:20:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-II">
<DESCRIPTION>
<P>Funding: not clear.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 15:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1969-III">
<DESCRIPTION>
<P>Funding: not clear.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-1976">
<DESCRIPTION>
<P>Funding: not clear. </P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 15:02:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2003">
<DESCRIPTION>
<P>Funding: supported by Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Development &amp; Commercialization, Inc. PI is consultant to Abbott, Bristol-Myers Squibb, Janssen, Eli Lilly, Pfizer, Wyeth and AstraZeneca; received honoraria from Bristol Myers-Squibb and Janssen. All other co-authors bar-one are either consultants, shareholders, have received grant support from or are employees of ACADIA, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Sanofi and Solvay, or Otsuka.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-26 16:48:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1983">
<DESCRIPTION>
<P>Funding: not clear.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-26 14:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1961">
<DESCRIPTION>
<P>Funding: Research Grant No. MY-2152 of the National Advisory Mental Health Council, National Institutes of Health, US Public Health Service and administered by Friends of Psychiatric Research Inc, Spring Grove State Hospital, Baltimore, Maryland (US). The study involved "preliminary correspondence with the drug companies"; further, the "ward physician could also drop a patient from the study if her felt he should later the plan of treatment because of the ineffectiveness of the drug" (p5).</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-04 11:52:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:53:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naukkarinen-2000">
<DESCRIPTION>
<P>Funding: involvement of Eli Lilly, unclear based on provided study report to what extent.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-07 15:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remvig-1987">
<DESCRIPTION>
<P>Funding: not stated - one author was affiliated with Lundbeck (producer of zuclopenthixol for the study drug).</P>
<P>Raters: not stated to be independent of treatment.</P>
<P>Quote: "as there was no information available about any causal relationship between symptoms and test treatment for may patients... it was assumed, when the side effects were analyzed, that all side effects were drug-induced" (p148).</P>
<P>Quote: "no additional neuroleptic treatment was allowed" (p148), however, it is later stated that "most patients received benzodiazepines... and 12 patients received an additional neuroleptic in the form of methotrimeprazine" (p149). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-07 10:41:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2000">
<DESCRIPTION>
<P>No details as to blinding; two raters involved in administering BPRS and TESS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:24:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takahashi-1982">
<DESCRIPTION>
<P>Funding: not stated - study drugs were supplied by Daiichi Seiyaku Co, Ltd, Tokyo, Japan.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 15:53:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Praag-1976">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:27:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008a">
<DESCRIPTION>
<P>No details of funding/ who administered rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 10:28:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008b">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 14:33:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2008c">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-09 11:52:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Woggon-1978">
<DESCRIPTION>
<P>Funding: no details.</P>
<P>Raters: not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 10:56:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2010">
<DESCRIPTION>
<P>No details as to funding or who administered rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-01-27 10:31:28 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-01-27 10:31:09 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-01-27 10:31:09 +0000" MODIFIED_BY="[Empty name]">PERPHENAZINE compared with PLACEBO for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>PERPHENAZINE compared with PLACEBO for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> hospitals, USA and Canada<BR/>
<B>Intervention:</B> PERPHENAZINE<BR/>
<B>Comparison: </B>PLACEBO</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PLACEBO</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PERPHENAZINE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: Change over time - no better or deterioration - short term</B>
<BR/>clinically defined<BR/>Follow-up: 6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>160 per 1000</B>
<BR/>(65 to 390)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.32 </B>
<BR/>(0.13 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>61<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Relapse - short term</B>
<BR/>clinical diagnosis<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>292 per 1000</B>
<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(6 to 312)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.14 </B>
<BR/>(0.02 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: death</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: extrapyramidal adverse effects - dystonia - short term</B>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<SUP>8</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<BR/>(3 to 628)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.07 to 15.08)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5,7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: serious adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Service use and hospitalisation: admission</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control risk: mean baseline risk presented for single study (50%)<BR/>
<SUP>2</SUP> Risk of bias: rated 'very serious' - randomisation methods not described in the single included study; data for participants who did not complete were excluded from data analysis; data to support this outcome taken from single study (n = 238), with n = 61 participants in the perphenazine vs placebo comparison<BR/>
<SUP>3</SUP> Indirectness: rated 'serious' - single included had a total of eight drug comparisons<BR/>
<SUP>4</SUP> Control risk: mean baseline risk presented for single study (29.2%)<BR/>
<SUP>5</SUP> Risk of bias: rated 'very serious' - randomisation methods not described in the single included study; selective reporting detected; data to support this outcome taken from single study with n=48 participants<BR/>
<SUP>6</SUP> Indirectness: rated 'serious' - single included had a total of four drug comparisons<BR/>
<SUP>7</SUP> Imprecision: rated 'serious' - 95% confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm.<BR/>
<SUP>8</SUP> Control risk: mean baseline risk presented for single study (4.2%)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-01-27 10:31:28 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-01-27 10:31:28 +0000" MODIFIED_BY="[Empty name]">PERPHENAZINE compared with ANY ANTIPSYCHOTICS for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="22">
<TR>
<TD COLSPAN="7">
<P>
<B>PERPHENAZINE compared with ANY ANTIPSYCHOTICS for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> multi-centre and single-centre; international<BR/>
<B>Intervention:</B> PERPHENAZINE<BR/>
<B>Comparison: </B>ANY ANTIPSYCHOTICS</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ANY ANTIPSYCHOTICS</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PERPHENAZINE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Global state: Change over time - no better or deterioration - short and medium term</B>
<BR/>as defined in each study<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.91 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1879<BR/>(17 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>52 per 1000</B>
<BR/>(46 to 58)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>450 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>468 per 1000</B>
<BR/>(410 to 526)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>900 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>936 per 1000</B>
<BR/>(819 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: State - 'no effect'</B>
<BR/>BPRS score reduction<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>267 per 1000</B>
<BR/>(132 to 543)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.24 </B>
<BR/>(0.61 to 2.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>383<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,6,7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: extrapyramidal adverse effects dystonia - short term</B>
<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
<BR/>(21 to 166)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(0.23 to 8.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>416<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,8,9,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Other adverse events: any serious adverse event - short and long term</B>
<BR/>Follow-up: mean 39 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.68 to 1.41)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1760<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,12,13</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
<SUP>11</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
<BR/>(81 to 147)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>152 per 1000</B>
<SUP>11</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(112 to 204)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Service use and hospitalisation: admission</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control risk: three risks presented based on control risk in included studies; 'moderate' equates with total control group risk (47.8%)<BR/>
<SUP>2</SUP> Risk of bias: rated 'serious' - only four studies of seventeen adequately reported randomisation methods; most studies rated 'high' on at least one risk of bias domain, including detected selective reporting and attrition bias<BR/>
<SUP>3</SUP> Indirectness: rated 'serious' - each included study involved different antipsychotic drugs as comparators (sulpiride, clopenthixol, benperidol, loxapine, risperidone, zotepine, clothiapine, thiothixene, methyperidol, penfluridol, aripiprazole, clocapramine, prochlorperazine, trifluopromazine, mepazine, promethazine, zuclopenthixol, timiperone)<BR/>
<SUP>4</SUP> Imprecision: rated 'serious' - 95% confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm.<BR/>
<SUP>5</SUP> Control risk: mean baseline risk presented; considerable heterogeneity in results to be wary of<BR/>
<SUP>6</SUP> Risk of bias: rated 'serious' - no studies adequately explained randomisation; two studies rated as 'high' on at least one risk of bias domain, including attrition bias and detected selective reporting<BR/>
<SUP>7</SUP> Inconsistency: rated 'serious' - heterogeneity was considerable (Chi² = 5.25, df=3 (P = 0.15); I² = 43%). Suspected heterogeneity due to different comparator drugs used in all four studies (quetiapine; risperidone; aripiprazole; clozapine and clozapine + perphenazine)<BR/>
<SUP>8</SUP> Indirectness: rated 'serious' - each included study involved different antipsychotic drugs as comparators<BR/>
<SUP>9</SUP> Risk of bias: rated 'serious' - three out of four studies did not adequately explain randomisation methods; three studies rated 'high' on at least one risk of bias domain, including selective reporting and incomplete outcome data<BR/>
<SUP>10</SUP> Inconsistency: rated 'serious' - heterogeneity was considerable (Chi² = 6.48, df = 3 (P = 0.09); I² = 54%). Suspected heterogeneity due to different comparator drugs used in all four studies (quetiapine; risperidone; timiperone; loxapine)<BR/>
<SUP>11</SUP> Control risk: median control group risk presented from the studies<BR/>
<SUP>12</SUP> Risk of bias: rated 'serious' - randomisation methods not described in one out of the two studies (<LINK REF="STD-Kane-2003" TYPE="STUDY">Kane 2003</LINK>), this same study was funded by pharmaceutical companies, with all authors affiliated with either company<BR/>
<SUP>13</SUP> Indirectness: rated 'serious' - one included study had five treatment arms (<LINK REF="STD-CATIE-2005" TYPE="STUDY">CATIE 2005</LINK>)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-12-11 11:15:09 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-28 11:36:20 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-14 16:38:04 +0000" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>PERPHENAZINE vs PLACEBO</NAME>
<DICH_OUTCOME CHI2="28.53425720556935" CI_END="2.3290451129496583" CI_START="0.03867304448183384" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3001187519188028" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="46" I2="89.48632172764442" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3671779007782827" LOG_CI_START="-1.4125916373498701" LOG_EFFECT_SIZE="-0.5227068682857937" METHOD="MH" MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.8053061460475703E-6" P_Q="0.799490365316122" P_Z="0.24962627928979952" Q="0.06451941697705875" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.7433559250604214" TOTALS="YES" TOTAL_1="131" TOTAL_2="130" WEIGHT="100.0" Z="1.151257636861643">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.500994847014635" CI_END="4.9168445139263515" CI_START="0.013738265922135397" DF="2" EFFECT_SIZE="0.25990174572348057" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" I2="92.1571687222464" ID="CMP-001.01.01" LOG_CI_END="0.6916864747511151" LOG_CI_START="-1.8620680815395607" LOG_EFFECT_SIZE="-0.5851908033942228" MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.900900319291466E-6" P_Z="0.36905317578644625" STUDIES="4" TAU2="6.1035047421877415" TOTAL_1="102" TOTAL_2="101" WEIGHT="75.0146635481234" Z="0.8982483425522957">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.074164305550164" CI_START="0.018999107641035875" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.031070716685767108" LOG_CI_START="-1.721266796714281" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="24449" O_E="0.0" SE="1.0293317295817754" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.0595238095238093" WEIGHT="22.756267520965075"/>
<DICH_DATA CI_END="0.5279359080225796" CI_START="0.011208102486297507" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.27741879807536607" LOG_CI_START="-1.9504679065383077" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="24450" O_E="0.0" SE="0.9827573280377846" STUDY_ID="STD-Chouinard-1977" TOTAL_1="18" TOTAL_2="18" VAR="0.9658119658119657" WEIGHT="23.209114358199944"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24451" O_E="0.0" SE="0.0" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6309236309007211" CI_START="0.9492365128912608" EFFECT_SIZE="1.2442396313364055" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.21243362538428642" LOG_CI_START="-0.022625564763370878" LOG_EFFECT_SIZE="0.09490403031045778" ORDER="24452" O_E="0.0" SE="0.13807493185449082" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="30" VAR="0.019064686806622287" WEIGHT="29.049281668958375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8977313843572232" CI_START="0.084311194576251" DF="0" EFFECT_SIZE="0.4000000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.2782347399420332" LOG_CI_START="-1.0741147572861083" LOG_EFFECT_SIZE="-0.39794000867203755" MODIFIED="2013-09-16 14:16:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.24871705994354565" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="24.985336451876602" Z="1.1534711797554995">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.897731384357223" CI_START="0.084311194576251" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2782347399420331" LOG_CI_START="-1.0741147572861083" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="24454" O_E="0.0" SE="0.7943767889097848" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.6310344827586207" WEIGHT="24.985336451876602"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3403634427933168" CI_END="73.10648615252525" CI_START="1.215115844637757" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="9.425118018875107" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.8639559101355119" LOG_CI_START="0.08461768393321378" LOG_EFFECT_SIZE="0.9742867970343628" METHOD="MH" MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5596196881157125" P_Q="0.569297115577869" P_Z="0.03184275950869464" Q="0.3238602153609267" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.0" Z="2.1463789229953103">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="273.2910953216886" CI_START="0.9924206503810512" DF="0" EFFECT_SIZE="16.468750000000004" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="2.43662548125118" LOG_CI_START="-0.0033042074658986374" LOG_EFFECT_SIZE="1.2166606368926407" MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05062374224366541" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="53.18172193664938" Z="1.954655530234541">
<NAME>short term</NAME>
<DICH_DATA CI_END="273.2910953216886" CI_START="0.9924206503810512" EFFECT_SIZE="16.46875" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.43662548125118" LOG_CI_START="-0.0033042074658986374" LOG_EFFECT_SIZE="1.2166606368926407" MODIFIED="2013-09-16 14:17:25 +0100" MODIFIED_BY="[Empty name]" ORDER="24456" O_E="0.0" SE="1.4332267769991602" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="30" VAR="2.0541389943074004" WEIGHT="53.18172193664938"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.81638537428941" CI_START="0.25045988097300376" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 14:17:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29205491191572275" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="46.81827806335062" Z="1.0536244371515675">
<NAME>medium term</NAME>
<DICH_DATA CI_END="99.81638537428941" CI_START="0.25045988097300376" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24455" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="46.81827806335062"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19134163697852902" CI_END="0.41619955895308236" CI_START="0.025657691450843366" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10333789172222976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.3806983843462662" LOG_CI_START="-1.5907824218216737" LOG_EFFECT_SIZE="-0.9857404030839698" METHOD="MH" MODIFIED="2013-09-16 14:18:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6618023306845672" P_Q="1.0" P_Z="0.0014070906938534835" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="3.193192585502296">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19134163697852902" CI_END="0.41619955895308236" CI_START="0.025657691450843366" DF="1" EFFECT_SIZE="0.10333789172222976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="20" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.3806983843462662" LOG_CI_START="-1.5907824218216737" LOG_EFFECT_SIZE="-0.9857404030839698" MODIFIED="2013-09-16 14:18:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6618023306845672" P_Z="0.0014070906938534835" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="3.193192585502296">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.074164305550164" CI_START="0.018999107641035875" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.031070716685767108" LOG_CI_START="-1.721266796714281" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="24458" O_E="0.0" SE="1.0293317295817754" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.0595238095238093" WEIGHT="47.68651092690279"/>
<DICH_DATA CI_END="0.5279359080225796" CI_START="0.011208102486297507" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.27741879807536607" LOG_CI_START="-1.9504679065383077" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="24459" O_E="0.0" SE="0.9827573280377846" STUDY_ID="STD-Chouinard-1977" TOTAL_1="18" TOTAL_2="18" VAR="0.9658119658119657" WEIGHT="52.31348907309721"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7768356372711485" CI_START="0.13395146623062754" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3225806451612903" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.10967085941931033" LOG_CI_START="-0.8730525282492352" LOG_EFFECT_SIZE="-0.4913616938342727" METHOD="MH" MODIFIED="2014-03-05 12:02:44 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.01163191811228409" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="2.52311854638556">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7768356372711485" CI_START="0.13395146623062754" DF="0" EFFECT_SIZE="0.3225806451612903" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.10967085941931033" LOG_CI_START="-0.8730525282492352" LOG_EFFECT_SIZE="-0.4913616938342727" MODIFIED="2013-12-10 16:27:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01163191811228409" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="2.52311854638556">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.7768356372711483" CI_START="0.1339514662306276" EFFECT_SIZE="0.3225806451612903" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.1096708594193104" LOG_CI_START="-0.873052528249235" LOG_EFFECT_SIZE="-0.4913616938342727" MODIFIED="2013-12-10 16:27:44 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.44841417107090215" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="30" VAR="0.2010752688172043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.074164305550164" CI_START="0.018999107641035875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.031070716685767108" LOG_CI_START="-1.721266796714281" LOG_EFFECT_SIZE="-0.8450980400142568" METHOD="MH" MODIFIED="2014-03-05 12:03:12 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.05869650597886094" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.8904596964536886">
<NAME>Mental state: 1. Relapse (clinical diagnosis)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.074164305550164" CI_START="0.018999107641035875" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.031070716685767108" LOG_CI_START="-1.721266796714281" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-10-09 11:12:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05869650597886094" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.8904596964536886">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.074164305550164" CI_START="0.018999107641035875" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.031070716685767108" LOG_CI_START="-1.721266796714281" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="24460" O_E="0.0" SE="1.0293317295817754" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.0595238095238093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0263216898816507" CI_START="-0.5063216898816507" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.76" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-01-14 16:36:55 +0000" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2394755335052563" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.1762987558000806">
<NAME>Behaviour: 1a. Wing-Scale B: social withdrawal - mean change from baseline to endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0263216898816507" CI_START="-0.5063216898816507" DF="0" EFFECT_SIZE="0.76" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2013-09-16 14:22:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2394755335052563" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.1762987558000806">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.0263216898816507" CI_START="-0.5063216898816507" EFFECT_SIZE="0.76" ESTIMABLE="YES" MEAN_1="0.62" MEAN_2="-0.14" ORDER="24462" SD_1="2.01" SD_2="2.84" SE="0.6460943669731866" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7407489547897183" CI_START="-0.5407489547897183" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-01-14 16:38:04 +0000" MODIFIED_BY="Heather Maxwell" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7596911328825113" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="99.99999999999999" Z="0.3058864115015649">
<NAME>Behaviour: 1b. Wing-Scale B: socially embarrassing behaviour - mean change from baseline to endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7407489547897183" CI_START="-0.5407489547897183" DF="0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2013-09-16 14:22:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7596911328825113" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="99.99999999999999" Z="0.3058864115015649">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.7407489547897183" CI_START="-0.5407489547897183" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="-0.24" ORDER="24463" SD_1="1.13" SD_2="1.35" SE="0.3269187392441209" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8858015296423147" CI_END="3.3499925843061455" CI_START="1.0070391130255607" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8367290384653547" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.5250438456641631" LOG_CI_START="0.003046338717760235" LOG_EFFECT_SIZE="0.26404509219096167" METHOD="MH" MODIFIED="2013-12-10 16:27:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9839851536040912" P_Q="0.9855750352684766" P_Z="0.04738526047885904" Q="2.8086635437823864" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="292" TOTAL_2="292" WEIGHT="1100.0" Z="1.9828403933047154">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-16 14:23:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24464" O_E="0.0" SE="0.0" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.16470334946774" CI_START="0.1282696223366598" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-16 14:23:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>body rocking - short term</NAME>
<DICH_DATA CI_END="70.16470334946774" CI_START="0.1282696223366598" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24465" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.081174850552697" CI_START="0.06630783144612581" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="1.1784351751702022" LOG_CI_START="-1.1784351751702025" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 14:23:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.00000000000001" Z="0.0">
<NAME>dystonia - short term</NAME>
<DICH_DATA CI_END="15.08117485055269" CI_START="0.06630783144612584" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1784351751702022" LOG_CI_START="-1.1784351751702022" LOG_EFFECT_SIZE="0.0" ORDER="24466" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.9166666666666665" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.207183349614179" CI_START="0.588129857234029" DF="0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.7166028698446569" LOG_CI_START="-0.23052677247206807" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2013-09-16 14:23:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.31447692833776353" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.0058724825312497">
<NAME>extrapyramidal signs - short term</NAME>
<DICH_DATA CI_END="5.207183349614179" CI_START="0.588129857234029" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7166028698446569" LOG_CI_START="-0.23052677247206807" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="24467" O_E="0.0" SE="0.5563486402641867" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.3095238095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.96498619891642" CI_START="0.25261459593144187" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="1.9954815684331297" LOG_CI_START="-0.5975415597610922" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 14:23:40 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.29067239224580455" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.0566477559546013">
<NAME>facial mask - short term</NAME>
<DICH_DATA CI_END="98.96498619891642" CI_START="0.25261459593144187" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9954815684331297" LOG_CI_START="-0.5975415597610922" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24468" O_E="0.0" SE="1.5231546211727816" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.32" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.16470334946774" CI_START="0.1282696223366598" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.06" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-16 14:23:44 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>oculogyric crisis - short term</NAME>
<DICH_DATA CI_END="70.16470334946774" CI_START="0.1282696223366598" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24469" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.74412565322564" CI_START="0.3776664242276759" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.08.07" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-09-16 14:23:50 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.19145408944677977" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.3062896089000702">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="24470" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.96498619891642" CI_START="0.25261459593144187" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.08" LOG_CI_END="1.9954815684331297" LOG_CI_START="-0.5975415597610922" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 14:23:55 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.29067239224580455" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.0566477559546013">
<NAME>posture and gait - short term</NAME>
<DICH_DATA CI_END="98.96498619891642" CI_START="0.25261459593144187" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9954815684331297" LOG_CI_START="-0.5975415597610922" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24471" O_E="0.0" SE="1.5231546211727816" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.32" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.331250877223173" CI_START="0.3334635376798752" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.08.09" LOG_CI_END="0.7268291199719785" LOG_CI_START="-0.4769516467553787" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-09-16 14:23:59 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.6841226509463061" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.40684388851290787">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="5.331250877223173" CI_START="0.3334635376798752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7268291199719785" LOG_CI_START="-0.4769516467553787" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-06-27 16:00:08 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.49999999999999994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.18942517519079" CI_START="0.27474455799610886" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.08.10" LOG_CI_END="0.9132534192202642" LOG_CI_START="-0.5610709011089017" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-09-16 14:24:33 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.6396481675128094" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.4681907786264988">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="8.18942517519079" CI_START="0.27474455799610886" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9132534192202642" LOG_CI_START="-0.5610709011089017" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="24472" O_E="0.0" SE="0.8660254037844386" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.75" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.627129539131202" CI_START="0.1508948925919286" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.08.11" LOG_CI_END="0.8213254597385299" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 14:24:33 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.0">
<NAME>tremor - medium term</NAME>
<DICH_DATA CI_END="6.627129539131202" CI_START="0.1508948925919286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8213254597385299" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 14:24:18 +0100" MODIFIED_BY="[Empty name]" ORDER="24473" O_E="0.0" SE="0.9649012813540154" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.9310344827586208" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.09028858730679" CI_START="0.1302643277951726" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.12" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-16 14:24:21 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.49243283298336993" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982625">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24474" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Chouinard-1977" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27106453548053233" CI_END="5.7394725157794415" CI_START="0.41249613617049685" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5386715817274914" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.7588719805490404" LOG_CI_START="-0.3845801151084592" LOG_EFFECT_SIZE="0.1871459327202906" METHOD="MH" MODIFIED="2013-12-10 16:27:00 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8732509923032654" P_Q="0.8736805840247719" P_Z="0.5211558202170881" Q="0.27008088643106937" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="101" WEIGHT="300.0" Z="0.6415647658138426">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-16 14:25:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24475" O_E="0.0" SE="0.0" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.081174850552697" CI_START="0.06630783144612581" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.1784351751702022" LOG_CI_START="-1.1784351751702025" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 14:25:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.00000000000001" Z="0.0">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="15.08117485055269" CI_START="0.06630783144612584" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1784351751702022" LOG_CI_START="-1.1784351751702022" LOG_EFFECT_SIZE="0.0" ORDER="24476" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.9166666666666665" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.323018553926179" CI_START="0.2703346130279401" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.9202808627764995" LOG_CI_START="-0.5680983446651372" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-09-16 14:25:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6428128167691762" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.00000000000001" Z="0.4637696146463824">
<NAME>dry mouth - medium term</NAME>
<DICH_DATA CI_END="8.323018553926179" CI_START="0.2703346130279401" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9202808627764995" LOG_CI_START="-0.5680983446651372" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-09-16 14:25:10 +0100" MODIFIED_BY="[Empty name]" ORDER="24477" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.16470334946774" CI_START="0.1282696223366598" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-16 14:25:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>nasal congestion - short term</NAME>
<DICH_DATA CI_END="70.16470334946774" CI_START="0.1282696223366598" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24478" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.525940356189872" CI_END="0.7395945878571439" CI_START="0.31983893945732444" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48636524198240755" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.13100627554474348" LOG_CI_START="-0.4950686632853487" LOG_EFFECT_SIZE="-0.3130374694150461" METHOD="MH" MODIFIED="2013-12-10 16:27:00 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.639996975526222" P_Q="0.6515353664600226" P_Z="7.502288999892907E-4" Q="2.4615419549486104" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="159" WEIGHT="500.0" Z="3.3705331092988295">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6823756366834695" CI_START="0.23859447246967463" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.4285195958554559" LOG_CI_START="-0.6223396218715687" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-09-16 15:43:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7177295014215997" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.36149492155178164">
<NAME>agitation - medium term</NAME>
<DICH_DATA CI_END="2.6823756366834695" CI_START="0.23859447246967463" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4285195958554559" LOG_CI_START="-0.6223396218715687" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-09-16 14:26:04 +0100" MODIFIED_BY="[Empty name]" ORDER="24482" O_E="0.0" SE="0.6172799063298762" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.3810344827586207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2817620388778646" CI_START="0.021671555979373675" DF="0" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.10780740521809008" LOG_CI_START="-1.6641099059853774" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2013-09-16 15:43:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08516614892810265" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.7214668152216277">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="1.2817620388778646" CI_START="0.021671555979373675" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10780740521809008" LOG_CI_START="-1.6641099059853774" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="24479" O_E="0.0" SE="1.0408329997330663" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.0833333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.859591833249636" CI_START="0.01413700780758877" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 15:43:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49566244472171195" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="99.99999999999999" Z="0.6813304182069593">
<NAME>drowsiness - medium term</NAME>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 14:26:00 +0100" MODIFIED_BY="[Empty name]" ORDER="24480" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7926641676036918" CI_START="0.1774080446011889" DF="0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="-0.10091077365183924" LOG_CI_START="-0.751026690892723" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2013-09-16 15:43:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.010216509342019791" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="2.568413883287559">
<NAME>excitement - short term</NAME>
<DICH_DATA CI_END="0.7926641676036918" CI_START="0.1774080446011889" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.10091077365183924" LOG_CI_START="-0.751026690892723" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="24481" O_E="0.0" SE="0.3818813079129867" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.14583333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0136237105083263" CI_START="0.3121535602608627" DF="0" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.005876760934670136" LOG_CI_START="-0.5056317073678698" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2013-09-16 14:26:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.055501734301255594" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="1.9149276244738014">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.0136237105083263" CI_START="0.3121535602608627" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.005876760934670136" LOG_CI_START="-0.5056317073678698" LOG_EFFECT_SIZE="-0.2498774732165999" ORDER="24483" O_E="0.0" SE="0.3004626062886658" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.09027777777777779" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-16 14:26:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>insomnia - medium term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 14:26:06 +0100" MODIFIED_BY="[Empty name]" ORDER="24484" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.764445608363342" CI_START="0.4722480189616245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.6780123733403383" LOG_CI_START="-0.32582985522897573" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2014-02-18 11:25:47 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.49169019590033114" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="0.6876230465684519">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.764445608363342" CI_START="0.4722480189616245" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.6780123733403383" LOG_CI_START="-0.32582985522897573" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-02-18 11:25:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49169019590033114" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="0.6876230465684519">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-18 11:25:47 +0000" MODIFIED_BY="[Empty name]" ORDER="24485" O_E="0.0" SE="0.0" STUDY_ID="STD-Chouinard-1977" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.764445608363342" CI_START="0.4722480189616245" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6780123733403383" LOG_CI_START="-0.32582985522897573" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-07-11 15:34:22 +0100" MODIFIED_BY="[Empty name]" ORDER="24486" O_E="0.0" SE="0.5896618941607871" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="0.3477011494252873" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.977774338441429" CI_END="3.0849985841756546" CI_START="0.5478685378359283" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3000667919527154" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.4892549690548872" LOG_CI_START="-0.2613236388545234" LOG_EFFECT_SIZE="0.11396566510018191" METHOD="MH" MODIFIED="2013-12-10 16:26:59 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.73984708035346" P_Q="0.7404511172097283" P_Z="0.5517161952141534" Q="1.9744902092955334" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="124" WEIGHT="500.0" Z="0.5951904216739118">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.580757796917673" CI_START="0.4175035090947484" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.9813998612710212" LOG_CI_START="-0.37933986994305885" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-09-16 15:33:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3858395290771939" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.8671870692586223">
<NAME>ECG abnormalities - short term</NAME>
<DICH_DATA CI_END="9.580757796917673" CI_START="0.4175035090947484" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9813998612710212" LOG_CI_START="-0.37933986994305885" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="24487" O_E="0.0" SE="0.7993052538854533" STUDY_ID="STD-Chouinard-1977" TOTAL_1="18" TOTAL_2="18" VAR="0.6388888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.530755602171816" CI_START="0.15312163873770565" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.8149634316379312" LOG_CI_START="-0.8149634316379312" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 15:34:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.0">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="6.530755602171816" CI_START="0.15312163873770565" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8149634316379312" LOG_CI_START="-0.8149634316379312" LOG_EFFECT_SIZE="0.0" ORDER="24488" O_E="0.0" SE="0.9574271077563381" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.9166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.550651407823445" CI_START="0.21974875910750002" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="0.6580735686514008" LOG_CI_START="-0.6580735686514008" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 15:34:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.0">
<NAME>faintness, dizziness, weakness - medium term</NAME>
<DICH_DATA CI_END="4.550651407823445" CI_START="0.21974875910750002" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6580735686514008" LOG_CI_START="-0.6580735686514008" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 15:34:08 +0100" MODIFIED_BY="[Empty name]" ORDER="24489" O_E="0.0" SE="0.7731113434850684" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="0.5977011494252874" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.81638537428941" CI_START="0.25045988097300376" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 15:34:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.29205491191572275" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.0536244371515675">
<NAME>hypotension - medium term</NAME>
<DICH_DATA CI_END="99.81638537428941" CI_START="0.25045988097300376" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24490" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.796078149940863" CI_START="0.01425218025962887" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.12.05" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 15:34:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24491" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.998828618438036" CI_START="0.18757323994492983" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829995" METHOD="MH" MODIFIED="2013-12-10 16:26:59 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.6841226509463061" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.4068438885129079">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.998828618438036" CI_START="0.18757323994492983" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-09-16 15:34:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6841226509463061" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.4068438885129079">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="2.998828618438036" CI_START="0.18757323994492983" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="24492" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.49999999999999994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-10 16:26:59 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events: 6. Endocrine</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-16 15:34:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>lactation - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24493" O_E="0.0" SE="0.0" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9448255930832112" CI_END="1.750339142774088" CI_START="0.3420382004440997" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7737459858127325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.24312220500933457" LOG_CI_START="-0.46592538717308746" LOG_EFFECT_SIZE="-0.11140159108187643" METHOD="MH" MODIFIED="2013-12-10 16:26:58 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.5839372412293352" P_Q="0.5906386362907121" P_Z="0.5379756047286992" Q="1.9130959071187688" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="101" WEIGHT="400.0" Z="0.6158771533766426">
<NAME>Other adverse events: 7. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.621308391127807" CI_START="0.24415288264676202" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.4185181177365015" LOG_CI_START="-0.6123381437526143" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-09-16 15:34:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7124934033656097" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.3685094466278394">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="2.621308391127807" CI_START="0.24415288264676202" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4185181177365015" LOG_CI_START="-0.6123381437526143" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24494" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.36666666666666664" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.796078149940863" CI_START="0.01425218025962887" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 15:35:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>diarrhoea - short term</NAME>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24495" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.234367492956461" CI_START="0.16111942244722538" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.3491546043379864" LOG_CI_START="-0.7928521035706992" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-09-16 15:35:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.44636213942232983" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.7614938795929915">
<NAME>nausea or vomiting - short term</NAME>
<DICH_DATA CI_END="2.234367492956461" CI_START="0.16111942244722538" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3491546043379864" LOG_CI_START="-0.7928521035706992" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="24496" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.44999999999999996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.81638537428941" CI_START="0.25045988097300376" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 15:35:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.29205491191572275" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.0536244371515675">
<NAME>nausea or vomiting - medium term</NAME>
<DICH_DATA CI_END="99.81638537428941" CI_START="0.25045988097300376" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992018388177863" LOG_CI_START="-0.6012618301457486" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-16 15:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="24497" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.650853923417994" CI_START="0.48378212626089867" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.6675326991654031" LOG_CI_START="-0.3153501810540406" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2013-12-10 16:26:58 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.48250072260559485" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.7022861679397484">
<NAME>Other adverse events: 8. Haematology - abnormal laboratory results</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.650853923417994" CI_START="0.48378212626089867" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.6675326991654031" LOG_CI_START="-0.3153501810540406" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-09-16 15:37:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48250072260559485" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.7022861679397484">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.650853923417994" CI_START="0.48378212626089867" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6675326991654031" LOG_CI_START="-0.3153501810540406" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="24498" O_E="0.0" SE="0.5773502691896257" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="0.33333333333333326" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1056289759465976" CI_START="0.03577732947872317" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33333333333333326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.49214957009059407" LOG_CI_START="-1.4463920795299192" LOG_EFFECT_SIZE="-0.47712125471966255" METHOD="MH" MODIFIED="2013-12-10 16:26:58 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.9999999999999999" P_Z="0.33465121874655235" Q="3.802375249442079E-32" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="199.99999999999997" Z="0.9647876027756866">
<NAME>Other adverse events: 9. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.796078149940863" CI_START="0.01425218025962887" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 15:37:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.494553663934557" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.6830841673583029">
<NAME>dermatitis - short term</NAME>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24499" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.859591833249636" CI_START="0.01413700780758877" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-09-16 15:37:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49566244472171195" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="99.99999999999999" Z="0.6813304182069593">
<NAME>oedema - medium term</NAME>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24500" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6748815546320873" CI_END="5.244651581571261" CI_START="0.19200873957675385" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0035033331766896" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.7197166419619723" LOG_CI_START="-0.7166790032569875" LOG_EFFECT_SIZE="0.0015188193524922982" METHOD="MH" MODIFIED="2013-12-10 16:26:58 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.41135517663554866" P_Q="0.41136113008347286" P_Z="0.9966928876653401" Q="0.6748643747468581" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="200.0" Z="0.004144862510292079">
<NAME>Other adverse events: 10. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.61400983214693" CI_START="0.1940427909257189" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="1.3141624788530009" LOG_CI_START="-0.7121024875250384" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-09-16 15:37:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5603241438828968" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.582360115342955">
<NAME>salivation increased - short term</NAME>
<DICH_DATA CI_END="20.61400983214693" CI_START="0.1940427909257189" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3141624788530009" LOG_CI_START="-0.7121024875250384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="24501" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Chouinard-1975" TOTAL_1="24" TOTAL_2="24" VAR="1.4166666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.214673425796684" CI_START="0.04794164074844354" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.717227115482503" LOG_CI_START="-1.3192871068104655" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-09-16 15:37:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5622995782043978" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.5794292456286855">
<NAME>tenseness - medium term</NAME>
<DICH_DATA CI_END="5.214673425796684" CI_START="0.04794164074844354" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.717227115482503" LOG_CI_START="-1.3192871068104655" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="24502" O_E="0.0" SE="1.1962585350828727" STUDY_ID="STD-Hanlon-1964" TOTAL_1="29" TOTAL_2="29" VAR="1.4310344827586206" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-01-28 11:36:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>PERPHENAZINE vs ANY ANTIPSYCHOTIC</NAME>
<DICH_OUTCOME CHI2="37.39348807890512" CI_END="1.3140054543138178" CI_START="0.9199985340408303" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0994921971939444" ESTIMABLE="YES" EVENTS_1="399" EVENTS_2="1294" I2="46.51475155835316" I2_Q="26.041734685315895" ID="CMP-002.01" LOG_CI_END="0.11859716794330331" LOG_CI_START="-0.03621286467453748" LOG_EFFECT_SIZE="0.04119215163438292" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010493085993315887" P_Q="0.2586930278557722" P_Z="0.29693812632264927" Q="2.7042278391606738" RANDOM="YES" SCALE="33.31106177581977" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.046322389901880506" TOTALS="YES" TOTAL_1="1264" TOTAL_2="2803" WEIGHT="99.99999999999999" Z="1.0430219835739387">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="34.31624398915104" CI_END="1.422930208576866" CI_START="0.8326638069346666" DF="17" EFFECT_SIZE="1.08849551421949" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="377" I2="50.460778850463676" ID="CMP-002.01.01" LOG_CI_END="0.15318359947061083" LOG_CI_START="-0.07953031223634167" LOG_EFFECT_SIZE="0.03682664361713453" MODIFIED="2014-02-26 15:38:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007640924593481313" P_Z="0.5350451632047863" STUDIES="21" TAU2="0.12192319746690033" TOTAL_1="949" TOTAL_2="1551" WEIGHT="69.39880708387729" Z="0.6203229934269477">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.7099337547351947" CI_START="0.23616813469395628" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24503" O_E="0.0" SE="0.6224949798994366" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.3875" WEIGHT="1.9061691907154903"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24504" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 11:47:50 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="0.8557587845579093"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24505" O_E="0.0" SE="0.0" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8783417879269204" CI_START="0.3190735657697006" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-07-18 14:52:49 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.5611194814509367" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.3148550724637681" WEIGHT="2.2895638849036253"/>
<DICH_DATA CI_END="1.0836406509064114" CI_START="0.46206095369980815" EFFECT_SIZE="0.7076072587429395" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="157" LOG_CI_END="0.0348852884737149" LOG_CI_START="-0.33530072983487563" LOG_EFFECT_SIZE="-0.15020772068058036" MODIFIED="2013-09-17 12:45:09 +0100" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.21744909960481015" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="0.04728411091894265" WEIGHT="8.834203464740254"/>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" ORDER="24509" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="5.6252416283509605"/>
<DICH_DATA CI_END="3.4790760305729287" CI_START="0.6255310526183312" EFFECT_SIZE="1.4752186588921283" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5414639197787692" LOG_CI_START="-0.20375112618471192" LOG_EFFECT_SIZE="0.16885639679702863" ORDER="24510" O_E="0.0" SE="0.4377430068729197" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.19161894006614505" WEIGHT="3.475389811365058"/>
<DICH_DATA CI_END="4.660501214038062" CI_START="0.2145691963319019" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422858" LOG_EFFECT_SIZE="0.0" ORDER="24511" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="1.2472888740479975"/>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" ORDER="24512" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="0.41350856270451186"/>
<DICH_DATA CI_END="2.8317856421488745" CI_START="0.3531340738210535" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45206037544594646" LOG_CI_START="-0.45206037544594646" LOG_EFFECT_SIZE="0.0" ORDER="24513" O_E="0.0" SE="0.5310850045437943" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.282051282051282" WEIGHT="2.518286161478493"/>
<DICH_DATA CI_END="1.188132026977886" CI_START="0.20100101978627324" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.074864702768126" LOG_CI_START="-0.696801739164448" LOG_EFFECT_SIZE="-0.310968518198161" ORDER="24514" O_E="0.0" SE="0.4532806878016867" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.20546338193397015" WEIGHT="3.284295485976238"/>
<DICH_DATA CI_END="1.1086062112203157" CI_START="0.4981687229645273" EFFECT_SIZE="0.7431506849315068" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.04477730749760454" LOG_CI_START="-0.3026235426973822" LOG_EFFECT_SIZE="-0.1289231175998888" MODIFIED="2013-12-17 15:05:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1295" O_E="0.0" SE="0.20406497906647802" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.04164251568140211" WEIGHT="9.40078169117803"/>
<DICH_DATA CI_END="2.092797663164798" CI_START="0.5299550842999619" EFFECT_SIZE="1.0531328320802005" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="0.32072724170762895" LOG_CI_START="-0.27576093694125786" LOG_EFFECT_SIZE="0.022483152383185535" ORDER="24515" O_E="0.0" SE="0.3503801088024604" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.122766220644424" WEIGHT="4.890565196566401"/>
<DICH_DATA CI_END="2.0562943085084546" CI_START="1.3628901338632051" EFFECT_SIZE="1.6740678676162548" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="77" LOG_CI_END="0.3130852734622687" LOG_CI_START="0.13446084763211166" LOG_EFFECT_SIZE="0.22377306054719018" MODIFIED="2014-02-26 15:38:21 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.10492487193780242" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="148" VAR="0.011009228751164238" WEIGHT="14.423783826476887"/>
<DICH_DATA CI_END="4.6740388197625435" CI_START="0.693190648374761" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6696923150606261" LOG_CI_START="-0.15914730485401402" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="24519" O_E="0.0" SE="0.48686449556014766" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.23703703703703705" WEIGHT="2.918339025480125"/>
<DICH_DATA CI_END="9.561571260135594" CI_START="0.4183412842068047" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.9805292660767962" LOG_CI_START="-0.3784692747488338" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-07 13:53:04 +0000" MODIFIED_BY="[Empty name]" ORDER="1032" O_E="0.0" SE="0.7982824700322463" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="102" VAR="0.6372549019607843" WEIGHT="1.2097225635161457"/>
<DICH_DATA CI_END="2.670809631751072" CI_START="0.6656325320394352" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="24520" O_E="0.0" SE="0.354445077736048" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1256313131313131" WEIGHT="4.809078602476486"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" ORDER="24518" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="0.6690086835904269"/>
<DICH_DATA CI_END="27.33325429307962" CI_START="0.32926924483626774" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-13 16:16:28 +0000" MODIFIED_BY="[Empty name]" ORDER="1343" O_E="0.0" SE="1.1273124382057236" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.2708333333333333" WEIGHT="0.6278216457522503"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24521" O_E="0.0" SE="0.0" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2477056014095735" CI_START="0.8648459794134622" DF="0" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.628154409176546" LOG_CI_START="-0.0630612292366097" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-10-01 17:34:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10908050422330752" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="3.9158481431209875" Z="1.6023397316851091">
<NAME>medium term</NAME>
<DICH_DATA CI_END="4.2477056014095735" CI_START="0.8648459794134622" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.628154409176546" LOG_CI_START="-0.0630612292366097" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-10-01 17:34:17 +0100" MODIFIED_BY="[Empty name]" ORDER="24522" O_E="0.0" SE="0.40602348757648016" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.16485507246376813" WEIGHT="3.9158481431209875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04920440635960511" CI_END="1.0896100419420127" CI_START="0.9361239127080696" DF="1" EFFECT_SIZE="1.0099554523783516" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="911" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.03727109708330909" LOG_CI_START="-0.028666660830769346" LOG_EFFECT_SIZE="0.004302218126269886" MODIFIED="2014-02-27 11:29:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8244534947750035" P_Z="0.7981344736934148" STUDIES="2" TAU2="0.0" TOTAL_1="291" TOTAL_2="1229" WEIGHT="26.68534477300171" Z="0.25576218688272967">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.0893424053129086" CI_START="0.9332589564427858" EFFECT_SIZE="1.008284957931635" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="893" LOG_CI_END="0.037164409934715224" LOG_CI_START="-0.029997833477720545" LOG_EFFECT_SIZE="0.0035832882284973105" MODIFIED="2014-02-27 11:29:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.039451434238931465" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.0015564156635087339" WEIGHT="17.271501745049946"/>
<DICH_DATA CI_END="1.5737175550829683" CI_START="0.7080034960946062" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.19692678947418224" LOG_CI_START="-0.14996459777513643" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-12-18 09:48:28 +0000" MODIFIED_BY="[Empty name]" ORDER="925" O_E="0.0" SE="0.20376571801031035" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.04152046783625731" WEIGHT="9.413843027951764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.42053746009363" CI_END="1.5184540119884398" CI_START="0.8177172592984963" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.114300701361169" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="258" I2="18.03606947405177" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.18140164337835835" LOG_CI_START="-0.087396835635452" LOG_EFFECT_SIZE="0.0470024038714532" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2667298506621353" P_Q="0.8206616622782432" P_Z="0.4930644183119556" Q="0.39528888813108504" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.048971202941659894" TOTALS="YES" TOTAL_1="870" TOTAL_2="2344" WEIGHT="100.00000000000004" Z="0.6854430063208888">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.820274390289958" CI_END="1.8275848742493435" CI_START="0.7033162879223946" DF="8" EFFECT_SIZE="1.133741685579288" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="84" I2="37.598839490836646" ID="CMP-002.02.01" LOG_CI_END="0.26187755502099036" LOG_CI_START="-0.15284932475507468" LOG_EFFECT_SIZE="0.05451411513295789" MODIFIED="2014-02-26 16:06:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11818491783608387" P_Z="0.6063726415373628" STUDIES="9" TAU2="0.17864137334940883" TOTAL_1="562" TOTAL_2="1099" WEIGHT="64.14591673194903" Z="0.5152581494952028">
<NAME>short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24523" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="0.9389859399759382"/>
<DICH_DATA CI_END="4.602379111604806" CI_START="0.24793326233034005" EFFECT_SIZE="1.0682148040638606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="0.6629823899294551" LOG_CI_START="-0.6056652050697092" LOG_EFFECT_SIZE="0.028658592429873012" ORDER="24524" O_E="0.0" SE="0.7452098772093854" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="0.5553377610904272" WEIGHT="4.125435310785221"/>
<DICH_DATA CI_END="2.131214611558949" CI_START="0.29526640305121676" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3286271850135134" LOG_CI_START="-0.529785966511224" LOG_EFFECT_SIZE="-0.10057939074885529" ORDER="24525" O_E="0.0" SE="0.5042361344192612" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2542540792540792" WEIGHT="8.221733757783076"/>
<DICH_DATA CI_END="34.198442693654755" CI_START="0.4678575613318402" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5340063298879694" LOG_CI_START="-0.3298863472320445" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="24526" O_E="0.0" SE="1.0948597849578496" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.198717948717949" WEIGHT="1.9981239201494252"/>
<DICH_DATA CI_END="1.0487960662113913" CI_START="0.2652068205683278" EFFECT_SIZE="0.5273972602739726" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.02069104974811323" LOG_CI_START="-0.5764153109720236" LOG_EFFECT_SIZE="-0.27786213061195525" MODIFIED="2013-12-17 15:06:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1296" O_E="0.0" SE="0.35074323201116325" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.12302081480163671" WEIGHT="14.495076989927195"/>
<DICH_DATA CI_END="1.9189441950856094" CI_START="0.15668027237571883" EFFECT_SIZE="0.5483253588516747" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.28306234517904616" LOG_CI_START="-0.8049856821384118" LOG_EFFECT_SIZE="-0.26096166847968283" ORDER="24527" O_E="0.0" SE="0.6391247971708731" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.4084805063587097" WEIGHT="5.449837629101617"/>
<DICH_DATA CI_END="5.080074837940288" CI_START="1.1216824931019298" EFFECT_SIZE="2.3870967741935485" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.7058701102101201" LOG_CI_START="0.04986994158328679" LOG_EFFECT_SIZE="0.37787002589670354" MODIFIED="2014-02-26 16:06:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.3853377463046077" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="148" VAR="0.1484851787271142" WEIGHT="12.625763309205107"/>
<DICH_DATA CI_END="2.670809631751072" CI_START="0.6656325320394352" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="24529" O_E="0.0" SE="0.354445077736048" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1256313131313131" WEIGHT="14.27835975628251"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-10-08 15:45:40 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="2.0126001187389346"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.28973413262064" CI_START="0.12326397342650598" DF="0" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" MODIFIED="2013-09-24 16:36:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.510593226807788" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.9464938477906459" Z="0.6579142667226608">
<NAME>medium term</NAME>
<DICH_DATA CI_END="67.28973413262064" CI_START="0.12326397342650598" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" ORDER="24530" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="0.9464938477906459"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.27851248944667856" CI_END="1.470554317788597" CI_START="0.7850158611615332" DF="1" EFFECT_SIZE="1.0744340203863736" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="174" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.16748107065212026" LOG_CI_START="-0.10512156829253072" LOG_EFFECT_SIZE="0.031179751179794744" MODIFIED="2013-12-18 09:48:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5976779056323949" P_Z="0.6538980133919865" STUDIES="2" TAU2="0.0" TOTAL_1="284" TOTAL_2="1222" WEIGHT="34.90758942026036" Z="0.44835361532744367">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.457966787958559" CI_START="0.7738156287578482" EFFECT_SIZE="1.0621664119770557" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="173" LOG_CI_END="0.16374763099799539" LOG_CI_START="-0.11136250307852602" LOG_EFFECT_SIZE="0.026192563959734672" MODIFIED="2013-12-11 14:46:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1616010545736755" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.02611490083932404" WEIGHT="33.20238250893752"/>
<DICH_DATA CI_END="20.552567517689006" CI_START="0.19462288575660025" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3128660835898294" LOG_CI_START="-0.710806092261867" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-18 09:48:46 +0000" MODIFIED_BY="[Empty name]" ORDER="926" O_E="0.0" SE="1.1887150534341144" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="1.4130434782608696" WEIGHT="1.7052069113228374"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.818766856814454" CI_END="1.3513161039682307" CI_START="0.898662907076994" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1019880481983675" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="315" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.13075695239073706" LOG_CI_START="-0.04640318373968633" LOG_EFFECT_SIZE="0.042176884325525334" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9710487369852665" P_Q="0.8257022812909949" P_Z="0.3507035859914379" Q="0.3830421503408839" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="746" TOTAL_2="1786" WEIGHT="100.0" Z="0.9332254542555147">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6715353911760373" CI_END="2.0272159070699263" CI_START="0.7809947728096976" DF="6" EFFECT_SIZE="1.2582706492556688" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.3069000053558559" LOG_CI_START="-0.10735187284165124" LOG_EFFECT_SIZE="0.09977406625710235" MODIFIED="2013-12-17 15:07:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9472975833202746" P_Z="0.3451038152819035" STUDIES="7" TAU2="0.0" TOTAL_1="438" TOTAL_2="541" WEIGHT="18.289550765942742" Z="0.944128858538561">
<NAME>short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24531" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="0.4155494418482092"/>
<DICH_DATA CI_END="14.434266565279833" CI_START="0.06362656347132332" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1593947213830598" LOG_CI_START="-1.1963615327710861" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-07-18 14:53:08 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="1.914855072463768" WEIGHT="0.5655503885616292"/>
<DICH_DATA CI_END="9.116851335277273" CI_START="0.27609359825809593" EFFECT_SIZE="1.5865384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9598448729969133" LOG_CI_START="-0.5589436631666614" LOG_EFFECT_SIZE="0.2004506049151259" ORDER="24533" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="1.3606216898119723"/>
<DICH_DATA CI_END="3.227063859812455" CI_START="0.5573395512830623" EFFECT_SIZE="1.3411078717201166" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5088075596678502" LOG_CI_START="-0.2538801363902431" LOG_EFFECT_SIZE="0.12746371163880357" ORDER="24534" O_E="0.0" SE="0.4480065280295078" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.20070984915705414" WEIGHT="5.3955848944098985"/>
<DICH_DATA CI_END="6.755362190128103" CI_START="0.14803055289342476" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.829648638769922" LOG_CI_START="-0.829648638769922" LOG_EFFECT_SIZE="0.0" ORDER="24535" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.95" WEIGHT="1.1399442423906216"/>
<DICH_DATA CI_END="2.0790429481562867" CI_START="0.3424934286236656" EFFECT_SIZE="0.8438356164383561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3178634609306164" LOG_CI_START="-0.4653477568426773" LOG_EFFECT_SIZE="-0.07374214795603046" MODIFIED="2013-12-17 15:07:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1297" O_E="0.0" SE="0.4600621462780875" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.21165717843800036" WEIGHT="5.116514536681838"/>
<DICH_DATA CI_END="4.706502829844879" CI_START="0.657562905577235" EFFECT_SIZE="1.7592105263157896" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.6726983241492234" LOG_CI_START="-0.18206269418683727" LOG_EFFECT_SIZE="0.24531781498119304" ORDER="24536" O_E="0.0" SE="0.5020908533058817" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.25209522497342834" WEIGHT="4.2957855722385725"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2533714519401724" CI_START="0.4065013846517025" DF="0" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.512333651452242" LOG_CI_START="-0.3909379707450186" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-09-24 16:37:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.792234256399401" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="3.8467616519281984" Z="0.26341042518982305">
<NAME>medium term</NAME>
<DICH_DATA CI_END="3.2533714519401724" CI_START="0.4065013846517025" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.512333651452242" LOG_CI_START="-0.3909379707450186" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-09-24 16:37:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24537" O_E="0.0" SE="0.5305862221453124" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.28152173913043477" WEIGHT="3.8467616519281984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7644978917805312" CI_END="1.3431289115132" CI_START="0.8459561171489929" DF="1" EFFECT_SIZE="1.065940016517937" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="280" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.12811769760694713" LOG_CI_START="-0.07265216482662698" LOG_EFFECT_SIZE="0.02773276639016003" MODIFIED="2013-12-18 09:49:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.38192461159450763" P_Z="0.588185082367943" STUDIES="2" TAU2="0.0" TOTAL_1="284" TOTAL_2="1222" WEIGHT="77.86368758212906" Z="0.5414679539799993">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.3732376186834294" CI_START="0.8585646143272961" EFFECT_SIZE="1.085823754789272" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="275" LOG_CI_END="0.13774569204678755" LOG_CI_START="-0.06622701490046629" LOG_EFFECT_SIZE="0.03575933857316061" MODIFIED="2013-12-11 14:45:39 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1198145777420002" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.014355533039493811" WEIGHT="75.4376049493789"/>
<DICH_DATA CI_END="2.222548430727091" CI_START="0.16197622289032795" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34685123329505907" LOG_CI_START="-0.7905487325277719" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-12-18 09:49:08 +0000" MODIFIED_BY="[Empty name]" ORDER="927" O_E="0.0" SE="0.6681143701449648" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.44637681159420295" WEIGHT="2.4260826327501706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.465605836098113" CI_END="1.1743583680774172" CI_START="0.918643705453764" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0386611202799851" ESTIMABLE="YES" EVENTS_1="409" EVENTS_2="494" I2="28.780019925877404" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.06980064676585676" LOG_CI_START="-0.036852896403540523" LOG_EFFECT_SIZE="0.016473875181158112" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12878394391213266" P_Q="0.5657151479367919" P_Z="0.5448612541005802" Q="0.3299050591077216" RANDOM="YES" SCALE="121.56333741221304" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.015640674109450522" TOTALS="YES" TOTAL_1="815" TOTAL_2="1035" WEIGHT="100.0" Z="0.6054782819469013">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.170182014771147" CI_END="1.1726477584395083" CI_START="0.9044964103182677" DF="15" EFFECT_SIZE="1.0298813951500911" ESTIMABLE="YES" EVENTS_1="394" EVENTS_2="482" I2="32.34155682616375" ID="CMP-002.04.01" LOG_CI_END="0.06916757772561027" LOG_CI_START="-0.04359315238853639" LOG_EFFECT_SIZE="0.01278721266853691" MODIFIED="2014-02-21 16:07:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10341865346119938" P_Z="0.656663129842169" STUDIES="16" TAU2="0.018146279064744777" TOTAL_1="791" TOTAL_2="1012" WEIGHT="95.12412181463307" Z="0.4445249027319386">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2400078608277645" CI_START="0.516125760342172" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.0934244383100579" LOG_CI_START="-0.2872444643261707" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-02-21 15:10:57 +0000" MODIFIED_BY="[Empty name]" ORDER="24538" O_E="0.0" SE="0.22360679774997896" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.05" WEIGHT="5.979333089674549"/>
<DICH_DATA CI_END="2.0787452782845226" CI_START="0.21380418711580704" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.31780127576104245" LOG_CI_START="-0.6699837938724049" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-01-07 11:48:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.5802298395176404" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.33666666666666667" WEIGHT="1.1140484721849646"/>
<DICH_DATA CI_END="0.47401233947198856" CI_START="0.03296327689993259" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="24539" O_E="0.0" SE="0.6800735254367721" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.46249999999999997" WEIGHT="0.8208618843443912"/>
<DICH_DATA CI_END="1.8242864964537722" CI_START="0.39777281633889333" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.26109304345420076" LOG_CI_START="-0.4003648997369896" LOG_EFFECT_SIZE="-0.06963592814139442" MODIFIED="2014-02-21 15:11:04 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.38854367010013074" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.15096618357487923" WEIGHT="2.3557701056629226"/>
<DICH_DATA CI_END="2.1191914188911776" CI_START="0.788585625544659" EFFECT_SIZE="1.2927350427350428" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3261701867313436" LOG_CI_START="-0.10315114357465391" LOG_EFFECT_SIZE="0.11150952157834487" MODIFIED="2014-02-21 15:11:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24542" O_E="0.0" SE="0.2521854745966024" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.06359751359751359" WEIGHT="4.953261376732446"/>
<DICH_DATA CI_END="1.470785059927998" CI_START="0.6524407901207728" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.16754920970390677" LOG_CI_START="-0.18545889500975965" LOG_EFFECT_SIZE="-0.008954842652926454" ORDER="24543" O_E="0.0" SE="0.20735870812710797" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.04299763383614315" WEIGHT="6.693362555675077"/>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="24544" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="5.180687650064863"/>
<DICH_DATA CI_END="1.834683253016549" CI_START="0.9273117027805688" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.26356109674016964" LOG_CI_START="-0.03277425933603051" LOG_EFFECT_SIZE="0.11539341870206957" ORDER="24545" O_E="0.0" SE="0.1740688550428301" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0302999662959218" WEIGHT="8.54336054673899"/>
<DICH_DATA CI_END="1.6412032187611698" CI_START="0.6751346989397249" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.21516236004289102" LOG_CI_START="-0.1706095706205866" LOG_EFFECT_SIZE="0.022276394711152208" ORDER="24546" O_E="0.0" SE="0.2266043416735812" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.051349527665317134" WEIGHT="5.858878527501529"/>
<DICH_DATA CI_END="1.3148084479691893" CI_START="0.6404553650899624" EFFECT_SIZE="0.9176470588235294" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.1188624858679191" LOG_CI_START="-0.19351113191554384" LOG_EFFECT_SIZE="-0.03732432302381235" ORDER="24547" O_E="0.0" SE="0.18348980936035214" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.03366851013909837" WEIGHT="7.959723137028603"/>
<DICH_DATA CI_END="1.1704617929798724" CI_START="0.8936396562909013" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="110" LOG_CI_END="0.06835724172437309" LOG_CI_START="-0.04883756714606064" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2014-02-21 15:11:32 +0000" MODIFIED_BY="[Empty name]" ORDER="1298" O_E="0.0" SE="0.06884081085415278" STUDY_ID="STD-Kane-2003" TOTAL_1="144" TOTAL_2="150" VAR="0.004739057239057238" WEIGHT="19.25871582992774"/>
<DICH_DATA CI_END="1.3322267045749063" CI_START="0.8651518058393982" EFFECT_SIZE="1.0735820132856413" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="103" LOG_CI_END="0.124578134870521" LOG_CI_START="-0.06290768137461825" LOG_EFFECT_SIZE="0.030835226747951413" ORDER="24548" O_E="0.0" SE="0.11013009653215294" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.012128638162181326" WEIGHT="14.133855779069199"/>
<DICH_DATA CI_END="1.1994138338466247" CI_START="0.2245201557490894" EFFECT_SIZE="0.5189340813464236" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="46" LOG_CI_END="0.07896905361348729" LOG_CI_START="-0.6487446651832283" LOG_EFFECT_SIZE="-0.28488780578487055" MODIFIED="2014-02-21 16:07:27 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.42746264066219497" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="148" VAR="0.1827243091618968" WEIGHT="1.978612597135099"/>
<DICH_DATA CI_END="15.180224957567825" CI_START="0.06587517660609293" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-10 16:26:22 +0000" MODIFIED_BY="[Empty name]" ORDER="24549" O_E="0.0" SE="1.387777332977422" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="1.925925925925926" WEIGHT="0.20214987975381818"/>
<DICH_DATA CI_END="1.5513490368040692" CI_START="0.787447968972911" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" LOG_CI_END="0.19070952038242597" LOG_CI_START="-0.10377813282024533" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="24550" O_E="0.0" SE="0.17298350522864256" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.02992329308118781" WEIGHT="8.613987739237558"/>
<DICH_DATA CI_END="6.661020653882245" CI_START="0.9382946435329412" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8235407802794655" LOG_CI_START="-0.027660762935390337" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="24551" O_E="0.0" SE="0.5" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.25" WEIGHT="1.477512643901312"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9733276554268837" CI_START="0.7272002377969754" DF="0" EFFECT_SIZE="1.1979166666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.29519920239836506" LOG_CI_START="-0.13834598777027854" LOG_EFFECT_SIZE="0.0784266073140433" MODIFIED="2014-02-21 15:11:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4782627756259622" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="4.875878185366923" Z="0.7090994399241192">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.9733276554268837" CI_START="0.7272002377969754" EFFECT_SIZE="1.1979166666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.29519920239836506" LOG_CI_START="-0.13834598777027854" LOG_EFFECT_SIZE="0.0784266073140433" MODIFIED="2014-02-21 15:11:25 +0000" MODIFIED_BY="[Empty name]" ORDER="24552" O_E="0.0" SE="0.2546665907883642" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.06485507246376812" WEIGHT="4.875878185366923"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.15595896455766411" CI_START="-0.5559589645576645" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2015-01-14 16:38:24 +0000" MODIFIED_BY="Heather Maxwell" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2707964554189738" Q="0.0" RANDOM="YES" SCALE="3.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="1.1012302988214517">
<NAME>Global state: 2. Average endpoint score (CGI-S, high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15595896455766411" CI_START="-0.5559589645576645" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" MODIFIED="2013-12-17 15:51:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2707964554189738" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0" Z="1.1012302988214517">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.15595896455766411" CI_START="-0.5559589645576645" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.7" MODIFIED="2013-12-17 15:51:59 +0000" MODIFIED_BY="[Empty name]" ORDER="1315" SD_1="1.21" SD_2="1.85" SE="0.18161505383028625" STUDY_ID="STD-Kane-2003" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.25266084960863" CI_END="2.5153835157985904" CI_START="0.6084461021692934" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2371237996451874" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" I2="42.88608981439328" I2_Q="56.788672686246656" ID="CMP-002.06" LOG_CI_END="0.4006042105040543" LOG_CI_START="-0.21577788673084894" LOG_EFFECT_SIZE="0.0924131618866027" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.15420387248758338" P_Q="0.09884460541884055" P_Z="0.5567280373514749" Q="4.628416029616933" RANDOM="YES" SCALE="47.22" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23208788773503933" TOTALS="YES" TOTAL_1="165" TOTAL_2="218" WEIGHT="100.0" Z="0.5877084029784324">
<NAME>Mental state: 2a. State - BPRS score reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.084940216223805" CI_START="0.6101353379980785" DF="0" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2014-01-13 16:01:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16009090857711306" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="51.682195326575666" Z="1.404765878729659">
<NAME>less than 20% reduction - short term</NAME>
<DICH_DATA CI_END="1.084940216223805" CI_START="0.6101353379980785" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2013-09-24 16:43:20 +0100" MODIFIED_BY="[Empty name]" ORDER="24554" O_E="0.0" SE="0.1468392711837387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02156177156177156" WEIGHT="51.682195326575666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005860200521136167" CI_END="4.119434574456482" CI_START="0.46290533240481646" DF="1" EFFECT_SIZE="1.3809084803160097" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.6148376097114524" LOG_CI_START="-0.33450781636420057" LOG_EFFECT_SIZE="0.14016489667362586" MODIFIED="2014-01-14 11:56:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9389799879255628" P_Z="0.5627560039534563" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="64" WEIGHT="30.469737355291763" Z="0.5787527739248676">
<NAME>less than 25% reduction - short term</NAME>
<DICH_DATA CI_END="5.485807156947744" CI_START="0.32406858770568187" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7392405367454522" LOG_CI_START="-0.48936306352885245" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-01-13 16:10:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1334" O_E="0.0" SE="0.7216878364870322" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5208333333333333" WEIGHT="17.411079498723158"/>
<DICH_DATA CI_END="8.137979643885442" CI_START="0.2599788365074738" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9105165991865608" LOG_CI_START="-0.5850620041911614" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-01-14 11:56:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1092" O_E="0.0" SE="0.8785102748575585" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" VAR="0.771780303030303" WEIGHT="13.058657856568605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.790350081623671" CI_START="0.8568604988314221" DF="0" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="1.139575291309101" LOG_CI_START="-0.06708987763246291" LOG_EFFECT_SIZE="0.536242706838319" MODIFIED="2014-01-13 16:02:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.08150524526556431" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="17.848067318132564" Z="1.7420182821673444">
<NAME>less than 30% reduction - short term</NAME>
<DICH_DATA CI_END="13.790350081623671" CI_START="0.8568604988314221" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.139575291309101" LOG_CI_START="-0.06708987763246291" LOG_EFFECT_SIZE="0.5362427068383191" MODIFIED="2014-01-13 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.7088010933251937" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.5023989898989899" WEIGHT="17.848067318132564"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.455967714722556" CI_START="-1.2559677147225532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2015-01-14 16:38:39 +0000" MODIFIED_BY="Heather Maxwell" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.360135953280884" Q="0.0" RANDOM="YES" SCALE="10.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" UNITS="" WEIGHT="100.0" Z="0.9151060812596723">
<NAME>Mental state: 2b. State - BPRS total score (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.455967714722556" CI_START="-1.2559677147225532" DF="0" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2014-01-14 10:35:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.360135953280884" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.9151060812596723">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.455967714722556" CI_START="-1.2559677147225532" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="24.92" MEAN_2="23.82" MODIFIED="2014-01-14 10:35:35 +0000" MODIFIED_BY="[Empty name]" ORDER="1072" SD_1="4.98" SD_2="4.63" SE="1.2020464321314714" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.08" MODIFIED="2015-01-14 16:38:51 +0000" MODIFIED_BY="Heather Maxwell" NO="8" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2c. State - BPRS end score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Subgroup</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.08.01" MODIFIED="2013-09-24 16:47:36 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>medium term</NAME>
<OTHER_DATA ORDER="2597" STUDY_ID="STD-Lepola-1989">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>Acute schizophrenia</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>23.8</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>Chronic schizophrenia</P>
</TD>
<TD>
<P>30.5</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulpiride</P>
</TD>
<TD>
<P>Acute schizophrenia</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>6.3</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulpiride</P>
</TD>
<TD>
<P>Chronic schizophrenia</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.09" MODIFIED="2015-01-14 16:39:03 +0000" MODIFIED_BY="Heather Maxwell" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2c. State - BPRS end score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention:</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.09.01" MODIFIED="2013-12-18 10:47:15 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>long term</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:47:15 +0000" MODIFIED_BY="[Empty name]" ORDER="2598" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine</P>
</TD>
<TD>
<P>11.7</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="1.7331335978116673" CI_END="1.1974542627251816" CI_START="0.673242194707129" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8978734520512945" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.07825893434095367" LOG_CI_START="-0.1718286729187147" LOG_EFFECT_SIZE="-0.04678486928888051" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4203927153031002" P_Q="0.45857305434743445" P_Z="0.4633655441818463" Q="1.5592719689556191" RANDOM="YES" SCALE="34.44" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="119" WEIGHT="100.0" Z="0.7333162952965544">
<NAME>Mental state: 2d. State - PANSS score reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1540465647134452" CI_START="0.6372860624161332" DF="0" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2014-01-13 16:02:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.31050387460315276" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="94.04138198221942" Z="1.014165347296331">
<NAME>less than 20% reduction - short term</NAME>
<DICH_DATA CI_END="1.1540465647134452" CI_START="0.6372860624161332" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2013-09-24 16:45:25 +0100" MODIFIED_BY="[Empty name]" ORDER="24556" O_E="0.0" SE="0.15148522352946822" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02294777294777295" WEIGHT="94.04138198221942"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.108042421948712" CI_START="0.39572449669526094" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="1.0046670559209654" LOG_CI_START="-0.402607064593003" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-13 16:03:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4017433540090516" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.158107728911352" Z="0.8385117599578504">
<NAME>less than 25% reduction - short term</NAME>
<DICH_DATA CI_END="10.108042421948712" CI_START="0.39572449669526094" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0046670559209654" LOG_CI_START="-0.402607064593003" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-13 16:03:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1043" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" VAR="0.6833333333333333" WEIGHT="3.158107728911352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.498619566602862" CI_START="0.3042547372000492" DF="0" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="0.9776604939026794" LOG_CI_START="-0.5167626511461317" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2014-01-13 16:03:34 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5455271140520102" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="2.8005102888692273" Z="0.6044761655009926">
<NAME>less than 40% reduction - short term</NAME>
<DICH_DATA CI_END="9.498619566602862" CI_START="0.3042547372000492" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9776604939026794" LOG_CI_START="-0.5167626511461317" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2014-01-13 16:03:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="0.8778315529155452" STUDY_ID="STD-Wang-2008a" TOTAL_1="30" TOTAL_2="34" VAR="0.7705882352941176" WEIGHT="2.8005102888692273"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="272.8220876357629" CI_END="0.3215529862262957" CI_START="-0.4087758380383434" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04361142590602387" ESTIMABLE="YES" I2="97.43422533686294" I2_Q="88.19067529962346" ID="CMP-002.11" MODIFIED="2015-01-14 16:39:25 +0000" MODIFIED_BY="Heather Maxwell" NO="11" P_CHI2="-3.1086244689504383E-15" P_Q="1.2712871873432618E-5" P_Z="0.814924704036167" Q="25.403654113298686" RANDOM="YES" SCALE="14.73" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.286636478996131" TOTALS="SUB" TOTAL_1="271" TOTAL_2="271" UNITS="" WEIGHT="400.0" Z="0.23407764078409382">
<NAME>Mental state: 2e. State - PANSS: mean change/ endpoint from baseline (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.5076430624844035" CI_END="5.434633651594315" CI_START="1.863683743369246" DF="2" EFFECT_SIZE="3.6491586974817807" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.01" MODIFIED="2014-01-14 11:57:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47056494422484374" P_Z="6.181319716890326E-5" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="117" WEIGHT="100.0" Z="4.005779865162195">
<NAME>total - short term</NAME>
<CONT_DATA CI_END="13.035065793456791" CI_START="-5.035065793456791" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-24.0" ORDER="24557" SD_1="21.63" SD_2="25.96" SE="4.609812152021281" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" WEIGHT="3.9052144359924923"/>
<CONT_DATA CI_END="6.250484733506245" CI_START="2.1695152664937494" EFFECT_SIZE="4.209999999999997" ESTIMABLE="YES" MEAN_1="27.65" MEAN_2="23.44" MODIFIED="2014-01-13 13:26:47 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="3.9" SD_2="4.16" SE="1.041082769684204" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="76.56685792433848"/>
<CONT_DATA CI_END="5.42041229409021" CI_START="-2.6604122940902046" EFFECT_SIZE="1.3800000000000026" ESTIMABLE="YES" MEAN_1="47.25" MEAN_2="45.87" MODIFIED="2014-01-14 11:57:56 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="8.47" SD_2="8.15" SE="2.061472723968636" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="19.527927639669024"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="74.07219579187714" CI_END="11.896811285463759" CI_START="-2.9987279820347297" DF="1" EFFECT_SIZE="4.449041651714515" ESTIMABLE="YES" I2="98.64996576743894" ID="CMP-002.11.02" MODIFIED="2014-01-14 11:58:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-2.220446049250313E-16" P_Z="0.2416731136381728" STUDIES="2" TAU2="28.490110113636366" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="1.1708151341798918">
<NAME>positive - short term</NAME>
<CONT_DATA CI_END="9.200475792553485" CI_START="7.259524207446516" EFFECT_SIZE="8.23" ESTIMABLE="YES" MEAN_1="20.37" MEAN_2="12.14" MODIFIED="2014-01-13 13:28:05 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="1.64" SD_2="2.16" SE="0.49514980898040684" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="50.250548048875174"/>
<CONT_DATA CI_END="2.063062672115121" CI_START="-0.8030626721151193" EFFECT_SIZE="0.6300000000000008" ESTIMABLE="YES" MEAN_1="10.08" MEAN_2="9.45" MODIFIED="2014-01-14 11:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="3.11" SD_2="2.78" SE="0.7311678599295373" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="49.749451951124826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.473548991842435" CI_END="2.3263766154773506" CI_START="0.06708883906810414" DF="1" EFFECT_SIZE="1.1967327272727275" ESTIMABLE="YES" I2="32.1366303030304" ID="CMP-002.11.03" MODIFIED="2014-01-14 11:58:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.22478690046429306" P_Z="0.037860204728606704" STUDIES="2" TAU2="0.25106742424242534" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="2.0763650111919767">
<NAME>negative - short term</NAME>
<CONT_DATA CI_END="2.5159041806894233" CI_START="0.6440958193105787" EFFECT_SIZE="1.580000000000001" ESTIMABLE="YES" MEAN_1="9.13" MEAN_2="7.55" MODIFIED="2014-01-13 13:28:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="2.17" SD_2="1.46" SE="0.4775109073797861" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="69.33861818181815"/>
<CONT_DATA CI_END="2.118136580077876" CI_START="-1.4581365800778763" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" MEAN_1="11.97" MEAN_2="11.64" MODIFIED="2014-01-14 11:58:20 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="3.59" SD_2="3.76" SE="0.9123313459749615" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="30.661381818181848"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.005780097838648746" CI_START="-0.7857800978386499" DF="0" EFFECT_SIZE="-0.39000000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.04" MODIFIED="2014-01-13 13:28:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.05344101363327524" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="1.9313400500553852">
<NAME>general psychopathology - short term</NAME>
<CONT_DATA CI_END="0.005780097838648746" CI_START="-0.7857800978386499" EFFECT_SIZE="-0.39000000000000057" ESTIMABLE="YES" MEAN_1="16.95" MEAN_2="17.34" MODIFIED="2014-01-13 13:28:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="0.28" SD_2="1.07" SE="0.20193233190023502" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.12" MODIFIED="2015-01-14 16:39:40 +0000" MODIFIED_BY="Heather Maxwell" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2f. State - PANSS total change score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.12.01" MODIFIED="2013-12-17 15:56:16 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2013-12-17 15:56:16 +0000" MODIFIED_BY="[Empty name]" ORDER="2610" STUDY_ID="STD-Kane-2003">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>-10.5</P>
</TD>
<TD>
<P>21.24</P>
</TD>
<TD>
<P>144</P>
</TD>
</TR>
<TR>
<TD>
<P>Aripiprazole</P>
</TD>
<TD>
<P>-9.8</P>
</TD>
<TD>
<P>21.07</P>
</TD>
<TD>
<P>150</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.13" MODIFIED="2015-01-14 16:39:52 +0000" MODIFIED_BY="Heather Maxwell" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2g. State - PANSS total endpoint score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.13.01" MODIFIED="2013-12-18 10:35:55 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>long term</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:35:55 +0000" MODIFIED_BY="[Empty name]" ORDER="2611" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>54.5</P>
</TD>
<TD>
<P>23.9</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine</P>
</TD>
<TD>
<P>53.7</P>
</TD>
<TD>
<P>23.9</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="1.8513984983122187" CI_END="1.2346781834245373" CI_START="0.8575535440991889" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0289813662149865" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.09155377429541688" LOG_CI_START="-0.06673875387313931" LOG_EFFECT_SIZE="0.01240751021113872" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.3962542967883985" P_Q="1.0" P_Z="0.7586474795102618" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="122" WEIGHT="100.0" Z="0.30725737257477964">
<NAME>Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3383479077117193" CI_START="0.6908190371803543" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.1265690243129547" LOG_CI_START="-0.16063570291051535" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="24558" O_E="0.0" SE="0.1687054784573947" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.02846153846153847" WEIGHT="30.376495140162643"/>
<DICH_DATA CI_END="1.5496623088792512" CI_START="0.896344064307452" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.19023707019066347" LOG_CI_START="-0.04752525311932696" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2013-09-26 14:35:45 +0100" MODIFIED_BY="[Empty name]" ORDER="24559" O_E="0.0" SE="0.13966276565477026" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.019505688110339273" WEIGHT="44.323572686482244"/>
<DICH_DATA CI_END="1.2642533680032177" CI_START="0.6125354455041714" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.10183411927769989" LOG_CI_START="-0.2128687749773626" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="24560" O_E="0.0" SE="0.1848580378898742" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.03417249417249417" WEIGHT="25.299932173355113"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="109.06581472448133" CI_END="1.2075557936216266" CI_START="0.9765708902435162" CI_STUDY="95" CI_TOTAL="95" DF="65" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0859391494903328" ESTIMABLE="YES" EVENTS_1="721" EVENTS_2="1024" I2="40.40295745811739" I2_Q="7.44011299467404" ID="CMP-002.15" LOG_CI_END="0.08190720592641576" LOG_CI_START="-0.010296225367304785" LOG_EFFECT_SIZE="0.03580549027955544" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="5.110003150836651E-4" P_Q="0.360835776385962" P_Z="0.12795115208317395" Q="22.688013868028648" RANDOM="YES" SCALE="481.5572857651611" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07948248581172457" TOTALS="SUB" TOTAL_1="3940" TOTAL_2="8011" WEIGHT="2200.0" Z="1.5222312317894646">
<NAME>Adverse events: Extrapyramidal and movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.739587381192493" CI_END="1.5787135621073958" CI_START="0.7904625754943744" DF="10" EFFECT_SIZE="1.117100706414292" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="164" I2="54.00096687827999" ID="CMP-002.15.01" LOG_CI_END="0.19830333983682333" LOG_CI_START="-0.10211868694749747" LOG_EFFECT_SIZE="0.048092326444662936" MODIFIED="2014-01-14 10:22:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.016487632827179466" P_Z="0.5303236137542953" STUDIES="11" TAU2="0.16162416557618817" TOTAL_1="657" TOTAL_2="1079" WEIGHT="100.00000000000001" Z="0.6275120953894182">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="3.085766525783107" CI_START="0.1822885805844461" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48936306352885245" LOG_CI_START="-0.7392405367454522" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-06-20 13:59:19 +0100" MODIFIED_BY="[Empty name]" ORDER="24561" O_E="0.0" SE="0.7216878364870322" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.5208333333333333" WEIGHT="4.563133106469092"/>
<DICH_DATA CI_END="7.57862723740502" CI_START="1.385373620191788" EFFECT_SIZE="3.240251572327044" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.8795905463692779" LOG_CI_START="0.14156691369333055" LOG_EFFECT_SIZE="0.5105787300313043" ORDER="24562" O_E="0.0" SE="0.43351873510975253" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="0.18793849369115978" WEIGHT="8.908687253836263"/>
<DICH_DATA CI_END="3.4884205615906234" CI_START="0.7569686491000236" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.542628837661829" LOG_CI_START="-0.12092210703204267" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24563" O_E="0.0" SE="0.3897731095433303" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.15192307692307694" WEIGHT="9.93197829523068"/>
<DICH_DATA CI_END="1.338840115547728" CI_START="0.25415863614048345" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.12672871660776514" LOG_CI_START="-0.594895128674501" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24564" O_E="0.0" SE="0.42388541881444736" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.17967884828349945" WEIGHT="9.124280421128601"/>
<DICH_DATA CI_END="4.309170813995455" CI_START="0.3625987614427503" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6343937097080784" LOG_CI_START="-0.4405736836919656" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24565" O_E="0.0" SE="0.631441168057602" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.3987179487179487" WEIGHT="5.557576929506754"/>
<DICH_DATA CI_END="1.1123540847331723" CI_START="0.3936988517973635" EFFECT_SIZE="0.6617647058823529" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="0.04624305394386099" LOG_CI_START="-0.4048358518056462" LOG_EFFECT_SIZE="-0.17929639893089266" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24566" O_E="0.0" SE="0.26496598211385536" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.07020697167755992" WEIGHT="13.432813399968705"/>
<DICH_DATA CI_END="5.853302320116343" CI_START="0.8923166119380715" EFFECT_SIZE="2.2853881278538815" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7674009557847004" LOG_CI_START="-0.04948102183426212" LOG_EFFECT_SIZE="0.35895996697521915" MODIFIED="2013-12-17 15:41:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1307" O_E="0.0" SE="0.47984051728438265" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.23024692202774394" WEIGHT="7.946859325788351"/>
<DICH_DATA CI_END="1.219221073457863" CI_START="0.47874500589508795" EFFECT_SIZE="0.764" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="50" LOG_CI_END="0.08608246056325008" LOG_CI_START="-0.31989574341187016" LOG_EFFECT_SIZE="-0.11690664142431006" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24567" O_E="0.0" SE="0.23847360663950612" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.056869661063653903" WEIGHT="14.252779837873328"/>
<DICH_DATA CI_END="2.7083055637046884" CI_START="0.4822655414084622" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.432697661912795" LOG_CI_START="-0.31671376795742145" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2013-10-07 16:40:15 +0100" MODIFIED_BY="[Empty name]" ORDER="24569" O_E="0.0" SE="0.4402079835521714" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.19378306878306878" WEIGHT="8.76218632028254"/>
<DICH_DATA CI_END="1.2907424487566335" CI_START="0.5577615726529009" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" LOG_CI_END="0.11083959296937186" LOG_CI_START="-0.25355141004070836" LOG_EFFECT_SIZE="-0.07135590853566824" MODIFIED="2013-09-26 12:13:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24570" O_E="0.0" SE="0.2140450789326767" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.04581529581529581" WEIGHT="15.012304728052946"/>
<DICH_DATA CI_END="53.683260158384115" CI_START="0.9127612565897287" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:22:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1075" O_E="0.0" SE="1.0394023007753748" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0803571428571428" WEIGHT="2.50740038186275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.815733993467754" CI_START="0.6449591575646803" DF="0" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="1.1077434845104472" LOG_CI_START="-0.1904677864591487" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-10-04 11:09:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16609846722492633" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3848495790146993">
<NAME>akathisia - medium term</NAME>
<DICH_DATA CI_END="12.815733993467754" CI_START="0.6449591575646803" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1077434845104472" LOG_CI_START="-0.1904677864591487" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-10-04 11:09:19 +0100" MODIFIED_BY="[Empty name]" ORDER="24568" O_E="0.0" SE="0.7625757268169732" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.5815217391304348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40008550875366405" CI_END="1.8492862285555165" CI_START="0.6516733476759615" DF="1" EFFECT_SIZE="1.09778438109395" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="65" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="0.2670041355300248" LOG_CI_START="-0.18597004054184807" LOG_EFFECT_SIZE="0.0405170474940884" MODIFIED="2014-02-27 11:29:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5270455202324844" P_Z="0.7258699688483232" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="1075" WEIGHT="100.0" Z="0.35062464062283266">
<NAME>akathisia - long term</NAME>
<DICH_DATA CI_END="1.8110830866622782" CI_START="0.6290329177218836" EFFECT_SIZE="1.067347590169167" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="65" LOG_CI_END="0.25793837480396664" LOG_CI_START="-0.20132662703341941" LOG_EFFECT_SIZE="0.028305873885273624" MODIFIED="2014-02-27 11:29:46 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.26977453547770464" STUDY_ID="STD-CATIE-2005" TOTAL_1="241" TOTAL_2="1045" VAR="0.07277829999221133" WEIGHT="97.27924350851946"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:52:52 +0000" MODIFIED_BY="[Empty name]" ORDER="935" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="2.7207564914805444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.67091086005631" CI_END="1.7036258292423847" CI_START="0.11449955418534304" DF="1" EFFECT_SIZE="0.4416609536136157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-002.15.04" LOG_CI_END="0.23137421593587587" LOG_CI_START="-0.9411962042867342" LOG_EFFECT_SIZE="-0.3549109941754292" MODIFIED="2013-12-11 15:14:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4127345499845978" P_Z="0.23543477522347234" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="395" WEIGHT="100.0" Z="1.1864750369007013">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="28.08622788771953" CI_START="0.06650155318986244" EFFECT_SIZE="1.3666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="1.4484934153299838" LOG_CI_START="-1.1771682113298376" LOG_EFFECT_SIZE="0.13566260200007307" MODIFIED="2013-09-17 13:06:01 +0100" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="1.5423266367346478" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="2.3787714543812104" WEIGHT="19.943453014319154"/>
<DICH_DATA CI_END="1.5070719917963586" CI_START="0.07372647870568672" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-10-07 16:39:21 +0100" MODIFIED_BY="[Empty name]" ORDER="24572" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="80.05654698568084"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5116910412213125" CI_END="2.4059448840503994" CI_START="0.24771863497643304" DF="2" EFFECT_SIZE="0.7720086673771852" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-002.15.05" LOG_CI_END="0.3812856741979463" LOG_CI_START="-0.6060413217830708" LOG_EFFECT_SIZE="-0.11237782379256224" MODIFIED="2013-12-11 15:14:58 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7742615783942062" P_Z="0.6554764363157972" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="305" WEIGHT="99.99999999999999" Z="0.4461672539917975">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" ORDER="24573" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="17.360231674424558"/>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" ORDER="24574" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="54.23716130158111"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24575" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3934409014383853" CI_START="0.047647401960277086" EFFECT_SIZE="0.40210526315789474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.5306402901260736" LOG_CI_START="-1.3219607748803517" LOG_EFFECT_SIZE="-0.39566024237713904" ORDER="24576" O_E="0.0" SE="1.0882270361079462" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="1.1842380821162855" WEIGHT="28.402607023994328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.309439245381109" CI_END="1.0387038975973901" CI_START="0.3881395068834236" DF="6" EFFECT_SIZE="0.6349504064187541" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="64" I2="17.91435979454311" ID="CMP-002.15.06" LOG_CI_END="0.016491761255817458" LOG_CI_START="-0.4110121502302456" LOG_EFFECT_SIZE="-0.19726019448721413" MODIFIED="2013-12-11 15:14:58 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2931759700752936" P_Z="0.07049055893313673" STUDIES="8" TAU2="0.07864105981575509" TOTAL_1="435" TOTAL_2="847" WEIGHT="99.99999999999997" Z="1.8087454471906526">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="13.955070317876341" CI_START="0.5527539460147356" EFFECT_SIZE="2.7773584905660376" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="1.1447320291864367" LOG_CI_START="-0.25746814838505466" LOG_EFFECT_SIZE="0.443631940400691" ORDER="24577" O_E="0.0" SE="0.823659325308316" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="0.6784146841673503" WEIGHT="8.329664905803968"/>
<DICH_DATA CI_END="1.5124577344609882" CI_START="0.20406651258829142" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17968324716130687" LOG_CI_START="-0.690228257367919" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="24578" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.26111111111111107" WEIGHT="18.56064861981647"/>
<DICH_DATA CI_END="8.533600678381148" CI_START="0.26366361455137033" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9311323166070647" LOG_CI_START="-0.5789497984957024" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="24579" O_E="0.0" SE="0.887029709438391" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.7868217054263564" WEIGHT="7.286299209682683"/>
<DICH_DATA CI_END="1.6343045942797216" CI_START="0.02447524172666784" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21333300157640056" LOG_CI_START="-1.6112730102484383" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="24580" O_E="0.0" SE="1.071782603291334" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.1487179487179489" WEIGHT="5.137877848737215"/>
<DICH_DATA CI_END="2.047090436051094" CI_START="0.3312998195379166" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3111370292821347" LOG_CI_START="-0.4797788006822065" LOG_EFFECT_SIZE="-0.08432088570003593" ORDER="24581" O_E="0.0" SE="0.4645878736175542" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.21584189231248055" WEIGHT="21.413873423977922"/>
<DICH_DATA CI_END="1.2978232835183237" CI_START="0.19466325451508032" EFFECT_SIZE="0.5026315789473684" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="0.11321556132591026" LOG_CI_START="-0.7107160200640754" LOG_EFFECT_SIZE="-0.29875022936908263" ORDER="24582" O_E="0.0" SE="0.4839814894355831" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.23423808211628547" WEIGHT="20.15481320823584"/>
<DICH_DATA CI_END="0.9538619065120527" CI_START="0.1337206355944896" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.020514494877505427" LOG_CI_START="-0.8738015678069329" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="24585" O_E="0.0" SE="0.5012250504778779" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.25122655122655124" WEIGHT="19.116822783745885"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24584" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.931409775025128" CI_START="0.046558835083477614" DF="0" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.15.07" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-12-11 15:14:58 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5362372749139819" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6185129387560958">
<NAME>dyskinesia - medium term</NAME>
<DICH_DATA CI_END="4.931409775025128" CI_START="0.046558835083477614" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-09-26 12:14:23 +0100" MODIFIED_BY="[Empty name]" ORDER="24583" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.483528847839828" CI_END="8.155938001576947" CI_START="0.22674026065633077" DF="3" EFFECT_SIZE="1.3598821670918515" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" I2="53.728901800143376" ID="CMP-002.15.08" LOG_CI_END="0.9114739157726843" LOG_CI_START="-0.6444713584423027" LOG_EFFECT_SIZE="0.13350127866519082" MODIFIED="2014-01-14 10:32:41 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.09031450343005143" P_Z="0.736619935637762" STUDIES="4" TAU2="1.7543440628527334" TOTAL_1="207" TOTAL_2="209" WEIGHT="100.0" Z="0.33633277777823173">
<NAME>dystonia - short term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-07-18 14:57:23 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="21.103042544343115"/>
<DICH_DATA CI_END="9.040130215485474" CI_START="0.6737481351752448" EFFECT_SIZE="2.467948717948718" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9561746861677867" LOG_CI_START="-0.17150242385970835" LOG_EFFECT_SIZE="0.3923361311540391" MODIFIED="2013-09-25 10:43:27 +0100" MODIFIED_BY="[Empty name]" ORDER="24587" O_E="0.0" SE="0.662403116521872" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.43877788877788876" WEIGHT="38.089130432627364"/>
<DICH_DATA CI_END="8.084677692131924" CI_START="0.013743418766000442" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9076627107830841" LOG_CI_START="-1.8619052202224093" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24588" O_E="0.0" SE="1.6268579122549907" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="2.646666666666667" WEIGHT="18.980664489186356"/>
<DICH_DATA CI_END="252.09458335193415" CI_START="0.8925221518381102" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.401563514277644" LOG_CI_START="-0.049380996166281346" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2014-01-14 10:32:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1082" O_E="0.0" SE="1.4396969378057567" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="2.0727272727272728" WEIGHT="21.827162533843165"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3094590501815557" CI_START="0.6212743012674088" DF="0" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-002.15.09" LOG_CI_END="0.11709192157892168" LOG_CI_START="-0.20671661041164627" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2013-12-11 15:16:55 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.58748467275381" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5424846626427561">
<NAME>extrapyramidal signs - short term</NAME>
<DICH_DATA CI_END="1.3094590501815557" CI_START="0.6212743012674088" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.11709192157892168" LOG_CI_START="-0.20671661041164627" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2013-07-18 14:55:52 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.19020673456934384" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.03617860187553282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6127781070571836" CI_END="5.671290469899933" CI_START="0.8782635458176016" DF="2" EFFECT_SIZE="2.2317902404697194" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" I2="23.453124679897368" ID="CMP-002.15.10" LOG_CI_END="0.7536818913777124" LOG_CI_START="-0.0563751431829963" LOG_EFFECT_SIZE="0.348653374097358" MODIFIED="2014-01-14 11:57:05 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.2707962672011093" P_Z="0.09157252256422017" STUDIES="3" TAU2="0.1670400349707263" TOTAL_1="209" TOTAL_2="220" WEIGHT="100.0" Z="1.6871603533194905">
<NAME>EPS - short term</NAME>
<DICH_DATA CI_END="5.532549360782344" CI_START="0.6515615427899005" EFFECT_SIZE="1.8986301369863015" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7429252973430397" LOG_CI_START="-0.18604455703237555" LOG_EFFECT_SIZE="0.2784403701553321" MODIFIED="2013-12-17 15:42:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1308" O_E="0.0" SE="0.5456814909350614" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.29776828954911144" WEIGHT="48.711612038482336"/>
<DICH_DATA CI_END="68.35100615687038" CI_START="1.202680824562837" EFFECT_SIZE="9.066666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8347449119566652" LOG_CI_START="0.08015038667240712" LOG_EFFECT_SIZE="0.9574476493145363" MODIFIED="2014-01-13 11:23:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1041" O_E="0.0" SE="1.0306575095349495" STUDY_ID="STD-Wang-2008a" TOTAL_1="30" TOTAL_2="34" VAR="1.0622549019607843" WEIGHT="18.418332408318374"/>
<DICH_DATA CI_END="5.326412263811734" CI_START="0.31384468075671434" EFFECT_SIZE="1.292929292929293" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7264347777561998" LOG_CI_START="-0.5032852276555627" LOG_EFFECT_SIZE="0.11157477505031849" MODIFIED="2014-01-14 11:57:05 +0000" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="0.0" SE="0.7223436183910694" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" VAR="0.521780303030303" WEIGHT="32.87005555319928"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.725948162054922" CI_START="0.5807336375696007" DF="0" EFFECT_SIZE="1.0011574074074074" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="64" I2="0.0" ID="CMP-002.15.11" LOG_CI_END="0.23702774776877406" LOG_CI_START="-0.2360230177969322" LOG_EFFECT_SIZE="5.023649859209456E-4" MODIFIED="2013-12-17 15:41:57 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.996678543979288" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="1038" WEIGHT="100.0" Z="0.004162839809894622">
<NAME>EPS - long term</NAME>
<DICH_DATA CI_END="1.725948162054922" CI_START="0.5807336375696007" EFFECT_SIZE="1.0011574074074074" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="64" LOG_CI_END="0.23702774776877406" LOG_CI_START="-0.2360230177969322" LOG_EFFECT_SIZE="5.023649859209456E-4" MODIFIED="2013-12-11 15:16:45 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.2778723613323509" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="1038" VAR="0.07721304919241657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.910465279553863" CI_START="0.8838868655449152" DF="0" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-002.15.12" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2013-12-17 15:41:56 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.08199900026365228" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="1.7392033508855447">
<NAME>hyperkinesia - short term</NAME>
<DICH_DATA CI_END="7.910465279553863" CI_START="0.8838868655449152" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2013-09-25 10:47:08 +0100" MODIFIED_BY="[Empty name]" ORDER="24591" O_E="0.0" SE="0.5590951731033033" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.31258741258741257" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-08 15:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.617294280320025" CI_START="0.9212984903585484" DF="0" EFFECT_SIZE="2.0624999999999996" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-002.15.13" LOG_CI_END="0.6643875549163717" LOG_CI_START="-0.035599640472446396" LOG_EFFECT_SIZE="0.3143939572219626" MODIFIED="2014-01-07 13:59:20 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.07830510996249901" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="99.99999999999999" Z="1.7606060144280085">
<NAME>myotony - short term</NAME>
<DICH_DATA CI_END="4.617294280320025" CI_START="0.9212984903585485" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.6643875549163717" LOG_CI_START="-0.03559964047244634" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2014-01-07 13:59:20 +0000" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="0.4111759435638916" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.16906565656565656" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.116729944688299" CI_END="1.3512748568167103" CI_START="0.8925139766495116" DF="6" EFFECT_SIZE="1.0981947441159885" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="188" I2="26.07860504307546" ID="CMP-002.15.14" LOG_CI_END="0.13074369591903207" LOG_CI_START="-0.04938497416901224" LOG_EFFECT_SIZE="0.0406793608750099" MODIFIED="2014-01-07 13:58:38 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.229675603588258" P_Z="0.37601805050097914" STUDIES="7" TAU2="0.019990080630673035" TOTAL_1="420" TOTAL_2="834" WEIGHT="99.99999999999999" Z="0.8852569909071811">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="4.882806308722088" CI_START="1.0970638173761578" EFFECT_SIZE="2.3144654088050314" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="0.6886694970218695" LOG_CI_START="0.040231891684262715" LOG_EFFECT_SIZE="0.36445069435306615" ORDER="24592" O_E="0.0" SE="0.380895459193224" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="368" VAR="0.14508135083401694" WEIGHT="6.78217468958465"/>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="24593" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="13.975227404340545"/>
<DICH_DATA CI_END="1.323574400090985" CI_START="0.4835391194903779" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.12174835866404682" LOG_CI_START="-0.3155683846801596" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24594" O_E="0.0" SE="0.2568820197931791" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.06598837209302326" WEIGHT="13.021207628045312"/>
<DICH_DATA CI_END="1.8107829986938895" CI_START="0.35343826425454045" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.25786640828395535" LOG_CI_START="-0.4516864343000681" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24595" O_E="0.0" SE="0.4167948520770725" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.17371794871794874" WEIGHT="5.779539899393917"/>
<DICH_DATA CI_END="1.6012747017033164" CI_START="0.8037255450418659" EFFECT_SIZE="1.134453781512605" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" LOG_CI_END="0.20446584235036858" LOG_CI_START="-0.09489222814541794" LOG_EFFECT_SIZE="0.05478680710247535" ORDER="24596" O_E="0.0" SE="0.17584441245557286" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.030921257391845633" WEIGHT="21.99005816657462"/>
<DICH_DATA CI_END="1.2983708249093964" CI_START="0.5718303543962353" EFFECT_SIZE="0.8616541353383459" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="56" LOG_CI_END="0.11339874809727704" LOG_CI_START="-0.24273279476870627" LOG_EFFECT_SIZE="-0.06466702333571461" ORDER="24597" O_E="0.0" SE="0.20919343115904715" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.043761891640095" WEIGHT="17.560919993163374"/>
<DICH_DATA CI_END="1.7271606421006642" CI_START="0.8419322520957465" EFFECT_SIZE="1.2058823529411764" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.23733273289654672" LOG_CI_START="-0.07472285354158605" LOG_EFFECT_SIZE="0.08130493967748034" ORDER="24598" O_E="0.0" SE="0.18330299617382464" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.03359998840630117" WEIGHT="20.890872218897574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.171767617999938" CI_END="8.642745762870776" CI_START="0.3777608826752424" DF="3" EFFECT_SIZE="1.806901012263753" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="67.29092880512599" ID="CMP-002.15.15" LOG_CI_END="0.9366517378749707" LOG_CI_START="-0.42278301549263747" LOG_EFFECT_SIZE="0.2569343611911666" MODIFIED="2014-01-14 10:32:24 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.027092244768297635" P_Z="0.45877237848761254" STUDIES="4" TAU2="1.5699410825428934" TOTAL_1="106" TOTAL_2="104" WEIGHT="100.0" Z="0.7408698256065805">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="1.087279415717843" CI_START="0.05748292398117026" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.036341166083179575" LOG_CI_START="-1.2404611487391044" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-06-20 14:00:21 +0100" MODIFIED_BY="[Empty name]" ORDER="24599" O_E="0.0" SE="0.75" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.5625" WEIGHT="29.90300956541056"/>
<DICH_DATA CI_END="5.480110751954462" CI_START="0.883193829298766" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-10-07 16:39:38 +0100" MODIFIED_BY="[Empty name]" ORDER="24602" O_E="0.0" SE="0.465655470101036" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.21683501683501682" WEIGHT="35.68796678618866"/>
<DICH_DATA CI_END="108.57523191221213" CI_START="0.34552654725465404" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0357307656703383" LOG_CI_START="-0.4615185795971981" LOG_EFFECT_SIZE="0.7871060930365701" ORDER="24601" O_E="0.0" SE="1.4668966269937749" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="2.151785714285714" WEIGHT="17.133553742658332"/>
<DICH_DATA CI_END="191.0359474772963" CI_START="0.6333886454243398" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-01-14 10:32:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.4564381625088383" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="2.121212121212121" WEIGHT="17.27546990574245"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4809410191236787" CI_START="0.11726111132110974" DF="0" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.15.16" LOG_CI_END="0.5416966646844225" LOG_CI_START="-0.9308459941838114" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2014-01-07 13:58:37 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Z="0.6044859550515078" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.5179603224621843">
<NAME>rigidity - medium term</NAME>
<DICH_DATA CI_END="3.4809410191236787" CI_START="0.11726111132110974" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5416966646844225" LOG_CI_START="-0.9308459941838114" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2013-09-26 12:16:08 +0100" MODIFIED_BY="[Empty name]" ORDER="24600" O_E="0.0" SE="0.8649788470229208" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.7481884057971014" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.695841465814257" CI_START="0.885797217010523" DF="0" EFFECT_SIZE="1.2256311235071158" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="118" I2="0.0" ID="CMP-002.15.17" LOG_CI_END="0.2293852501965353" LOG_CI_START="-0.052665688511490005" LOG_EFFECT_SIZE="0.08835978084252263" MODIFIED="2014-01-07 13:58:37 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Z="0.21943977285478533" STUDIES="1" TAU2="0.0" TOTAL_1="237" TOTAL_2="836" WEIGHT="100.0" Z="1.228019228912916">
<NAME>tardive dyskinesia - long term</NAME>
<DICH_DATA CI_END="1.695841465814257" CI_START="0.885797217010523" EFFECT_SIZE="1.2256311235071158" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="118" LOG_CI_END="0.2293852501965353" LOG_CI_START="-0.052665688511490005" LOG_EFFECT_SIZE="0.08835978084252263" MODIFIED="2013-12-11 15:15:29 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.16567811757175785" STUDY_ID="STD-CATIE-2005" TOTAL_1="237" TOTAL_2="836" VAR="0.027449238642121215" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.850585097847233" CI_END="4.386689271796172" CI_START="0.7267284561689678" DF="3" EFFECT_SIZE="1.7854780654450522" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" I2="69.54495626198259" ID="CMP-002.15.18" LOG_CI_END="0.6421368725349563" LOG_CI_START="-0.1386278340062715" LOG_EFFECT_SIZE="0.25175451926434245" MODIFIED="2014-01-14 10:23:12 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.019879893173999075" P_Z="0.2062424679142708" STUDIES="4" TAU2="0.549427757463271" TOTAL_1="139" TOTAL_2="190" WEIGHT="100.0" Z="1.2639654087060126">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="1.432086880200709" CI_START="0.2827752165631144" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15596936604949246" LOG_CI_START="-0.548558656337429" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2013-06-20 14:00:51 +0100" MODIFIED_BY="[Empty name]" ORDER="24603" O_E="0.0" SE="0.4138432478200336" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.17126623376623376" WEIGHT="29.185332780626602"/>
<DICH_DATA CI_END="5.480110751954462" CI_START="0.883193829298766" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-10-07 16:39:58 +0100" MODIFIED_BY="[Empty name]" ORDER="24605" O_E="0.0" SE="0.465655470101036" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.21683501683501682" WEIGHT="27.449713952622695"/>
<DICH_DATA CI_END="3.6940896911182275" CI_START="0.7996832263175973" EFFECT_SIZE="1.71875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.5675074357400763" LOG_CI_START="-0.09708201339140055" LOG_EFFECT_SIZE="0.23521271117433787" MODIFIED="2014-01-07 13:58:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1034" O_E="0.0" SE="0.39038313219065945" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.1523989898989899" WEIGHT="29.969923554615043"/>
<DICH_DATA CI_END="86.93682317138818" CI_START="1.6563752245250192" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9392037662396384" LOG_CI_START="0.21915872585561133" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2014-01-14 10:23:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1076" O_E="0.0" SE="1.0103629710818451" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0208333333333333" WEIGHT="13.39502971213567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6287762406689716" CI_START="0.4960541309410133" DF="0" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-002.15.19" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2014-01-07 13:58:35 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Z="0.5626142092360964" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5789629004672663">
<NAME>tremor - medium term</NAME>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2013-10-04 11:11:48 +0100" MODIFIED_BY="[Empty name]" ORDER="24604" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.593571226790893" CI_END="1.3018241608758467" CI_START="0.833852520152939" DF="7" EFFECT_SIZE="1.0418874014701924" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="239" I2="52.03367365522297" ID="CMP-002.15.20" LOG_CI_END="0.11455232745911911" LOG_CI_START="-0.07891075433531922" LOG_EFFECT_SIZE="0.017820786561899962" MODIFIED="2014-01-07 13:58:35 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.04157686469065314" P_Z="0.7180375189612017" STUDIES="8" TAU2="0.04993793940753381" TOTAL_1="445" TOTAL_2="551" WEIGHT="100.0" Z="0.36108284343998664">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="0.8925803334475861" CI_START="0.31034552282746863" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.04935268636092187" LOG_CI_START="-0.5081545155447361" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-01-07 11:48:53 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.26950246556825486" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.07263157894736841" WEIGHT="10.536319408765793"/>
<DICH_DATA CI_END="1.8621015575312443" CI_START="0.7471074823754769" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.27000336336532577" LOG_CI_START="-0.126616914055176" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2013-07-18 15:00:10 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.23297671425883973" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.054278149386845054" WEIGHT="12.391863963671295"/>
<DICH_DATA CI_END="2.1445467233256057" CI_START="0.6700365652795333" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.33133551266949035" LOG_CI_START="-0.17390149630541574" LOG_EFFECT_SIZE="0.07871700818203736" ORDER="24608" O_E="0.0" SE="0.2967787200353893" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.08807760866584396" WEIGHT="9.357145721576417"/>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="24609" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="11.734208159395816"/>
<DICH_DATA CI_END="1.7265335316978874" CI_START="0.8089586383546878" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.2371750173741189" LOG_CI_START="-0.09207368307689538" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="24610" O_E="0.0" SE="0.19340231645227823" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.037404456009107176" WEIGHT="14.785850433863645"/>
<DICH_DATA CI_END="2.4082232426278054" CI_START="1.0139847907011161" EFFECT_SIZE="1.5626585489599187" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" LOG_CI_END="0.3816967436104806" LOG_CI_START="0.006031440831521361" LOG_EFFECT_SIZE="0.19386409222100104" MODIFIED="2013-12-17 15:44:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1311" O_E="0.0" SE="0.22066765842560027" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.04869421547503739" WEIGHT="13.093413569878656"/>
<DICH_DATA CI_END="1.0900661603274893" CI_START="0.7045880852253487" EFFECT_SIZE="0.87638326585695" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="117" LOG_CI_END="0.0374528577508727" LOG_CI_START="-0.15206470512956374" LOG_EFFECT_SIZE="-0.05730592368934553" ORDER="24611" O_E="0.0" SE="0.11132355456303453" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.012392933800548926" WEIGHT="20.718971653975885"/>
<DICH_DATA CI_END="1.5996876010856382" CI_START="0.4000781149804874" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.20403517867378293" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24613" O_E="0.0" SE="0.35355339059327373" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.12499999999999999" WEIGHT="7.3822270888724955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.15.21" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2014-01-07 13:58:35 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>use of antiparkinsonian drugs - medium term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-09-26 12:16:18 +0100" MODIFIED_BY="[Empty name]" ORDER="24612" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.755512560869924" CI_START="0.33637927808426854" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.15.22" LOG_CI_END="1.4274132752588893" LOG_CI_START="-0.47317076581956424" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-07 13:58:35 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Z="0.32508803826320287" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.9840559062870702">
<NAME>use of antiparkinsonian drugs - long term</NAME>
<DICH_DATA CI_END="26.755512560869924" CI_START="0.33637927808426854" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4274132752588893" LOG_CI_START="-0.47317076581956424" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:50:02 +0000" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="1.1164124737722179" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="1.2463768115942029" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.16" MODIFIED="2015-01-14 16:40:02 +0000" MODIFIED_BY="Heather Maxwell" NO="16" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse events: Movement disorders - TESS total score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.16.01" MODIFIED="2014-01-14 11:57:20 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2014-01-14 11:57:20 +0000" MODIFIED_BY="[Empty name]" ORDER="2684" STUDY_ID="STD-Zhang-2010">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>5.13</P>
</TD>
<TD>
<P>4.21</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P>Aripiprazole</P>
</TD>
<TD>
<P>4.26</P>
</TD>
<TD>
<P>3.75</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="55.35786062948198" CI_END="1.7368679163477132" CI_START="0.7557554842100263" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1457082757527002" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="196" I2="62.06500800210474" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.23976679289589936" LOG_CI_START="-0.12161869264037323" LOG_EFFECT_SIZE="0.05907405012776305" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="6.268148150390118E-5" P_Q="0.705819419399323" P_Z="0.5216702538985735" Q="2.9621634963125096" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7157280216169516" TOTALS="SUB" TOTAL_1="1045" TOTAL_2="1398" WEIGHT="600.0" Z="0.6407728882609377">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.84762580173145" CI_END="1.6055233201796502" CI_START="0.39532992442737425" DF="7" EFFECT_SIZE="0.7966877762542915" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="61" I2="35.46975045099094" ID="CMP-002.17.01" LOG_CI_END="0.20561661806308532" LOG_CI_START="-0.4030403105702475" LOG_EFFECT_SIZE="-0.09871184625358108" MODIFIED="2014-01-14 10:23:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14540514276569205" P_Z="0.5249504332863728" STUDIES="8" TAU2="0.3186338052588422" TOTAL_1="439" TOTAL_2="589" WEIGHT="100.0" Z="0.6357330522430485">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24614" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="4.370587799938943"/>
<DICH_DATA CI_END="1.2979525579624327" CI_START="0.06289340281387018" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.11325881866491228" LOG_CI_START="-1.2013949073654637" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="24615" O_E="0.0" SE="0.7722341063111405" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.596345514950166" WEIGHT="13.970407232528993"/>
<DICH_DATA CI_END="4.035499078344917" CI_START="0.009912032991073124" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.60589725245782" LOG_CI_START="-2.0038372611298576" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="24616" O_E="0.0" SE="1.5329709716755893" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.35" WEIGHT="4.789954203335346"/>
<DICH_DATA CI_END="7.2383708843989485" CI_START="0.15488392130504644" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8596408320080514" LOG_CI_START="-0.8099936645579872" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="24617" O_E="0.0" SE="0.9807515681069424" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.9618736383442266" WEIGHT="9.982475132432533"/>
<DICH_DATA CI_END="1.3428804803367465" CI_START="0.07124517367981752" EFFECT_SIZE="0.30931174089068825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="0.1280373611124423" LOG_CI_START="-1.1472445504803939" LOG_EFFECT_SIZE="-0.5096035946839759" ORDER="24618" O_E="0.0" SE="0.7491069076169051" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.5611611590393624" WEIGHT="14.529105338604488"/>
<DICH_DATA CI_END="1.5005876308629236" CI_START="0.5517612999389011" EFFECT_SIZE="0.9099264705882353" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="34" LOG_CI_END="0.17626136229932687" LOG_CI_START="-0.2582487638285493" LOG_EFFECT_SIZE="-0.04099370076461119" MODIFIED="2014-01-07 14:01:48 +0000" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="0.2552333989473274" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.06514408793820559" WEIGHT="33.30737371602393"/>
<DICH_DATA CI_END="72.76209922918737" CI_START="0.12369076889400406" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8619052202224093" LOG_CI_START="-0.9076627107830841" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24619" O_E="0.0" SE="1.6268579122549907" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="2.646666666666667" WEIGHT="4.310738096757535"/>
<DICH_DATA CI_END="19.21688159072022" CI_START="1.0537609811666153" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2836829141430686" LOG_CI_START="0.02274211340761895" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2014-01-14 10:23:43 +0000" MODIFIED_BY="[Empty name]" ORDER="1077" O_E="0.0" SE="0.7406828681096325" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5486111111111112" WEIGHT="14.739358480378241"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.63705481214206" CI_END="2.471632004623661" CI_START="0.8227790420123893" DF="8" EFFECT_SIZE="1.4260459364871165" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="56" I2="41.33630677441423" ID="CMP-002.17.02" LOG_CI_END="0.39298381016345857" LOG_CI_START="-0.08471677926984315" LOG_EFFECT_SIZE="0.1541335154468077" MODIFIED="2014-01-14 10:24:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09172993134098639" P_Z="0.205945629005996" STUDIES="9" TAU2="0.24904119616302142" TOTAL_1="432" TOTAL_2="585" WEIGHT="100.0" Z="1.2647928253329943">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24620" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="3.0419317934225827"/>
<DICH_DATA CI_END="139.80596033832603" CI_START="0.39128635897179836" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" MODIFIED="2013-09-25 10:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="24621" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="3.152020523202666"/>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="24622" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="5.433829731626885"/>
<DICH_DATA CI_END="2.6080061992060575" CI_START="0.38343467139933374" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4163086193749835" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" ORDER="24623" O_E="0.0" SE="0.4890834875635335" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.23920265780730898" WEIGHT="16.12686584794427"/>
<DICH_DATA CI_END="21.16211905093586" CI_START="0.18901698787216242" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3255591532521103" LOG_CI_START="-0.7234991619241479" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="24624" O_E="0.0" SE="1.2036269973367784" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.448717948717949" WEIGHT="4.63778572938557"/>
<DICH_DATA CI_END="3.0881509570563295" CI_START="0.5672423816599961" EFFECT_SIZE="1.3235294117647058" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4896985216553348" LOG_CI_START="-0.24623132818915763" LOG_EFFECT_SIZE="0.12173359673308855" ORDER="24625" O_E="0.0" SE="0.4322888367101637" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.18687363834422657" WEIGHT="18.06280151709747"/>
<DICH_DATA CI_END="1.4519777859244263" CI_START="0.2505544158526919" EFFECT_SIZE="0.6031578947368421" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="0.1619599720636335" LOG_CI_START="-0.601097938706549" LOG_EFFECT_SIZE="-0.21956898332145777" ORDER="24626" O_E="0.0" SE="0.44822399398398133" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.20090474878295214" WEIGHT="17.4995312714914"/>
<DICH_DATA CI_END="4.8679034246346715" CI_START="1.4445577204559135" EFFECT_SIZE="2.6517857142857144" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.6873419535834389" LOG_CI_START="0.15973489971062257" LOG_EFFECT_SIZE="0.4235384266470308" MODIFIED="2014-01-07 14:02:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="0.3099189951419299" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.09604978354978355" WEIGHT="22.81671674123635"/>
<DICH_DATA CI_END="13.763996126583722" CI_START="0.6538798701503148" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1387445417312558" LOG_CI_START="-0.18450203229193088" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:24:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1078" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="9.228516844592814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.725639100100512" CI_START="0.18623534033391048" DF="0" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.17.03" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-10-04 11:13:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5844112219801221" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5469527129537599">
<NAME>dry mouth - medium term</NAME>
<DICH_DATA CI_END="19.725639100100512" CI_START="0.18623534033391048" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-10-04 11:13:58 +0100" MODIFIED_BY="[Empty name]" ORDER="24627" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.3342910798778975" CI_END="35.79151513181816" CI_START="0.0049808245521036" DF="1" EFFECT_SIZE="0.42222181057537445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="77" I2="86.36541706473083" ID="CMP-002.17.04" LOG_CI_END="1.5537800833986721" LOG_CI_START="-2.302698755877583" LOG_EFFECT_SIZE="-0.37445933623945543" MODIFIED="2014-01-07 14:08:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.006765166724863048" P_Z="0.703485114412078" STUDIES="2" TAU2="8.935932043701124" TOTAL_1="80" TOTAL_2="131" WEIGHT="100.0" Z="0.3806201684445612">
<NAME>increased salivation - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-18 10:25:41 +0000" MODIFIED_BY="[Empty name]" ORDER="24769" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="45.51221818225302"/>
<DICH_DATA CI_END="0.20889236615042367" CI_START="0.013738644508995868" EFFECT_SIZE="0.05357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="77" LOG_CI_END="-0.6800774307680136" LOG_CI_START="-1.8620561138050626" LOG_EFFECT_SIZE="-1.271066772286538" MODIFIED="2014-01-07 14:08:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="0.0" SE="0.6943001293048054" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.48205266955266957" WEIGHT="54.487781817746985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.17.05" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:26:52 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>increased salivation - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:26:52 +0000" MODIFIED_BY="[Empty name]" ORDER="1022" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.17.06" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 16:21:12 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>nasal congestion - short term</NAME>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24628" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="87.85313427861877" CI_END="1.0975929268109803" CI_START="0.9340683637975913" CI_STUDY="95" CI_TOTAL="95" DF="48" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0125348533567335" ESTIMABLE="YES" EVENTS_1="738" EVENTS_2="1223" I2="45.36336080193557" I2_Q="35.123579207502154" ID="CMP-002.18" LOG_CI_END="0.040441299659270305" LOG_CI_START="-0.02962133690316827" LOG_EFFECT_SIZE="0.0054099813780510535" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="3.9461898754056257E-4" P_Q="0.0575046926823467" P_Z="0.7621317997975882" Q="30.827841233671684" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0636688719564876" TOTALS="SUB" TOTAL_1="3051" TOTAL_2="5324" WEIGHT="2100.0" Z="0.3026825474534592">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7715742595051232" CI_START="0.6280241850481414" DF="0" EFFECT_SIZE="1.0547945205479452" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="0.2483593614771941" LOG_CI_START="-0.2020236313731422" LOG_EFFECT_SIZE="0.02316786505202597" MODIFIED="2013-12-17 15:36:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.840196200932467" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.20164252123856005">
<NAME>agitation - short term</NAME>
<DICH_DATA CI_END="1.7715742595051232" CI_START="0.6280241850481414" EFFECT_SIZE="1.0547945205479452" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.2483593614771941" LOG_CI_START="-0.2020236313731422" LOG_EFFECT_SIZE="0.02316786505202597" MODIFIED="2013-12-17 15:36:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1303" O_E="0.0" SE="0.26455719943205797" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.06999051177133368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.234348125670902" CI_START="0.33046504210308847" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:52:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3289937987651492" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.9761426344273544">
<NAME>agitation - long term</NAME>
<DICH_DATA CI_END="27.234348125670902" CI_START="0.33046504210308847" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:52:26 +0000" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.237503115793944" CI_START="0.6293281035753292" DF="0" EFFECT_SIZE="1.1866438356164384" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-002.18.03" LOG_CI_END="0.34976364875718957" LOG_CI_START="-0.20112287375837498" LOG_EFFECT_SIZE="0.07432038749940727" MODIFIED="2013-12-18 09:51:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.596916780329366" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.5288395227050904">
<NAME>anxiety - short term</NAME>
<DICH_DATA CI_END="2.237503115793944" CI_START="0.6293281035753292" EFFECT_SIZE="1.1866438356164384" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.34976364875718957" LOG_CI_START="-0.20112287375837498" LOG_EFFECT_SIZE="0.07432038749940727" MODIFIED="2013-12-17 15:38:05 +0000" MODIFIED_BY="[Empty name]" ORDER="1305" O_E="0.0" SE="0.32359347025790847" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.1047127339935559" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.206513090488437" CI_START="0.3714477921233738" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.18.04" LOG_CI_END="0.6239222447595453" LOG_CI_START="-0.43010221874343246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-18 10:10:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7185410371511193" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.3604093487656743">
<NAME>anxiety - long term</NAME>
<DICH_DATA CI_END="4.206513090488437" CI_START="0.3714477921233738" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6239222447595453" LOG_CI_START="-0.43010221874343246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-18 10:10:50 +0000" MODIFIED_BY="[Empty name]" ORDER="941" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3474627755623407" CI_START="0.7646182529258909" DF="0" EFFECT_SIZE="1.3397435897435896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" I2="0.0" ID="CMP-002.18.05" LOG_CI_END="0.3705987142518677" LOG_CI_START="-0.11655533873868298" LOG_EFFECT_SIZE="0.12702168775659237" MODIFIED="2013-12-18 10:10:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.30673775597612163" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.00000000000001" Z="1.0220911916060458">
<NAME>depression - short term</NAME>
<DICH_DATA CI_END="2.3474627755623407" CI_START="0.7646182529258909" EFFECT_SIZE="1.3397435897435896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.3705987142518677" LOG_CI_START="-0.11655533873868298" LOG_EFFECT_SIZE="0.12702168775659237" MODIFIED="2013-09-25 10:18:03 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.28615670217810324" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.08188565820144766" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.375031477325011" CI_END="1.4438938180861556" CI_START="0.5317317690512546" DF="4" EFFECT_SIZE="0.8762215554373916" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" I2="25.581831159979036" ID="CMP-002.18.06" LOG_CI_END="0.15953525700453008" LOG_CI_START="-0.27430739138512017" LOG_EFFECT_SIZE="-0.05738606719029509" MODIFIED="2014-01-14 10:22:29 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.25093481781305493" P_Z="0.6041065092501076" STUDIES="5" TAU2="0.08263893429969316" TOTAL_1="221" TOTAL_2="221" WEIGHT="100.0" Z="0.5185042333890438">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="5.932232668008023" CI_START="0.4300436226850036" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7732181761477139" LOG_CI_START="-0.3664874883030273" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-07-18 14:58:09 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.6694687489323915" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.4481884057971014" WEIGHT="12.23450509724285"/>
<DICH_DATA CI_END="1.938794663718921" CI_START="0.4927097304986385" EFFECT_SIZE="0.9773755656108597" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.28753181571308195" LOG_CI_START="-0.3074088607814416" LOG_EFFECT_SIZE="-0.009938522534179813" ORDER="24631" O_E="0.0" SE="0.3494710983767282" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.12213004860063684" WEIGHT="31.71578872045875"/>
<DICH_DATA CI_END="3.6020759301611425" CI_START="0.5665667148885767" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5565528633148392" LOG_CI_START="-0.2467489433433528" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="24633" O_E="0.0" SE="0.47186345763909565" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.22265512265512263" WEIGHT="21.272637479252616"/>
<DICH_DATA CI_END="0.9407225477876046" CI_START="0.1996101594666721" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.026538446426452467" LOG_CI_START="-0.6998173583991988" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2013-10-08 15:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="24632" O_E="0.0" SE="0.3954873656771559" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.15641025641025647" WEIGHT="27.167671134474123"/>
<DICH_DATA CI_END="3.725968125983914" CI_START="0.11928294322890384" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.571239135378122" LOG_CI_START="-0.9234216534894846" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-01-14 10:22:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1074" O_E="0.0" SE="0.8779711460710615" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.7708333333333333" WEIGHT="7.609397568571666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9408215709147434" CI_START="0.5764120898678028" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-002.18.07" LOG_CI_END="0.28798561043778126" LOG_CI_START="-0.2392669187188919" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-18 10:10:13 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.856286928914289" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.18110274652577157">
<NAME>emotional indifference - short term</NAME>
<DICH_DATA CI_END="1.9408215709147434" CI_START="0.5764120898678028" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.28798561043778126" LOG_CI_START="-0.2392669187188919" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-09-25 10:22:32 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.3097107455687418" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.09592074592074593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.680854921544878" CI_END="11.837728841002997" CI_START="0.5673023223706011" DF="3" EFFECT_SIZE="2.5914418888129527" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" I2="85.49382986641108" ID="CMP-002.18.08" LOG_CI_END="1.073268387654346" LOG_CI_START="-0.2461854385564462" LOG_EFFECT_SIZE="0.4135414745489499" MODIFIED="2014-01-07 14:11:01 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.2262798007867115E-4" P_Z="0.219229849831439" STUDIES="4" TAU2="2.019250414793693" TOTAL_1="206" TOTAL_2="257" WEIGHT="99.99999999999999" Z="1.2285786438729713">
<NAME>excitation - short term</NAME>
<DICH_DATA CI_END="1.5293329029537468" CI_START="0.07265331890559054" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18450203229193085" LOG_CI_START="-1.1387445417312556" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-06-20 14:03:27 +0100" MODIFIED_BY="[Empty name]" ORDER="24634" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="22.897931707189684"/>
<DICH_DATA CI_END="2.952381873973146" CI_START="0.5599076593249779" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4701725303302891" LOG_CI_START="-0.251883591480153" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-10-07 16:41:11 +0100" MODIFIED_BY="[Empty name]" ORDER="24636" O_E="0.0" SE="0.4241393401869012" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.17989417989417988" WEIGHT="27.31554137725087"/>
<DICH_DATA CI_END="88.5999741202331" CI_START="5.293378115732413" EFFECT_SIZE="21.65625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.9474335950310508" LOG_CI_START="0.7237329175527508" LOG_EFFECT_SIZE="1.3355832562919008" MODIFIED="2014-01-07 14:11:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1039" O_E="0.0" SE="0.7188078353667997" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.5166847041847042" WEIGHT="23.68783992981404"/>
<DICH_DATA CI_END="13.460370892631461" CI_START="1.6762168130412567" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" LOG_CI_END="1.1290570267827587" LOG_CI_START="0.22433019246697458" LOG_EFFECT_SIZE="0.6766936096248666" ORDER="24637" O_E="0.0" SE="0.5314410209471492" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.2824295587453482" WEIGHT="26.0986869857454"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.096292470222609" CI_START="0.32037330253759905" DF="0" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.18.09" LOG_CI_END="0.7072543436913086" LOG_CI_START="-0.4943436818627349" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2013-12-18 10:10:11 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.7283770574725384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.3472852153832226">
<NAME>excitation - medium term</NAME>
<DICH_DATA CI_END="5.096292470222609" CI_START="0.32037330253759905" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7072543436913086" LOG_CI_START="-0.4943436818627349" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2013-10-04 11:31:51 +0100" MODIFIED_BY="[Empty name]" ORDER="24635" O_E="0.0" SE="0.7058246282165999" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.49818840579710144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6734729783430042" CI_START="0.6215066246000762" DF="0" EFFECT_SIZE="1.510989010989011" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-002.18.10" LOG_CI_END="0.5650768495704356" LOG_CI_START="-0.20655423788005994" LOG_EFFECT_SIZE="0.17926130584518785" MODIFIED="2013-12-18 10:10:11 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.3624760315280888" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.9106572013293296">
<NAME>increased dream activity - short term</NAME>
<DICH_DATA CI_END="3.6734729783430042" CI_START="0.6215066246000762" EFFECT_SIZE="1.510989010989011" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5650768495704356" LOG_CI_START="-0.20655423788005994" LOG_EFFECT_SIZE="0.17926130584518785" MODIFIED="2013-09-25 10:21:49 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.4532599204039062" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.20544455544455542" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.646051103196216" CI_END="1.177558928308352" CI_START="0.8623783725578912" DF="10" EFFECT_SIZE="1.0077208701746585" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="237" I2="0.0" ID="CMP-002.18.11" LOG_CI_END="0.07098264964278625" LOG_CI_START="-0.06430214361900542" LOG_EFFECT_SIZE="0.0033402530118903724" MODIFIED="2014-01-14 10:22:07 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4720757335003475" P_Z="0.9228970629631701" STUDIES="11" TAU2="0.0" TOTAL_1="656" TOTAL_2="766" WEIGHT="100.00000000000003" Z="0.09678509231836369">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="3.031136242063711" CI_START="0.5453602518916572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.481605457267226" LOG_CI_START="-0.26331651841708975" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-06-20 14:04:04 +0100" MODIFIED_BY="[Empty name]" ORDER="24638" O_E="0.0" SE="0.4375708559402168" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.19146825396825395" WEIGHT="3.298195476749668"/>
<DICH_DATA CI_END="5.954930516701607" CI_START="0.5753314177646484" EFFECT_SIZE="1.8509615384615385" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7748766984150807" LOG_CI_START="-0.24008190932360235" LOG_EFFECT_SIZE="0.26739739454573913" MODIFIED="2013-09-25 10:21:06 +0100" MODIFIED_BY="[Empty name]" ORDER="24639" O_E="0.0" SE="0.5961917103118387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.35544455544455544" WEIGHT="1.7766476360551744"/>
<DICH_DATA CI_END="1.897274438862189" CI_START="0.4355965927034584" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2781301556977779" LOG_CI_START="-0.36091552601422794" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="24640" O_E="0.0" SE="0.3753785967647742" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.14090909090909093" WEIGHT="4.481610981272109"/>
<DICH_DATA CI_END="1.2941353876382815" CI_START="0.38502145985134056" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.11197971298530651" LOG_CI_START="-0.4145150636466047" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="24641" O_E="0.0" SE="0.3092656379847611" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.09564523483812129" WEIGHT="6.602521602336588"/>
<DICH_DATA CI_END="1.470019361633962" CI_START="0.2754784652875789" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.16732305488111143" LOG_CI_START="-0.559912345169048" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="24642" O_E="0.0" SE="0.42718167386275185" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.1824841824841825" WEIGHT="3.4605724210315567"/>
<DICH_DATA CI_END="1.5178282654189783" CI_START="0.6157542935236369" EFFECT_SIZE="0.9667519181585678" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18122263611802777" LOG_CI_START="-0.2105925512353107" LOG_EFFECT_SIZE="-0.014684957558641477" ORDER="24643" O_E="0.0" SE="0.23015418056780854" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.05297094683283941" WEIGHT="11.921624341963861"/>
<DICH_DATA CI_END="1.3081511307657707" CI_START="0.5591352471309653" EFFECT_SIZE="0.8552388004442799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.11665792095006171" LOG_CI_START="-0.2524831295406748" LOG_EFFECT_SIZE="-0.06791260429530659" MODIFIED="2013-12-17 15:34:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1302" O_E="0.0" SE="0.21683528033592853" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.047017538798360715" WEIGHT="13.431152402245036"/>
<DICH_DATA CI_END="1.3979254352443558" CI_START="0.7969922967524731" EFFECT_SIZE="1.0555263157894736" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="80" LOG_CI_END="0.14548400694216984" LOG_CI_START="-0.09854587621249658" LOG_EFFECT_SIZE="0.023469065364836634" ORDER="24644" O_E="0.0" SE="0.14334436133245454" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.020547605925809287" WEIGHT="30.733494279547294"/>
<DICH_DATA CI_END="1.5070719917963586" CI_START="0.07372647870568672" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-10-07 16:40:36 +0100" MODIFIED_BY="[Empty name]" ORDER="24646" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="1.0656557929899875"/>
<DICH_DATA CI_END="1.8212949576564716" CI_START="0.935859016946485" EFFECT_SIZE="1.3055555555555556" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="36" LOG_CI_END="0.2603802852289142" LOG_CI_START="-0.02878957089205377" LOG_EFFECT_SIZE="0.1157953571684302" ORDER="24647" O_E="0.0" SE="0.16985980489932992" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.028852353320438423" WEIGHT="21.88728670295016"/>
<DICH_DATA CI_END="2.302622448212179" CI_START="0.1563434770991285" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36222273427339696" LOG_CI_START="-0.8059202335061098" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-01-14 10:22:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1073" O_E="0.0" SE="0.68617296167463" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.4708333333333333" WEIGHT="1.341238362858588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9867592830922347" CI_START="0.02889135795141335" DF="0" EFFECT_SIZE="0.23958333333333337" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.18.12" LOG_CI_END="0.2981452509257821" LOG_CI_START="-1.539232044969733" LOG_EFFECT_SIZE="-0.6205433970219755" MODIFIED="2013-12-18 10:10:11 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.18553958168620477" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3238899944221094">
<NAME>insomnia - medium term</NAME>
<DICH_DATA CI_END="1.9867592830922347" CI_START="0.02889135795141335" EFFECT_SIZE="0.23958333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2981452509257821" LOG_CI_START="-1.539232044969733" LOG_EFFECT_SIZE="-0.6205433970219755" MODIFIED="2013-10-04 11:30:58 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="1.079284518773325" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.164855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9507437486123367" CI_END="11.290543598533507" CI_START="0.40857253343689925" DF="1" EFFECT_SIZE="2.1477909586206474" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="257" I2="66.11023913986853" ID="CMP-002.18.13" LOG_CI_END="1.0527148521251575" LOG_CI_START="-0.3887308324606339" LOG_EFFECT_SIZE="0.3319920098322618" MODIFIED="2013-12-18 10:28:47 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.08583821144519133" P_Z="0.3666145319910248" STUDIES="2" TAU2="1.0637237851968435" TOTAL_1="291" TOTAL_2="1229" WEIGHT="100.0" Z="0.9028330229637218">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="1.4983027828513718" CI_START="0.9361936818088646" EFFECT_SIZE="1.184357040229885" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="256" LOG_CI_END="0.17559958614980684" LOG_CI_START="-0.02863429416863318" LOG_EFFECT_SIZE="0.07348264599058683" MODIFIED="2013-12-11 14:50:33 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.119967992273064" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.014392319170029942" WEIGHT="66.49764042502436"/>
<DICH_DATA CI_END="53.472577975118114" CI_START="0.9163575397991978" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7281311224466887" LOG_CI_START="-0.03793504241817497" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-18 10:28:47 +0000" MODIFIED_BY="[Empty name]" ORDER="1040" O_E="0.0" SE="1.0373960074101287" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.076190476190476" WEIGHT="33.50235957497564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6991837086641404" CI_END="1.1573778328002509" CI_START="0.7420671215299564" DF="4" EFFECT_SIZE="0.9267427026465659" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="87" I2="0.0" ID="CMP-002.18.14" LOG_CI_END="0.06347516008669238" LOG_CI_START="-0.12955681009607434" LOG_EFFECT_SIZE="-0.03304082500469099" MODIFIED="2014-01-07 11:49:24 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.44824474627699706" P_Z="0.5022429688063842" STUDIES="5" TAU2="0.0" TOTAL_1="223" TOTAL_2="225" WEIGHT="100.0" Z="0.6709647833710629">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="1.0253991183113356" CI_START="0.24380750435177775" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.010892939676755791" LOG_CI_START="-0.6129529310047181" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-01-07 11:49:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.36645015252516167" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.13428571428571426" WEIGHT="9.574230459764056"/>
<DICH_DATA CI_END="2.837874370854859" CI_START="0.5505881500770327" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.45299316587405014" LOG_CI_START="-0.2591731398579374" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="24648" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.17500000000000002" WEIGHT="7.3467564344311915"/>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" ORDER="24649" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="2.0731628313410524"/>
<DICH_DATA CI_END="1.236857024048411" CI_START="0.7182118157377608" EFFECT_SIZE="0.9425101214574899" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.09231949974587314" LOG_CI_START="-0.14374745430950275" LOG_EFFECT_SIZE="-0.02571397728181484" ORDER="24650" O_E="0.0" SE="0.13866689736239654" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.019228508424113416" WEIGHT="66.86334413818365"/>
<DICH_DATA CI_END="1.9862760542852527" CI_START="0.6091801778456267" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.29803960695960363" LOG_CI_START="-0.21525423664315357" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-10-09 12:06:42 +0100" MODIFIED_BY="[Empty name]" ORDER="24652" O_E="0.0" SE="0.30151134457776363" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.09090909090909093" WEIGHT="14.142506136280044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.187886799492831E-32" CI_END="5.932232668008021" CI_START="0.43004362268500357" DF="0" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-002.18.15" LOG_CI_END="0.7732181761477137" LOG_CI_START="-0.36648748830302735" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-12-18 10:10:10 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Z="0.484265168923087" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6994591011065763">
<NAME>need of additional benzodiazepines - medium term</NAME>
<DICH_DATA CI_END="5.932232668008023" CI_START="0.4300436226850036" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7732181761477139" LOG_CI_START="-0.3664874883030273" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-10-04 11:16:56 +0100" MODIFIED_BY="[Empty name]" ORDER="24651" O_E="0.0" SE="0.6694687489323915" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.4481884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0891184016575972" CI_START="0.7588213363523336" DF="0" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-002.18.16" LOG_CI_END="0.03707509590945529" LOG_CI_START="-0.11986046622590536" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2013-12-18 10:10:10 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Z="0.30118094383578364" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="1.0339042474458628">
<NAME>need of additional benzodiazepines - long term</NAME>
<DICH_DATA CI_END="1.0891184016575972" CI_START="0.7588213363523336" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.03707509590945529" LOG_CI_START="-0.11986046622590536" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2013-12-18 09:51:36 +0000" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.09218472604187218" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.008498023715415026" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.183076222571957" CI_START="1.9577266848164965" DF="0" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" I2="0.0" ID="CMP-002.18.17" LOG_CI_END="0.8563104749348668" LOG_CI_START="0.2917520605205709" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2014-01-07 14:14:08 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Z="6.728110105031629E-5" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="3.9857013269864">
<NAME>restlessness - short term</NAME>
<DICH_DATA CI_END="7.183076222571957" CI_START="1.9577266848164965" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.8563104749348668" LOG_CI_START="0.2917520605205709" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2014-01-07 14:14:08 +0000" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.33162440723617964" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.1099747474747475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5258845598077135" CI_END="1.6177620142900169" CI_START="0.8702665664176864" DF="6" EFFECT_SIZE="1.1865429589598233" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="67" I2="0.0" ID="CMP-002.18.18" LOG_CI_END="0.20891463378893432" LOG_CI_START="-0.06034770072358623" LOG_EFFECT_SIZE="0.07428346653267402" MODIFIED="2014-01-07 14:13:46 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.605889021989509" P_Z="0.2795100743143164" STUDIES="7" TAU2="0.0" TOTAL_1="442" TOTAL_2="549" WEIGHT="100.0" Z="1.0814206102343482">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" MODIFIED="2013-09-25 09:56:46 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="24.84687510226316"/>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="24653" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.2" WEIGHT="12.508246232383062"/>
<DICH_DATA CI_END="1.9933442682238067" CI_START="0.4063522859108327" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.29958231168491917" LOG_CI_START="-0.3910972928062695" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="24654" O_E="0.0" SE="0.40570861859730606" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.16459948320413437" WEIGHT="15.198402800415211"/>
<DICH_DATA CI_END="2.5732610372821907" CI_START="0.0971529885145439" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41048384423635903" LOG_CI_START="-1.0125438355643215" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="24655" O_E="0.0" SE="0.8358935032155405" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.6987179487179487" WEIGHT="3.5803420408289135"/>
<DICH_DATA CI_END="8.222302468369584" CI_START="0.8457116215758933" EFFECT_SIZE="2.636986301369863" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.914993448840305" LOG_CI_START="-0.07277770139217773" LOG_EFFECT_SIZE="0.4211078737240636" MODIFIED="2013-12-17 15:42:44 +0000" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="0.5802216631926115" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.3366571784380003" WEIGHT="7.430850748775354"/>
<DICH_DATA CI_END="2.212049061640384" CI_START="0.5527772332517961" EFFECT_SIZE="1.1057894736842104" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="0.34479475507542784" LOG_CI_START="-0.25744985216918065" LOG_EFFECT_SIZE="0.04367245145312358" ORDER="24656" O_E="0.0" SE="0.3537614634543684" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.1251471730253764" WEIGHT="19.989658463714136"/>
<DICH_DATA CI_END="3.681880652108193" CI_START="0.7981723982610299" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.566069706772315" LOG_CI_START="-0.09790329470557912" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2013-10-07 16:40:55 +0100" MODIFIED_BY="[Empty name]" ORDER="24657" O_E="0.0" SE="0.3900210277874798" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.1521164021164021" WEIGHT="16.44562461162017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2077797578139566" CI_START="0.7900863458646281" DF="0" EFFECT_SIZE="0.976857356762232" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="348" I2="0.0" ID="CMP-002.18.19" LOG_CI_END="0.08198774663066186" LOG_CI_START="-0.10232544354073583" LOG_EFFECT_SIZE="-0.01016884845503699" MODIFIED="2014-01-07 14:13:46 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Z="0.8287783925975584" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.0" Z="0.21626858845625">
<NAME>sleepiness/ sedation - long term</NAME>
<DICH_DATA CI_END="1.2077797578139566" CI_START="0.7900863458646281" EFFECT_SIZE="0.976857356762232" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="348" LOG_CI_END="0.08198774663066186" LOG_CI_START="-0.10232544354073583" LOG_EFFECT_SIZE="-0.01016884845503699" MODIFIED="2013-12-11 14:51:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.10826648027168477" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.011721630750419109" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.97920496740791" CI_START="0.13139493279844805" DF="0" EFFECT_SIZE="0.3586956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" I2="0.0" ID="CMP-002.18.20" LOG_CI_END="-0.009126392060878483" LOG_CI_START="-0.881421382874457" LOG_EFFECT_SIZE="-0.4452738874676677" MODIFIED="2014-01-07 14:13:46 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Z="0.04539494868607794" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="2.0009762566188627">
<NAME>somnolence - short term</NAME>
<DICH_DATA CI_END="0.97920496740791" CI_START="0.13139493279844805" EFFECT_SIZE="0.358695652173913" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" LOG_CI_END="-0.009126392060878483" LOG_CI_START="-0.881421382874457" LOG_EFFECT_SIZE="-0.44527388746766783" MODIFIED="2014-01-07 14:13:26 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="0.5123903955337392" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.26254391743522176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.500893367336776" CI_START="0.6263134403713821" DF="0" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-002.18.21" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2014-01-07 14:13:45 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Z="0.889693784449851" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.13869169080556756">
<NAME>tension - short term</NAME>
<DICH_DATA CI_END="1.500893367336776" CI_START="0.6263134403713821" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2013-09-25 10:19:19 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.22295431080969194" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.049708624708624714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.858070943737886" CI_END="1.0908329674789492" CI_START="0.9504350161307845" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0182169950663005" ESTIMABLE="YES" EVENTS_1="325" EVENTS_2="398" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.03775825484516289" LOG_CI_START="-0.02207757169764772" LOG_EFFECT_SIZE="0.007840341573757572" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.4474559087988558" P_Q="1.0" P_Z="0.6075095502199683" Q="0.0" RANDOM="YES" SCALE="29.402977755848397" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="439" TOTAL_2="535" WEIGHT="99.99999999999997" Z="0.5136316484259642">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.858070943737886" CI_END="1.0908329674789492" CI_START="0.9504350161307845" DF="8" EFFECT_SIZE="1.0182169950663005" ESTIMABLE="YES" EVENTS_1="325" EVENTS_2="398" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="0.03775825484516289" LOG_CI_START="-0.02207757169764772" LOG_EFFECT_SIZE="0.007840341573757572" MODIFIED="2013-10-08 15:49:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4474559087988558" P_Z="0.6075095502199683" STUDIES="9" TAU2="0.0" TOTAL_1="439" TOTAL_2="535" WEIGHT="99.99999999999997" Z="0.5136316484259642">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1685521339826255" CI_START="0.49676762322508666" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.06764809284797227" LOG_CI_START="-0.30384671700396126" LOG_EFFECT_SIZE="-0.11809931207799451" MODIFIED="2013-06-20 14:04:46 +0100" MODIFIED_BY="[Empty name]" ORDER="24658" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.047619047619047616" WEIGHT="2.5942814352486496"/>
<DICH_DATA CI_END="1.676059642552924" CI_START="1.0030014225087676" EFFECT_SIZE="1.2965686274509804" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.22428946893074173" LOG_CI_START="0.0013015489598698841" LOG_EFFECT_SIZE="0.11279550894530582" MODIFIED="2013-07-18 14:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.13098420799889596" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.01715686274509804" WEIGHT="7.200454595792169"/>
<DICH_DATA CI_END="1.205202052683593" CI_START="0.8475605080785928" EFFECT_SIZE="1.0106837606837606" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.08105986268634968" LOG_CI_START="-0.07182928735897469" LOG_EFFECT_SIZE="0.0046152876636875164" MODIFIED="2013-09-25 09:51:48 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.08980784355012197" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.008065448763123186" WEIGHT="15.316842847871406"/>
<DICH_DATA CI_END="1.301085657147728" CI_START="0.9146843162017692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" LOG_CI_END="0.11430588933792712" LOG_CI_START="-0.038728767559127575" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="24661" O_E="0.0" SE="0.08989331499509892" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.008080808080808077" WEIGHT="15.28772988628669"/>
<DICH_DATA CI_END="1.2036297827132891" CI_START="0.6777971674987193" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.08049292541899883" LOG_CI_START="-0.1689002504031058" LOG_EFFECT_SIZE="-0.04420366249205347" ORDER="24662" O_E="0.0" SE="0.14649478599403462" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.021460722323438" WEIGHT="5.756433047334915"/>
<DICH_DATA CI_END="1.3283039695893817" CI_START="0.6960426485088043" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.12329747052093552" LOG_CI_START="-0.15736414911849625" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="24663" O_E="0.0" SE="0.16486202467362576" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.02717948717948719" WEIGHT="4.54523701593429"/>
<DICH_DATA CI_END="1.1297688145289948" CI_START="0.8454755194106562" EFFECT_SIZE="0.9773391812865497" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="144" LOG_CI_END="0.05298958255741834" LOG_CI_START="-0.07289896280164447" LOG_EFFECT_SIZE="-0.009954690122113044" ORDER="24664" O_E="0.0" SE="0.0739475547022632" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.005468240846444209" WEIGHT="22.591764823718076"/>
<DICH_DATA CI_END="1.1571766123961384" CI_START="0.8859116568880813" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" LOG_CI_END="0.06339964757364357" LOG_CI_START="-0.05260958380023124" LOG_EFFECT_SIZE="0.005395031886706144" ORDER="24666" O_E="0.0" SE="0.06814439676397081" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.004643658810325475" WEIGHT="26.603421191846323"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-10-08 15:49:19 +0100" MODIFIED_BY="[Empty name]" ORDER="24665" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="0.10383515596746443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.02304976148776" CI_END="1.1175438857739202" CI_START="0.7685097726741268" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9267380415249369" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="393" I2="50.02879560856197" I2_Q="36.93629812579619" ID="CMP-002.20" LOG_CI_END="0.048264586815351125" LOG_CI_START="-0.11435060546877607" LOG_EFFECT_SIZE="-0.03304300932671248" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.004962007122826573" P_Q="0.11299716505489377" P_Z="0.42572999311709625" Q="14.271284007324422" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16774766485024328" TOTALS="SUB" TOTAL_1="1483" TOTAL_2="2738" WEIGHT="1000.0" Z="0.7965197754465778">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03752405859020125" CI_END="1.2626796033652534" CI_START="0.2609818666235742" DF="1" EFFECT_SIZE="0.574052680364597" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="0.10129316516914652" LOG_CI_START="-0.5833896669870231" LOG_EFFECT_SIZE="-0.24104825090893828" MODIFIED="2013-09-26 12:18:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8464020384781941" P_Z="0.167573391781611" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="245" WEIGHT="100.0" Z="1.38004304512818">
<NAME>angina pectoris - short term</NAME>
<DICH_DATA CI_END="1.6513453735745025" CI_START="0.1697263462229644" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21783791405694483" LOG_CI_START="-0.770250737934843" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="24667" O_E="0.0" SE="0.5804081652976865" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.33687363834422657" WEIGHT="48.01611893306678"/>
<DICH_DATA CI_END="1.8460443265451798" CI_START="0.20730542961962137" EFFECT_SIZE="0.6186234817813765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.266242124936291" LOG_CI_START="-0.6833893229762802" LOG_EFFECT_SIZE="-0.20857359901999462" ORDER="24668" O_E="0.0" SE="0.5578182132553242" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.3111611590393624" WEIGHT="51.98388106693322"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:12:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>bradycardia - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:12:57 +0000" MODIFIED_BY="[Empty name]" ORDER="943" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3974173278371012" CI_START="0.5867310705613672" DF="0" EFFECT_SIZE="0.9054878048780488" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="41" I2="0.0" ID="CMP-002.20.03" LOG_CI_END="0.1453261241604734" LOG_CI_START="-0.23156091294940687" LOG_EFFECT_SIZE="-0.04311739439446671" MODIFIED="2014-01-07 14:15:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6538244665717263" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="0.44845554131237353">
<NAME>dizziness - short term</NAME>
<DICH_DATA CI_END="1.3974173278371012" CI_START="0.5867310705613672" EFFECT_SIZE="0.9054878048780488" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="41" LOG_CI_END="0.1453261241604734" LOG_CI_START="-0.23156091294940687" LOG_EFFECT_SIZE="-0.04311739439446671" MODIFIED="2014-01-07 14:15:10 +0000" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.22138531121926572" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.04901145602365114" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.6309784367634865" CI_END="1.9563189054788042" CI_START="0.823557378227529" DF="5" EFFECT_SIZE="1.269307239707185" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" I2="24.596346562085195" ID="CMP-002.20.04" LOG_CI_END="0.29143965188334026" LOG_CI_START="-0.08430613762415141" LOG_EFFECT_SIZE="0.10356675712959443" MODIFIED="2014-01-07 14:14:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.24956294362544573" P_Z="0.27994222484753495" STUDIES="7" TAU2="0.0711042310809424" TOTAL_1="458" TOTAL_2="472" WEIGHT="99.99999999999997" Z="1.0804491740848359">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="2.371284396738129" CI_START="0.3612028381724999" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3749836436142605" LOG_CI_START="-0.4422488458507446" LOG_EFFECT_SIZE="-0.033632601118242046" MODIFIED="2013-09-25 10:52:39 +0100" MODIFIED_BY="[Empty name]" ORDER="24669" O_E="0.0" SE="0.48004640967780965" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.23044455544455544" WEIGHT="16.154959154804278"/>
<DICH_DATA CI_END="6.510623893834799" CI_START="0.4266530862592416" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.813622607718267" LOG_CI_START="-0.3699251084855542" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="24670" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.4833333333333333" WEIGHT="8.786396597507995"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24671" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4456037308157093" CI_START="0.49633840534858287" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16004926038200157" LOG_CI_START="-0.30422211894805007" LOG_EFFECT_SIZE="-0.07208642928302428" ORDER="24672" O_E="0.0" SE="0.2727153063988646" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.07437363834422658" WEIGHT="33.48625016814686"/>
<DICH_DATA CI_END="23.664827465355344" CI_START="1.1753640315007297" EFFECT_SIZE="5.273972602739726" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3741033424774858" LOG_CI_START="0.07017239629860393" LOG_EFFECT_SIZE="0.7221378693880448" MODIFIED="2013-12-17 15:43:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1310" O_E="0.0" SE="0.7659354923477566" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.5866571784380004" WEIGHT="7.406193581747241"/>
<DICH_DATA CI_END="4.724017763609372" CI_START="0.4762894875909387" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-10-07 16:41:29 +0100" MODIFIED_BY="[Empty name]" ORDER="24673" O_E="0.0" SE="0.5853140973807077" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.34259259259259256" WEIGHT="11.775551685996309"/>
<DICH_DATA CI_END="3.1757919718571133" CI_START="0.7084846929329139" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5018520465152974" LOG_CI_START="-0.14966952840393485" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="24674" O_E="0.0" SE="0.38270699819136633" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.14646464646464646" WEIGHT="22.390648811797305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.497921083369168" CI_START="0.701096354894045" DF="0" EFFECT_SIZE="1.0247863247863247" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="130" I2="0.0" ID="CMP-002.20.05" LOG_CI_END="0.17548893355029177" LOG_CI_START="-0.1542222908449178" LOG_EFFECT_SIZE="0.010633321352686995" MODIFIED="2014-01-07 14:14:49 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.8994000457520896" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.0" Z="0.12641927447593468">
<NAME>faintness, dizziness, weakness - long term</NAME>
<DICH_DATA CI_END="1.497921083369168" CI_START="0.701096354894045" EFFECT_SIZE="1.0247863247863247" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="130" LOG_CI_END="0.17548893355029177" LOG_CI_START="-0.1542222908449178" LOG_EFFECT_SIZE="0.010633321352686995" MODIFIED="2013-12-11 14:58:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1772" O_E="0.0" SE="0.19367400530662895" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.03750962033151214" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3070303481526142" CI_START="0.021252588218046743" DF="0" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.20.06" LOG_CI_END="0.11628567165261806" LOG_CI_START="-1.6725881724199052" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2014-01-14 10:35:13 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.08816659675843644" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.705149225956171">
<NAME>orthostatic hypotension - short term</NAME>
<DICH_DATA CI_END="1.3070303481526142" CI_START="0.021252588218046743" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11628567165261806" LOG_CI_START="-1.6725881724199052" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2014-01-14 10:35:13 +0000" MODIFIED_BY="[Empty name]" ORDER="1086" O_E="0.0" SE="1.050793351076541" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.1041666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.20.07" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-01-14 10:35:03 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>hypotension - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:24:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1018" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06498042478341914" CI_END="1.4536120496198779" CI_START="0.684673290836294" DF="1" EFFECT_SIZE="0.9976218449956537" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" ID="CMP-002.20.08" LOG_CI_END="0.16244851436996433" LOG_CI_START="-0.16451661366716688" LOG_EFFECT_SIZE="-0.0010340496486013042" MODIFIED="2014-01-14 10:35:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7987906214446248" P_Z="0.9901088456420956" STUDIES="2" TAU2="0.0" TOTAL_1="151" TOTAL_2="154" WEIGHT="100.0" Z="0.012397041125772081">
<NAME>lassitude - short term</NAME>
<DICH_DATA CI_END="1.5208062611490192" CI_START="0.61323610608356" EFFECT_SIZE="0.9657190635451505" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18207389184849138" LOG_CI_START="-0.21237228269694933" LOG_EFFECT_SIZE="-0.01514919542422894" MODIFIED="2013-09-25 09:55:58 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.23169963546804603" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.05368472107602542" WEIGHT="68.71117499222973"/>
<DICH_DATA CI_END="2.1000431855074875" CI_START="0.5466359890099396" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3222282257028509" LOG_CI_START="-0.26230177894796447" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="24675" O_E="0.0" SE="0.3433558182020772" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1178932178932179" WEIGHT="31.288825007770278"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5765172866710961" CI_END="0.7293231893925338" CI_START="0.06753765145901397" DF="1" EFFECT_SIZE="0.22193867478690904" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" I2="0.0" ID="CMP-002.20.09" LOG_CI_END="-0.13707997748992048" LOG_CI_START="-1.170454045508787" LOG_EFFECT_SIZE="-0.6537670114993538" MODIFIED="2014-01-14 10:34:58 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4476808086738798" P_Z="0.013139953276213924" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="245" WEIGHT="100.0" Z="2.479953458239331">
<NAME>palpitations - short term</NAME>
<DICH_DATA CI_END="0.8959793459734955" CI_START="0.01544771150364936" EFFECT_SIZE="0.11764705882352941" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.04770200153556025" LOG_CI_START="-1.811135849893025" LOG_EFFECT_SIZE="-0.9294189257142927" ORDER="24676" O_E="0.0" SE="1.035849771663506" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.0729847494553377" WEIGHT="34.339721815677905"/>
<DICH_DATA CI_END="1.3428804803367465" CI_START="0.07124517367981752" EFFECT_SIZE="0.30931174089068825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="0.1280373611124423" LOG_CI_START="-1.1472445504803939" LOG_EFFECT_SIZE="-0.5096035946839759" ORDER="24677" O_E="0.0" SE="0.7491069076169051" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.5611611590393624" WEIGHT="65.6602781843221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.034754811126687" CI_END="1.3884975056220832" CI_START="0.2109402637327546" DF="3" EFFECT_SIZE="0.5411931540847447" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="88" I2="62.662208486492446" ID="CMP-002.20.10" LOG_CI_END="0.1425451038950354" LOG_CI_START="-0.6758405153388519" LOG_EFFECT_SIZE="-0.2666477057219082" MODIFIED="2014-01-14 16:21:23 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.04529898423529766" P_Z="0.20153267037059508" STUDIES="4" TAU2="0.5035468376567388" TOTAL_1="181" TOTAL_2="232" WEIGHT="100.0" Z="1.2771971732944516">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="1.3152720650028022" CI_START="0.24661101512156308" EFFECT_SIZE="0.5695266272189349" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.1190155962540893" LOG_CI_START="-0.6079875291203599" LOG_EFFECT_SIZE="-0.24448596643313528" MODIFIED="2013-09-25 10:53:14 +0100" MODIFIED_BY="[Empty name]" ORDER="24678" O_E="0.0" SE="0.42704523456846155" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.18236763236763237" WEIGHT="33.69156756315329"/>
<DICH_DATA CI_END="7.502624006449645" CI_START="0.013085792076662656" EFFECT_SIZE="0.31333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752131823537016" LOG_CI_START="-1.8831999845936291" LOG_EFFECT_SIZE="-0.5039934011199637" ORDER="24679" O_E="0.0" SE="1.6203055486302531" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="2.6253900709219855" WEIGHT="7.385746144644306"/>
<DICH_DATA CI_END="0.4702930353776471" CI_START="0.14133163826863082" EFFECT_SIZE="0.2578125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="72" LOG_CI_END="-0.327631452722032" LOG_CI_START="-0.8497606068179296" LOG_EFFECT_SIZE="-0.5886960297699809" MODIFIED="2014-01-07 14:15:55 +0000" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.3067012496969267" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.09406565656565657" WEIGHT="38.66976332119758"/>
<DICH_DATA CI_END="11.955560443773642" CI_START="0.5227693029861222" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 16:21:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1080" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="20.25292297100483"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.185120416056849" CI_END="1.0832211311933881" CI_START="0.6979109354038379" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8694779312440201" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="161" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.03471712352641908" LOG_CI_START="-0.15619999676172602" LOG_EFFECT_SIZE="-0.06074143661765348" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.9478610387097051" P_Q="0.9091744883378099" P_Z="0.21234296869951452" Q="4.033790273085351" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1733" TOTAL_2="2155" WEIGHT="1000.0" Z="1.2471487937817556">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.903637374245642" CI_START="0.11385392694943419" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.21.01" LOG_CI_END="0.5914694673761394" LOG_CI_START="-0.9436519854875018" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-10-04 11:21:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.652963915781958" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.4496484953651478">
<NAME>confusion - short term</NAME>
<DICH_DATA CI_END="3.903637374245641" CI_START="0.11385392694943419" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5914694673761393" LOG_CI_START="-0.9436519854875018" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="24680" O_E="0.0" SE="0.9017379403858491" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.8131313131313131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5849640174898032" CI_START="0.705828653147122" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-002.21.02" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-09-25 09:54:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7857800257893043" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.2717945116579573">
<NAME>difficulty in concentration - short term</NAME>
<DICH_DATA CI_END="1.5849640174898032" CI_START="0.705828653147122" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-09-25 09:54:34 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.20636717904602125" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.04258741258741259" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03557261781435806" CI_END="6.775023152843606" CI_START="0.10435722391296587" DF="1" EFFECT_SIZE="0.8408463641931433" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.21.03" LOG_CI_END="0.8309107836992163" LOG_CI_START="-0.981477482420764" LOG_EFFECT_SIZE="-0.07528334936077385" MODIFIED="2013-10-04 11:21:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8504008736234558" P_Z="0.8706548391349584" STUDIES="4" TAU2="0.0" TOTAL_1="276" TOTAL_2="372" WEIGHT="100.0" Z="0.16282675863770493">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24681" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24682" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.212006660499437" CI_START="0.027414523923638235" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2098367734941284" LOG_CI_START="-1.5620192916054911" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="24683" O_E="0.0" SE="1.6282019735483269" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="2.6510416666666665" WEIGHT="42.75246242459357"/>
<DICH_DATA CI_END="15.76469725839569" CI_START="0.06343287052134396" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1976856350731" LOG_CI_START="-1.1976856350731" LOG_EFFECT_SIZE="0.0" ORDER="24684" O_E="0.0" SE="1.407052941362897" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="1.9797979797979797" WEIGHT="57.24753757540643"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.839140681370606" CI_START="0.37759180223609373" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-002.21.04" LOG_CI_END="0.26461495099237303" LOG_CI_START="-0.4229774430876227" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2013-10-04 11:21:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6516954428165782" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.45140810701374273">
<NAME>dysarticulation - short term</NAME>
<DICH_DATA CI_END="1.839140681370606" CI_START="0.37759180223609373" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.26461495099237303" LOG_CI_START="-0.4229774430876227" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="24685" O_E="0.0" SE="0.40389517591983337" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.16313131313131313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6414286772711852" CI_START="0.08967101684100356" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-002.21.05" LOG_CI_END="0.5612718080783154" LOG_CI_START="-1.0473479054509045" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-10-04 11:21:46 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5536887645343453" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="20" WEIGHT="100.0" Z="0.5922416818490355">
<NAME>electroencephalogram (increase) - short term</NAME>
<DICH_DATA CI_END="3.6414286772711852" CI_START="0.08967101684100356" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.5612718080783154" LOG_CI_START="-1.0473479054509045" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2013-06-27 09:55:08 +0100" MODIFIED_BY="[Empty name]" ORDER="24686" O_E="0.0" SE="0.944911182523068" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="20" VAR="0.8928571428571428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.047995964115266" CI_END="1.0316174997003367" CI_START="0.5011330645894003" DF="8" EFFECT_SIZE="0.7190115709144634" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="72" I2="0.0" ID="CMP-002.21.06" LOG_CI_END="0.013518700622578683" LOG_CI_START="-0.300046941709756" LOG_EFFECT_SIZE="-0.14326412054358864" MODIFIED="2013-12-17 15:36:45 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6418556466710441" P_Z="0.07329894116643021" STUDIES="9" TAU2="0.0" TOTAL_1="597" TOTAL_2="707" WEIGHT="99.99999999999999" Z="1.7909648165128935">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="5.242335393587904" CI_START="0.04768866950134176" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-06-19 16:35:04 +0100" MODIFIED_BY="[Empty name]" ORDER="24687" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="2.3600667798944053"/>
<DICH_DATA CI_END="2.0056894317039746" CI_START="0.13944245306226868" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3022636861424311" LOG_CI_START="-0.8556049857515041" LOG_EFFECT_SIZE="-0.2766706498045365" MODIFIED="2013-09-25 11:01:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24688" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="7.3339565750875835"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24689" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.2959295264598745"/>
<DICH_DATA CI_END="21.24440546987425" CI_START="0.18828486425154256" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3272445817533365" LOG_CI_START="-0.7251845904253741" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="24690" O_E="0.0" SE="1.2056070554260303" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.4534883720930232" WEIGHT="2.334106045315567"/>
<DICH_DATA CI_END="15.425791638464126" CI_START="0.06482649470685871" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" ORDER="24691" O_E="0.0" SE="1.3959648809042255" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.948717948717949" WEIGHT="1.7409374190503957"/>
<DICH_DATA CI_END="1.723554801119091" CI_START="0.3658849935962485" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2364250965314668" LOG_CI_START="-0.4366554022980026" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="24692" O_E="0.0" SE="0.39537081681463415" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.15631808278867101" WEIGHT="21.703157661450557"/>
<DICH_DATA CI_END="1.0306731150442916" CI_START="0.29189151434822735" EFFECT_SIZE="0.5484931506849315" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="0.013120947686449353" LOG_CI_START="-0.534778530312799" LOG_EFFECT_SIZE="-0.2608287913131748" MODIFIED="2013-12-17 15:36:45 +0000" MODIFIED_BY="[Empty name]" ORDER="1304" O_E="0.0" SE="0.3218388655229155" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.10358025536107729" WEIGHT="32.753307898998045"/>
<DICH_DATA CI_END="2.86998861253773" CI_START="0.6259747743052688" EFFECT_SIZE="1.3403508771929824" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.4578801735556515" LOG_CI_START="-0.20344316774925458" LOG_EFFECT_SIZE="0.1272185029031985" ORDER="24693" O_E="0.0" SE="0.3884646042858373" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.15090474878295215" WEIGHT="22.481704674369215"/>
<DICH_DATA CI_END="1.194811688029269" CI_START="0.09299466369832604" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07729946236010206" LOG_CI_START="-1.031541971799427" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24694" O_E="0.0" SE="0.6513389472789296" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.4242424242424242" WEIGHT="7.996833419374346"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0008335136944777" CI_START="0.25499576958333575" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-002.21.07" LOG_CI_END="0.30121095315801366" LOG_CI_START="-0.5934670245144897" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-12-18 10:22:22 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5220145904262905" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6402430689218759">
<NAME>headache - long term</NAME>
<DICH_DATA CI_END="2.0008335136944777" CI_START="0.25499576958333575" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.30121095315801366" LOG_CI_START="-0.5934670245144897" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-12-18 10:22:22 +0000" MODIFIED_BY="[Empty name]" ORDER="988" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.2761904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.21.08" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:23:11 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>hypertonia - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6836133721267887" CI_END="3.256628465586508" CI_START="0.5735877094514134" DF="4" EFFECT_SIZE="1.3667340861008903" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-002.21.09" LOG_CI_END="0.5127682146442629" LOG_CI_START="-0.2414001630840103" LOG_EFFECT_SIZE="0.13568402578012628" MODIFIED="2013-12-18 10:22:58 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6120852791639049" P_Z="0.4806593291826392" STUDIES="6" TAU2="0.0" TOTAL_1="312" TOTAL_2="414" WEIGHT="100.0" Z="0.7052425205297281">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-09-27 15:17:36 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="8.388966894741696"/>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-09-27 15:17:36 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="24.657101114549032"/>
<DICH_DATA CI_END="101.18091723147054" CI_START="0.24708216414768958" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0050986120834273" LOG_CI_START="-0.6071586034113897" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24697" O_E="0.0" SE="1.5344528192634188" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.354545454545454" WEIGHT="8.33498383879098"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24698" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.661924390573287" CI_START="0.049502041580710296" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7529640654925155" LOG_CI_START="-1.3053768893704134" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="24699" O_E="0.0" SE="1.2090796658385363" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.4618736383442266" WEIGHT="13.424620156338031"/>
<DICH_DATA CI_END="5.852128418430089" CI_START="0.4420645101363785" EFFECT_SIZE="1.608421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.7673138476657881" LOG_CI_START="-0.35451434976414137" LOG_EFFECT_SIZE="0.20639974895082336" ORDER="24700" O_E="0.0" SE="0.6589674363094776" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.4342380821162855" WEIGHT="45.19432799558025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.21.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-18 10:22:57 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>seizure - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24701" O_E="0.0" SE="0.0" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.37180868040278864" CI_END="1.7354788612682193" CI_START="0.4375082867364558" DF="1" EFFECT_SIZE="0.8713704053161284" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" I2="0.0" ID="CMP-002.21.11" LOG_CI_END="0.2394193281828978" LOG_CI_START="-0.35901371669919313" LOG_EFFECT_SIZE="-0.05979719425814765" MODIFIED="2013-12-18 10:22:57 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.5420203135288444" P_Z="0.6952867188832665" STUDIES="2" TAU2="0.0" TOTAL_1="134" TOTAL_2="230" WEIGHT="100.0" Z="0.39169076014379084">
<NAME>vertigo - short term</NAME>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24702" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="4.722347430758834"/>
<DICH_DATA CI_END="1.8510967729679597" CI_START="0.45117501201096166" EFFECT_SIZE="0.9138755980861244" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="0.26742912370556704" LOG_CI_START="-0.34565496143221996" LOG_EFFECT_SIZE="-0.03911291886332647" ORDER="24703" O_E="0.0" SE="0.36012862642510235" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.12969262757083092" WEIGHT="95.27765256924117"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.014164989322837" CI_END="1.4487211101178272" CI_START="0.1442386566278398" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4571231636570041" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.16098478851159323" LOG_CI_START="-0.8409183310848305" LOG_EFFECT_SIZE="-0.3399667712866187" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5473784268862891" P_Q="0.5478829854909145" P_Z="0.18348074989596838" Q="4.010655052137832" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="182" TOTAL_2="186" WEIGHT="600.0" Z="1.3301138895156641">
<NAME>Other adverse events: 6. Endocrine</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-26 16:30:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>amenorrhoea (women only) - short term</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-26 16:30:03 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853499025422034" CI_START="0.035761271399532814" DF="0" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-10-04 11:35:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.30704811123910736" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0214356188366485">
<NAME>amenorrhoea - medium term</NAME>
<DICH_DATA CI_END="2.853499025422034" CI_START="0.035761271399532814" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-10-04 11:35:32 +0100" MODIFIED_BY="[Empty name]" ORDER="24705" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.22.03" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-26 16:30:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>gynaecomastia - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-26 16:28:47 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0862492931267673E-32" CI_END="4.300210912127464" CI_START="0.010384714212089977" DF="0" EFFECT_SIZE="0.2113207547169811" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.0" ID="CMP-002.22.04" LOG_CI_END="0.6334897569113976" LOG_CI_START="-1.9836054507726129" LOG_EFFECT_SIZE="-0.6750578469306074" MODIFIED="2013-10-04 11:26:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.31196251858008384" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0111126745258967">
<NAME>lactation - short term</NAME>
<DICH_DATA CI_END="4.300210912127464" CI_START="0.010384714212089977" EFFECT_SIZE="0.21132075471698114" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6334897569113976" LOG_CI_START="-1.9836054507726129" LOG_EFFECT_SIZE="-0.6750578469306074" ORDER="24707" O_E="0.0" SE="1.5372946798237985" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.363274932614555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7961818474222007" CI_START="0.00971080982989066" DF="0" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.22.05" LOG_CI_END="0.5793470081389256" LOG_CI_START="-2.0127445507318265" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2013-10-04 11:27:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.27843661098111394" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0838380879702514">
<NAME>lactation - medium term</NAME>
<DICH_DATA CI_END="3.7961818474222007" CI_START="0.00971080982989066" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5793470081389256" LOG_CI_START="-2.0127445507318265" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2013-10-04 11:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="24708" O_E="0.0" SE="1.5226074127408329" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.3183333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.22.06" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-10-04 11:26:37 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>menorrhagia (women only) - short term</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-09-26 16:30:56 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.295621101798076" CI_END="1.0341904530764037" CI_START="0.7154721276127018" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8601944221042814" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="495" I2="27.145275421137747" I2_Q="1.2696526052918693" ID="CMP-002.23" LOG_CI_END="0.014600524351372678" LOG_CI_START="-0.14540728022674795" LOG_EFFECT_SIZE="-0.06540337793768762" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.07521796014802229" P_Q="0.43336730611649643" P_Z="0.10909477640737639" Q="12.154317610193267" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08818172183730669" TOTALS="SUB" TOTAL_1="2016" TOTAL_2="3312" WEIGHT="1300.0" Z="1.6022751585538317">
<NAME>Other adverse events: 7. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.82994119970993" CI_END="1.2818389533294599" CI_START="0.3982966529351512" DF="8" EFFECT_SIZE="0.7145293308976346" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="128" I2="57.514471685534325" ID="CMP-002.23.01" LOG_CI_END="0.10783346506283037" LOG_CI_START="-0.3997933431460374" LOG_EFFECT_SIZE="-0.14597993904160353" MODIFIED="2014-01-14 10:24:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01579608302679747" P_Z="0.25962971481143005" STUDIES="9" TAU2="0.36323070146262504" TOTAL_1="432" TOTAL_2="585" WEIGHT="99.99999999999999" Z="1.1272667966313183">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="5.242335393587904" CI_START="0.04768866950134176" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="24710" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="4.937595787939672"/>
<DICH_DATA CI_END="1.2031855130165963" CI_START="0.004123910226555628" EFFECT_SIZE="0.07044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.08033259414614691" LOG_CI_START="-2.384690797446687" LOG_EFFECT_SIZE="-1.1521791016502698" MODIFIED="2013-09-25 10:51:27 +0100" MODIFIED_BY="[Empty name]" ORDER="24711" O_E="0.0" SE="1.4479669422842112" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.0966082659478884" WEIGHT="3.614578207985464"/>
<DICH_DATA CI_END="1.1050846251014352" CI_START="0.05655675464153993" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04339553667030915" LOG_CI_START="-1.2475155193262337" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="24712" O_E="0.0" SE="0.758287544405155" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.575" WEIGHT="9.476646109421413"/>
<DICH_DATA CI_END="3.6375601547959784" CI_START="0.39586974200314384" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.560810184036558" LOG_CI_START="-0.4024476919413084" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="24713" O_E="0.0" SE="0.5658224445527854" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.32015503875969" WEIGHT="13.010631921969939"/>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24714" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="2.9837538775160035"/>
<DICH_DATA CI_END="2.8568388370093993" CI_START="0.6632055178374009" EFFECT_SIZE="1.3764705882352941" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4558857411976872" LOG_CI_START="-0.17835186913394935" LOG_EFFECT_SIZE="0.1387669360318689" ORDER="24715" O_E="0.0" SE="0.37255431183560805" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.1387967152673035" WEIGHT="17.710746525898752"/>
<DICH_DATA CI_END="1.9855598365273692" CI_START="0.5089516810472455" EFFECT_SIZE="1.0052631578947369" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.29788297942915565" LOG_CI_START="-0.2933234468393585" LOG_EFFECT_SIZE="0.0022797662948985833" ORDER="24716" O_E="0.0" SE="0.3472775813091335" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.12060171847992182" WEIGHT="18.376776669515678"/>
<DICH_DATA CI_END="0.6105301601259533" CI_START="0.23358814548339707" EFFECT_SIZE="0.37764084507042256" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="71" LOG_CI_END="-0.21429287708725517" LOG_CI_START="-0.6315492012932964" LOG_EFFECT_SIZE="-0.4229210391902758" MODIFIED="2014-01-07 14:17:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1045" O_E="0.0" SE="0.24509843029074466" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.06007324053098701" WEIGHT="21.00448270072969"/>
<DICH_DATA CI_END="11.955560443773642" CI_START="0.5227693029861222" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 10:24:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1079" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="8.884788199023369"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.23.02" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-25 10:51:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>diarrhoea - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-25 10:51:01 +0100" MODIFIED_BY="[Empty name]" ORDER="24717" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5639184979939795" CI_START="0.21910996010107084" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-002.23.03" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:17:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>diarrhoea - long term</NAME>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:17:57 +0000" MODIFIED_BY="[Empty name]" ORDER="972" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3003382873118703" CI_START="0.27072255088278646" DF="0" EFFECT_SIZE="0.5933219178082192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-002.23.04" LOG_CI_END="0.11405635015360835" LOG_CI_START="-0.5674755664827562" LOG_EFFECT_SIZE="-0.22670960816457392" MODIFIED="2013-12-18 10:16:58 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.19224973461156694" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.3039526282048928">
<NAME>dyspepsia - short term</NAME>
<DICH_DATA CI_END="1.3003382873118703" CI_START="0.27072255088278646" EFFECT_SIZE="0.5933219178082192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.11405635015360835" LOG_CI_START="-0.5674755664827562" LOG_EFFECT_SIZE="-0.22670960816457392" MODIFIED="2013-12-17 15:39:45 +0000" MODIFIED_BY="[Empty name]" ORDER="1306" O_E="0.0" SE="0.4003352214695972" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.16026828954911146" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.23.05" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:21:26 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>gastroenteritis - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:21:26 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.961364031061661" CI_START="0.013956290740833538" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.23.06" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:20:55 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.497411635240814" STUDIES="3" TAU2="0.0" TOTAL_1="177" TOTAL_2="273" WEIGHT="100.0" Z="0.6785679898446393">
<NAME>icterus - short term</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24718" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24719" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24720" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9667536745294448" CI_END="1.3296132538175678" CI_START="0.6860198008861818" DF="5" EFFECT_SIZE="0.9550607413351029" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="71" I2="0.0" ID="CMP-002.23.07" LOG_CI_END="0.12372533558500046" LOG_CI_START="-0.16366334888289844" LOG_EFFECT_SIZE="-0.019969006648948948" MODIFIED="2013-12-18 10:20:54 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9652025096836033" P_Z="0.7853348313417092" STUDIES="6" TAU2="0.0" TOTAL_1="300" TOTAL_2="399" WEIGHT="100.00000000000001" Z="0.2723735202827904">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="2.7099337547351947" CI_START="0.23616813469395628" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-06-20 14:06:11 +0100" MODIFIED_BY="[Empty name]" ORDER="24721" O_E="0.0" SE="0.6224949798994366" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.3875" WEIGHT="7.3543251322113115"/>
<DICH_DATA CI_END="5.579155313499883" CI_START="0.31864640395941085" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="24722" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="5.343376853872282"/>
<DICH_DATA CI_END="2.2002701344388558" CI_START="0.34796863713066783" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3424760038649878" LOG_CI_START="-0.4584598978203613" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="24723" O_E="0.0" SE="0.47047371334662913" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.22134551495016613" WEIGHT="12.874898275546668"/>
<DICH_DATA CI_END="2.339589918993734" CI_START="0.15387311984778823" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36913974137361255" LOG_CI_START="-0.8128372406063252" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="24724" O_E="0.0" SE="0.6942991300954381" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.482051282051282" WEIGHT="5.911821200028907"/>
<DICH_DATA CI_END="1.7724691599176847" CI_START="0.4647023843093167" EFFECT_SIZE="0.907563025210084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.24857868741273917" LOG_CI_START="-0.33282509922390124" LOG_EFFECT_SIZE="-0.04212320590558106" ORDER="24725" O_E="0.0" SE="0.3415194622655221" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.11663554310613136" WEIGHT="24.433383793984092"/>
<DICH_DATA CI_END="1.7465707396767658" CI_START="0.6446671552117238" EFFECT_SIZE="1.0611111111111111" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="36" LOG_CI_END="0.2421861801420674" LOG_CI_START="-0.19066445585322442" LOG_EFFECT_SIZE="0.02576086214442147" ORDER="24726" O_E="0.0" SE="0.2542586062288387" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.06464743884143166" WEIGHT="44.08219474435675"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.162386112457482" CI_END="1.669292652648942" CI_START="0.7515722671657725" DF="5" EFFECT_SIZE="1.1200866321470548" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="48" I2="0.0" ID="CMP-002.23.08" LOG_CI_END="0.22253248184930818" LOG_CI_START="-0.1240292536368182" LOG_EFFECT_SIZE="0.049251614106245" MODIFIED="2013-12-18 10:20:54 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5262813702091929" P_Z="0.5774724428341356" STUDIES="7" TAU2="0.0" TOTAL_1="352" TOTAL_2="454" WEIGHT="100.0" Z="0.5570804849144658">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="1.9128896710037826" CI_START="0.08364308847777954" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28168992211510563" LOG_CI_START="-1.077569939459181" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-06-20 14:06:39 +0100" MODIFIED_BY="[Empty name]" ORDER="24727" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="6.500641775847167"/>
<DICH_DATA CI_END="2.2318509903721298" CI_START="0.2557392721532988" EFFECT_SIZE="0.7554945054945055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.34866519554358555" LOG_CI_START="-0.5922025751811721" LOG_EFFECT_SIZE="-0.12176868981879335" MODIFIED="2013-09-25 10:50:32 +0100" MODIFIED_BY="[Empty name]" ORDER="24728" O_E="0.0" SE="0.5526703858943008" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.30544455544455545" WEIGHT="13.567631369532855"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24729" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.5830173082255155"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24730" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.488676176282748" CI_START="0.2650589978077466" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.92883996654976" LOG_CI_START="-0.5766574484383975" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="24731" O_E="0.0" SE="0.8843366338964376" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.7820512820512819" WEIGHT="5.299088726295087"/>
<DICH_DATA CI_END="1.976416612516051" CI_START="0.3630351242623974" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.295878495639222" LOG_CI_START="-0.44005135420527053" LOG_EFFECT_SIZE="-0.07208642928302428" ORDER="24732" O_E="0.0" SE="0.4322888367101637" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.18687363834422657" WEIGHT="22.176263965433737"/>
<DICH_DATA CI_END="2.6382418153450513" CI_START="0.8618415962369781" EFFECT_SIZE="1.5078947368421052" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.42131459949576794" LOG_CI_START="-0.06457254879460829" LOG_EFFECT_SIZE="0.1783710253505798" ORDER="24733" O_E="0.0" SE="0.28541251608594126" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.08146030433850768" WEIGHT="50.87335685466563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853499025422034" CI_START="0.035761271399532814" DF="0" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.23.09" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-12-18 10:20:53 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.30704811123910736" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0214356188366485">
<NAME>nausea and vomiting - medium term</NAME>
<DICH_DATA CI_END="2.853499025422034" CI_START="0.035761271399532814" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-10-04 11:30:42 +0100" MODIFIED_BY="[Empty name]" ORDER="24734" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.23.10" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:31:38 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>nausea and vomiting - long term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:31:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1045" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1411460120286314" CI_END="12.19594919575825" CI_START="0.75472862887267" DF="1" EFFECT_SIZE="3.033913646482933" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="12.368795100787686" ID="CMP-002.23.11" LOG_CI_END="1.0862156065716797" LOG_CI_START="-0.12220917574650385" LOG_EFFECT_SIZE="0.482003215412588" MODIFIED="2013-12-18 10:30:57 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.2854103423636756" P_Z="0.11792614034351585" STUDIES="2" TAU2="0.18234650003862057" TOTAL_1="84" TOTAL_2="87" WEIGHT="100.0" Z="1.563537849379239">
<NAME>weight loss - short term</NAME>
<DICH_DATA CI_END="191.0359474772963" CI_START="0.6333886454243398" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="24735" O_E="0.0" SE="1.4564381625088383" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.121212121212121" WEIGHT="21.873343927992003"/>
<DICH_DATA CI_END="8.022757726815898" CI_START="0.5577698122490747" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9043236774703935" LOG_CI_START="-0.2535449944235417" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2013-09-25 11:01:07 +0100" MODIFIED_BY="[Empty name]" ORDER="24736" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="78.12665607200799"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.333909508537067" CI_END="8.098841427408532" CI_START="0.28780868723075265" DF="2" EFFECT_SIZE="1.5267340696114975" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="68.42392526599362" ID="CMP-002.23.12" LOG_CI_END="0.9084228957093513" LOG_CI_START="-0.5408961014368046" LOG_EFFECT_SIZE="0.1837633971362734" MODIFIED="2014-01-14 10:33:12 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.042131750644091914" P_Z="0.6191755566835566" STUDIES="3" TAU2="1.4721351666997446" TOTAL_1="116" TOTAL_2="119" WEIGHT="100.0" Z="0.4970191390205116">
<NAME>weight gain - short term</NAME>
<DICH_DATA CI_END="40.4396582525386" CI_START="0.6182050264589122" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.606807476798691" LOG_CI_START="-0.20886746812665352" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="24737" O_E="0.0" SE="1.0665364503850772" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.1375" WEIGHT="27.77303730472962"/>
<DICH_DATA CI_END="0.9654204139337209" CI_START="0.262762644747902" EFFECT_SIZE="0.5036630036630036" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.015283522209852666" LOG_CI_START="-0.5804363755390965" LOG_EFFECT_SIZE="-0.2978599488744746" MODIFIED="2013-09-25 11:00:42 +0100" MODIFIED_BY="[Empty name]" ORDER="24738" O_E="0.0" SE="0.33197358359734014" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.11020646020646019" WEIGHT="45.80394878329425"/>
<DICH_DATA CI_END="27.33325429307962" CI_START="0.32926924483626774" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:33:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1083" O_E="0.0" SE="1.1273124382057236" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.2708333333333333" WEIGHT="26.423013911976124"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9453803236952482" CI_START="0.45614940296066625" DF="0" EFFECT_SIZE="0.6566846048327529" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="195" I2="0.0" ID="CMP-002.23.13" LOG_CI_END="-0.024393440957903512" LOG_CI_START="-0.3408928892339426" LOG_EFFECT_SIZE="-0.18264316509592307" MODIFIED="2013-12-18 10:30:56 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.02369226990969934" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="1073" WEIGHT="100.0" Z="2.262083094048244">
<NAME>weight gain - long term</NAME>
<DICH_DATA CI_END="0.9453803236952482" CI_START="0.45614940296066625" EFFECT_SIZE="0.6566846048327529" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="195" LOG_CI_END="-0.024393440957903512" LOG_CI_START="-0.3408928892339426" LOG_EFFECT_SIZE="-0.18264316509592307" MODIFIED="2013-12-11 15:00:48 +0000" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.1859133426148817" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="1073" VAR="0.034563770962238394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6780812614589875" CI_END="1.345758920401307" CI_START="0.48970163608806694" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8118006806480459" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.12896726723060062" LOG_CI_START="-0.3100684450060163" LOG_EFFECT_SIZE="-0.09055058888770787" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9986154305724569" P_Q="0.9476854057566086" P_Z="0.41881406884681116" Q="2.204103111172092" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="773" TOTAL_2="983" WEIGHT="800.0" Z="0.808480440439206">
<NAME>Other adverse events: 8. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:16:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>cellulitis - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:16:09 +0000" MODIFIED_BY="[Empty name]" ORDER="957" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.24.02" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:19:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>eczema - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:19:14 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.24.03" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:20:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>fungal dermatitis - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:20:08 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.15558495228966" CI_START="0.1322085197831653" DF="0" EFFECT_SIZE="3.173076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.24.04" LOG_CI_END="1.8817017582960938" LOG_CI_START="-0.8787405571378796" LOG_EFFECT_SIZE="0.5014806005791071" MODIFIED="2013-12-18 10:19:55 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.47639010543338767" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.00000000000001" Z="0.7121205979093574">
<NAME>oedema</NAME>
<DICH_DATA CI_END="76.15558495228966" CI_START="0.1322085197831653" EFFECT_SIZE="3.173076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8817017582960938" LOG_CI_START="-0.8787405571378796" LOG_EFFECT_SIZE="0.5014806005791071" ORDER="24753" O_E="0.0" SE="1.6214974804957543" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="2.6292540792540793" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.013874582957062998" CI_END="1.9334790071802563" CI_START="0.30782870931298656" DF="2" EFFECT_SIZE="0.7714793239381422" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-002.24.05" LOG_CI_END="0.28633946106630254" LOG_CI_START="-0.5116908786086009" LOG_EFFECT_SIZE="-0.11267570877114914" MODIFIED="2013-12-18 10:19:54 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9930867160763092" P_Z="0.5799460722248027" STUDIES="3" TAU2="0.0" TOTAL_1="198" TOTAL_2="300" WEIGHT="100.0" Z="0.5534634966734243">
<NAME>pruritus - short term</NAME>
<DICH_DATA CI_END="3.375539620476798" CI_START="0.1864223630106055" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-09-25 10:59:54 +0100" MODIFIED_BY="[Empty name]" ORDER="24761" O_E="0.0" SE="0.7388644976724391" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.5459207459207458" WEIGHT="40.251717035670374"/>
<DICH_DATA CI_END="4.05308776088479" CI_START="0.12293587644522143" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="24762" O_E="0.0" SE="0.8917437814067222" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.7952069716775598" WEIGHT="27.633368634014023"/>
<DICH_DATA CI_END="4.0688574525801755" CI_START="0.15895237868974596" EFFECT_SIZE="0.8042105263157895" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.6094724751464152" LOG_CI_START="-0.7987329685727309" LOG_EFFECT_SIZE="-0.09463024671315783" ORDER="24763" O_E="0.0" SE="0.8271868483699952" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.6842380821162855" WEIGHT="32.11491433031561"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4578385852665938" CI_END="2.1661983346919493" CI_START="0.37246729013293156" DF="6" EFFECT_SIZE="0.898241628746508" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-002.24.06" LOG_CI_END="0.33569821762583013" LOG_CI_START="-0.42891186073722465" LOG_EFFECT_SIZE="-0.04660682155569725" MODIFIED="2013-12-18 10:30:02 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9622458466729652" P_Z="0.8111526649378028" STUDIES="7" TAU2="0.0" TOTAL_1="352" TOTAL_2="454" WEIGHT="99.99999999999999" Z="0.23893928230351602">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24754" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="7.7405305497494705"/>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-09-25 10:59:18 +0100" MODIFIED_BY="[Empty name]" ORDER="24755" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="25.344598490613294"/>
<DICH_DATA CI_END="5.296053860021452" CI_START="0.0472049579947035" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="24756" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="13.911925334972922"/>
<DICH_DATA CI_END="71.652276279555" CI_START="0.12560661666750192" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017108" LOG_CI_START="-0.9009874823623856" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24757" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="7.69578759859485"/>
<DICH_DATA CI_END="15.425791638464126" CI_START="0.06482649470685871" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" ORDER="24758" O_E="0.0" SE="1.3959648809042255" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.948717948717949" WEIGHT="10.35157075911472"/>
<DICH_DATA CI_END="16.484477848028508" CI_START="0.06800987430548595" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2170751952576753" LOG_CI_START="-1.1674280278076108" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="24759" O_E="0.0" SE="1.4006689967098673" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.9618736383442266" WEIGHT="10.28215647605911"/>
<DICH_DATA CI_END="7.886276657198984" CI_START="0.227805915526946" EFFECT_SIZE="1.3403508771929824" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.8968720084190938" LOG_CI_START="-0.6424350026126966" LOG_EFFECT_SIZE="0.1272185029031985" ORDER="24760" O_E="0.0" SE="0.9041965579726671" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.8175714154496188" WEIGHT="24.673430790895623"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.24.07" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:30:15 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>rash - long term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:30:15 +0000" MODIFIED_BY="[Empty name]" ORDER="1042" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.891100991947133" CI_START="0.23108087533137314" DF="0" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-002.24.08" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-12-18 10:30:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.4402112377838353" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.7718365664995955">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="1.891100991947133" CI_START="0.23108087533137314" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-09-25 10:58:43 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.536271771201331" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2875874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.279681737033364" CI_END="1.1796553143580943" CI_START="0.7717629569199713" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.954156315052917" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="355" I2="0.0" I2_Q="7.653434647910453" ID="CMP-002.25" LOG_CI_END="0.07175512854343088" LOG_CI_START="-0.11251607053182795" LOG_EFFECT_SIZE="-0.020380470994198492" METHOD="MH" MODIFIED="2015-01-26 14:52:41 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.7629101621996215" P_Q="0.37106697871918615" P_Z="0.6646184048415438" Q="7.580141149062897" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1269" TOTAL_2="3364" WEIGHT="800.0" Z="0.43354565810665024">
<NAME>Other adverse events: 9. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0016134384012108113" CI_END="1.2968356411634798" CI_START="0.8155813733349366" DF="2" EFFECT_SIZE="1.0284332711507362" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="291" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="0.11288493779659918" LOG_CI_START="-0.08853270142041572" LOG_EFFECT_SIZE="0.012176118188091693" MODIFIED="2013-12-11 14:54:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9991936061972936" P_Z="0.8126817270439929" STUDIES="4" TAU2="0.0" TOTAL_1="459" TOTAL_2="1499" WEIGHT="100.0" Z="0.2369678565684118">
<NAME>diminished sexual desire</NAME>
<DICH_DATA CI_END="1.301174148964213" CI_START="0.8121753548738241" EFFECT_SIZE="1.0279988211022695" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="286" LOG_CI_END="0.11433542636379791" LOG_CI_START="-0.09035019313297411" LOG_EFFECT_SIZE="0.011992616615411922" MODIFIED="2013-12-11 14:54:50 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.12023334610256127" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.014456057515018286" WEIGHT="96.83232046960062"/>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-09-26 16:25:51 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="2.2245602216525553"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24740" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.94693992395439" CI_START="0.09231383597978618" EFFECT_SIZE="1.0052631578947369" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.0392927347129126" LOG_CI_START="-1.0347332021231155" LOG_EFFECT_SIZE="0.0022797662948985833" ORDER="24741" O_E="0.0" SE="1.2182931018914478" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="1.4842380821162855" WEIGHT="0.943119308746828"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.42684164198362" CI_START="0.022752978588870532" DF="0" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.25.02" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-09-26 16:27:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10453041457457127" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="1.6232760143036378">
<NAME>ejaculatory dysfunction (men only) - short term</NAME>
<DICH_DATA CI_END="1.42684164198362" CI_START="0.022752978588870532" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-09-26 16:27:14 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.0557649547317054" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="1.1146396396396399" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.704826166858263" CI_START="0.3000645450671526" DF="0" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-002.25.03" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-09-26 16:27:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.852406310146861" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="0.18604903261707173">
<NAME>erectile dysfunction (men only) - short term</NAME>
<DICH_DATA CI_END="2.704826166858263" CI_START="0.3000645450671526" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-09-26 16:27:10 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.5609274816227492" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="0.31463963963963965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.25.04" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-26 16:29:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>galactorrhoea - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-09-26 16:29:35 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5581732309163305" CI_START="0.19899112871775804" DF="0" EFFECT_SIZE="0.5568326947637292" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="33" I2="0.0" ID="CMP-002.25.05" LOG_CI_END="0.19261573899049356" LOG_CI_START="-0.7011662845692084" LOG_EFFECT_SIZE="-0.2542752727893574" MODIFIED="2015-01-26 14:52:41 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2647671211531385" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.0" Z="1.1151944516434962">
<NAME>galactorrhoea/ gynaecomastia - long term</NAME>
<DICH_DATA CI_END="1.5581732309163305" CI_START="0.19899112871775804" EFFECT_SIZE="0.5568326947637292" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="33" LOG_CI_END="0.19261573899049356" LOG_CI_START="-0.7011662845692084" LOG_EFFECT_SIZE="-0.2542752727893574" MODIFIED="2013-12-11 14:55:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.5250119849313396" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.2756375843215451" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.007022459510349" CI_START="0.2234287996105537" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-002.25.06" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-11 14:55:10 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9436301877371425" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="109" WEIGHT="100.0" Z="0.07070795723063611">
<NAME>increased sexual desire - short term</NAME>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-09-26 16:25:44 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24745" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5429866302783413" CI_END="1.628157926253459" CI_START="0.21523532878416593" DF="3" EFFECT_SIZE="0.5919772855183795" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" ID="CMP-002.25.07" LOG_CI_END="0.21169652780992612" LOG_CI_START="-0.6670864419427451" LOG_EFFECT_SIZE="-0.22769495706640955" MODIFIED="2013-12-11 14:55:10 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9093508837950847" P_Z="0.30978964514095897" STUDIES="5" TAU2="0.0" TOTAL_1="268" TOTAL_2="367" WEIGHT="100.0" Z="1.0156635498686508">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="5.296053860021452" CI_START="0.0472049579947035" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="24747" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="18.376824413422923"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24748" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24749" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="10.18333582145092"/>
<DICH_DATA CI_END="7.2383708843989485" CI_START="0.15488392130504644" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8596408320080514" LOG_CI_START="-0.8099936645579872" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="24750" O_E="0.0" SE="0.9807515681069424" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.9618736383442266" WEIGHT="27.702594537607308"/>
<DICH_DATA CI_END="2.3208341686785467" CI_START="0.10885676691798012" EFFECT_SIZE="0.5026315789473684" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.36564410977914324" LOG_CI_START="-0.9631445685173083" LOG_EFFECT_SIZE="-0.29875022936908263" ORDER="24751" O_E="0.0" SE="0.7805370472413756" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="0.6092380821162855" WEIGHT="43.73724522751884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.50527280318661" CI_START="0.2596178553022495" DF="0" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.25.08" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-12-11 14:55:10 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2789217673806622" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0827447147660128">
<NAME>orgastic dysfunction - short term</NAME>
<DICH_DATA CI_END="107.50527280318661" CI_START="0.2596178553022495" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-09-26 16:25:36 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5372946798237985" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.363274932614555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.774136163582941" CI_END="0.9882810911382424" CI_START="0.6587007440411777" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8068342395155198" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="439" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="-0.005119513946918242" LOG_CI_START="-0.18131184599708455" LOG_EFFECT_SIZE="-0.09321567997200142" METHOD="MH" MODIFIED="2015-01-28 11:34:10 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.696038653524431" P_Q="0.6233941768448001" P_Z="0.038092039999388656" Q="8.055720733330123" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1594" TOTAL_2="4616" WEIGHT="1100.0" Z="2.07386295888876">
<NAME>Other adverse events: 10. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.26.01" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2013-10-04 11:34:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>abdominal pain - medium term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-10-04 11:34:52 +0100" MODIFIED_BY="[Empty name]" ORDER="24764" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.26.02" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:07:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>allergic reaction - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:07:43 +0000" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.26.03" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:11:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>back pain - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:11:55 +0000" MODIFIED_BY="[Empty name]" ORDER="942" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09117886060233743" CI_END="4.464419481435155" CI_START="0.049581460263958065" DF="1" EFFECT_SIZE="0.47048106988530086" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.26.04" LOG_CI_END="0.6497649946018885" LOG_CI_START="-1.3046806866194263" LOG_EFFECT_SIZE="-0.3274578460087689" MODIFIED="2013-12-18 10:11:39 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7626838110873173" P_Z="0.51133215112528" STUDIES="3" TAU2="0.0" TOTAL_1="177" TOTAL_2="273" WEIGHT="100.0" Z="0.6567648216564319">
<NAME>cramps - short term</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="24765" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="50.28289178266727"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24766" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.212006660499437" CI_START="0.027414523923638235" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2098367734941284" LOG_CI_START="-1.5620192916054911" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="24767" O_E="0.0" SE="1.6282019735483269" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="2.6510416666666665" WEIGHT="49.71710821733273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.683465127741492" CI_START="0.6003233389948932" DF="0" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-002.26.05" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-12-18 10:11:38 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5325490557720918" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.6241195857360581">
<NAME>failing memory - short term</NAME>
<DICH_DATA CI_END="2.683465127741492" CI_START="0.6003233389948932" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-09-25 09:58:05 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.3819957407102152" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.14592074592074594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.26.06" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:11:38 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>muscle pain - short term</NAME>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24768" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6253661517968636" CI_END="1.3693848164533702" CI_START="0.3876657810048541" DF="4" EFFECT_SIZE="0.7286038940100337" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" I2="0.0" ID="CMP-002.26.07" LOG_CI_END="0.1365255081617408" LOG_CI_START="-0.41154253217989173" LOG_EFFECT_SIZE="-0.13750851200907555" MODIFIED="2014-01-14 16:21:49 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.45907390563805317" P_Z="0.32536273448056374" STUDIES="6" TAU2="0.0" TOTAL_1="312" TOTAL_2="414" WEIGHT="100.00000000000001" Z="0.9834973443716373">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="4.008199669020626" CI_START="0.009979542763091372" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6029493478377236" LOG_CI_START="-2.0008893565097607" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="24770" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="4.430378174216179"/>
<DICH_DATA CI_END="2.0723149610069576" CI_START="0.4461465705813854" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.31645576238212664" LOG_CI_START="-0.3505224409796873" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="24772" O_E="0.0" SE="0.39178629825008365" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1534965034965035" WEIGHT="67.5220582481907"/>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" ORDER="24773" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="5.305585637492075"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24774" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.05308776088479" CI_START="0.12293587644522143" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="24775" O_E="0.0" SE="0.8917437814067222" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.7952069716775598" WEIGHT="13.033587756555873"/>
<DICH_DATA CI_END="1.2694583161742763" CI_START="0.02211253772453232" EFFECT_SIZE="0.1675438596491228" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="0.10361844498704834" LOG_CI_START="-1.6553614131645384" LOG_EFFECT_SIZE="-0.7758714840887451" ORDER="24776" O_E="0.0" SE="1.033233475768966" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="191" VAR="1.0675714154496188" WEIGHT="9.708390183545186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9239250126722633" CI_START="0.17783011212014527" DF="0" EFFECT_SIZE="0.4053414469235971" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="68" I2="0.0" ID="CMP-002.26.08" LOG_CI_END="-0.034363275429452396" LOG_CI_START="-0.7499946976945976" LOG_EFFECT_SIZE="-0.39217898656202493" MODIFIED="2014-01-14 16:21:49 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.03169854125575253" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.00000000000001" Z="2.148191555708954">
<NAME>incontinence nocturia - long term</NAME>
<DICH_DATA CI_END="0.9239250126722633" CI_START="0.17783011212014527" EFFECT_SIZE="0.405341446923597" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="68" LOG_CI_END="-0.034363275429452396" LOG_CI_START="-0.7499946976945976" LOG_EFFECT_SIZE="-0.392178986562025" MODIFIED="2013-12-11 14:56:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.42036543987121805" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.17670710303812262" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1014135696910377" CI_START="0.6692015857119585" DF="0" EFFECT_SIZE="0.8585264744676842" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="305" I2="0.0" ID="CMP-002.26.09" LOG_CI_END="0.041950422795014534" LOG_CI_START="-0.17444303862246802" LOG_EFFECT_SIZE="-0.06624630791372675" MODIFIED="2014-01-14 16:21:49 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.23012392503011592" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.0" Z="1.2000397495297457">
<NAME>urinary hesitancy, dry mouth, constipation - long term</NAME>
<DICH_DATA CI_END="1.1014135696910377" CI_START="0.6692015857119585" EFFECT_SIZE="0.8585264744676842" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="305" LOG_CI_END="0.041950422795014534" LOG_CI_START="-0.17444303862246802" LOG_EFFECT_SIZE="-0.06624630791372675" MODIFIED="2013-12-11 14:53:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.12711059040153877" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.01615710219222776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.332715923170002" CI_START="0.09256884481928429" DF="0" EFFECT_SIZE="0.7656449553001277" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.26.10" LOG_CI_END="0.8015900066177445" LOG_CI_START="-1.0335351558638963" LOG_EFFECT_SIZE="-0.11597257462307595" MODIFIED="2014-01-14 16:21:49 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.8043481330002937" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="100.0" Z="0.24772377830428957">
<NAME>suicide attempt - long term</NAME>
<DICH_DATA CI_END="6.332715923170002" CI_START="0.09256884481928429" EFFECT_SIZE="0.7656449553001277" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.8015900066177445" LOG_CI_START="-1.0335351558638963" LOG_EFFECT_SIZE="-0.11597257462307595" MODIFIED="2013-12-11 14:54:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="1.0779616044577753" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="1.1620012206851815" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4011553218769022" CI_START="0.28585905270768946" DF="0" EFFECT_SIZE="0.6328767123287671" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-002.26.11" LOG_CI_END="0.14648628067842998" LOG_CI_START="-0.5438480498070909" LOG_EFFECT_SIZE="-0.19868088456433042" MODIFIED="2015-01-28 11:34:10 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.25924798152858397" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.128170397925227">
<NAME>psychosis - short term</NAME>
<DICH_DATA CI_END="1.4011553218769022" CI_START="0.28585905270768946" EFFECT_SIZE="0.6328767123287671" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.14648628067842998" LOG_CI_START="-0.5438480498070909" LOG_EFFECT_SIZE="-0.19868088456433042" MODIFIED="2015-01-28 11:33:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1300" O_E="0.0" SE="0.4055058029372429" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.1644349562157781" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.853607788418444" CI_END="4.188019275167201" CI_START="1.8013528543906612" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7466525946259646" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="68" I2="71.34295575337441" I2_Q="69.43520326347799" ID="CMP-002.27" LOG_CI_END="0.6220086718318977" LOG_CI_START="0.2555987920560566" LOG_EFFECT_SIZE="0.4388037319439771" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="9.48709277226456E-6" P_Q="5.357645019743451E-5" P_Z="2.6737437333764317E-6" Q="42.53259104604561" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3130328899115677" TOTALS="SUB" TOTAL_1="893" TOTAL_2="1119" WEIGHT="1400.0" Z="4.6944122326511">
<NAME>Other adverse events: 11. Lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0598122421460827" CI_END="9.590930574546432" CI_START="0.6213264127604082" DF="1" EFFECT_SIZE="2.4411264795002032" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="51.45188578168089" ID="CMP-002.27.01" LOG_CI_END="0.9818607472940806" LOG_CI_START="-0.20668018401399307" LOG_EFFECT_SIZE="0.3875902816400438" MODIFIED="2014-01-14 10:33:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1512288482317392" P_Z="0.20113950839304595" STUDIES="2" TAU2="0.611353155173118" TOTAL_1="80" TOTAL_2="131" WEIGHT="100.0" Z="1.27831187426782">
<NAME>abnormal EKG/ ECG - short term</NAME>
<DICH_DATA CI_END="2.7098359921084167" CI_START="0.9373405142957363" EFFECT_SIZE="1.59375" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.43294300678668474" LOG_CI_START="-0.028102611230623957" LOG_EFFECT_SIZE="0.2024201977780304" MODIFIED="2014-01-07 14:25:49 +0000" MODIFIED_BY="[Empty name]" ORDER="994" O_E="0.0" SE="0.2708204782359834" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.07334373143196674" WEIGHT="71.18772864212873"/>
<DICH_DATA CI_END="53.683260158384115" CI_START="0.9127612565897287" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="1084" O_E="0.0" SE="1.0394023007753748" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0803571428571428" WEIGHT="28.81227135787127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.39647065148549" CI_START="0.9197267836987244" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-002.27.02" LOG_CI_END="1.2404611487391044" LOG_CI_START="-0.03634116608317959" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2014-01-14 10:34:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06454558558747073" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8483924814931874">
<NAME>abnormal liver function - short term</NAME>
<DICH_DATA CI_END="17.39647065148549" CI_START="0.9197267836987244" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2404611487391044" LOG_CI_START="-0.03634116608317959" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2014-01-14 10:34:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1085" O_E="0.0" SE="0.75" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.27.03" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-14 10:34:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>anemia - long term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:09:53 +0000" MODIFIED_BY="[Empty name]" ORDER="939" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.304614839074713" CI_START="0.06533976911636269" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.27.04" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-14 10:34:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>decrease in white blood cell count and haemoglobin level - short term</NAME>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-20 15:06:07 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="123.32924773826663" CI_START="0.36616131881252256" DF="0" EFFECT_SIZE="6.720000000000001" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.27.05" LOG_CI_END="2.091066082476124" LOG_CI_START="-0.43632753636847327" LOG_EFFECT_SIZE="0.8273692730538252" MODIFIED="2014-01-14 10:34:24 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.19941141973957965" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.2832302534987863">
<NAME>ECG &#8211; atrial extrasystole &amp; flattening of T-wave in V<SUB>6 </SUB>- short term</NAME>
<DICH_DATA CI_END="123.32924773826663" CI_START="0.36616131881252256" EFFECT_SIZE="6.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.091066082476124" LOG_CI_START="-0.43632753636847327" LOG_EFFECT_SIZE="0.8273692730538252" MODIFIED="2013-07-18 15:02:18 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="118.26618899447777" CI_START="2.1166918902048337" DF="0" EFFECT_SIZE="15.821917808219178" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" ID="CMP-002.27.06" LOG_CI_END="2.072860602346328" LOG_CI_START="0.3256576458690867" LOG_EFFECT_SIZE="1.1992591241077073" MODIFIED="2014-01-14 10:34:24 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.007132547751664976" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="2.690591476700921">
<NAME>ECG abnormality (1st degree atrioventricular block)</NAME>
<DICH_DATA CI_END="118.26618899447777" CI_START="2.1166918902048337" EFFECT_SIZE="15.821917808219178" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="2.072860602346328" LOG_CI_START="0.3256576458690867" LOG_EFFECT_SIZE="1.1992591241077073" MODIFIED="2013-12-17 15:48:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1313" O_E="0.0" SE="1.0263156654288519" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="1.053323845104667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.09335602998937" CI_START="0.0958660805282943" DF="0" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.27.07" LOG_CI_END="1.045062951452725" LOG_CI_START="-1.0183350283367618" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2014-01-14 10:34:23 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.9797453980643506" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="0.025388106027993497">
<NAME>high white blood cell count - short term</NAME>
<DICH_DATA CI_END="11.09335602998937" CI_START="0.0958660805282943" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.045062951452725" LOG_CI_START="-1.0183350283367618" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2014-01-07 14:26:11 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.2120501873130736" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="1.4690656565656566" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5395048073116095" CI_START="0.09844438934717235" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.27.08" LOG_CI_END="0.40474903928980993" LOG_CI_START="-1.0068090306177724" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-01-14 10:34:23 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.4031735023958657" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.83596695360366">
<NAME>increase in white blood cell count and haemoglobin level - short term</NAME>
<DICH_DATA CI_END="2.5395048073116095" CI_START="0.09844438934717235" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40474903928980993" LOG_CI_START="-1.0068090306177724" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-06-20 15:06:19 +0100" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.82915619758885" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.02001865940832" CI_START="0.23398608116741104" DF="0" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-002.27.09" LOG_CI_END="0.30535538114991134" LOG_CI_START="-0.6308099761453109" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2014-01-14 10:34:23 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.4956345026588652" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="0.6813745881785453">
<NAME>liver function (GPT+) - short term</NAME>
<DICH_DATA CI_END="2.02001865940832" CI_START="0.23398608116741104" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.30535538114991134" LOG_CI_START="-0.6308099761453109" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2014-01-07 14:27:12 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.5499081649684698" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.3023989898989899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2836025726343843" CI_START="0.023014144918993035" DF="0" EFFECT_SIZE="0.171875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-002.27.10" LOG_CI_END="0.10843057885023288" LOG_CI_START="-1.6380051565015572" LOG_EFFECT_SIZE="-0.7647872888256622" MODIFIED="2014-01-14 10:34:22 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.08605442865790533" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="1.7165882621273674">
<NAME>low white blood cell count - short term</NAME>
<DICH_DATA CI_END="1.2836025726343843" CI_START="0.023014144918993035" EFFECT_SIZE="0.171875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="0.10843057885023288" LOG_CI_START="-1.6380051565015572" LOG_EFFECT_SIZE="-0.7647872888256622" MODIFIED="2014-01-07 14:26:45 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.0258649959419561" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="1.0523989898989898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.451460373328665" CI_START="6.056874400960204" DF="0" EFFECT_SIZE="12.657534246575343" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="7" I2="0.0" ID="CMP-002.27.11" LOG_CI_END="1.4224496542377452" LOG_CI_START="0.7822485679615564" LOG_EFFECT_SIZE="1.1023491110996508" MODIFIED="2014-01-14 10:34:22 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="1.4820884353588828E-11" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="6.749643518139767">
<NAME>prolactin: clinically significant high levels</NAME>
<DICH_DATA CI_END="26.451460373328665" CI_START="6.056874400960204" EFFECT_SIZE="12.657534246575343" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="7" LOG_CI_END="1.4224496542377452" LOG_CI_START="0.7822485679615564" LOG_EFFECT_SIZE="1.1023491110996508" MODIFIED="2013-12-17 15:47:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1312" O_E="0.0" SE="0.3760572871251202" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.14141908319990512" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.27.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-14 10:34:22 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="0.0" Z="0.0">
<NAME>prolonged QTc interval (&#8805;450 msec and &#8805;10% increase from baseline) - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-17 15:49:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1314" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.99720406421005" CI_START="0.12676555532891653" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.27.13" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:34:22 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6805377123908883">
<NAME>rise in alkaline phosphate and GOT levels - short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-06-20 15:06:33 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.553055387930549" CI_START="0.15260057191669785" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.27.14" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-14 10:34:21 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>slight T-wave changes on EKG - short term</NAME>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 11:49:42 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.476637125846737" CI_START="0.013695997047389556" DF="0" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.27.15" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" MODIFIED="2014-01-14 10:34:21 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Z="0.4785141381784974" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.7086944123517833">
<NAME>ventricular extrasystole - short term</NAME>
<DICH_DATA CI_END="7.476637125846737" CI_START="0.013695997047389556" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" MODIFIED="2013-07-18 15:02:00 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.28" MODIFIED="2014-01-14 16:18:31 +0000" MODIFIED_BY="[Empty name]" NO="28" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Other adverse events: 11a. Lab data (skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.28.01" MODIFIED="2013-12-18 10:44:59 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>weight change</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:44:59 +0000" MODIFIED_BY="[Empty name]" ORDER="2924" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>0.37</P>
</TD>
<TD>
<P>3.19</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine </P>
</TD>
<TD>
<P>2.63</P>
</TD>
<TD>
<P>4.97</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="1.4180904887297134" CI_END="1.4070426356484416" CI_START="0.6833744416066054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.98057991793272" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="148" I2="29.482638241529102" I2_Q="29.46421014587092" ID="CMP-002.29" LOG_CI_END="0.14830725745344434" LOG_CI_START="-0.16534126796743465" LOG_EFFECT_SIZE="-0.008517005256995185" METHOD="MH" MODIFIED="2015-01-26 14:15:25 +0000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.23371819475845812" P_Q="0.23377928384342217" P_Z="0.9152299744289888" Q="1.417720000113476" RANDOM="YES" SCALE="344.49" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.020488910590184168" TOTALS="YES" TOTAL_1="407" TOTAL_2="1353" WEIGHT="100.0" Z="0.10644413862586356">
<NAME>Other adverse events: 12. Any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Any antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours any antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2764044405383823" CI_START="0.49030909635595926" DF="0" EFFECT_SIZE="0.791095890410959" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" I2="0.0" ID="CMP-002.29.01" LOG_CI_END="0.10598830640987891" LOG_CI_START="-0.30953004952242685" LOG_EFFECT_SIZE="-0.10177087155627396" MODIFIED="2013-12-17 15:32:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3370105778166257" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="42.39661371009957" Z="0.9600887184779149">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2764044405383823" CI_START="0.49030909635595926" EFFECT_SIZE="0.791095890410959" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.10598830640987891" LOG_CI_START="-0.30953004952242685" LOG_EFFECT_SIZE="-0.10177087155627396" MODIFIED="2013-12-17 15:32:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1299" O_E="0.0" SE="0.24407753912367072" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.05957384510466701" WEIGHT="42.39661371009957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.686560623577516" CI_START="0.7820516061553724" DF="0" EFFECT_SIZE="1.1484674329501916" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="116" I2="0.0" ID="CMP-002.29.02" LOG_CI_END="0.2270019565610891" LOG_CI_START="-0.10676458769587847" LOG_EFFECT_SIZE="0.06011868443260533" MODIFIED="2013-12-17 15:32:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.48014765141544946" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="1199" WEIGHT="57.60338628990043" Z="0.7060651123566017">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.686560623577516" CI_START="0.7820516061553724" EFFECT_SIZE="1.1484674329501916" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="116" LOG_CI_END="0.2270019565610891" LOG_CI_START="-0.10676458769587847" LOG_EFFECT_SIZE="0.06011868443260533" MODIFIED="2013-12-11 14:49:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.19605612026758273" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="1199" VAR="0.03843800229437686" WEIGHT="57.60338628990043"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-05-12 09:11:15 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>PERPHENAZINE vs ANY ANTIPSYCHOTIC (ACUTE)</NAME>
<DICH_OUTCOME CHI2="76.52032677249375" CI_END="1.1131796619378111" CI_START="0.9432091145419907" CI_STUDY="95" CI_TOTAL="95" DF="60" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0246761455516156" ESTIMABLE="YES" EVENTS_1="474" EVENTS_2="620" I2="21.589461871498695" I2_Q="4.814386713058112" ID="CMP-003.01" LOG_CI_END="0.04656526306905836" LOG_CI_START="-0.025392011161307026" LOG_EFFECT_SIZE="0.01058662595387571" METHOD="MH" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07380765624434005" P_Q="0.38401354280757594" P_Z="0.5641322656731674" Q="40.97257836899418" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03124897070154922" TOTALS="SUB" TOTAL_1="2303" TOTAL_2="2658" WEIGHT="4000.0" Z="0.5767146076424687">
<NAME>Dichotomous outcomes for acute participants</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antipsychotic drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.105650005114352" CI_END="1.4687223039301127" CI_START="1.0644472655452295" DF="5" EFFECT_SIZE="1.2503509268456188" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="128" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.16693969009156867" LOG_CI_START="0.027124150649858642" LOG_EFFECT_SIZE="0.09703192037071365" MODIFIED="2014-02-26 15:16:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8343417487426458" P_Z="0.006519742578149024" STUDIES="7" TAU2="0.0" TOTAL_1="162" TOTAL_2="285" WEIGHT="100.0" Z="2.7204282161589624">
<NAME>Leaving the study early: 1. Any reason</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-26 15:16:56 +0000" MODIFIED_BY="[Empty name]" ORDER="24505" O_E="0.0" SE="0.0" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.884638505683547" CI_START="0.16475149465352495" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5893506107067091" LOG_CI_START="-0.7831706367228218" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-02-26 15:16:55 +0000" MODIFIED_BY="[Empty name]" ORDER="24506" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="0.6499999999999999" WEIGHT="1.037702188552973"/>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" MODIFIED="2013-10-04 16:18:43 +0100" MODIFIED_BY="[Empty name]" ORDER="24509" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="6.699331195455515"/>
<DICH_DATA CI_END="1.4710241891868536" CI_START="1.0443379946786564" EFFECT_SIZE="1.239454094292804" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="104" LOG_CI_END="0.1676198142258299" LOG_CI_START="0.018841078615953494" LOG_EFFECT_SIZE="0.09323044642089169" MODIFIED="2014-02-26 15:16:55 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.08739336576386025" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="148" VAR="0.007637600379535862" WEIGHT="88.31391916847345"/>
<DICH_DATA CI_END="25.72286879431293" CI_START="0.3173543888668927" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.410319402512737" LOG_CI_START="-0.4984554912132884" LOG_EFFECT_SIZE="0.4559319556497244" MODIFIED="2014-02-26 15:16:55 +0000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="1.121223821162776" STUDY_ID="STD-Lepola-1989" TOTAL_1="7" TOTAL_2="10" VAR="1.2571428571428571" WEIGHT="0.5365391997631848"/>
<DICH_DATA CI_END="4.6740388197625435" CI_START="0.693190648374761" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6696923150606261" LOG_CI_START="-0.15914730485401402" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2014-02-26 15:16:54 +0000" MODIFIED_BY="[Empty name]" ORDER="24519" O_E="0.0" SE="0.48686449556014766" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.23703703703703705" WEIGHT="2.845573970172605"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2014-02-26 15:16:54 +0000" MODIFIED_BY="[Empty name]" ORDER="24518" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="0.5669342775822814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9723213309703094" CI_END="3.336881447538544" CI_START="0.716750301595258" DF="2" EFFECT_SIZE="1.5465156914531686" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" I2="32.712524074673205" ID="CMP-003.01.02" LOG_CI_END="0.5233407773487025" LOG_CI_START="-0.1446321156383614" LOG_EFFECT_SIZE="0.18935433085517056" MODIFIED="2013-10-08 15:50:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2262396615705654" P_Z="0.26647980297302565" STUDIES="3" TAU2="0.15654524726667685" TOTAL_1="98" TOTAL_2="216" WEIGHT="99.99999999999999" Z="1.1112057770284496">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<DICH_DATA CI_END="2.131214611558949" CI_START="0.29526640305121676" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3286271850135134" LOG_CI_START="-0.529785966511224" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-10-04 16:17:31 +0100" MODIFIED_BY="[Empty name]" ORDER="24525" O_E="0.0" SE="0.5042361344192612" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2542540792540792" WEIGHT="37.47685673741269"/>
<DICH_DATA CI_END="4.736473415706975" CI_START="1.0656806256304354" EFFECT_SIZE="2.2466793168880455" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.6754551040936174" LOG_CI_START="0.02762707025509128" LOG_EFFECT_SIZE="0.35154108717435434" MODIFIED="2013-10-04 16:17:31 +0100" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.38053739387723634" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="148" VAR="0.14480870813887892" WEIGHT="51.087656994994795"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-10-08 15:50:27 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="11.435486267592507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.029877119761030232" CI_END="6.262500969996985" CI_START="0.3390504737399328" DF="1" EFFECT_SIZE="1.4571561071739247" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.7967478061430555" LOG_CI_START="-0.4697356444664586" LOG_EFFECT_SIZE="0.16350608083829846" MODIFIED="2013-10-04 16:20:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8627693750316578" P_Z="0.6128059712135896" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="67" WEIGHT="100.0" Z="0.5060721946933149">
<NAME>Leaving the study early: 3. Due to relapse/ worsening or no improvement</NAME>
<DICH_DATA CI_END="16.8446828987975" CI_START="0.08548691647396922" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2264628397992592" LOG_CI_START="-1.0681003477040096" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-07-16 16:27:56 +0100" MODIFIED_BY="[Empty name]" ORDER="24532" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="1.8166666666666667" WEIGHT="30.464846538187007"/>
<DICH_DATA CI_END="9.116851335277273" CI_START="0.27609359825809593" EFFECT_SIZE="1.5865384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9598448729969133" LOG_CI_START="-0.5589436631666614" LOG_EFFECT_SIZE="0.2004506049151259" MODIFIED="2013-10-04 16:19:48 +0100" MODIFIED_BY="[Empty name]" ORDER="24533" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="69.535153461813"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.712745265320976" CI_END="2.8243142604056475" CI_START="0.26694494142007247" DF="4" EFFECT_SIZE="0.8682951138845945" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" I2="70.83005683686218" ID="CMP-003.01.04" LOG_CI_END="0.4509130188552071" LOG_CI_START="-0.5735783045650695" LOG_EFFECT_SIZE="-0.061332642854931216" MODIFIED="2014-02-26 15:21:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.008270623974829028" P_Z="0.8144632352570502" STUDIES="5" TAU2="1.1193768850068395" TOTAL_1="116" TOTAL_2="124" WEIGHT="100.0" Z="0.2346721115626462">
<NAME>Global state: 1. Change over time - no better or deterioration</NAME>
<DICH_DATA CI_END="0.47401233947198856" CI_START="0.03296327689993259" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2014-02-26 15:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24539" O_E="0.0" SE="0.6800735254367721" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.46249999999999997" WEIGHT="22.893863721420086"/>
<DICH_DATA CI_END="16.8446828987975" CI_START="0.08548691647396922" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2264628397992592" LOG_CI_START="-1.0681003477040096" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-07-16 16:28:08 +0100" MODIFIED_BY="[Empty name]" ORDER="24540" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="1.8166666666666667" WEIGHT="12.334719561216609"/>
<DICH_DATA CI_END="2.1191914188911776" CI_START="0.788585625544659" EFFECT_SIZE="1.2927350427350428" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3261701867313436" LOG_CI_START="-0.10315114357465391" LOG_EFFECT_SIZE="0.11150952157834487" MODIFIED="2013-10-04 16:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="24542" O_E="0.0" SE="0.2521854745966024" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.06359751359751359" WEIGHT="30.613742674513553"/>
<DICH_DATA CI_END="11.53735644741953" CI_START="0.7075507585577163" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.062106310395276" LOG_CI_START="-0.1502423990958273" LOG_EFFECT_SIZE="0.4559319556497244" MODIFIED="2013-10-04 14:03:40 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.7121396331779725" STUDY_ID="STD-Lepola-1989" TOTAL_1="7" TOTAL_2="10" VAR="0.5071428571428572" WEIGHT="22.265499084288404"/>
<DICH_DATA CI_END="15.180224957567825" CI_START="0.06587517660609293" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-07 16:43:13 +0100" MODIFIED_BY="[Empty name]" ORDER="24549" O_E="0.0" SE="1.387777332977422" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="1.925925925925926" WEIGHT="11.892174958561338"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.084940216223805" CI_START="0.6101353379980785" DF="0" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2014-01-13 11:12:37 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.16009090857711306" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.404765878729659">
<NAME>Mental state: 1. State - less than 20% BPRS reduction ('no effect')</NAME>
<DICH_DATA CI_END="1.084940216223805" CI_START="0.6101353379980785" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2013-10-07 09:53:56 +0100" MODIFIED_BY="[Empty name]" ORDER="24554" O_E="0.0" SE="0.1468392711837387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02156177156177156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1540465647134452" CI_START="0.6372860624161332" DF="0" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2014-01-13 11:12:44 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.31050387460315276" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="1.014165347296331">
<NAME>Mental state: 2. State - less than 20% PANSS reduction ('no effect')</NAME>
<DICH_DATA CI_END="1.1540465647134452" CI_START="0.6372860624161332" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2013-10-07 10:00:31 +0100" MODIFIED_BY="[Empty name]" ORDER="24556" O_E="0.0" SE="0.15148522352946822" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02294777294777295" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.100777685191538" CI_END="10.023816249150107" CI_START="0.1231671918151642" DF="1" EFFECT_SIZE="1.1111279398336766" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="52.39858043766182" ID="CMP-003.01.07" LOG_CI_END="1.001033096821729" LOG_CI_START="-0.9095049602815775" LOG_EFFECT_SIZE="0.04576406827007567" MODIFIED="2013-10-07 10:00:36 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.14722429475656262" P_Z="0.9251917839091571" STUDIES="2" TAU2="1.4700587239874374" TOTAL_1="62" TOTAL_2="67" WEIGHT="100.0" Z="0.09389598418298412">
<NAME>Adverse events: 1. Movement disorders - dystonia</NAME>
<DICH_DATA CI_END="4.418891348608109" CI_START="0.012642937829335616" EFFECT_SIZE="0.23636363636363636" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6453133232911785" LOG_CI_START="-1.8981519976659926" LOG_EFFECT_SIZE="-0.626419337187407" MODIFIED="2013-07-16 16:29:04 +0100" MODIFIED_BY="[Empty name]" ORDER="24586" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="2.232167832167832" WEIGHT="34.01916099141922"/>
<DICH_DATA CI_END="9.040130215485474" CI_START="0.6737481351752448" EFFECT_SIZE="2.467948717948718" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9561746861677867" LOG_CI_START="-0.17150242385970835" LOG_EFFECT_SIZE="0.3923361311540391" MODIFIED="2013-10-04 16:20:57 +0100" MODIFIED_BY="[Empty name]" ORDER="24587" O_E="0.0" SE="0.662403116521872" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.43877788877788876" WEIGHT="65.98083900858079"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8751101407418485" CI_START="0.3918137188785902" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-003.01.08" LOG_CI_END="0.27302678252323676" LOG_CI_START="-0.4069203617844632" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2013-10-07 10:00:35 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.6995326188798944" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0" Z="0.3859514600658514">
<NAME>Adverse events: 2. Movement disorders - extrapyramidal signs</NAME>
<DICH_DATA CI_END="1.8751101407418485" CI_START="0.3918137188785902" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27302678252323676" LOG_CI_START="-0.4069203617844632" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2013-07-16 16:28:28 +0100" MODIFIED_BY="[Empty name]" ORDER="24589" O_E="0.0" SE="0.3994043183589901" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="0.1595238095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5127568340289713" CI_END="1.7612836638904525" CI_START="0.653655724404286" DF="1" EFFECT_SIZE="1.0729739741493027" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-003.01.09" LOG_CI_END="0.24582930698449226" LOG_CI_START="-0.1846509311242095" LOG_EFFECT_SIZE="0.030589187930141357" MODIFIED="2013-10-07 10:00:35 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.47394793442899386" P_Z="0.7805952828287854" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="67" WEIGHT="100.0" Z="0.27854336321132295">
<NAME>Adverse events: 3. Movement disorders - use of antiparkinson drugs</NAME>
<DICH_DATA CI_END="2.0618610534892707" CI_START="0.31039918956562723" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3142593953140879" LOG_CI_START="-0.5080794213302007" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-07-16 16:28:51 +0100" MODIFIED_BY="[Empty name]" ORDER="24606" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="0.23333333333333334" WEIGHT="27.403425694844394"/>
<DICH_DATA CI_END="2.1445467233256057" CI_START="0.6700365652795333" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.33133551266949035" LOG_CI_START="-0.17390149630541574" LOG_EFFECT_SIZE="0.07871700818203736" MODIFIED="2013-10-04 16:21:20 +0100" MODIFIED_BY="[Empty name]" ORDER="24608" O_E="0.0" SE="0.2967787200353893" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.08807760866584396" WEIGHT="72.5965743051556"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.910465279553863" CI_START="0.8838868655449152" DF="0" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-003.01.10" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2013-10-08 15:51:25 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.08199900026365228" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="1.7392033508855447">
<NAME>Adverse events: 4. Movement disorders - hyperkinesia</NAME>
<DICH_DATA CI_END="7.910465279553863" CI_START="0.8838868655449152" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2013-10-04 16:22:42 +0100" MODIFIED_BY="[Empty name]" ORDER="24591" O_E="0.0" SE="0.5590951731033033" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.31258741258741257" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-08 15:51:25 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="139.80596033832603" CI_START="0.39128635897179836" DF="0" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.01.11" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" MODIFIED="2013-10-07 10:00:34 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.18211221189433172" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.3342796879264842">
<NAME>Other adverse events: 5. Anticholinergic - dry mouth</NAME>
<DICH_DATA CI_END="139.80596033832603" CI_START="0.39128635897179836" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" MODIFIED="2013-10-04 16:23:40 +0100" MODIFIED_BY="[Empty name]" ORDER="24621" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.71754543376308" CI_END="8.329110269304099" CI_START="0.12145494311741292" DF="1" EFFECT_SIZE="1.005789050436019" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="73.10053050279062" ID="CMP-003.01.12" LOG_CI_END="0.9205986117586334" LOG_CI_START="-0.915584805066925" LOG_EFFECT_SIZE="0.0025069033458541205" MODIFIED="2013-10-08 15:52:14 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.05384371331719351" P_Z="0.9957299043411422" STUDIES="2" TAU2="1.7751146134644724" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0053517968037109275">
<NAME>Other adverse events: 6. Arousal - drowsiness</NAME>
<DICH_DATA CI_END="29.451977659230835" CI_START="0.44003836176814676" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4691144623711299" LOG_CI_START="-0.3565094608365555" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2013-07-16 16:29:25 +0100" MODIFIED_BY="[Empty name]" ORDER="24629" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="1.15" WEIGHT="39.77081017647827"/>
<DICH_DATA CI_END="0.9407225477876046" CI_START="0.1996101594666721" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.026538446426452467" LOG_CI_START="-0.6998173583991988" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2013-10-08 15:52:14 +0100" MODIFIED_BY="[Empty name]" ORDER="24632" O_E="0.0" SE="0.3954873656771559" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.15641025641025647" WEIGHT="60.22918982352172"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1092740161646377" CI_END="4.502229070889792" CI_START="0.1573063799690369" DF="1" EFFECT_SIZE="0.8415636380767846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="67.83815145268144" ID="CMP-003.01.13" LOG_CI_END="0.6534275878862932" LOG_CI_START="-0.803253663078185" LOG_EFFECT_SIZE="-0.07491303759594599" MODIFIED="2013-10-07 16:45:30 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.07784793419027247" P_Z="0.8402365455922274" STUDIES="2" TAU2="0.9998350613567919" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="0.20159091848451288">
<NAME>Other adverse events: 7. Arousal - insomnia</NAME>
<DICH_DATA CI_END="5.954930516701607" CI_START="0.5753314177646484" EFFECT_SIZE="1.8509615384615385" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7748766984150807" LOG_CI_START="-0.24008190932360235" LOG_EFFECT_SIZE="0.26739739454573913" MODIFIED="2013-10-04 16:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="24639" O_E="0.0" SE="0.5961917103118387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.35544455544455544" WEIGHT="54.02258459483393"/>
<DICH_DATA CI_END="1.5070719917963586" CI_START="0.07372647870568672" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-10-07 16:45:30 +0100" MODIFIED_BY="[Empty name]" ORDER="24646" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="45.97741540516607"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4564518929144552" CI_START="0.3503061681026083" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-003.01.14" LOG_CI_END="0.16329614431086484" LOG_CI_START="-0.4555522156673408" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-10-07 10:06:45 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.3546494248570994" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="10" WEIGHT="100.0" Z="0.9256086162077479">
<NAME>Other adverse events: 8. Arousal - need of additional benzodiazepines</NAME>
<DICH_DATA CI_END="1.4564518929144552" CI_START="0.3503061681026083" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.16329614431086484" LOG_CI_START="-0.4555522156673408" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-10-04 14:12:34 +0100" MODIFIED_BY="[Empty name]" ORDER="24651" O_E="0.0" SE="0.3635145899999849" STUDY_ID="STD-Lepola-1989" TOTAL_1="7" TOTAL_2="10" VAR="0.13214285714285715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08308896617063496" CI_END="1.995182240416724" CI_START="0.7134109407658012" DF="1" EFFECT_SIZE="1.1930569303830032" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="0.0" ID="CMP-003.01.15" LOG_CI_END="0.2999825703950204" LOG_CI_START="-0.14666023466996528" LOG_EFFECT_SIZE="0.07666116786252755" MODIFIED="2013-10-07 16:46:06 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.7731541891109328" P_Z="0.5010674523564449" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="0.6728111426824479">
<NAME>Other adverse events: 9. Arousal - sleepiness/sedation</NAME>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" MODIFIED="2013-10-04 16:26:44 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="68.3661695937875"/>
<DICH_DATA CI_END="3.3265740728498856" CI_START="0.5344170124715575" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5219971983282286" LOG_CI_START="-0.27211972511162885" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-10-04 16:26:44 +0100" MODIFIED_BY="[Empty name]" ORDER="24657" O_E="0.0" SE="0.46646821177074066" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.21759259259259256" WEIGHT="31.633830406212496"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.500893367336776" CI_START="0.6263134403713821" DF="0" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-003.01.16" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2013-10-07 10:06:46 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Z="0.889693784449851" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.13869169080556756">
<NAME>Other adverse events: 10. Arousal - tension</NAME>
<DICH_DATA CI_END="1.500893367336776" CI_START="0.6263134403713821" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2013-10-04 16:27:19 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.22295431080969194" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.049708624708624714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.954339306802694" CI_END="1.234325020274679" CI_START="0.882675542447134" DF="2" EFFECT_SIZE="1.0437952418108745" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" I2="0.0" ID="CMP-003.01.17" LOG_CI_END="0.09142953240864145" LOG_CI_START="-0.05419890686389712" LOG_EFFECT_SIZE="0.018615312772372168" MODIFIED="2013-10-08 15:51:55 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.37637495433259505" P_Z="0.6163187532681393" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="0.5010744161930736">
<NAME>Other adverse events: 11. At least one</NAME>
<DICH_DATA CI_END="2.4246152760983026" CI_START="0.7757174282747352" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3846428370732183" LOG_CI_START="-0.1102964510225951" LOG_EFFECT_SIZE="0.13717319302531158" MODIFIED="2013-07-16 16:29:45 +0100" MODIFIED_BY="[Empty name]" ORDER="24659" O_E="0.0" SE="0.29072978781646974" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="10" TOTAL_2="12" VAR="0.08452380952380951" WEIGHT="8.657420887693966"/>
<DICH_DATA CI_END="1.205202052683593" CI_START="0.8475605080785928" EFFECT_SIZE="1.0106837606837606" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.08105986268634968" LOG_CI_START="-0.07182928735897469" LOG_EFFECT_SIZE="0.0046152876636875164" MODIFIED="2013-10-04 16:21:44 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.08980784355012197" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.008065448763123186" WEIGHT="90.72752373366212"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-10-08 15:51:55 +0100" MODIFIED_BY="[Empty name]" ORDER="24665" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="0.6150553786438986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4070124730394722" CI_END="2.3262332503091554" CI_START="0.5429511174182886" DF="1" EFFECT_SIZE="1.1238464942468493" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" ID="CMP-003.01.18" LOG_CI_END="0.36665325907832" LOG_CI_START="-0.2652392687373526" LOG_EFFECT_SIZE="0.05070699517048375" MODIFIED="2013-10-07 16:47:02 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.5234897784775321" P_Z="0.7530961688149724" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="0.314559454095604">
<NAME>Other adverse events: 12. Cardiovascular - faintness, dizziness, weakness</NAME>
<DICH_DATA CI_END="2.371284396738129" CI_START="0.3612028381724999" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3749836436142605" LOG_CI_START="-0.4422488458507446" LOG_EFFECT_SIZE="-0.033632601118242046" MODIFIED="2013-10-07 10:05:55 +0100" MODIFIED_BY="[Empty name]" ORDER="24669" O_E="0.0" SE="0.48004640967780965" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.23044455544455544" WEIGHT="59.78540724036681"/>
<DICH_DATA CI_END="4.724017763609372" CI_START="0.4762894875909387" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-10-07 16:47:02 +0100" MODIFIED_BY="[Empty name]" ORDER="24673" O_E="0.0" SE="0.5853140973807077" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.34259259259259256" WEIGHT="40.21459275963319"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5208062611490192" CI_START="0.61323610608356" DF="0" EFFECT_SIZE="0.9657190635451505" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-003.01.19" LOG_CI_END="0.18207389184849138" LOG_CI_START="-0.21237228269694933" LOG_EFFECT_SIZE="-0.01514919542422894" MODIFIED="2013-10-08 11:03:11 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Z="0.880330939412093" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.15054970407794976">
<NAME>Other adverse events: 13. Cardiovascular - lassitude</NAME>
<DICH_DATA CI_END="1.5208062611490192" CI_START="0.61323610608356" EFFECT_SIZE="0.9657190635451505" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18207389184849138" LOG_CI_START="-0.21237228269694933" LOG_EFFECT_SIZE="-0.01514919542422894" MODIFIED="2013-10-07 10:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.23169963546804603" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.05368472107602542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3152720650028022" CI_START="0.24661101512156308" DF="0" EFFECT_SIZE="0.5695266272189349" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-003.01.20" LOG_CI_END="0.1190155962540893" LOG_CI_START="-0.6079875291203599" LOG_EFFECT_SIZE="-0.24448596643313528" MODIFIED="2013-10-07 10:13:00 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Z="0.1874220404881491" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="1.3182438209948717">
<NAME>Other adverse events: 14. Cardiovascular - tachycardia</NAME>
<DICH_DATA CI_END="1.3152720650028022" CI_START="0.24661101512156308" EFFECT_SIZE="0.5695266272189349" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.1190155962540893" LOG_CI_START="-0.6079875291203599" LOG_EFFECT_SIZE="-0.24448596643313528" MODIFIED="2013-10-07 10:07:24 +0100" MODIFIED_BY="[Empty name]" ORDER="24678" O_E="0.0" SE="0.42704523456846155" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.18236763236763237" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5849640174898032" CI_START="0.705828653147122" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-003.01.21" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:09:59 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Z="0.7857800257893043" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.2717945116579573">
<NAME>Other adverse events: 15. Central nervous system - difficulty in concentration</NAME>
<DICH_DATA CI_END="1.5849640174898032" CI_START="0.705828653147122" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:09:35 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.20636717904602125" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.04258741258741259" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0056894317039746" CI_START="0.13944245306226868" DF="0" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-003.01.22" LOG_CI_END="0.3022636861424311" LOG_CI_START="-0.8556049857515041" LOG_EFFECT_SIZE="-0.2766706498045365" MODIFIED="2013-10-07 10:11:46 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Z="0.3489336010839931" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.9366597825109111">
<NAME>Other adverse events: 16. Central nervous system - headache</NAME>
<DICH_DATA CI_END="2.0056894317039746" CI_START="0.13944245306226868" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3022636861424311" LOG_CI_START="-0.8556049857515041" LOG_EFFECT_SIZE="-0.2766706498045365" MODIFIED="2013-10-07 10:10:17 +0100" MODIFIED_BY="[Empty name]" ORDER="24688" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4844413016390655E-32" CI_END="4.051933926789899" CI_START="0.12270826589248707" DF="0" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="100.0" ID="CMP-003.01.23" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-10-07 10:11:58 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Z="0.6953437754874789" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.39161354999581366">
<NAME>Other adverse events: 17. Central nervous system - paraesthesia</NAME>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-10-07 10:10:47 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2031855130165963" CI_START="0.004123910226555628" DF="0" EFFECT_SIZE="0.07044025157232703" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-003.01.24" LOG_CI_END="0.08033259414614691" LOG_CI_START="-2.384690797446687" LOG_EFFECT_SIZE="-1.15217910165027" MODIFIED="2014-02-26 15:05:56 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Z="0.06691901719066125" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.8322175364956959">
<NAME>Other adverse events: 18. Gastrointestinal - constipation</NAME>
<DICH_DATA CI_END="1.2031855130165963" CI_START="0.004123910226555628" EFFECT_SIZE="0.07044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.08033259414614691" LOG_CI_START="-2.384690797446687" LOG_EFFECT_SIZE="-1.1521791016502698" MODIFIED="2013-10-07 10:25:44 +0100" MODIFIED_BY="[Empty name]" ORDER="24711" O_E="0.0" SE="1.4479669422842112" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.0966082659478884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.01.25" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2014-02-26 15:05:56 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>Other adverse events: 19. Gastrointestinal - diarrhoea</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-10-07 10:26:18 +0100" MODIFIED_BY="[Empty name]" ORDER="24717" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4801729396117431" CI_END="1.6842132267571632" CI_START="0.24158673881348966" DF="1" EFFECT_SIZE="0.6378742673276665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-003.01.26" LOG_CI_END="0.22639707370867374" LOG_CI_START="-0.6169269087023577" LOG_EFFECT_SIZE="-0.19526491749684202" MODIFIED="2013-10-07 10:27:38 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.48834403327577014" P_Z="0.36407483610772284" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="78" WEIGHT="100.00000000000003" Z="0.9076279430447018">
<NAME>Other adverse events: 20. Gastrointestinal - nausea and vomiting</NAME>
<DICH_DATA CI_END="2.2318509903721298" CI_START="0.2557392721532988" EFFECT_SIZE="0.7554945054945055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.34866519554358555" LOG_CI_START="-0.5922025751811721" LOG_EFFECT_SIZE="-0.12176868981879335" MODIFIED="2013-10-07 10:27:12 +0100" MODIFIED_BY="[Empty name]" ORDER="24728" O_E="0.0" SE="0.5526703858943008" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.30544455544455545" WEIGHT="80.33997970791987"/>
<DICH_DATA CI_END="2.853499025422034" CI_START="0.035761271399532814" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-10-07 10:27:38 +0100" MODIFIED_BY="[Empty name]" ORDER="24734" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="19.660020292080155"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.022757726815898" CI_START="0.5577698122490747" DF="0" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-003.01.27" LOG_CI_END="0.9043236774703935" LOG_CI_START="-0.2535449944235417" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2013-10-08 11:04:19 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Z="0.27063763474898905" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.1015953809268253">
<NAME>Other adverse events: 21. Gastrointestinal - weight loss</NAME>
<DICH_DATA CI_END="8.022757726815898" CI_START="0.5577698122490747" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9043236774703935" LOG_CI_START="-0.2535449944235417" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2013-10-07 10:27:49 +0100" MODIFIED_BY="[Empty name]" ORDER="24736" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9654204139337209" CI_START="0.262762644747902" DF="0" EFFECT_SIZE="0.5036630036630036" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" ID="CMP-003.01.28" LOG_CI_END="-0.015283522209852666" LOG_CI_START="-0.5804363755390965" LOG_EFFECT_SIZE="-0.2978599488744746" MODIFIED="2013-10-08 11:04:23 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Z="0.03883119472955918" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="2.0659712458031527">
<NAME>Other adverse events: 22. Gastrointestinal - weight gain</NAME>
<DICH_DATA CI_END="0.9654204139337209" CI_START="0.262762644747902" EFFECT_SIZE="0.5036630036630036" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.015283522209852666" LOG_CI_START="-0.5804363755390965" LOG_EFFECT_SIZE="-0.2978599488744746" MODIFIED="2013-10-07 10:28:19 +0100" MODIFIED_BY="[Empty name]" ORDER="24738" O_E="0.0" SE="0.33197358359734014" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.11020646020646019" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.375539620476798" CI_START="0.1864223630106055" DF="0" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.01.29" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-10-07 10:30:45 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Z="0.7539433993150382" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.31344394882999155">
<NAME>Other adverse events: 23. Skin - pruritus</NAME>
<DICH_DATA CI_END="3.375539620476798" CI_START="0.1864223630106055" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-10-07 10:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="24761" O_E="0.0" SE="0.7388644976724391" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.5459207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4844413016390655E-32" CI_END="4.051933926789899" CI_START="0.12270826589248707" DF="0" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="100.0" ID="CMP-003.01.30" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-10-07 10:30:47 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0" P_Z="0.6953437754874789" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.39161354999581366">
<NAME>Other adverse events: 24. Skin - rash</NAME>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-10-07 10:30:47 +0100" MODIFIED_BY="[Empty name]" ORDER="24755" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.891100991947133" CI_START="0.23108087533137314" DF="0" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-003.01.31" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-10-07 10:30:50 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="1.0" P_Z="0.4402112377838353" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.7718365664995955">
<NAME>Other adverse events: 25. Skin - sweating</NAME>
<DICH_DATA CI_END="1.891100991947133" CI_START="0.23108087533137314" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-10-07 10:30:50 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.536271771201331" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2875874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.007022459510349" CI_START="0.2234287996105537" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.01.32" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:33:35 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="1.0" P_Z="0.9436301877371425" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.07070795723063611">
<NAME>Other adverse events: 26. Genitourinary - diminished sexual desire</NAME>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:33:35 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.42684164198362" CI_START="0.022752978588870532" DF="0" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-003.01.33" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-10-07 10:33:38 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="1.0" P_Z="0.10453041457457127" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="1.6232760143036378">
<NAME>Other adverse events: 27. Genitourinary - ejaculatory dysfunction (men only)</NAME>
<DICH_DATA CI_END="1.42684164198362" CI_START="0.022752978588870532" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-10-07 10:33:38 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.0557649547317054" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="1.1146396396396399" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.704826166858263" CI_START="0.3000645450671526" DF="0" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-003.01.34" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-10-07 10:33:42 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="1.0" P_Z="0.852406310146861" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="0.18604903261707173">
<NAME>Other adverse events: 28. Genitourinary - erectile dysfunction (men only)</NAME>
<DICH_DATA CI_END="2.704826166858263" CI_START="0.3000645450671526" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-10-07 10:33:42 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.5609274816227492" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="0.31463963963963965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.01.35" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-10-07 10:33:44 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>Other adverse events: 29. Genitourinary - galactorrhoea</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-10-07 10:33:44 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.007022459510349" CI_START="0.2234287996105537" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.01.36" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:33:47 +0100" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="1.0" P_Z="0.9436301877371425" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.07070795723063611">
<NAME>Other adverse events: 30. Genitourinary - increased sexual desire</NAME>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-10-07 10:33:47 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.50527280318661" CI_START="0.2596178553022495" DF="0" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.01.37" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-10-07 10:33:49 +0100" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="1.0" P_Z="0.2789217673806622" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0827447147660128">
<NAME>Other adverse events: 31. Genitourinary - orgastic dysfunction</NAME>
<DICH_DATA CI_END="107.50527280318661" CI_START="0.2596178553022495" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-10-07 10:33:49 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5372946798237985" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.363274932614555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.01.38" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2013-10-07 10:36:36 +0100" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>Other adverse events: 32. Others - abdominal pain</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-10-07 10:36:36 +0100" MODIFIED_BY="[Empty name]" ORDER="24764" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.683465127741492" CI_START="0.6003233389948932" DF="0" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-003.01.39" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-10-07 10:36:41 +0100" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="1.0" P_Z="0.5325490557720918" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.6241195857360581">
<NAME>Other adverse events: 33. Others - failing memory</NAME>
<DICH_DATA CI_END="2.683465127741492" CI_START="0.6003233389948932" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-10-07 10:36:41 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.3819957407102152" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.14592074592074594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0723149610069576" CI_START="0.4461465705813854" DF="0" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-003.01.40" LOG_CI_END="0.31645576238212664" LOG_CI_START="-0.3505224409796873" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-10-07 10:36:47 +0100" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="1.0" P_Z="0.9202590494012456" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.10010741398681083">
<NAME>Other adverse events: 34. Others - sweating</NAME>
<DICH_DATA CI_END="2.0723149610069576" CI_START="0.4461465705813854" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.31645576238212664" LOG_CI_START="-0.3505224409796873" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-10-07 10:36:47 +0100" MODIFIED_BY="[Empty name]" ORDER="24772" O_E="0.0" SE="0.39178629825008365" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1534965034965035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.035065793456791" CI_START="-5.035065793456791" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2014-05-12 09:04:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.38555075560580787" Q="0.0" RANDOM="YES" SCALE="52.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" UNITS="" WEIGHT="99.99999999999999" Z="0.8677143163515038">
<NAME>Continuous outcomes for acute participants</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other antipsychotic drugs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.035065793456791" CI_START="-5.035065793456791" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2013-10-07 09:59:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38555075560580787" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="0.8677143163515038">
<NAME>Mental state: 1. State - PANSS: mean change from baseline to endpoint</NAME>
<CONT_DATA CI_END="13.035065793456791" CI_START="-5.035065793456791" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-24.0" MODIFIED="2013-10-07 09:54:41 +0100" MODIFIED_BY="[Empty name]" ORDER="24557" SD_1="21.63" SD_2="25.96" SE="4.609812152021281" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-01-14 16:40:48 +0000" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>PERPHENAZINE vs ARIPIPRAZOLE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1086062112203157" CI_START="0.4981687229645273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7431506849315068" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.04477730749760454" LOG_CI_START="-0.3026235426973822" LOG_EFFECT_SIZE="-0.1289231175998888" METHOD="MH" MODIFIED="2014-02-18 12:05:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.14574809307715067" Q="0.0" RANDOM="YES" SCALE="45.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.454715307280215">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1086062112203157" CI_START="0.4981687229645273" DF="0" EFFECT_SIZE="0.7431506849315068" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.04477730749760454" LOG_CI_START="-0.3026235426973822" LOG_EFFECT_SIZE="-0.1289231175998888" MODIFIED="2013-12-17 15:57:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14574809307715067" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.454715307280215">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1086062112203157" CI_START="0.4981687229645273" EFFECT_SIZE="0.7431506849315068" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.04477730749760454" LOG_CI_START="-0.3026235426973822" LOG_EFFECT_SIZE="-0.1289231175998888" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1295" O_E="0.0" SE="0.20406497906647802" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.04164251568140211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0487960662113913" CI_START="0.26520682056832773" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5273972602739726" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.02069104974811323" LOG_CI_START="-0.5764153109720236" LOG_EFFECT_SIZE="-0.27786213061195525" METHOD="MH" MODIFIED="2014-02-18 12:06:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06813244346558278" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.8241298518749158">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0487960662113913" CI_START="0.26520682056832773" DF="0" EFFECT_SIZE="0.5273972602739726" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.02069104974811323" LOG_CI_START="-0.5764153109720236" LOG_EFFECT_SIZE="-0.27786213061195525" MODIFIED="2013-12-17 15:57:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06813244346558278" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.8241298518749158">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0487960662113913" CI_START="0.2652068205683278" EFFECT_SIZE="0.5273972602739726" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.02069104974811323" LOG_CI_START="-0.5764153109720236" LOG_EFFECT_SIZE="-0.27786213061195525" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1296" O_E="0.0" SE="0.35074323201116325" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.12302081480163671" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0790429481562867" CI_START="0.3424934286236656" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8438356164383561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.3178634609306164" LOG_CI_START="-0.4653477568426773" LOG_EFFECT_SIZE="-0.07374214795603046" METHOD="MH" MODIFIED="2014-02-18 12:06:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7120716063639172" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.36907529120268423">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0790429481562867" CI_START="0.3424934286236656" DF="0" EFFECT_SIZE="0.8438356164383561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.3178634609306164" LOG_CI_START="-0.4653477568426773" LOG_EFFECT_SIZE="-0.07374214795603046" MODIFIED="2013-12-17 15:58:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7120716063639172" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.36907529120268423">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.0790429481562867" CI_START="0.3424934286236656" EFFECT_SIZE="0.8438356164383561" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3178634609306164" LOG_CI_START="-0.4653477568426773" LOG_EFFECT_SIZE="-0.07374214795603046" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1297" O_E="0.0" SE="0.4600621462780875" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.21165717843800036" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1704617929798724" CI_START="0.8936396562909013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.06835724172437309" LOG_CI_START="-0.04883756714606064" LOG_EFFECT_SIZE="0.00975983728915624" METHOD="MH" MODIFIED="2014-02-18 12:07:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7440864064738706" Q="0.0" RANDOM="YES" SCALE="2.7480261679687805" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0" Z="0.3264467046977398">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1704617929798724" CI_START="0.8936396562909013" DF="0" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="110" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.06835724172437309" LOG_CI_START="-0.04883756714606064" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2013-12-17 15:58:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7440864064738706" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0" Z="0.3264467046977398">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1704617929798724" CI_START="0.8936396562909013" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="110" LOG_CI_END="0.06835724172437309" LOG_CI_START="-0.04883756714606064" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1298" O_E="0.0" SE="0.06884081085415278" STUDY_ID="STD-Kane-2003" TOTAL_1="144" TOTAL_2="150" VAR="0.004739057239057238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.15595896455766411" CI_START="-0.5559589645576645" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2707964554189738" Q="0.0" RANDOM="YES" SCALE="3.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="1.1012302988214517">
<NAME>Global state: 2. Average endpoint score (CGI-S)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15595896455766411" CI_START="-0.5559589645576645" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2707964554189738" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0" Z="1.1012302988214517">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.15595896455766411" CI_START="-0.5559589645576645" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.7" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1315" SD_1="1.21" SD_2="1.85" SE="0.18161505383028625" STUDY_ID="STD-Kane-2003" TOTAL_1="144" TOTAL_2="150" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.137979643885442" CI_START="0.2599788365074738" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.9105165991865608" LOG_CI_START="-0.5850620041911614" LOG_EFFECT_SIZE="0.16272729749769976" METHOD="MH" MODIFIED="2014-02-18 12:08:06 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6697362373877482" Q="0.0" RANDOM="YES" SCALE="47.22" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.42651003655268965">
<NAME>Mental state: 2a. State - BPRS score reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.137979643885442" CI_START="0.2599788365074738" DF="0" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.9105165991865608" LOG_CI_START="-0.5850620041911614" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-01-14 11:15:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6697362373877482" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.42651003655268965">
<NAME>less than 25% reduction - short term</NAME>
<DICH_DATA CI_END="8.137979643885442" CI_START="0.2599788365074738" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9105165991865608" LOG_CI_START="-0.5850620041911614" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-01-14 11:15:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1092" O_E="0.0" SE="0.8785102748575585" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" VAR="0.771780303030303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.23026065273266866" CI_END="1.6521212183158833" CI_START="-0.5033560529606284" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5743825826776275" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2015-01-14 16:40:26 +0000" MODIFIED_BY="Heather Maxwell" NO="7" P_CHI2="0.8912499858966476" P_Q="0.8912499858966476" P_Z="0.2962235985667534" Q="0.23026065273266866" RANDOM="YES" SCALE="14.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="96" UNITS="" WEIGHT="300.0" Z="1.0445660368560041">
<NAME>Mental state: 2b. State - PANSS: mean endpoint from baseline (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.42041229409021" CI_START="-2.6604122940902046" DF="0" EFFECT_SIZE="1.3800000000000026" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" MODIFIED="2014-01-14 11:20:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5032248391955028" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6694243314281166">
<NAME>total - short term</NAME>
<CONT_DATA CI_END="5.42041229409021" CI_START="-2.6604122940902046" EFFECT_SIZE="1.3800000000000026" ESTIMABLE="YES" MEAN_1="47.25" MEAN_2="45.87" MODIFIED="2014-01-14 11:20:45 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="8.47" SD_2="8.15" SE="2.061472723968636" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.063062672115121" CI_START="-0.8030626721151193" DF="0" EFFECT_SIZE="0.6300000000000008" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" MODIFIED="2014-01-14 11:21:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.388888277191588" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.861635247562323">
<NAME>positive - short term</NAME>
<CONT_DATA CI_END="2.063062672115121" CI_START="-0.8030626721151193" EFFECT_SIZE="0.6300000000000008" ESTIMABLE="YES" MEAN_1="10.08" MEAN_2="9.45" MODIFIED="2014-01-14 11:21:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="3.11" SD_2="2.78" SE="0.7311678599295373" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.118136580077876" CI_START="-1.4581365800778763" DF="0" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.03" MODIFIED="2014-01-14 11:21:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7175682390270773" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.36171068927522826">
<NAME>negative - short term</NAME>
<CONT_DATA CI_END="2.118136580077876" CI_START="-1.4581365800778763" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" MEAN_1="11.97" MEAN_2="11.64" MODIFIED="2014-01-14 11:21:18 +0000" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="3.59" SD_2="3.76" SE="0.9123313459749615" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.08" MODIFIED="2015-01-14 16:40:36 +0000" MODIFIED_BY="Heather Maxwell" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2c. State - PANSS total change score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.08.01" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="3000" STUDY_ID="STD-Kane-2003">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>-10.5</P>
</TD>
<TD>
<P>21.24</P>
</TD>
<TD>
<P>144</P>
</TD>
</TR>
<TR>
<TD>
<P>Aripiprazole</P>
</TD>
<TD>
<P>-9.8</P>
</TD>
<TD>
<P>21.07</P>
</TD>
<TD>
<P>150</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.7038481532877575" CI_END="2.3814507991305653" CI_START="1.1663343727612163" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666037093639403" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.37684161339880506" LOG_CI_START="0.06682307480319208" LOG_EFFECT_SIZE="0.22183234410099859" METHOD="MH" MODIFIED="2014-02-18 12:10:23 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8722984741568013" P_Q="0.7715834165223687" P_Z="0.005033430243310195" Q="0.5186210133415391" RANDOM="YES" SCALE="17.419838241695896" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="471" TOTAL_2="494" WEIGHT="300.0" Z="2.804886488489538">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.853302320116343" CI_START="0.8923166119380715" DF="0" EFFECT_SIZE="2.2853881278538815" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="0.7674009557847004" LOG_CI_START="-0.04948102183426212" LOG_EFFECT_SIZE="0.35895996697521915" MODIFIED="2013-12-17 15:59:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0849749929335219" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.722522044650346">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="5.853302320116343" CI_START="0.8923166119380715" EFFECT_SIZE="2.2853881278538815" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7674009557847004" LOG_CI_START="-0.04948102183426212" LOG_EFFECT_SIZE="0.35895996697521915" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1307" O_E="0.0" SE="0.47984051728438265" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.23024692202774394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1805189002785249" CI_END="3.87643151487425" CI_START="0.7033854481860383" DF="1" EFFECT_SIZE="1.6512496838613802" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="0.5884321156691437" LOG_CI_START="-0.15280662071893023" LOG_EFFECT_SIZE="0.2178127474751067" MODIFIED="2014-01-14 11:17:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.670927690397628" P_Z="0.24937472928294335" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="186" WEIGHT="100.0" Z="1.1518694840616683">
<NAME>EPS - short term</NAME>
<DICH_DATA CI_END="5.532549360782344" CI_START="0.6515615427899005" EFFECT_SIZE="1.8986301369863015" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7429252973430397" LOG_CI_START="-0.18604455703237555" LOG_EFFECT_SIZE="0.2784403701553321" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1308" O_E="0.0" SE="0.5456814909350614" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.29776828954911144" WEIGHT="63.66679264106507"/>
<DICH_DATA CI_END="5.326412263811734" CI_START="0.31384468075671434" EFFECT_SIZE="1.292929292929293" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7264347777561998" LOG_CI_START="-0.5032852276555627" LOG_EFFECT_SIZE="0.11157477505031849" MODIFIED="2014-01-14 11:17:45 +0000" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="0.0" SE="0.7223436183910694" STUDY_ID="STD-Zhang-2010" TOTAL_1="33" TOTAL_2="32" VAR="0.521780303030303" WEIGHT="36.333207358934935"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.695418013951461E-31" CI_END="2.4082232426278054" CI_START="1.0139847907011161" DF="0" EFFECT_SIZE="1.5626585489599187" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" I2="100.0" ID="CMP-004.09.03" LOG_CI_END="0.3816967436104806" LOG_CI_START="0.006031440831521361" LOG_EFFECT_SIZE="0.19386409222100104" MODIFIED="2013-12-17 16:00:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.043083476046915196" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="2.0228998304497945">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="2.4082232426278054" CI_START="1.0139847907011161" EFFECT_SIZE="1.5626585489599187" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" LOG_CI_END="0.3816967436104806" LOG_CI_START="0.006031440831521361" LOG_EFFECT_SIZE="0.19386409222100104" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1311" O_E="0.0" SE="0.22066765842560027" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.04869421547503739" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.10" MODIFIED="2015-01-14 16:40:48 +0000" MODIFIED_BY="Heather Maxwell" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse events: Movement disorders - TESS total score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.10.01" MODIFIED="2014-01-14 11:19:27 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2014-01-14 11:19:27 +0000" MODIFIED_BY="[Empty name]" ORDER="3005" STUDY_ID="STD-Zhang-2010">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>5.13</P>
</TD>
<TD>
<P>4.21</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P>Aripiprazole</P>
</TD>
<TD>
<P>4.26</P>
</TD>
<TD>
<P>3.75</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.5841399082547554" CI_END="1.3816068810743574" CI_START="0.7849819455445961" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0414108015012857" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="81" I2="16.2979103273676" I2_Q="15.587984585597354" ID="CMP-004.11" LOG_CI_END="0.14038448756257338" LOG_CI_START="-0.10514033184140385" LOG_EFFECT_SIZE="0.017622077860584742" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.3100124618787041" P_Q="0.31382634721181624" P_Z="0.7784455003912056" Q="3.55399641303687" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.018061915994932086" TOTALS="SUB" TOTAL_1="584" TOTAL_2="616" WEIGHT="400.0" Z="0.2813453892225717">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7715742595051232" CI_START="0.6280241850481414" DF="0" EFFECT_SIZE="1.0547945205479452" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="0.2483593614771941" LOG_CI_START="-0.2020236313731422" LOG_EFFECT_SIZE="0.02316786505202597" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.840196200932467" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.20164252123856005">
<NAME>agitation - short term</NAME>
<DICH_DATA CI_END="1.7715742595051232" CI_START="0.6280241850481414" EFFECT_SIZE="1.0547945205479452" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.2483593614771941" LOG_CI_START="-0.2020236313731422" LOG_EFFECT_SIZE="0.02316786505202597" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1303" O_E="0.0" SE="0.26455719943205797" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.06999051177133368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.237503115793944" CI_START="0.6293281035753292" DF="0" EFFECT_SIZE="1.1866438356164384" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="0.34976364875718957" LOG_CI_START="-0.20112287375837498" LOG_EFFECT_SIZE="0.07432038749940727" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.596916780329366" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.5288395227050904">
<NAME>anxiety - short term</NAME>
<DICH_DATA CI_END="2.237503115793944" CI_START="0.6293281035753292" EFFECT_SIZE="1.1866438356164384" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.34976364875718957" LOG_CI_START="-0.20112287375837498" LOG_EFFECT_SIZE="0.07432038749940727" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1305" O_E="0.0" SE="0.32359347025790847" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.1047127339935559" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3081511307657707" CI_START="0.5591352471309653" DF="0" EFFECT_SIZE="0.8552388004442799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" I2="0.0" ID="CMP-004.11.03" LOG_CI_END="0.11665792095006171" LOG_CI_START="-0.2524831295406748" LOG_EFFECT_SIZE="-0.06791260429530659" MODIFIED="2013-12-17 16:01:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.47080648960529425" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.7211674688478535">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.3081511307657707" CI_START="0.5591352471309653" EFFECT_SIZE="0.8552388004442799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.11665792095006171" LOG_CI_START="-0.2524831295406748" LOG_EFFECT_SIZE="-0.06791260429530659" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1302" O_E="0.0" SE="0.21683528033592853" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.047017538798360715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.222302468369584" CI_START="0.8457116215758933" DF="0" EFFECT_SIZE="2.636986301369863" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-004.11.04" LOG_CI_END="0.914993448840305" LOG_CI_START="-0.07277770139217773" LOG_EFFECT_SIZE="0.4211078737240636" MODIFIED="2013-12-17 16:01:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09469229841292028" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.6711487593278043">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="8.222302468369584" CI_START="0.8457116215758933" EFFECT_SIZE="2.636986301369863" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.914993448840305" LOG_CI_START="-0.07277770139217773" LOG_EFFECT_SIZE="0.4211078737240636" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="0.5802216631926115" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.3366571784380003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="23.664827465355334" CI_START="1.1753640315007294" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.273972602739725" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="1.3741033424774856" LOG_CI_START="0.07017239629860385" LOG_EFFECT_SIZE="0.7221378693880447" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.029937297796837663" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="2.170918973923775">
<NAME>Other adverse events: 2. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.664827465355334" CI_START="1.1753640315007294" DF="0" EFFECT_SIZE="5.273972602739725" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="1.3741033424774856" LOG_CI_START="0.07017239629860385" LOG_EFFECT_SIZE="0.7221378693880447" MODIFIED="2013-12-17 16:02:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.029937297796837663" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="2.170918973923775">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="23.664827465355344" CI_START="1.1753640315007297" EFFECT_SIZE="5.273972602739726" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3741033424774858" LOG_CI_START="0.07017239629860393" LOG_EFFECT_SIZE="0.7221378693880448" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1310" O_E="0.0" SE="0.7659354923477566" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.5866571784380004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0306731150442916" CI_START="0.29189151434822735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5484931506849315" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="0.013120947686449353" LOG_CI_START="-0.534778530312799" LOG_EFFECT_SIZE="-0.2608287913131748" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.06202868870526807" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="99.99999999999999" Z="1.8660906156425934">
<NAME>Other adverse events: 3. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0306731150442916" CI_START="0.29189151434822735" DF="0" EFFECT_SIZE="0.5484931506849315" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" ID="CMP-004.13.01" LOG_CI_END="0.013120947686449353" LOG_CI_START="-0.534778530312799" LOG_EFFECT_SIZE="-0.2608287913131748" MODIFIED="2013-12-17 16:03:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06202868870526807" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="99.99999999999999" Z="1.8660906156425934">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="1.0306731150442916" CI_START="0.29189151434822735" EFFECT_SIZE="0.5484931506849315" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="0.013120947686449353" LOG_CI_START="-0.534778530312799" LOG_EFFECT_SIZE="-0.2608287913131748" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1304" O_E="0.0" SE="0.3218388655229155" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.10358025536107729" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3003382873118703" CI_START="0.27072255088278646" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5933219178082192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.11405635015360835" LOG_CI_START="-0.5674755664827562" LOG_EFFECT_SIZE="-0.22670960816457392" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.19224973461156694" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.3039526282048928">
<NAME>Other adverse events: 4. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3003382873118703" CI_START="0.27072255088278646" DF="0" EFFECT_SIZE="0.5933219178082192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-004.14.01" LOG_CI_END="0.11405635015360835" LOG_CI_START="-0.5674755664827562" LOG_EFFECT_SIZE="-0.22670960816457392" MODIFIED="2013-12-17 16:03:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19224973461156694" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.3039526282048928">
<NAME>dyspepsia - short term</NAME>
<DICH_DATA CI_END="1.3003382873118703" CI_START="0.27072255088278646" EFFECT_SIZE="0.5933219178082192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.11405635015360835" LOG_CI_START="-0.5674755664827562" LOG_EFFECT_SIZE="-0.22670960816457392" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1306" O_E="0.0" SE="0.4003352214695972" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.16026828954911146" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.041829158397406085" CI_END="25.96446692573313" CI_START="6.505203100027351" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="12.996312197536529" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="1.4143794105594556" LOG_CI_START="0.8132608602894887" LOG_EFFECT_SIZE="1.1138201354244721" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.837945885802284" P_Q="0.8382372299142036" P_Z="3.7780375190511126E-13" Q="0.04167678528449407" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="438" TOTAL_2="462" WEIGHT="200.0" Z="7.263283921972024">
<NAME>Other adverse events: 5. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="118.26618899447777" CI_START="2.1166918902048337" DF="0" EFFECT_SIZE="15.821917808219178" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" ID="CMP-004.15.01" LOG_CI_END="2.072860602346328" LOG_CI_START="0.3256576458690867" LOG_EFFECT_SIZE="1.1992591241077073" MODIFIED="2013-12-17 16:05:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.007132547751664976" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="2.690591476700921">
<NAME>ECG abnormality (1st degree atrioventricular block)</NAME>
<DICH_DATA CI_END="118.26618899447777" CI_START="2.1166918902048337" EFFECT_SIZE="15.821917808219178" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="2.072860602346328" LOG_CI_START="0.3256576458690867" LOG_EFFECT_SIZE="1.1992591241077073" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1313" O_E="0.0" SE="1.0263156654288519" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="1.053323845104667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.451460373328665" CI_START="6.056874400960204" DF="0" EFFECT_SIZE="12.657534246575343" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="7" I2="0.0" ID="CMP-004.15.02" LOG_CI_END="1.4224496542377452" LOG_CI_START="0.7822485679615564" LOG_EFFECT_SIZE="1.1023491110996508" MODIFIED="2013-12-17 16:05:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.4820884353588828E-11" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="6.749643518139767">
<NAME>prolactin: clinically significant high levels</NAME>
<DICH_DATA CI_END="26.451460373328665" CI_START="6.056874400960204" EFFECT_SIZE="12.657534246575343" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="7" LOG_CI_END="1.4224496542377452" LOG_CI_START="0.7822485679615564" LOG_EFFECT_SIZE="1.1023491110996508" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1312" O_E="0.0" SE="0.3760572871251202" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.14141908319990512" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.15.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-17 16:05:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="0.0" Z="0.0">
<NAME>prolonged QTc interval (&#8805;450 msec and &#8805;10% increase from baseline) - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1314" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22328204415076175" CI_END="1.123203420054052" CI_START="0.4948282944756095" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7455151458518586" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="0.05045841717563501" LOG_CI_START="-0.305545475204399" LOG_EFFECT_SIZE="-0.12754352901438204" METHOD="MH" MODIFIED="2014-01-14 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.6365504824874306" P_Q="0.6373069108119218" P_Z="0.16020848184920805" Q="0.22228164339796794" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="292" TOTAL_2="308" WEIGHT="200.0" Z="1.404370731219275">
<NAME>Other adverse events: 6. any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Aripiprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aripiprazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2764044405383823" CI_START="0.49030909635595926" DF="0" EFFECT_SIZE="0.791095890410959" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" I2="0.0" ID="CMP-004.16.01" LOG_CI_END="0.10598830640987891" LOG_CI_START="-0.30953004952242685" LOG_EFFECT_SIZE="-0.10177087155627396" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3370105778166257" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="0.9600887184779149">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2764044405383823" CI_START="0.49030909635595926" EFFECT_SIZE="0.791095890410959" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.10598830640987891" LOG_CI_START="-0.30953004952242685" LOG_EFFECT_SIZE="-0.10177087155627396" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1299" O_E="0.0" SE="0.24407753912367072" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.05957384510466701" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4011553218769022" CI_START="0.28585905270768946" DF="0" EFFECT_SIZE="0.6328767123287671" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-004.16.02" LOG_CI_END="0.14648628067842998" LOG_CI_START="-0.5438480498070909" LOG_EFFECT_SIZE="-0.19868088456433042" MODIFIED="2013-12-17 16:05:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25924798152858397" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="154" WEIGHT="100.0" Z="1.128170397925227">
<NAME>psychosis - short term</NAME>
<DICH_DATA CI_END="1.4011553218769022" CI_START="0.28585905270768946" EFFECT_SIZE="0.6328767123287671" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.14648628067842998" LOG_CI_START="-0.5438480498070909" LOG_EFFECT_SIZE="-0.19868088456433042" MODIFIED="2013-12-17 15:57:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1300" O_E="0.0" SE="0.4055058029372429" STUDY_ID="STD-Kane-2003" TOTAL_1="146" TOTAL_2="154" VAR="0.1644349562157781" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-02-18 12:18:10 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>PERPHENAZINE vs BENPERIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-14 16:28:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="833.8118537723943" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Benperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-05 16:06:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-05 16:05:43 +0000" MODIFIED_BY="[Empty name]" ORDER="24505" O_E="0.0" SE="0.0" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.47401233947198856" CI_START="0.03296327689993259" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12500000000000003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" METHOD="MH" MODIFIED="2014-02-18 12:18:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.002230638439298464" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.057671654464611">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Benperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours benperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.47401233947198856" CI_START="0.03296327689993259" DF="0" EFFECT_SIZE="0.12500000000000003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2013-12-05 16:06:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.002230638439298464" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.057671654464611">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.47401233947198856" CI_START="0.03296327689993259" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2013-12-05 16:05:43 +0000" MODIFIED_BY="[Empty name]" ORDER="24539" O_E="0.0" SE="0.6800735254367721" STUDY_ID="STD-Eckmann-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.46249999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-02-18 12:20:21 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>PERPHENAZINE vs BROMPERIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-14 16:28:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="833.8118537723943" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bromperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-09 16:11:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:10:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24521" O_E="0.0" SE="0.0" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.661020653882245" CI_START="0.9382946435329412" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.8235407802794655" LOG_CI_START="-0.027660762935390337" LOG_EFFECT_SIZE="0.3979400086720376" METHOD="MH" MODIFIED="2014-02-18 12:20:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06686483681942845" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.8325814637483102">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bromperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.661020653882245" CI_START="0.9382946435329412" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.8235407802794655" LOG_CI_START="-0.027660762935390337" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2013-12-09 16:11:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06686483681942845" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.8325814637483102">
<NAME>short term</NAME>
<DICH_DATA CI_END="6.661020653882245" CI_START="0.9382946435329412" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8235407802794655" LOG_CI_START="-0.027660762935390337" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2013-12-09 16:10:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24551" O_E="0.0" SE="0.5" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.25" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5996876010856382" CI_START="0.4000781149804874" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.20403517867378293" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2014-01-14 16:28:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5279455450200201" Q="0.0" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6311452732493041">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bromperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5996876010856382" CI_START="0.4000781149804874" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.20403517867378293" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-09 16:13:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5279455450200201" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6311452732493041">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="1.5996876010856382" CI_START="0.4000781149804874" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.20403517867378293" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-09 16:10:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24613" O_E="0.0" SE="0.35355339059327373" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.12499999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9862760542852527" CI_START="0.6091801778456267" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.29803960695960363" LOG_CI_START="-0.21525423664315357" LOG_EFFECT_SIZE="0.04139268515822508" METHOD="MH" MODIFIED="2014-01-14 16:28:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7519204554350457" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.3161081051122546">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bromperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9862760542852527" CI_START="0.6091801778456267" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.29803960695960363" LOG_CI_START="-0.21525423664315357" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-12-09 16:13:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7519204554350457" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.3161081051122546">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="1.9862760542852527" CI_START="0.6091801778456267" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.29803960695960363" LOG_CI_START="-0.21525423664315357" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-12-09 16:10:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24652" O_E="0.0" SE="0.30151134457776363" STUDY_ID="STD-Woggon-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.09090909090909093" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>PERPHENAZINE vs CHLORPROMAZINE</NAME>
<DICH_OUTCOME CHI2="0.24722318459752102" CI_END="1.3546738246794787" CI_START="0.886422310116691" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0958161803546236" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.13183473934747938" LOG_CI_START="-0.052359321841010296" LOG_EFFECT_SIZE="0.03973770875323456" METHOD="MH" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6190371727759624" P_Q="1.0" P_Z="0.39773213296618126" Q="0.0" RANDOM="YES" SCALE="3.7563299552981384" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="0.845678492367688">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorpromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorpromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.24722318459752102" CI_END="1.3546738246794787" CI_START="0.886422310116691" DF="1" EFFECT_SIZE="1.0958161803546236" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.13183473934747938" LOG_CI_START="-0.052359321841010296" LOG_EFFECT_SIZE="0.03973770875323456" MODIFIED="2013-12-10 16:41:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6190371727759624" P_Z="0.39773213296618126" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="0.845678492367688">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:33:05 +0000" MODIFIED_BY="[Empty name]" ORDER="24504" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7484507795816437" CI_START="0.5505560469650341" EFFECT_SIZE="0.9811320754716981" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.24265341104791438" LOG_CI_START="-0.25919846297989413" LOG_EFFECT_SIZE="-0.008272525965989885" MODIFIED="2013-12-09 16:40:06 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2947902750107759" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.08690130624092889" WEIGHT="13.47100962747598"/>
<DICH_DATA CI_END="1.4002925915844306" CI_START="0.8875754653453615" EFFECT_SIZE="1.1148387096774193" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.1462187911310174" LOG_CI_START="-0.05179471118585143" LOG_EFFECT_SIZE="0.04721203997258296" MODIFIED="2013-12-10 16:41:21 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.1163141114435734" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="32" VAR="0.013528972520908011" WEIGHT="86.52899037252402"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4008558940295979E-4" CI_END="0.5887839490920749" CI_START="0.18480601138699604" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3298648408066408" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-0.23004403786172048" LOG_CI_START="-0.7332839061151558" LOG_EFFECT_SIZE="-0.4816639719884382" METHOD="MH" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9905566376960213" P_Q="1.0" P_Z="1.7552393975698083E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.0" Z="3.75186505403193">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorpromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorpromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4008558940295979E-4" CI_END="0.5887839490920749" CI_START="0.18480601138699604" DF="1" EFFECT_SIZE="0.3298648408066408" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="-0.23004403786172048" LOG_CI_START="-0.7332839061151558" LOG_EFFECT_SIZE="-0.4816639719884382" MODIFIED="2013-12-10 16:41:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9905566376960213" P_Z="1.7552393975698083E-4" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.0" Z="3.75186505403193">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.5468856113853904" CI_START="0.06914395841800693" EFFECT_SIZE="0.3270440251572327" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18945819981386552" LOG_CI_START="-1.1602457611851702" LOG_EFFECT_SIZE="-0.48539378068565237" MODIFIED="2013-12-09 16:41:29 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="0.7928227878331926" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.6285679729075955" WEIGHT="13.901863986407243"/>
<DICH_DATA CI_END="0.616754517502415" CI_START="0.17691480838428048" EFFECT_SIZE="0.3303225806451613" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="25" LOG_CI_END="-0.2098876607775282" LOG_CI_START="-0.7522358136113931" LOG_EFFECT_SIZE="-0.4810617371944607" MODIFIED="2013-12-10 16:41:42 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.3185779896412666" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="32" VAR="0.10149193548387098" WEIGHT="86.09813601359276"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5207973478584975" CI_START="0.21625203961833248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5734767025089605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.18207134648532985" LOG_CI_START="-0.6650397877206755" LOG_EFFECT_SIZE="-0.2414842206176728" METHOD="MH" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2638037941559407" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.1174457662842232">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorpromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorpromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5207973478584975" CI_START="0.21625203961833248" DF="0" EFFECT_SIZE="0.5734767025089605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.18207134648532985" LOG_CI_START="-0.6650397877206755" LOG_EFFECT_SIZE="-0.2414842206176728" MODIFIED="2013-12-10 16:30:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2638037941559407" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.1174457662842232">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.5207973478584975" CI_START="0.21625203961833248" EFFECT_SIZE="0.5734767025089605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18207134648532985" LOG_CI_START="-0.6650397877206755" LOG_EFFECT_SIZE="-0.2414842206176728" MODIFIED="2013-12-10 16:30:55 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.49759727350035" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="32" VAR="0.2476030465949821" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.183554942927361" CI_END="6.302904901556654" CI_START="1.0048331729180584" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5166183522401555" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.7995407545251463" LOG_CI_START="0.002093964149341147" LOG_EFFECT_SIZE="0.4008173593372437" METHOD="MH" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5533430797939185" P_Q="0.5659656026865094" P_Z="0.04880891575501903" Q="1.1384445339015787" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="208" WEIGHT="300.0" Z="1.9702570708428846">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorpromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorpromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.889244178211314" CI_START="0.8752838909832399" DF="0" EFFECT_SIZE="6.867924528301886" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="1.7315020924560358" LOG_CI_START="-0.05785106435950177" LOG_EFFECT_SIZE="0.8368255140482669" MODIFIED="2013-12-09 16:43:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06676838672035991" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.8332299162203916">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="53.889244178211314" CI_START="0.8752838909832399" EFFECT_SIZE="6.867924528301887" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7315020924560358" LOG_CI_START="-0.05785106435950177" LOG_EFFECT_SIZE="0.836825514048267" MODIFIED="2013-12-09 16:43:45 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="1.0510749017544239" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="1.1047584490980717" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-14 16:27:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:44:05 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.986387438410016" CI_START="0.18347515070794534" DF="0" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.04.03" LOG_CI_END="1.3219376862912349" LOG_CI_START="-0.736422746895252" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2014-01-14 16:27:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5771685224490003" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.557525385313461">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="20.986387438410016" CI_START="0.18347515070794534" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3219376862912349" LOG_CI_START="-0.736422746895252" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2013-12-09 16:44:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.2090911075022135" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="1.461901306240929" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.12099582883438" CI_START="0.6290611373951638" DF="0" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-007.04.04" LOG_CI_END="0.7868220835483903" LOG_CI_START="-0.20130714415240764" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2014-01-14 16:27:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.24548961090179044" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.1613746071417332">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="6.12099582883438" CI_START="0.6290611373951638" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7868220835483903" LOG_CI_START="-0.20130714415240764" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2013-12-09 16:44:43 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.580431999670012" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.3369013062409289" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2142036478624396" CI_START="0.05018107129322823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:29:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.25546651089494854" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="1.1371717552202147">
<NAME>Other adverse events: 1. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorpromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorpromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2142036478624396" CI_START="0.05018107129322823" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-007.05.01" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:34:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25546651089494854" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="1.1371717552202147">
<NAME>electroencephalogram (increase) - short term</NAME>
<DICH_DATA CI_END="2.2142036478624396" CI_START="0.05018107129322823" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:34:49 +0000" MODIFIED_BY="[Empty name]" ORDER="24686" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.9333333333333333" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-02-18 12:25:38 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>PERPHENAZINE vs CLOCAPRAMINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3365841337765048" CI_START="0.5907443463940022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4039473684210526" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.523302080295497" LOG_CI_START="-0.2286004260081398" LOG_EFFECT_SIZE="0.14735082714367853" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.44237381267515574" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="0.7681908541934597">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3365841337765048" CI_START="0.5907443463940022" DF="0" EFFECT_SIZE="1.4039473684210526" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.523302080295497" LOG_CI_START="-0.2286004260081398" LOG_EFFECT_SIZE="0.14735082714367853" MODIFIED="2013-12-10 14:44:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44237381267515574" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="0.7681908541934597">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.3365841337765048" CI_START="0.5907443463940022" EFFECT_SIZE="1.4039473684210526" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.523302080295497" LOG_CI_START="-0.2286004260081398" LOG_EFFECT_SIZE="0.14735082714367853" MODIFIED="2013-12-10 14:44:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24515" O_E="0.0" SE="0.4416712541801897" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.19507349676910177" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.492100799574844" CI_START="0.15060283740833252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6126315789473684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.3965656045255706" LOG_CI_START="-0.8221668458034892" LOG_EFFECT_SIZE="-0.2128006206389593" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4936901870820246" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.6844513777039718">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.492100799574844" CI_START="0.15060283740833252" DF="0" EFFECT_SIZE="0.6126315789473684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.3965656045255706" LOG_CI_START="-0.8221668458034892" LOG_EFFECT_SIZE="-0.2128006206389593" MODIFIED="2013-12-10 14:49:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4936901870820246" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.6844513777039718">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.492100799574844" CI_START="0.15060283740833252" EFFECT_SIZE="0.6126315789473684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3965656045255706" LOG_CI_START="-0.8221668458034892" LOG_EFFECT_SIZE="-0.2128006206389593" MODIFIED="2013-12-10 14:49:51 +0000" MODIFIED_BY="[Empty name]" ORDER="24527" O_E="0.0" SE="0.715889474146215" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.5124977391933442" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.94160778442931" CI_START="0.6347960453577275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.382456140350877" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.9514156160135772" LOG_CI_START="-0.19736578746959427" LOG_EFFECT_SIZE="0.3770249142719915" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19826763790402946" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.286502812470414">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.94160778442931" CI_START="0.6347960453577275" DF="0" EFFECT_SIZE="2.382456140350877" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.9514156160135772" LOG_CI_START="-0.19736578746959427" LOG_EFFECT_SIZE="0.3770249142719915" MODIFIED="2013-12-10 14:51:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19826763790402946" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.286502812470414">
<NAME>short term</NAME>
<DICH_DATA CI_END="8.94160778442931" CI_START="0.6347960453577275" EFFECT_SIZE="2.382456140350877" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9514156160135772" LOG_CI_START="-0.19736578746959427" LOG_EFFECT_SIZE="0.3770249142719915" MODIFIED="2013-12-10 14:51:45 +0000" MODIFIED_BY="[Empty name]" ORDER="24536" O_E="0.0" SE="0.6747998829656737" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.455354882050487" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.488105049812089" CI_START="0.8826649602368706" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.146079484425349" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.17263359044598936" LOG_CI_START="-0.05420411355973489" LOG_EFFECT_SIZE="0.05921473844312724" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.30617752596168735" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.0232756958213618">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.488105049812089" CI_START="0.8826649602368706" DF="0" EFFECT_SIZE="1.146079484425349" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.17263359044598936" LOG_CI_START="-0.05420411355973489" LOG_EFFECT_SIZE="0.05921473844312724" MODIFIED="2013-12-10 15:32:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30617752596168735" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.0232756958213618">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.488105049812089" CI_START="0.8826649602368706" EFFECT_SIZE="1.146079484425349" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" LOG_CI_END="0.17263359044598936" LOG_CI_START="-0.05420411355973489" LOG_EFFECT_SIZE="0.05921473844312724" MODIFIED="2013-12-10 15:32:33 +0000" MODIFIED_BY="[Empty name]" ORDER="24548" O_E="0.0" SE="0.1332455901977066" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.01775438730713516" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5873908676024404" CI_END="1.0639852781966945" CI_START="0.715418744280838" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8724649056900668" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.026935618896838168" LOG_CI_START="-0.14543968533453117" LOG_EFFECT_SIZE="-0.0592520332188465" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8110565995293763" P_Q="0.8159212226852748" P_Z="0.17784169799918784" Q="1.560232820515071" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="475" TOTAL_2="485" WEIGHT="500.0" Z="1.347430267201536">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4441451507080916" CI_START="0.49264824675740265" DF="0" EFFECT_SIZE="0.8434782608695652" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.15961084626927619" LOG_CI_START="-0.30746305844400984" LOG_EFFECT_SIZE="-0.07392610608736683" MODIFIED="2013-12-16 16:25:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5349770576555031" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.620426463505679">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="1.4441451507080916" CI_START="0.49264824675740265" EFFECT_SIZE="0.8434782608695652" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.15961084626927619" LOG_CI_START="-0.30746305844400984" LOG_EFFECT_SIZE="-0.07392610608736683" MODIFIED="2013-12-16 16:25:08 +0000" MODIFIED_BY="[Empty name]" ORDER="24567" O_E="0.0" SE="0.2743615236817008" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.07527424567694448" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2143999321776358" CI_START="0.03603743219579906" DF="0" EFFECT_SIZE="0.34035087719298246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-008.05.02" LOG_CI_END="0.5070999102407596" LOG_CI_START="-1.4432461617252903" LOG_EFFECT_SIZE="-0.46807312574226534" MODIFIED="2013-12-16 16:25:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3468264645138659" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="0.9407627515676076">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="3.2143999321776358" CI_START="0.03603743219579906" EFFECT_SIZE="0.34035087719298246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5070999102407596" LOG_CI_START="-1.4432461617252903" LOG_EFFECT_SIZE="-0.46807312574226534" MODIFIED="2013-12-16 16:25:16 +0000" MODIFIED_BY="[Empty name]" ORDER="24576" O_E="0.0" SE="1.1456429370416177" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="1.3124977391933441" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6307199277344098" CI_START="0.19732034646496008" DF="0" EFFECT_SIZE="0.5672514619883041" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-008.05.03" LOG_CI_END="0.21237937840137744" LOG_CI_START="-0.7048281306531954" LOG_EFFECT_SIZE="-0.24622437612590897" MODIFIED="2013-12-16 16:25:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29265976840603514" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.052304750143322">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="1.6307199277344098" CI_START="0.19732034646496008" EFFECT_SIZE="0.5672514619883041" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21237937840137744" LOG_CI_START="-0.7048281306531954" LOG_EFFECT_SIZE="-0.24622437612590897" MODIFIED="2013-12-16 16:25:23 +0000" MODIFIED_BY="[Empty name]" ORDER="24582" O_E="0.0" SE="0.5387722310690501" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.29027551697112197" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.589495621976585" CI_START="0.6044764531691367" DF="0" EFFECT_SIZE="0.9802105263157894" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-008.05.04" LOG_CI_END="0.20125933605448515" LOG_CI_START="-0.2186206120205542" LOG_EFFECT_SIZE="-0.008680637983034525" MODIFIED="2013-12-16 16:25:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.935409375324871" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.08104096367344246">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.589495621976585" CI_START="0.6044764531691367" EFFECT_SIZE="0.9802105263157894" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.20125933605448515" LOG_CI_START="-0.2186206120205542" LOG_EFFECT_SIZE="-0.008680637983034525" MODIFIED="2013-12-16 16:25:29 +0000" MODIFIED_BY="[Empty name]" ORDER="24597" O_E="0.0" SE="0.24663955993854172" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.060831072526677514" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1284808930249954" CI_START="0.6903007999795416" DF="0" EFFECT_SIZE="0.8826048171275647" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="59" I2="0.0" ID="CMP-008.05.05" LOG_CI_END="0.05249421018023226" LOG_CI_START="-0.16096162331385372" LOG_EFFECT_SIZE="-0.054233706566810744" MODIFIED="2013-12-16 16:25:37 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3192724363463517" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.995954150131086">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="1.1284808930249954" CI_START="0.6903007999795416" EFFECT_SIZE="0.8826048171275647" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="59" LOG_CI_END="0.05249421018023226" LOG_CI_START="-0.16096162331385372" LOG_EFFECT_SIZE="-0.054233706566810744" MODIFIED="2013-12-16 16:25:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24611" O_E="0.0" SE="0.1253850132178429" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.015721401539638635" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27979565129822287" CI_END="1.3790460801438114" CI_START="0.2538335592238874" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5916486920940955" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.1395787781539697" LOG_CI_START="-0.5954509605618066" LOG_EFFECT_SIZE="-0.22793609120391847" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.596835247230596" P_Q="0.5975195633668275" P_Z="0.2241420707406604" Q="0.27875331807663434" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="194" WEIGHT="200.0" Z="1.2155876313713794">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0539766298330147" CI_START="0.0812121003763554" DF="0" EFFECT_SIZE="0.40842105263157896" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-008.06.01" LOG_CI_END="0.31259549788233854" LOG_CI_START="-1.0903792572716196" LOG_EFFECT_SIZE="-0.3888918796946405" MODIFIED="2013-12-16 16:25:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2772275753232054" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.0865684863986538">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="2.0539766298330147" CI_START="0.0812121003763554" EFFECT_SIZE="0.40842105263157896" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31259549788233854" LOG_CI_START="-1.0903792572716196" LOG_EFFECT_SIZE="-0.3888918796946405" MODIFIED="2013-12-16 16:25:59 +0000" MODIFIED_BY="[Empty name]" ORDER="24618" O_E="0.0" SE="0.8241143160144779" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.6791644058600108" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8383422819251474" CI_START="0.2520503841857439" DF="0" EFFECT_SIZE="0.6807017543859649" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-008.06.02" LOG_CI_END="0.26442637609893327" LOG_CI_START="-0.5985126362555016" LOG_EFFECT_SIZE="-0.16704313007828414" MODIFIED="2013-12-16 16:26:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.44797296407811904" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.7587987427408232">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="1.8383422819251474" CI_START="0.2520503841857439" EFFECT_SIZE="0.6807017543859649" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.26442637609893327" LOG_CI_START="-0.5985126362555016" LOG_EFFECT_SIZE="-0.16704313007828414" MODIFIED="2013-12-16 16:26:05 +0000" MODIFIED_BY="[Empty name]" ORDER="24626" O_E="0.0" SE="0.5068946474739979" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.25694218363778865" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1220638115344857" CI_END="1.3748054724210146" CI_START="0.8976304085373616" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1108857717464364" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.13824125218028746" LOG_CI_START="-0.0469024434806436" LOG_EFFECT_SIZE="0.045669404349821904" METHOD="MH" MODIFIED="2014-02-18 12:25:18 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9407932292746151" P_Q="0.940922467013263" P_Z="0.3335796296777134" Q="0.1217890881755821" RANDOM="YES" SCALE="6.439165653244372" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="285" TOTAL_2="291" WEIGHT="300.0" Z="0.9669288214379774">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6275355295949214" CI_START="0.8253932491677058" DF="0" EFFECT_SIZE="1.1590327169274537" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.21153047812415782" LOG_CI_START="-0.08333908750755276" LOG_EFFECT_SIZE="0.06409569530830252" MODIFIED="2013-12-16 16:26:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3941733718293067" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.8520733843738263">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.6275355295949214" CI_START="0.8253932491677058" EFFECT_SIZE="1.1590327169274537" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" LOG_CI_END="0.21153047812415782" LOG_CI_START="-0.08333908750755276" LOG_EFFECT_SIZE="0.06409569530830252" MODIFIED="2013-12-16 16:26:28 +0000" MODIFIED_BY="[Empty name]" ORDER="24644" O_E="0.0" SE="0.17320784247995727" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.030000956696561693" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4586800121318508" CI_START="0.8131930779199255" DF="0" EFFECT_SIZE="1.0891228070175438" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="0.0" ID="CMP-008.07.02" LOG_CI_END="0.16396003198462508" LOG_CI_START="-0.08980632682934386" LOG_EFFECT_SIZE="0.03707685257764061" MODIFIED="2013-12-16 16:26:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5668302335959365" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.5727259992373465">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="1.4586800121318508" CI_START="0.8131930779199255" EFFECT_SIZE="1.0891228070175438" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" LOG_CI_END="0.16396003198462508" LOG_CI_START="-0.08980632682934386" LOG_EFFECT_SIZE="0.03707685257764061" MODIFIED="2013-12-16 16:26:34 +0000" MODIFIED_BY="[Empty name]" ORDER="24650" O_E="0.0" SE="0.14906361533106063" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.02221996141556641" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.241674859694867" CI_START="0.4650756874688793" DF="0" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" ID="CMP-008.07.03" LOG_CI_END="0.3505726212471706" LOG_CI_START="-0.33247636329237634" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:26:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.958587642891943" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.05192601797110152">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="2.241674859694867" CI_START="0.4650756874688793" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3505726212471706" LOG_CI_START="-0.33247636329237634" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:26:40 +0000" MODIFIED_BY="[Empty name]" ORDER="24656" O_E="0.0" SE="0.40122635466553375" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.16098258767819268" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.487792322326877E-30" CI_END="1.0701778116706238" CI_START="0.7845979882355221" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9163292847503374" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="78" I2="100.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.02945594236902841" LOG_CI_START="-0.10535280976668142" LOG_EFFECT_SIZE="-0.03794843369882649" METHOD="MH" MODIFIED="2014-02-18 12:25:38 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.2698304938193854" Q="0.0" RANDOM="YES" SCALE="4.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="1.1034530346298486">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.487792322326877E-30" CI_END="1.0701778116706238" CI_START="0.7845979882355221" DF="0" EFFECT_SIZE="0.9163292847503374" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="78" I2="100.0" ID="CMP-008.08.01" LOG_CI_END="0.02945594236902841" LOG_CI_START="-0.10535280976668142" LOG_EFFECT_SIZE="-0.03794843369882649" MODIFIED="2013-12-16 16:26:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.2698304938193854" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="1.1034530346298486">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0701778116706238" CI_START="0.7845979882355221" EFFECT_SIZE="0.9163292847503374" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="78" LOG_CI_END="0.02945594236902841" LOG_CI_START="-0.10535280976668142" LOG_EFFECT_SIZE="-0.03794843369882649" MODIFIED="2013-12-16 16:26:56 +0000" MODIFIED_BY="[Empty name]" ORDER="24664" O_E="0.0" SE="0.07918732831860134" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.006270632966237961" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4636403067888202" CI_END="1.3811663393363105" CI_START="0.19810036294091915" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5230770049469808" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.140245985534184" LOG_CI_START="-0.703114728787076" LOG_EFFECT_SIZE="-0.281434371626446" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4959275998470235" P_Q="0.49704650676361484" P_Z="0.1908384628001443" Q="0.4612368954749644" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="194" WEIGHT="200.0" Z="1.3081027442532138">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3360989493098767" CI_START="0.19834557031970476" DF="0" EFFECT_SIZE="0.6807017543859649" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.3684912340864046" LOG_CI_START="-0.7025774942429729" LOG_EFFECT_SIZE="-0.16704313007828414" MODIFIED="2013-12-16 16:27:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5409684122173637" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.6113492256074796">
<NAME>angina pectoris - short term</NAME>
<DICH_DATA CI_END="2.3360989493098767" CI_START="0.19834557031970476" EFFECT_SIZE="0.6807017543859649" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3684912340864046" LOG_CI_START="-0.7025774942429729" LOG_EFFECT_SIZE="-0.16704313007828414" MODIFIED="2013-12-16 16:27:34 +0000" MODIFIED_BY="[Empty name]" ORDER="24668" O_E="0.0" SE="0.629151072896389" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.3958310725266775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6443081565893867" CI_START="0.07044830322213116" DF="0" EFFECT_SIZE="0.34035087719298246" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-008.09.02" LOG_CI_END="0.2159832111146601" LOG_CI_START="-1.1521294625991907" LOG_EFFECT_SIZE="-0.46807312574226534" MODIFIED="2013-12-16 16:27:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17987920075401354" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="99.99999999999999" Z="1.3411270668161495">
<NAME>palpitations - short term</NAME>
<DICH_DATA CI_END="1.6443081565893867" CI_START="0.07044830322213116" EFFECT_SIZE="0.34035087719298246" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2159832111146601" LOG_CI_START="-1.1521294625991907" LOG_EFFECT_SIZE="-0.46807312574226534" MODIFIED="2013-12-16 16:27:45 +0000" MODIFIED_BY="[Empty name]" ORDER="24677" O_E="0.0" SE="0.8036361568064726" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.6458310725266775" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5211054960863772" CI_END="2.9260300535394292" CI_START="0.816561454006177" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5457306864340656" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="20.669721949173177" I2_Q="19.750124163296846" ID="CMP-008.10" LOG_CI_END="0.46627878249308763" LOG_CI_START="-0.08801112491207383" LOG_EFFECT_SIZE="0.18913382879050686" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.2834973818484764" P_Q="0.2876221806527536" P_Z="0.18104286698851815" Q="2.492215693977782" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10254109952781809" TOTALS="SUB" TOTAL_1="380" TOTAL_2="388" WEIGHT="300.0" Z="1.3375509376417214">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-16 16:28:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="0.0" Z="0.0">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:28:12 +0000" MODIFIED_BY="[Empty name]" ORDER="24683" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.858628026323226" CI_START="0.8291431985346059" DF="0" EFFECT_SIZE="2.5526315789473686" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-008.10.02" LOG_CI_END="0.8953467327308093" LOG_CI_START="-0.08137045743193985" LOG_EFFECT_SIZE="0.4069881376494347" MODIFIED="2013-12-16 16:28:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10238611815926021" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="99.99999999999999" Z="1.6333941901749582">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="7.858628026323226" CI_START="0.8291431985346059" EFFECT_SIZE="2.5526315789473686" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8953467327308093" LOG_CI_START="-0.08137045743193985" LOG_EFFECT_SIZE="0.4069881376494347" MODIFIED="2013-12-16 16:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="24693" O_E="0.0" SE="0.5737285123296653" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.32916440586001083" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.87695570656899" CI_START="0.46494400917674544" DF="0" EFFECT_SIZE="4.08421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-008.10.03" LOG_CI_END="1.5548155844297413" LOG_CI_START="-0.33259934381902234" LOG_EFFECT_SIZE="0.6111081203053595" MODIFIED="2013-12-16 16:28:30 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.20437112919473177" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.2691961778322975">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="35.87695570656899" CI_START="0.46494400917674544" EFFECT_SIZE="4.08421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5548155844297413" LOG_CI_START="-0.33259934381902234" LOG_EFFECT_SIZE="0.6111081203053595" MODIFIED="2013-12-16 16:28:30 +0000" MODIFIED_BY="[Empty name]" ORDER="24700" O_E="0.0" SE="1.108676871707898" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="1.2291644058600109" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3406859976975616" CI_START="0.4454029619862752" DF="0" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-008.10.04" LOG_CI_END="0.36934315713370003" LOG_CI_START="-0.35124689917890584" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:28:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9607433410979097" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.04922079278728825">
<NAME>vertigo - short term</NAME>
<DICH_DATA CI_END="2.3406859976975616" CI_START="0.4454029619862752" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.36934315713370003" LOG_CI_START="-0.35124689917890584" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24703" O_E="0.0" SE="0.42327816605633095" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.17916440586001087" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0952045789250011" CI_END="2.701165648587642" CI_START="1.122567853752439" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.741333318111396" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.43155121804959073" LOG_CI_START="0.05021260145231303" LOG_EFFECT_SIZE="0.24088190975095186" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.5783349522362409" P_Q="0.5784895787157806" P_Z="0.01328193577461492" Q="1.094669918874135" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="380" TOTAL_2="388" WEIGHT="300.0" Z="2.4761188460369725">
<NAME>Other adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8742128461533527" CI_START="0.5418482602439073" DF="0" EFFECT_SIZE="1.247953216374269" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-008.11.01" LOG_CI_END="0.45851892611105494" LOG_CI_START="-0.2661223167184603" LOG_EFFECT_SIZE="0.09619830469629727" MODIFIED="2013-12-16 16:29:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.602797195790604" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.5203822289836507">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="2.8742128461533527" CI_START="0.5418482602439073" EFFECT_SIZE="1.247953216374269" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.45851892611105494" LOG_CI_START="-0.2661223167184603" LOG_EFFECT_SIZE="0.09619830469629727" MODIFIED="2013-12-16 16:29:08 +0000" MODIFIED_BY="[Empty name]" ORDER="24716" O_E="0.0" SE="0.4256578530700601" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.18118460788021287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-16 16:29:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="0.0" Z="0.0">
<NAME>icterus - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:29:15 +0000" MODIFIED_BY="[Empty name]" ORDER="24720" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.004518482394274E-31" CI_END="3.504119054366944" CI_START="0.8876448473587678" DF="0" EFFECT_SIZE="1.7636363636363637" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="100.0" ID="CMP-008.11.03" LOG_CI_END="0.544578853139951" LOG_CI_START="-0.05176076359594903" LOG_EFFECT_SIZE="0.246409044772001" MODIFIED="2013-12-16 16:29:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.10529153612867977" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.6197241962944222">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="3.504119054366944" CI_START="0.8876448473587678" EFFECT_SIZE="1.7636363636363637" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.544578853139951" LOG_CI_START="-0.05176076359594903" LOG_EFFECT_SIZE="0.246409044772001" MODIFIED="2013-12-16 16:29:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24726" O_E="0.0" SE="0.3502928427993786" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.12270507571647017" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.028207277625601" CI_START="1.049658729371668" DF="0" EFFECT_SIZE="2.2973684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-008.11.04" LOG_CI_END="0.7014131722902843" LOG_CI_START="0.02104812188723488" LOG_EFFECT_SIZE="0.36123064708875957" MODIFIED="2013-12-16 16:29:45 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.03741259488993478" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="2.0812328851596584">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="5.028207277625601" CI_START="1.049658729371668" EFFECT_SIZE="2.2973684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.7014131722902843" LOG_CI_START="0.02104812188723488" LOG_EFFECT_SIZE="0.36123064708875957" MODIFIED="2013-12-16 16:29:45 +0000" MODIFIED_BY="[Empty name]" ORDER="24733" O_E="0.0" SE="0.3996497984680668" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.1597199614155664" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.023788397088675" CI_START="0.2590962480056374" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="0.6046351339780238" LOG_CI_START="-0.5865388760232296" LOG_EFFECT_SIZE="0.009048128977397114" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.9762459562510719" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="194" WEIGHT="200.0" Z="0.029775678069324085">
<NAME>Other adverse events: 7. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.101258939831673" CI_START="0.14681178158516864" DF="0" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-008.12.01" LOG_CI_END="0.8513353490224558" LOG_CI_START="-0.8332390910676616" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9832021136689946" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.021054583877246628">
<NAME>pruritus - short term</NAME>
<DICH_DATA CI_END="7.101258939831673" CI_START="0.14681178158516864" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513353490224558" LOG_CI_START="-0.8332390910676616" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="24763" O_E="0.0" SE="0.9895273648868994" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.9791644058600109" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.101258939831673" CI_START="0.14681178158516864" DF="0" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-008.12.02" LOG_CI_END="0.8513353490224558" LOG_CI_START="-0.8332390910676616" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9832021136689946" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.021054583877246628">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="7.101258939831673" CI_START="0.14681178158516864" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513353490224558" LOG_CI_START="-0.8332390910676616" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:20 +0000" MODIFIED_BY="[Empty name]" ORDER="24760" O_E="0.0" SE="0.9895273648868994" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.9791644058600109" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1774329471095909" CI_END="2.57284264313037" CI_START="0.1471349628689745" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.615268320950056" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.13" LOG_CI_END="0.41041322526593743" LOG_CI_START="-0.8322841160089915" LOG_EFFECT_SIZE="-0.2109354453715271" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.673588675466625" P_Q="0.6736186776906358" P_Z="0.5058147873444185" Q="0.17739833207810257" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="194" WEIGHT="200.0" Z="0.6653685692559066">
<NAME>Other adverse events: 8. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.08948367107776" CI_START="0.06479688831334998" DF="0" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-008.13.01" LOG_CI_END="1.206542107343295" LOG_CI_START="-1.1884458493885006" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9881843471497984" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="0.014809266053572502">
<NAME>diminished sexual desire</NAME>
<DICH_DATA CI_END="16.08948367107776" CI_START="0.06479688831334998" EFFECT_SIZE="1.0210526315789474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.206542107343295" LOG_CI_START="-1.1884458493885006" LOG_EFFECT_SIZE="0.009048128977397114" MODIFIED="2013-12-16 16:30:32 +0000" MODIFIED_BY="[Empty name]" ORDER="24741" O_E="0.0" SE="1.4068277811658436" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="1.9791644058600109" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7218782710122076" CI_START="0.09575634659688445" DF="0" EFFECT_SIZE="0.5105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-008.13.02" LOG_CI_END="0.43486869860066596" LOG_CI_START="-1.018832431973834" LOG_EFFECT_SIZE="-0.2919818666865841" MODIFIED="2013-12-16 16:30:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4310865555102704" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.00000000000001" Z="0.7873336971517917">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="2.7218782710122076" CI_START="0.09575634659688445" EFFECT_SIZE="0.5105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43486869860066596" LOG_CI_START="-1.018832431973834" LOG_EFFECT_SIZE="-0.2919818666865841" MODIFIED="2013-12-16 16:30:38 +0000" MODIFIED_BY="[Empty name]" ORDER="24751" O_E="0.0" SE="0.8539112400361122" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.7291644058600109" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3869244228284683" CI_START="0.020880503237839246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1701754385964912" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.14" LOG_CI_END="0.14205279586576003" LOG_CI_START="-1.680259038678253" LOG_EFFECT_SIZE="-0.7691031214062466" METHOD="MH" MODIFIED="2014-01-14 16:29:33 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.09804669683471126" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="194" WEIGHT="100.0" Z="1.6543978805150787">
<NAME>Other adverse events: 9. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clocaprimine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clocaprimine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-16 16:30:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="0.0" Z="0.0">
<NAME>cramps - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:30:51 +0000" MODIFIED_BY="[Empty name]" ORDER="24767" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3869244228284683" CI_START="0.020880503237839246" DF="0" EFFECT_SIZE="0.1701754385964912" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.14.02" LOG_CI_END="0.14205279586576003" LOG_CI_START="-1.680259038678253" LOG_EFFECT_SIZE="-0.7691031214062466" MODIFIED="2013-12-16 16:30:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09804669683471126" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="97" WEIGHT="100.0" Z="1.6543978805150787">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="1.3869244228284685" CI_START="0.020880503237839246" EFFECT_SIZE="0.17017543859649123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1420527958657601" LOG_CI_START="-1.680259038678253" LOG_EFFECT_SIZE="-0.7691031214062466" MODIFIED="2013-12-16 16:30:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24776" O_E="0.0" SE="1.0704349922002165" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="97" VAR="1.1458310725266776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-02-18 13:20:11 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>PERPHENAZINE vs CLOPENTHIXOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.553055387930549" CI_START="0.15260057191669785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 13:20:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="45.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.553055387930549" CI_START="0.15260057191669785" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:56:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:56:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0787452782845226" CI_START="0.21380418711580704" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.31780127576104245" LOG_CI_START="-0.6699837938724049" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2014-02-18 13:20:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4846764988835336" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="99.99999999999999" Z="0.6988008552701077">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0787452782845226" CI_START="0.21380418711580704" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.31780127576104245" LOG_CI_START="-0.6699837938724049" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-12-16 16:56:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4846764988835336" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="99.99999999999999" Z="0.6988008552701077">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.0787452782845226" CI_START="0.21380418711580704" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.31780127576104245" LOG_CI_START="-0.6699837938724049" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-12-16 16:56:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.5802298395176404" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.33666666666666667" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8925803334475861" CI_START="0.31034552282746863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-0.04935268636092187" LOG_CI_START="-0.5081545155447361" LOG_EFFECT_SIZE="-0.278753600952829" METHOD="MH" MODIFIED="2014-01-14 16:29:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.017236426520710224" Q="0.0" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.381625284277176">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8925803334475861" CI_START="0.31034552282746863" DF="0" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="-0.04935268636092187" LOG_CI_START="-0.5081545155447361" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2013-12-16 16:57:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.017236426520710224" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.381625284277176">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="0.8925803334475861" CI_START="0.31034552282746863" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.04935268636092187" LOG_CI_START="-0.5081545155447361" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2013-12-16 16:57:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.26950246556825486" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.07263157894736841" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0253991183113356" CI_START="0.24380750435177775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.010892939676755791" LOG_CI_START="-0.6129529310047181" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2014-01-14 16:29:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.05855518646788226" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.8915183300745155">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0253991183113356" CI_START="0.24380750435177775" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.010892939676755791" LOG_CI_START="-0.6129529310047181" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-16 16:57:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05855518646788226" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.8915183300745155">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="1.0253991183113356" CI_START="0.24380750435177775" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.010892939676755791" LOG_CI_START="-0.6129529310047181" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-16 16:57:58 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.36645015252516167" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.13428571428571426" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.553055387930549" CI_START="0.15260057191669785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-01-14 16:29:50 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Other adverse events: 2. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.553055387930549" CI_START="0.15260057191669785" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:58:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>slight T-wave changes on EKG - short term</NAME>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 16:58:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1460" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Dehnel-1968" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-02-18 13:23:00 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>PERPHENAZINE vs CLOTHIAPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.660501214038062" CI_START="0.2145691963319019" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422858" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 13:21:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.660501214038062" CI_START="0.2145691963319019" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422858" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:04:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.660501214038062" CI_START="0.2145691963319019" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422858" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24511" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.755362190128105" CI_START="0.14803055289342473" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.8296486387699221" LOG_CI_START="-0.8296486387699221" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 13:21:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 2. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.755362190128105" CI_START="0.14803055289342473" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.8296486387699221" LOG_CI_START="-0.8296486387699221" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:04:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="6.755362190128103" CI_START="0.14803055289342476" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.829648638769922" LOG_CI_START="-0.829648638769922" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24535" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.95" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.122301107339212" CI_START="0.8116926688879422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150848" LOG_EFFECT_SIZE="0.11809931207799448" METHOD="MH" MODIFIED="2014-02-18 13:21:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.26740214842856214" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.109065026957839">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.122301107339212" CI_START="0.8116926688879422" DF="0" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150848" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:04:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.26740214842856214" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.109065026957839">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24544" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3383479077117193" CI_START="0.6908190371803543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.1265690243129547" LOG_CI_START="-0.16063570291051535" LOG_EFFECT_SIZE="-0.017033339298780342" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8161649271879621" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.23248037652307874">
<NAME>Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3383479077117193" CI_START="0.6908190371803543" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.1265690243129547" LOG_CI_START="-0.16063570291051535" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24558" O_E="0.0" SE="0.1687054784573947" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.02846153846153847" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.079429924486118" CI_END="1.6909602746427395" CI_START="0.934429000665808" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2570132535498564" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="49" I2="2.5793710665253404" I2_Q="1.6204460794416617" ID="CMP-010.05" LOG_CI_END="0.22813340493298542" LOG_CI_START="-0.029453691385694133" LOG_EFFECT_SIZE="0.09933985677364568" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3795402939673884" P_Q="0.3840692943041204" P_Z="0.13059965685686709" Q="3.0494141114143547" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0026759342505442373" TOTALS="SUB" TOTAL_1="160" TOTAL_2="160" WEIGHT="400.0" Z="1.5117414209664628">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4884205615906234" CI_START="0.7569686491000236" DF="0" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="0.542628837661829" LOG_CI_START="-0.12092210703204267" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2013-12-06 10:05:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21290524649110387" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.2456164981482076">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="3.4884205615906234" CI_START="0.7569686491000236" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.542628837661829" LOG_CI_START="-0.12092210703204267" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24563" O_E="0.0" SE="0.3897731095433303" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.15192307692307694" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5124577344609882" CI_START="0.20406651258829142" DF="0" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-010.05.02" LOG_CI_END="0.17968324716130687" LOG_CI_START="-0.690228257367919" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2013-12-06 10:05:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25002478576705356" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.150289227446326">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="1.5124577344609882" CI_START="0.20406651258829142" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17968324716130687" LOG_CI_START="-0.690228257367919" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24578" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.26111111111111107" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.122301107339212" CI_START="0.8116926688879422" DF="0" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" ID="CMP-010.05.03" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150848" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:05:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.26740214842856214" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.109065026957839">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24593" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.122301107339212" CI_START="0.8116926688879422" DF="0" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" ID="CMP-010.05.04" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150848" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:05:35 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.26740214842856214" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.109065026957839">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="2.122301107339212" CI_START="0.8116926688879421" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.32680700066749746" LOG_CI_START="-0.09060837651150853" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24609" O_E="0.0" SE="0.24519185879438907" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.06011904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.617695748791123" CI_END="3.230437042818976" CI_START="0.09226006599735065" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5459307050998002" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="38.1836788068904" I2_Q="38.16949120944473" ID="CMP-010.06" LOG_CI_END="0.5092612816019287" LOG_CI_START="-1.0349862390592615" LOG_EFFECT_SIZE="-0.26286247872866625" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.20341343878157758" P_Q="0.20346530094390958" P_Z="0.5046112945287238" Q="1.6173245531383236" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.1791460310256556" TOTALS="SUB" TOTAL_1="80" TOTAL_2="80" WEIGHT="200.0" Z="0.6672518288707006">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1398561589712335" CI_START="0.029207570676174695" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-010.06.01" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-06 10:05:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.20568937143051014" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.2655078215459612">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24622" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-010.06.02" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:05:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>nasal congestion - short term</NAME>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24628" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32900857116876453" CI_END="1.645470454338307" CI_START="0.6499907241520042" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0341859272810106" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="0.21629008861578491" LOG_CI_START="-0.18709284101613502" LOG_EFFECT_SIZE="0.014598623799824979" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8483141453250658" P_Q="0.8483714071775735" P_Z="0.8871873564892562" Q="0.3288735740586986" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="120" WEIGHT="300.0" Z="0.14186409374147202">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.897274438862189" CI_START="0.4355965927034584" DF="0" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-010.07.01" LOG_CI_END="0.2781301556977779" LOG_CI_START="-0.36091552601422794" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2013-12-06 10:06:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7995696165343411" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.25390414004890555">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.897274438862189" CI_START="0.4355965927034584" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2781301556977779" LOG_CI_START="-0.36091552601422794" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24640" O_E="0.0" SE="0.3753785967647742" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.14090909090909093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.837874370854859" CI_START="0.5505881500770327" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-010.07.02" LOG_CI_END="0.45299316587405014" LOG_CI_START="-0.2591731398579374" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-06 10:06:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5937462603217476" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.5334151130384417">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="2.837874370854859" CI_START="0.5505881500770327" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.45299316587405014" LOG_CI_START="-0.2591731398579374" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24648" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.17500000000000002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.402530460804138" CI_START="0.4162278132637267" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-010.07.03" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:06:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24653" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.2" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.301085657147728" CI_START="0.9146843162017692" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="0.11430588933792712" LOG_CI_START="-0.038728767559127575" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" MODIFIED="2014-02-18 13:23:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.33307411662471853" Q="0.0" RANDOM="YES" SCALE="3.835361684925254" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.9679404635859035">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.301085657147728" CI_START="0.9146843162017692" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" I2="0.0" ID="CMP-010.08.01" LOG_CI_END="0.11430588933792712" LOG_CI_START="-0.038728767559127575" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-12-06 10:07:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.33307411662471853" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.9679404635859035">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.301085657147728" CI_START="0.9146843162017692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" LOG_CI_END="0.11430588933792712" LOG_CI_START="-0.038728767559127575" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24661" O_E="0.0" SE="0.08989331499509892" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.008080808080808077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.510623893834799" CI_START="0.4266530862592416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.09" LOG_CI_END="0.813622607718267" LOG_CI_START="-0.3699251084855542" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.462481766836056" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.7347664201625179">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.510623893834799" CI_START="0.4266530862592416" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-010.09.01" LOG_CI_END="0.813622607718267" LOG_CI_START="-0.3699251084855542" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2013-12-06 10:07:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.462481766836056" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.7347664201625179">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="6.510623893834799" CI_START="0.4266530862592416" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.813622607718267" LOG_CI_START="-0.3699251084855542" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24670" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.4833333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.9453474498525" CI_START="0.01398442444617999" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.10" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.4971385617323206" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.9453474498525" CI_START="0.01398442444617999" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.10.01" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:07:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24689" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.447421985594918" CI_END="1.8536072821941487" CI_START="0.26085720620606484" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6953609257330918" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="41.98563424039711" I2_Q="41.707830614555505" ID="CMP-010.11" LOG_CI_END="0.26801772698094944" LOG_CI_START="-0.5835971613479661" LOG_EFFECT_SIZE="-0.15778971718350834" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.17840316113559263" P_Q="0.17987471025220148" P_Z="0.4676574525628652" Q="3.4309925691312464" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6230922819568063" TOTALS="SUB" TOTAL_1="120" TOTAL_2="120" WEIGHT="300.0" Z="0.7262958105800338">
<NAME>Other adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1050846251014352" CI_START="0.05655675464153993" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-010.11.01" LOG_CI_END="0.04339553667030915" LOG_CI_START="-1.2475155193262337" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-06 10:08:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06752091164647528" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.8281908642022873">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="1.1050846251014352" CI_START="0.05655675464153993" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04339553667030915" LOG_CI_START="-1.2475155193262337" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24712" O_E="0.0" SE="0.758287544405155" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.579155313499883" CI_START="0.31864640395941085" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-010.11.02" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-06 10:08:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6936364862031998" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.39392490117918977">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="5.579155313499883" CI_START="0.31864640395941085" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24722" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-010.11.03" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:08:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24729" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.296053860021452" CI_START="0.0472049579947035" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.12" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.5648670580356441" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.5756274021886759">
<NAME>Other adverse events: 7. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.296053860021452" CI_START="0.0472049579947035" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-010.12.01" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:09:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5648670580356441" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.5756274021886759">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="5.296053860021452" CI_START="0.0472049579947035" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24756" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.296053860021452" CI_START="0.0472049579947035" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.13" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5648670580356441" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.5756274021886759">
<NAME>Other adverse events: 8. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.296053860021452" CI_START="0.0472049579947035" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-010.13.01" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:09:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5648670580356441" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.5756274021886759">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="5.296053860021452" CI_START="0.0472049579947035" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24747" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.14" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:30:42 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4971385617323206" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>Other adverse events: 9. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clothiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clothiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-010.14.01" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:09:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4971385617323206" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057508">
<NAME>muscle pain - short term</NAME>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24768" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Itoh-1969" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2015-01-14 16:41:01 +0000" MODIFIED_BY="Heather Maxwell" NO="11">
<NAME>PERPHENAZINE vs CLOZAPINE</NAME>
<DICH_OUTCOME CHI2="0.15262760654237384" CI_END="7.229849187679644" CI_START="0.48338924193117744" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.869446794671943" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.8591292381463079" LOG_CI_START="-0.31570301926125205" LOG_EFFECT_SIZE="0.27171310944252797" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6960370326097726" P_Q="1.0" P_Z="0.3646215723041156" Q="0.0" RANDOM="YES" SCALE="833.8118537723943" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="64" WEIGHT="100.0" Z="0.9065939503736306">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15262760654237384" CI_END="7.229849187679644" CI_START="0.48338924193117744" DF="1" EFFECT_SIZE="1.869446794671943" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="0.8591292381463079" LOG_CI_START="-0.31570301926125205" LOG_EFFECT_SIZE="0.27171310944252797" MODIFIED="2014-01-07 10:42:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6960370326097726" P_Z="0.3646215723041156" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="64" WEIGHT="100.0" Z="0.9065939503736306">
<NAME>short term</NAME>
<DICH_DATA CI_END="8.602503618833898" CI_START="0.2615517644275046" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.93462486398861" LOG_CI_START="-0.5824423458772475" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-01-07 10:42:49 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.8911327886790068" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" VAR="0.7941176470588234" WEIGHT="59.97110925264198"/>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24518" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="40.02889074735801"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.050810822496313" CI_START="0.3065646907234551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" METHOD="MH" MODIFIED="2014-02-18 13:46:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3810244502283552" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8760102879547425">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.050810822496313" CI_START="0.3065646907234551" DF="0" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-12-09 16:07:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3810244502283552" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8760102879547425">
<NAME>short term</NAME>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.524591062568065" CI_START="0.5200273053020793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5520833333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="1.097763554725353" LOG_CI_START="-0.28397385207542497" LOG_EFFECT_SIZE="0.40689485132496406" METHOD="MH" MODIFIED="2014-02-18 13:46:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2483597108813198" Q="0.0" RANDOM="YES" SCALE="147.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="1.1543427139867461">
<NAME>Mental state: 1. State - less than 30% BPRS reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.524591062568065" CI_START="0.5200273053020793" DF="0" EFFECT_SIZE="2.5520833333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="1.097763554725353" LOG_CI_START="-0.28397385207542497" LOG_EFFECT_SIZE="0.40689485132496406" MODIFIED="2014-01-07 10:44:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2483597108813198" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="1.1543427139867461">
<NAME>short term</NAME>
<DICH_DATA CI_END="12.524591062568065" CI_START="0.5200273053020793" EFFECT_SIZE="2.5520833333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.097763554725353" LOG_CI_START="-0.28397385207542497" LOG_EFFECT_SIZE="0.40689485132496406" MODIFIED="2014-01-07 10:44:55 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.8116393924652502" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.6587585034013604" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.456668107750849E-4" CI_END="1.4811944204124705" CI_START="0.36092428723559444" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9210593538240325" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.04" MODIFIED="2015-01-14 16:41:01 +0000" MODIFIED_BY="Heather Maxwell" NO="4" P_CHI2="0.9874946594808905" P_Q="0.9874946594808905" P_Z="0.0012691261719600603" Q="2.456668107750849E-4" RANDOM="YES" SCALE="5.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="102" UNITS="" WEIGHT="200.0" Z="3.2228711766143534">
<NAME>Mental state: 2. State - BPRS end score (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.373813190554312" CI_START="-1.4938131905543166" DF="0" EFFECT_SIZE="0.9399999999999977" ESTIMABLE="YES" I2="0.0" ID="CMP-011.04.01" MODIFIED="2014-01-07 11:41:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4490573617059912" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.7569874929669674">
<NAME>total score - short term</NAME>
<CONT_DATA CI_END="3.373813190554312" CI_START="-1.4938131905543166" EFFECT_SIZE="0.9399999999999977" ESTIMABLE="YES" MEAN_1="26.72" MEAN_2="25.78" MODIFIED="2014-01-07 11:41:40 +0000" MODIFIED_BY="[Empty name]" ORDER="997" SD_1="6.53" SD_2="6.0" SE="1.2417642414615382" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4955861884480701" CI_START="0.34441381155192974" DF="0" EFFECT_SIZE="0.9199999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-011.04.02" MODIFIED="2014-01-07 11:41:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0017317766232864025" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999" Z="3.132748669037136">
<NAME>anxiety-depression score - short term</NAME>
<CONT_DATA CI_END="1.4955861884480701" CI_START="0.34441381155192974" EFFECT_SIZE="0.9199999999999999" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.08" MODIFIED="2014-01-07 11:41:58 +0000" MODIFIED_BY="[Empty name]" ORDER="998" SD_1="1.72" SD_2="1.2" SE="0.29367181896617517" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8638445403698067" CI_END="22.187085332780956" CI_START="2.0789391884390067" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="6.791583112615102" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="1.3461002536952626" LOG_CI_START="0.31784178586266876" LOG_EFFECT_SIZE="0.8319710197789658" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.649259862054244" P_Q="0.672502555456534" P_Z="0.0015158038786974475" Q="0.7934993810743235" RANDOM="YES" SCALE="700.2076122326761" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="141" TOTAL_2="137" WEIGHT="300.0" Z="3.171640761461368">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-09 16:09:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24584" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-09 16:09:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>hyperkinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="355.76500155782423" CI_START="1.2906937766748094" DF="0" EFFECT_SIZE="21.42857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-011.05.03" LOG_CI_END="2.551163222056167" LOG_CI_START="0.11082321602668145" LOG_EFFECT_SIZE="1.3309932190414244" MODIFIED="2014-01-07 11:08:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03251838579587731" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.137979762281292">
<NAME>myotony - short term</NAME>
<DICH_DATA CI_END="355.76500155782423" CI_START="1.2906937766748094" EFFECT_SIZE="21.428571428571427" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.551163222056167" LOG_CI_START="0.11082321602668145" LOG_EFFECT_SIZE="1.3309932190414244" MODIFIED="2014-01-07 11:08:39 +0000" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="1.4334677994195717" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="2.0548299319727894" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="108.57523191221213" CI_START="0.34552654725465404" DF="0" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-011.05.04" LOG_CI_END="2.0357307656703383" LOG_CI_START="-0.4615185795971981" LOG_EFFECT_SIZE="0.7871060930365701" MODIFIED="2014-01-07 11:08:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2166374071741448" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="1.2355190700417924">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="108.57523191221213" CI_START="0.34552654725465404" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0357307656703383" LOG_CI_START="-0.4615185795971981" LOG_EFFECT_SIZE="0.7871060930365701" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24601" O_E="0.0" SE="1.4668966269937749" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="2.151785714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.090181467517922" CI_START="1.179370907360789" DF="0" EFFECT_SIZE="5.104166666666665" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-011.05.05" LOG_CI_END="1.3441992835499306" LOG_CI_START="0.07165041042795964" LOG_EFFECT_SIZE="0.7079248469889451" MODIFIED="2014-01-07 11:09:09 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.029207527762363038" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.180674130739451">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="22.090181467517933" CI_START="1.1793709073607892" EFFECT_SIZE="5.104166666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3441992835499308" LOG_CI_START="0.07165041042795972" LOG_EFFECT_SIZE="0.7079248469889453" MODIFIED="2014-01-07 11:09:09 +0000" MODIFIED_BY="[Empty name]" ORDER="984" O_E="0.0" SE="0.7475015072903602" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.5587585034013605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.321995820290475" CI_END="1.389233193907519" CI_START="0.5542635422780949" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8774971858105831" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="62" I2="93.40412810603428" I2_Q="92.62108088298308" ID="CMP-011.06" LOG_CI_END="0.14277515166049412" LOG_CI_START="-0.2562836870004849" LOG_EFFECT_SIZE="-0.056754267669995404" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.6041715583957625E-7" P_Q="1.301347792304064E-6" P_Z="0.5771904169183626" Q="27.10424071985957" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.2187917529633676" TOTALS="SUB" TOTAL_1="144" TOTAL_2="147" WEIGHT="300.0" Z="0.5574933309352804">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.485938988570969" CI_START="0.4870193482873799" DF="0" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-011.06.01" LOG_CI_END="0.1720009780174739" LOG_CI_START="-0.31245378480687075" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2014-01-07 11:23:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5698778068728696" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="0.5682314716649682">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="1.485938988570969" CI_START="0.4870193482873799" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.1720009780174739" LOG_CI_START="-0.31245378480687075" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2014-01-07 11:23:57 +0000" MODIFIED_BY="[Empty name]" ORDER="987" O_E="0.0" SE="0.28457112577277194" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.08098072562358277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.58295645156128" CI_START="1.6770732016545775" DF="0" EFFECT_SIZE="4.59375" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" I2="0.0" ID="CMP-011.06.02" LOG_CI_END="1.0997826935534816" LOG_CI_START="0.22455201930305857" LOG_EFFECT_SIZE="0.6621673564282701" MODIFIED="2014-01-07 11:23:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0030202102155652026" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.9656734127811655">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="12.58295645156128" CI_START="1.6770732016545775" EFFECT_SIZE="4.59375" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.0997826935534816" LOG_CI_START="0.22455201930305857" LOG_EFFECT_SIZE="0.6621673564282701" MODIFIED="2014-01-07 11:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="986" O_E="0.0" SE="0.5141148305164092" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.2643140589569161" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.19950736303501143" CI_START="0.013058423992371233" DF="0" EFFECT_SIZE="0.05104166666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="40" I2="0.0" ID="CMP-011.06.03" LOG_CI_END="-0.7000410715738894" LOG_CI_START="-1.8841092344482202" LOG_EFFECT_SIZE="-1.2920751530110548" MODIFIED="2014-01-07 11:26:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.8901115263204225E-5" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="4.277491523922549">
<NAME>increased salivation - short term</NAME>
<DICH_DATA CI_END="0.19950736303501143" CI_START="0.013058423992371233" EFFECT_SIZE="0.051041666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="40" LOG_CI_END="-0.7000410715738894" LOG_CI_START="-1.8841092344482202" LOG_EFFECT_SIZE="-1.2920751530110548" MODIFIED="2014-01-07 11:26:28 +0000" MODIFIED_BY="[Empty name]" ORDER="990" O_E="0.0" SE="0.6955275001043169" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.4837585034013605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.59143884033982" CI_END="1.413208176208713" CI_START="0.5162509954978086" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8541487738171791" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" I2="92.0194595031551" I2_Q="91.21748432920178" ID="CMP-011.07" LOG_CI_END="0.15020614140932287" LOG_CI_START="-0.2871390978754202" LOG_EFFECT_SIZE="-0.06846647823304865" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="3.449360264085044E-8" P_Q="1.8340370389058336E-7" P_Z="0.5394364273282632" Q="34.15877764926707" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.3262276981007486" TOTALS="SUB" TOTAL_1="159" TOTAL_2="160" WEIGHT="400.0" Z="0.6136654497693179">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.880526460968097E-32" CI_END="0.9407225477876046" CI_START="0.1996101594666721" DF="0" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="100.0" ID="CMP-011.07.01" LOG_CI_END="-0.026538446426452467" LOG_CI_START="-0.6998173583991988" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2014-01-07 11:00:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.034474744432903305" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="2.114474688132678">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="0.9407225477876046" CI_START="0.1996101594666721" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.026538446426452467" LOG_CI_START="-0.6998173583991988" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24632" O_E="0.0" SE="0.3954873656771559" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="0.15641025641025647" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="153.13894729550384" CI_START="3.0009766579053183" DF="0" EFFECT_SIZE="21.4375" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" ID="CMP-011.07.02" LOG_CI_END="2.1850856573502853" LOG_CI_START="0.47726261742340603" LOG_EFFECT_SIZE="1.3311741373868458" MODIFIED="2014-01-07 11:01:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002247499134053825" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.0554141798451186">
<NAME>excitement - short term</NAME>
<DICH_DATA CI_END="153.13894729550384" CI_START="3.0009766579053183" EFFECT_SIZE="21.4375" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="2.1850856573502853" LOG_CI_START="0.47726261742340603" LOG_EFFECT_SIZE="1.3311741373868458" MODIFIED="2014-01-07 11:01:03 +0000" MODIFIED_BY="[Empty name]" ORDER="976" O_E="0.0" SE="1.0031837075134387" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="1.0063775510204083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9230937490462477E-31" CI_END="0.5245546071129606" CI_START="0.07207760919954462" DF="0" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" I2="100.0" ID="CMP-011.07.03" LOG_CI_END="-0.28020929425141244" LOG_CI_START="-1.1421996272546484" LOG_EFFECT_SIZE="-0.7112044607530305" MODIFIED="2014-01-07 11:02:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0012197353387671031" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.2342245042670035">
<NAME>somnolence - short term</NAME>
<DICH_DATA CI_END="0.5245546071129606" CI_START="0.07207760919954462" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="-0.28020929425141244" LOG_CI_START="-1.1421996272546484" LOG_EFFECT_SIZE="-0.7112044607530305" MODIFIED="2014-01-07 11:02:09 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="0.5063373885270652" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.25637755102040816" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.83301005815065" CI_START="1.8833585207841663" DF="0" EFFECT_SIZE="5.104166666666666" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" I2="0.0" ID="CMP-011.07.04" LOG_CI_END="1.1409166927200096" LOG_CI_START="0.2749330012578808" LOG_EFFECT_SIZE="0.7079248469889452" MODIFIED="2014-01-07 11:02:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0013531375316961393" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="3.204464974430848">
<NAME>restlessness - short term</NAME>
<DICH_DATA CI_END="13.83301005815065" CI_START="1.8833585207841663" EFFECT_SIZE="5.104166666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" LOG_CI_END="1.1409166927200096" LOG_CI_START="0.2749330012578808" LOG_EFFECT_SIZE="0.7079248469889453" MODIFIED="2014-01-07 11:02:50 +0000" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.5086831070532621" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.25875850340136053" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.050810822496313" CI_START="0.3065646907234551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.08" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" METHOD="MH" MODIFIED="2014-02-18 13:55:42 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3810244502283552" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8760102879547425">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.050810822496313" CI_START="0.3065646907234551" DF="0" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-011.08.01" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-12-09 16:09:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3810244502283552" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8760102879547425">
<NAME>short term</NAME>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-12-09 16:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24665" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Van-Praag-1976" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.534770574767002" CI_END="0.7701908733841567" CI_START="0.35752194439264495" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5247476904244297" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="60" I2="92.02219143912342" I2_Q="91.71700099395727" ID="CMP-011.09" LOG_CI_END="-0.11340163199007722" LOG_CI_START="-0.4466972964191336" LOG_EFFECT_SIZE="-0.2800494642046054" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="3.994553162137704E-4" P_Q="5.115977593932453E-4" P_Z="9.88802940240269E-4" Q="12.072921888200959" RANDOM="YES" SCALE="38.68912948928023" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.9180735763590063" TOTALS="SUB" TOTAL_1="96" TOTAL_2="98" WEIGHT="200.0" Z="3.2936933918478806">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5103023833998623" CI_START="0.5588957362298742" DF="0" EFFECT_SIZE="0.91875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-011.09.01" LOG_CI_END="0.17906390775324782" LOG_CI_START="-0.2526692035687453" LOG_EFFECT_SIZE="-0.0368026479077487" MODIFIED="2014-01-07 11:28:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7382661805209434" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="0.3341502541420725">
<NAME>dizziness - short term</NAME>
<DICH_DATA CI_END="1.5103023833998623" CI_START="0.5588957362298742" EFFECT_SIZE="0.91875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.17906390775324782" LOG_CI_START="-0.2526692035687453" LOG_EFFECT_SIZE="-0.0368026479077487" MODIFIED="2014-01-07 11:28:02 +0000" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.25360216670390673" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.06431405895691611" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4200637394720974" CI_START="0.12559129174670008" DF="0" EFFECT_SIZE="0.22968749999999996" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="40" I2="0.0" ID="CMP-011.09.02" LOG_CI_END="-0.37668480579084385" LOG_CI_START="-0.9010404726805783" LOG_EFFECT_SIZE="-0.6388626392357112" MODIFIED="2014-01-07 11:28:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.7886239245181068E-6" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="4.7759482467212875">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="0.4200637394720974" CI_START="0.12559129174670008" EFFECT_SIZE="0.2296875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="40" LOG_CI_END="-0.37668480579084385" LOG_CI_START="-0.9010404726805783" LOG_EFFECT_SIZE="-0.6388626392357111" MODIFIED="2014-01-07 11:28:47 +0000" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.3080091143334425" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.09486961451247165" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5376752621441673" CI_START="0.20471815164369755" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33177083333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-011.10" LOG_CI_END="-0.26947994448145846" LOG_CI_START="-0.6888436482549398" LOG_EFFECT_SIZE="-0.47916179636819917" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="7.503568040819006E-6" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="4.478880051843785">
<NAME>Other adverse events: 5. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5376752621441673" CI_START="0.20471815164369755" DF="0" EFFECT_SIZE="0.33177083333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" I2="0.0" ID="CMP-011.10.01" LOG_CI_END="-0.26947994448145846" LOG_CI_START="-0.6888436482549398" LOG_EFFECT_SIZE="-0.47916179636819917" MODIFIED="2014-01-07 11:25:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.503568040819006E-6" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="4.478880051843785">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="0.5376752621441673" CI_START="0.20471815164369755" EFFECT_SIZE="0.33177083333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" LOG_CI_END="-0.26947994448145846" LOG_CI_START="-0.6888436482549398" LOG_EFFECT_SIZE="-0.47916179636819917" MODIFIED="2014-01-07 11:25:23 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="0.246336315480356" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.060681580324437476" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.775266986632483" CI_END="1.6592953433502002" CI_START="0.5994754503387473" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9973499000851443" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" I2="37.17628755841358" I2_Q="33.28503089509897" ID="CMP-011.11" LOG_CI_END="0.2199236943856279" LOG_CI_START="-0.22222859738702047" LOG_EFFECT_SIZE="-0.0011524515006963183" METHOD="MH" MODIFIED="2014-01-14 16:32:25 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.1890125790511924" P_Q="0.21258138629560375" P_Z="0.9918480525828594" Q="4.496741945998463" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26674578739603577" TOTALS="SUB" TOTAL_1="192" TOTAL_2="196" WEIGHT="400.0" Z="0.010217128701236446">
<NAME>Other adverse events: 6. Lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.438563646223533" CI_START="0.7307801266629852" DF="0" EFFECT_SIZE="1.3349358974358974" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-011.11.01" LOG_CI_END="0.38713409511026103" LOG_CI_START="-0.1362132716615339" LOG_EFFECT_SIZE="0.12546041172436356" MODIFIED="2014-01-07 11:29:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3473653427669601" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.00000000000001" Z="0.939711954536471">
<NAME>abnormal EKG - short term</NAME>
<DICH_DATA CI_END="2.438563646223533" CI_START="0.7307801266629852" EFFECT_SIZE="1.3349358974358974" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.38713409511026103" LOG_CI_START="-0.1362132716615339" LOG_EFFECT_SIZE="0.12546041172436356" MODIFIED="2014-01-07 11:29:33 +0000" MODIFIED_BY="[Empty name]" ORDER="994" O_E="0.0" SE="0.30741683385299867" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.0945051097362022" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.858405833616244" CI_START="0.06571282797136054" DF="0" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-011.11.02" LOG_CI_END="1.2002595277192167" LOG_CI_START="-1.1823498424133638" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2014-01-07 11:29:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9882454082179284" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="0.014732729004572197">
<NAME>high white blood cell count - short term</NAME>
<DICH_DATA CI_END="15.858405833616244" CI_START="0.06571282797136054" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2002595277192167" LOG_CI_START="-1.1823498424133638" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2014-01-07 11:05:29 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.3995565381224728" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="1.9587585034013606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.38090491376988E-32" CI_END="1.3608484251656123" CI_START="0.021271466371299112" DF="0" EFFECT_SIZE="0.17013888888888887" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="100.0" ID="CMP-011.11.03" LOG_CI_END="0.13380975504897238" LOG_CI_START="-1.6722025705104069" LOG_EFFECT_SIZE="-0.7691964077307173" MODIFIED="2014-01-07 11:29:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.09501208805196919" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="1.6695315251769858">
<NAME>low white blood cell count - short term</NAME>
<DICH_DATA CI_END="1.3608484251656128" CI_START="0.021271466371299112" EFFECT_SIZE="0.1701388888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13380975504897255" LOG_CI_START="-1.6722025705104069" LOG_EFFECT_SIZE="-0.7691964077307172" MODIFIED="2014-01-07 11:05:59 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.0608605799387718" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="1.1254251700680273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8648992327722098" CI_START="0.18246443121323408" DF="0" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-011.11.04" LOG_CI_END="0.2706553702823517" LOG_CI_START="-0.7388217823490876" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-01-07 11:29:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3633634311801186" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="0.9089748133776269">
<NAME>liver function (GPT+) - short term</NAME>
<DICH_DATA CI_END="1.8648992327722098" CI_START="0.18246443121323408" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2706553702823517" LOG_CI_START="-0.7388217823490876" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2014-01-07 11:06:34 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.5929718764482034" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.3516156462585034" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-011.12" MODIFIED="2014-01-14 16:32:27 +0000" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Other adverse events: 7. Average endpoint score (TESS, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-011.12.01" MODIFIED="2014-01-07 13:41:30 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2014-01-07 13:41:30 +0000" MODIFIED_BY="[Empty name]" ORDER="3119" STUDY_ID="STD-Sun-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>3.38</P>
</TD>
<TD>
<P>2.19</P>
</TD>
<TD>
<P>51</P>
</TD>
</TR>
<TR>
<TD>
<P>Clozapine</P>
</TD>
<TD>
<P>5.37</P>
</TD>
<TD>
<P>2.67</P>
</TD>
<TD>
<P>51</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2015-01-14 16:41:10 +0000" MODIFIED_BY="Heather Maxwell" NO="12">
<NAME>PERPHENAZINE vs CLOZAPINE + PERPHENAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.889588217092594" CI_START="0.32270107145161075" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="1.445442102062226" LOG_CI_START="-0.49119959262290114" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.33417725678443855" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.9657341139308079">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.889588217092594" CI_START="0.32270107145161075" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="1.445442102062226" LOG_CI_START="-0.49119959262290114" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-07 11:53:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.33417725678443855" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.9657341139308079">
<NAME>short term</NAME>
<DICH_DATA CI_END="27.889588217092594" CI_START="0.32270107145161075" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445442102062226" LOG_CI_START="-0.49119959262290114" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-07 11:53:33 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="1.137592917989042" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" VAR="1.2941176470588236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.790350081623671" CI_START="0.8568604988314221" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="1.139575291309101" LOG_CI_START="-0.06708987763246291" LOG_EFFECT_SIZE="0.536242706838319" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.08150524526556431" Q="0.0" RANDOM="YES" SCALE="147.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="1.7420182821673444">
<NAME>Mental state: 1. State - less than 30% BPRS reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.790350081623671" CI_START="0.8568604988314221" DF="0" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="1.139575291309101" LOG_CI_START="-0.06708987763246291" LOG_EFFECT_SIZE="0.536242706838319" MODIFIED="2014-01-07 13:54:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08150524526556431" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="99" WEIGHT="100.0" Z="1.7420182821673444">
<NAME>short term</NAME>
<DICH_DATA CI_END="13.790350081623671" CI_START="0.8568604988314221" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.139575291309101" LOG_CI_START="-0.06708987763246291" LOG_EFFECT_SIZE="0.5362427068383191" MODIFIED="2014-01-07 13:54:18 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.7088010933251937" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="99" VAR="0.5023989898989899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.031699610966262615" CI_END="1.112451976827685" CI_START="-0.06601941972103431" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5232162785533253" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" MODIFIED="2015-01-14 16:41:10 +0000" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.858688584538554" P_Q="0.858688584538554" P_Z="0.08179498408515527" Q="0.031699610966262615" RANDOM="YES" SCALE="5.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="102" UNITS="" WEIGHT="200.0" Z="1.7403647896636916">
<NAME>Mental state: 1a. State - BPRS end score (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.1980933763381705" CI_START="-1.7180933763381736" DF="0" EFFECT_SIZE="0.7399999999999984" ESTIMABLE="YES" I2="0.0" ID="CMP-012.03.01" MODIFIED="2014-01-07 13:48:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5551638541138366" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.5900399726556613">
<NAME>total score - short term</NAME>
<CONT_DATA CI_END="3.1980933763381705" CI_START="-1.7180933763381736" EFFECT_SIZE="0.7399999999999984" ESTIMABLE="YES" MEAN_1="26.72" MEAN_2="25.98" MODIFIED="2014-01-07 13:48:05 +0000" MODIFIED_BY="[Empty name]" ORDER="997" SD_1="6.53" SD_2="6.13" SE="1.254152318985093" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1169314391393617" CI_START="-0.09693143913936209" DF="0" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-012.03.02" MODIFIED="2014-01-07 11:54:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09956971261158647" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.6469432421112495">
<NAME>anxiety-depression score - short term</NAME>
<CONT_DATA CI_END="1.1169314391393617" CI_START="-0.09693143913936209" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.49" MODIFIED="2014-01-07 11:54:29 +0000" MODIFIED_BY="[Empty name]" ORDER="998" SD_1="1.72" SD_2="1.39" SE="0.309664587679549" STUDY_ID="STD-Sun-2000" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8107443245502708" CI_START="0.5992394562462262" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.25785713265758703" LOG_CI_START="-0.22239959873672385" LOG_EFFECT_SIZE="0.017728766960431616" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8849438913665137" Q="0.0" RANDOM="YES" SCALE="700.2076122326761" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="96" TOTAL_2="100" WEIGHT="200.0" Z="0.14470487329503048">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.276782572336422" CI_START="0.4765801783746754" DF="0" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="0.357321558439835" LOG_CI_START="-0.32186402451897184" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 11:55:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9185012544728057" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.1023217971776562">
<NAME>myotony - short term</NAME>
<DICH_DATA CI_END="2.276782572336422" CI_START="0.4765801783746754" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.357321558439835" LOG_CI_START="-0.32186402451897184" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 11:55:11 +0000" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="0.3989569734528608" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.15916666666666668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.276782572336422" CI_START="0.4765801783746754" DF="0" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-012.04.02" LOG_CI_END="0.357321558439835" LOG_CI_START="-0.32186402451897184" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 11:55:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9185012544728057" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.1023217971776562">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="2.276782572336422" CI_START="0.4765801783746754" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.357321558439835" LOG_CI_START="-0.32186402451897184" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 11:55:21 +0000" MODIFIED_BY="[Empty name]" ORDER="984" O_E="0.0" SE="0.3989569734528608" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.15916666666666668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.311717744663234" CI_END="1.4696175752150247" CI_START="0.6383013983165765" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9685344357586708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" I2="92.39882390268626" I2_Q="90.22096628402619" ID="CMP-012.05" LOG_CI_END="0.16720433707378804" LOG_CI_START="-0.194974204167237" LOG_EFFECT_SIZE="-0.013884933546724456" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.9341363912683818E-6" P_Q="3.621812234400057E-5" P_Z="0.8805442600524889" Q="20.451918441932058" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.9198628491260936" TOTALS="SUB" TOTAL_1="144" TOTAL_2="150" WEIGHT="300.0" Z="0.15027930471011208">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7485779942895312" CI_START="0.545399930412449" DF="0" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-012.05.01" LOG_CI_END="0.24268500852637362" LOG_CI_START="-0.2632849218059975" LOG_EFFECT_SIZE="-0.010299956639811952" MODIFIED="2014-01-07 11:55:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9363983872121663" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.07979740631264175">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="1.7485779942895312" CI_START="0.545399930412449" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.24268500852637362" LOG_CI_START="-0.2632849218059975" LOG_EFFECT_SIZE="-0.010299956639811952" MODIFIED="2014-01-07 11:55:41 +0000" MODIFIED_BY="[Empty name]" ORDER="987" O_E="0.0" SE="0.29720924166878343" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.08833333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0744170924620319E-31" CI_END="3.6417399446796" CI_START="0.9653695907463551" DF="0" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="100.0" ID="CMP-012.05.02" LOG_CI_END="0.5613089297556979" LOG_CI_START="-0.015306385628222669" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2014-01-07 11:55:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.06346658715777698" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="1.8559085986895294">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="3.6417399446796" CI_START="0.9653695907463551" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5613089297556979" LOG_CI_START="-0.015306385628222669" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2014-01-07 11:55:51 +0000" MODIFIED_BY="[Empty name]" ORDER="986" O_E="0.0" SE="0.33870669054835956" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.11472222222222221" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.22084082892950402" CI_START="0.014356041612539094" DF="0" EFFECT_SIZE="0.0563063063063063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="37" I2="0.0" ID="CMP-012.05.03" LOG_CI_END="-0.6559206313977124" LOG_CI_START="-1.8429652914874524" LOG_EFFECT_SIZE="-1.2494429614425822" MODIFIED="2014-01-07 11:56:04 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="3.691541019853253E-5" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="4.125983271731995">
<NAME>increased salivation - short term</NAME>
<DICH_DATA CI_END="0.22084082892950402" CI_START="0.014356041612539094" EFFECT_SIZE="0.05630630630630631" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="37" LOG_CI_END="-0.6559206313977124" LOG_CI_START="-1.8429652914874524" LOG_EFFECT_SIZE="-1.2494429614425822" MODIFIED="2014-01-07 11:56:04 +0000" MODIFIED_BY="[Empty name]" ORDER="990" O_E="0.0" SE="0.6972759093025469" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.4861936936936936" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.641612762564837" CI_END="6.747988596731966" CI_START="1.8243814322942813" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.508689940876985" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="10" I2="56.911528334930495" I2_Q="48.56065421173531" ID="CMP-012.06" LOG_CI_END="0.8291743400136248" LOG_CI_START="0.2611156435441418" LOG_EFFECT_SIZE="0.5451449917788833" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0981945464524937" P_Q="0.14312511355556112" P_Z="1.686879191300823E-4" Q="3.8880743317234754" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6892918794689968" TOTALS="SUB" TOTAL_1="144" TOTAL_2="150" WEIGHT="300.0" Z="3.7618103793835496">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="156.32654421814289" CI_START="3.0610004679196683" DF="0" EFFECT_SIZE="21.875000000000004" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" ID="CMP-012.06.01" LOG_CI_END="2.19403272740296" LOG_CI_START="0.4858633959857418" LOG_EFFECT_SIZE="1.3399480616943509" MODIFIED="2014-01-07 13:40:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.002105524761641728" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="3.074929275186389">
<NAME>excitement - short term</NAME>
<DICH_DATA CI_END="156.32654421814289" CI_START="3.0610004679196683" EFFECT_SIZE="21.875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="2.19403272740296" LOG_CI_START="0.4858633959857418" LOG_EFFECT_SIZE="1.3399480616943509" MODIFIED="2014-01-07 13:40:09 +0000" MODIFIED_BY="[Empty name]" ORDER="976" O_E="0.0" SE="1.0033871208490341" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="1.0067857142857144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.39066671079693" CI_START="1.3860384450345276" DF="0" EFFECT_SIZE="2.9761904761904763" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="0.0" ID="CMP-012.06.02" LOG_CI_END="0.8055461685990754" LOG_CI_START="0.14177527662123662" LOG_EFFECT_SIZE="0.47366072261015596" MODIFIED="2014-01-07 14:14:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.005154377349966495" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="2.7972240676022824">
<NAME>restlessness - short term</NAME>
<DICH_DATA CI_END="6.39066671079693" CI_START="1.3860384450345276" EFFECT_SIZE="2.9761904761904763" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.8055461685990754" LOG_CI_START="0.14177527662123662" LOG_EFFECT_SIZE="0.47366072261015596" MODIFIED="2014-01-07 13:40:26 +0000" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.38990230766668915" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.1520238095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.853577093538455" CI_START="0.3998937622474447" DF="0" EFFECT_SIZE="2.0833333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-012.06.03" LOG_CI_END="1.0355728954154853" LOG_CI_START="-0.39805537016665965" LOG_EFFECT_SIZE="0.31875876262441283" MODIFIED="2014-01-07 14:14:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.38344148863448324" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.8715727912168509">
<NAME>somnolence - short term</NAME>
<DICH_DATA CI_END="10.853577093538455" CI_START="0.3998937622474447" EFFECT_SIZE="2.0833333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0355728954154853" LOG_CI_START="-0.39805537016665965" LOG_EFFECT_SIZE="0.31875876262441283" MODIFIED="2014-01-07 13:40:17 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="0.8421203397773187" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.7091666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.818418934694666" CI_END="0.8589243433187979" CI_START="0.397538656250241" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5843420481734782" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="53" I2="87.20969024104804" I2_Q="86.80390610423058" ID="CMP-012.07" LOG_CI_END="-0.0660450884693485" LOG_CI_START="-0.40062063460521957" LOG_EFFECT_SIZE="-0.23333286153728403" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.005171657944810892" P_Q="0.00590854686000597" P_Z="0.006261636796409292" Q="7.578000034696574" RANDOM="YES" SCALE="38.68912948928023" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.558663908548048" TOTALS="SUB" TOTAL_1="96" TOTAL_2="100" WEIGHT="200.0" Z="2.7337563088787658">
<NAME>Other adverse events: 3. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4565049623986146" CI_START="0.5473334441910712" DF="0" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-012.07.01" LOG_CI_END="0.16331196863321165" LOG_CI_START="-0.2617480139735749" LOG_EFFECT_SIZE="-0.04921802267018159" MODIFIED="2014-01-07 13:46:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6499069391535628" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.4538914777732438">
<NAME>dizziness - short term</NAME>
<DICH_DATA CI_END="1.4565049623986146" CI_START="0.5473334441910712" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.16331196863321165" LOG_CI_START="-0.2617480139735749" LOG_EFFECT_SIZE="-0.04921802267018159" MODIFIED="2014-01-07 13:46:34 +0000" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.24968233786407448" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.062341269841269836" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5470704454484145" CI_START="0.1568914738324241" DF="0" EFFECT_SIZE="0.29296875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="32" I2="0.0" ID="CMP-012.07.02" LOG_CI_END="-0.2619567466105169" LOG_CI_START="-0.804400657229782" LOG_EFFECT_SIZE="-0.5331787019201495" MODIFIED="2014-01-07 13:46:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.1669194199080137E-4" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="3.8529736720403176">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="0.5470704454484145" CI_START="0.1568914738324241" EFFECT_SIZE="0.29296875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="32" LOG_CI_END="-0.2619567466105169" LOG_CI_START="-0.804400657229782" LOG_EFFECT_SIZE="-0.5331787019201495" MODIFIED="2014-01-07 13:46:40 +0000" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.31863423823841935" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.10152777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7291948058991347" CI_START="0.26168406914543296" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4368279569892473" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-012.08" LOG_CI_END="-0.13715643351319165" LOG_CI_START="-0.582222715620817" LOG_EFFECT_SIZE="-0.35968957456700434" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0015350665559931153" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="3.1679713341905593">
<NAME>Other adverse events: 4. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7291948058991347" CI_START="0.26168406914543296" DF="0" EFFECT_SIZE="0.4368279569892473" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="31" I2="0.0" ID="CMP-012.08.01" LOG_CI_END="-0.13715643351319165" LOG_CI_START="-0.582222715620817" LOG_EFFECT_SIZE="-0.35968957456700434" MODIFIED="2014-01-07 13:46:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0015350665559931153" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="3.1679713341905593">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="0.7291948058991347" CI_START="0.26168406914543296" EFFECT_SIZE="0.4368279569892473" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="31" LOG_CI_END="-0.13715643351319165" LOG_CI_START="-0.582222715620817" LOG_EFFECT_SIZE="-0.35968957456700434" MODIFIED="2014-01-07 13:46:52 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="0.2614341372236469" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.06834780810587263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.694716783425334" CI_END="2.3567382911755685" CI_START="0.7451103994628804" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3251529004485838" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="47.319592631338544" I2_Q="44.80118453220489" ID="CMP-012.09" LOG_CI_END="0.3723113580827397" LOG_CI_START="-0.1277793751370732" LOG_EFFECT_SIZE="0.12226599147283328" METHOD="MH" MODIFIED="2014-01-14 16:40:52 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.12744544882522502" P_Q="0.14258471151160768" P_Z="0.3378742902630858" Q="5.434899235745926" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.46419774137231984" TOTALS="SUB" TOTAL_1="192" TOTAL_2="200" WEIGHT="400.0" Z="0.9583738465935664">
<NAME>Other adverse events: 5. Lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine+perphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine+perphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.547503361822459E-32" CI_END="3.9790335354923223" CI_START="0.9729550092736861" DF="0" EFFECT_SIZE="1.9675925925925926" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="100.0" ID="CMP-012.09.01" LOG_CI_END="0.5997775994172828" LOG_CI_START="-0.011907241618521455" LOG_EFFECT_SIZE="0.29393517889938064" MODIFIED="2014-01-07 13:47:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.05961132081000498" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="1.8836574843233767">
<NAME>abnormal EKG - short term</NAME>
<DICH_DATA CI_END="3.9790335354923223" CI_START="0.9729550092736861" EFFECT_SIZE="1.9675925925925926" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5997775994172828" LOG_CI_START="-0.011907241618521455" LOG_EFFECT_SIZE="0.29393517889938064" MODIFIED="2014-01-07 13:47:04 +0000" MODIFIED_BY="[Empty name]" ORDER="994" O_E="0.0" SE="0.3593067035132277" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.1291013071895425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.186672010901734" CI_START="0.06703474585224496" DF="0" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.09.02" LOG_CI_END="1.209157566735394" LOG_CI_START="-1.1737000328145306" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 13:47:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9767331802012503" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.02916476816685377">
<NAME>high white blood cell count - short term</NAME>
<DICH_DATA CI_END="16.186672010901734" CI_START="0.06703474585224496" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.209157566735394" LOG_CI_START="-1.1737000328145306" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2014-01-07 13:47:13 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.3997023493109764" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="1.9591666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3891444664065045" CI_START="0.02169739622488946" DF="0" EFFECT_SIZE="0.1736111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-012.09.03" LOG_CI_END="0.14274741326866408" LOG_CI_START="-1.663592380115088" LOG_EFFECT_SIZE="-0.7604224834232121" MODIFIED="2014-01-07 13:47:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09890436475727865" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="1.6501886145707805">
<NAME>low white blood cell count - short term</NAME>
<DICH_DATA CI_END="1.3891444664065045" CI_START="0.02169739622488946" EFFECT_SIZE="0.1736111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14274741326866408" LOG_CI_START="-1.663592380115088" LOG_EFFECT_SIZE="-0.7604224834232121" MODIFIED="2014-01-07 13:47:21 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="1.0610529361598005" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="1.1258333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.919439623931874" CI_START="0.23786908924294625" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-012.09.04" LOG_CI_END="0.4652994981643369" LOG_CI_START="-0.6236619902595866" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-01-07 13:47:27 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7756225036721133" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.2850282441649288">
<NAME>liver function (GPT+) - short term</NAME>
<DICH_DATA CI_END="2.9194396239318734" CI_START="0.23786908924294628" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4652994981643368" LOG_CI_START="-0.6236619902595866" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-01-07 13:47:27 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.6396613687465162" STUDY_ID="STD-Sun-2000" TOTAL_1="48" TOTAL_2="50" VAR="0.4091666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-012.10" MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Other adverse events: 6. Average endpoint score (TESS, skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-012.10.01" MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2014-05-12 09:18:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3139" STUDY_ID="STD-Sun-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>3.38</P>
</TD>
<TD>
<P>2.19</P>
</TD>
<TD>
<P>51</P>
</TD>
</TR>
<TR>
<TD>
<P>Clozapine + perphenazine</P>
</TD>
<TD>
<P>5.65</P>
</TD>
<TD>
<P>3.53</P>
</TD>
<TD>
<P>51</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2014-02-18 14:06:24 +0000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>PERPHENAZINE vs FLUPHENAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0073464747160892" CI_START="0.37593641746629775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.003178870928071117" LOG_CI_START="-0.42488560155785743" LOG_EFFECT_SIZE="-0.21085336531489315" METHOD="MH" MODIFIED="2014-02-18 14:05:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0535011087046192" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.9308540119495325">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0073464747160892" CI_START="0.37593641746629775" DF="0" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="0.003178870928071117" LOG_CI_START="-0.42488560155785743" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2013-12-09 16:58:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0535011087046192" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.9308540119495325">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0073464747160892" CI_START="0.37593641746629775" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="0.003178870928071117" LOG_CI_START="-0.42488560155785743" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2013-12-09 16:58:13 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.25144719009154726" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.0632256894049347" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.838906961027783" CI_START="0.1462221968654645" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.8349866954734765" LOG_CI_START="-0.8349866954734765" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 14:06:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.838906961027783" CI_START="0.1462221968654645" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="0.8349866954734765" LOG_CI_START="-0.8349866954734765" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:59:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="6.838906961027785" CI_START="0.14622219686546445" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8349866954734766" LOG_CI_START="-0.8349866954734767" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:59:14 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="0.9809506363438459" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.9622641509433962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19213837537877002" CI_END="2.340451930937796" CI_START="0.6200416421389234" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2046483547516615" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.3692997258553239" LOG_CI_START="-0.20757914220522877" LOG_EFFECT_SIZE="0.08086029182504752" METHOD="MH" MODIFIED="2014-01-14 16:41:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9084012266690474" P_Q="0.9086524120578486" P_Z="0.5826961653077879" Q="0.19158542242523527" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="212" WEIGHT="300.0" Z="0.5494507375155107">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluphenazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2412022550154473" CI_START="0.4199401962666548" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-013.03.01" LOG_CI_END="0.5107061323887302" LOG_CI_START="-0.3768125531275038" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-12-09 16:59:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.767470111250479" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.2956857105048103">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="3.2412022550154473" CI_START="0.4199401962666548" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5107061323887302" LOG_CI_START="-0.3768125531275038" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-12-09 16:59:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="0.5213328691605832" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.27178796046720577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-14 16:40:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:59:42 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.39626291789819" CI_START="0.18694853467396683" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-013.03.03" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-14 16:40:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5665036016214859" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.5732083980392908">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="21.39626291789819" CI_START="0.18694853467396683" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:59:39 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.2092411467293842" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.4622641509433962" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9263178268612497" CI_START="0.4463364973518718" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-013.03.04" LOG_CI_END="0.4663214929977809" LOG_CI_START="-0.3503375990424075" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-01-14 16:40:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7807369338363447" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.27835881233054105">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="2.9263178268612497" CI_START="0.4463364973518718" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4663214929977809" LOG_CI_START="-0.3503375990424075" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2013-12-09 16:59:27 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.4797095931921094" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.23012129380053908" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2014-02-18 14:08:10 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>PERPHENAZINE vs HALOPERIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7735357211495788" CI_START="0.3952457622565864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8372469635627531" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.24883994011098834" LOG_CI_START="-0.40313277778650997" LOG_EFFECT_SIZE="-0.07714641883776081" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6427652641926602" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.46383598057864006">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7735357211495788" CI_START="0.3952457622565864" DF="0" EFFECT_SIZE="0.8372469635627531" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="0.24883994011098834" LOG_CI_START="-0.40313277778650997" LOG_EFFECT_SIZE="-0.07714641883776081" MODIFIED="2013-12-10 14:44:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6427652641926602" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.46383598057864006">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.7735357211495788" CI_START="0.3952457622565864" EFFECT_SIZE="0.8372469635627531" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.24883994011098834" LOG_CI_START="-0.40313277778650997" LOG_EFFECT_SIZE="-0.07714641883776081" MODIFIED="2013-12-10 14:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="24515" O_E="0.0" SE="0.3829720018099936" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.14666755417035374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5741522025635943E-32" CI_END="1.9203841906371335" CI_START="0.12745602891840174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.28338812202774843" LOG_CI_START="-0.8946396167340092" LOG_EFFECT_SIZE="-0.3056257473531303" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.3091628506808879" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.0169802252532818">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5741522025635943E-32" CI_END="1.9203841906371335" CI_START="0.12745602891840174" DF="0" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" ID="CMP-014.02.01" LOG_CI_END="0.28338812202774843" LOG_CI_START="-0.8946396167340092" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-10 14:49:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.3091628506808879" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.0169802252532818">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.9203841906371335" CI_START="0.12745602891840174" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.28338812202774843" LOG_CI_START="-0.8946396167340092" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-10 14:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="24527" O_E="0.0" SE="0.6919793250800098" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.4788353863381859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.210331658191947" CI_START="0.4557726498545152" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3852631578947368" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.624316307628876" LOG_CI_START="-0.34125173965069816" LOG_EFFECT_SIZE="0.1415322839890889" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5655751951316403" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" WEIGHT="99.99999999999999" Z="0.5745802795563932">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.210331658191947" CI_START="0.4557726498545152" DF="0" EFFECT_SIZE="1.3852631578947368" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="0.624316307628876" LOG_CI_START="-0.34125173965069816" LOG_EFFECT_SIZE="0.1415322839890889" MODIFIED="2013-12-10 14:51:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5655751951316403" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="99.99999999999999" Z="0.5745802795563932">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.210331658191947" CI_START="0.45577264985451515" EFFECT_SIZE="1.3852631578947368" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.624316307628876" LOG_CI_START="-0.3412517396506982" LOG_EFFECT_SIZE="0.1415322839890889" MODIFIED="2013-12-10 14:51:31 +0000" MODIFIED_BY="[Empty name]" ORDER="24536" O_E="0.0" SE="0.5671794506109409" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.32169252919532876" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2866753020661976" CI_START="0.7893641369455817" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0077972709551657" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="0.10946896468819126" LOG_CI_START="-0.10272260872393876" LOG_EFFECT_SIZE="0.0033731779821262317" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.950312370645263" Q="0.0" RANDOM="YES" SCALE="80.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.06231451373962028">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2866753020661976" CI_START="0.7893641369455817" DF="0" EFFECT_SIZE="1.0077972709551657" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="54" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="0.10946896468819126" LOG_CI_START="-0.10272260872393876" LOG_EFFECT_SIZE="0.0033731779821262317" MODIFIED="2013-12-10 15:32:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.950312370645263" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.06231451373962028">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2866753020661976" CI_START="0.7893641369455817" EFFECT_SIZE="1.0077972709551657" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="54" LOG_CI_END="0.10946896468819126" LOG_CI_START="-0.10272260872393876" LOG_EFFECT_SIZE="0.0033731779821262317" MODIFIED="2013-12-10 15:32:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24548" O_E="0.0" SE="0.12464238058751362" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.015535723038522591" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.335719502976961" CI_END="0.9720400599464529" CI_START="0.658970121190075" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.800340774985582" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="129" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="-0.012315836457281492" LOG_CI_START="-0.18113427659939407" LOG_EFFECT_SIZE="-0.09672505652833775" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6742736174950498" P_Q="0.7078295611713104" P_Z="0.02470816744670418" Q="2.1519815480620843" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="475" TOTAL_2="470" WEIGHT="500.0" Z="2.2459350653702885">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.163004397507968" CI_START="0.41687592349161173" DF="0" EFFECT_SIZE="0.6962962962962963" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" I2="0.0" ID="CMP-014.05.01" LOG_CI_END="0.06558135686932028" LOG_CI_START="-0.37999318665993514" LOG_EFFECT_SIZE="-0.15720591489530744" MODIFIED="2013-12-16 14:49:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16666055191169013" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.3830140694796722">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="1.163004397507968" CI_START="0.41687592349161173" EFFECT_SIZE="0.6962962962962963" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" LOG_CI_END="0.06558135686932028" LOG_CI_START="-0.37999318665993514" LOG_EFFECT_SIZE="-0.15720591489530744" MODIFIED="2013-12-16 14:49:28 +0000" MODIFIED_BY="[Empty name]" ORDER="24567" O_E="0.0" SE="0.26173269249864706" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.06850400232259134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.364115402747002" CI_START="0.04562999200407626" DF="0" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-014.05.02" LOG_CI_END="0.7294981126242093" LOG_CI_START="-1.34074960733047" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-16 14:49:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.562798608098052" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.5786896435498904">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="5.364115402747002" CI_START="0.04562999200407626" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7294981126242093" LOG_CI_START="-1.34074960733047" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-16 14:49:40 +0000" MODIFIED_BY="[Empty name]" ORDER="24576" O_E="0.0" SE="1.2160737585928683" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="1.4788353863381858" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2447138536394444" CI_START="0.16251505969574673" DF="0" EFFECT_SIZE="0.44976076555023925" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-014.05.03" LOG_CI_END="0.0950695232641354" LOG_CI_START="-0.7891063882868461" LOG_EFFECT_SIZE="-0.34701843251135533" MODIFIED="2013-12-16 14:49:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.12393121124511437" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.5384803426746216">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="1.2447138536394444" CI_START="0.16251505969574673" EFFECT_SIZE="0.44976076555023925" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0950695232641354" LOG_CI_START="-0.7891063882868461" LOG_EFFECT_SIZE="-0.34701843251135533" MODIFIED="2013-12-16 14:49:49 +0000" MODIFIED_BY="[Empty name]" ORDER="24582" O_E="0.0" SE="0.5193693071863958" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.2697444772472768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2016310333751838" CI_START="0.4883559196917943" DF="0" EFFECT_SIZE="0.766044142614601" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="0.0" ID="CMP-014.05.04" LOG_CI_END="0.07977113591305492" LOG_CI_START="-0.3112635435366865" LOG_EFFECT_SIZE="-0.1157462038118158" MODIFIED="2013-12-16 14:49:58 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.24592749233497435" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.160298064292526">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.2016310333751838" CI_START="0.4883559196917943" EFFECT_SIZE="0.766044142614601" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.07977113591305492" LOG_CI_START="-0.3112635435366865" LOG_EFFECT_SIZE="-0.1157462038118158" MODIFIED="2013-12-16 14:49:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24597" O_E="0.0" SE="0.2296957063616592" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.05276011752098157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1121142021720087" CI_START="0.6806807595191913" DF="0" EFFECT_SIZE="0.8700544464609801" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="58" I2="0.0" ID="CMP-014.05.05" LOG_CI_END="0.04614938691013857" LOG_CI_START="-0.16705652521843864" LOG_EFFECT_SIZE="-0.060453569154150004" MODIFIED="2013-12-16 14:50:09 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.26636276163735784" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.1114777924880457">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="1.1121142021720087" CI_START="0.6806807595191913" EFFECT_SIZE="0.8700544464609801" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="58" LOG_CI_END="0.04614938691013857" LOG_CI_START="-0.16705652521843864" LOG_EFFECT_SIZE="-0.060453569154150004" MODIFIED="2013-12-16 14:50:09 +0000" MODIFIED_BY="[Empty name]" ORDER="24611" O_E="0.0" SE="0.1252382081706123" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.01568460878578562" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7334847780015001" CI_END="0.9720390866576225" CI_START="0.19318901141349656" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4333442859974782" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="-0.012316271309915026" LOG_CI_START="-0.7140175798781002" LOG_EFFECT_SIZE="-0.36316692559400765" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3917559910210019" P_Q="0.3947150041036239" P_Z="0.04248206713084351" Q="0.7243676147465901" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" WEIGHT="200.0" Z="2.028766615792129">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1344520035994055" CI_START="0.05393893751337554" DF="0" EFFECT_SIZE="0.2473684210526316" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-014.06.01" LOG_CI_END="0.05478612647668917" LOG_CI_START="-1.2680976125109122" LOG_EFFECT_SIZE="-0.6066557430171114" MODIFIED="2013-12-16 14:50:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07223670159175007" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.7976234377752363">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="1.1344520035994055" CI_START="0.05393893751337554" EFFECT_SIZE="0.24736842105263157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05478612647668917" LOG_CI_START="-1.2680976125109122" LOG_EFFECT_SIZE="-0.6066557430171116" MODIFIED="2013-12-16 14:50:52 +0000" MODIFIED_BY="[Empty name]" ORDER="24618" O_E="0.0" SE="0.7770684566614359" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.6038353863381859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3997005293906555" CI_START="0.20810882646134" DF="0" EFFECT_SIZE="0.539712918660287" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-014.06.02" LOG_CI_END="0.14603512686012607" LOG_CI_START="-0.6817094997875871" LOG_EFFECT_SIZE="-0.26783718646373056" MODIFIED="2013-12-16 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20465896412937368" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.2683893613793744">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="1.3997005293906555" CI_START="0.20810882646134" EFFECT_SIZE="0.539712918660287" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.14603512686012607" LOG_CI_START="-0.6817094997875871" LOG_EFFECT_SIZE="-0.26783718646373056" MODIFIED="2013-12-16 14:51:08 +0000" MODIFIED_BY="[Empty name]" ORDER="24626" O_E="0.0" SE="0.4862212910948506" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.23641114391394347" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2537000920972101" CI_END="1.2300047431543515" CI_START="0.8171554477902818" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0025492889012813" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="99" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="0.08990678617256045" LOG_CI_START="-0.0876953196047955" LOG_EFFECT_SIZE="0.00110573328388249" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8808657571850823" P_Q="0.8827791780969899" P_Z="0.980529490770959" Q="0.24936039279178274" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="285" TOTAL_2="282" WEIGHT="300.0" Z="0.02440508690402234">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3248750516890135" CI_START="0.7050099464279156" DF="0" EFFECT_SIZE="0.9664626682986536" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="43" I2="0.0" ID="CMP-014.07.01" LOG_CI_END="0.12217492210624048" LOG_CI_START="-0.15180475584791084" LOG_EFFECT_SIZE="-0.014814916870835188" MODIFIED="2013-12-16 14:51:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.83213632023242" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.21196246172426633">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.3248750516890135" CI_START="0.7050099464279156" EFFECT_SIZE="0.9664626682986536" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="43" LOG_CI_END="0.12217492210624048" LOG_CI_START="-0.15180475584791084" LOG_EFFECT_SIZE="-0.014814916870835188" MODIFIED="2013-12-16 14:51:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24644" O_E="0.0" SE="0.16093701905154723" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.02590072410119807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3419543457394663" CI_START="0.7609524408524856" DF="0" EFFECT_SIZE="1.0105263157894737" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" I2="0.0" ID="CMP-014.07.02" LOG_CI_END="0.12773774107090732" LOG_CI_START="-0.11864248556946598" LOG_EFFECT_SIZE="0.004547627750720661" MODIFIED="2013-12-16 14:51:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9423209075797612" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.07235310014969216">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="1.3419543457394663" CI_START="0.7609524408524856" EFFECT_SIZE="1.0105263157894737" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" LOG_CI_END="0.12773774107090732" LOG_CI_START="-0.11864248556946598" LOG_EFFECT_SIZE="0.004547627750720661" MODIFIED="2013-12-16 14:51:49 +0000" MODIFIED_BY="[Empty name]" ORDER="24650" O_E="0.0" SE="0.14472496473034663" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.020945315416200073" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7832096437380414" CI_START="0.52548815068492" DF="0" EFFECT_SIZE="1.2093567251461987" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-014.07.03" LOG_CI_END="0.44454592055950964" LOG_CI_START="-0.27943707250000754" LOG_EFFECT_SIZE="0.08255442402975102" MODIFIED="2013-12-16 14:51:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.654888028294593" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.44698204077691217">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="2.7832096437380414" CI_START="0.52548815068492" EFFECT_SIZE="1.2093567251461987" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44454592055950964" LOG_CI_START="-0.27943707250000754" LOG_EFFECT_SIZE="0.08255442402975102" MODIFIED="2013-12-16 14:51:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24656" O_E="0.0" SE="0.4252711938967744" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.18085558835838791" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2542337149834588" CI_START="0.8780883894619671" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0494417862838916" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="0.09837847084092038" LOG_CI_START="-0.05646176527444224" LOG_EFFECT_SIZE="0.02095835278323908" METHOD="MH" MODIFIED="2014-02-18 14:08:10 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5957094091321424" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.5305806508823562">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2542337149834588" CI_START="0.8780883894619671" DF="0" EFFECT_SIZE="1.0494417862838916" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="66" I2="0.0" ID="CMP-014.08.01" LOG_CI_END="0.09837847084092038" LOG_CI_START="-0.05646176527444224" LOG_EFFECT_SIZE="0.02095835278323908" MODIFIED="2013-12-16 14:52:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5957094091321424" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.5305806508823562">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2542337149834588" CI_START="0.8780883894619671" EFFECT_SIZE="1.0494417862838916" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="66" LOG_CI_END="0.09837847084092038" LOG_CI_START="-0.05646176527444224" LOG_EFFECT_SIZE="0.02095835278323908" MODIFIED="2013-12-16 14:52:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24664" O_E="0.0" SE="0.09095392116569427" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.008272615775415328" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.48710231852313957" CI_END="1.1227123271153645" CI_START="0.16950891746284846" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4362450586442451" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="0.05026849112249475" LOG_CI_START="-0.770807449655375" LOG_EFFECT_SIZE="-0.3602694792664401" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.48522279356177245" P_Q="0.48677263771831336" P_Z="0.08543691585918232" Q="0.4836523459458546" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" WEIGHT="200.0" Z="1.7199753860093965">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8677328969486604" CI_START="0.17116605097313475" DF="0" EFFECT_SIZE="0.5654135338345865" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-014.09.01" LOG_CI_END="0.27131476821338113" LOG_CI_START="-0.7665823689642682" LOG_EFFECT_SIZE="-0.24763380037544352" MODIFIED="2013-12-16 14:52:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.34965285404590885" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.9352628747208429">
<NAME>angina pectoris - short term</NAME>
<DICH_DATA CI_END="1.8677328969486604" CI_START="0.17116605097313475" EFFECT_SIZE="0.5654135338345865" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.27131476821338113" LOG_CI_START="-0.7665823689642682" LOG_EFFECT_SIZE="-0.24763380037544352" MODIFIED="2013-12-16 14:52:54 +0000" MODIFIED_BY="[Empty name]" ORDER="24668" O_E="0.0" SE="0.6096659160518396" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.37169252919532875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3258279821419108" CI_START="0.060281663335926015" DF="0" EFFECT_SIZE="0.2827067669172933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-014.09.02" LOG_CI_END="0.12248718074093304" LOG_CI_START="-1.2198147728197823" LOG_EFFECT_SIZE="-0.5486637960394246" MODIFIED="2013-12-16 14:52:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.109097166716883" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.6022643444803144">
<NAME>palpitations - short term</NAME>
<DICH_DATA CI_END="1.3258279821419103" CI_START="0.06028166333592599" EFFECT_SIZE="0.28270676691729324" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12248718074093289" LOG_CI_START="-1.2198147728197826" LOG_EFFECT_SIZE="-0.5486637960394247" MODIFIED="2013-12-16 14:52:59 +0000" MODIFIED_BY="[Empty name]" ORDER="24677" O_E="0.0" SE="0.7884748120233954" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.6216925291953287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4113049991388658" CI_END="1.4319680686545144" CI_START="0.5119526798488063" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8562125263073405" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-014.10" LOG_CI_END="0.15593333378066404" LOG_CI_START="-0.2907701793176912" LOG_EFFECT_SIZE="-0.06741842276851358" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9378973874848112" P_Q="0.9380280384121937" P_Z="0.5541101361688113" Q="0.4106776168586622" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="380" TOTAL_2="376" WEIGHT="400.0" Z="0.5916124527620974">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.99591867425035" CI_START="0.013607986406097115" DF="0" EFFECT_SIZE="0.3298611111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.10.01" LOG_CI_END="0.9028683682995156" LOG_CI_START="-1.8662061332402815" LOG_EFFECT_SIZE="-0.4816688824703831" MODIFIED="2013-12-16 14:53:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49533064010288896" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.6818550108280929">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="7.99591867425035" CI_START="0.013607986406097115" EFFECT_SIZE="0.3298611111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9028683682995156" LOG_CI_START="-1.8662061332402815" LOG_EFFECT_SIZE="-0.4816688824703831" MODIFIED="2013-12-16 14:53:16 +0000" MODIFIED_BY="[Empty name]" ORDER="24683" O_E="0.0" SE="1.6265680693443254" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="2.6457236842105263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0170055441390327" CI_START="0.4011585328877882" DF="0" EFFECT_SIZE="0.8995215311004785" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-014.10.02" LOG_CI_END="0.3047070919587643" LOG_CI_START="-0.39668396565351244" LOG_EFFECT_SIZE="-0.04598843684737413" MODIFIED="2013-12-16 14:53:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7971635209223993" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.2570197579450017">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="2.0170055441390327" CI_START="0.4011585328877882" EFFECT_SIZE="0.8995215311004785" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3047070919587643" LOG_CI_START="-0.39668396565351244" LOG_EFFECT_SIZE="-0.04598843684737413" MODIFIED="2013-12-16 14:53:31 +0000" MODIFIED_BY="[Empty name]" ORDER="24693" O_E="0.0" SE="0.4120005791831813" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.16974447724727681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8407683812742675" CI_START="0.25491205783680354" DF="0" EFFECT_SIZE="0.9894736842105263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-014.10.03" LOG_CI_END="0.5844181176917297" LOG_CI_START="-0.5936096210700279" LOG_EFFECT_SIZE="-0.004595751689149121" MODIFIED="2013-12-16 14:53:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9877988080446066" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.015292522402043473">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="3.8407683812742675" CI_START="0.25491205783680354" EFFECT_SIZE="0.9894736842105263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5844181176917297" LOG_CI_START="-0.5936096210700279" LOG_EFFECT_SIZE="-0.004595751689149121" MODIFIED="2013-12-16 14:53:49 +0000" MODIFIED_BY="[Empty name]" ORDER="24700" O_E="0.0" SE="0.6919793250800098" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.4788353863381859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1876087745456104E-31" CI_END="1.815529770298363" CI_START="0.37449207348696967" DF="0" EFFECT_SIZE="0.8245614035087719" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="100.0" ID="CMP-014.10.04" LOG_CI_END="0.25900337468669704" LOG_CI_START="-0.4265573701602449" LOG_EFFECT_SIZE="-0.08377699773677393" MODIFIED="2013-12-16 14:54:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.6319218198566126" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.47902363001729276">
<NAME>vertigo - short term</NAME>
<DICH_DATA CI_END="1.815529770298363" CI_START="0.37449207348696967" EFFECT_SIZE="0.8245614035087719" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.25900337468669704" LOG_CI_START="-0.4265573701602449" LOG_EFFECT_SIZE="-0.08377699773677393" MODIFIED="2013-12-16 14:54:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24703" O_E="0.0" SE="0.4027017751035116" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.16216871967151925" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.14873980731437" CI_END="1.3747429051843765" CI_START="0.6621408412938175" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9540825036659512" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="49" I2="36.48252563282311" I2_Q="36.337136315951724" ID="CMP-014.11" LOG_CI_END="0.13822148703933132" LOG_CI_START="-0.17904962371586147" LOG_EFFECT_SIZE="-0.020414068338265094" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.2071381424312556" P_Q="0.2078842343506373" P_Z="0.8008720972056801" Q="3.1415489097785136" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0632414766726272" TOTALS="SUB" TOTAL_1="380" TOTAL_2="376" WEIGHT="300.0" Z="0.25221860651417116">
<NAME>Other adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7735357211495788" CI_START="0.3952457622565864" DF="0" EFFECT_SIZE="0.8372469635627531" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-014.11.01" LOG_CI_END="0.24883994011098834" LOG_CI_START="-0.40313277778650997" LOG_EFFECT_SIZE="-0.07714641883776081" MODIFIED="2013-12-16 14:54:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6427652641926602" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.46383598057864006">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="1.7735357211495788" CI_START="0.3952457622565864" EFFECT_SIZE="0.8372469635627531" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.24883994011098834" LOG_CI_START="-0.40313277778650997" LOG_EFFECT_SIZE="-0.07714641883776081" MODIFIED="2013-12-16 14:54:53 +0000" MODIFIED_BY="[Empty name]" ORDER="24716" O_E="0.0" SE="0.3829720018099936" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.14666755417035374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-16 14:55:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>icterus - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-16 14:55:10 +0000" MODIFIED_BY="[Empty name]" ORDER="24720" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.724706176459093E-31" CI_END="1.2699076935756703" CI_START="0.44531110635900967" DF="0" EFFECT_SIZE="0.752" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="100.0" ID="CMP-014.11.03" LOG_CI_END="0.10377215432001208" LOG_CI_START="-0.3513364731367276" LOG_EFFECT_SIZE="-0.12378215940835775" MODIFIED="2013-12-16 14:55:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.28635279191460683" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.0661567798647729">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="1.2699076935756703" CI_START="0.44531110635900967" EFFECT_SIZE="0.752" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.10377215432001208" LOG_CI_START="-0.3513364731367276" LOG_EFFECT_SIZE="-0.12378215940835775" MODIFIED="2013-12-16 14:55:25 +0000" MODIFIED_BY="[Empty name]" ORDER="24726" O_E="0.0" SE="0.26733306059212786" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.07146696528555431" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.240337278611831" CI_START="0.8090547636579224" DF="0" EFFECT_SIZE="1.6191387559808612" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="0.0" ID="CMP-014.11.04" LOG_CI_END="0.510590217186995" LOG_CI_START="-0.0920220806751313" LOG_EFFECT_SIZE="0.2092840682559319" MODIFIED="2013-12-16 14:55:39 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.1733967033182132" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.3613702799457224">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="3.240337278611831" CI_START="0.8090547636579224" EFFECT_SIZE="1.6191387559808612" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.510590217186995" LOG_CI_START="-0.0920220806751313" LOG_EFFECT_SIZE="0.2092840682559319" MODIFIED="2013-12-16 14:55:39 +0000" MODIFIED_BY="[Empty name]" ORDER="24733" O_E="0.0" SE="0.3539774467431963" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.12530003280283236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5273094683705193" CI_END="4.025026784952552" CI_START="0.23558053689262576" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.973764843792546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.12" LOG_CI_END="0.6047687747705671" LOG_CI_START="-0.6278605927868697" LOG_EFFECT_SIZE="-0.011545909008151284" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.4677402897703692" P_Q="0.4679465458117128" P_Z="0.9707102144138438" Q="0.5268209505371655" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" WEIGHT="200.0" Z="0.03671755098549296">
<NAME>Other adverse events: 7. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8585066927614813" CI_START="0.11277341206544497" DF="0" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-014.12.01" LOG_CI_END="0.5864192578908473" LOG_CI_START="-0.9477932793805078" LOG_EFFECT_SIZE="-0.18068701074483032" MODIFIED="2013-12-16 14:56:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6443272619539884" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.46165707153445423">
<NAME>pruritus - short term</NAME>
<DICH_DATA CI_END="3.8585066927614813" CI_START="0.11277341206544497" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5864192578908473" LOG_CI_START="-0.9477932793805078" LOG_EFFECT_SIZE="-0.18068701074483032" MODIFIED="2013-12-16 14:56:00 +0000" MODIFIED_BY="[Empty name]" ORDER="24763" O_E="0.0" SE="0.9012040388677356" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.8121687196715192" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.456461610988015" CI_START="0.1825199680163051" DF="0" EFFECT_SIZE="1.9789473684210526" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-014.12.02" LOG_CI_END="1.3315581039521718" LOG_CI_START="-0.7386896160025075" LOG_EFFECT_SIZE="0.2964342439748321" MODIFIED="2013-12-16 14:56:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.574602645090996" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.5612859141202188">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="21.456461610988015" CI_START="0.1825199680163051" EFFECT_SIZE="1.9789473684210526" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3315581039521718" LOG_CI_START="-0.7386896160025075" LOG_EFFECT_SIZE="0.2964342439748321" MODIFIED="2013-12-16 14:56:07 +0000" MODIFIED_BY="[Empty name]" ORDER="24760" O_E="0.0" SE="1.2160737585928683" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="1.4788353863381858" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17747544875049032" CI_END="2.492505343613613" CI_START="0.14261706161254106" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5962162260117805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.13" LOG_CI_END="0.3966360980566795" LOG_CI_START="-0.8458285157118" LOG_EFFECT_SIZE="-0.22459620882756026" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6735518423171805" P_Q="0.6735813107163292" P_Z="0.47857746995371964" Q="0.17744144478957546" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" WEIGHT="200.0" Z="0.7085923824117569">
<NAME>Other adverse events: 8. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.588297508140442" CI_START="0.06280725468793968" DF="0" EFFECT_SIZE="0.9894736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-014.13.01" LOG_CI_END="1.192798685862681" LOG_CI_START="-1.2019901892409792" LOG_EFFECT_SIZE="-0.004595751689149121" MODIFIED="2013-12-16 14:56:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9939978979433858" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.007522590309537412">
<NAME>diminished sexual desire</NAME>
<DICH_DATA CI_END="15.588297508140442" CI_START="0.06280725468793968" EFFECT_SIZE="0.9894736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.192798685862681" LOG_CI_START="-1.2019901892409792" LOG_EFFECT_SIZE="-0.004595751689149121" MODIFIED="2013-12-16 14:56:20 +0000" MODIFIED_BY="[Empty name]" ORDER="24741" O_E="0.0" SE="1.406710839632007" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="1.9788353863381858" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6367005616686696" CI_START="0.0928298595959587" DF="0" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-014.13.02" LOG_CI_END="0.42106081170508775" LOG_CI_START="-1.0323123064113484" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-16 14:56:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.40976308624101065" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.8243106330968804">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="2.6367005616686696" CI_START="0.0928298595959587" EFFECT_SIZE="0.49473684210526314" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42106081170508775" LOG_CI_START="-1.0323123064113484" LOG_EFFECT_SIZE="-0.3056257473531303" MODIFIED="2013-12-16 14:56:27 +0000" MODIFIED_BY="[Empty name]" ORDER="24751" O_E="0.0" SE="0.8537185638945577" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="0.7288353863381859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1276877783206144" CI_END="1.1729288302021577" CI_START="0.03525114057226612" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20333981182916422" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-014.14" LOG_CI_END="0.06927166123046176" LOG_CI_START="-1.452826826581016" LOG_EFFECT_SIZE="-0.6917775826752771" METHOD="MH" MODIFIED="2014-01-14 16:41:43 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7208416559050199" P_Q="0.7218068343672541" P_Z="0.07482009952821722" Q="0.12676814150454419" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" WEIGHT="200.0" Z="1.7815655927826601">
<NAME>Other adverse events: 9. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.99591867425035" CI_START="0.013607986406097115" DF="0" EFFECT_SIZE="0.3298611111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.14.01" LOG_CI_END="0.9028683682995156" LOG_CI_START="-1.8662061332402815" LOG_EFFECT_SIZE="-0.4816688824703831" MODIFIED="2013-12-16 14:56:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49533064010288896" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.6818550108280929">
<NAME>cramps - short term</NAME>
<DICH_DATA CI_END="7.99591867425035" CI_START="0.013607986406097115" EFFECT_SIZE="0.3298611111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9028683682995156" LOG_CI_START="-1.8662061332402815" LOG_EFFECT_SIZE="-0.4816688824703831" MODIFIED="2013-12-16 14:56:42 +0000" MODIFIED_BY="[Empty name]" ORDER="24767" O_E="0.0" SE="1.6265680693443254" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="2.6457236842105263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3436250403325047" CI_START="0.02024081087348898" DF="0" EFFECT_SIZE="0.1649122807017544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-014.14.02" LOG_CI_END="0.12827808893034184" LOG_CI_START="-1.6937720930759272" LOG_EFFECT_SIZE="-0.7827470020727927" MODIFIED="2013-12-16 14:56:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09218385802333984" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.6839886719037622">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="1.3436250403325047" CI_START="0.02024081087348898" EFFECT_SIZE="0.1649122807017544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12827808893034184" LOG_CI_START="-1.6937720930759272" LOG_EFFECT_SIZE="-0.7827470020727927" MODIFIED="2013-12-16 14:56:59 +0000" MODIFIED_BY="[Empty name]" ORDER="24776" O_E="0.0" SE="1.0702812962043449" STUDY_ID="STD-Kurihara-1983" TOTAL_1="95" TOTAL_2="94" VAR="1.1455020530048525" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2014-02-18 14:10:36 +0000" MODIFIED_BY="[Empty name]" NO="15">
<NAME>PERPHENAZINE vs LOXAPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8783417879269204" CI_START="0.3190735657697006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" METHOD="MH" MODIFIED="2014-02-18 14:09:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9395402771640293" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.07584768632296582">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8783417879269204" CI_START="0.3190735657697006" DF="0" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-015.01.01" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-12-05 16:17:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9395402771640293" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.07584768632296582">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.8783417879269204" CI_START="0.3190735657697006" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.5611194814509367" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.3148550724637681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.434266565279833" CI_START="0.06362656347132332" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="1.1593947213830598" LOG_CI_START="-1.1963615327710861" LOG_EFFECT_SIZE="-0.018483405694013126" METHOD="MH" MODIFIED="2014-02-18 14:09:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.975464137624704" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.030755991336561973">
<NAME>Leaving the study early: 2. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.434266565279833" CI_START="0.06362656347132332" DF="0" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.02.01" LOG_CI_END="1.1593947213830598" LOG_CI_START="-1.1963615327710861" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-12-05 16:17:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.975464137624704" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.030755991336561973">
<NAME>short term</NAME>
<DICH_DATA CI_END="14.434266565279833" CI_START="0.06362656347132332" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1593947213830598" LOG_CI_START="-1.1963615327710861" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="1.914855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8242864964537722" CI_START="0.39777281633889333" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="0.26109304345420076" LOG_CI_START="-0.4003648997369896" LOG_EFFECT_SIZE="-0.06963592814139442" METHOD="MH" MODIFIED="2014-02-18 14:10:05 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6798440073059846" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.41267600636463286">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8242864964537722" CI_START="0.39777281633889333" DF="0" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-015.03.01" LOG_CI_END="0.26109304345420076" LOG_CI_START="-0.4003648997369896" LOG_EFFECT_SIZE="-0.06963592814139442" MODIFIED="2013-12-05 16:18:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6798440073059846" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.41267600636463286">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.8242864964537722" CI_START="0.39777281633889333" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.26109304345420076" LOG_CI_START="-0.4003648997369896" LOG_EFFECT_SIZE="-0.06963592814139442" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.38854367010013074" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.15096618357487923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7298545938027665" CI_END="1.3126646435494709" CI_START="0.7388385295379596" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9848082123015429" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" I2="26.73602452891302" I2_Q="22.369288093848006" ID="CMP-015.04" LOG_CI_END="0.11815378773557704" LOG_CI_START="-0.13145046470795843" LOG_EFFECT_SIZE="-0.006648338486190717" METHOD="MH" MODIFIED="2014-01-14 16:42:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.25539946452131357" P_Q="0.27578063614592196" P_Z="0.9168445340985256" Q="2.5762999602757812" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.032021087820940465" TOTALS="SUB" TOTAL_1="72" TOTAL_2="69" WEIGHT="300.0" Z="0.10440931083826831">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-015.04.01" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2013-12-05 16:18:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>dystonia - short term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3094590501815557" CI_START="0.6212743012674088" DF="0" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-015.04.02" LOG_CI_END="0.11709192157892168" LOG_CI_START="-0.20671661041164627" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2013-12-05 16:18:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.58748467275381" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5424846626427561">
<NAME>extrapyramidal signs - short term</NAME>
<DICH_DATA CI_END="1.3094590501815557" CI_START="0.6212743012674088" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.11709192157892168" LOG_CI_START="-0.20671661041164627" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.19020673456934384" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.03617860187553282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8621015575312443" CI_START="0.7471074823754769" DF="0" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-015.04.03" LOG_CI_END="0.27000336336532577" LOG_CI_START="-0.126616914055176" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2013-12-05 16:18:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4785928559711483" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.7085675960561586">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="1.8621015575312443" CI_START="0.7471074823754769" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.27000336336532577" LOG_CI_START="-0.126616914055176" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.23297671425883973" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.054278149386845054" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.187886799492831E-32" CI_END="5.932232668008021" CI_START="0.43004362268500357" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-015.05" LOG_CI_END="0.7732181761477137" LOG_CI_START="-0.36648748830302735" LOG_EFFECT_SIZE="0.20336534392234326" METHOD="MH" MODIFIED="2014-01-14 16:42:08 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.484265168923087" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6994591011065763">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.187886799492831E-32" CI_END="5.932232668008021" CI_START="0.43004362268500357" DF="0" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-015.05.01" LOG_CI_END="0.7732181761477137" LOG_CI_START="-0.36648748830302735" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-12-05 16:19:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.484265168923087" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6994591011065763">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="5.932232668008023" CI_START="0.4300436226850036" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7732181761477139" LOG_CI_START="-0.3664874883030273" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.6694687489323915" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.4481884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.676059642552924" CI_START="1.0030014225087676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2965686274509804" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-015.06" LOG_CI_END="0.22428946893074173" LOG_CI_START="0.0013015489598698841" LOG_EFFECT_SIZE="0.11279550894530582" METHOD="MH" MODIFIED="2014-02-18 14:10:36 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.047384851914507246" Q="0.0" RANDOM="YES" SCALE="3.9165823282937247" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.9828440498439848">
<NAME>Other adverse events: 2. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.676059642552924" CI_START="1.0030014225087676" DF="0" EFFECT_SIZE="1.2965686274509804" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" I2="0.0" ID="CMP-015.06.01" LOG_CI_END="0.22428946893074173" LOG_CI_START="0.0013015489598698841" LOG_EFFECT_SIZE="0.11279550894530582" MODIFIED="2013-12-05 16:20:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.047384851914507246" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.9828440498439848">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.676059642552924" CI_START="1.0030014225087676" EFFECT_SIZE="1.2965686274509804" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.22428946893074173" LOG_CI_START="0.0013015489598698841" LOG_EFFECT_SIZE="0.11279550894530582" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.13098420799889596" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="0.01715686274509804" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.953995419751143" CI_END="14.037100191670556" CI_START="0.19517306414107652" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6551929966211294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="48.82280736730908" I2_Q="48.333291248235454" ID="CMP-015.07" LOG_CI_END="1.1472773997575623" LOG_CI_START="-0.70958011956936" LOG_EFFECT_SIZE="0.2188486400941011" METHOD="MH" MODIFIED="2014-01-14 16:42:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.16215724935017517" P_Q="0.16416017045892295" P_Z="0.6440802670735704" Q="1.935482294420094" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.284364746770773" TOTALS="SUB" TOTAL_1="48" TOTAL_2="46" WEIGHT="200.0" Z="0.4620014709642215">
<NAME>Other adverse events: 3. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours loxapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="123.32924773826663" CI_START="0.36616131881252256" DF="0" EFFECT_SIZE="6.720000000000001" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-015.07.01" LOG_CI_END="2.091066082476124" LOG_CI_START="-0.43632753636847327" LOG_EFFECT_SIZE="0.8273692730538252" MODIFIED="2013-12-05 16:20:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19941141973957965" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.2832302534987863">
<NAME>ECG &#8211; atrial extrasystole &amp; flattening of T-wave in V<SUB>6 </SUB>- short term</NAME>
<DICH_DATA CI_END="123.32924773826663" CI_START="0.36616131881252256" EFFECT_SIZE="6.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.091066082476124" LOG_CI_START="-0.43632753636847327" LOG_EFFECT_SIZE="0.8273692730538252" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.476637125846737" CI_START="0.013695997047389556" DF="0" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-015.07.02" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" MODIFIED="2013-12-05 16:20:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4785141381784974" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.7086944123517833">
<NAME>ventricular extrasystole - short term</NAME>
<DICH_DATA CI_END="7.476637125846737" CI_START="0.013695997047389556" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" MODIFIED="2013-12-05 16:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2014-01-14 16:42:42 +0000" MODIFIED_BY="[Empty name]" NO="16">
<NAME>PERPHENAZINE vs MEPAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5265636306012502" CI_START="0.905642440276144" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1758064516129032" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.1837149113815282" LOG_CI_START="-0.043043233742086746" LOG_EFFECT_SIZE="0.07033583881972075" METHOD="MH" MODIFIED="2014-01-14 16:42:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2240294367499306" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="32" WEIGHT="100.0" Z="1.215883211903292">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mepazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mepazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5265636306012502" CI_START="0.905642440276144" DF="0" EFFECT_SIZE="1.1758064516129032" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" I2="0.0" ID="CMP-016.01.01" LOG_CI_END="0.1837149113815282" LOG_CI_START="-0.043043233742086746" LOG_EFFECT_SIZE="0.07033583881972075" MODIFIED="2013-12-10 16:40:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2240294367499306" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="32" WEIGHT="100.0" Z="1.215883211903292">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:36:41 +0000" MODIFIED_BY="[Empty name]" ORDER="24504" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5265636306012502" CI_START="0.905642440276144" EFFECT_SIZE="1.1758064516129032" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" LOG_CI_END="0.1837149113815282" LOG_CI_START="-0.043043233742086746" LOG_EFFECT_SIZE="0.07033583881972075" MODIFIED="2013-12-10 16:40:22 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.13319885691653277" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="27" VAR="0.01774193548387097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="52.20118626331567" CI_START="0.9300445287700024" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.967741935483873" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="1.7176803723846044" LOG_CI_START="-0.03149625775128761" LOG_EFFECT_SIZE="0.8430920573166584" METHOD="MH" MODIFIED="2014-01-14 16:42:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05884086801009104" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="1.8893804542358354">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mepazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mepazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="52.20118626331567" CI_START="0.9300445287700024" DF="0" EFFECT_SIZE="6.967741935483873" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-016.02.01" LOG_CI_END="1.7176803723846044" LOG_CI_START="-0.03149625775128761" LOG_EFFECT_SIZE="0.8430920573166584" MODIFIED="2013-12-10 16:40:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05884086801009104" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="1.8893804542358354">
<NAME>short term</NAME>
<DICH_DATA CI_END="52.20118626331565" CI_START="0.9300445287700022" EFFECT_SIZE="6.967741935483871" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7176803723846041" LOG_CI_START="-0.03149625775128771" LOG_EFFECT_SIZE="0.8430920573166583" MODIFIED="2013-12-10 16:40:48 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="1.0274750111057855" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="27" VAR="1.055704898446834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9960706295440872" CI_START="0.15735068738441507" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39589442815249265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-0.0017098654581171567" LOG_CI_START="-0.8031313555368661" LOG_EFFECT_SIZE="-0.4024206104974916" METHOD="MH" MODIFIED="2014-01-14 16:42:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.049030389521365916" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="1.968327310849134">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mepazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mepazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9960706295440872" CI_START="0.15735068738441507" DF="0" EFFECT_SIZE="0.39589442815249265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-016.03.01" LOG_CI_END="-0.0017098654581171567" LOG_CI_START="-0.8031313555368661" LOG_EFFECT_SIZE="-0.4024206104974916" MODIFIED="2013-12-10 16:30:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.049030389521365916" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="1.968327310849134">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.9960706295440871" CI_START="0.15735068738441504" EFFECT_SIZE="0.39589442815249265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="-0.001709865458117205" LOG_CI_START="-0.8031313555368661" LOG_EFFECT_SIZE="-0.4024206104974916" MODIFIED="2013-12-10 16:30:17 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.47075895037261356" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="27" VAR="0.22161398935592486" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.931478136347037" CI_START="0.08381191236932206" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.04" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-01-14 16:42:42 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>Other adverse events: 1. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Mepazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mepazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.931478136347037" CI_START="0.08381191236932206" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-016.04.01" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:37:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>electroencephalogram (increase) - short term</NAME>
<DICH_DATA CI_END="11.931478136347037" CI_START="0.08381191236932206" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:37:01 +0000" MODIFIED_BY="[Empty name]" ORDER="24686" O_E="0.0" SE="1.2649110640673518" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="1.6" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2014-02-18 14:15:21 +0000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>PERPHENAZINE vs METHYPERIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8317856421488745" CI_START="0.3531340738210535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.45206037544594646" LOG_CI_START="-0.45206037544594646" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 14:12:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8317856421488745" CI_START="0.3531340738210535" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-017.01.01" LOG_CI_END="0.45206037544594646" LOG_CI_START="-0.45206037544594646" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:21:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.8317856421488745" CI_START="0.3531340738210535" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45206037544594646" LOG_CI_START="-0.45206037544594646" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24513" O_E="0.0" SE="0.5310850045437943" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.282051282051282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="34.198442693654755" CI_START="0.4678575613318402" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="1.5340063298879694" LOG_CI_START="-0.3298863472320445" LOG_EFFECT_SIZE="0.6020599913279624" METHOD="MH" MODIFIED="2014-02-18 14:13:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2054471024991802" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="1.2661843828461201">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.198442693654755" CI_START="0.4678575613318402" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-017.02.01" LOG_CI_END="1.5340063298879694" LOG_CI_START="-0.3298863472320445" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2013-12-06 10:21:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2054471024991802" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="1.2661843828461201">
<NAME>short term</NAME>
<DICH_DATA CI_END="34.198442693654755" CI_START="0.4678575613318402" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5340063298879694" LOG_CI_START="-0.3298863472320445" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24526" O_E="0.0" SE="1.0948597849578496" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.198717948717949" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6412032187611698" CI_START="0.6751346989397249" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.21516236004289102" LOG_CI_START="-0.1706095706205866" LOG_EFFECT_SIZE="0.022276394711152208" METHOD="MH" MODIFIED="2014-02-18 14:13:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8209244026634025" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.2263561854496036">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6412032187611698" CI_START="0.6751346989397249" DF="0" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" ID="CMP-017.03.01" LOG_CI_END="0.21516236004289102" LOG_CI_START="-0.1706095706205866" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2013-12-06 10:21:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8209244026634025" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.2263561854496036">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.6412032187611698" CI_START="0.6751346989397249" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.21516236004289102" LOG_CI_START="-0.1706095706205866" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24546" O_E="0.0" SE="0.2266043416735812" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.051349527665317134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2642533680032177" CI_START="0.6125354455041714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.10183411927769989" LOG_CI_START="-0.2128687749773626" LOG_EFFECT_SIZE="-0.05551732784983137" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4892376620023784" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.6915218454608897">
<NAME>Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2642533680032177" CI_START="0.6125354455041714" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.10183411927769989" LOG_CI_START="-0.2128687749773626" LOG_EFFECT_SIZE="-0.05551732784983137" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24560" O_E="0.0" SE="0.1848580378898742" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.03417249417249417" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2199248318595224" CI_END="1.5155087537891927" CI_START="0.414286188037519" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7923726046152881" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="9.906859399167228" I2_Q="7.906212946324076" ID="CMP-017.05" LOG_CI_END="0.18055844925617323" LOG_CI_START="-0.38269954548297713" LOG_EFFECT_SIZE="-0.10107054811340188" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3295716339086908" P_Q="0.33761506818388454" P_Z="0.4818135962490071" Q="2.171699160155419" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04643639894476634" TOTALS="SUB" TOTAL_1="156" TOTAL_2="156" WEIGHT="300.0" Z="0.7033886284800265">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.309170813995455" CI_START="0.3625987614427503" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-017.05.01" LOG_CI_END="0.6343937097080784" LOG_CI_START="-0.4405736836919656" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-06 10:22:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7237977954163055" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.3533877146474776">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="4.309170813995455" CI_START="0.3625987614427503" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6343937097080784" LOG_CI_START="-0.4405736836919656" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24565" O_E="0.0" SE="0.631441168057602" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.3987179487179487" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:23:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24575" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6343045942797216" CI_START="0.02447524172666784" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-017.05.03" LOG_CI_END="0.21333300157640056" LOG_CI_START="-1.6112730102484383" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-12-06 10:23:04 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.13318859208453826" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="1.5016458631551606">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="1.6343045942797216" CI_START="0.02447524172666784" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21333300157640056" LOG_CI_START="-1.6112730102484383" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24580" O_E="0.0" SE="1.071782603291334" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.1487179487179489" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8107829986938895" CI_START="0.35343826425454045" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-017.05.04" LOG_CI_END="0.25786640828395535" LOG_CI_START="-0.4516864343000681" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-06 10:23:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5923872463985306" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="99.99999999999999" Z="0.5353798162385812">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.8107829986938895" CI_START="0.35343826425454045" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.25786640828395535" LOG_CI_START="-0.4516864343000681" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24595" O_E="0.0" SE="0.4167948520770725" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.17371794871794874" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4213112083287198" CI_END="5.314750648306624" CI_START="0.1299680586891428" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8311124016505078" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="29.642431992366255" I2_Q="28.351736122383063" ID="CMP-017.06" LOG_CI_END="0.7254828935808938" LOG_CI_START="-0.8861633679971097" LOG_EFFECT_SIZE="-0.08034023720810794" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2331879491434926" P_Q="0.2374438558449341" P_Z="0.8450738602527355" Q="1.3957072312430476" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8002212245371776" TOTALS="SUB" TOTAL_1="78" TOTAL_2="78" WEIGHT="200.0" Z="0.19540760921459205">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.035499078344917" CI_START="0.009912032991073124" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-017.06.01" LOG_CI_END="0.60589725245782" LOG_CI_START="-2.0038372611298576" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-12-06 10:39:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.29377259872973227" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="1.0498815321172912">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="4.035499078344917" CI_START="0.009912032991073124" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.60589725245782" LOG_CI_START="-2.0038372611298576" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24616" O_E="0.0" SE="1.5329709716755893" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.35" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.16211905093586" CI_START="0.18901698787216242" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-017.06.02" LOG_CI_END="1.3255591532521103" LOG_CI_START="-0.7234991619241479" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-06 10:39:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5646949131511061" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.00000000000001" Z="0.5758820482538584">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="21.16211905093586" CI_START="0.18901698787216242" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3255591532521103" LOG_CI_START="-0.7234991619241479" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24624" O_E="0.0" SE="1.2036269973367784" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.448717948717949" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06654711764268212" CI_END="1.2758578173567567" CI_START="0.2872301904927195" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6053634312716671" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-017.07" LOG_CI_END="0.10580227894788453" LOG_CI_START="-0.5417699137497309" LOG_EFFECT_SIZE="-0.21798381740092324" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7964321635472882" P_Q="0.7972527297836506" P_Z="0.18699718408055263" Q="0.06599976962017962" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="78" WEIGHT="200.0" Z="1.3195144452963423">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.470019361633962" CI_START="0.27547846528757897" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-017.07.01" LOG_CI_END="0.16732305488111143" LOG_CI_START="-0.5599123451690479" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2013-12-06 10:40:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.29002673665679446" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="1.0580630008212253">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.470019361633962" CI_START="0.2754784652875789" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.16732305488111143" LOG_CI_START="-0.559912345169048" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24642" O_E="0.0" SE="0.42718167386275185" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.1824841824841825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5732610372821907" CI_START="0.0971529885145439" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-017.07.02" LOG_CI_END="0.41048384423635903" LOG_CI_START="-1.0125438355643215" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:40:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.40697481433009" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="99.99999999999999" Z="0.8292290559664905">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="2.5732610372821907" CI_START="0.0971529885145439" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41048384423635903" LOG_CI_START="-1.0125438355643215" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24655" O_E="0.0" SE="0.8358935032155405" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.6987179487179487" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3283039695893817" CI_START="0.6960426485088043" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-017.08" LOG_CI_END="0.12329747052093552" LOG_CI_START="-0.15736414911849625" LOG_EFFECT_SIZE="-0.017033339298780342" METHOD="MH" MODIFIED="2014-02-18 14:15:21 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.8119584793678185" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.2379002273624006">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3283039695893817" CI_START="0.6960426485088043" DF="0" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-017.08.01" LOG_CI_END="0.12329747052093552" LOG_CI_START="-0.15736414911849625" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-12-06 10:40:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8119584793678185" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.2379002273624006">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.3283039695893817" CI_START="0.6960426485088043" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.12329747052093552" LOG_CI_START="-0.15736414911849625" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24663" O_E="0.0" SE="0.16486202467362576" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.02717948717948719" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26594047093934675" CI_END="4.965099306816452" CI_START="0.07884190132502845" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6256659409117535" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-017.09" LOG_CI_END="0.6959279392304115" LOG_CI_START="-1.1032429109652542" LOG_EFFECT_SIZE="-0.20365748586742127" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6060680782678233" P_Q="0.6071339857411266" P_Z="0.65724721126143" Q="0.26436961230941136" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="156" WEIGHT="200.0" Z="0.4437169904555875">
<NAME>Other adverse events: 4. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:40:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24682" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.425791638464126" CI_START="0.06482649470685871" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-017.09.02" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:40:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.0">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="15.425791638464126" CI_START="0.06482649470685871" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24691" O_E="0.0" SE="1.3959648809042255" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.948717948717949" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:40:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24698" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.939480235674019" CI_START="0.013994758827141083" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-017.09.04" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:40:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4970383244017067" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.679157109900482">
<NAME>vertigo - short term</NAME>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24702" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9659592538196391" CI_END="2.1314716350829244" CI_START="0.2804379935108646" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7731401092738478" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-017.10" LOG_CI_END="0.32867955757478506" LOG_CI_START="-0.5521631488568138" LOG_EFFECT_SIZE="-0.1117417956410143" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6169424401285004" P_Q="0.6170810916152929" P_Z="0.6189961547169334" Q="0.9655098242490529" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="156" WEIGHT="300.0" Z="0.49727356184047583">
<NAME>Other adverse events: 5. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.939480235674019" CI_START="0.013994758827141083" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-017.10.01" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:41:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4970383244017067" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.679157109900482">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24714" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:41:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>icterus - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24719" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.339589918993734" CI_START="0.15387311984778823" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-017.10.03" LOG_CI_END="0.36913974137361255" LOG_CI_START="-0.8128372406063252" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-12-06 10:41:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.46188721002140687" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.7357428543742707">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="2.339589918993734" CI_START="0.15387311984778823" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36913974137361255" LOG_CI_START="-0.8128372406063252" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24724" O_E="0.0" SE="0.6942991300954381" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.482051282051282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.488676176282752" CI_START="0.26505899780774655" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-017.10.04" LOG_CI_END="0.9288399665497601" LOG_CI_START="-0.5766574484383976" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-06 10:41:32 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6465958943565459" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.45849633789528993">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="8.488676176282748" CI_START="0.2650589978077466" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.92883996654976" LOG_CI_START="-0.5766574484383975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24731" O_E="0.0" SE="0.8843366338964376" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.7820512820512819" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.425791638464126" CI_START="0.06482649470685871" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.11" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.0">
<NAME>Other adverse events: 6. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.425791638464126" CI_START="0.06482649470685871" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-017.11.01" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:42:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.0">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="15.425791638464126" CI_START="0.06482649470685871" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24758" O_E="0.0" SE="1.3959648809042255" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="1.948717948717949" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.939480235674019" CI_START="0.013994758827141083" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.12" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4970383244017067" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.679157109900482">
<NAME>Other adverse events: 7. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.939480235674019" CI_START="0.013994758827141083" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-017.12.01" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:42:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4970383244017067" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.679157109900482">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24749" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-14 16:44:13 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="78" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events: 8. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Methyperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:42:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>cramps - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24766" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:42:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24774" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-III" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2015-01-26 14:51:44 +0000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>PERPHENAZINE vs OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="0.23228667673598202" CI_END="1.2855632524412766" CI_START="1.0474094010615924" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1603926216011158" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="234" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.10909344971509605" LOG_CI_START="0.02011646760905194" LOG_EFFECT_SIZE="0.06460495866207401" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6298334742004776" P_Q="1.0" P_Z="0.004424361916724398" Q="0.0" RANDOM="YES" SCALE="3.11" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="291" TOTAL_2="366" WEIGHT="100.00000000000001" Z="2.8462055961721053">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23228667673598202" CI_END="1.2855632524412766" CI_START="1.0474094010615924" DF="1" EFFECT_SIZE="1.1603926216011158" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="234" I2="0.0" ID="CMP-018.01.01" LOG_CI_END="0.10909344971509605" LOG_CI_START="0.02011646760905194" LOG_EFFECT_SIZE="0.06460495866207401" MODIFIED="2013-12-18 09:43:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6298334742004776" P_Z="0.004424361916724398" STUDIES="2" TAU2="0.0" TOTAL_1="291" TOTAL_2="366" WEIGHT="100.00000000000001" Z="2.8462055961721053">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.2987617003265775" CI_START="1.050685424114875" EFFECT_SIZE="1.1681566624095359" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="216" LOG_CI_END="0.11352947306908777" LOG_CI_START="0.021472707445128636" LOG_EFFECT_SIZE="0.0675010902571082" MODIFIED="2013-12-11 15:21:45 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.05407459981585264" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.0029240623452446105" WEIGHT="93.42087241488804"/>
<DICH_DATA CI_END="1.5737175550829683" CI_START="0.7080034960946062" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.19692678947418224" LOG_CI_START="-0.14996459777513643" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-12-18 09:43:27 +0000" MODIFIED_BY="[Empty name]" ORDER="922" O_E="0.0" SE="0.20376571801031035" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.04152046783625731" WEIGHT="6.579127585111976"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5341599808910534" CI_END="1.2140330198962679" CI_START="0.5923855036313245" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8480421934764262" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="0.0842304990652043" LOG_CI_START="-0.22739557771658586" LOG_EFFECT_SIZE="-0.07158253932569082" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.46486322832591176" P_Q="1.0" P_Z="0.36788988467924766" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="284" TOTAL_2="359" WEIGHT="99.99999999999999" Z="0.9004329833316079">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5341599808910534" CI_END="1.2140330198962679" CI_START="0.5923855036313245" DF="1" EFFECT_SIZE="0.8480421934764262" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="63" I2="0.0" ID="CMP-018.02.01" LOG_CI_END="0.0842304990652043" LOG_CI_START="-0.22739557771658586" LOG_EFFECT_SIZE="-0.07158253932569082" MODIFIED="2013-12-18 09:43:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46486322832591176" P_Z="0.36788988467924766" STUDIES="2" TAU2="0.0" TOTAL_1="284" TOTAL_2="359" WEIGHT="99.99999999999999" Z="0.9004329833316079">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1941559020000023" CI_START="0.5776610885809792" EFFECT_SIZE="0.8305524657026325" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="62" LOG_CI_END="0.0770610294385655" LOG_CI_START="-0.2383268856760224" LOG_EFFECT_SIZE="-0.08063292811872841" MODIFIED="2013-12-11 15:22:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.18526042253366737" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.03432142415735297" WEIGHT="97.62869583889939"/>
<DICH_DATA CI_END="20.552567517689006" CI_START="0.19462288575660025" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3128660835898294" LOG_CI_START="-0.710806092261867" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-18 09:43:48 +0000" MODIFIED_BY="[Empty name]" ORDER="923" O_E="0.0" SE="1.1887150534341144" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="1.4130434782608696" WEIGHT="2.3713041611006007"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.392574253492006" CI_END="3.289485457724777" CI_START="0.469965615218481" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2433603889829654" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="53" I2="58.20401400121724" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="0.5171279707928351" LOG_CI_START="-0.3279339158241734" LOG_EFFECT_SIZE="0.09459702748433081" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12191291269161819" P_Q="1.0" P_Z="0.6608061374704937" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.33128446915596726" TOTALS="YES" TOTAL_1="284" TOTAL_2="359" WEIGHT="100.00000000000001" Z="0.43880044728099904">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.392574253492006" CI_END="3.289485457724777" CI_START="0.469965615218481" DF="1" EFFECT_SIZE="1.2433603889829654" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="53" I2="58.20401400121724" ID="CMP-018.03.01" LOG_CI_END="0.5171279707928351" LOG_CI_START="-0.3279339158241734" LOG_EFFECT_SIZE="0.09459702748433081" MODIFIED="2013-12-18 09:44:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12191291269161819" P_Z="0.6608061374704937" STUDIES="2" TAU2="0.33128446915596726" TOTAL_1="284" TOTAL_2="359" WEIGHT="100.00000000000001" Z="0.43880044728099904">
<NAME>long term</NAME>
<DICH_DATA CI_END="2.43976061098916" CI_START="1.2456457859551102" EFFECT_SIZE="1.7432950191570882" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" LOG_CI_END="0.38734721550807294" LOG_CI_START="0.09539456312958991" LOG_EFFECT_SIZE="0.24137088931883147" MODIFIED="2013-12-11 15:22:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1714944331960579" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.029410340617237168" WEIGHT="68.31441297007775"/>
<DICH_DATA CI_END="2.222548430727091" CI_START="0.16197622289032795" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34685123329505907" LOG_CI_START="-0.7905487325277719" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-12-18 09:44:09 +0000" MODIFIED_BY="[Empty name]" ORDER="924" O_E="0.0" SE="0.6681143701449648" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.44637681159420295" WEIGHT="31.68558702992226"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-018.04" MODIFIED="2015-01-14 16:41:24 +0000" MODIFIED_BY="Heather Maxwell" NO="4" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 1a. State - BPRS end score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention:</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-018.04.01" MODIFIED="2013-12-18 10:47:24 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>long term</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:47:24 +0000" MODIFIED_BY="[Empty name]" ORDER="3223" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine</P>
</TD>
<TD>
<P>11.7</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-018.05" MODIFIED="2015-01-14 16:41:37 +0000" MODIFIED_BY="Heather Maxwell" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 1b. State - PANSS total endpoint score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-018.05.01" MODIFIED="2013-12-18 10:36:03 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>long term</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:36:03 +0000" MODIFIED_BY="[Empty name]" ORDER="3224" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>54.5</P>
</TD>
<TD>
<P>23.9</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine</P>
</TD>
<TD>
<P>53.7</P>
</TD>
<TD>
<P>23.9</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="271.54843389246093" CI_END="1.363305832744294" CI_START="0.6901606832432323" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0267332579937631" ESTIMABLE="YES" I2="98.89522470927301" I2_Q="98.89522470927301" ID="CMP-018.06" MODIFIED="2015-01-14 16:41:59 +0000" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="-2.220446049250313E-16" P_Q="-2.220446049250313E-16" P_Z="2.2454110883161954E-9" Q="271.54843389246093" RANDOM="YES" SCALE="10.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="17.793259664705037" TOTALS="SUB" TOTAL_1="120" TOTAL_2="120" UNITS="" WEIGHT="400.0" Z="5.978978557266047">
<NAME>Mental state: 1c. State - PANSS: mean endpoint score from baseline (high = poor)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.250484733506245" CI_START="2.1695152664937494" DF="0" EFFECT_SIZE="4.209999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-018.06.01" MODIFIED="2014-02-05 14:27:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.2576807222447434E-5" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="4.043866753531071">
<NAME>total - short term</NAME>
<CONT_DATA CI_END="6.250484733506245" CI_START="2.1695152664937494" EFFECT_SIZE="4.209999999999997" ESTIMABLE="YES" MEAN_1="27.65" MEAN_2="23.44" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="3.9" SD_2="4.16" SE="1.041082769684204" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.200475792553485" CI_START="7.259524207446516" DF="0" EFFECT_SIZE="8.23" ESTIMABLE="YES" I2="0.0" ID="CMP-018.06.02" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.8916727348898735E-62" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="16.62123230330412">
<NAME>positive - short term</NAME>
<CONT_DATA CI_END="9.200475792553485" CI_START="7.259524207446516" EFFECT_SIZE="8.23" ESTIMABLE="YES" MEAN_1="20.37" MEAN_2="12.14" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="1.64" SD_2="2.16" SE="0.49514980898040684" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5159041806894233" CI_START="0.6440958193105787" DF="0" EFFECT_SIZE="1.580000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-018.06.03" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="9.368839702746363E-4" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.308824941130309">
<NAME>negative - short term</NAME>
<CONT_DATA CI_END="2.5159041806894233" CI_START="0.6440958193105787" EFFECT_SIZE="1.580000000000001" ESTIMABLE="YES" MEAN_1="9.13" MEAN_2="7.55" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="2.17" SD_2="1.46" SE="0.4775109073797861" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.005780097838648746" CI_START="-0.7857800978386499" DF="0" EFFECT_SIZE="-0.39000000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-018.06.04" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.05344101363327524" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="1.9313400500553852">
<NAME>general psychopathology - short term</NAME>
<CONT_DATA CI_END="0.005780097838648746" CI_START="-0.7857800978386499" EFFECT_SIZE="-0.39000000000000057" ESTIMABLE="YES" MEAN_1="16.95" MEAN_2="17.34" MODIFIED="2014-01-13 13:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1046" SD_1="0.28" SD_2="1.07" SE="0.20193233190023502" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.108042421948712" CI_START="0.39572449669526094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-018.07" LOG_CI_END="1.0046670559209654" LOG_CI_START="-0.402607064593003" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4017433540090516" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.8385117599578504">
<NAME>Mental state: 1d. State - less than 25% PANSS reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.108042421948712" CI_START="0.39572449669526094" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-018.07.01" LOG_CI_END="1.0046670559209654" LOG_CI_START="-0.402607064593003" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-13 13:23:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4017433540090516" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.8385117599578504">
<NAME>short term</NAME>
<DICH_DATA CI_END="10.108042421948712" CI_START="0.39572449669526094" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0046670559209654" LOG_CI_START="-0.402607064593003" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-01-13 13:23:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1043" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Wang-2008b" TOTAL_1="30" TOTAL_2="30" VAR="0.6833333333333333" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.741670429202198" CI_END="1.5906671624264364" CI_START="0.8581612487828536" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1683530795550414" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-018.08" LOG_CI_END="0.2015793156342781" LOG_CI_START="-0.06643110040663748" LOG_EFFECT_SIZE="0.06757410761382032" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6019429969845564" P_Q="0.479455400908131" P_Z="0.3229857730903526" Q="2.477037912519747" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="774" TOTAL_2="875" WEIGHT="400.0" Z="0.9883408202336615">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.26523779572249984" CI_END="2.5998838629466032" CI_START="0.6835639524498384" DF="1" EFFECT_SIZE="1.3331117317263148" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" ID="CMP-018.08.01" LOG_CI_END="0.41495394842930033" LOG_CI_START="-0.1652208477431406" LOG_EFFECT_SIZE="0.12486655034307985" MODIFIED="2013-12-18 09:53:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.606544385428391" P_Z="0.3988617322924295" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="320" WEIGHT="100.0" Z="0.8436558884004113">
<NAME>akathisia - long term</NAME>
<DICH_DATA CI_END="2.542119593090056" CI_START="0.6480721817430375" EFFECT_SIZE="1.2835408022130015" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.4051959779242637" LOG_CI_START="-0.18837662007560113" LOG_EFFECT_SIZE="0.10840967892433127" MODIFIED="2013-12-11 15:23:02 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.3486674822968679" STUDY_ID="STD-CATIE-2005" TOTAL_1="241" TOTAL_2="290" VAR="0.12156901321123667" WEIGHT="95.53665452915324"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:53:21 +0000" MODIFIED_BY="[Empty name]" ORDER="936" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="4.463345470846755"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4885636497083308" CI_START="0.4239652989411579" DF="0" EFFECT_SIZE="0.7944176060118089" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" ID="CMP-018.08.02" LOG_CI_END="0.1727674094403216" LOG_CI_START="-0.37266968844289217" LOG_EFFECT_SIZE="-0.09995113950128526" MODIFIED="2013-12-11 15:23:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.47255673895738015" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="296" WEIGHT="100.0" Z="0.7183253005581336">
<NAME>EPS - long term</NAME>
<DICH_DATA CI_END="1.4885636497083308" CI_START="0.4239652989411579" EFFECT_SIZE="0.7944176060118089" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.1727674094403216" LOG_CI_START="-0.37266968844289217" LOG_EFFECT_SIZE="-0.09995113950128526" MODIFIED="2013-12-11 15:23:19 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.3203924512537787" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="296" VAR="0.10265132282040496" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9529611800446531" CI_START="0.8334920465923173" DF="0" EFFECT_SIZE="1.27584388185654" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="32" I2="0.0" ID="CMP-018.08.03" LOG_CI_END="0.29069361069187183" LOG_CI_START="-0.07909853997220734" LOG_EFFECT_SIZE="0.10579753535983223" MODIFIED="2013-12-11 15:23:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.26207876708754974" STUDIES="1" TAU2="0.0" TOTAL_1="237" TOTAL_2="236" WEIGHT="99.99999999999999" Z="1.1214914031354886">
<NAME>tardive dyskinesia - long term</NAME>
<DICH_DATA CI_END="1.9529611800446531" CI_START="0.8334920465923173" EFFECT_SIZE="1.27584388185654" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="32" LOG_CI_END="0.29069361069187183" LOG_CI_START="-0.07909853997220734" LOG_EFFECT_SIZE="0.10579753535983223" MODIFIED="2013-12-11 15:23:10 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.21721773980074782" STUDY_ID="STD-CATIE-2005" TOTAL_1="237" TOTAL_2="236" VAR="0.04718354648414538" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.755512560869924" CI_START="0.33637927808426854" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-018.08.04" LOG_CI_END="1.4274132752588893" LOG_CI_START="-0.47317076581956424" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 16:44:51 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.32508803826320287" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.9840559062870702">
<NAME>use of antiparkinsonian drugs - long term</NAME>
<DICH_DATA CI_END="26.755512560869924" CI_START="0.33637927808426854" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4274132752588893" LOG_CI_START="-0.47317076581956424" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 09:50:28 +0000" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="1.1164124737722179" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="23" TOTAL_2="23" VAR="1.2463768115942029" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.09" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.09.01" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-01-14 16:44:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>increased salivation - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:27:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1022" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.362293572951817" CI_END="1.2317236994001304" CI_START="0.7625261352733574" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9691344139118083" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="165" I2="61.398507272164125" I2_Q="1.4826943542235045" ID="CMP-018.10" LOG_CI_END="0.09051329769560465" LOG_CI_START="-0.11774526645922942" LOG_EFFECT_SIZE="-0.01361598438181235" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.03474769631810204" P_Q="0.3847163717275467" P_Z="0.7977302901120493" Q="3.045150271147932" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11978241390298333" TOTALS="SUB" TOTAL_1="612" TOTAL_2="762" WEIGHT="400.0" Z="0.2562856333012192">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.234348125670902" CI_START="0.33046504210308847" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-018.10.01" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3289937987651492" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.9761426344273544">
<NAME>agitation - long term</NAME>
<DICH_DATA CI_END="27.234348125670902" CI_START="0.33046504210308847" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:52 +0000" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.206513090488437" CI_START="0.3714477921233738" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-018.10.02" LOG_CI_END="0.6239222447595453" LOG_CI_START="-0.43010221874343246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-18 10:13:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7185410371511193" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.3604093487656743">
<NAME>anxiety - long term</NAME>
<DICH_DATA CI_END="4.206513090488437" CI_START="0.3714477921233738" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6239222447595453" LOG_CI_START="-0.43010221874343246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-12-18 10:13:52 +0000" MODIFIED_BY="[Empty name]" ORDER="941" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1128117421266017" CI_END="8.894614818143644" CI_START="0.6154650706654805" DF="1" EFFECT_SIZE="2.3397274921646343" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="56" I2="52.66970643615067" ID="CMP-018.10.03" LOG_CI_END="0.9491271456771919" LOG_CI_START="-0.21079658943890203" LOG_EFFECT_SIZE="0.36916527811914496" MODIFIED="2013-12-18 10:29:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1460707699579873" P_Z="0.21218377907778418" STUDIES="2" TAU2="0.6135577685884358" TOTAL_1="291" TOTAL_2="366" WEIGHT="99.99999999999999" Z="1.247583142841401">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="2.125753139312135" CI_START="1.1226572958881118" EFFECT_SIZE="1.5448275862068965" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="55" LOG_CI_END="0.3275128291151314" LOG_CI_START="0.050247203083244416" LOG_EFFECT_SIZE="0.18888001609918792" MODIFIED="2013-12-11 15:24:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.16286720121811446" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.026525725232621783" WEIGHT="72.52662142006471"/>
<DICH_DATA CI_END="53.472577975118114" CI_START="0.9163575397991978" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7281311224466887" LOG_CI_START="-0.03793504241817497" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-18 10:29:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1040" O_E="0.0" SE="1.0373960074101287" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.076190476190476" WEIGHT="27.473378579935275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.55808794684466E-31" CI_END="1.1766362852380943" CI_START="0.7131026722201161" DF="0" EFFECT_SIZE="0.9160035366931919" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="104" I2="100.0" ID="CMP-018.10.04" LOG_CI_END="0.07064223707853591" LOG_CI_START="-0.14684793611101798" LOG_EFFECT_SIZE="-0.03810284951624106" MODIFIED="2013-12-18 10:13:58 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.4922430432146545" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.68674562776769">
<NAME>sleepiness/ sedation - long term</NAME>
<DICH_DATA CI_END="1.1766362852380943" CI_START="0.7131026722201161" EFFECT_SIZE="0.9160035366931919" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="104" LOG_CI_END="0.07064223707853591" LOG_CI_START="-0.14684793611101798" LOG_EFFECT_SIZE="-0.03810284951624106" MODIFIED="2013-12-11 15:24:42 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.12775480432526434" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.01632129002818658" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9532655177979212" CI_END="1.9095227868117306" CI_START="0.747196487822756" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.194482615915044" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-018.11" LOG_CI_END="0.2809248452846431" LOG_CI_START="-0.12656517816284177" LOG_EFFECT_SIZE="0.07717983356090065" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6208705398923753" P_Q="0.6209384172740477" P_Z="0.4578170889426759" Q="0.9530468772050016" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="321" TOTAL_2="396" WEIGHT="300.0" Z="0.7424461233792925">
<NAME>Other adverse events: 3. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-018.11.01" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>bradycardia - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:04 +0000" MODIFIED_BY="[Empty name]" ORDER="943" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9458974427165323" CI_START="0.7453327436768244" DF="0" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" I2="0.0" ID="CMP-018.11.02" LOG_CI_END="0.28911994732185203" LOG_CI_START="-0.12764979908935903" LOG_EFFECT_SIZE="0.0807350741162465" MODIFIED="2013-12-18 10:13:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4476409709442677" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.7593537626931671">
<NAME>faintness, dizziness, weakness - long term</NAME>
<DICH_DATA CI_END="1.9458974427165325" CI_START="0.7453327436768244" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.2891199473218521" LOG_CI_START="-0.12764979908935903" LOG_EFFECT_SIZE="0.0807350741162465" MODIFIED="2013-12-11 15:25:03 +0000" MODIFIED_BY="[Empty name]" ORDER="1772" O_E="0.0" SE="0.24481261208546248" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.05993321503610713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.11.03" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-01-14 16:45:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>hypotension - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:24:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1018" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7279163318947536" CI_END="2.1827871672515338" CI_START="0.3078505894245924" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8197391756082059" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-018.12" LOG_CI_END="0.3390113918729606" LOG_CI_START="-0.5116600105519442" LOG_EFFECT_SIZE="-0.08632430933949187" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.3935594476955583" P_Q="0.3976227886921081" P_Z="0.6907880254376209" Q="0.7155050721346448" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="60" WEIGHT="200.0" Z="0.3977858825708781">
<NAME>Other adverse events: 4. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0008335136944777" CI_START="0.25499576958333575" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-018.12.01" LOG_CI_END="0.30121095315801366" LOG_CI_START="-0.5934670245144897" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2014-01-14 16:45:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5220145904262905" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6402430689218759">
<NAME>headache - long term</NAME>
<DICH_DATA CI_END="2.0008335136944777" CI_START="0.25499576958333575" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.30121095315801366" LOG_CI_START="-0.5934670245144897" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-12-18 10:23:35 +0000" MODIFIED_BY="[Empty name]" ORDER="988" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.2761904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-018.12.02" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 16:45:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>hypertonia - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:23:35 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5472183391914138" CI_END="0.5990266734530534" CI_START="0.28058862553387853" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40997569557514474" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="92" I2="35.36788088211219" I2_Q="35.25360168561222" ID="CMP-018.13" LOG_CI_END="-0.22255383892026878" LOG_CI_START="-0.5519299383254624" LOG_EFFECT_SIZE="-0.38724188862286557" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.21354703428321287" P_Q="0.2139515585626992" P_Z="4.0540348330047325E-6" Q="1.5444874557258308" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7223638606887445" TOTALS="SUB" TOTAL_1="273" TOTAL_2="337" WEIGHT="200.0" Z="4.608592769036357">
<NAME>Other adverse events: 5. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-018.13.01" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:21:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>gastroenteritis - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:21:34 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5834824840209575" CI_START="0.27180454946865773" DF="0" EFFECT_SIZE="0.3982376095902666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="92" I2="0.0" ID="CMP-018.13.02" LOG_CI_END="-0.23397217682036517" LOG_CI_START="-0.5657432783150845" LOG_EFFECT_SIZE="-0.39985772756772486" MODIFIED="2014-01-14 16:45:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.308159504753016E-6" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="307" WEIGHT="100.0" Z="4.724382210758904">
<NAME>weight gain - long term</NAME>
<DICH_DATA CI_END="0.5834824840209575" CI_START="0.27180454946865773" EFFECT_SIZE="0.3982376095902666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="92" LOG_CI_END="-0.23397217682036517" LOG_CI_START="-0.5657432783150845" LOG_EFFECT_SIZE="-0.39985772756772486" MODIFIED="2013-12-11 15:25:13 +0000" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.1948839873114371" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="307" VAR="0.03797976851040438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.284759495351912" CI_END="3.538894383900818" CI_START="0.17043601368358618" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7766305760393973" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-018.14" LOG_CI_END="0.5488676015825484" LOG_CI_START="-0.7684386320371052" LOG_EFFECT_SIZE="-0.10978551522727835" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7327553374065567" P_Q="0.7327562029694992" P_Z="0.7439020559098897" Q="1.2847558565300046" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="120" WEIGHT="400.0" Z="0.32669040862030424">
<NAME>Other adverse events: 6. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.14.01" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:17:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>cellulitis - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:17:10 +0000" MODIFIED_BY="[Empty name]" ORDER="957" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-018.14.02" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:19:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>eczema - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:19:32 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.14.03" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:20:30 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>fungal dermatitis - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:20:30 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-018.14.04" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-14 16:45:14 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>rash - long term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:30:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1042" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10682583278065565" CI_END="1.1729270495996293" CI_START="0.6848605984796909" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8962653185088779" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-018.15" LOG_CI_END="0.0692710019351835" LOG_CI_START="-0.1643978189778388" LOG_EFFECT_SIZE="-0.04756340852132763" METHOD="MH" MODIFIED="2015-01-26 14:51:44 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.7437872636446952" P_Q="0.7444776898532424" P_Z="0.42492658544817996" Q="0.10623007280788667" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="522" TOTAL_2="672" WEIGHT="200.0" Z="0.7979033515855126">
<NAME>Other adverse events: 7. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.192975131071497" CI_START="0.6871369660950812" DF="0" EFFECT_SIZE="0.905393457117595" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="91" I2="0.0" ID="CMP-018.15.01" LOG_CI_END="0.07663139040044027" LOG_CI_START="-0.16295668697172697" LOG_EFFECT_SIZE="-0.04316264828564336" MODIFIED="2013-12-11 15:26:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4800705958069347" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.706189031149662">
<NAME>diminished sexual desire - long term</NAME>
<DICH_DATA CI_END="1.192975131071497" CI_START="0.6871369660950812" EFFECT_SIZE="0.905393457117595" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="91" LOG_CI_END="0.07663139040044027" LOG_CI_START="-0.16295668697172697" LOG_EFFECT_SIZE="-0.04316264828564336" MODIFIED="2013-12-11 15:26:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.14073522262852126" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.01980640288829944" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4862041889115387" CI_START="0.21766301915782665" DF="0" EFFECT_SIZE="0.735632183908046" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-018.15.02" LOG_CI_END="0.3955367938454227" LOG_CI_START="-0.6622153511148855" LOG_EFFECT_SIZE="-0.13333927863473136" MODIFIED="2015-01-26 14:51:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6212054942090821" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.4941425741253049">
<NAME>galactorrhea/ gynaecomastia - long term</NAME>
<DICH_DATA CI_END="2.4862041889115387" CI_START="0.21766301915782665" EFFECT_SIZE="0.735632183908046" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3955367938454227" LOG_CI_START="-0.6622153511148855" LOG_EFFECT_SIZE="-0.13333927863473136" MODIFIED="2013-12-11 15:26:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.6213288459072469" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.38604953475643133" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.536792236124162" CI_END="1.1381449472180425" CI_START="0.6494762504805447" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8597663129144755" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-018.16" LOG_CI_END="0.05619757468501243" LOG_CI_START="-0.18743672522810065" LOG_EFFECT_SIZE="-0.06561957527154409" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.47230615290041533" P_Q="0.4781083667296605" P_Z="0.29106915218347995" Q="3.4984877612591525" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="843" TOTAL_2="1068" WEIGHT="500.0" Z="1.0557791268217025">
<NAME>Other adverse events: 8. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.16.01" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:07:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>allergic reaction - long term</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-18 10:07:51 +0000" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-018.16.02" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>back pain - long term</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-18 10:13:17 +0000" MODIFIED_BY="[Empty name]" ORDER="942" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.065721713497053" CI_START="0.1727870604690805" DF="0" EFFECT_SIZE="0.4291187739463601" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-018.16.03" LOG_CI_END="0.027643814380233483" LOG_CI_START="-0.7624887837164321" LOG_EFFECT_SIZE="-0.3674224846680994" MODIFIED="2013-12-18 10:13:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.06833062464841888" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="1.8228202172506567">
<NAME>incontinence nocturia - long term</NAME>
<DICH_DATA CI_END="1.065721713497053" CI_START="0.1727870604690805" EFFECT_SIZE="0.42911877394636017" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" LOG_CI_END="0.027643814380233483" LOG_CI_START="-0.7624887837164321" LOG_EFFECT_SIZE="-0.36742248466809935" MODIFIED="2013-12-11 15:32:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.46412779934142134" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.21541461412151067" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.060007367172436" CI_START="0.05868571423470045" DF="0" EFFECT_SIZE="0.6436781609195402" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-018.16.04" LOG_CI_END="0.8488051542416999" LOG_CI_START="-1.231467605466536" LOG_EFFECT_SIZE="-0.1913312256124181" MODIFIED="2013-12-18 10:13:20 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7184494306937799" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="99.99999999999999" Z="0.360531867341129">
<NAME>suicide attempt - long term</NAME>
<DICH_DATA CI_END="7.060007367172436" CI_START="0.05868571423470045" EFFECT_SIZE="0.6436781609195402" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8488051542416999" LOG_CI_START="-1.231467605466536" LOG_EFFECT_SIZE="-0.1913312256124181" MODIFIED="2013-12-11 15:28:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="1.2219625165688546" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="1.4931923918992884" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.253545124958359" CI_START="0.6882608977254372" DF="0" EFFECT_SIZE="0.9288520296813618" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="79" I2="0.0" ID="CMP-018.16.05" LOG_CI_END="0.09813997225328808" LOG_CI_START="-0.16224690338606199" LOG_EFFECT_SIZE="-0.032053465566386954" MODIFIED="2013-12-18 10:13:20 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6294218649939286" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.00000000000001" Z="0.4825407420059631">
<NAME>urinary hesitancy, dry mouth, constipation - long term</NAME>
<DICH_DATA CI_END="1.253545124958359" CI_START="0.6882608977254372" EFFECT_SIZE="0.9288520296813618" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="79" LOG_CI_END="0.09813997225328808" LOG_CI_START="-0.16224690338606199" LOG_EFFECT_SIZE="-0.032053465566386954" MODIFIED="2013-12-11 15:28:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.15295253968637632" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.02339447939651252" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.877464506484897" CI_START="0.7249730188825066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-018.17" LOG_CI_END="0.2735717354053891" LOG_CI_START="-0.13967815614416265" LOG_EFFECT_SIZE="0.06694678963061322" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.5254080409569855" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.6350312449669356">
<NAME>Other adverse events: 9. any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.877464506484897" CI_START="0.7249730188825066" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" ID="CMP-018.17.01" LOG_CI_END="0.2735717354053891" LOG_CI_START="-0.13967815614416265" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-12-11 15:32:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5254080409569855" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="0.6350312449669356">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.877464506484897" CI_START="0.7249730188825066" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.2735717354053891" LOG_CI_START="-0.13967815614416265" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-12-11 15:32:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.24274503191616117" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" VAR="0.05892515051997811" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.18" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Other adverse events: 10. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-018.18.01" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:14:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>anemia - long term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-18 10:14:14 +0000" MODIFIED_BY="[Empty name]" ORDER="939" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Naukkarinen-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="92.79660878283704" CI_END="-0.16687787741682897" CI_START="-0.5856833606623775" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.37628061903960325" ESTIMABLE="YES" I2="94.61187206560425" I2_Q="94.61187206560425" ID="CMP-018.19" MODIFIED="2014-01-14 16:46:08 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="-4.440892098500626E-16" P_Q="-4.440892098500626E-16" P_Z="4.284584355642187E-4" Q="92.79660878283704" RANDOM="YES" SCALE="70.91152127338229" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="48.123418447601914" TOTALS="SUB" TOTAL_1="1566" TOTAL_2="2016" UNITS="" WEIGHT="600.0" Z="3.521904516066996">
<NAME>Other adverse events: 11a. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.61495816629437" CI_START="-14.18504183370563" DF="0" EFFECT_SIZE="-11.4" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.01" MODIFIED="2013-12-11 15:41:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0343540120468105E-15" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="8.022712317404373">
<NAME>mean weight change (lb) - long term</NAME>
<CONT_DATA CI_END="-8.61495816629437" CI_START="-14.18504183370563" EFFECT_SIZE="-11.4" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="9.4" MODIFIED="2013-12-11 15:41:27 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="17.77" SD_2="16.49" SE="1.4209658216547265" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.0563924399220097" CI_START="-16.54360756007799" DF="0" EFFECT_SIZE="-9.8" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.02" MODIFIED="2013-12-11 15:41:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.004395695958532324" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="2.848274736833944">
<NAME>change in blood glucose - long term</NAME>
<CONT_DATA CI_END="-3.056392439922009" CI_START="-16.543607560077994" EFFECT_SIZE="-9.8" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="15.0" MODIFIED="2013-12-11 15:41:51 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="32.31" SD_2="51.32" SE="3.4406793253706227" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09949041165169656" CI_START="-0.5205095883483033" DF="0" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.03" MODIFIED="2013-12-11 15:41:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0038982976408517295" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="2.886276297315811">
<NAME>change in glycosylated haemoglobin - long term</NAME>
<CONT_DATA CI_END="-0.09949041165169656" CI_START="-0.5205095883483033" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.41" MODIFIED="2013-12-11 15:41:57 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="0.96" SD_2="1.64" SE="0.10740482478697372" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.0966732111825923" CI_START="-15.303326788817406" DF="0" EFFECT_SIZE="-9.2" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.04" MODIFIED="2013-12-11 15:42:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0031327766508709937" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="2.9543999988344636">
<NAME>change in cholesterol - long term</NAME>
<CONT_DATA CI_END="-3.0966732111825923" CI_START="-15.303326788817406" EFFECT_SIZE="-9.2" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="9.7" MODIFIED="2013-12-11 15:42:04 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="37.15" SD_2="38.49" SE="3.1139994596633764" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.688971701877488" CI_START="-62.5110282981225" DF="0" EFFECT_SIZE="-34.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.05" MODIFIED="2013-12-11 15:42:09 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.015112328193851719" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="2.42967593815408">
<NAME>change in triglycerides - long term</NAME>
<CONT_DATA CI_END="-6.688971701877488" CI_START="-62.5110282981225" EFFECT_SIZE="-34.599999999999994" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="42.9" MODIFIED="2013-12-11 15:42:09 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="185.78" SD_2="153.97" SE="14.240582234306924" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.577598287528915" CI_START="2.4224017124710846" DF="0" EFFECT_SIZE="6.5" ESTIMABLE="YES" I2="0.0" ID="CMP-018.19.06" MODIFIED="2013-12-11 15:42:18 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.0017820998506542598" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0" Z="3.124330795035437">
<NAME>change in prolactin - long term</NAME>
<CONT_DATA CI_END="10.577598287528915" CI_START="2.4224017124710846" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-6.1" MODIFIED="2013-12-11 15:42:18 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="27.46" SD_2="21.99" SE="2.0804455182301766" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="336" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-018.20" MODIFIED="2014-02-18 14:51:31 +0000" MODIFIED_BY="[Empty name]" NO="20" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Other adverse events: 11b. lab data (skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>
<B>Mean</B>
</P>
</TH>
<TH>
<P>
<B>SD</B>
</P>
</TH>
<TH>
<P>
<B>N</B>
</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-018.20.01" MODIFIED="2013-12-18 10:45:07 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>weight change</NAME>
<OTHER_DATA MODIFIED="2013-12-18 10:45:07 +0000" MODIFIED_BY="[Empty name]" ORDER="3267" STUDY_ID="STD-Naukkarinen-2000">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>0.37</P>
</TD>
<TD>
<P>3.19</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Olanzapine </P>
</TD>
<TD>
<P>2.63</P>
</TD>
<TD>
<P>4.97</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2014-02-18 14:56:00 +0000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>PERPHENAZINE vs PENFLURIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1881320269778861" CI_START="0.20100101978627322" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.07486470276812608" LOG_CI_START="-0.6968017391644481" LOG_EFFECT_SIZE="-0.310968518198161" METHOD="MH" MODIFIED="2014-02-18 14:55:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.11418368754141797" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="1.5796646397315777">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1881320269778861" CI_START="0.20100101978627322" DF="0" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-019.01.01" LOG_CI_END="0.07486470276812608" LOG_CI_START="-0.6968017391644481" LOG_EFFECT_SIZE="-0.310968518198161" MODIFIED="2013-12-06 10:44:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11418368754141797" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="1.5796646397315777">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.188132026977886" CI_START="0.20100101978627324" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.074864702768126" LOG_CI_START="-0.696801739164448" LOG_EFFECT_SIZE="-0.310968518198161" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24514" O_E="0.0" SE="0.4532806878016867" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.20546338193397015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3148084479691893" CI_START="0.6404553650899624" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9176470588235294" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="0.1188624858679191" LOG_CI_START="-0.19351113191554384" LOG_EFFECT_SIZE="-0.03732432302381235" METHOD="MH" MODIFIED="2014-02-18 14:56:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6395149233416774" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.4683771273201558">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3148084479691893" CI_START="0.6404553650899624" DF="0" EFFECT_SIZE="0.9176470588235294" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" I2="0.0" ID="CMP-019.02.01" LOG_CI_END="0.1188624858679191" LOG_CI_START="-0.19351113191554384" LOG_EFFECT_SIZE="-0.03732432302381235" MODIFIED="2013-12-06 10:44:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6395149233416774" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.4683771273201558">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.3148084479691893" CI_START="0.6404553650899624" EFFECT_SIZE="0.9176470588235294" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.1188624858679191" LOG_CI_START="-0.19351113191554384" LOG_EFFECT_SIZE="-0.03732432302381235" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24547" O_E="0.0" SE="0.18348980936035214" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.03366851013909837" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.101429191197171" CI_END="1.247507905101039" CI_START="0.7213804032039135" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9486452211347807" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="61" I2="35.51360109472667" I2_Q="32.76536923584443" ID="CMP-019.03" LOG_CI_END="0.09604330630415109" LOG_CI_START="-0.14183565976648146" LOG_EFFECT_SIZE="-0.022896176731165188" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21209645363253582" P_Q="0.2259755471515983" P_Z="0.7059518298564842" Q="2.974657519895609" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.041695971618234774" TOTALS="SUB" TOTAL_1="153" TOTAL_2="162" WEIGHT="300.0" Z="0.3772984431370281">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1123540847331723" CI_START="0.3936988517973635" DF="0" EFFECT_SIZE="0.6617647058823529" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="0.0" ID="CMP-019.03.01" LOG_CI_END="0.04624305394386099" LOG_CI_START="-0.4048358518056462" LOG_EFFECT_SIZE="-0.17929639893089266" MODIFIED="2013-12-06 10:44:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11920800733848019" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="1.5581064863956315">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="1.1123540847331723" CI_START="0.3936988517973635" EFFECT_SIZE="0.6617647058823529" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="0.04624305394386099" LOG_CI_START="-0.4048358518056462" LOG_EFFECT_SIZE="-0.17929639893089266" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24566" O_E="0.0" SE="0.26496598211385536" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.07020697167755992" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.047090436051094" CI_START="0.33129981953791654" DF="0" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-019.03.02" LOG_CI_END="0.3111370292821347" LOG_CI_START="-0.4797788006822066" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2013-12-06 10:46:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.676012770604468" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.4179102070166934">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="2.047090436051094" CI_START="0.3312998195379166" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3111370292821347" LOG_CI_START="-0.4797788006822065" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24581" O_E="0.0" SE="0.4645878736175542" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.21584189231248055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6012747017033164" CI_START="0.8037255450418659" DF="0" EFFECT_SIZE="1.134453781512605" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" I2="0.0" ID="CMP-019.03.03" LOG_CI_END="0.20446584235036858" LOG_CI_START="-0.09489222814541794" LOG_EFFECT_SIZE="0.05478680710247535" MODIFIED="2013-12-06 10:46:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.47312555749270024" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.717402865210586">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.6012747017033164" CI_START="0.8037255450418659" EFFECT_SIZE="1.134453781512605" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" LOG_CI_END="0.20446584235036858" LOG_CI_START="-0.09489222814541794" LOG_EFFECT_SIZE="0.05478680710247535" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24596" O_E="0.0" SE="0.17584441245557286" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.030921257391845633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.043476193620842235" CI_END="2.771254865617756" CI_START="0.5878423270396651" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2763467040834695" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-019.04" LOG_CI_END="0.44267646863371735" LOG_CI_START="-0.23073914616755362" LOG_EFFECT_SIZE="0.1059686612330818" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8348313273870807" P_Q="0.8350761662422794" P_Z="0.5373404342342122" Q="0.0433455168979012" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="108" WEIGHT="200.0" Z="0.6168397493071445">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.23837088439895" CI_START="0.1548839213050464" DF="0" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-019.04.01" LOG_CI_END="0.8596408320080515" LOG_CI_START="-0.8099936645579873" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:46:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9535254255748178" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.05828021662027665">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="7.2383708843989485" CI_START="0.15488392130504644" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8596408320080514" LOG_CI_START="-0.8099936645579872" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24617" O_E="0.0" SE="0.9807515681069424" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.9618736383442266" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0881509570563295" CI_START="0.5672423816599961" DF="0" EFFECT_SIZE="1.3235294117647058" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-019.04.02" LOG_CI_END="0.4896985216553348" LOG_CI_START="-0.24623132818915763" LOG_EFFECT_SIZE="0.12173359673308855" MODIFIED="2013-12-06 10:46:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5167174739163933" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.6484136099542449">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="3.0881509570563295" CI_START="0.5672423816599961" EFFECT_SIZE="1.3235294117647058" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4896985216553348" LOG_CI_START="-0.24623132818915763" LOG_EFFECT_SIZE="0.12173359673308855" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24625" O_E="0.0" SE="0.4322888367101637" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.18687363834422657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.937297237688412E-4" CI_END="1.413722192824292" CI_START="0.6654842161238038" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9699535067767419" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-019.05" LOG_CI_END="0.15036407567233698" LOG_CI_START="-0.17686224061248515" LOG_EFFECT_SIZE="-0.013249082470074074" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9789871486873076" P_Q="0.9791632684722674" P_Z="0.8738940839410425" Q="6.821467942080796E-4" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="108" WEIGHT="200.0" Z="0.15871415700529098">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.938794663718921" CI_START="0.4927097304986385" DF="0" EFFECT_SIZE="0.9773755656108597" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-019.05.01" LOG_CI_END="0.28753181571308195" LOG_CI_START="-0.3074088607814416" LOG_EFFECT_SIZE="-0.009938522534179813" MODIFIED="2013-12-06 10:46:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9477897194916163" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.06548265061083444">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="1.938794663718921" CI_START="0.4927097304986385" EFFECT_SIZE="0.9773755656108597" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.28753181571308195" LOG_CI_START="-0.3074088607814416" LOG_EFFECT_SIZE="-0.009938522534179813" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24631" O_E="0.0" SE="0.3494710983767282" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.12213004860063684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5178282654189783" CI_START="0.6157542935236369" DF="0" EFFECT_SIZE="0.9667519181585678" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-019.05.02" LOG_CI_END="0.18122263611802777" LOG_CI_START="-0.2105925512353107" LOG_EFFECT_SIZE="-0.014684957558641477" MODIFIED="2013-12-06 10:47:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8831982104317737" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.14691614239792586">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.5178282654189783" CI_START="0.6157542935236369" EFFECT_SIZE="0.9667519181585678" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18122263611802777" LOG_CI_START="-0.2105925512353107" LOG_EFFECT_SIZE="-0.014684957558641477" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24643" O_E="0.0" SE="0.23015418056780854" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.05297094683283941" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.110576750263503" CI_END="1.1253709892366177" CI_START="0.4390782683055204" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7029409257934016" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" I2="51.34502719425461" I2_Q="45.7163212425494" ID="CMP-019.06" LOG_CI_END="0.05129571535249677" LOG_CI_START="-0.35745805728994523" LOG_EFFECT_SIZE="-0.15308117096872423" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1280561830449437" P_Q="0.15847256077296235" P_Z="0.1420931750131252" Q="3.6843486767659313" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3315508972377901" TOTALS="SUB" TOTAL_1="153" TOTAL_2="162" WEIGHT="300.0" Z="1.468040673338924">
<NAME>Other adverse events: 3. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6513453735745025" CI_START="0.1697263462229644" DF="0" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-019.06.01" LOG_CI_END="0.21783791405694483" LOG_CI_START="-0.770250737934843" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27318329513243367" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="99.99999999999999" Z="1.095761232776254">
<NAME>angina pectoris - short term</NAME>
<DICH_DATA CI_END="1.6513453735745025" CI_START="0.1697263462229644" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21783791405694483" LOG_CI_START="-0.770250737934843" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24667" O_E="0.0" SE="0.5804081652976865" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.33687363834422657" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4456037308157093" CI_START="0.49633840534858287" DF="0" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-019.06.02" LOG_CI_END="0.16004926038200157" LOG_CI_START="-0.30422211894805007" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2013-12-06 10:47:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.542763833697455" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.6086388757054093">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="1.4456037308157093" CI_START="0.49633840534858287" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.16004926038200157" LOG_CI_START="-0.30422211894805007" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24672" O_E="0.0" SE="0.2727153063988646" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.07437363834422658" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8959793459734955" CI_START="0.01544771150364936" DF="0" EFFECT_SIZE="0.11764705882352941" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-019.06.03" LOG_CI_END="-0.04770200153556025" LOG_CI_START="-1.811135849893025" LOG_EFFECT_SIZE="-0.9294189257142927" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03882843079817272" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="2.0660005167153406">
<NAME>palpitations - short term</NAME>
<DICH_DATA CI_END="0.8959793459734955" CI_START="0.01544771150364936" EFFECT_SIZE="0.11764705882352941" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.04770200153556025" LOG_CI_START="-1.811135849893025" LOG_EFFECT_SIZE="-0.9294189257142927" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24676" O_E="0.0" SE="1.035849771663506" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.0729847494553377" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10225170132879093" CI_END="1.5949492771771958" CI_START="0.3655963244865364" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7636148201013655" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-019.07" LOG_CI_END="0.20274687611274486" LOG_CI_START="-0.4369981790849221" LOG_EFFECT_SIZE="-0.1171256514860886" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7491440844035728" P_Q="0.7499226322119064" P_Z="0.47296244529988396" Q="0.10159609133216144" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="108" WEIGHT="200.0" Z="0.7176673167332085">
<NAME>Other adverse events: 4. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.723554801119091" CI_START="0.3658849935962485" DF="0" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" ID="CMP-019.07.01" LOG_CI_END="0.2364250965314668" LOG_CI_START="-0.4366554022980026" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2013-12-06 10:47:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5598550407610008" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.5830568388154739">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="1.723554801119091" CI_START="0.3658849935962485" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2364250965314668" LOG_CI_START="-0.4366554022980026" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24692" O_E="0.0" SE="0.39537081681463415" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.15631808278867101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.661924390573287" CI_START="0.049502041580710296" DF="0" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-019.07.02" LOG_CI_END="0.7529640654925155" LOG_CI_START="-1.3053768893704134" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2013-12-06 10:47:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5988808176869693" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="99.99999999999999" Z="0.5260106382476606">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="5.661924390573287" CI_START="0.049502041580710296" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7529640654925155" LOG_CI_START="-1.3053768893704134" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24699" O_E="0.0" SE="1.2090796658385363" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.4618736383442266" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9476139608733747" CI_END="1.5745068735281387" CI_START="0.6711069483840075" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0279409044799772" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-019.08" LOG_CI_END="0.19714456089433216" LOG_CI_START="-0.17320826464189476" LOG_EFFECT_SIZE="0.011968148126218704" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6226274616308018" P_Q="0.6226278801165448" P_Z="0.8991979874530616" Q="0.9476126166150469" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="153" TOTAL_2="162" WEIGHT="300.0" Z="0.1266745528676123">
<NAME>Other adverse events: 5. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8568388370093993" CI_START="0.6632055178374009" DF="0" EFFECT_SIZE="1.3764705882352941" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-019.08.01" LOG_CI_END="0.4558857411976872" LOG_CI_START="-0.17835186913394935" LOG_EFFECT_SIZE="0.1387669360318689" MODIFIED="2013-12-06 10:48:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.39108358221589623" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.8576539531461148">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="2.8568388370093993" CI_START="0.6632055178374009" EFFECT_SIZE="1.3764705882352941" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4558857411976872" LOG_CI_START="-0.17835186913394935" LOG_EFFECT_SIZE="0.1387669360318689" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24715" O_E="0.0" SE="0.37255431183560805" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.1387967152673035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3375024571490626E-31" CI_END="1.7724691599176847" CI_START="0.4647023843093167" DF="0" EFFECT_SIZE="0.907563025210084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="100.0" ID="CMP-019.08.02" LOG_CI_END="0.24857868741273917" LOG_CI_START="-0.33282509922390124" LOG_EFFECT_SIZE="-0.04212320590558106" MODIFIED="2013-12-06 10:48:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.7764087233879213" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.28400216299210745">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="1.7724691599176847" CI_START="0.4647023843093167" EFFECT_SIZE="0.907563025210084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.24857868741273917" LOG_CI_START="-0.33282509922390124" LOG_EFFECT_SIZE="-0.04212320590558106" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24725" O_E="0.0" SE="0.3415194622655221" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.11663554310613136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.976416612516051" CI_START="0.3630351242623974" DF="0" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-019.08.03" LOG_CI_END="0.295878495639222" LOG_CI_START="-0.44005135420527053" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2013-12-06 10:48:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7010020676344242" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.38396813282862785">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="1.976416612516051" CI_START="0.3630351242623974" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.295878495639222" LOG_CI_START="-0.44005135420527053" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24732" O_E="0.0" SE="0.4322888367101637" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.18687363834422657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6648511893410891" CI_END="3.863388625856925" CI_START="0.26624844149168975" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0142096432745684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-019.09" LOG_CI_END="0.5869683968779408" LOG_CI_START="-0.5747129257261266" LOG_EFFECT_SIZE="0.00612773557590711" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7171820956330333" P_Q="0.7185951567650275" P_Z="0.9835031809096526" Q="0.6609144663814325" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="153" TOTAL_2="162" WEIGHT="300.0" Z="0.02067716989482159">
<NAME>Other adverse events: 6. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.15558495228966" CI_START="0.1322085197831653" DF="0" EFFECT_SIZE="3.173076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.09.01" LOG_CI_END="1.8817017582960938" LOG_CI_START="-0.8787405571378796" LOG_EFFECT_SIZE="0.5014806005791071" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.47639010543338767" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.00000000000001" Z="0.7121205979093574">
<NAME>oedema</NAME>
<DICH_DATA CI_END="76.15558495228966" CI_START="0.1322085197831653" EFFECT_SIZE="3.173076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8817017582960938" LOG_CI_START="-0.8787405571378796" LOG_EFFECT_SIZE="0.5014806005791071" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24753" O_E="0.0" SE="1.6214974804957543" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="2.6292540792540793" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4875689206635274E-32" CI_END="4.05308776088479" CI_START="0.12293587644522143" DF="0" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" ID="CMP-019.09.02" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.6960999125842287" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.39059055025734335">
<NAME>pruritus - short term</NAME>
<DICH_DATA CI_END="4.05308776088479" CI_START="0.12293587644522143" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24762" O_E="0.0" SE="0.8917437814067222" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.7952069716775598" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.484477848028508" CI_START="0.06800987430548595" DF="0" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-019.09.03" LOG_CI_END="1.2170751952576753" LOG_CI_START="-1.1674280278076108" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:48:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9674490108706681" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.040807938188260146">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="16.484477848028508" CI_START="0.06800987430548595" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2170751952576753" LOG_CI_START="-1.1674280278076108" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24759" O_E="0.0" SE="1.4006689967098673" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="1.9618736383442266" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.23837088439895" CI_START="0.1548839213050464" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-019.10" LOG_CI_END="0.8596408320080515" LOG_CI_START="-0.8099936645579873" LOG_EFFECT_SIZE="0.024823583725032145" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9535254255748178" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="153" TOTAL_2="162" WEIGHT="100.0" Z="0.05828021662027665">
<NAME>Other adverse events: 7. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>diminished sexual desire</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24740" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>increased sexual desire - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24745" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.23837088439895" CI_START="0.1548839213050464" DF="0" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-019.10.03" LOG_CI_END="0.8596408320080515" LOG_CI_START="-0.8099936645579873" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:48:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9535254255748178" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.05828021662027665">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="7.2383708843989485" CI_START="0.15488392130504644" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8596408320080514" LOG_CI_START="-0.8099936645579872" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24750" O_E="0.0" SE="0.9807515681069424" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.9618736383442266" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4875689206635274E-32" CI_END="4.05308776088479" CI_START="0.12293587644522143" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" I2_Q="0.0" ID="CMP-019.11" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" METHOD="MH" MODIFIED="2014-01-14 16:46:59 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="0.6960999125842287" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.39059055025734335">
<NAME>Other adverse events: 8. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Penfluridol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours penfluridol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4875689206635274E-32" CI_END="4.05308776088479" CI_START="0.12293587644522143" DF="0" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" ID="CMP-019.11.01" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:49:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6960999125842287" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0" Z="0.39059055025734335">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="4.05308776088479" CI_START="0.12293587644522143" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24775" O_E="0.0" SE="0.8917437814067222" STUDY_ID="STD-Itoh-1976" TOTAL_1="51" TOTAL_2="54" VAR="0.7952069716775598" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2014-02-21 16:10:01 +0000" MODIFIED_BY="[Empty name]" NO="20">
<NAME>PERPHENAZINE vs PROCHLORPERAZINE</NAME>
<DICH_OUTCOME CHI2="9.865174767812363" CI_END="2.1889361339763114" CI_START="0.3668730495019597" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8961370847347628" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" I2="89.86333214021961" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.3402330904549587" LOG_CI_START="-0.43548419034946917" LOG_EFFECT_SIZE="-0.04762554994725525" METHOD="MH" MODIFIED="2014-01-14 16:48:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016843734251779097" P_Q="1.0" P_Z="0.80981404256343" Q="0.0" RANDOM="YES" SCALE="3.7563299552981384" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3739602706190363" TOTALS="YES" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0" Z="0.24066593577426712">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Prochlorperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prochlorperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.865174767812363" CI_END="2.1889361339763114" CI_START="0.3668730495019597" DF="1" EFFECT_SIZE="0.8961370847347628" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" I2="89.86333214021961" ID="CMP-020.01.01" LOG_CI_END="0.3402330904549587" LOG_CI_START="-0.43548419034946917" LOG_EFFECT_SIZE="-0.04762554994725525" MODIFIED="2013-12-10 16:38:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016843734251779097" P_Z="0.80981404256343" STUDIES="3" TAU2="0.3739602706190363" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0" Z="0.24066593577426712">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:35:29 +0000" MODIFIED_BY="[Empty name]" ORDER="24504" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9450808637632074" CI_START="0.3576830955962458" EFFECT_SIZE="0.5814116002795248" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" LOG_CI_END="-0.02453103044980844" LOG_CI_START="-0.44650158448829647" LOG_EFFECT_SIZE="-0.23551630746905244" MODIFIED="2013-12-09 16:52:57 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2478675922301379" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.06143834327796592" WEIGHT="47.68646119914077"/>
<DICH_DATA CI_END="1.7886887545475652" CI_START="0.9880027603345711" EFFECT_SIZE="1.3293718166383701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.2525347765973775" LOG_CI_START="-0.00524184205569393" LOG_EFFECT_SIZE="0.12364646727084176" MODIFIED="2013-12-10 16:38:39 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.1514192618116558" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.022927792847586767" WEIGHT="52.313538800859234"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.031118316014443512" CI_END="7.047529697076946" CI_START="0.797854765324103" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3712665713866867" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.8480369145896808" LOG_CI_START="-0.098076156717889" LOG_EFFECT_SIZE="0.37498037893589586" METHOD="MH" MODIFIED="2014-01-14 16:48:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8599767252182111" P_Q="1.0" P_Z="0.12027612375485949" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="81" WEIGHT="100.0" Z="1.553615651050688">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Prochlorperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prochlorperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.031118316014443512" CI_END="7.047529697076946" CI_START="0.797854765324103" DF="1" EFFECT_SIZE="2.3712665713866867" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-020.02.01" LOG_CI_END="0.8480369145896808" LOG_CI_START="-0.098076156717889" LOG_EFFECT_SIZE="0.37498037893589586" MODIFIED="2013-12-10 16:37:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8599767252182111" P_Z="0.12027612375485949" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="81" WEIGHT="100.0" Z="1.553615651050688">
<NAME>short term</NAME>
<DICH_DATA CI_END="20.986387438410016" CI_START="0.18347515070794534" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3219376862912349" LOG_CI_START="-0.736422746895252" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2013-12-09 16:53:44 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="1.2090911075022135" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="1.461901306240929" WEIGHT="21.12726283323595"/>
<DICH_DATA CI_END="8.50480636820959" CI_START="0.731721207423057" EFFECT_SIZE="2.4946236559139785" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9296644303324352" LOG_CI_START="-0.13565435765850595" LOG_EFFECT_SIZE="0.39700503633696455" MODIFIED="2013-12-10 16:37:54 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.6257735294789278" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.3915925101965146" WEIGHT="78.87273716676405"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8714886537916011" CI_START="0.23857742028959789" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6682027649769585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.2721871984765506" LOG_CI_START="-0.6223706617036597" LOG_EFFECT_SIZE="-0.17509173161355462" METHOD="MH" MODIFIED="2014-01-14 16:48:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.44293458591763557" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.7672471580187946">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Prochlorperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prochlorperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8714886537916011" CI_START="0.23857742028959789" DF="0" EFFECT_SIZE="0.6682027649769585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-020.03.01" LOG_CI_END="0.2721871984765506" LOG_CI_START="-0.6223706617036597" LOG_EFFECT_SIZE="-0.17509173161355462" MODIFIED="2013-12-10 16:29:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44293458591763557" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.7672471580187946">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.8714886537916011" CI_START="0.23857742028959789" EFFECT_SIZE="0.6682027649769585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2721871984765506" LOG_CI_START="-0.6223706617036597" LOG_EFFECT_SIZE="-0.17509173161355462" MODIFIED="2013-12-10 16:29:09 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.5254677152026794" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.2761163197203242" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2632845657389935" CI_END="4.062734084474482" CI_START="0.853852797694038" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8625189567667393" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-020.04" LOG_CI_END="0.6088183976587508" LOG_CI_START="-0.06861699425186966" LOG_EFFECT_SIZE="0.2701007017034405" METHOD="MH" MODIFIED="2014-01-14 16:48:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.737869520508698" P_Q="0.7392282774368509" P_Z="0.11807211691060929" Q="1.257587217538414" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="208" WEIGHT="400.0" Z="1.5629170068740263">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Prochlorperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prochlorperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.377256469089136" CI_START="0.625614357695681" DF="0" EFFECT_SIZE="2.289308176100629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-020.04.01" LOG_CI_END="0.9231018115394722" LOG_CI_START="-0.2036932928822632" LOG_EFFECT_SIZE="0.3597042593286045" MODIFIED="2013-12-09 16:54:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21080692162728998" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.251349762886175">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="8.377256469089136" CI_START="0.625614357695681" EFFECT_SIZE="2.289308176100629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9231018115394722" LOG_CI_START="-0.2036932928822632" LOG_EFFECT_SIZE="0.3597042593286045" MODIFIED="2013-12-09 16:54:23 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="0.6618850220630507" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.43809178243140506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.852155200171944" CI_START="0.013631160616754972" DF="0" EFFECT_SIZE="0.3271604938271605" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-020.04.02" LOG_CI_END="0.8949888749717976" LOG_CI_START="-1.8654671648554813" LOG_EFFECT_SIZE="-0.4852391449418419" MODIFIED="2014-01-14 16:47:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49078946870631723" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.6890537173955709">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="7.852155200171944" CI_START="0.013631160616754972" EFFECT_SIZE="0.3271604938271605" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8949888749717976" LOG_CI_START="-1.8654671648554813" LOG_EFFECT_SIZE="-0.4852391449418419" MODIFIED="2013-12-09 16:54:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="1.6215055422723186" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="2.629280223619846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.986387438410016" CI_START="0.18347515070794534" DF="0" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-020.04.03" LOG_CI_END="1.3219376862912349" LOG_CI_START="-0.736422746895252" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2014-01-14 16:47:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5771685224490003" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.557525385313461">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="20.986387438410016" CI_START="0.18347515070794534" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3219376862912349" LOG_CI_START="-0.736422746895252" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2013-12-09 16:54:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.2090911075022135" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="1.461901306240929" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.12099582883438" CI_START="0.6290611373951638" DF="0" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-020.04.04" LOG_CI_END="0.7868220835483903" LOG_CI_START="-0.20130714415240764" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2014-01-14 16:47:40 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.24548961090179044" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.1613746071417332">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="6.12099582883438" CI_START="0.6290611373951638" EFFECT_SIZE="1.9622641509433962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7868220835483903" LOG_CI_START="-0.20130714415240764" LOG_EFFECT_SIZE="0.2927574696979913" MODIFIED="2013-12-09 16:54:13 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.580431999670012" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.3369013062409289" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2142036478624396" CI_START="0.05018107129322823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-020.05" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:48:07 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.25546651089494854" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="1.1371717552202147">
<NAME>Other adverse events: 1. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Prochlorperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prochlorperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2142036478624396" CI_START="0.05018107129322823" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-020.05.01" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:35:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25546651089494854" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="1.1371717552202147">
<NAME>electroencephalogram (increase) - short term</NAME>
<DICH_DATA CI_END="2.2142036478624396" CI_START="0.05018107129322823" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.34521756192462605" LOG_CI_START="-1.299460071363951" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:35:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24686" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.9333333333333333" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2015-01-26 14:51:25 +0000" MODIFIED_BY="[Empty name]" NO="21">
<NAME>PERPHENAZINE vs QUETIAPINE</NAME>
<DICH_OUTCOME CHI2="1.1407036290280004" CI_END="1.7476991979811387" CI_START="0.5547754068055549" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9846728053184612" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="278" I2="12.334810326490738" I2_Q="9.964684539892994" ID="CMP-021.01" LOG_CI_END="0.24246668693772327" LOG_CI_START="-0.2558827994469392" LOG_EFFECT_SIZE="-0.006708056254607964" METHOD="MH" MODIFIED="2014-01-14 10:05:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2855037388836099" P_Q="0.2919352372840648" P_Z="0.9579196495283293" Q="1.110675288790521" RANDOM="YES" SCALE="45.68045106834288" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0895400401681862" TOTALS="YES" TOTAL_1="293" TOTAL_2="369" WEIGHT="99.99999999999999" Z="0.052764371287631125">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.33325429307962" CI_START="0.32926924483626774" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-021.01.01" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-13 16:15:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3297879615190883" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="6.299195846741646" Z="0.9745410867786626">
<NAME>short term</NAME>
<DICH_DATA CI_END="27.33325429307962" CI_START="0.32926924483626774" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-13 16:15:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1343" O_E="0.0" SE="1.1273124382057236" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.2708333333333333" WEIGHT="6.299195846741646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9954032396381512" CI_START="0.8385565233605916" DF="0" EFFECT_SIZE="0.9136202055410322" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="277" I2="0.0" ID="CMP-021.01.02" LOG_CI_END="-0.0020009501354124807" LOG_CI_START="-0.07646765821441712" LOG_EFFECT_SIZE="-0.039234304174914816" MODIFIED="2014-01-13 16:15:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03889518981693549" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="93.70080415325835" Z="2.0652940119157295">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.9954032396381512" CI_START="0.8385565233605916" EFFECT_SIZE="0.9136202055410322" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="277" LOG_CI_END="-0.0020009501354124807" LOG_CI_START="-0.07646765821441712" LOG_EFFECT_SIZE="-0.039234304174914816" MODIFIED="2013-12-11 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.043742112941757304" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.0019133724446094517" WEIGHT="93.70080415325835"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5492025603899533" CI_START="0.7171308465657251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.054030807725389" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-021.02" LOG_CI_END="0.19010820607954304" LOG_CI_START="-0.1444015964145302" LOG_EFFECT_SIZE="0.02285330483250641" METHOD="MH" MODIFIED="2014-02-18 15:05:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7888496265971909" Q="0.0" RANDOM="YES" SCALE="3.9165823282937247" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.26780473436333063">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5492025603899533" CI_START="0.7171308465657251" DF="0" EFFECT_SIZE="1.054030807725389" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="49" I2="0.0" ID="CMP-021.02.01" LOG_CI_END="0.19010820607954304" LOG_CI_START="-0.1444015964145302" LOG_EFFECT_SIZE="0.02285330483250641" MODIFIED="2013-12-11 15:43:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7888496265971909" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.26780473436333063">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.5492025603899533" CI_START="0.7171308465657251" EFFECT_SIZE="1.054030807725389" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="49" LOG_CI_END="0.19010820607954304" LOG_CI_START="-0.1444015964145302" LOG_EFFECT_SIZE="0.02285330483250641" MODIFIED="2013-12-11 15:43:16 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1964927138352462" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.03860938659033995" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1990650715956308" CI_START="0.6940441426486178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9122522072297184" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.07884275229657627" LOG_CI_START="-0.1586129066358604" LOG_EFFECT_SIZE="-0.03988507716964204" METHOD="MH" MODIFIED="2014-02-18 15:05:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5102653844006864" Q="0.0" RANDOM="YES" SCALE="3.0748144957102723" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.6584245254423844">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1990650715956308" CI_START="0.6940441426486178" DF="0" EFFECT_SIZE="0.9122522072297184" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="92" I2="0.0" ID="CMP-021.03.01" LOG_CI_END="0.07884275229657627" LOG_CI_START="-0.1586129066358604" LOG_EFFECT_SIZE="-0.03988507716964204" MODIFIED="2013-12-11 15:43:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5102653844006864" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.6584245254423844">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1990650715956308" CI_START="0.6940441426486178" EFFECT_SIZE="0.9122522072297184" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="92" LOG_CI_END="0.07884275229657627" LOG_CI_START="-0.1586129066358604" LOG_EFFECT_SIZE="-0.03988507716964204" MODIFIED="2013-12-11 15:43:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.13948262948138204" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.01945540392704051" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.485807156947744" CI_START="0.32406858770568187" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="0.7392405367454522" LOG_CI_START="-0.48936306352885245" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2014-02-18 15:06:01 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6901702959034299" Q="0.0" RANDOM="YES" SCALE="47.22" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.3986239727305563">
<NAME>Mental state: 2a. State - BPRS score reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.485807156947744" CI_START="0.32406858770568187" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-021.04.01" LOG_CI_END="0.7392405367454522" LOG_CI_START="-0.48936306352885245" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-01-13 16:13:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6901702959034299" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.3986239727305563">
<NAME>less than 25% reduction - short term</NAME>
<DICH_DATA CI_END="5.485807156947744" CI_START="0.32406858770568187" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7392405367454522" LOG_CI_START="-0.48936306352885245" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-01-13 16:12:55 +0000" MODIFIED_BY="[Empty name]" ORDER="1334" O_E="0.0" SE="0.7216878364870322" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5208333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.455967714722556" CI_START="-1.2559677147225532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.05" MODIFIED="2015-01-14 16:42:09 +0000" MODIFIED_BY="Heather Maxwell" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.360135953280884" Q="0.0" RANDOM="YES" SCALE="10.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" UNITS="" WEIGHT="100.0" Z="0.9151060812596723">
<NAME>Mental state: 2b. State - BPRS total score (high = worse)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.455967714722556" CI_START="-1.2559677147225532" DF="0" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-021.05.01" MODIFIED="2014-01-14 10:15:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.360135953280884" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.9151060812596723">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.455967714722556" CI_START="-1.2559677147225532" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="24.92" MEAN_2="23.82" MODIFIED="2014-01-14 10:15:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1072" SD_1="4.98" SD_2="4.63" SE="1.2020464321314714" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.070623512506232" CI_END="2.178516734312566" CI_START="1.1599165692558455" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5896218596038114" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="60" I2="50.292542934642356" I2_Q="46.29745232587958" ID="CMP-021.06" LOG_CI_END="0.3381609003248793" LOG_CI_START="0.0644267523175372" LOG_EFFECT_SIZE="0.2012938263212082" METHOD="MH" MODIFIED="2014-01-14 10:15:37 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.06041181001954565" P_Q="0.08318480253462823" P_Z="0.003944479689980672" Q="11.172654296420719" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2445400205742506" TOTALS="SUB" TOTAL_1="849" TOTAL_2="967" WEIGHT="700.0" Z="2.8825680155129705">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.683260158384115" CI_START="0.9127612565897287" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-021.06.01" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:04:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.061186768182128155" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8721433920279957">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="53.683260158384115" CI_START="0.9127612565897287" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:04:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1056" O_E="0.0" SE="1.0394023007753748" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0803571428571428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3588445204107162E-31" CI_END="2.4782737986271193" CI_START="0.6462734402430388" DF="0" EFFECT_SIZE="1.2655601659751037" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="100.0" ID="CMP-021.06.02" LOG_CI_END="0.3941492853589099" LOG_CI_START="-0.18958369181507495" LOG_EFFECT_SIZE="0.10228279677191744" MODIFIED="2014-01-14 10:04:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.49217272748957286" STUDIES="1" TAU2="0.0" TOTAL_1="241" TOTAL_2="305" WEIGHT="100.0" Z="0.6868571958415723">
<NAME>akathisia - long term</NAME>
<DICH_DATA CI_END="2.4782737986271193" CI_START="0.6462734402430387" EFFECT_SIZE="1.2655601659751037" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3941492853589099" LOG_CI_START="-0.18958369181507503" LOG_EFFECT_SIZE="0.10228279677191744" MODIFIED="2013-12-11 15:43:42 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.3428876403168374" STUDY_ID="STD-CATIE-2005" TOTAL_1="241" TOTAL_2="305" VAR="0.11757193388204884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.212730613086821" CI_START="0.7314180865792383" DF="0" EFFECT_SIZE="1.5329218106995885" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-021.06.03" LOG_CI_END="0.5068743115600193" LOG_CI_START="-0.1358343045880202" LOG_EFFECT_SIZE="0.18552000348599948" MODIFIED="2014-01-14 10:04:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.25784455762749237" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="298" WEIGHT="100.0" Z="1.1315003910280579">
<NAME>EPS - long term</NAME>
<DICH_DATA CI_END="3.21273061308682" CI_START="0.7314180865792382" EFFECT_SIZE="1.5329218106995885" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.5068743115600192" LOG_CI_START="-0.1358343045880203" LOG_EFFECT_SIZE="0.18552000348599948" MODIFIED="2013-12-11 15:43:53 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.37753022258431823" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="298" VAR="0.14252906896456485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="191.0359474772963" CI_START="0.6333886454243398" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-021.06.04" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-01-14 10:10:26 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09967924600633656" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.6464106300728845">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="191.0359474772963" CI_START="0.6333886454243398" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-01-14 10:10:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1063" O_E="0.0" SE="1.4564381625088383" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="2.121212121212121" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.102617028153362" CI_START="0.8808304926739486" DF="0" EFFECT_SIZE="1.360900140646976" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="30" I2="0.0" ID="CMP-021.06.05" LOG_CI_END="0.32276017724845046" LOG_CI_START="-0.055107659328298884" LOG_EFFECT_SIZE="0.13382625896007577" MODIFIED="2014-01-14 10:10:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.16504943539090655" STUDIES="1" TAU2="0.0" TOTAL_1="237" TOTAL_2="236" WEIGHT="99.99999999999999" Z="1.3882877681451153">
<NAME>tardive dyskinesia - long term</NAME>
<DICH_DATA CI_END="2.102617028153362" CI_START="0.8808304926739486" EFFECT_SIZE="1.360900140646976" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="30" LOG_CI_END="0.32276017724845046" LOG_CI_START="-0.055107659328298884" LOG_EFFECT_SIZE="0.13382625896007577" MODIFIED="2013-12-11 15:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.22196143768114027" STUDY_ID="STD-CATIE-2005" TOTAL_1="237" TOTAL_2="236" VAR="0.049266879817478716" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="252.09458335193415" CI_START="0.8925221518381102" DF="0" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-021.06.06" LOG_CI_END="2.401563514277644" LOG_CI_START="-0.049380996166281346" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2014-01-14 10:11:07 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.05997378391758825" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8809862895378187">
<NAME>torsion dystonia - short term</NAME>
<DICH_DATA CI_END="252.09458335193415" CI_START="0.8925221518381102" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.401563514277644" LOG_CI_START="-0.049380996166281346" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2014-01-14 10:11:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1064" O_E="0.0" SE="1.4396969378057567" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="2.0727272727272728" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="86.93682317138818" CI_START="1.6563752245250192" DF="0" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" ID="CMP-021.06.07" LOG_CI_END="1.9392037662396384" LOG_CI_START="0.21915872585561133" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2014-01-14 10:10:53 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.013916180419219564" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.459419753999188">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="86.93682317138818" CI_START="1.6563752245250192" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9392037662396384" LOG_CI_START="0.21915872585561133" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2014-01-14 10:05:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1057" O_E="0.0" SE="1.0103629710818451" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0208333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1430075370657432" CI_END="10.612945912634018" CI_START="1.297131910067376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.710308720726176" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-021.07" LOG_CI_END="1.0258359509154213" LOG_CI_START="0.11298414331720798" LOG_EFFECT_SIZE="0.5694100471163146" METHOD="MH" MODIFIED="2014-01-14 10:15:36 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7053093583007075" P_Q="0.7056964253990448" P_Z="0.014479772603807652" Q="0.1426137431362399" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="64" WEIGHT="200.0" Z="2.44513550938696">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.21688159072022" CI_START="1.0537609811666153" DF="0" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-021.07.01" LOG_CI_END="1.2836829141430686" LOG_CI_START="0.02274211340761895" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2014-01-14 10:07:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04228917818153632" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.030663137403156">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="19.21688159072022" CI_START="1.0537609811666153" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2836829141430686" LOG_CI_START="0.02274211340761895" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2014-01-14 10:07:32 +0000" MODIFIED_BY="[Empty name]" ORDER="1059" O_E="0.0" SE="0.7406828681096325" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5486111111111112" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.763996126583722" CI_START="0.6538798701503148" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-021.07.02" LOG_CI_END="1.1387445417312558" LOG_CI_START="-0.18450203229193088" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:08:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1575372032790995" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.4134032067295021">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="13.763996126583722" CI_START="0.6538798701503148" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1387445417312558" LOG_CI_START="-0.18450203229193088" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:08:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1060" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.804177652492198" CI_END="1.2915987055296276" CI_START="0.8812794403135102" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0668923958482432" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="173" I2="37.5543492142983" I2_Q="37.53614803626564" ID="CMP-021.08" LOG_CI_END="0.11112760108527468" LOG_CI_START="-0.05488636157258703" LOG_EFFECT_SIZE="0.028120619756343824" METHOD="MH" MODIFIED="2014-01-14 10:15:36 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18671087777679263" P_Q="0.18682172232750138" P_Z="0.5066998275615239" Q="4.802777775763426" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.033426207837123134" TOTALS="SUB" TOTAL_1="586" TOTAL_2="738" WEIGHT="400.0" Z="0.6639851379123669">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.725968125983914" CI_START="0.11928294322890384" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-021.08.01" LOG_CI_END="0.571239135378122" LOG_CI_START="-0.9234216534894846" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-01-14 10:03:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.644210022006261" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.46182053923141886">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="3.725968125983914" CI_START="0.11928294322890384" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.571239135378122" LOG_CI_START="-0.9234216534894846" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-01-14 10:03:43 +0000" MODIFIED_BY="[Empty name]" ORDER="1055" O_E="0.0" SE="0.8779711460710615" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.7708333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.302622448212179" CI_START="0.1563434770991285" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-021.08.02" LOG_CI_END="0.36222273427339696" LOG_CI_START="-0.8059202335061098" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-01-14 10:03:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4566006167395694" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.7444560661779827">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="2.302622448212179" CI_START="0.1563434770991285" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36222273427339696" LOG_CI_START="-0.8059202335061098" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-01-14 10:03:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1054" O_E="0.0" SE="0.68617296167463" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.4708333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8677819741814337" CI_START="1.0114795330897384" DF="0" EFFECT_SIZE="1.374490174267705" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" I2="0.0" ID="CMP-021.08.03" LOG_CI_END="0.27132617974411627" LOG_CI_START="0.004957099409228784" LOG_EFFECT_SIZE="0.13814163957667247" MODIFIED="2014-01-14 10:03:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.04206127150450737" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="99.99999999999999" Z="2.0329134146890655">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="1.8677819741814337" CI_START="1.0114795330897381" EFFECT_SIZE="1.374490174267705" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.27132617974411627" LOG_CI_START="0.004957099409228689" LOG_EFFECT_SIZE="0.13814163957667247" MODIFIED="2013-12-11 15:44:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.15646651633692588" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.024481770734613488" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.192528757559101" CI_START="0.7216039741500584" DF="0" EFFECT_SIZE="0.927649443886471" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="103" I2="0.0" ID="CMP-021.08.04" LOG_CI_END="0.07646886075084476" LOG_CI_START="-0.14170108363312153" LOG_EFFECT_SIZE="-0.032616111441138365" MODIFIED="2014-01-14 10:03:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5578594390926153" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.5860239266309687">
<NAME>sleepiness/ sedation - long term</NAME>
<DICH_DATA CI_END="1.192528757559101" CI_START="0.7216039741500584" EFFECT_SIZE="0.927649443886471" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="103" LOG_CI_END="0.07646886075084476" LOG_CI_START="-0.14170108363312153" LOG_EFFECT_SIZE="-0.032616111441138365" MODIFIED="2013-12-11 15:44:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.12815410528978385" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.016423474702625007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.25287200487171" CI_END="1.5007242942023469" CI_START="0.6378861194654176" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9784125900744597" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="46" I2="52.97295574122666" I2_Q="52.590391459643605" ID="CMP-021.09" LOG_CI_END="0.17630091309292173" LOG_CI_START="-0.19525684808494068" LOG_EFFECT_SIZE="-0.009477967496009498" METHOD="MH" MODIFIED="2014-01-14 16:48:51 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.11926164682039431" P_Q="0.12132570096298678" P_Z="0.9203503642660034" Q="4.218554131906708" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5005641253060126" TOTALS="SUB" TOTAL_1="325" TOTAL_2="401" WEIGHT="300.0" Z="0.09999239353758209">
<NAME>Other adverse events: 3. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5538344295882753" CI_START="0.6248889562548448" DF="0" EFFECT_SIZE="0.9853801169590644" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="38" I2="0.0" ID="CMP-021.09.01" LOG_CI_END="0.1914047402389831" LOG_CI_START="-0.20419715060857585" LOG_EFFECT_SIZE="-0.006396205184796393" MODIFIED="2013-12-11 15:44:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9494650889001937" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.06337852315655404">
<NAME>faintness, dizziness, weakness - long term</NAME>
<DICH_DATA CI_END="1.5538344295882753" CI_START="0.6248889562548448" EFFECT_SIZE="0.9853801169590644" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="38" LOG_CI_END="0.1914047402389831" LOG_CI_START="-0.20419715060857585" LOG_EFFECT_SIZE="-0.006396205184796393" MODIFIED="2013-12-11 15:44:58 +0000" MODIFIED_BY="[Empty name]" ORDER="1772" O_E="0.0" SE="0.23237850894479828" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.05399977141940769" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3070303481526142" CI_START="0.021252588218046743" DF="0" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-021.09.02" LOG_CI_END="0.11628567165261806" LOG_CI_START="-1.6725881724199052" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2014-01-14 10:14:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08816659675843644" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.705149225956171">
<NAME>orthostatic hypotension - short term</NAME>
<DICH_DATA CI_END="1.3070303481526142" CI_START="0.021252588218046743" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11628567165261806" LOG_CI_START="-1.6725881724199052" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2014-01-14 10:14:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1071" O_E="0.0" SE="1.050793351076541" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.1041666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.955560443773642" CI_START="0.5227693029861222" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-021.09.03" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 10:14:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2511308465779948" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.147607027991571">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="11.955560443773642" CI_START="0.5227693029861222" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 10:09:42 +0000" MODIFIED_BY="[Empty name]" ORDER="1062" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4747646836404593" CI_END="1.266246121290646" CI_START="0.5631976072272631" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8444801866661494" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="52" I2="42.442145523804804" I2_Q="42.170521260852794" ID="CMP-021.10" LOG_CI_END="0.10251812805864341" LOG_CI_START="-0.24933919898349316" LOG_EFFECT_SIZE="-0.07341053546242486" METHOD="MH" MODIFIED="2014-01-14 16:48:54 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.17598077513441135" P_Q="0.1774227169383854" P_Z="0.4134469149649408" Q="3.4584437619115453" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.33961603130337864" TOTALS="SUB" TOTAL_1="307" TOTAL_2="369" WEIGHT="300.0" Z="0.8178428842263252">
<NAME>Other adverse events: 4. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.955560443773642" CI_START="0.5227693029861222" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-021.10.01" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 10:08:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2511308465779948" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.147607027991571">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="11.955560443773642" CI_START="0.5227693029861222" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-01-14 10:08:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1061" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.33325429307962" CI_START="0.32926924483626774" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-021.10.02" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:11:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3297879615190883" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.9745410867786626">
<NAME>weight gain - short term</NAME>
<DICH_DATA CI_END="27.33325429307962" CI_START="0.32926924483626774" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.48244883236635133" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-01-14 10:11:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1065" O_E="0.0" SE="1.1273124382057236" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.2708333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1386879222847512" CI_START="0.48460317253599366" DF="0" EFFECT_SIZE="0.7428403460149492" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" I2="0.0" ID="CMP-021.10.03" LOG_CI_END="0.05640471424533026" LOG_CI_START="-0.3146137470074981" LOG_EFFECT_SIZE="-0.12910451638108392" MODIFIED="2014-01-14 10:11:30 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1725580450792374" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="305" WEIGHT="100.0" Z="1.3640302506454156">
<NAME>weight gain - long term</NAME>
<DICH_DATA CI_END="1.1386879222847512" CI_START="0.48460317253599366" EFFECT_SIZE="0.7428403460149492" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" LOG_CI_END="0.05640471424533026" LOG_CI_START="-0.3146137470074981" LOG_EFFECT_SIZE="-0.12910451638108392" MODIFIED="2013-12-11 15:45:13 +0000" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.21793808071091442" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="305" VAR="0.047497007023957045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2528849199393801" CI_END="1.5741129589919785" CI_START="0.8793534703619729" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1765210126603562" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-021.11" LOG_CI_END="0.19703589429157403" LOG_CI_START="-0.055836518133707186" LOG_EFFECT_SIZE="0.07059968807893342" METHOD="MH" MODIFIED="2015-01-26 14:51:25 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6150510382835209" P_Q="0.6158378378531703" P_Z="0.2737759192424978" Q="0.2517610298703935" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="522" TOTAL_2="674" WEIGHT="200.0" Z="1.0944083985069568">
<NAME>Other adverse events: 5. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6154869501598894" CI_START="0.8878448899115692" DF="0" EFFECT_SIZE="1.1976234105169636" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="69" I2="0.0" ID="CMP-021.11.01" LOG_CI_END="0.20830345415407106" LOG_CI_START="-0.05166290059469208" LOG_EFFECT_SIZE="0.07832027677968949" MODIFIED="2013-12-11 15:45:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23761866974475032" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.00000000000001" Z="1.1809599122605725">
<NAME>diminished sexual desire - long term</NAME>
<DICH_DATA CI_END="1.6154869501598894" CI_START="0.8878448899115692" EFFECT_SIZE="1.1976234105169636" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="69" LOG_CI_END="0.20830345415407106" LOG_CI_START="-0.05166290059469208" LOG_EFFECT_SIZE="0.07832027677968949" MODIFIED="2013-12-11 15:45:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.1527055236336336" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.023318976948222228" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0188757594337647" CI_START="0.24544321372784111" DF="0" EFFECT_SIZE="0.8607918263090677" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-021.11.02" LOG_CI_END="0.47984524018354224" LOG_CI_START="-0.6100489712287894" LOG_EFFECT_SIZE="-0.06510186552262358" MODIFIED="2015-01-26 14:51:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8148714551320378" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.2341462325694271">
<NAME>galactorrhoea/ gynaecomastia - long term</NAME>
<DICH_DATA CI_END="3.0188757594337647" CI_START="0.24544321372784111" EFFECT_SIZE="0.8607918263090677" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.47984524018354224" LOG_CI_START="-0.6100489712287894" LOG_EFFECT_SIZE="-0.06510186552262358" MODIFIED="2013-12-11 15:45:30 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.6402092548469606" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.4098678899917005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5814260040487199" CI_END="0.8972241820956401" CI_START="0.5269549416709628" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6876021498962793" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="121" I2="0.0" I2_Q="0.0" ID="CMP-021.12" LOG_CI_END="-0.04709902977345632" LOG_CI_START="-0.27822651841224677" LOG_EFFECT_SIZE="-0.16266277409285151" METHOD="MH" MODIFIED="2014-02-18 15:10:53 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7477302713060724" P_Q="0.7486687709962133" P_Z="0.005802029433225385" Q="0.578917313260265" RANDOM="YES" SCALE="33.31106177581977" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="783" TOTAL_2="1011" WEIGHT="300.0" Z="2.758764703627357">
<NAME>Other adverse events: 6. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.368273634188896E-30" CI_END="0.9265301242122226" CI_START="0.5302618176784898" DF="0" EFFECT_SIZE="0.7009304871373837" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="105" I2="100.0" ID="CMP-021.12.01" LOG_CI_END="-0.03314045592796773" LOG_CI_START="-0.2755096438008102" LOG_EFFECT_SIZE="-0.154325049864389" MODIFIED="2013-12-11 15:45:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.012561781603001376" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="2.4959570339876715">
<NAME>urinary hesitancy, dry mouth, constipation - long term</NAME>
<DICH_DATA CI_END="0.9265301242122226" CI_START="0.5302618176784897" EFFECT_SIZE="0.7009304871373837" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="105" LOG_CI_END="-0.03314045592796773" LOG_CI_START="-0.27550964380081033" LOG_EFFECT_SIZE="-0.154325049864389" MODIFIED="2013-12-11 15:45:53 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.14236886070333693" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.02026889249796615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.545767030159794" CI_START="0.08114400285440007" DF="0" EFFECT_SIZE="1.2911877394636015" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-021.12.02" LOG_CI_END="1.3127223593115764" LOG_CI_START="-1.0907435722454613" LOG_EFFECT_SIZE="0.11098939353305767" MODIFIED="2013-12-11 15:46:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.856353502408871" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.18101793009382075">
<NAME>suicide attempt - long term</NAME>
<DICH_DATA CI_END="20.545767030159794" CI_START="0.08114400285440007" EFFECT_SIZE="1.2911877394636015" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3127223593115764" LOG_CI_START="-1.0907435722454613" LOG_EFFECT_SIZE="0.11098939353305767" MODIFIED="2013-12-11 15:46:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="1.4118077855448432" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="1.9932012233250338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3127567572663754" CI_START="0.2031956972151039" DF="0" EFFECT_SIZE="0.5164750957854406" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-021.12.03" LOG_CI_END="0.11818426244638973" LOG_CI_START="-0.6920854927243496" LOG_EFFECT_SIZE="-0.28695061513897996" MODIFIED="2013-12-11 15:46:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.16507267033963688" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="1.3882114380426396">
<NAME>incontinence nocturia - long term</NAME>
<DICH_DATA CI_END="1.3127567572663754" CI_START="0.2031956972151039" EFFECT_SIZE="0.5164750957854406" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.11818426244638973" LOG_CI_START="-0.6920854927243496" LOG_EFFECT_SIZE="-0.28695061513897996" MODIFIED="2013-12-11 15:46:09 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.47595646508726736" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.22653455665836716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8831193339944694" CI_START="0.7271047535716846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1701388888888888" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-021.13" LOG_CI_END="0.27487784229661544" LOG_CI_START="-0.1384030160723999" LOG_EFFECT_SIZE="0.06823741311210775" METHOD="MH" MODIFIED="2014-01-14 16:49:03 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5174862737917598" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.6472250983300778">
<NAME>Other adverse events: 7. any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8831193339944694" CI_START="0.7271047535716846" DF="0" EFFECT_SIZE="1.1701388888888888" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" ID="CMP-021.13.01" LOG_CI_END="0.27487784229661544" LOG_CI_START="-0.1384030160723999" LOG_EFFECT_SIZE="0.06823741311210775" MODIFIED="2013-12-11 15:46:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5174862737917598" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.6472250983300778">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.8831193339944694" CI_START="0.7271047535716846" EFFECT_SIZE="1.1701388888888888" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.27487784229661544" LOG_CI_START="-0.1384030160723999" LOG_EFFECT_SIZE="0.06823741311210775" MODIFIED="2013-12-11 15:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.24276322197920236" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" VAR="0.05893398194572348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1933136902513239" CI_END="15.957808198404674" CI_START="1.4708723052177282" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.844780503904159" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-021.14" LOG_CI_END="1.2029732408551839" LOG_CI_START="0.16757497079244274" LOG_EFFECT_SIZE="0.6852741058238133" METHOD="MH" MODIFIED="2014-01-14 16:49:20 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.6601728623861136" P_Q="0.6623968568968948" P_Z="0.00947594053046473" Q="0.19062511397792067" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="64" WEIGHT="200.0" Z="2.594388277027306">
<NAME>Other adverse events: 8a. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.683260158384115" CI_START="0.9127612565897287" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-021.14.01" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:12:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.061186768182128155" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8721433920279957">
<NAME>abnormal ECG - short term</NAME>
<DICH_DATA CI_END="53.683260158384115" CI_START="0.9127612565897287" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7298388824553277" LOG_CI_START="-0.03964280242681407" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-14 10:12:55 +0000" MODIFIED_BY="[Empty name]" ORDER="1069" O_E="0.0" SE="1.0394023007753748" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="1.0803571428571428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.39647065148549" CI_START="0.9197267836987244" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-021.14.02" LOG_CI_END="1.2404611487391044" LOG_CI_START="-0.03634116608317959" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2014-01-14 10:13:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06454558558747073" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8483924814931874">
<NAME>abnormal liver function - short term</NAME>
<DICH_DATA CI_END="17.39647065148549" CI_START="0.9197267836987244" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2404611487391044" LOG_CI_START="-0.03634116608317959" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2014-01-14 10:13:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1070" O_E="0.0" SE="0.75" STUDY_ID="STD-Wang-2008c" TOTAL_1="32" TOTAL_2="32" VAR="0.5625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="27.33311991229484" CI_END="0.19948849944984576" CI_START="-0.1030205592088713" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04823397012048723" ESTIMABLE="YES" I2="81.70717424119987" I2_Q="81.70717424119987" ID="CMP-021.15" MODIFIED="2014-01-14 16:49:18 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="4.912341911555984E-5" P_Q="4.912341911555984E-5" P_Z="0.5319590706530708" Q="27.33311991229484" RANDOM="YES" SCALE="50.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="12.197433272864036" TOTALS="SUB" TOTAL_1="1566" TOTAL_2="2022" UNITS="" WEIGHT="600.0" Z="0.6250182701086655">
<NAME>Other adverse events: 8b. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.31458775193044897" CI_START="-5.885412248069551" DF="0" EFFECT_SIZE="-3.1" ESTIMABLE="YES" I2="0.0" ID="CMP-021.15.01" MODIFIED="2013-12-11 15:46:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.029159413646486734" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="2.1813246338257843">
<NAME>mean weight change (lb) - long term</NAME>
<CONT_DATA CI_END="-0.31458775193044897" CI_START="-5.885412248069551" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="1.1" MODIFIED="2013-12-11 15:46:50 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="17.77" SD_2="16.52" SE="1.4211548120478372" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.299833382780355" CI_START="-7.499833382780355" DF="0" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-021.15.02" MODIFIED="2013-12-11 15:48:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5950510978609556" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.5315306673603454">
<NAME>change in blood glucose - long term</NAME>
<CONT_DATA CI_END="4.299833382780355" CI_START="-7.499833382780355" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="6.8" MODIFIED="2013-12-11 15:48:33 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="32.31" SD_2="41.3" SE="3.01017438550784" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.040380797222516E-33" CI_END="0.20167011963562617" CI_START="-0.1016701196356262" DF="0" EFFECT_SIZE="0.049999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-021.15.03" MODIFIED="2013-12-11 15:48:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.5181969447253301" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.00000000000001" Z="0.6461272626568407">
<NAME>change in glycosylated haemoglobin - long term</NAME>
<CONT_DATA CI_END="0.20167011963562614" CI_START="-0.10167011963562615" EFFECT_SIZE="0.05" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.05" MODIFIED="2013-12-11 15:48:38 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="0.96" SD_2="0.91" SE="0.07738413605146865" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3035259098185117" CI_START="-10.903525909818512" DF="0" EFFECT_SIZE="-4.8" ESTIMABLE="YES" I2="0.0" ID="CMP-021.15.04" MODIFIED="2013-12-11 15:48:45 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.12322535056009969" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="1.5413757989719097">
<NAME>change in cholesterol - long term</NAME>
<CONT_DATA CI_END="1.3035259098185117" CI_START="-10.903525909818512" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="5.3" MODIFIED="2013-12-11 15:48:45 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="37.15" SD_2="38.55" SE="3.1141010538776963" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.753121921673028" CI_START="-41.553121921673025" DF="0" EFFECT_SIZE="-10.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-021.15.05" MODIFIED="2013-12-11 15:48:52 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.48583584376113265" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="0.6969471979420678">
<NAME>change in triglycerides - long term</NAME>
<CONT_DATA CI_END="19.753121921673028" CI_START="-41.553121921673025" EFFECT_SIZE="-10.899999999999999" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="19.2" MODIFIED="2013-12-11 15:48:52 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="185.78" SD_2="194.59" SE="15.639635301189685" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.015926839507863" CI_START="5.384073160492139" DF="0" EFFECT_SIZE="9.700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-021.15.06" MODIFIED="2013-12-11 15:48:59 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="1.0578467815305756E-5" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0" Z="4.40499836002929">
<NAME>change in prolactin - long term</NAME>
<CONT_DATA CI_END="14.015926839507863" CI_START="5.384073160492139" EFFECT_SIZE="9.700000000000001" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-9.3" MODIFIED="2013-12-11 15:48:59 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="27.46" SD_2="25.7" SE="2.2020439526192024" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="337" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2014-02-21 16:10:02 +0000" MODIFIED_BY="[Empty name]" NO="22">
<NAME>PERPHENAZINE vs PROMAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5635519527595938" CI_START="0.9252289872714405" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2027649769585254" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.1941123162933464" LOG_CI_START="-0.033750769313843444" LOG_EFFECT_SIZE="0.08018077348975146" METHOD="MH" MODIFIED="2014-01-14 16:49:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.16778698984109855" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="1.3793496026239904">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Promazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours promazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5635519527595938" CI_START="0.9252289872714405" DF="0" EFFECT_SIZE="1.2027649769585254" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="0.0" ID="CMP-022.01.01" LOG_CI_END="0.1941123162933464" LOG_CI_START="-0.033750769313843444" LOG_EFFECT_SIZE="0.08018077348975146" MODIFIED="2013-12-10 16:42:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16778698984109855" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="1.3793496026239904">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.5635519527595938" CI_START="0.9252289872714405" EFFECT_SIZE="1.2027649769585254" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.1941123162933464" LOG_CI_START="-0.033750769313843444" LOG_EFFECT_SIZE="0.08018077348975146" MODIFIED="2013-12-10 16:42:15 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.13384790442612826" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.017915261519265965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.50480636820959" CI_START="0.731721207423057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.494623655913979" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-022.02" LOG_CI_END="0.9296644303324352" LOG_CI_START="-0.13565435765850595" LOG_EFFECT_SIZE="0.39700503633696466" METHOD="MH" MODIFIED="2014-01-14 16:49:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.14406686741274993" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="29" WEIGHT="99.99999999999999" Z="1.4608126350027029">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Promazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours promazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.50480636820959" CI_START="0.731721207423057" DF="0" EFFECT_SIZE="2.494623655913979" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-022.02.01" LOG_CI_END="0.9296644303324352" LOG_CI_START="-0.13565435765850595" LOG_EFFECT_SIZE="0.39700503633696466" MODIFIED="2013-12-10 16:42:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14406686741274993" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="99.99999999999999" Z="1.4608126350027029">
<NAME>short term</NAME>
<DICH_DATA CI_END="8.50480636820959" CI_START="0.731721207423057" EFFECT_SIZE="2.4946236559139785" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9296644303324352" LOG_CI_START="-0.13565435765850595" LOG_EFFECT_SIZE="0.39700503633696455" MODIFIED="2013-12-10 16:42:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.6257735294789278" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.3915925101965146" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9704429478157467" CI_START="0.15655974898329" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3897849462365592" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="-0.013029991627621026" LOG_CI_START="-0.8053198836662242" LOG_EFFECT_SIZE="-0.4091749376469226" METHOD="MH" MODIFIED="2014-01-14 16:49:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.042925816519570004" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="2.0244310806512624">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Promazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours promazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9704429478157467" CI_START="0.15655974898329" DF="0" EFFECT_SIZE="0.3897849462365592" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-022.03.01" LOG_CI_END="-0.013029991627621026" LOG_CI_START="-0.8053198836662242" LOG_EFFECT_SIZE="-0.4091749376469226" MODIFIED="2013-12-10 16:31:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.042925816519570004" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="2.0244310806512624">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.9704429478157466" CI_START="0.15655974898329" EFFECT_SIZE="0.3897849462365591" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.013029991627621076" LOG_CI_START="-0.8053198836662242" LOG_EFFECT_SIZE="-0.40917493764692264" MODIFIED="2013-12-10 16:31:22 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.4653950044816926" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="29" VAR="0.21659251019651465" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2015-01-26 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="23">
<NAME>PERPHENAZINE vs RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="0.13282941937681644" CI_END="1.1133313484926222" CI_START="0.9248209735249064" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0147079291937873" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="267" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.04662443783489302" LOG_CI_START="-0.03394232967738849" LOG_EFFECT_SIZE="0.006341054078752325" METHOD="MH" MODIFIED="2014-02-26 20:42:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7155163416928089" P_Q="1.0" P_Z="0.7576865323660802" Q="0.0" RANDOM="YES" SCALE="2.666601923658031" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="396" WEIGHT="100.0" Z="0.3085202001304256">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13282941937681644" CI_END="1.1133313484926222" CI_START="0.9248209735249064" DF="1" EFFECT_SIZE="1.0147079291937873" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="267" I2="0.0" ID="CMP-023.01.01" LOG_CI_END="0.04662443783489302" LOG_CI_START="-0.03394232967738849" LOG_EFFECT_SIZE="0.006341054078752325" MODIFIED="2014-02-26 20:42:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7155163416928089" P_Z="0.7576865323660802" STUDIES="2" TAU2="0.0" TOTAL_1="313" TOTAL_2="396" WEIGHT="100.0" Z="0.3085202001304256">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1117022229438187" CI_START="0.9215318917822112" EFFECT_SIZE="1.01216058637348" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="253" LOG_CI_END="0.045988474070852166" LOG_CI_START="-0.035489630401102375" LOG_EFFECT_SIZE="0.005249421834874897" MODIFIED="2013-12-16 16:36:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.04786064188994794" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" VAR="0.002290641042117839" WEIGHT="97.77549983714188"/>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" MODIFIED="2014-02-26 20:42:24 +0000" MODIFIED_BY="[Empty name]" ORDER="24509" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="2.224500162858116"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4494095992451428" CI_END="2.2858797617128204" CI_START="0.7289551494189446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2908539124366902" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" I2="31.006390428157562" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="0.3590533825780826" LOG_CI_START="-0.1372991917904957" LOG_EFFECT_SIZE="0.11087709539379345" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2286229955071194" P_Q="1.0" P_Z="0.38122133491830235" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06783880033110225" TOTALS="YES" TOTAL_1="313" TOTAL_2="396" WEIGHT="100.0" Z="0.8756481779456822">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4494095992451428" CI_END="2.2858797617128204" CI_START="0.7289551494189446" DF="1" EFFECT_SIZE="1.2908539124366902" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" I2="31.006390428157562" ID="CMP-023.02.01" LOG_CI_END="0.3590533825780826" LOG_CI_START="-0.1372991917904957" LOG_EFFECT_SIZE="0.11087709539379345" MODIFIED="2013-12-16 16:36:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2286229955071194" P_Z="0.38122133491830235" STUDIES="2" TAU2="0.06783880033110225" TOTAL_1="313" TOTAL_2="396" WEIGHT="100.0" Z="0.8756481779456822">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.3577535709068207" CI_START="1.0020548181877662" EFFECT_SIZE="1.5370745999549245" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="34" LOG_CI_END="0.37249841128150907" LOG_CI_START="8.914805983389245E-4" LOG_EFFECT_SIZE="0.186694945939924" MODIFIED="2013-12-16 16:36:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.21828375056726781" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" VAR="0.04764779576171319" WEIGHT="73.60785811220292"/>
<DICH_DATA CI_END="2.131214611558949" CI_START="0.29526640305121676" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3286271850135134" LOG_CI_START="-0.529785966511224" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24525" O_E="0.0" SE="0.5042361344192612" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2542540792540792" WEIGHT="26.392141887797077"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3461107107260974" CI_END="1.239604681644365" CI_START="0.7207284144088992" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9452080811627626" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="0.09328320778060016" LOG_CI_START="-0.14222835572918782" LOG_EFFECT_SIZE="-0.024472573974293844" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5563232565512075" P_Q="1.0" P_Z="0.6837662500507329" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="396" WEIGHT="99.99999999999999" Z="0.4073291594161126">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3461107107260974" CI_END="1.239604681644365" CI_START="0.7207284144088992" DF="1" EFFECT_SIZE="0.9452080811627626" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="93" I2="0.0" ID="CMP-023.03.01" LOG_CI_END="0.09328320778060016" LOG_CI_START="-0.14222835572918782" LOG_EFFECT_SIZE="-0.024472573974293844" MODIFIED="2013-12-16 16:36:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5563232565512075" P_Z="0.6837662500507329" STUDIES="2" TAU2="0.0" TOTAL_1="313" TOTAL_2="396" WEIGHT="99.99999999999999" Z="0.4073291594161126">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2279577009044031" CI_START="0.7092319060989236" EFFECT_SIZE="0.933223864258347" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="91" LOG_CI_END="0.08918340704928479" LOG_CI_START="-0.14921173509732727" LOG_EFFECT_SIZE="-0.030014164024021264" MODIFIED="2013-12-16 16:36:56 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1400344865719056" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" VAR="0.01960965742945721" WEIGHT="97.59547193471872"/>
<DICH_DATA CI_END="9.116851335277273" CI_START="0.27609359825809593" EFFECT_SIZE="1.5865384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9598448729969133" LOG_CI_START="-0.5589436631666614" LOG_EFFECT_SIZE="0.2004506049151259" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24533" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="2.404528065281274"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1191914188911776" CI_START="0.788585625544659" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2927350427350428" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-023.04" LOG_CI_END="0.3261701867313436" LOG_CI_START="-0.10315114357465391" LOG_EFFECT_SIZE="0.11150952157834487" METHOD="MH" MODIFIED="2014-02-18 15:16:09 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3086113614521464" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0181401705388071">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1191914188911776" CI_START="0.788585625544659" DF="0" EFFECT_SIZE="1.2927350427350428" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="0.0" ID="CMP-023.04.01" LOG_CI_END="0.3261701867313436" LOG_CI_START="-0.10315114357465391" LOG_EFFECT_SIZE="0.11150952157834487" MODIFIED="2013-12-05 16:44:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3086113614521464" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0181401705388071">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.1191914188911776" CI_START="0.788585625544659" EFFECT_SIZE="1.2927350427350428" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3261701867313436" LOG_CI_START="-0.10315114357465391" LOG_EFFECT_SIZE="0.11150952157834487" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24542" O_E="0.0" SE="0.2521854745966024" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.06359751359751359" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.084940216223805" CI_START="0.6101353379980785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-023.05" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" METHOD="MH" MODIFIED="2014-02-18 15:16:24 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.16009090857711306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.404765878729659">
<NAME>Mental state: 1a. State - less than 20% BPRS reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.084940216223805" CI_START="0.6101353379980785" DF="0" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" I2="0.0" ID="CMP-023.05.01" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2014-01-07 15:10:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16009090857711306" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.404765878729659">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.084940216223805" CI_START="0.6101353379980785" EFFECT_SIZE="0.8136094674556213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" LOG_CI_END="0.03540580778875102" LOG_CI_START="-0.21457382068353517" LOG_EFFECT_SIZE="-0.08958400644739206" MODIFIED="2014-01-07 15:10:51 +0000" MODIFIED_BY="[Empty name]" ORDER="24554" O_E="0.0" SE="0.1468392711837387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02156177156177156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6245665686461717" CI_END="1.1720304580491192" CI_START="0.6528391721703011" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8747270397050533" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-023.06" LOG_CI_END="0.0689388980223302" LOG_CI_START="-0.18519379459273036" LOG_EFFECT_SIZE="-0.058127448285200056" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.429355576642073" P_Q="0.44240729619836394" P_Z="0.36993232796201936" Q="0.5900309574353204" RANDOM="YES" SCALE="55.73678177938118" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="89" WEIGHT="200.0" Z="0.896600149944305">
<NAME>Mental state: 1b. State - PANSS reduction ('no effect')</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1540465647134452" CI_START="0.6372860624161332" DF="0" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" I2="0.0" ID="CMP-023.06.01" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2014-01-13 16:11:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.31050387460315276" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="1.014165347296331">
<NAME>less than 20% reduction - short term</NAME>
<DICH_DATA CI_END="1.1540465647134452" CI_START="0.6372860624161332" EFFECT_SIZE="0.8575883575883576" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.06222333255464293" LOG_CI_START="-0.19566557953041866" LOG_EFFECT_SIZE="-0.06672112348788786" MODIFIED="2014-01-13 11:21:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24556" O_E="0.0" SE="0.15148522352946822" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.02294777294777295" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.498619566602862" CI_START="0.3042547372000492" DF="0" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-023.06.02" LOG_CI_END="0.9776604939026794" LOG_CI_START="-0.5167626511461317" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2014-01-13 16:12:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5455271140520102" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.6044761655009926">
<NAME>less than 40% reduction - short term</NAME>
<DICH_DATA CI_END="9.498619566602862" CI_START="0.3042547372000492" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9776604939026794" LOG_CI_START="-0.5167626511461317" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2014-01-13 16:12:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="0.8778315529155452" STUDY_ID="STD-Wang-2008a" TOTAL_1="30" TOTAL_2="34" VAR="0.7705882352941176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.035065793456791" CI_START="-5.035065793456791" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.07" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.38555075560580787" Q="0.0" RANDOM="YES" SCALE="52.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" UNITS="" WEIGHT="99.99999999999999" Z="0.8677143163515038">
<NAME>Mental state: 1c. State - PANSS: mean change from baseline to endpoint</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.035065793456791" CI_START="-5.035065793456791" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-023.07.01" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38555075560580787" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="0.8677143163515038">
<NAME>short term</NAME>
<CONT_DATA CI_END="13.035065793456791" CI_START="-5.035065793456791" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-24.0" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24557" SD_1="21.63" SD_2="25.96" SE="4.609812152021281" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.412631032288918" CI_END="1.8165607542599767" CI_START="1.0205011348450554" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3615440908164878" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="62" I2="42.377675907324715" I2_Q="41.349478206419896" ID="CMP-023.08" LOG_CI_END="0.2592499272736756" LOG_CI_START="0.008813492008161193" LOG_EFFECT_SIZE="0.13403170964091843" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.10831668466925992" P_Q="0.11529108900312113" P_Z="0.03591255124283771" Q="10.230088013738287" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12168500564053339" TOTALS="SUB" TOTAL_1="925" TOTAL_2="668" WEIGHT="700.0" Z="2.0979161710556737">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4917828131749589" CI_START="0.3763209387032329" DF="0" EFFECT_SIZE="0.7492590397154713" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" ID="CMP-023.08.01" LOG_CI_END="0.17370559933938998" LOG_CI_START="-0.42444161662490804" LOG_EFFECT_SIZE="-0.12536800864275902" MODIFIED="2013-12-16 16:38:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41130858435797435" STUDIES="1" TAU2="0.0" TOTAL_1="241" TOTAL_2="158" WEIGHT="100.0" Z="0.8215929964906169">
<NAME>akathisia - long term</NAME>
<DICH_DATA CI_END="1.4917828131749589" CI_START="0.3763209387032329" EFFECT_SIZE="0.7492590397154713" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.17370559933938998" LOG_CI_START="-0.42444161662490804" LOG_EFFECT_SIZE="-0.12536800864275902" MODIFIED="2013-12-16 16:38:14 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.3513546355339001" STUDY_ID="STD-CATIE-2005" TOTAL_1="241" TOTAL_2="158" VAR="0.12345007991115978" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.040130215485474" CI_START="0.6737481351752447" DF="0" EFFECT_SIZE="2.4679487179487176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-023.08.02" LOG_CI_END="0.9561746861677867" LOG_CI_START="-0.17150242385970843" LOG_EFFECT_SIZE="0.39233613115403904" MODIFIED="2013-12-16 16:37:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1726295903537741" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="1.3638029539802414">
<NAME>dystonia - short term</NAME>
<DICH_DATA CI_END="9.040130215485474" CI_START="0.6737481351752448" EFFECT_SIZE="2.467948717948718" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9561746861677867" LOG_CI_START="-0.17150242385970835" LOG_EFFECT_SIZE="0.3923361311540391" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24587" O_E="0.0" SE="0.662403116521872" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.43877788877788876" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.35100615687038" CI_START="1.202680824562837" DF="0" EFFECT_SIZE="9.066666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-023.08.03" LOG_CI_END="1.8347449119566652" LOG_CI_START="0.08015038667240712" LOG_EFFECT_SIZE="0.9574476493145363" MODIFIED="2014-01-13 11:19:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03243344686901497" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="2.1390274307792096">
<NAME>EPS - short term</NAME>
<DICH_DATA CI_END="68.35100615687038" CI_START="1.202680824562837" EFFECT_SIZE="9.066666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8347449119566652" LOG_CI_START="0.08015038667240712" LOG_EFFECT_SIZE="0.9574476493145363" MODIFIED="2014-01-13 11:19:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="1.0306575095349495" STUDY_ID="STD-Wang-2008a" TOTAL_1="30" TOTAL_2="34" VAR="1.0622549019607843" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.105765293421067" CI_START="0.9719655604100694" DF="0" EFFECT_SIZE="2.2276956759715385" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" I2="0.0" ID="CMP-023.08.04" LOG_CI_END="0.7080608468734589" LOG_CI_START="-0.012349123128094316" LOG_EFFECT_SIZE="0.34785586187268236" MODIFIED="2014-01-13 11:19:09 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.058388547124984924" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.8927693659767846">
<NAME>EPS - long term</NAME>
<DICH_DATA CI_END="5.105765293421066" CI_START="0.9719655604100693" EFFECT_SIZE="2.227695675971538" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" LOG_CI_END="0.7080608468734589" LOG_CI_START="-0.012349123128094365" LOG_EFFECT_SIZE="0.34785586187268225" MODIFIED="2013-12-16 16:38:32 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.423172382465777" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.17907486528176184" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.910465279553863" CI_START="0.8838868655449152" DF="0" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-023.08.05" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2014-01-13 11:19:09 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.08199900026365228" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.7392033508855447">
<NAME>hyperkinesia - short term</NAME>
<DICH_DATA CI_END="7.910465279553863" CI_START="0.8838868655449152" EFFECT_SIZE="2.644230769230769" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8982020286809911" LOG_CI_START="-0.053603319618026446" LOG_EFFECT_SIZE="0.42229935453148226" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24591" O_E="0.0" SE="0.5590951731033033" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.31258741258741257" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0172352898770596" CI_START="0.726960048917626" DF="0" EFFECT_SIZE="1.2109704641350212" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="18" I2="0.0" ID="CMP-023.08.06" LOG_CI_END="0.30475655717934924" LOG_CI_START="-0.13848945573157223" LOG_EFFECT_SIZE="0.08313355072388849" MODIFIED="2014-01-13 11:19:08 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.4622134982071322" STUDIES="1" TAU2="0.0" TOTAL_1="237" TOTAL_2="126" WEIGHT="100.0" Z="0.7352069080359706">
<NAME>tardive dyskinesia - long term</NAME>
<DICH_DATA CI_END="2.0172352898770596" CI_START="0.726960048917626" EFFECT_SIZE="1.2109704641350212" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="18" LOG_CI_END="0.30475655717934924" LOG_CI_START="-0.13848945573157223" LOG_EFFECT_SIZE="0.08313355072388849" MODIFIED="2013-12-16 16:38:48 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.2603649020870252" STUDY_ID="STD-CATIE-2005" TOTAL_1="237" TOTAL_2="126" VAR="0.06778988223878621" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1445467233256057" CI_START="0.6700365652795333" DF="0" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" ID="CMP-023.08.07" LOG_CI_END="0.33133551266949035" LOG_CI_START="-0.17390149630541574" LOG_EFFECT_SIZE="0.07871700818203736" MODIFIED="2014-01-13 11:19:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5413762436747482" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.6107331738051708">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="2.1445467233256057" CI_START="0.6700365652795333" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.33133551266949035" LOG_CI_START="-0.17390149630541574" LOG_EFFECT_SIZE="0.07871700818203736" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24608" O_E="0.0" SE="0.2967787200353893" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.08807760866584396" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="139.80596033832603" CI_START="0.39128635897179836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.09" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.18211221189433172" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.3342796879264842">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="139.80596033832603" CI_START="0.39128635897179836" DF="0" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-023.09.01" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" MODIFIED="2013-12-05 16:45:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18211221189433172" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.3342796879264842">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="139.80596033832603" CI_START="0.39128635897179836" EFFECT_SIZE="7.39622641509434" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1455256870524804" LOG_CI_START="-0.4075052922131441" LOG_EFFECT_SIZE="0.8690101974196682" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24621" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.084843851989003" CI_END="1.3691011592357467" CI_START="0.9320111057124493" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1296094392538973" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="180" I2="0.0" I2_Q="0.0" ID="CMP-023.10" LOG_CI_END="0.1364355381813209" LOG_CI_START="-0.03057891262359565" LOG_EFFECT_SIZE="0.052928312778862625" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6496101994614404" P_Q="0.9222101082926709" P_Z="0.21414110978015344" Q="1.4191226204965497" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="834" TOTAL_2="700" WEIGHT="600.0" Z="1.242258814241337">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3474627755623407" CI_START="0.7646182529258909" DF="0" EFFECT_SIZE="1.3397435897435896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" I2="0.0" ID="CMP-023.10.01" LOG_CI_END="0.3705987142518677" LOG_CI_START="-0.11655533873868298" LOG_EFFECT_SIZE="0.12702168775659237" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30673775597612163" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.00000000000001" Z="1.0220911916060458">
<NAME>depression - short term</NAME>
<DICH_DATA CI_END="2.3474627755623407" CI_START="0.7646182529258909" EFFECT_SIZE="1.3397435897435896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.3705987142518677" LOG_CI_START="-0.11655533873868298" LOG_EFFECT_SIZE="0.12702168775659237" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.28615670217810324" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.08188565820144766" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9408215709147434" CI_START="0.5764120898678028" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-023.10.02" LOG_CI_END="0.28798561043778126" LOG_CI_START="-0.2392669187188919" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:45:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.856286928914289" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.18110274652577157">
<NAME>emotional indifference - short term</NAME>
<DICH_DATA CI_END="1.9408215709147434" CI_START="0.5764120898678028" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.28798561043778126" LOG_CI_START="-0.2392669187188919" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.3097107455687418" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.09592074592074593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6734729783430042" CI_START="0.6215066246000762" DF="0" EFFECT_SIZE="1.510989010989011" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-023.10.03" LOG_CI_END="0.5650768495704356" LOG_CI_START="-0.20655423788005994" LOG_EFFECT_SIZE="0.17926130584518785" MODIFIED="2013-12-05 16:45:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3624760315280888" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.9106572013293296">
<NAME>increased dream activity - short term</NAME>
<DICH_DATA CI_END="3.6734729783430042" CI_START="0.6215066246000762" EFFECT_SIZE="1.510989010989011" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5650768495704356" LOG_CI_START="-0.20655423788005994" LOG_EFFECT_SIZE="0.17926130584518785" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.4532599204039062" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.20544455544455542" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6805071040153559" CI_END="1.9717173942352184" CI_START="0.5183435250620677" DF="1" EFFECT_SIZE="1.0109534828834004" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="60" I2="40.4941521752197" ID="CMP-023.10.04" LOG_CI_END="0.29484466774540324" LOG_CI_START="-0.28538232212586895" LOG_EFFECT_SIZE="0.004731172809767119" MODIFIED="2013-12-16 16:39:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.19485716312584378" P_Z="0.9745014732156723" STUDIES="2" TAU2="0.12902972382105393" TOTAL_1="313" TOTAL_2="240" WEIGHT="100.0" Z="0.03196310572810838">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.1301247453628027" CI_START="0.6175155166214399" EFFECT_SIZE="0.8353858784893268" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" LOG_CI_END="0.05312638439718956" LOG_CI_START="-0.2093521251963873" LOG_EFFECT_SIZE="-0.0781128703995989" MODIFIED="2013-12-16 16:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.15418117582484422" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.02377183497873153" WEIGHT="76.02269697472737"/>
<DICH_DATA CI_END="5.954930516701607" CI_START="0.5753314177646484" EFFECT_SIZE="1.8509615384615385" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7748766984150807" LOG_CI_START="-0.24008190932360235" LOG_EFFECT_SIZE="0.26739739454573913" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24639" O_E="0.0" SE="0.5961917103118387" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.35544455544455544" WEIGHT="23.97730302527264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.00623422638729936" CI_END="1.539175344932669" CI_START="0.872403271950714" DF="1" EFFECT_SIZE="1.1587845386546756" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" I2="0.0" ID="CMP-023.10.05" LOG_CI_END="0.1872880980633771" LOG_CI_START="-0.05928271426771213" LOG_EFFECT_SIZE="0.06400269189783248" MODIFIED="2013-12-16 16:39:41 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9370667320334934" P_Z="0.3089153753452075" STUDIES="2" TAU2="0.0" TOTAL_1="313" TOTAL_2="240" WEIGHT="100.0" Z="1.0175005698965172">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="1.6036631744836565" CI_START="0.8472034147744603" EFFECT_SIZE="1.1656023839931886" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="45" LOG_CI_END="0.20511315645178815" LOG_CI_START="-0.0720123024110574" LOG_EFFECT_SIZE="0.06655042702036536" MODIFIED="2013-12-16 16:39:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.16278486632918082" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.026498912705809265" WEIGHT="79.1645015206554"/>
<DICH_DATA CI_END="2.1106359281408382" CI_START="0.6084596900395307" EFFECT_SIZE="1.1332417582417582" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.32441332661151606" LOG_CI_START="-0.21576818813774024" LOG_EFFECT_SIZE="0.05432256923688789" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.31730529570533594" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1006826506826507" WEIGHT="20.8354984793446"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.500893367336776" CI_START="0.6263134403713821" DF="0" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-023.10.06" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2013-12-05 16:45:40 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.889693784449851" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.13869169080556756">
<NAME>tension - short term</NAME>
<DICH_DATA CI_END="1.500893367336776" CI_START="0.6263134403713821" EFFECT_SIZE="0.969551282051282" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.17634983839765933" LOG_CI_START="-0.20320826845756948" LOG_EFFECT_SIZE="-0.013429215029955102" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.22295431080969194" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.049708624708624714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.205202052683593" CI_START="0.8475605080785928" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0106837606837606" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-023.11" LOG_CI_END="0.08105986268634968" LOG_CI_START="-0.07182928735897469" LOG_EFFECT_SIZE="0.0046152876636875164" METHOD="MH" MODIFIED="2014-02-18 15:20:16 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.9058050369817947" Q="0.0" RANDOM="YES" SCALE="2.95973723907678" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.11833145251233192">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.205202052683593" CI_START="0.8475605080785928" DF="0" EFFECT_SIZE="1.0106837606837606" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" I2="0.0" ID="CMP-023.11.01" LOG_CI_END="0.08105986268634968" LOG_CI_START="-0.07182928735897469" LOG_EFFECT_SIZE="0.0046152876636875164" MODIFIED="2013-12-05 16:45:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9058050369817947" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.11833145251233192">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.205202052683593" CI_START="0.8475605080785928" EFFECT_SIZE="1.0106837606837606" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.08105986268634968" LOG_CI_START="-0.07182928735897469" LOG_EFFECT_SIZE="0.0046152876636875164" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.08980784355012197" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.008065448763123186" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2283634051769454" CI_END="1.251451207786069" CI_START="0.6001299551826952" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8666218075042789" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-023.12" LOG_CI_END="0.09741392178095673" LOG_CI_START="-0.2217546951038161" LOG_EFFECT_SIZE="-0.062170386661429704" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5410837728801267" P_Q="0.5478694617540689" P_Z="0.4451312776016959" Q="1.2034373708217927" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="165" WEIGHT="300.0" Z="0.7635570185481165">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.371284396738129" CI_START="0.3612028381724999" DF="0" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-023.12.01" LOG_CI_END="0.3749836436142605" LOG_CI_START="-0.4422488458507446" LOG_EFFECT_SIZE="-0.033632601118242046" MODIFIED="2013-12-05 16:47:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8718399951554947" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.1613217480898468">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="2.371284396738129" CI_START="0.3612028381724999" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3749836436142605" LOG_CI_START="-0.4422488458507446" LOG_EFFECT_SIZE="-0.033632601118242046" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24669" O_E="0.0" SE="0.48004640967780965" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.23044455544455544" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5208062611490192" CI_START="0.61323610608356" DF="0" EFFECT_SIZE="0.9657190635451505" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-023.12.02" LOG_CI_END="0.18207389184849138" LOG_CI_START="-0.21237228269694933" LOG_EFFECT_SIZE="-0.01514919542422894" MODIFIED="2013-12-05 16:47:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.880330939412093" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.15054970407794976">
<NAME>lassitude - short term</NAME>
<DICH_DATA CI_END="1.5208062611490192" CI_START="0.61323610608356" EFFECT_SIZE="0.9657190635451505" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18207389184849138" LOG_CI_START="-0.21237228269694933" LOG_EFFECT_SIZE="-0.01514919542422894" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.23169963546804603" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.05368472107602542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3152720650028022" CI_START="0.24661101512156308" DF="0" EFFECT_SIZE="0.5695266272189349" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-023.12.03" LOG_CI_END="0.1190155962540893" LOG_CI_START="-0.6079875291203599" LOG_EFFECT_SIZE="-0.24448596643313528" MODIFIED="2013-12-05 16:47:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1874220404881491" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="99.99999999999999" Z="1.3182438209948717">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="1.3152720650028022" CI_START="0.24661101512156308" EFFECT_SIZE="0.5695266272189349" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.1190155962540893" LOG_CI_START="-0.6079875291203599" LOG_EFFECT_SIZE="-0.24448596643313528" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24678" O_E="0.0" SE="0.42704523456846155" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.18236763236763237" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1639600007179023" CI_END="1.4323941276615244" CI_START="0.672701016064643" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9816175350323239" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-023.13" LOG_CI_END="0.15606253188089886" LOG_CI_START="-0.17217791634732346" LOG_EFFECT_SIZE="-0.008057692233212283" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5587910592930194" P_Q="0.5783058122606544" P_Z="0.92334033692673" Q="1.0953053537484685" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="165" WEIGHT="300.0" Z="0.09622693766627832">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5849640174898032" CI_START="0.705828653147122" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-023.13.01" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:46:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7857800257893043" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.2717945116579573">
<NAME>difficulty in concentration - short term</NAME>
<DICH_DATA CI_END="1.5849640174898032" CI_START="0.705828653147122" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.20001940713231445" LOG_CI_START="-0.1513007154134251" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.20636717904602125" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.04258741258741259" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0056894317039746" CI_START="0.13944245306226868" DF="0" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-023.13.02" LOG_CI_END="0.3022636861424311" LOG_CI_START="-0.8556049857515041" LOG_EFFECT_SIZE="-0.2766706498045365" MODIFIED="2013-12-05 16:46:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3489336010839931" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.9366597825109111">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="2.0056894317039746" CI_START="0.13944245306226868" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3022636861424311" LOG_CI_START="-0.8556049857515041" LOG_EFFECT_SIZE="-0.2766706498045365" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24688" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4844413016390655E-32" CI_END="4.051933926789899" CI_START="0.12270826589248707" DF="0" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="100.0" ID="CMP-023.13.03" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-12-05 16:46:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.6953437754874789" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.39161354999581366">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3540438190082247" CI_END="3.1283929156666863" CI_START="0.14855055226625272" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6817070450920387" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="10.555730280021024" I2_Q="9.60869803481498" ID="CMP-023.14" LOG_CI_END="0.4953212937450582" LOG_CI_START="-0.8281257292811165" LOG_EFFECT_SIZE="-0.1664022177680291" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.3401913846773982" P_Q="0.34502036774367595" P_Z="0.6221058502173685" Q="3.318903406386906" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2855480551186635" TOTALS="SUB" TOTAL_1="134" TOTAL_2="140" WEIGHT="400.0" Z="0.4928680152639217">
<NAME>Other adverse events: 6. Endocrine</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-023.14.01" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>amenorrhoea (women only) - short term</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-023.14.02" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>gynaecomastia - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0862492931267673E-32" CI_END="4.300210912127464" CI_START="0.010384714212089977" DF="0" EFFECT_SIZE="0.2113207547169811" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.0" ID="CMP-023.14.03" LOG_CI_END="0.6334897569113976" LOG_CI_START="-1.9836054507726129" LOG_EFFECT_SIZE="-0.6750578469306074" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.31196251858008384" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0111126745258967">
<NAME>lactation - short term</NAME>
<DICH_DATA CI_END="4.300210912127464" CI_START="0.010384714212089977" EFFECT_SIZE="0.21132075471698114" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6334897569113976" LOG_CI_START="-1.9836054507726129" LOG_EFFECT_SIZE="-0.6750578469306074" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24707" O_E="0.0" SE="1.5372946798237985" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.363274932614555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-023.14.04" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>menorrhagia (women only) - short term</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.381464454543305" CI_END="1.2606292213803314" CI_START="0.568818070050841" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8467990793306606" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" I2="51.540465814620696" I2_Q="18.552454812208744" ID="CMP-023.15" LOG_CI_END="0.1005873698506349" LOG_CI_START="-0.2450266155154306" LOG_EFFECT_SIZE="-0.07221962283239787" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0539802337355596" P_Q="0.2929352110438598" P_Z="0.412723915773765" Q="6.138920440722485" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2170898711418539" TOTALS="SUB" TOTAL_1="764" TOTAL_2="621" WEIGHT="600.0" Z="0.8191095599250274">
<NAME>Other adverse events: 7. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2031855130165963" CI_START="0.004123910226555628" DF="0" EFFECT_SIZE="0.07044025157232703" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-023.15.01" LOG_CI_END="0.08033259414614691" LOG_CI_START="-2.384690797446687" LOG_EFFECT_SIZE="-1.15217910165027" MODIFIED="2013-12-05 16:47:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06691901719066125" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.8322175364956959">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="1.2031855130165963" CI_START="0.004123910226555628" EFFECT_SIZE="0.07044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.08033259414614691" LOG_CI_START="-2.384690797446687" LOG_EFFECT_SIZE="-1.1521791016502698" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24711" O_E="0.0" SE="1.4479669422842112" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.0966082659478884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-023.15.02" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>diarrhoea - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24717" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4220088003380484" CI_START="0.5158621577773126" DF="0" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" I2="0.0" ID="CMP-023.15.03" LOG_CI_END="0.15290228410572143" LOG_CI_START="-0.2874663296015556" LOG_EFFECT_SIZE="-0.06728202274791709" MODIFIED="2013-12-16 16:40:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5492336381610415" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.5989089017165031">
<NAME>faintness, dizziness, weakness - long term</NAME>
<DICH_DATA CI_END="1.4220088003380484" CI_START="0.5158621577773126" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.15290228410572143" LOG_CI_START="-0.2874663296015556" LOG_EFFECT_SIZE="-0.06728202274791709" MODIFIED="2013-12-16 16:40:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1772" O_E="0.0" SE="0.25867470355144867" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.06691260225742984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2318509903721298" CI_START="0.2557392721532988" DF="0" EFFECT_SIZE="0.7554945054945055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-023.15.04" LOG_CI_END="0.34866519554358555" LOG_CI_START="-0.5922025751811721" LOG_EFFECT_SIZE="-0.12176868981879335" MODIFIED="2013-12-16 16:40:03 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6119277331231854" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.5073236727103975">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="2.2318509903721298" CI_START="0.2557392721532988" EFFECT_SIZE="0.7554945054945055" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.34866519554358555" LOG_CI_START="-0.5922025751811721" LOG_EFFECT_SIZE="-0.12176868981879335" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24728" O_E="0.0" SE="0.5526703858943008" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.30544455544455545" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.022757726815898" CI_START="0.5577698122490747" DF="0" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-023.15.05" LOG_CI_END="0.9043236774703935" LOG_CI_START="-0.2535449944235417" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2013-12-16 16:40:02 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.27063763474898905" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.1015953809268253">
<NAME>weight loss - short term</NAME>
<DICH_DATA CI_END="8.022757726815898" CI_START="0.5577698122490747" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9043236774703935" LOG_CI_START="-0.2535449944235417" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24736" O_E="0.0" SE="0.6801377894128605" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.4625874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.206011616732374" CI_END="2.808557397839512" CI_START="0.28780820359292325" DF="1" EFFECT_SIZE="0.8990694407885328" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" I2="83.88659155416589" ID="CMP-023.15.06" LOG_CI_END="0.44848330387897684" LOG_CI_START="-0.540896831232069" LOG_EFFECT_SIZE="-0.046206763676546095" MODIFIED="2013-12-16 16:40:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.012731799394551713" P_Z="0.8547420128768718" STUDIES="2" TAU2="0.5666643317129365" TOTAL_1="295" TOTAL_2="216" WEIGHT="100.0" Z="0.18307137860215744">
<NAME>weight gain - short term</NAME>
<DICH_DATA CI_END="3.044444452848875" CI_START="0.8421019130955489" EFFECT_SIZE="1.6011659807956105" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.4835080545799675" LOG_CI_START="-0.07463534601022986" LOG_EFFECT_SIZE="0.20443635428486878" MODIFIED="2013-12-16 16:40:50 +0000" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.32785619636107355" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="161" VAR="0.10748968549235083" WEIGHT="50.10054496023169"/>
<DICH_DATA CI_END="0.9654204139337209" CI_START="0.262762644747902" EFFECT_SIZE="0.5036630036630036" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.015283522209852666" LOG_CI_START="-0.5804363755390965" LOG_EFFECT_SIZE="-0.2978599488744746" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24738" O_E="0.0" SE="0.33197358359734014" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.11020646020646019" WEIGHT="49.89945503976831"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.039895147532580576" CI_END="1.5132033750691145" CI_START="0.32771238016200177" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.704198466139393" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-023.16" LOG_CI_END="0.17989730127802725" LOG_CI_START="-0.4845071517379075" LOG_EFFECT_SIZE="-0.15230492522994013" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.980250069271184" P_Q="0.9802556710523519" P_Z="0.36887339179871426" Q="0.03988371826002688" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="165" WEIGHT="300.0" Z="0.8985856935898323">
<NAME>Other adverse events: 8. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.375539620476798" CI_START="0.1864223630106055" DF="0" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-023.16.01" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-12-05 16:47:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7539433993150382" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.31344394882999155">
<NAME>pruritus - short term</NAME>
<DICH_DATA CI_END="3.375539620476798" CI_START="0.1864223630106055" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24761" O_E="0.0" SE="0.7388644976724391" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.5459207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4844413016390655E-32" CI_END="4.051933926789899" CI_START="0.12270826589248707" DF="0" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="100.0" ID="CMP-023.16.02" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-12-05 16:47:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.6953437754874789" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.39161354999581366">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="4.051933926789899" CI_START="0.12270826589248707" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6076623548855509" LOG_CI_START="-0.9111261812780239" LOG_EFFECT_SIZE="-0.15173191319623652" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24755" O_E="0.0" SE="0.8921439042669886" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.7959207459207458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.891100991947133" CI_START="0.23108087533137314" DF="0" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-023.16.03" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4402112377838353" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.7718365664995955">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="1.891100991947133" CI_START="0.23108087533137314" EFFECT_SIZE="0.6610576923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27671472243265693" LOG_CI_START="-0.6362359960256172" LOG_EFFECT_SIZE="-0.1797606367964801" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.536271771201331" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.2875874125874126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.589001628866075" CI_END="1.2916567728895998" CI_START="0.386958188807261" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7069774857787137" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-023.17" LOG_CI_END="0.11114712554518932" LOG_CI_START="-0.4123359583693765" LOG_EFFECT_SIZE="-0.15059441641209356" METHOD="MH" MODIFIED="2015-01-26 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.4707656312176566" P_Q="0.4755176210409924" P_Z="0.2594568320480931" Q="5.549307545438651" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="543" TOTAL_2="485" WEIGHT="700.0" Z="1.1276759135494896">
<NAME>Other adverse events: 9. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.007022459510349" CI_START="0.2234287996105537" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-023.17.01" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-16 16:41:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9436301877371425" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.07070795723063611">
<NAME>diminished sexual desire</NAME>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.42684164198362" CI_START="0.022752978588870532" DF="0" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-023.17.02" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10453041457457127" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="1.6232760143036378">
<NAME>ejaculatory dysfunction (men only) - short term</NAME>
<DICH_DATA CI_END="1.42684164198362" CI_START="0.022752978588870532" EFFECT_SIZE="0.18018018018018017" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.15437577561711396" LOG_CI_START="-1.6429617418624667" LOG_EFFECT_SIZE="-0.7442929831226762" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.0557649547317054" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="1.1146396396396399" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.704826166858263" CI_START="0.3000645450671526" DF="0" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-023.17.03" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.852406310146861" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="40" WEIGHT="100.0" Z="0.18604903261707173">
<NAME>erectile dysfunction (men only) - short term</NAME>
<DICH_DATA CI_END="2.704826166858263" CI_START="0.3000645450671526" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4321393592022494" LOG_CI_START="-0.5227853167755643" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.5609274816227492" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="37" TOTAL_2="40" VAR="0.31463963963963965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853182864047471" CI_START="0.007985435897383642" DF="0" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-023.17.04" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.20736286396929804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.2608501562241463">
<NAME>galactorrhoea - short term</NAME>
<DICH_DATA CI_END="2.853182864047471" CI_START="0.007985435897383642" EFFECT_SIZE="0.1509433962264151" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4553296070239668" LOG_CI_START="-2.0977013722416578" LOG_EFFECT_SIZE="-0.8211858826088455" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.4996630349277935" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.2489892183288407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6510638796667785" CI_START="0.13524338979896414" DF="0" EFFECT_SIZE="0.4725415070242657" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-023.17.05" LOG_CI_END="0.21776387644274542" LOG_CI_START="-0.8688839524246421" LOG_EFFECT_SIZE="-0.3255600379909484" MODIFIED="2015-01-26 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2402301911386564" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999" Z="1.1744116765646646">
<NAME>galactorrhoea/ gynaecomastia - long term</NAME>
<DICH_DATA CI_END="1.6510638796667785" CI_START="0.13524338979896414" EFFECT_SIZE="0.4725415070242657" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.21776387644274542" LOG_CI_START="-0.8688839524246421" LOG_EFFECT_SIZE="-0.3255600379909484" MODIFIED="2013-12-16 16:41:50 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.6383023136702076" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.4074298436367402" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.007022459510349" CI_START="0.2234287996105537" DF="0" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-023.17.06" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-16 16:41:39 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9436301877371425" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.07070795723063611">
<NAME>increased sexual desire - short term</NAME>
<DICH_DATA CI_END="5.007022459510349" CI_START="0.2234287996105537" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6995795394755088" LOG_CI_START="-0.6508608477566193" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7932553682478797" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.6292540792540792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.50527280318661" CI_START="0.2596178553022495" DF="0" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-023.17.07" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-12-16 16:41:37 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.2789217673806622" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="1.0827447147660128">
<NAME>orgastic dysfunction - short term</NAME>
<DICH_DATA CI_END="107.50527280318661" CI_START="0.2596178553022495" EFFECT_SIZE="5.283018867924528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0314297655834355" LOG_CI_START="-0.585665442100575" LOG_EFFECT_SIZE="0.7228821617414302" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.5372946798237985" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="2.363274932614555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5324772899385852" CI_END="1.345709978027315" CI_START="0.7552635467230628" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0081496371400056" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-023.18" LOG_CI_END="0.12895147258183412" LOG_CI_START="-0.12190147629723556" LOG_EFFECT_SIZE="0.0035249981422993014" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.47295736620202855" P_Q="0.47565243777076716" P_Z="0.9560723211115946" Q="3.514662465908648" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="887" TOTAL_2="665" WEIGHT="500.0" Z="0.055083023224157875">
<NAME>Other adverse events: 10. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.683465127741492" CI_START="0.6003233389948932" DF="0" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-023.18.01" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-12-05 16:48:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5325490557720918" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.6241195857360581">
<NAME>failing memory - short term</NAME>
<DICH_DATA CI_END="2.683465127741492" CI_START="0.6003233389948932" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.42869595590110665" LOG_CI_START="-0.22161477208696762" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.3819957407102152" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.14592074592074594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1496383281228006" CI_START="0.1573271619628004" DF="0" EFFECT_SIZE="0.42528735632183906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-023.18.02" LOG_CI_END="0.0605612344361494" LOG_CI_START="-0.8031962915393964" LOG_EFFECT_SIZE="-0.37131752855162353" MODIFIED="2013-12-16 16:42:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0919647777592386" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.6851233382138069">
<NAME>incontinence nocturia - long term</NAME>
<DICH_DATA CI_END="1.1496383281228006" CI_START="0.1573271619628004" EFFECT_SIZE="0.42528735632183906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.0605612344361494" LOG_CI_START="-0.8031962915393964" LOG_EFFECT_SIZE="-0.37131752855162353" MODIFIED="2013-12-16 16:42:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.5073754464267464" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.2574298436367402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.259756361127295" CI_START="0.04462039892987694" DF="0" EFFECT_SIZE="0.7088122605363985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-023.18.03" LOG_CI_END="1.0515289933427914" LOG_CI_START="-1.3504665512133256" LOG_EFFECT_SIZE="-0.14946877893526717" MODIFIED="2013-12-16 16:42:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8072888798700267" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.24392503490712333">
<NAME>suicide attempt - long term</NAME>
<DICH_DATA CI_END="11.259756361127295" CI_START="0.04462039892987694" EFFECT_SIZE="0.7088122605363985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0515289933427914" LOG_CI_START="-1.3504665512133256" LOG_EFFECT_SIZE="-0.14946877893526717" MODIFIED="2013-12-16 16:42:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="1.4109440729419693" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="1.9907631769700735" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0723149610069576" CI_START="0.4461465705813854" DF="0" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-023.18.04" LOG_CI_END="0.31645576238212664" LOG_CI_START="-0.3505224409796873" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-12-16 16:42:14 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9202590494012456" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="55" WEIGHT="100.0" Z="0.10010741398681083">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="2.0723149610069576" CI_START="0.4461465705813854" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.31645576238212664" LOG_CI_START="-0.3505224409796873" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-12-05 16:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="24772" O_E="0.0" SE="0.39178629825008365" STUDY_ID="STD-Hoyberg-1993" TOTAL_1="52" TOTAL_2="55" VAR="0.1534965034965035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5783661085446528" CI_START="0.7554417076404487" DF="0" EFFECT_SIZE="1.0919540229885059" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="37" I2="0.0" ID="CMP-023.18.05" LOG_CI_END="0.19820774695899457" LOG_CI_START="-0.12179904161853604" LOG_EFFECT_SIZE="0.038204352670229286" MODIFIED="2013-12-16 16:43:04 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6397954664395198" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.46798479256745196">
<NAME>urinary hesitancy, dry mouth, constipation - long term</NAME>
<DICH_DATA CI_END="1.5783661085446528" CI_START="0.7554417076404487" EFFECT_SIZE="1.0919540229885059" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="37" LOG_CI_END="0.19820774695899457" LOG_CI_START="-0.12179904161853604" LOG_EFFECT_SIZE="0.038204352670229286" MODIFIED="2013-12-16 16:43:04 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.1879735716695923" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.03533406364622336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8694615754101014" CI_START="0.6260870095383573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-023.19" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" METHOD="MH" MODIFIED="2014-01-14 16:50:31 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.7779550037703511" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.28198501124085223">
<NAME>Other adverse events: 11. any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8694615754101014" CI_START="0.6260870095383573" DF="0" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" ID="CMP-023.19.01" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" MODIFIED="2013-12-16 16:44:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7779550037703511" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.28198501124085223">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.8694615754101014" CI_START="0.6260870095383573" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" MODIFIED="2013-12-16 16:44:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.27906543056805083" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.07787751453813159" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="49.488671544842894" CI_END="0.13847781763361927" CI_START="-0.1406280041147721" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0010750932405764098" ESTIMABLE="YES" I2="89.89667767608314" I2_Q="89.89667767608314" ID="CMP-023.20" MODIFIED="2014-02-18 15:28:03 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.763211909810991E-9" P_Q="1.763211909810991E-9" P_Z="0.9879530007811681" Q="49.488671544842894" RANDOM="YES" SCALE="39.524003291187725" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="23.91374481357382" TOTALS="SUB" TOTAL_1="1566" TOTAL_2="2046" UNITS="" WEIGHT="600.0" Z="0.015099248151489794">
<NAME>Other adverse events: 12. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.015108702230616" CI_START="-5.584891297769383" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.01" MODIFIED="2013-12-11 15:59:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04876996046546003" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0" Z="1.970597258538528">
<NAME>mean weight change (lb) - long term</NAME>
<CONT_DATA CI_END="-0.015108702230616" CI_START="-5.584891297769383" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="0.8" MODIFIED="2013-12-11 15:59:47 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="17.77" SD_2="16.61" SE="1.420889016194303" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.043352552452935" CI_START="-7.043352552452935" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.02" MODIFIED="2013-12-11 15:59:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5958656677840899" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0" Z="0.5303552225826147">
<NAME>change in blood glucose - long term</NAME>
<CONT_DATA CI_END="4.043352552452935" CI_START="-7.043352552452935" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="6.7" MODIFIED="2013-12-11 15:59:52 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="32.31" SD_2="36.93" SE="2.8282930687391157" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15988419738797166" CI_START="-0.11988419738797167" DF="0" EFFECT_SIZE="0.020000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.03" MODIFIED="2013-12-11 16:00:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7793036238261714" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0" Z="0.2802266476325492">
<NAME>change in glycosylated haemoglobin - long term</NAME>
<CONT_DATA CI_END="0.15988419738797166" CI_START="-0.11988419738797167" EFFECT_SIZE="0.020000000000000004" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.08" MODIFIED="2013-12-11 16:00:03 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="0.96" SD_2="0.73" SE="0.07137079991844766" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.446031495116102" CI_START="-3.2460314951161027" DF="0" EFFECT_SIZE="2.6" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.04" MODIFIED="2013-12-11 16:00:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.383379470999628" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0" Z="0.8716864361851914">
<NAME>change in cholesterol - long term</NAME>
<CONT_DATA CI_END="8.446031495116102" CI_START="-3.2460314951161027" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-2.1" MODIFIED="2013-12-11 16:00:08 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="37.15" SD_2="35.08" SE="2.9827239384135895" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="36.59897664334216" CI_START="-14.79897664334216" DF="0" EFFECT_SIZE="10.9" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.05" MODIFIED="2013-12-11 16:00:15 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.40580312450971423" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="99.99999999999999" Z="0.8313018735328228">
<NAME>change in triglycerides - long term</NAME>
<CONT_DATA CI_END="36.59897664334216" CI_START="-14.79897664334216" EFFECT_SIZE="10.9" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="-2.6" MODIFIED="2013-12-11 16:00:15 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="185.78" SD_2="116.33" SE="13.111963712625542" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-10.557500671162435" CI_START="-19.442499328837563" DF="0" EFFECT_SIZE="-15.0" ESTIMABLE="YES" I2="0.0" ID="CMP-023.20.06" MODIFIED="2013-12-11 16:00:20 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="3.6464613902512975E-11" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0" Z="6.617774723624674">
<NAME>change in prolactin - long term</NAME>
<CONT_DATA CI_END="-10.557500671162435" CI_START="-19.442499328837563" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="15.4" MODIFIED="2013-12-11 16:00:20 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="27.46" SD_2="27.69" SE="2.266622939951669" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="341" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2015-01-14 16:42:22 +0000" MODIFIED_BY="Heather Maxwell" NO="24">
<NAME>PERPHENAZINE vs SULPIRIDE</NAME>
<DICH_OUTCOME CHI2="1.397892445344541" CI_END="3.2034782434159816" CI_START="0.6157881075529638" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.404515505468067" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="28.463738155940295" I2_Q="27.64596754643807" ID="CMP-024.01" LOG_CI_END="0.5056217788050231" LOG_CI_START="-0.21056870269166586" LOG_EFFECT_SIZE="0.1475265380566786" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23707697695586005" P_Q="0.23974515471331714" P_Z="0.419402936426307" Q="1.3820929754562294" RANDOM="YES" SCALE="833.8118537723943" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10988895524053495" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.8074575376950316">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7099337547351947" CI_START="0.23616813469395628" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-024.01.01" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:23:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7199942888160342" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="35.5824752695393" Z="0.35846642707103965">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.7099337547351947" CI_START="0.23616813469395628" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24503" O_E="0.0" SE="0.6224949798994366" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.3875" WEIGHT="35.5824752695393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2477056014095735" CI_START="0.8648459794134622" DF="0" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-024.01.02" LOG_CI_END="0.628154409176546" LOG_CI_START="-0.0630612292366097" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10908050422330752" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="64.4175247304607" Z="1.6023397316851091">
<NAME>medium term</NAME>
<DICH_DATA CI_END="4.2477056014095735" CI_START="0.8648459794134622" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.628154409176546" LOG_CI_START="-0.0630612292366097" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24522" O_E="0.0" SE="0.40602348757648016" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.16485507246376813" WEIGHT="64.4175247304607"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2102574392864694E-4" CI_END="27.40926773277343" CI_START="0.31516964474987885" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9391442928499645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="1.437897433063619" LOG_CI_START="-0.501455617808318" LOG_EFFECT_SIZE="0.46822090762765045" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9857049146428738" P_Q="0.9857050383958766" P_Z="0.3439476391894868" Q="3.2102018509785326E-4" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.9463940723389713">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.99720406421005" CI_START="0.12676555532891653" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-024.02.01" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:23:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="49.79714544233969" Z="0.6805377123908883">
<NAME>short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24523" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="49.79714544233969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.28973413262064" CI_START="0.12326397342650598" DF="0" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-024.02.02" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.510593226807788" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="50.20285455766032" Z="0.6579142667226608">
<NAME>medium term</NAME>
<DICH_DATA CI_END="67.28973413262064" CI_START="0.12326397342650598" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24530" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="50.20285455766032"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32487879488159405" CI_END="3.3911894949420955" CI_START="0.47015507617997004" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2626895720386762" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="0.5303520582264343" LOG_CI_START="-0.327758870530569" LOG_EFFECT_SIZE="0.10129659384793264" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5686904524905516" P_Q="0.5725734546334277" P_Z="0.6435565087050727" Q="0.3183957638878298" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.4627319593426382">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.99720406421005" CI_START="0.12676555532891653" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-024.03.01" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:23:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="9.749392587860884" Z="0.6805377123908883">
<NAME>short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24531" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="9.749392587860884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2533714519401724" CI_START="0.4065013846517025" DF="0" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-024.03.02" LOG_CI_END="0.512333651452242" LOG_CI_START="-0.3909379707450186" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.792234256399401" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="90.25060741213912" Z="0.26341042518982305">
<NAME>medium term</NAME>
<DICH_DATA CI_END="3.2533714519401724" CI_START="0.4065013846517025" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.512333651452242" LOG_CI_START="-0.3909379707450186" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24537" O_E="0.0" SE="0.5305862221453124" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.28152173913043477" WEIGHT="90.25060741213912"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4193938158005337" CI_END="1.4252687609897983" CI_START="0.6481012539093353" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9611027370449493" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="29.54738925391167" I2_Q="29.534986328176753" ID="CMP-024.04" LOG_CI_END="0.15389676638602326" LOG_CI_START="-0.1883571382978468" LOG_EFFECT_SIZE="-0.01723018595591176" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.23350344518262267" P_Q="0.23354459210741196" P_Z="0.8435598737268343" Q="1.4191439806672013" RANDOM="YES" SCALE="121.56333741221304" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02408475355231327" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.19734205195822538">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2400078608277645" CI_START="0.516125760342172" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-024.04.01" LOG_CI_END="0.0934244383100579" LOG_CI_START="-0.2872444643261707" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:24:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.31831414171413397" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="54.55608366023599" Z="0.9979282989585709">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2400078608277645" CI_START="0.516125760342172" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.0934244383100579" LOG_CI_START="-0.2872444643261707" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24538" O_E="0.0" SE="0.22360679774997896" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.05" WEIGHT="54.55608366023599"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9733276554268837" CI_START="0.7272002377969754" DF="0" EFFECT_SIZE="1.1979166666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-024.04.02" LOG_CI_END="0.29519920239836506" LOG_CI_START="-0.13834598777027854" LOG_EFFECT_SIZE="0.0784266073140433" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4782627756259622" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="45.443916339764" Z="0.7090994399241192">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.9733276554268837" CI_START="0.7272002377969754" EFFECT_SIZE="1.1979166666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.29519920239836506" LOG_CI_START="-0.13834598777027854" LOG_EFFECT_SIZE="0.0784266073140433" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24552" O_E="0.0" SE="0.2546665907883642" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.06485507246376812" WEIGHT="45.443916339764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-024.05" MODIFIED="2015-01-14 16:42:22 +0000" MODIFIED_BY="Heather Maxwell" NO="5" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 1. State - BPRS end score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Subgroup</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-024.05.01" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>medium term</NAME>
<OTHER_DATA MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="3420" STUDY_ID="STD-Lepola-1989">
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>Acute schizophrenia</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>23.8</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Perphenazine</P>
</TD>
<TD>
<P>Chronic schizophrenia</P>
</TD>
<TD>
<P>30.5</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulpiride</P>
</TD>
<TD>
<P>Acute schizophrenia</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>6.3</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulpiride</P>
</TD>
<TD>
<P>Chronic schizophrenia</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="8.284866145958945" CI_END="1.2214244078795427" CI_START="0.4867042542664231" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.771020398938848" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="39" I2="3.438391652204215" I2_Q="2.861535132869967" ID="CMP-024.06" LOG_CI_END="0.08686659430851798" LOG_CI_START="-0.3127348575856344" LOG_EFFECT_SIZE="-0.11293413163855819" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.40614998265960356" P_Q="0.4107948907840385" P_Z="0.26793181625535456" Q="8.235666490038449" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.019313433348464686" TOTALS="SUB" TOTAL_1="248" TOTAL_2="243" WEIGHT="900.0" Z="1.1078379699957175">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.085766525783107" CI_START="0.1822885805844461" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-024.06.01" LOG_CI_END="0.48936306352885245" LOG_CI_START="-0.7392405367454522" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-12-05 15:24:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6901702959034299" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.39862397273055633">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="3.085766525783107" CI_START="0.1822885805844461" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48936306352885245" LOG_CI_START="-0.7392405367454522" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24561" O_E="0.0" SE="0.7216878364870322" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.5208333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.815733993467754" CI_START="0.6449591575646803" DF="0" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-024.06.02" LOG_CI_END="1.1077434845104472" LOG_CI_START="-0.1904677864591487" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16609846722492633" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3848495790146993">
<NAME>akathisia - medium term</NAME>
<DICH_DATA CI_END="12.815733993467754" CI_START="0.6449591575646803" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1077434845104472" LOG_CI_START="-0.1904677864591487" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24568" O_E="0.0" SE="0.7625757268169732" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.5815217391304348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.304614839074713" CI_START="0.06533976911636269" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-024.06.03" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24573" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.931409775025128" CI_START="0.046558835083477614" DF="0" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-024.06.04" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5362372749139819" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6185129387560958">
<NAME>dyskinesia - medium term</NAME>
<DICH_DATA CI_END="4.931409775025128" CI_START="0.046558835083477614" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24583" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.087279415717843" CI_START="0.05748292398117026" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-024.06.05" LOG_CI_END="0.036341166083179575" LOG_CI_START="-1.2404611487391044" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.06454558558747073" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.8483924814931874">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="1.087279415717843" CI_START="0.05748292398117026" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.036341166083179575" LOG_CI_START="-1.2404611487391044" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24599" O_E="0.0" SE="0.75" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.5625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4809410191236787" CI_START="0.11726111132110974" DF="0" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-024.06.06" LOG_CI_END="0.5416966646844225" LOG_CI_START="-0.9308459941838114" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6044859550515078" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.5179603224621843">
<NAME>rigidity - medium term</NAME>
<DICH_DATA CI_END="3.4809410191236787" CI_START="0.11726111132110974" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5416966646844225" LOG_CI_START="-0.9308459941838114" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24600" O_E="0.0" SE="0.8649788470229208" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.7481884057971014" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.432086880200709" CI_START="0.2827752165631144" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-024.06.07" LOG_CI_END="0.15596936604949246" LOG_CI_START="-0.548558656337429" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.2747605865930951" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="1.092165031383115">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="1.432086880200709" CI_START="0.2827752165631144" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.15596936604949246" LOG_CI_START="-0.548558656337429" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24603" O_E="0.0" SE="0.4138432478200336" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.17126623376623376" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6287762406689716" CI_START="0.4960541309410133" DF="0" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-024.06.08" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.5626142092360964" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5789629004672663">
<NAME>tremor - medium term</NAME>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24604" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-024.06.09" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2013-12-05 15:25:46 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>use of antiparkinsonian drugs - medium term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24612" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9498099453617104" CI_END="8.43295286185647" CI_START="0.5074955482723668" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.06874020509654" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-024.07" LOG_CI_END="0.9259796727339764" LOG_CI_START="-0.2945677630092829" LOG_EFFECT_SIZE="0.3157059548623468" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5828891963292316" P_Q="0.5831140261123349" P_Z="0.3106181470157934" Q="1.9487401775103046" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="119" WEIGHT="400.0" Z="1.0139258550950505">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.888578229356675" CI_START="0.014085061703212953" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-024.07.01" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:25:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6805377123908883">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24614" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="100.2049917255156" CI_START="0.2494885690772842" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-024.07.02" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-05 15:26:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2926808653233127" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.0522587535741466">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24620" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.725639100100512" CI_START="0.18623534033391048" DF="0" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-024.07.03" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5844112219801221" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.5469527129537599">
<NAME>dry mouth - medium term</NAME>
<DICH_DATA CI_END="19.725639100100512" CI_START="0.18623534033391048" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24627" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="100.2049917255156" CI_START="0.2494885690772842" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-024.07.04" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-18 10:26:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2926808653233127" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.0522587535741466">
<NAME>increased salivation - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-18 10:26:23 +0000" MODIFIED_BY="[Empty name]" ORDER="24769" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.7927821504295185" CI_END="1.7333353207937918" CI_START="0.5583761446250357" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.983795249921058" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="16.5411680636991" I2_Q="14.655988802696307" ID="CMP-024.08" LOG_CI_END="0.23888258688203015" LOG_CI_START="-0.2530731442513298" LOG_EFFECT_SIZE="-0.007095278684649811" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.30922787025358545" P_Q="0.3209561020085734" P_Z="0.9549151864730993" Q="4.686913520800594" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09160327945377762" TOTALS="SUB" TOTAL_1="136" TOTAL_2="133" WEIGHT="500.0" Z="0.056535536846580914">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5293329029537468" CI_START="0.07265331890559054" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-024.08.01" LOG_CI_END="0.18450203229193085" LOG_CI_START="-1.1387445417312556" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:26:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1575372032790995" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.4134032067295021">
<NAME>excitation - short term</NAME>
<DICH_DATA CI_END="1.5293329029537468" CI_START="0.07265331890559054" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18450203229193085" LOG_CI_START="-1.1387445417312556" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24634" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.096292470222609" CI_START="0.32037330253759905" DF="0" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-024.08.02" LOG_CI_END="0.7072543436913086" LOG_CI_START="-0.4943436818627349" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2013-12-05 15:26:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7283770574725384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.3472852153832226">
<NAME>excitation - medium term</NAME>
<DICH_DATA CI_END="5.096292470222609" CI_START="0.32037330253759905" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7072543436913086" LOG_CI_START="-0.4943436818627349" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24635" O_E="0.0" SE="0.7058246282165999" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.49818840579710144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.031136242063711" CI_START="0.5453602518916572" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-024.08.03" LOG_CI_END="0.481605457267226" LOG_CI_START="-0.26331651841708975" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-12-05 15:26:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5657377754733713" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5743399608753698">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="3.031136242063711" CI_START="0.5453602518916572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.481605457267226" LOG_CI_START="-0.26331651841708975" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24638" O_E="0.0" SE="0.4375708559402168" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.19146825396825395" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9867592830922347" CI_START="0.02889135795141335" DF="0" EFFECT_SIZE="0.23958333333333337" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-024.08.04" LOG_CI_END="0.2981452509257821" LOG_CI_START="-1.539232044969733" LOG_EFFECT_SIZE="-0.6205433970219755" MODIFIED="2013-12-05 15:26:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.18553958168620477" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3238899944221094">
<NAME>insomnia - medium term</NAME>
<DICH_DATA CI_END="1.9867592830922347" CI_START="0.02889135795141335" EFFECT_SIZE="0.23958333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2981452509257821" LOG_CI_START="-1.539232044969733" LOG_EFFECT_SIZE="-0.6205433970219755" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="1.079284518773325" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.164855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.187886799492831E-32" CI_END="5.932232668008021" CI_START="0.43004362268500357" DF="0" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-024.08.05" LOG_CI_END="0.7732181761477137" LOG_CI_START="-0.36648748830302735" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-12-05 15:26:43 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.484265168923087" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6994591011065763">
<NAME>need of additional benzodiazepines - medium term</NAME>
<DICH_DATA CI_END="5.932232668008023" CI_START="0.4300436226850036" EFFECT_SIZE="1.5972222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7732181761477139" LOG_CI_START="-0.3664874883030273" LOG_EFFECT_SIZE="0.20336534392234326" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24651" O_E="0.0" SE="0.6694687489323915" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="0.4481884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1685521339826255" CI_START="0.49676762322508666" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-024.09" LOG_CI_END="0.06764809284797227" LOG_CI_START="-0.30384671700396126" LOG_EFFECT_SIZE="-0.11809931207799451" METHOD="MH" MODIFIED="2014-02-18 15:33:16 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.2127068465563433" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.2461568352143737">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1685521339826255" CI_START="0.49676762322508666" DF="0" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" ID="CMP-024.09.01" LOG_CI_END="0.06764809284797227" LOG_CI_START="-0.30384671700396126" LOG_EFFECT_SIZE="-0.11809931207799451" MODIFIED="2013-12-05 15:26:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2127068465563433" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.2461568352143737">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1685521339826255" CI_START="0.49676762322508666" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.06764809284797227" LOG_CI_START="-0.30384671700396126" LOG_EFFECT_SIZE="-0.11809931207799451" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24658" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.047619047619047616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4301479188529993" CI_END="7.634279382165236" CI_START="0.1889641686715522" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2010850331501202" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="30.077162871235345" I2_Q="28.763362465802913" ID="CMP-024.10" LOG_CI_END="0.8827680492353646" LOG_CI_START="-0.7236205388082372" LOG_EFFECT_SIZE="0.07957375521356372" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.2317405557440444" P_Q="0.23609324907834717" P_Z="0.8460374515233282" Q="1.403772040082536" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8123115338794047" TOTALS="SUB" TOTAL_1="64" TOTAL_2="64" WEIGHT="200.0" Z="0.1941767956944151">
<NAME>Other adverse events: 4. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.242335393587904" CI_START="0.04768866950134176" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-024.10.01" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:27:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5631799263271209" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.5781247128390816">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="5.242335393587904" CI_START="0.04768866950134176" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24687" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="100.2049917255156" CI_START="0.2494885690772842" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-024.10.02" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-05 15:27:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2926808653233127" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.0522587535741466">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="100.2049917255156" CI_START="0.2494885690772842" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0008893565097607" LOG_CI_START="-0.6029493478377235" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07325447181146155" CI_END="1.562213302466476" CI_START="0.04573999887117474" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2673118678460625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.11" LOG_CI_END="0.19374033156412207" LOG_CI_START="-1.339703850447298" LOG_EFFECT_SIZE="-0.572981759441588" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.7866559094043567" P_Q="0.7874916299212482" P_Z="0.14300073242118735" Q="0.07266760576228365" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="46" WEIGHT="200.0" Z="1.464707519814428">
<NAME>Other adverse events: 5. Endocrine</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853499025422034" CI_START="0.035761271399532814" DF="0" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-024.11.01" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-12-05 15:27:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30704811123910736" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0214356188366485">
<NAME>amenorrhoea - medium term</NAME>
<DICH_DATA CI_END="2.853499025422034" CI_START="0.035761271399532814" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24705" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7961818474222007" CI_START="0.00971080982989066" DF="0" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-024.11.02" LOG_CI_END="0.5793470081389256" LOG_CI_START="-2.0127445507318265" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2013-12-05 15:27:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27843661098111394" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0838380879702514">
<NAME>lactation - medium term</NAME>
<DICH_DATA CI_END="3.7961818474222007" CI_START="0.00971080982989066" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5793470081389256" LOG_CI_START="-2.0127445507318265" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24708" O_E="0.0" SE="1.5226074127408329" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.3183333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.083747421112488" CI_END="1.8541832632387831" CI_START="0.4212598548174351" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8837946437249367" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="38.14749843690814" I2_Q="35.09981327042107" ID="CMP-024.12" LOG_CI_END="0.268152656604569" LOG_CI_START="-0.37544992625646106" LOG_EFFECT_SIZE="-0.05364863482594606" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.1516802717170529" P_Q="0.1733126917366884" P_Z="0.7438550523754115" Q="7.704138080270266" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5721263959298447" TOTALS="SUB" TOTAL_1="184" TOTAL_2="183" WEIGHT="600.0" Z="0.3267525484785071">
<NAME>Other adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.242335393587904" CI_START="0.04768866950134176" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-024.12.01" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:27:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5631799263271209" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.5781247128390816">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="5.242335393587904" CI_START="0.04768866950134176" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24710" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7099337547351947" CI_START="0.23616813469395628" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-024.12.02" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:28:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7199942888160342" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.35846642707103965">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="2.7099337547351947" CI_START="0.23616813469395628" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43295867452584486" LOG_CI_START="-0.6267787005419576" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24721" O_E="0.0" SE="0.6224949798994366" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.3875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9128896710037826" CI_START="0.08364308847777954" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-024.12.03" LOG_CI_END="0.28168992211510563" LOG_CI_START="-1.077569939459181" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-12-05 15:28:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2511308465779948" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.147607027991571">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="1.9128896710037826" CI_START="0.08364308847777954" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28168992211510563" LOG_CI_START="-1.077569939459181" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24727" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.853499025422034" CI_START="0.035761271399532814" DF="0" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-024.12.04" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-12-05 15:28:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.30704811123910736" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.0214356188366485">
<NAME>nausea and vomiting - medium term</NAME>
<DICH_DATA CI_END="2.853499025422034" CI_START="0.035761271399532814" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.455377728556992" LOG_CI_START="-1.4465870493843431" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24734" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="191.0359474772963" CI_START="0.6333886454243398" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-024.12.05" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2013-12-05 15:28:18 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.09967924600633656" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.6464106300728845">
<NAME>weight loss - short term</NAME>
<DICH_DATA CI_END="191.0359474772963" CI_START="0.6333886454243398" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2811150966827576" LOG_CI_START="-0.19832972636630716" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24735" O_E="0.0" SE="1.4564381625088383" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.121212121212121" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.4396582525386" CI_START="0.6182050264589121" DF="0" EFFECT_SIZE="4.999999999999998" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-024.12.06" LOG_CI_END="1.606807476798691" LOG_CI_START="-0.2088674681266536" LOG_EFFECT_SIZE="0.6989700043360186" MODIFIED="2013-12-05 15:28:18 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.13129053833326138" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.5090322621913261">
<NAME>weight gain - short term</NAME>
<DICH_DATA CI_END="40.4396582525386" CI_START="0.6182050264589122" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.606807476798691" LOG_CI_START="-0.20886746812665352" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24737" O_E="0.0" SE="1.0665364503850772" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.1375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.888578229356675" CI_START="0.014085061703212953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-024.13" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.49616405585225376" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6805377123908883">
<NAME>Other adverse events: 7. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.888578229356675" CI_START="0.014085061703212953" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-024.13.01" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:28:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6805377123908883">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24754" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.031421785245579315" CI_END="1.328744068951648" CI_START="0.020411769558245935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16468763686848836" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.14" LOG_CI_END="0.12344133899715193" LOG_CI_START="-1.69011934334525" LOG_EFFECT_SIZE="-0.7833390021740491" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.8593027085249658" P_Q="0.8595038123681544" P_Z="0.09042668876942549" Q="0.03133108130072643" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="55" WEIGHT="200.0" Z="1.6931512100975403">
<NAME>Other adverse events: 8. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51692342322993" CI_START="0.007472679975765767" DF="0" EFFECT_SIZE="0.13714285714285712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-024.14.01" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746885" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18082341038738384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="1.3382240533939282">
<NAME>abdominal pain - medium term</NAME>
<DICH_DATA CI_END="2.51692342322993" CI_START="0.007472679975765767" EFFECT_SIZE="0.13714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4008700024476101" LOG_CI_START="-2.126523616396987" LOG_EFFECT_SIZE="-0.8628268069746884" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24764" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Lepola-1989" TOTAL_1="24" TOTAL_2="23" VAR="2.204047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.008199669020626" CI_START="0.009979542763091372" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-024.14.02" LOG_CI_END="0.6029493478377236" LOG_CI_START="-2.0008893565097607" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-01-14 16:50:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2926808653233127" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.0522587535741466">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="4.008199669020626" CI_START="0.009979542763091372" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6029493478377236" LOG_CI_START="-2.0008893565097607" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24770" O_E="0.0" SE="1.5295077441431735" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.3393939393939394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.021332481870983" CI_END="2.795949501114935" CI_START="0.21729068122432318" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7794445277029474" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.15" LOG_CI_END="0.4465293231590583" LOG_CI_START="-0.6629588985282354" LOG_EFFECT_SIZE="-0.10821478768458861" METHOD="MH" MODIFIED="2014-01-14 16:51:02 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6000957102673925" P_Q="0.6017599233242203" P_Z="0.7022142388520631" Q="1.0157936560545469" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="96" TOTAL_2="96" WEIGHT="300.0" Z="0.38233319166541146">
<NAME>Other adverse events: 9. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulpiride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulpiride</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.304614839074713" CI_START="0.06533976911636269" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-024.15.01" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>decrease in white blood cell count and haemoglobin level - short term</NAME>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5395048073116095" CI_START="0.09844438934717235" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-024.15.02" LOG_CI_END="0.40474903928980993" LOG_CI_START="-1.0068090306177724" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:29:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4031735023958657" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.83596695360366">
<NAME>increase in white blood cell count and haemoglobin level - short term</NAME>
<DICH_DATA CI_END="2.5395048073116095" CI_START="0.09844438934717235" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40474903928980993" LOG_CI_START="-1.0068090306177724" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.82915619758885" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="0.6875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.99720406421005" CI_START="0.12676555532891653" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-024.15.03" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:29:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49616405585225376" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6805377123908883">
<NAME>rise in alkaline phosphate and GOT levels - short term</NAME>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-05 15:20:58 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Amakusa-1973" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2014-02-21 16:10:02 +0000" MODIFIED_BY="[Empty name]" NO="25">
<NAME>PERPHENAZINE vs THIOPROPRAZATE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2225189133079537" CI_START="0.43265230016238926" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" MODIFIED="2014-02-18 15:35:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2294541729699583" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.201766131137683">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioproprazate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioproprazate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2225189133079537" CI_START="0.43265230016238926" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-025.01.01" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2013-12-09 16:55:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2294541729699583" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.201766131137683">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2225189133079537" CI_START="0.43265230016238926" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2013-12-09 16:55:22 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2649881061442979" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.07021869639794169" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.39626291789819" CI_START="0.18694853467396683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2014-02-18 15:35:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5665036016214859" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.5732083980392908">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioproprazate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioproprazate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.39626291789819" CI_START="0.18694853467396683" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-025.02.01" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:55:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5665036016214859" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.5732083980392908">
<NAME>short term</NAME>
<DICH_DATA CI_END="21.39626291789819" CI_START="0.18694853467396683" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:55:52 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="1.2092411467293842" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.4622641509433962" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6778072156379218" CI_END="10.038633283728387" CI_START="1.3101222188462271" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.626546085721485" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="1.0016745895282853" LOG_CI_START="0.11731181206385984" LOG_EFFECT_SIZE="0.5594932007960726" METHOD="MH" MODIFIED="2014-01-14 16:51:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7125512059288259" P_Q="0.7190204896030583" P_Z="0.01314018170968622" Q="0.6597310244668461" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="212" WEIGHT="300.0" Z="2.4799472594253333">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioproprazate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioproprazate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.94415887447036" CI_START="0.8918145441437945" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-025.03.01" LOG_CI_END="1.7399215292722836" LOG_CI_START="-0.04972544924376984" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-09 16:56:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06416256893212866" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.8510485494818223">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="54.94415887447036" CI_START="0.8918145441437945" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7399215292722836" LOG_CI_START="-0.04972544924376984" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-09 16:56:15 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="1.0512474940757477" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.105121293800539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-025.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-14 16:51:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:56:18 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.72582867659102" CI_START="0.24575862713766183" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-025.03.03" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-01-14 16:51:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29510060682471295" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.0469978026272877">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="101.72582867659102" CI_START="0.24575862713766183" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-09 16:56:19 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.5371932093796676" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="2.3629629629629627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.50610525879393" CI_START="0.7480572660956755" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-025.03.04" LOG_CI_END="0.9780026188226455" LOG_CI_START="-0.12606515427808324" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2014-01-14 16:51:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.13043797312713779" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.5123770372340826">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="9.50610525879393" CI_START="0.7480572660956755" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9780026188226455" LOG_CI_START="-0.12606515427808324" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2013-12-09 16:56:09 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.6485348751429869" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.42059748427672955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="26">
<NAME>PERPHENAZINE vs THIORIDAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2225189133079537" CI_START="0.43265230016238926" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" MODIFIED="2014-02-18 15:36:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2294541729699583" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.201766131137683">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioridazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioridazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2225189133079537" CI_START="0.43265230016238926" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2013-12-09 16:48:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2294541729699583" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.201766131137683">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2225189133079537" CI_START="0.43265230016238926" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.08725558671732696" LOG_CI_START="-0.3638609830498899" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2013-12-09 16:48:42 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2649881061442979" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.07021869639794169" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.39626291789819" CI_START="0.18694853467396683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2014-02-18 15:36:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5665036016214859" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.5732083980392908">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioridazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioridazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.39626291789819" CI_START="0.18694853467396683" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:49:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5665036016214859" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.5732083980392908">
<NAME>short term</NAME>
<DICH_DATA CI_END="21.39626291789819" CI_START="0.18694853467396683" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:49:09 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="1.2092411467293842" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.4622641509433962" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3471311753879018" CI_END="10.978414461536136" CI_START="1.259590219056662" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.718642692771266" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="1.0405396224157526" LOG_CI_START="0.10022927960327098" LOG_EFFECT_SIZE="0.5703844510095119" METHOD="MH" MODIFIED="2014-01-14 16:51:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5098873278727956" P_Q="0.5412075917355397" P_Z="0.017416468797994206" Q="1.2279057844827221" RANDOM="YES" SCALE="564.8720620492264" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="212" WEIGHT="300.0" Z="2.3777957774590477">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thioridazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thioridazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="256.15996440879053" CI_START="0.8783573987422009" DF="0" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-026.03.01" LOG_CI_END="2.4085112542337703" LOG_CI_START="-0.05632873612240765" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2013-12-09 16:45:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06143075204997282" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.870382271709579">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="256.15996440879053" CI_START="0.8783573987422009" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4085112542337703" LOG_CI_START="-0.05632873612240765" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2013-12-09 16:45:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="1.4478592114899487" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="2.096296296296296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-026.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-14 16:51:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:45:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.72582867659102" CI_START="0.24575862713766183" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-026.03.03" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-01-14 16:51:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29510060682471295" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.0469978026272877">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="101.72582867659102" CI_START="0.24575862713766183" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-09 16:45:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.5371932093796676" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="2.3629629629629627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.50610525879393" CI_START="0.7480572660956755" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-026.03.04" LOG_CI_END="0.9780026188226455" LOG_CI_START="-0.12606515427808324" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2014-01-14 16:51:33 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.13043797312713779" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.5123770372340826">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="9.50610525879393" CI_START="0.7480572660956755" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9780026188226455" LOG_CI_START="-0.12606515427808324" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2013-12-09 16:49:40 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.6485348751429869" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.42059748427672955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="27">
<NAME>PERPHENAZINE vs THIOTHIXENE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.477505790203251" CI_START="0.06460989345149959" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="1.189700975156456" LOG_CI_START="-1.189700975156456" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-18 15:38:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.477505790203251" CI_START="0.06460989345149959" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-027.01.01" LOG_CI_END="1.189700975156456" LOG_CI_START="-1.189700975156456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:12:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24512" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.834683253016549" CI_START="0.9273117027805688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="0.26356109674016964" LOG_CI_START="-0.03277425933603051" LOG_EFFECT_SIZE="0.11539341870206957" METHOD="MH" MODIFIED="2014-02-18 15:38:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.12690389296601348" Q="0.0" RANDOM="YES" SCALE="12.943442191130694" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.5264256530418878">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.834683253016549" CI_START="0.9273117027805688" DF="0" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" I2="0.0" ID="CMP-027.02.01" LOG_CI_END="0.26356109674016964" LOG_CI_START="-0.03277425933603051" LOG_EFFECT_SIZE="0.11539341870206957" MODIFIED="2013-12-06 10:12:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12690389296601348" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.5264256530418878">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.834683253016549" CI_START="0.9273117027805688" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.26356109674016964" LOG_CI_START="-0.03277425933603051" LOG_EFFECT_SIZE="0.11539341870206957" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24545" O_E="0.0" SE="0.1740688550428301" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0302999662959218" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5496623088792512" CI_START="0.896344064307452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="0.19023707019066347" LOG_CI_START="-0.04752525311932696" LOG_EFFECT_SIZE="0.07135590853566827" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2394243001510853" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.1764270206234775">
<NAME>Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5496623088792512" CI_START="0.896344064307452" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.19023707019066347" LOG_CI_START="-0.04752525311932696" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24559" O_E="0.0" SE="0.13966276565477026" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.019505688110339273" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3780209431716868" CI_END="1.2820234261813324" CI_START="0.737817915073436" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9725738282415447" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="0.10789596103953152" LOG_CI_START="-0.132050803808217" LOG_EFFECT_SIZE="-0.012077421384342738" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4966663929298023" P_Q="0.5109079259358494" P_Z="0.8435891100839236" Q="3.2875469775244275" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="215" TOTAL_2="215" WEIGHT="500.0" Z="0.19730468926676845">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.338840115547728" CI_START="0.25415863614048345" DF="0" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-027.04.01" LOG_CI_END="0.12672871660776514" LOG_CI_START="-0.594895128674501" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2013-12-06 10:13:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2035288864977256" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.271561787240029">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="1.338840115547728" CI_START="0.25415863614048345" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.12672871660776514" LOG_CI_START="-0.594895128674501" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24564" O_E="0.0" SE="0.42388541881444736" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.17967884828349945" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.680805125661779" CI_START="0.21363846029770756" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-027.04.02" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:14:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>ataxia - short term</NAME>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24574" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.533600678381152" CI_START="0.26366361455137033" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-027.04.03" LOG_CI_END="0.931132316607065" LOG_CI_START="-0.5789497984957024" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-06 10:14:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.64759607006631" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.45710431544043584">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="8.533600678381148" CI_START="0.26366361455137033" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9311323166070647" LOG_CI_START="-0.5789497984957024" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24579" O_E="0.0" SE="0.887029709438391" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.7868217054263564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.323574400090985" CI_START="0.4835391194903779" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-027.04.04" LOG_CI_END="0.12174835866404682" LOG_CI_START="-0.3155683846801596" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-06 10:14:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.38503224914591294" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8686616194230607">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.323574400090985" CI_START="0.4835391194903779" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.12174835866404682" LOG_CI_START="-0.3155683846801596" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24594" O_E="0.0" SE="0.2568820197931791" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.06598837209302326" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7265335316978874" CI_START="0.8089586383546878" DF="0" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" I2="0.0" ID="CMP-027.04.05" LOG_CI_END="0.2371750173741189" LOG_CI_START="-0.09207368307689538" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2013-12-06 10:14:11 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3877171982296378" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8637646525003573">
<NAME>use of antiparkinsonian drugs - short term</NAME>
<DICH_DATA CI_END="1.7265335316978874" CI_START="0.8089586383546878" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.2371750173741189" LOG_CI_START="-0.09207368307689538" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24610" O_E="0.0" SE="0.19340231645227823" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.037404456009107176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9188416302769464" CI_END="1.5701748616507154" CI_START="0.31084069480347937" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6986231065162856" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="47.88522490750474" I2_Q="46.76053540003454" ID="CMP-027.05" LOG_CI_END="0.19594802006608503" LOG_CI_START="-0.5074621289584894" LOG_EFFECT_SIZE="-0.15575705444620225" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.16598466535846912" P_Q="0.17052702774592832" P_Z="0.3853971242107441" Q="1.878305891154001" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.38386822261570097" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="200.0" Z="0.8679949172639401">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2979525579624331" CI_START="0.06289340281387021" DF="0" EFFECT_SIZE="0.28571428571428575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-027.05.01" LOG_CI_END="0.11325881866491243" LOG_CI_START="-1.2013949073654635" LOG_EFFECT_SIZE="-0.5440680443502756" MODIFIED="2013-12-06 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10474811430771723" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.6222580150981023">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="1.2979525579624327" CI_START="0.06289340281387018" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.11325881866491228" LOG_CI_START="-1.2013949073654637" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24615" O_E="0.0" SE="0.7722341063111405" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.596345514950166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6080061992060575" CI_START="0.38343467139933374" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-027.05.02" LOG_CI_END="0.4163086193749835" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:14:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="2.6080061992060575" CI_START="0.38343467139933374" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4163086193749835" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24623" O_E="0.0" SE="0.4890834875635335" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.23920265780730898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32836453810203076" CI_END="1.2512504936358813" CI_START="0.4985057793265312" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7897819967957372" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-027.06" LOG_CI_END="0.09734426182267736" LOG_CI_START="-0.3023298024173759" LOG_EFFECT_SIZE="-0.10249277029734924" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8485873602122376" P_Q="0.8498603749018202" P_Z="0.31478622583272775" Q="0.32536646833945526" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="129" WEIGHT="300.0" Z="1.0052297931340712">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2941353876382815" CI_START="0.38502145985134056" DF="0" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" ID="CMP-027.06.01" LOG_CI_END="0.11197971298530651" LOG_CI_START="-0.4145150636466047" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:15:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.26006483788589674" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.1262379375149927">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.2941353876382815" CI_START="0.38502145985134056" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.11197971298530651" LOG_CI_START="-0.4145150636466047" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24641" O_E="0.0" SE="0.3092656379847611" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.09564523483812129" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.680805125661779" CI_START="0.21363846029770756" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-027.06.02" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:15:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>need of additional benzodiazepines - short term</NAME>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24649" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9933442682238067" CI_START="0.4063522859108327" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-027.06.03" LOG_CI_END="0.29958231168491917" LOG_CI_START="-0.3910972928062695" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-12-06 10:15:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.795099019711533" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.2596950393168845">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="1.9933442682238067" CI_START="0.4063522859108327" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.29958231168491917" LOG_CI_START="-0.3910972928062695" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24654" O_E="0.0" SE="0.40570861859730606" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.16459948320413437" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2036297827132891" CI_START="0.6777971674987193" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-027.07" LOG_CI_END="0.08049292541899883" LOG_CI_START="-0.1689002504031058" LOG_EFFECT_SIZE="-0.04420366249205347" METHOD="MH" MODIFIED="2014-02-18 15:39:28 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.48718870945680715" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6947871463089957">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2036297827132891" CI_START="0.6777971674987193" DF="0" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" I2="0.0" ID="CMP-027.07.01" LOG_CI_END="0.08049292541899883" LOG_CI_START="-0.1689002504031058" LOG_EFFECT_SIZE="-0.04420366249205347" MODIFIED="2013-12-06 10:15:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48718870945680715" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6947871463089957">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2036297827132891" CI_START="0.6777971674987193" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.08049292541899883" LOG_CI_START="-0.1689002504031058" LOG_EFFECT_SIZE="-0.04420366249205347" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24662" O_E="0.0" SE="0.14649478599403462" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.021460722323438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-027.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:15:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24671" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22393367929220626" CI_END="18.19113763987167" CI_START="0.44256754545232635" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8373944269811044" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.09" LOG_CI_END="1.259859859880922" LOG_CI_START="-0.35402043710500736" LOG_EFFECT_SIZE="0.45291971138795734" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6360588788635329" P_Q="0.6386757601244439" P_Z="0.27129317923171226" Q="0.22047826871843135" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="129" WEIGHT="200.0" Z="1.1000894228234224">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-027.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:15:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24681" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.24440546987425" CI_START="0.18828486425154256" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-027.09.02" LOG_CI_END="1.3272445817533365" LOG_CI_START="-0.7251845904253741" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-06 10:15:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5653344259186854" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.5749362343562306">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="21.24440546987425" CI_START="0.18828486425154256" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3272445817533365" LOG_CI_START="-0.7251845904253741" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24690" O_E="0.0" SE="1.2056070554260303" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.4534883720930232" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.18091723147054" CI_START="0.24708216414768958" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-027.09.03" LOG_CI_END="2.0050986120834273" LOG_CI_START="-0.6071586034113897" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-06 10:15:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.294239054635855" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.048867643390089">
<NAME>paraesthesia - short term</NAME>
<DICH_DATA CI_END="101.18091723147054" CI_START="0.24708216414768958" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0050986120834273" LOG_CI_START="-0.6071586034113897" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24697" O_E="0.0" SE="1.5344528192634188" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.354545454545454" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6210761928863456" CI_END="1.8879894239932742" CI_START="0.4731137102475687" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9451104069333001" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-027.10" LOG_CI_END="0.27599955716849817" LOG_CI_START="-0.32503446645452094" LOG_EFFECT_SIZE="-0.024517454643011413" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.733052439324098" P_Q="0.7337148459851917" P_Z="0.8729581240016937" Q="0.61926975073745" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="172" TOTAL_2="172" WEIGHT="300.0" Z="0.15990218924124258">
<NAME>Other adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6375601547959784" CI_START="0.3958697420031439" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-027.10.01" LOG_CI_END="0.560810184036558" LOG_CI_START="-0.4024476919413083" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-12-06 10:16:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7472830239702244" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.00000000000001" Z="0.32222397423286714">
<NAME>constipation - short term</NAME>
<DICH_DATA CI_END="3.6375601547959784" CI_START="0.39586974200314384" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.560810184036558" LOG_CI_START="-0.4024476919413084" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24713" O_E="0.0" SE="0.5658224445527854" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.32015503875969" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.961364031061661" CI_START="0.013956290740833538" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-027.10.02" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:16:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.497411635240814" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6785679898446393">
<NAME>icterus - short term</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24718" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2002701344388558" CI_START="0.34796863713066783" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-027.10.03" LOG_CI_END="0.3424760038649878" LOG_CI_START="-0.4584598978203613" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2013-12-06 10:16:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7765458131041261" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.2838232803160699">
<NAME>loss of appetite - short term</NAME>
<DICH_DATA CI_END="2.2002701344388558" CI_START="0.34796863713066783" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3424760038649878" LOG_CI_START="-0.4584598978203613" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24723" O_E="0.0" SE="0.47047371334662913" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.22134551495016613" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-027.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:16:26 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>nausea and vomiting - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24730" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.652276279555" CI_START="0.12560661666750192" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.11" LOG_CI_END="1.8552299918017108" LOG_CI_START="-0.9009874823623856" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.497411635240814" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6785679898446393">
<NAME>Other adverse events: 7. Skin</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.652276279555" CI_START="0.12560661666750192" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-027.11.01" LOG_CI_END="1.8552299918017108" LOG_CI_START="-0.9009874823623856" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:16:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.497411635240814" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6785679898446393">
<NAME>rash - short term</NAME>
<DICH_DATA CI_END="71.652276279555" CI_START="0.12560661666750192" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017108" LOG_CI_START="-0.9009874823623856" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24757" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events: 8. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-027.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-06 10:17:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>micturition disturbances - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24748" O_E="0.0" SE="0.0" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26538451145204217" CI_END="4.975184174718462" CI_START="0.07865208678458116" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6255466549181055" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.13" LOG_CI_END="0.6968091623849457" LOG_CI_START="-1.1042897502561326" LOG_EFFECT_SIZE="-0.20374029393559343" METHOD="MH" MODIFIED="2014-01-14 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6064448685361543" P_Q="0.6075002115640277" P_Z="0.6574603688386987" Q="0.2638312524675429" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="200.0" Z="0.4434222190804737">
<NAME>Other adverse events: 9. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Thiothixene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours thiothixene</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.961364031061661" CI_START="0.013956290740833538" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-027.13.01" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:17:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.497411635240814" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.6785679898446393">
<NAME>cramps - short term</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24765" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.477505790203251" CI_START="0.06460989345149959" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-027.13.02" LOG_CI_END="1.189700975156456" LOG_CI_START="-1.189700975156456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:17:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>sweating - short term</NAME>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-06 10:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="24773" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Itoh-1969-II" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="28">
<NAME>PERPHENAZINE vs TIMIPERONE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.670809631751072" CI_START="0.6656325320394352" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2014-02-18 15:43:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.41699780296405475" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.8116407605073728">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.670809631751072" CI_START="0.6656325320394352" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-028.01.01" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-09 15:59:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41699780296405475" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.8116407605073728">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.670809631751072" CI_START="0.6656325320394352" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24520" O_E="0.0" SE="0.354445077736048" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1256313131313131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.670809631751072" CI_START="0.6656325320394352" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2014-02-18 15:43:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.41699780296405475" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.8116407605073728">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.670809631751072" CI_START="0.6656325320394352" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-028.02.01" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-09 15:59:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41699780296405475" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.8116407605073728">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.670809631751072" CI_START="0.6656325320394352" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4266429337621336" LOG_CI_START="-0.17676546054553374" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24529" O_E="0.0" SE="0.354445077736048" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1256313131313131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5513490368040692" CI_START="0.787447968972911" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="0.19070952038242597" LOG_CI_START="-0.10377813282024533" LOG_EFFECT_SIZE="0.043465693781090345" METHOD="MH" MODIFIED="2014-02-18 15:43:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5628778257817251" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.5785722657469358">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5513490368040692" CI_START="0.787447968972911" DF="0" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="0.0" ID="CMP-028.03.01" LOG_CI_END="0.19070952038242597" LOG_CI_START="-0.10377813282024533" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-12-09 15:59:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5628778257817251" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.5785722657469358">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.5513490368040692" CI_START="0.787447968972911" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" LOG_CI_END="0.19070952038242597" LOG_CI_START="-0.10377813282024533" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24550" O_E="0.0" SE="0.17298350522864256" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.02992329308118781" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.3744892679894045" CI_END="1.2421596457927113" CI_START="0.7354895180211956" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9558218449007432" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="82" I2="52.937406059101605" I2_Q="51.565193118996255" ID="CMP-028.04" LOG_CI_END="0.09417741615552905" LOG_CI_START="-0.13342351232869148" LOG_EFFECT_SIZE="-0.019623048086581194" METHOD="MH" MODIFIED="2014-01-14 16:53:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09474607149894543" P_Q="0.10254875606530434" P_Z="0.7353902684621569" Q="6.193892766766885" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10776447703259068" TOTALS="SUB" TOTAL_1="396" TOTAL_2="396" WEIGHT="400.0" Z="0.3379640651972403">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2907424487566335" CI_START="0.5577615726529009" DF="0" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="0.0" ID="CMP-028.04.01" LOG_CI_END="0.11083959296937186" LOG_CI_START="-0.25355141004070836" LOG_EFFECT_SIZE="-0.07135590853566824" MODIFIED="2013-12-09 16:01:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44271918073061867" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.7676095713602193">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="1.2907424487566335" CI_START="0.5577615726529009" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" LOG_CI_END="0.11083959296937186" LOG_CI_START="-0.25355141004070836" LOG_EFFECT_SIZE="-0.07135590853566824" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24570" O_E="0.0" SE="0.2140450789326767" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.04581529581529581" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9538619065120527" CI_START="0.1337206355944896" DF="0" EFFECT_SIZE="0.3571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" I2="0.0" ID="CMP-028.04.02" LOG_CI_END="-0.020514494877505427" LOG_CI_START="-0.8738015678069329" LOG_EFFECT_SIZE="-0.44715803134221915" MODIFIED="2013-12-09 16:01:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03995577509358081" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="2.0542058227127686">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="0.9538619065120527" CI_START="0.1337206355944896" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.020514494877505427" LOG_CI_START="-0.8738015678069329" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24585" O_E="0.0" SE="0.5012250504778779" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.25122655122655124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.084677692131924" CI_START="0.013743418766000442" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-028.04.03" LOG_CI_END="0.9076627107830841" LOG_CI_START="-1.8619052202224093" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:01:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4994870857638588" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.6752970129673594">
<NAME>dystonia - short term</NAME>
<DICH_DATA CI_END="8.084677692131924" CI_START="0.013743418766000442" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9076627107830841" LOG_CI_START="-1.8619052202224093" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24588" O_E="0.0" SE="1.6268579122549907" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="2.646666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7271606421006642" CI_START="0.8419322520957465" DF="0" EFFECT_SIZE="1.2058823529411764" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" I2="0.0" ID="CMP-028.04.04" LOG_CI_END="0.23733273289654672" LOG_CI_START="-0.07472285354158605" LOG_EFFECT_SIZE="0.08130493967748034" MODIFIED="2013-12-09 16:01:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3071015088263591" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="1.0213228697615793">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.7271606421006642" CI_START="0.8419322520957465" EFFECT_SIZE="1.2058823529411764" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.23733273289654672" LOG_CI_START="-0.07472285354158605" LOG_EFFECT_SIZE="0.08130493967748034" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24598" O_E="0.0" SE="0.18330299617382464" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.03359998840630117" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.76209922918737" CI_START="0.12369076889400406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.05" LOG_CI_END="1.8619052202224093" LOG_CI_START="-0.9076627107830841" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-02-18 15:44:30 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4994870857638588" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.6752970129673594">
<NAME>Other adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.76209922918737" CI_START="0.12369076889400406" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-028.05.01" LOG_CI_END="1.8619052202224093" LOG_CI_START="-0.9076627107830841" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-02-18 15:44:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4994870857638588" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.6752970129673594">
<NAME>blurred vision - short term</NAME>
<DICH_DATA CI_END="72.76209922918737" CI_START="0.12369076889400406" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8619052202224093" LOG_CI_START="-0.9076627107830841" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-02-18 15:44:30 +0000" MODIFIED_BY="[Empty name]" ORDER="24619" O_E="0.0" SE="1.6268579122549907" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="2.646666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.766805937904918" CI_END="1.9801804353396226" CI_START="1.0868094455349837" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4669965238509182" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="47" I2="65.31875666468845" I2_Q="62.7009441676972" ID="CMP-028.06" LOG_CI_END="0.2967047652625555" LOG_CI_START="0.036153404245205384" LOG_EFFECT_SIZE="0.1664290847538804" METHOD="MH" MODIFIED="2014-01-14 16:53:24 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.055944135982678" P_Q="0.06849253102256969" P_Z="0.01228387802108462" Q="5.362066023847989" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.27322182633322256" TOTALS="SUB" TOTAL_1="297" TOTAL_2="297" WEIGHT="300.0" Z="2.5038826189501155">
<NAME>Other adverse events: 2. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6020759301611425" CI_START="0.5665667148885767" DF="0" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-028.06.01" LOG_CI_END="0.5565528633148392" LOG_CI_START="-0.2467489433433528" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-12-09 16:03:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4497176024065723" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.7558859203111569">
<NAME>drowsiness - short term</NAME>
<DICH_DATA CI_END="3.6020759301611425" CI_START="0.5665667148885767" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5565528633148392" LOG_CI_START="-0.2467489433433528" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24633" O_E="0.0" SE="0.47186345763909565" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.22265512265512263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.460370892631461" CI_START="1.6762168130412567" DF="0" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="0.0" ID="CMP-028.06.02" LOG_CI_END="1.1290570267827587" LOG_CI_START="0.22433019246697458" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2013-12-09 16:03:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0033686930822411565" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="2.9319238760861563">
<NAME>excitation - short term</NAME>
<DICH_DATA CI_END="13.460370892631461" CI_START="1.6762168130412567" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" LOG_CI_END="1.1290570267827587" LOG_CI_START="0.22433019246697458" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24637" O_E="0.0" SE="0.5314410209471492" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.2824295587453482" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8212949576564716" CI_START="0.935859016946485" DF="0" EFFECT_SIZE="1.3055555555555556" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="36" I2="0.0" ID="CMP-028.06.03" LOG_CI_END="0.2603802852289142" LOG_CI_START="-0.02878957089205377" LOG_EFFECT_SIZE="0.1157953571684302" MODIFIED="2013-12-09 16:03:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1164852946227785" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="1.569698395756255">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.8212949576564716" CI_START="0.935859016946485" EFFECT_SIZE="1.3055555555555556" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="36" LOG_CI_END="0.2603802852289142" LOG_CI_START="-0.02878957089205377" LOG_EFFECT_SIZE="0.1157953571684302" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24647" O_E="0.0" SE="0.16985980489932992" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.028852353320438423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1571766123961384" CI_START="0.8859116568880813" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-028.07" LOG_CI_END="0.06339964757364357" LOG_CI_START="-0.05260958380023124" LOG_EFFECT_SIZE="0.005395031886706144" METHOD="MH" MODIFIED="2014-02-18 15:45:36 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8553496425951033" Q="0.0" RANDOM="YES" SCALE="2.2394016375991423" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.18229701323183659">
<NAME>Other adverse events: 3. At least one</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1571766123961384" CI_START="0.8859116568880813" DF="0" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" I2="0.0" ID="CMP-028.07.01" LOG_CI_END="0.06339964757364357" LOG_CI_START="-0.05260958380023124" LOG_EFFECT_SIZE="0.005395031886706144" MODIFIED="2013-12-09 16:03:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8553496425951033" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.18229701323183659">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1571766123961384" CI_START="0.8859116568880813" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" LOG_CI_END="0.06339964757364357" LOG_CI_START="-0.05260958380023124" LOG_EFFECT_SIZE="0.005395031886706144" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24666" O_E="0.0" SE="0.06814439676397081" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.004643658810325475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4285157582357571" CI_END="2.0543506759116665" CI_START="0.7543737872262947" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2448888704130912" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-028.08" LOG_CI_END="0.31267457928763837" LOG_CI_START="-0.12241341075423608" LOG_EFFECT_SIZE="0.09513058426670111" METHOD="MH" MODIFIED="2014-01-14 16:53:24 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5127181630373274" P_Q="0.5128446167607363" P_Z="0.3914009064589259" Q="0.4282587404459547" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="198" TOTAL_2="198" WEIGHT="200.0" Z="0.8570795942818006">
<NAME>Other adverse events: 4. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1757919718571133" CI_START="0.7084846929329139" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-028.08.01" LOG_CI_END="0.5018520465152974" LOG_CI_START="-0.14966952840393485" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-09 16:03:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.28938755523529436" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="1.0594661451824778">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="3.1757919718571133" CI_START="0.7084846929329139" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5018520465152974" LOG_CI_START="-0.14966952840393485" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24674" O_E="0.0" SE="0.38270699819136633" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.14646464646464646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1000431855074875" CI_START="0.5466359890099396" DF="0" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-028.08.02" LOG_CI_END="0.3222282257028509" LOG_CI_START="-0.26230177894796447" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2013-12-09 16:03:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.840747873700644" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.20093695178436335">
<NAME>lassitude - short term</NAME>
<DICH_DATA CI_END="2.1000431855074875" CI_START="0.5466359890099396" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3222282257028509" LOG_CI_START="-0.26230177894796447" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24675" O_E="0.0" SE="0.3433558182020772" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.1178932178932179" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5328094425240224" CI_END="1.2233292092090653" CI_START="0.3589851769162006" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6626892579442284" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-028.09" LOG_CI_END="0.08754334542825958" LOG_CI_START="-0.4449234837793583" LOG_EFFECT_SIZE="-0.17869006917554936" METHOD="MH" MODIFIED="2014-01-14 16:53:24 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6747189268157608" P_Q="0.6775694251999741" P_Z="0.1883469091623787" Q="1.5204030237707427" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="495" TOTAL_2="495" WEIGHT="400.0" Z="1.315485137356748">
<NAME>Other adverse events: 5. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Timiperone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours timiperone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.903637374245642" CI_START="0.11385392694943419" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-028.09.01" LOG_CI_END="0.5914694673761394" LOG_CI_START="-0.9436519854875018" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.652963915781958" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.4496484953651478">
<NAME>confusion - short term</NAME>
<DICH_DATA CI_END="3.903637374245641" CI_START="0.11385392694943419" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5914694673761393" LOG_CI_START="-0.9436519854875018" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24680" O_E="0.0" SE="0.9017379403858491" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.8131313131313131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.76469725839569" CI_START="0.06343287052134396" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-028.09.02" LOG_CI_END="1.1976856350731" LOG_CI_START="-1.1976856350731" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:04:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.0">
<NAME>disturbance of consciousness - short term</NAME>
<DICH_DATA CI_END="15.76469725839569" CI_START="0.06343287052134396" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1976856350731" LOG_CI_START="-1.1976856350731" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24684" O_E="0.0" SE="1.407052941362897" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="1.9797979797979797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.839140681370606" CI_START="0.37759180223609373" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-028.09.03" LOG_CI_END="0.26461495099237303" LOG_CI_START="-0.4229774430876227" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2013-12-09 16:04:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6516954428165782" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="0.45140810701374273">
<NAME>dysarticulation - short term</NAME>
<DICH_DATA CI_END="1.839140681370606" CI_START="0.37759180223609373" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.26461495099237303" LOG_CI_START="-0.4229774430876227" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24685" O_E="0.0" SE="0.40389517591983337" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.16313131313131313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.194811688029269" CI_START="0.09299466369832604" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-028.09.04" LOG_CI_END="0.07729946236010206" LOG_CI_START="-1.031541971799427" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 16:04:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09166138105015977" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="1.6866982901264151">
<NAME>headache - short term</NAME>
<DICH_DATA CI_END="1.194811688029269" CI_START="0.09299466369832604" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07729946236010206" LOG_CI_START="-1.031541971799427" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24694" O_E="0.0" SE="0.6513389472789296" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.4242424242424242" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-028.09.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-09 16:04:18 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>seizure - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 15:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24701" O_E="0.0" SE="0.0" STUDY_ID="STD-Takahashi-1982" TOTAL_1="99" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="29">
<NAME>PERPHENAZINE vs TRIFLUOPERAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0325720717176068" CI_START="0.3818515182066433" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6279245283018868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="0.013920374378683464" LOG_CI_START="-0.4181054783428888" LOG_EFFECT_SIZE="-0.20209255198210269" METHOD="MH" MODIFIED="2014-02-18 15:46:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.06670457540921139" Q="0.0" RANDOM="YES" SCALE="3.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.833659355955167">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluoperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluoperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0325720717176068" CI_START="0.3818515182066433" DF="0" EFFECT_SIZE="0.6279245283018868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-029.01.01" LOG_CI_END="0.013920374378683464" LOG_CI_START="-0.4181054783428888" LOG_EFFECT_SIZE="-0.20209255198210269" MODIFIED="2013-12-09 16:56:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06670457540921139" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.833659355955167">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0325720717176068" CI_START="0.3818515182066433" EFFECT_SIZE="0.6279245283018868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="0.013920374378683464" LOG_CI_START="-0.4181054783428888" LOG_EFFECT_SIZE="-0.20209255198210269" MODIFIED="2013-12-09 16:56:50 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2537741244511128" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.0644013062409289" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7558055792435145" CI_START="0.11391196070653674" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6540880503144654" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="0.5747031027508627" LOG_CI_START="-0.9434306727942049" LOG_EFFECT_SIZE="-0.18436378502167114" METHOD="MH" MODIFIED="2014-02-18 15:46:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6340457162193889" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.476040233761644">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluoperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluoperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7558055792435145" CI_START="0.11391196070653674" DF="0" EFFECT_SIZE="0.6540880503144654" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-029.02.01" LOG_CI_END="0.5747031027508627" LOG_CI_START="-0.9434306727942049" LOG_EFFECT_SIZE="-0.18436378502167114" MODIFIED="2013-12-09 16:57:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6340457162193889" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.476040233761644">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.7558055792435145" CI_START="0.11391196070653674" EFFECT_SIZE="0.6540880503144654" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5747031027508627" LOG_CI_START="-0.9434306727942049" LOG_EFFECT_SIZE="-0.18436378502167114" MODIFIED="2013-12-09 16:57:17 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="0.8917592946385601" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.7952346395742621" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9522092448200112" CI_END="4.090777384945432" CI_START="0.8346694391263181" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8478221953107474" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="0.6118058463719117" LOG_CI_START="-0.07848548761506248" LOG_EFFECT_SIZE="0.2666601793784246" METHOD="MH" MODIFIED="2014-01-14 16:54:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.58238515607669" P_Q="0.5830100429265666" P_Z="0.12995691976805715" Q="1.9492349077003726" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="208" WEIGHT="400.0" Z="1.514271792096886">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluoperazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluoperazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.377256469089136" CI_START="0.625614357695681" DF="0" EFFECT_SIZE="2.289308176100629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-029.03.01" LOG_CI_END="0.9231018115394722" LOG_CI_START="-0.2036932928822632" LOG_EFFECT_SIZE="0.3597042593286045" MODIFIED="2013-12-09 16:57:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21080692162728998" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.251349762886175">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="8.377256469089136" CI_START="0.625614357695681" EFFECT_SIZE="2.289308176100629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9231018115394722" LOG_CI_START="-0.2036932928822632" LOG_EFFECT_SIZE="0.3597042593286045" MODIFIED="2013-12-09 16:57:39 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="0.6618850220630507" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.43809178243140506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.852155200171944" CI_START="0.013631160616754972" DF="0" EFFECT_SIZE="0.3271604938271605" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-029.03.02" LOG_CI_END="0.8949888749717976" LOG_CI_START="-1.8654671648554813" LOG_EFFECT_SIZE="-0.4852391449418419" MODIFIED="2014-01-14 16:53:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49078946870631723" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.6890537173955709">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="7.852155200171944" CI_START="0.013631160616754972" EFFECT_SIZE="0.3271604938271605" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8949888749717976" LOG_CI_START="-1.8654671648554813" LOG_EFFECT_SIZE="-0.4852391449418419" MODIFIED="2013-12-09 16:57:45 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="1.6215055422723186" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="2.629280223619846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.707438955118482" CI_START="0.14351530531408288" DF="0" EFFECT_SIZE="0.9811320754716981" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-029.03.03" LOG_CI_END="0.8265567288168305" LOG_CI_START="-0.8431017807488103" LOG_EFFECT_SIZE="-0.008272525965989885" MODIFIED="2014-01-14 16:53:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9845046521620167" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.019421759433586937">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="6.707438955118482" CI_START="0.14351530531408288" EFFECT_SIZE="0.9811320754716981" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8265567288168305" LOG_CI_START="-0.8431017807488103" LOG_EFFECT_SIZE="-0.008272525965989885" MODIFIED="2013-12-09 16:57:43 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="0.9807656734617749" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.9619013062409288" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.32163137644983" CI_START="0.7343455844350184" DF="0" EFFECT_SIZE="2.6163522012578615" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-029.03.04" LOG_CI_END="0.9694919247777407" LOG_CI_START="-0.13409951216515842" LOG_EFFECT_SIZE="0.41769620630629123" MODIFIED="2014-01-14 16:53:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.1379028541187697" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="1.4836460186881673">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="9.32163137644983" CI_START="0.7343455844350184" EFFECT_SIZE="2.6163522012578615" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9694919247777407" LOG_CI_START="-0.13409951216515842" LOG_EFFECT_SIZE="0.41769620630629123" MODIFIED="2013-12-09 16:57:28 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="0.6482550729259758" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="52" VAR="0.4202346395742622" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="30">
<NAME>PERPHENAZINE vs TRIFLUOPROMAZINE</NAME>
<DICH_OUTCOME CHI2="3.1907961198908907" CI_END="1.9836260665326106" CI_START="0.6558417372234248" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1405896569215486" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="38" I2="68.65985909390554" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="0.2974598066552157" LOG_CI_START="-0.18320094864707218" LOG_EFFECT_SIZE="0.05712942900407172" METHOD="MH" MODIFIED="2014-01-14 16:54:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07405398501936589" P_Q="1.0" P_Z="0.6412820181776189" Q="0.0" RANDOM="YES" SCALE="3.7563299552981384" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11233111778059073" TOTALS="YES" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="0.46590707508417073">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluopromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluopromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1907961198908907" CI_END="1.9836260665326106" CI_START="0.6558417372234248" DF="1" EFFECT_SIZE="1.1405896569215486" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="38" I2="68.65985909390554" ID="CMP-030.01.01" LOG_CI_END="0.2974598066552157" LOG_CI_START="-0.18320094864707218" LOG_EFFECT_SIZE="0.05712942900407172" MODIFIED="2013-12-10 16:39:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07405398501936589" P_Z="0.6412820181776189" STUDIES="3" TAU2="0.11233111778059073" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="0.46590707508417073">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:36:03 +0000" MODIFIED_BY="[Empty name]" ORDER="24504" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4526848271402186" CI_START="0.4881590700126299" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.1621714004775087" LOG_CI_START="-0.311438637071317" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2013-12-09 16:50:33 +0000" MODIFIED_BY="[Empty name]" ORDER="24508" O_E="0.0" SE="0.2782008804636762" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.07739572989076465" WEIGHT="42.0168743762961"/>
<DICH_DATA CI_END="1.9391293288230227" CI_START="1.04139035581662" EFFECT_SIZE="1.4210526315789473" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.2876067749998742" LOG_CI_START="0.017613551412442387" LOG_EFFECT_SIZE="0.15261016320615833" MODIFIED="2013-12-10 16:39:20 +0000" MODIFIED_BY="[Empty name]" ORDER="24516" O_E="0.0" SE="0.15859535602326882" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="31" VAR="0.02515248695214739" WEIGHT="57.9831256237039"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.3925715366769165" CI_START="0.7417611380385938" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="0.731795915068596" LOG_CI_START="-0.12973592374063384" LOG_EFFECT_SIZE="0.30102999566398114" METHOD="MH" MODIFIED="2014-01-14 16:54:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1707893626671378" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.00000000000001" Z="1.369671840760137">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluopromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluopromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.3925715366769165" CI_START="0.7417611380385938" DF="1" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-030.02.01" LOG_CI_END="0.731795915068596" LOG_CI_START="-0.12973592374063384" LOG_EFFECT_SIZE="0.30102999566398114" MODIFIED="2013-12-10 16:39:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1707893626671378" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.00000000000001" Z="1.369671840760137">
<NAME>short term</NAME>
<DICH_DATA CI_END="21.39626291789819" CI_START="0.18694853467396683" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3303379258789352" LOG_CI_START="-0.7282779345509727" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-09 16:51:05 +0000" MODIFIED_BY="[Empty name]" ORDER="24524" O_E="0.0" SE="1.2092411467293842" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.4622641509433962" WEIGHT="17.514269773829454"/>
<DICH_DATA CI_END="5.961131262114313" CI_START="0.6710135751282328" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7753286849538349" LOG_CI_START="-0.17326869362587247" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-12-10 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="24528" O_E="0.0" SE="0.5572107958104742" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="31" VAR="0.310483870967742" WEIGHT="82.48573022617056"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0088576481625897" CI_START="0.2539772203865781" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="0.30294916282696294" LOG_CI_START="-0.595205234183439" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="MH" MODIFIED="2014-01-14 16:54:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5236267170061404" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.6377649277546511">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluopromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluopromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0088576481625897" CI_START="0.2539772203865781" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-030.03.01" LOG_CI_END="0.30294916282696294" LOG_CI_START="-0.595205234183439" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-12-10 16:29:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5236267170061404" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.6377649277546511">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.0088576481625897" CI_START="0.2539772203865781" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.30294916282696294" LOG_CI_START="-0.595205234183439" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-12-10 16:29:54 +0000" MODIFIED_BY="[Empty name]" ORDER="2099" O_E="0.0" SE="0.5275803387398784" STUDY_ID="STD-Kurland-1961" TOTAL_1="31" TOTAL_2="31" VAR="0.27834101382488485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.397768326505732" CI_END="35.17439418665576" CI_START="1.9071596358181266" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="8.190432516488103" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.04" LOG_CI_END="1.5462266262586477" LOG_CI_START="0.2803870465086745" LOG_EFFECT_SIZE="0.9133068363836612" METHOD="MH" MODIFIED="2014-02-18 16:13:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8196449053300701" P_Q="0.8262570643117132" P_Z="0.004680483247361867" Q="0.38169881398663186" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="212" WEIGHT="300.0" Z="2.8282391146273995">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluopromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluopromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.94415887447036" CI_START="0.8918145441437945" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-030.04.01" LOG_CI_END="1.7399215292722836" LOG_CI_START="-0.04972544924376984" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-09 16:51:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06416256893212866" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.8510485494818223">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="54.94415887447036" CI_START="0.8918145441437945" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7399215292722836" LOG_CI_START="-0.04972544924376984" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-12-09 16:51:33 +0000" MODIFIED_BY="[Empty name]" ORDER="24562" O_E="0.0" SE="1.0512474940757477" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="1.105121293800539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-030.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-02-18 16:13:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-18 16:13:41 +0000" MODIFIED_BY="[Empty name]" ORDER="24571" O_E="0.0" SE="0.0" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.72582867659102" CI_START="0.24575862713766183" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-030.04.03" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-02-18 16:13:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29510060682471295" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.0469978026272877">
<NAME>dyskinesia - short term</NAME>
<DICH_DATA CI_END="101.72582867659102" CI_START="0.24575862713766183" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0074312363793894" LOG_CI_START="-0.6094912277073515" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-02-18 16:13:42 +0000" MODIFIED_BY="[Empty name]" ORDER="24577" O_E="0.0" SE="1.5371932093796676" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="2.3629629629629627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="287.2428652518482" CI_START="1.0061172441885067" DF="0" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-030.04.04" LOG_CI_END="2.4582492501706477" LOG_CI_START="0.002648592585900365" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2014-02-18 16:13:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.04950783141480149" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.9641919896613678">
<NAME>parkinsonism - short term</NAME>
<DICH_DATA CI_END="287.2428652518482" CI_START="1.0061172441885067" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4582492501706477" LOG_CI_START="0.002648592585900365" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2014-02-18 16:13:43 +0000" MODIFIED_BY="[Empty name]" ORDER="24592" O_E="0.0" SE="1.4424319816845756" STUDY_ID="STD-Hanlon-1965" TOTAL_1="53" TOTAL_2="53" VAR="2.0806100217864922" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.931478136347037" CI_START="0.08381191236932206" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.05" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-01-14 16:54:39 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>Other adverse events: 1. Central nervous system</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluopromazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trifluopromazine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.931478136347037" CI_START="0.08381191236932206" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-030.05.01" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:36:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>electroencephalogram (increase) - short term</NAME>
<DICH_DATA CI_END="11.931478136347037" CI_START="0.08381191236932206" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 16:36:21 +0000" MODIFIED_BY="[Empty name]" ORDER="24686" O_E="0.0" SE="1.2649110640673518" STUDY_ID="STD-Bennett-1961" TOTAL_1="5" TOTAL_2="5" VAR="1.6" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2015-01-26 14:50:48 +0000" MODIFIED_BY="[Empty name]" NO="31">
<NAME>PERPHENAZINE vs ZIPRASIDONE</NAME>
<DICH_OUTCOME CHI2="5.215578205125156E-30" CI_END="1.0457702919052314" CI_START="0.854089956806688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9450830140485313" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="147" I2="100.0" I2_Q="0.0" ID="CMP-031.01" LOG_CI_END="0.019436300292561937" LOG_CI_START="-0.06849638494649626" LOG_EFFECT_SIZE="-0.02453004232696718" METHOD="MH" MODIFIED="2014-02-18 16:38:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.27416632307457456" Q="0.0" RANDOM="YES" SCALE="3.02" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.0935182832047383">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.215578205125156E-30" CI_END="1.0457702919052314" CI_START="0.854089956806688" DF="0" EFFECT_SIZE="0.9450830140485313" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="147" I2="100.0" ID="CMP-031.01.01" LOG_CI_END="0.019436300292561937" LOG_CI_START="-0.06849638494649626" LOG_EFFECT_SIZE="-0.02453004232696718" MODIFIED="2013-12-11 15:49:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.27416632307457456" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.0935182832047383">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.0457702919052314" CI_START="0.854089956806688" EFFECT_SIZE="0.9450830140485313" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="147" LOG_CI_END="0.019436300292561937" LOG_CI_START="-0.06849638494649626" LOG_EFFECT_SIZE="-0.02453004232696718" MODIFIED="2013-12-11 15:49:58 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.05165209458323473" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.0026679388748354262" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5796442109107118" CI_START="0.6490932335688868" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0125889436234263" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-031.02" LOG_CI_END="0.1985592802214248" LOG_CI_START="-0.18769291812047278" LOG_EFFECT_SIZE="0.005433181050475987" METHOD="MH" MODIFIED="2014-02-18 16:39:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9560274816795824" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999" Z="0.05513930652631488">
<NAME>Leaving the study early: 2. Due to adverse events</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5796442109107118" CI_START="0.6490932335688868" DF="0" EFFECT_SIZE="1.0125889436234263" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" I2="0.0" ID="CMP-031.02.01" LOG_CI_END="0.1985592802214248" LOG_CI_START="-0.18769291812047278" LOG_EFFECT_SIZE="0.005433181050475987" MODIFIED="2013-12-11 15:50:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9560274816795824" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999" Z="0.05513930652631488">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.5796442109107118" CI_START="0.6490932335688868" EFFECT_SIZE="1.0125889436234263" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" LOG_CI_END="0.1985592802214248" LOG_CI_START="-0.18769291812047278" LOG_EFFECT_SIZE="0.005433181050475987" MODIFIED="2013-12-11 15:50:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.22688645328524848" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.05147746268435924" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4609445232173663" CI_START="0.7504989306247718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0471090212469523" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-031.03" LOG_CI_END="0.16463372468308854" LOG_CI_START="-0.12464992224028651" LOG_EFFECT_SIZE="0.019991901221400977" METHOD="MH" MODIFIED="2014-02-18 16:41:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7864682835195759" Q="0.0" RANDOM="YES" SCALE="4.357565566449639" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.2708995602976968">
<NAME>Leaving the study early: 3. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4609445232173663" CI_START="0.7504989306247718" DF="0" EFFECT_SIZE="1.0471090212469523" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="44" I2="0.0" ID="CMP-031.03.01" LOG_CI_END="0.16463372468308854" LOG_CI_START="-0.12464992224028651" LOG_EFFECT_SIZE="0.019991901221400977" MODIFIED="2013-12-11 15:50:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7864682835195759" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.2708995602976968">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.4609445232173663" CI_START="0.7504989306247718" EFFECT_SIZE="1.0471090212469523" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="44" LOG_CI_END="0.16463372468308854" LOG_CI_START="-0.12464992224028651" LOG_EFFECT_SIZE="0.019991901221400977" MODIFIED="2013-12-11 15:50:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.1699266461799374" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.028875065081961637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8870230600038798" CI_END="1.593630861795906" CI_START="0.7530509601773631" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0954840257364258" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-031.04" LOG_CI_END="0.20238773158281279" LOG_CI_START="-0.12317563339430088" LOG_EFFECT_SIZE="0.039606049094256024" METHOD="MH" MODIFIED="2014-02-18 16:44:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.38925860511549426" P_Q="0.3894514158018265" P_Z="0.6334515087694468" Q="1.8860326474930478" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="721" TOTAL_2="436" WEIGHT="300.0" Z="0.4768744775698206">
<NAME>Adverse events: Movement disorders (completer-only data)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4917828131749589" CI_START="0.3763209387032329" DF="0" EFFECT_SIZE="0.7492590397154713" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" ID="CMP-031.04.01" LOG_CI_END="0.17370559933938998" LOG_CI_START="-0.42444161662490804" LOG_EFFECT_SIZE="-0.12536800864275902" MODIFIED="2013-12-11 15:50:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41130858435797435" STUDIES="1" TAU2="0.0" TOTAL_1="241" TOTAL_2="158" WEIGHT="100.0" Z="0.8215929964906169">
<NAME>akathisia - long term</NAME>
<DICH_DATA CI_END="1.4917828131749589" CI_START="0.3763209387032329" EFFECT_SIZE="0.7492590397154713" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.17370559933938998" LOG_CI_START="-0.42444161662490804" LOG_EFFECT_SIZE="-0.12536800864275902" MODIFIED="2013-12-11 15:50:32 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.3513546355339001" STUDY_ID="STD-CATIE-2005" TOTAL_1="241" TOTAL_2="158" VAR="0.12345007991115978" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9428824369785755" CI_START="0.6202129327019092" DF="0" EFFECT_SIZE="1.5637860082304527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-031.04.02" LOG_CI_END="0.5958138281174424" LOG_CI_START="-0.20745918208044653" LOG_EFFECT_SIZE="0.19417732301849797" MODIFIED="2013-12-11 15:50:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34334606202903795" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="152" WEIGHT="100.0" Z="0.9475746225729634">
<NAME>EPS - long term</NAME>
<DICH_DATA CI_END="3.9428824369785755" CI_START="0.6202129327019092" EFFECT_SIZE="1.5637860082304527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.5958138281174424" LOG_CI_START="-0.20745918208044653" LOG_EFFECT_SIZE="0.19417732301849797" MODIFIED="2013-12-11 15:50:39 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.4718465424557689" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="152" VAR="0.22263915962746372" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0172352898770596" CI_START="0.726960048917626" DF="0" EFFECT_SIZE="1.2109704641350212" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="18" I2="0.0" ID="CMP-031.04.03" LOG_CI_END="0.30475655717934924" LOG_CI_START="-0.13848945573157223" LOG_EFFECT_SIZE="0.08313355072388849" MODIFIED="2013-12-11 15:50:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4622134982071322" STUDIES="1" TAU2="0.0" TOTAL_1="237" TOTAL_2="126" WEIGHT="100.0" Z="0.7352069080359706">
<NAME>tardive dyskinesia - long term</NAME>
<DICH_DATA CI_END="2.0172352898770596" CI_START="0.726960048917626" EFFECT_SIZE="1.2109704641350212" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="18" LOG_CI_END="0.30475655717934924" LOG_CI_START="-0.13848945573157223" LOG_EFFECT_SIZE="0.08313355072388849" MODIFIED="2013-12-11 15:50:45 +0000" MODIFIED_BY="[Empty name]" ORDER="2665" O_E="0.0" SE="0.2603649020870252" STUDY_ID="STD-CATIE-2005" TOTAL_1="237" TOTAL_2="126" VAR="0.06778988223878621" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2089204934882636" CI_END="1.217808423430002" CI_START="0.7852553727729629" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9779011235838624" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="101" I2="54.72901795479163" I2_Q="54.692797539299676" ID="CMP-031.05" LOG_CI_END="0.08557897369002347" LOG_CI_START="-0.10498908344564005" LOG_EFFECT_SIZE="-0.009705054877808263" METHOD="MH" MODIFIED="2014-02-18 16:47:23 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1372147457707883" P_Q="0.13737192749639104" P_Z="0.8417699027430602" Q="2.2071545928429472" RANDOM="YES" SCALE="4.755964778897011" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.030386668549409517" TOTALS="SUB" TOTAL_1="522" TOTAL_2="370" WEIGHT="200.0" Z="0.19963007772018945">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1301247453628027" CI_START="0.6175155166214399" DF="0" EFFECT_SIZE="0.8353858784893268" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" I2="0.0" ID="CMP-031.05.01" LOG_CI_END="0.05312638439718956" LOG_CI_START="-0.2093521251963873" LOG_EFFECT_SIZE="-0.0781128703995989" MODIFIED="2013-12-11 15:51:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2433882863581408" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.1665596010074661">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="1.1301247453628027" CI_START="0.6175155166214399" EFFECT_SIZE="0.8353858784893268" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" LOG_CI_END="0.05312638439718956" LOG_CI_START="-0.2093521251963873" LOG_EFFECT_SIZE="-0.0781128703995989" MODIFIED="2013-12-11 15:51:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.15418117582484422" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.02377183497873153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6036631744836565" CI_START="0.8472034147744603" DF="0" EFFECT_SIZE="1.1656023839931886" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="45" I2="0.0" ID="CMP-031.05.02" LOG_CI_END="0.20511315645178815" LOG_CI_START="-0.0720123024110574" LOG_EFFECT_SIZE="0.06655042702036536" MODIFIED="2013-12-11 15:51:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3465240054753086" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.9413529933403396">
<NAME>sleepiness/ sedation - long term</NAME>
<DICH_DATA CI_END="1.6036631744836565" CI_START="0.8472034147744603" EFFECT_SIZE="1.1656023839931886" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="45" LOG_CI_END="0.20511315645178815" LOG_CI_START="-0.0720123024110574" LOG_EFFECT_SIZE="0.06655042702036536" MODIFIED="2013-12-11 15:51:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="0.16278486632918082" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.026498912705809265" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4220088003380484" CI_START="0.5158621577773126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-031.06" LOG_CI_END="0.15290228410572143" LOG_CI_START="-0.2874663296015556" LOG_EFFECT_SIZE="-0.06728202274791709" METHOD="MH" MODIFIED="2014-01-14 16:55:45 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5492336381610415" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.5989089017165031">
<NAME>Other adverse events: 2. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4220088003380484" CI_START="0.5158621577773126" DF="0" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" I2="0.0" ID="CMP-031.06.01" LOG_CI_END="0.15290228410572143" LOG_CI_START="-0.2874663296015556" LOG_EFFECT_SIZE="-0.06728202274791709" MODIFIED="2013-12-11 15:51:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5492336381610415" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.5989089017165031">
<NAME>faintness, dizziness, weakness - long term</NAME>
<DICH_DATA CI_END="1.4220088003380484" CI_START="0.5158621577773126" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.15290228410572143" LOG_CI_START="-0.2874663296015556" LOG_EFFECT_SIZE="-0.06728202274791709" MODIFIED="2013-12-11 15:51:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1772" O_E="0.0" SE="0.25867470355144867" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.06691260225742984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.044444452848875" CI_START="0.8421019130955489" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6011659807956105" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-031.07" LOG_CI_END="0.4835080545799675" LOG_CI_START="-0.07463534601022986" LOG_EFFECT_SIZE="0.20443635428486878" METHOD="MH" MODIFIED="2014-01-14 16:55:45 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.15106258050299218" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="243" TOTAL_2="161" WEIGHT="100.0" Z="1.4357883336264998">
<NAME>Other adverse events: 3. Gastrointestinal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.044444452848875" CI_START="0.8421019130955489" DF="0" EFFECT_SIZE="1.6011659807956105" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" I2="0.0" ID="CMP-031.07.01" LOG_CI_END="0.4835080545799675" LOG_CI_START="-0.07463534601022986" LOG_EFFECT_SIZE="0.20443635428486878" MODIFIED="2013-12-11 15:51:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.15106258050299218" STUDIES="1" TAU2="0.0" TOTAL_1="243" TOTAL_2="161" WEIGHT="100.0" Z="1.4357883336264998">
<NAME>weight gain - long term</NAME>
<DICH_DATA CI_END="3.044444452848875" CI_START="0.8421019130955489" EFFECT_SIZE="1.6011659807956105" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.4835080545799675" LOG_CI_START="-0.07463534601022986" LOG_EFFECT_SIZE="0.20443635428486878" MODIFIED="2013-12-11 15:51:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.32785619636107355" STUDY_ID="STD-CATIE-2005" TOTAL_1="243" TOTAL_2="161" VAR="0.10748968549235083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3112347520816807" CI_END="1.7011780123786444" CI_START="0.8419357751589835" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1967801086813872" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="41" I2="56.733083945742806" I2_Q="56.54674478731199" ID="CMP-031.08" LOG_CI_END="0.23074976084874832" LOG_CI_START="-0.07472103624130065" LOG_EFFECT_SIZE="0.07801436230372383" METHOD="MH" MODIFIED="2015-01-26 14:50:48 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.12844211807818073" P_Q="0.12926393693510174" P_Z="0.31677236085514326" Q="2.3013235604682794" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.29003820985839207" TOTALS="SUB" TOTAL_1="522" TOTAL_2="370" WEIGHT="200.0" Z="1.0011126552767227">
<NAME>Other adverse events: 4. Genitourinary</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.869805602053353" CI_START="0.8984415838269877" DF="0" EFFECT_SIZE="1.2961138478379857" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="35" I2="0.0" ID="CMP-031.08.01" LOG_CI_END="0.2717964566198553" LOG_CI_START="-0.046510155223166684" LOG_EFFECT_SIZE="0.11264315069834434" MODIFIED="2013-12-11 15:51:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16538260033197394" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.3871940466178707">
<NAME>diminished sexual desire - long term</NAME>
<DICH_DATA CI_END="1.869805602053353" CI_START="0.8984415838269877" EFFECT_SIZE="1.2961138478379857" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="35" LOG_CI_END="0.2717964566198553" LOG_CI_START="-0.046510155223166684" LOG_EFFECT_SIZE="0.11264315069834434" MODIFIED="2013-12-11 15:51:55 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.1869748794397314" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.03495960554150209" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6510638796667785" CI_START="0.13524338979896414" DF="0" EFFECT_SIZE="0.4725415070242657" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-031.08.02" LOG_CI_END="0.21776387644274542" LOG_CI_START="-0.8688839524246421" LOG_EFFECT_SIZE="-0.3255600379909484" MODIFIED="2015-01-26 14:50:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2402301911386564" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999" Z="1.1744116765646646">
<NAME>galactorrhea/ gynaecomastia - long term</NAME>
<DICH_DATA CI_END="1.6510638796667785" CI_START="0.13524338979896414" EFFECT_SIZE="0.4725415070242657" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.21776387644274542" LOG_CI_START="-0.8688839524246421" LOG_EFFECT_SIZE="-0.3255600379909484" MODIFIED="2013-12-11 15:52:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.6383023136702076" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.4074298436367402" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1089601450078534" CI_END="1.366263307010224" CI_START="0.6882939031427202" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9697374409100371" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="48" I2="35.66980898061825" I2_Q="35.21808724447102" ID="CMP-031.09" LOG_CI_END="0.1355344048812484" LOG_CI_START="-0.1622260773781288" LOG_EFFECT_SIZE="-0.013345836248440194" METHOD="MH" MODIFIED="2014-01-14 16:55:45 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.21129931397608392" P_Q="0.2136021063278496" P_Z="0.8605343846924295" Q="3.087281487886146" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1437283805215524" TOTALS="SUB" TOTAL_1="783" TOTAL_2="555" WEIGHT="300.0" Z="0.17569395503414337">
<NAME>Other adverse events: 5. Others</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5783661085446528" CI_START="0.7554417076404487" DF="0" EFFECT_SIZE="1.0919540229885059" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="37" I2="0.0" ID="CMP-031.09.01" LOG_CI_END="0.19820774695899457" LOG_CI_START="-0.12179904161853604" LOG_EFFECT_SIZE="0.038204352670229286" MODIFIED="2013-12-11 15:52:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6397954664395198" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.46798479256745196">
<NAME>urinary hesitancy, dry mouth, constipation - long term</NAME>
<DICH_DATA CI_END="1.5783661085446528" CI_START="0.7554417076404487" EFFECT_SIZE="1.0919540229885059" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="37" LOG_CI_END="0.19820774695899457" LOG_CI_START="-0.12179904161853604" LOG_EFFECT_SIZE="0.038204352670229286" MODIFIED="2013-12-11 15:52:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.1879735716695923" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.03533406364622336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.259756361127295" CI_START="0.04462039892987694" DF="0" EFFECT_SIZE="0.7088122605363985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-031.09.02" LOG_CI_END="1.0515289933427914" LOG_CI_START="-1.3504665512133256" LOG_EFFECT_SIZE="-0.14946877893526717" MODIFIED="2013-12-11 15:52:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8072888798700267" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.24392503490712333">
<NAME>suicide attempt - long term</NAME>
<DICH_DATA CI_END="11.259756361127295" CI_START="0.04462039892987694" EFFECT_SIZE="0.7088122605363985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0515289933427914" LOG_CI_START="-1.3504665512133256" LOG_EFFECT_SIZE="-0.14946877893526717" MODIFIED="2013-12-11 15:52:32 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="1.4109440729419693" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="1.9907631769700735" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1496383281228006" CI_START="0.1573271619628004" DF="0" EFFECT_SIZE="0.42528735632183906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-031.09.03" LOG_CI_END="0.0605612344361494" LOG_CI_START="-0.8031962915393964" LOG_EFFECT_SIZE="-0.37131752855162353" MODIFIED="2013-12-11 15:52:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0919647777592386" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.6851233382138069">
<NAME>incontinence nocturia - long term</NAME>
<DICH_DATA CI_END="1.1496383281228006" CI_START="0.1573271619628004" EFFECT_SIZE="0.42528735632183906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.0605612344361494" LOG_CI_START="-0.8031962915393964" LOG_EFFECT_SIZE="-0.37131752855162353" MODIFIED="2013-12-11 15:52:48 +0000" MODIFIED_BY="[Empty name]" ORDER="1760" O_E="0.0" SE="0.5073754464267464" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.2574298436367402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8694615754101014" CI_START="0.6260870095383573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-031.10" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" METHOD="MH" MODIFIED="2014-01-14 16:55:45 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.7779550037703511" Q="0.0" RANDOM="YES" SCALE="344.4904241098801" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.28198501124085223">
<NAME>Other adverse events: 6. any serious adverse event</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8694615754101014" CI_START="0.6260870095383573" DF="0" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" ID="CMP-031.10.01" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" MODIFIED="2013-12-11 15:53:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7779550037703511" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.28198501124085223">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.8694615754101014" CI_START="0.6260870095383573" EFFECT_SIZE="1.0818713450292399" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.2717165431683031" LOG_CI_START="-0.2033653071465831" LOG_EFFECT_SIZE="0.034175618010860005" MODIFIED="2013-12-11 15:53:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.27906543056805083" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" VAR="0.07787751453813159" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.455712989941716" CI_END="0.5217082553053847" CI_START="-0.06871615135008718" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22649605197764877" ESTIMABLE="YES" I2="52.17925353526875" I2_Q="52.17925353526875" ID="CMP-031.11" MODIFIED="2014-02-18 16:56:12 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.06330584916680104" P_Q="0.06330584916680104" P_Z="0.13264683710816527" Q="10.455712989941716" RANDOM="YES" SCALE="58.432030295853515" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.03116878444231" TOTALS="SUB" TOTAL_1="1566" TOTAL_2="1110" UNITS="" WEIGHT="600.0" Z="1.5037457785031745">
<NAME>Other adverse events: 7. lab data</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6487340472642624" CI_START="-3.4487340472642622" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-031.11.01" MODIFIED="2013-12-11 15:53:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7970620607739944" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.25715119182649593">
<NAME>mean weight change (lb) - long term</NAME>
<CONT_DATA CI_END="2.6487340472642624" CI_START="-3.4487340472642622" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.6" MODIFIED="2013-12-11 15:53:23 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="17.77" SD_2="14.96" SE="1.5555051374985904" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.489578001397046" CI_START="-5.689578001397045" DF="0" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-031.11.02" MODIFIED="2013-12-11 15:53:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5081506888558481" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="0.6617200000095121">
<NAME>change in blood glucose - long term</NAME>
<CONT_DATA CI_END="11.489578001397046" CI_START="-5.689578001397045" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="2.3" MODIFIED="2013-12-11 15:53:34 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="32.31" SD_2="53.04" SE="4.382518285616746" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.342968488162648E-32" CI_END="0.4975309768228994" CI_START="-0.09753097682289943" DF="0" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-031.11.03" MODIFIED="2013-12-11 15:53:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.18767588295441456" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.00000000000001" Z="1.3174856651693725">
<NAME>change in glycosylated haemoglobin - long term</NAME>
<CONT_DATA CI_END="0.49753097682289943" CI_START="-0.0975309768228994" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.1" MODIFIED="2013-12-11 15:53:45 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="0.96" SD_2="1.9" SE="0.1518043082269806" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.842870009055712" CI_START="-1.4428700090557136" DF="0" EFFECT_SIZE="9.7" ESTIMABLE="YES" I2="0.0" ID="CMP-031.11.04" MODIFIED="2013-12-11 15:53:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0879760963700232" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="1.7061718062391396">
<NAME>change in cholesterol - long term</NAME>
<CONT_DATA CI_END="20.842870009055712" CI_START="-1.4428700090557136" EFFECT_SIZE="9.7" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-9.2" MODIFIED="2013-12-11 15:53:50 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="37.15" SD_2="70.72" SE="5.685242227382365" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="55.51012136728265" CI_START="-2.7101213672826425" DF="0" EFFECT_SIZE="26.400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-031.11.05" MODIFIED="2013-12-11 15:53:55 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.07548709246060205" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999" Z="1.7774934202099315">
<NAME>change in triglycerides - long term</NAME>
<CONT_DATA CI_END="55.51012136728265" CI_START="-2.710121367282646" EFFECT_SIZE="26.400000000000002" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="-18.1" MODIFIED="2013-12-11 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="185.78" SD_2="127.85" SE="14.852375654297512" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.474966168908782" CI_START="0.32503383109121753" DF="0" EFFECT_SIZE="4.9" ESTIMABLE="YES" I2="0.0" ID="CMP-031.11.06" MODIFIED="2013-12-11 15:54:00 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.035798223530205855" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0" Z="2.099211921940171">
<NAME>change in prolactin - long term</NAME>
<CONT_DATA CI_END="9.474966168908782" CI_START="0.32503383109121753" EFFECT_SIZE="4.9" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-4.5" MODIFIED="2013-12-11 15:54:00 +0000" MODIFIED_BY="[Empty name]" ORDER="2703" SD_1="27.46" SD_2="21.76" SE="2.33420930435229" STUDY_ID="STD-CATIE-2005" TOTAL_1="261" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="32">
<NAME>PERPHENAZINE vs ZOTEPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4790760305729287" CI_START="0.6255310526183312" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4752186588921283" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="0.5414639197787692" LOG_CI_START="-0.20375112618471192" LOG_EFFECT_SIZE="0.16885639679702863" METHOD="MH" MODIFIED="2014-02-18 16:59:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3744296458833909" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.8882065870087085">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4790760305729287" CI_START="0.6255310526183312" DF="0" EFFECT_SIZE="1.4752186588921283" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-032.01.01" LOG_CI_END="0.5414639197787692" LOG_CI_START="-0.20375112618471192" LOG_EFFECT_SIZE="0.16885639679702863" MODIFIED="2013-12-06 10:00:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3744296458833909" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.8882065870087085">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.4790760305729287" CI_START="0.6255310526183312" EFFECT_SIZE="1.4752186588921283" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5414639197787692" LOG_CI_START="-0.20375112618471192" LOG_EFFECT_SIZE="0.16885639679702863" MODIFIED="2013-12-06 10:00:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24510" O_E="0.0" SE="0.4377430068729197" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.19161894006614505" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.227063859812455" CI_START="0.5573395512830623" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3411078717201166" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-032.02" LOG_CI_END="0.5088075596678502" LOG_CI_START="-0.2538801363902431" LOG_EFFECT_SIZE="0.12746371163880357" METHOD="MH" MODIFIED="2014-02-19 09:02:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5123933661531156" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.6551155484454675">
<NAME>Leaving the study early: 2. Due to relapse / worsening or no improvement</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.227063859812455" CI_START="0.5573395512830623" DF="0" EFFECT_SIZE="1.3411078717201166" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-032.02.01" LOG_CI_END="0.5088075596678502" LOG_CI_START="-0.2538801363902431" LOG_EFFECT_SIZE="0.12746371163880357" MODIFIED="2013-12-06 10:01:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5123933661531156" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.6551155484454675">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.227063859812455" CI_START="0.5573395512830623" EFFECT_SIZE="1.3411078717201166" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5088075596678502" LOG_CI_START="-0.2538801363902431" LOG_EFFECT_SIZE="0.12746371163880357" MODIFIED="2013-12-06 10:00:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24534" O_E="0.0" SE="0.4480065280295078" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.20070984915705414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8666581261309556E-31" CI_END="1.470785059927998" CI_START="0.6524407901207728" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="100.0" I2_Q="0.0" ID="CMP-032.03" LOG_CI_END="0.16754920970390677" LOG_CI_START="-0.18545889500975965" LOG_EFFECT_SIZE="-0.008954842652926454" METHOD="MH" MODIFIED="2014-02-19 09:03:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.9207906964788901" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.09943776843987845">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8666581261309556E-31" CI_END="1.470785059927998" CI_START="0.6524407901207728" DF="0" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="100.0" ID="CMP-032.03.01" LOG_CI_END="0.16754920970390677" LOG_CI_START="-0.18545889500975965" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2013-12-06 10:01:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.9207906964788901" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.09943776843987845">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.470785059927998" CI_START="0.6524407901207728" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.16754920970390677" LOG_CI_START="-0.18545889500975965" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2013-12-06 10:00:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24543" O_E="0.0" SE="0.20735870812710797" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="0.04299763383614315" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.502624006449645" CI_START="0.013085792076662656" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-032.04" LOG_CI_END="0.8752131823537016" LOG_CI_START="-1.8831999845936291" LOG_EFFECT_SIZE="-0.5039934011199637" METHOD="MH" MODIFIED="2014-01-14 16:56:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.47385839658708795" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.7162153418330455">
<NAME>Other adverse events: 1. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.502624006449645" CI_START="0.013085792076662656" DF="0" EFFECT_SIZE="0.31333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-032.04.01" LOG_CI_END="0.8752131823537016" LOG_CI_START="-1.8831999845936291" LOG_EFFECT_SIZE="-0.5039934011199637" MODIFIED="2013-12-06 10:02:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.47385839658708795" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="0.7162153418330455">
<NAME>tachycardia - short term</NAME>
<DICH_DATA CI_END="7.502624006449645" CI_START="0.013085792076662656" EFFECT_SIZE="0.31333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752131823537016" LOG_CI_START="-1.8831999845936291" LOG_EFFECT_SIZE="-0.5039934011199637" MODIFIED="2013-12-06 10:00:37 +0000" MODIFIED_BY="[Empty name]" ORDER="24679" O_E="0.0" SE="1.6203055486302531" STUDY_ID="STD-Imai-1980" TOTAL_1="49" TOTAL_2="46" VAR="2.6253900709219855" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2014-02-21 16:10:03 +0000" MODIFIED_BY="[Empty name]" NO="33">
<NAME>PERPHENAZINE vs ZUCLOPENTHIXOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.6740388197625435" CI_START="0.693190648374761" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="0.6696923150606261" LOG_CI_START="-0.15914730485401402" LOG_EFFECT_SIZE="0.25527250510330607" METHOD="MH" MODIFIED="2014-02-19 09:04:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2273204804421608" Q="0.0" RANDOM="YES" SCALE="833.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.2072900576285777">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zuclopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zuclopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.6740388197625435" CI_START="0.693190648374761" DF="0" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="0.6696923150606261" LOG_CI_START="-0.15914730485401402" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-12-09 15:49:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2273204804421608" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.2072900576285777">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.6740388197625435" CI_START="0.693190648374761" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6696923150606261" LOG_CI_START="-0.15914730485401402" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24519" O_E="0.0" SE="0.48686449556014766" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.23703703703703705" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.180224957567825" CI_START="0.06587517660609293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.02" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-02-19 09:07:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.0">
<NAME>Global state: 1. Change over time - no better or deterioration (ITT)</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zuclopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zuclopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.180224957567825" CI_START="0.06587517660609293" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-033.02.01" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 15:49:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="15.180224957567825" CI_START="0.06587517660609293" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24549" O_E="0.0" SE="1.387777332977422" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="1.925925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.58152407029509" CI_END="2.384346842871437" CI_START="0.8968433553980842" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.462321997028578" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" I2="46.2512395858683" I2_Q="45.86490770243817" ID="CMP-033.03" LOG_CI_END="0.37736943101310716" LOG_CI_START="-0.04728340514655416" LOG_EFFECT_SIZE="0.1650430129332765" METHOD="MH" MODIFIED="2014-01-14 16:56:34 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13384319028729597" P_Q="0.13616624459550963" P_Z="0.12763476357013168" Q="5.5416918539827" RANDOM="YES" SCALE="172.304115854729" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.22272551075670252" TOTALS="SUB" TOTAL_1="108" TOTAL_2="108" WEIGHT="400.0" Z="1.5234955884179173">
<NAME>Adverse events: Movement disorders</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zuclopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zuclopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7083055637046884" CI_START="0.4822655414084622" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-033.03.01" LOG_CI_END="0.432697661912795" LOG_CI_START="-0.31671376795742145" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2013-12-09 15:49:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7616330114443802" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.3033370534241959">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="2.7083055637046884" CI_START="0.4822655414084622" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.432697661912795" LOG_CI_START="-0.31671376795742145" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24569" O_E="0.0" SE="0.4402079835521714" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.19378306878306878" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5070719917963586" CI_START="0.07372647870568672" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-033.03.02" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:50:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.15353976777529646" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.427139226344519">
<NAME>akinesia - short term</NAME>
<DICH_DATA CI_END="1.5070719917963586" CI_START="0.07372647870568672" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24572" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.480110751954462" CI_START="0.883193829298766" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-033.03.03" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-12-09 15:50:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09041351517301702" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.00000000000001" Z="1.6932204408405083">
<NAME>rigidity - short term</NAME>
<DICH_DATA CI_END="5.480110751954462" CI_START="0.883193829298766" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24602" O_E="0.0" SE="0.465655470101036" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.21683501683501682" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.480110751954462" CI_START="0.883193829298766" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-033.03.04" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-12-09 15:50:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09041351517301702" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.00000000000001" Z="1.6932204408405083">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="5.480110751954462" CI_START="0.883193829298766" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7387893355786473" LOG_CI_START="-0.05394397393423473" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24605" O_E="0.0" SE="0.465655470101036" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.21683501683501682" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7048787599609794" CI_END="2.1181526459614664" CI_START="0.7379405719453084" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2502282891649321" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="46.017126886466194" I2_Q="44.5733473125313" ID="CMP-033.04" LOG_CI_END="0.3259572545958093" LOG_CI_START="-0.13197861150410636" LOG_EFFECT_SIZE="0.09698932154585155" METHOD="MH" MODIFIED="2014-01-14 16:56:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.15685416023928023" P_Q="0.16460843101717215" P_Z="0.40640992481783034" Q="3.608372331768423" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.20662029524971604" TOTALS="SUB" TOTAL_1="81" TOTAL_2="81" WEIGHT="300.0" Z="0.8302279475675193">
<NAME>Other adverse events: 1. Arousal</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zuclopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zuclopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.952381873973146" CI_START="0.5599076593249779" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-033.04.01" LOG_CI_END="0.4701725303302891" LOG_CI_START="-0.251883591480153" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-12-09 15:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5534970902843848" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.592527984247257">
<NAME>excitation - short term</NAME>
<DICH_DATA CI_END="2.952381873973146" CI_START="0.5599076593249779" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4701725303302891" LOG_CI_START="-0.251883591480153" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24636" O_E="0.0" SE="0.4241393401869012" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.17989417989417988" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5070719917963586" CI_START="0.07372647870568672" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-033.04.02" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.15353976777529646" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.427139226344519">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.5070719917963586" CI_START="0.07372647870568672" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17813399875996683" LOG_CI_START="-1.1323765081992918" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24646" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.681880652108193" CI_START="0.7981723982610299" DF="0" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-033.04.03" LOG_CI_END="0.566069706772315" LOG_CI_START="-0.09790329470557912" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2013-12-09 15:51:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.16698158903681912" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.3819677974552258">
<NAME>sleepiness/sedation - short term</NAME>
<DICH_DATA CI_END="3.681880652108193" CI_START="0.7981723982610299" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.566069706772315" LOG_CI_START="-0.09790329470557912" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24657" O_E="0.0" SE="0.3900210277874798" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.1521164021164021" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.724017763609372" CI_START="0.4762894875909387" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-033.05" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2014-01-14 16:56:34 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.48847850567314477" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.6927308088471281">
<NAME>Other adverse events: 2. Cardiovascular</NAME>
<GROUP_LABEL_1>Perphenazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zuclopenthixol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perphenazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zuclopenthixol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.724017763609372" CI_START="0.4762894875909387" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-033.05.01" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-09 15:51:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48847850567314477" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.6927308088471281">
<NAME>faintness, dizziness, weakness - short term</NAME>
<DICH_DATA CI_END="4.724017763609372" CI_START="0.4762894875909387" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-12-09 15:48:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24673" O_E="0.0" SE="0.5853140973807077" STUDY_ID="STD-Remvig-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.34259259259259256" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-27 10:28:56 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-05-12 09:04:07 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-002.04" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 PERPHENAZINE vs ANY ANTIPSYCHOTICS, outcome: 2.4 Global state: 1. Change over time - no better or deterioration (ITT).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-20 12:12:05 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: 2013 update search</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAANCCAYAAABMI0r8AABNf0lEQVR42u2dD4RVXfu/X5IkSSSP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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-27 10:28:56 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-01-27 10:28:56 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATMAAAS8CAIAAABv5PqjAAA8yUlEQVR42u3dv24cyfX28QEM/OCA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-01-14 16:00:38 +0000" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2013-03-01 11:32:23 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-01 11:32:20 +0000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-01 11:32:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Electronic searching<BR/>We searched Cochrane Schizophrenia Group's Register (June 2001) with the phrase:</P>
<P>[aethaperazin or apo-perphenazine or decentan or fentazin or f-mon or peratsin or perfenazine or perfenazin leciva or pms-perphenazine or trilafon or trilifan or trilafon prolongatum or trilafon repetabs or 10-{3-[4-(2-hydroxyethyl)-1-piperazinyl]-propyl}-2-chlor-phenothiazin]</P>
<P>2. Reference searching<BR/>We inspected references of all identified studies for more studies.</P>
<P>3. Personal contact<BR/>We contacted the first author of each included study for more information regarding unpublished trials.</P>
<P>4. Drug company<BR/>We contacted the German manufacturers of perphenazine (Merck, Germany) for additional data.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-01-14 16:00:38 +0000" MODIFIED_BY="Heather Maxwell" NO="2">
<TITLE MODIFIED="2013-03-01 11:33:21 +0000" MODIFIED_BY="[Empty name]">Previous data collection and analyses</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-14 16:00:38 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Selection of trials<BR/>We (Benno Hartung BH, Stefan Leucht SL) independently inspected all citations of studies identified by the search. Where disagreement occurred we resolved this by discussion, or, when there was still doubt, we acquired the full article for further inspection. Once we had obtained the full articles BH decided whether they met review criteria and this was checked by SL. Once again, we resolved disagreement by discussion, but if doubt remained, we put the study on the list of those awaiting assessment, pending acquisition of more information. These rules could not be respected for the Japanese studies. They were analysed by Makoto Wada (MW)who had to explain his analysis to one of the other reviewers.</P>
<P>2. Quality assessment<BR/>We used criteria in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>) to assess trial quality. This simple set of criteria is based on evidence of strong association between overestimation of effect and poor concealment of allocation, and is defined as follows:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>The Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) measures a wider range of factors that impact on the quality of a trial. The scale includes three items:</P>
<P>1. Was the study described as randomised?<BR/>2. Was the study described as double blind?<BR/>3. Was there a description of withdrawals and dropouts?</P>
<P>Each item scores one point if the answer is positive and an additional point for the first two items if the means of randomisation/blinding is described. In addition, a point can be deducted if either the randomisation or the blinding/masking described were inadequate.</P>
<P>For the purpose of analysis of this review, we included studies if they met criteria A and B of the Handbook. We gave studies not described as randomised by the authors a 'C' rating and excluded them from analyses. We did not use the Jadad scale to exclude studies, but for a further description of the quality of included trials.</P>
<P>3. Data extraction<BR/>3.1 Reliable extraction<BR/>BH extracted data from selected trials and SL checked all data extraction. When disputes arose we attempted resolution by discussion. If doubt remained and further information was necessary to resolve the dilemma, we did not enter data but contacted the authors of the studies for further information. This rule could not be respected for the Japanese studies. These were analysed by MW who had to explain his analysis to the reviewers.</P>
<P>3.2 Multiple doses<BR/>If several doses of perphenazine were compared with one dose of the control drug, we pooled different dose groups of perphenazine. For example, for dichotomous data we considered all patients treated with perphenazine as a single group. For continuous data we used the mean of all patients on perphenazine in the comparisons.</P>
<P>4. Data synthesis<BR/>4.1 Data types<BR/>Outcomes are assessed using continuous (for example, average changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently the RevMan software does not support categorical data, so we presented them only in the text of the review.</P>
<P>4.2 Incomplete data<BR/>With the exception of the outcome of leaving the study early, we included trial outcomes of studies with a remark 'prone to bias' if more than 50% of people in short and medium-term studies or 60% of people in long-term studies were not reported in the final analysis. We felt that with such a great degree of attrition, great assumptions would have to be made. We checked whether the exclusion of these results made a substantial difference in a sensitivity analysis.</P>
<P>4.3 Dichotomous/binary data<BR/>4.3.1 Defining cut offs: we recorded in RevMan where the original authors of the studies gave outcomes such as 'clinically improved' or 'not clinically improved', based on their clinical judgement, predetermined criteria, or any scale. We only included data from a rater not clearly stated to be independent if they did not change the results.Otherwise we presented such data separately with a label 'prone to bias'. We made efforts to convert relevant categorical or continuous outcome measures to dichotomous data by identifying cut off points on rating scales and dividing people accordingly into groups. For example, for end of study data, we used the cut off points 'moderate or severe impairment' and 'no better or worse' for change data. For another example, the Brief Psychiatric Rating Scale (BPRS - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is frequently used as a measure of change of symptoms in studies. We defined a 50% change on this particular scale as clinically important, although it was recognised that for many people, especially those with chronic or severe illnesses, a less rigorous definition of important improvement would be equally valid. If individual patient data had been available, the 50% cut off would also have been used in the case of non-chronically ill people and 20% for those with chronic illness.</P>
<P>4.3.2 Intention-to-treat analysis: the review presents an intention to treat analysis. As long as more than 50% of people in short and medium term studies and 40% in long term studies completed the trial, we counted everyone allocated to the intervention whether or not they completed follow up. It was assumed that those who left the study early had no change in their outcome.</P>
<P>4.3.3 Summary statistic: we used relative risk (RR) and 95% confidence interval (CI) based on the random effects model. This method takes into account differences between studies, even if heterogeneity is not statistically significant. It has also been shown that RR is more intuitive and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. Where possible, reviewers estimated the number needed to treat (NNT) using an on-line calculator (http://www.nntonline.net/).</P>
<P>4.4 Continuous data<BR/>4.4.1 Intention-to-treat versus completer analyses: in the case of continuous data we supposed that in many cases an intention-to-treat analysis would not be available, so presented a completer analysis.</P>
<P>4.4.2 Rating scales: a wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. We included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, such data were commented on with 'prone to bias'.</P>
<P>4.4.3 Normal distribution of data: mental health continuous data are often not normally distributed. Most statistics assume a normal distribution. To avoid including non-normally distributed data in the statistical analysis, the following criteria are applied to all data before inclusion:<BR/>a. Standard deviations and means were reported or derivable from data in the paper, or were obtainable from the authors.<BR/>b. When a scale starts from zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied.<BR/>c. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale end point data, which typically cannot have negative values. If end point data were not available, reviewers chose to use change data, because the statistics used in Metaview are rather robust towards skew.<BR/>d. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.4.4 Endpoint versus change data: endpoint scale-derived data are finite, ranging from one score to another. Change data are more problematic and for them the rule described above does not hold. Although most change scores are likely to be skewed, this cannot be proven so we presented them in MetaView. Where both endpoint and change were available for the same outcome, we presented only the former.</P>
<P>4.4.5 Summary statistic: for continuous outcomes, a weighted mean difference (WMD) between groups was estimated. Again, a random effects model was used.</P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra class correlation co-efficients of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) Design effect=1+(m-1)*ICC (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account intra-class correlation co-efficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>4.6 Sensitivity analyses<BR/>For binary data, we compared results for intention-to-treat analysis with those using completer only data. If analyses using completer data did result in a substantive change in the estimate of effect, we discussed this in the section Discussion.</P>
<P>5. Heterogeneity<BR/>Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. This was supplemented, primarily, by employing the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was greater than or equal to 75%, this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If inconsistency was high, we did not summate the data, but presented them separately and investigated reasons for heterogeneity.</P>
<P>6. Addressing publication bias<BR/>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>7. Tables and figures<BR/>Where possible, we entered data into RevMan so the area to the left of the line of no effect indicated a favourable outcome for perphenazine.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-02-04 12:56:32 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-02-04 12:56:25 +0000" MODIFIED_BY="[Empty name]">Previous results of search</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-04 12:56:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Results of the search</HEADING>
<P>The original searches yielded 133 electronic records and we inspected the abstract of each identified reference. We then ordered and inspected 90 possibly relevant reports. During this inspection process, we examined the papers' reference lists and identified a further six references as being relevant. Personal mail contact with the first authors of each included trial revealed no additional reports. One unpublished manuscript was provided by the manufacturers (<LINK REF="STD-Eckmann-1984" TYPE="STUDY">Eckmann 1984</LINK>). All these papers were considered to match the review's inclusion criteria closely enough to be mentioned in either the 'Included studies' (25 references) or 'Excluded studies' (88 references) section. Fourteen remaining reports are still 'awaiting assessment' for the reasons mentioned above.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;31 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;31 studies (84 references) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;210 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;615 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;615 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;618 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;405 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;108 studies (112 references) excluded, with reasons&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;14 studies awaiting classification&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>